A	O
novel	O
missense	O
mutation	O
Asp506Gly	B-ProteinMutation
in	O
Exon	O
13	O
of	O
the	O
F11	O
gene	O
in	O
an	O
asymptomatic	O
Korean	O
woman	O
with	O
mild	O
factor	O
XI	O
deficiency	O
.	O

Factor	O
XI	O
(FXI)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
coagulation	O
disorder	O
most	O
commonly	O
found	O
in	O
Ashkenazi	O
and	O
Iraqi	O
Jews	O
,	O
but	O
it	O
is	O
also	O
found	O
in	O
other	O
ethnic	O
groups	O
.	O

It	O
is	O
a	O
trauma	O
or	O
surgery-related	O
bleeding	O
disorder	O
,	O
but	O
spontaneous	O
bleeding	O
is	O
rarely	O
seen	O
.	O

The	O
clinical	O
manifestation	O
of	O
bleeding	O
in	O
FXI	O
deficiency	O
cases	O
is	O
variable	O
and	O
seems	O
to	O
poorly	O
correlate	O
with	O
plasma	O
FXI	O
levels	O
.	O

The	O
molecular	O
pathology	O
of	O
FXI	O
deficiency	O
is	O
mutation	O
in	O
the	O
F11	O
gene	O
on	O
the	O
chromosome	O
band	O
4q35	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
F11	O
gene	O
in	O
an	O
18-year-old	O
asymptomatic	O
Korean	O
woman	O
with	O
mild	O
FXI	O
deficiency	O
.	O

Pre-operative	O
laboratory	O
screen	O
tests	O
for	O
lipoma	O
on	O
her	O
back	O
revealed	O
slightly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
45.2	O
sec	O
;	O
reference	O
range	O
,	O
23.2-39.4	O
sec	O
)	O
.	O

Her	O
FXI	O
activity	O
(35%)	O
was	O
slightly	O
lower	O
than	O
the	O
normal	O
FXI	O
activity	O
(	O
reference	O
range	O
,	O
50-150%	O
)	O
.	O

Direct	O
sequence	O
analysis	O
of	O
the	O
F11	O
gene	O
revealed	O
a	O
heterozygous	O
A	O
to	O
G	O
substitution	O
in	O
nucleotide	O
1517	O
c.1517A>G	B-DNAMutation
of	O
exon	O
13	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
aspartic	O
acid	O
with	O
glycine	O
in	O
codon	O
506	O
p.Asp506Gly	B-ProteinMutation
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
Asp506Gly	B-ProteinMutation
is	O
a	O
novel	O
missense	O
mutation	O
,	O
and	O
this	O
is	O
the	O
first	O
genetically	O
confirmed	O
case	O
of	O
mild	O
FXI	O
deficiency	O
in	O
Korea	O
.	O

Mutations	O
in	O
mitochondrially	O
encoded	O
complex	O
I	O
enzyme	O
as	O
the	O
second	O
common	O
cause	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
with	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
stroke-like	O
episodes	O
.	O

The	O
mutation	O
pattern	O
of	O
mitochondrial	O
DNA	O
(mtDNA)	O
in	O
mainland	O
Chinese	O
patients	O
with	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
stroke-like	O
episodes	O
(MELAS)	O
has	O
been	O
rarely	O
reported	O
,	O
though	O
previous	O
data	O
suggested	O
that	O
the	O
mutation	O
pattern	O
of	O
MELAS	O
could	O
be	O
different	O
among	O
geographically	O
localized	O
populations	O
.	O

We	O
presented	O
the	O
results	O
of	O
comprehensive	O
mtDNA	O
mutation	O
analysis	O
in	O
92	O
unrelated	O
Chinese	O
patients	O
with	O
MELAS	O
(	O
85	O
with	O
classic	O
MELAS	O
and	O
7	O
with	O
MELAS/Leigh	O
syndrome	O
(LS)	O
overlap	O
syndrome	O
)	O
.	O

The	O
mtDNA	O
A3243G	B-DNAMutation
mutation	O
was	O
the	O
most	O
common	O
causal	O
genotype	O
in	O
this	O
patient	O
group	O
(	O
79/92	O
and	O
85.9%	O
)	O
.	O

The	O
second	O
common	O
gene	O
mutation	O
was	O
G13513A	B-DNAMutation
(	O
7/92	O
and	O
7.6%	O
)	O
.	O

Additionally	O
,	O
we	O
identified	O
T10191C	B-DNAMutation
p.S45P	B-ProteinMutation
in	O
ND3	O
,	O
A11470C	B-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
K237N	I-ProteinMutation
)	O
in	O
ND4	O
,	O
T13046C	B-DNAMutation
p.M237T	B-ProteinMutation
in	O
ND5	O
and	O
a	O
large-scale	O
deletion	O
(13025-13033:14417-14425)	O
involving	O
partial	O
ND5	O
and	O
ND6	O
subunits	O
of	O
complex	O
I	O
in	O
one	O
patient	O
each	O
.	O

Among	O
them	O
,	O
A11470C	B-DNAMutation
,	O
T13046C	B-DNAMutation
and	O
the	O
single	O
deletion	O
were	O
novel	O
mutations	O
.	O

In	O
summary	O
,	O
patients	O
with	O
mutations	O
affecting	O
mitochondrially	O
encoded	O
complex	O
I	O
(MTND)	O
reached	O
12.0%	O
(11/92)	O
in	O
this	O
group	O
.	O

It	O
is	O
noteworthy	O
that	O
all	O
seven	O
patients	O
with	O
MELAS/LS	O
overlap	O
syndrome	O
were	O
associated	O
with	O
MTND	O
mutations	O
.	O

Our	O
data	O
emphasize	O
the	O
important	O
role	O
of	O
MTND	O
mutations	O
in	O
the	O
pathogenicity	O
of	O
MELAS	O
,	O
especially	O
MELAS/LS	O
overlap	O
syndrome	O
.	O

Novel	O
compound	O
heterozygous	O
mutation	O
of	O
MLYCD	O
in	O
a	O
Chinese	O
patient	O
with	O
malonic	O
aciduria	O
.	O

A	O
3-year-old	O
Chinese	O
boy	O
presented	O
with	O
prominent	O
clinical	O
features	O
of	O
malonic	O
aciduria	O
,	O
including	O
developmental	O
delay	O
,	O
short	O
stature	O
,	O
brain	O
abnormalities	O
and	O
massive	O
excretion	O
of	O
malonic	O
acid	O
and	O
methylmalonic	O
acid	O
.	O

Molecular	O
characterization	O
by	O
DNA	O
sequencing	O
analysis	O
and	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
of	O
the	O
MLYCD	O
gene	O
revealed	O
a	O
heterozygous	O
mutation	O
(	O
c.920T>G	B-DNAMutation
,	O
p.Leu307Arg	B-ProteinMutation
)	O
in	O
the	O
patient	O
and	O
his	O
father	O
and	O
a	O
heterozygous	O
deletion	O
comprising	O
exon	O
1	O
in	O
the	O
patient	O
and	O
his	O
mother	O
.	O

The	O
missense	O
mutation	O
c.920T>G	B-DNAMutation
was	O
not	O
found	O
in	O
100	O
healthy	O
controls	O
and	O
has	O
not	O
been	O
reported	O
previously	O
.	O

Our	O
findings	O
expand	O
the	O
number	O
of	O
reported	O
cases	O
and	O
add	O
a	O
novel	O
entry	O
to	O
the	O
repertoire	O
of	O
MLYCD	O
mutations	O
.	O

Genetic	O
and	O
epigenetic	O
alterations	O
of	O
the	O
NF2	O
gene	O
in	O
sporadic	O
vestibular	O
schwannomas	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
neurofibromatosis	O
type	O
2	O
(NF2)	O
tumor-suppressor	O
gene	O
have	O
been	O
identified	O
in	O
not	O
only	O
NF2-related	O
tumors	O
but	O
also	O
sporadic	O
vestibular	O
schwannomas	O
(VS)	O
.	O

This	O
study	O
investigated	O
the	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
tumors	O
and	O
blood	O
from	O
30	O
Korean	O
patients	O
with	O
sporadic	O
VS	O
and	O
correlated	O
these	O
alterations	O
with	O
tumor	O
behavior	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
NF2	O
gene	O
mutations	O
were	O
detected	O
using	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
and	O
three	O
highly	O
polymorphic	O
microsatellite	O
DNA	O
markers	O
were	O
used	O
to	O
assess	O
the	O
loss	O
of	O
heterozygosity	O
(LOH)	O
from	O
chromosome	O
22	O
.	O

Aberrant	O
hypermethylation	O
of	O
the	O
CpG	O
island	O
of	O
the	O
NF2	O
gene	O
was	O
also	O
analyzed	O
.	O

The	O
tumor	O
size	O
,	O
the	O
clinical	O
growth	O
index	O
,	O
and	O
the	O
proliferative	O
activity	O
assessed	O
using	O
the	O
Ki-67	O
labeling	O
index	O
were	O
evaluated	O
.	O

We	O
found	O
18	O
mutations	O
in	O
16	O
cases	O
of	O
30	O
schwannomas	O
(53%)	O
.	O

The	O
mutations	O
included	O
eight	O
frameshift	O
mutations	O
,	O
seven	O
nonsense	O
mutations	O
,	O
one	O
in-frame	O
deletion	O
,	O
one	O
splicing	O
donor	O
site	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

Nine	O
patients	O
(30%)	O
showed	O
allelic	O
loss	O
.	O

No	O
patient	O
had	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
and	O
correlation	O
between	O
NF2	O
genetic	O
alterations	O
and	O
tumor	O
behavior	O
was	O
not	O
observed	O
in	O
this	O
study	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
The	O
molecular	O
genetic	O
changes	O
in	O
sporadic	O
VS	O
identified	O
here	O
included	O
mutations	O
and	O
allelic	O
loss	O
,	O
but	O
no	O
aberrant	O
hypermethylation	O
of	O
the	O
NF2	O
gene	O
was	O
detected	O
.	O

In	O
addition	O
,	O
no	O
clear	O
genotype/phenotype	O
correlation	O
was	O
identified	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
other	O
factors	O
contribute	O
to	O
tumor	O
formation	O
and	O
growth	O
.	O

RET	O
mutational	O
spectrum	O
in	O
Hirschsprung	O
disease	O
:	O
evaluation	O
of	O
601	O
Chinese	O
patients	O
.	O

Rare	O
(RVs)	O
and	O
common	O
variants	O
of	O
the	O
RET	O
gene	O
contribute	O
to	O
Hirschsprung	O
disease	O
(	O
HSCR	O
;	O
congenital	O
aganglionosis	O
)	O
.	O

While	O
RET	O
common	O
variants	O
are	O
strongly	O
associated	O
with	O
the	O
commonest	O
manifestation	O
of	O
the	O
disease	O
(	O
males	O
;	O
short-segment	O
aganglionosis	O
;	O
sporadic	O
)	O
,	O
rare	O
coding	O
sequence	O
(CDS)	O
variants	O
are	O
more	O
frequently	O
found	O
in	O
the	O
lesser	O
common	O
and	O
more	O
severe	O
forms	O
of	O
the	O
disease	O
(	O
females	O
;	O
long/total	O
colonic	O
aganglionosis	O
;	O
familial).Here	O
we	O
present	O
the	O
screening	O
for	O
RVs	O
in	O
the	O
RET	O
CDS	O
and	O
intron/exon	O
boundaries	O
of	O
601	O
Chinese	O
HSCR	O
patients	O
,	O
the	O
largest	O
number	O
of	O
patients	O
ever	O
reported	O
.	O

We	O
identified	O
61	O
different	O
heterozygous	O
RVs	O
(	O
50	O
novel	O
)	O
distributed	O
among	O
100	O
patients	O
(16.64%)	O
.	O

Those	O
include	O
14	O
silent	O
,	O
29	O
missense	O
,	O
5	O
nonsense	O
,	O
4	O
frame-shifts	O
,	O
and	O
one	O
in-frame	O
amino-acid	O
deletion	O
in	O
the	O
CDS	O
,	O
two	O
splice-site	O
deletions	O
,	O
4	O
nucleotide	O
substitutions	O
and	O
a	O
22-bp	O
deletion	O
in	O
the	O
intron/exon	O
boundaries	O
and	O
1	O
single-nucleotide	O
substitution	O
in	O
the	O
5'	O
untranslated	O
region	O
.	O

Exonic	O
variants	O
were	O
mainly	O
clustered	O
in	O
RET	O
the	O
extracellular	O
domain	O
.	O

RET	O
RVs	O
were	O
more	O
frequent	O
among	O
patients	O
with	O
the	O
most	O
severe	O
phenotype	O
(	O
24%	O
vs	O
.	O

15%	O
in	O
short-HSCR	O
)	O
.	O

Phasing	O
RVs	O
with	O
the	O
RET	O
HSCR-associated	O
haplotype	O
suggests	O
that	O
RVs	O
do	O
not	O
underlie	O
the	O
undisputable	O
association	O
of	O
RET	O
common	O
variants	O
with	O
HSCR	O
.	O

None	O
of	O
the	O
variants	O
were	O
found	O
in	O
250	O
Chinese	O
controls	O
.	O

A	O
deletion	O
of	O
FGFR2	O
creating	O
a	O
chimeric	O
IIIb/IIIc	O
exon	O
in	O
a	O
child	O
with	O
Apert	O
syndrome	O
.	O

BACKGROUND	O
:	O
Signalling	O
by	O
fibroblast	O
growth	O
factor	O
receptor	O
type	O
2	O
(FGFR2)	O
normally	O
involves	O
a	O
tissue-specific	O
alternative	O
splice	O
choice	O
between	O
two	O
exons	O
(	O
IIIb	O
and	O
IIIc	O
)	O
,	O
which	O
generates	O
two	O
receptor	O
isoforms	O
(	O
FGFR2b	O
and	O
FGFR2c	O
respectively	O
)	O
with	O
differing	O
repertoires	O
of	O
FGF-binding	O
specificity	O
.	O

Here	O
we	O
describe	O
a	O
unique	O
chimeric	O
IIIb/c	O
exon	O
in	O
a	O
patient	O
with	O
Apert	O
syndrome	O
,	O
generated	O
by	O
a	O
non-allelic	O
homologous	O
recombination	O
event	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
present	O
a	O
child	O
with	O
Apert	O
syndrome	O
in	O
whom	O
routine	O
genetic	O
testing	O
had	O
excluded	O
the	O
FGFR2	O
missense	O
mutations	O
commonly	O
associated	O
with	O
this	O
disorder	O
.	O

The	O
patient	O
was	O
found	O
to	O
harbour	O
a	O
heterozygous	O
1372	O
bp	O
deletion	O
between	O
FGFR2	O
exons	O
IIIb	O
and	O
IIIc	O
,	O
apparently	O
originating	O
from	O
recombination	O
between	O
13	O
bp	O
of	O
identical	O
DNA	O
sequence	O
present	O
in	O
both	O
exons	O
.	O

The	O
rearrangement	O
was	O
not	O
present	O
in	O
the	O
unaffected	O
parents	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
known	O
pathogenesis	O
of	O
Apert	O
syndrome	O
,	O
the	O
chimeric	O
FGFR2	O
protein	O
is	O
predicted	O
to	O
act	O
in	O
a	O
dominant	O
gain-of-function	O
manner	O
.	O

This	O
is	O
likely	O
to	O
result	O
from	O
its	O
expression	O
in	O
mesenchymal	O
tissues	O
,	O
where	O
retention	O
of	O
most	O
of	O
the	O
residues	O
essential	O
for	O
FGFR2b	O
binding	O
activity	O
would	O
result	O
in	O
autocrine	O
activation	O
.	O

This	O
report	O
adds	O
to	O
the	O
repertoire	O
of	O
rare	O
cases	O
of	O
Apert	O
syndrome	O
for	O
which	O
a	O
pathogenesis	O
based	O
on	O
atypical	O
FGFR2	O
rearrangements	O
can	O
be	O
demonstrated	O
.	O

Detection	O
of	O
a-thalassemia-1	O
Southeast	O
Asian	O
and	O
Thai	O
type	O
deletions	O
and	O
b-thalassemia	O
3.5-kb	O
deletion	O
by	O
single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
high-resolution	O
melting	O
analysis	O
.	O

BACKGROUND	O
:	O
Prevention	O
and	O
control	O
of	O
thalassemia	O
requires	O
simple	O
,	O
rapid	O
,	O
and	O
accurate	O
screening	O
tests	O
for	O
carrier	O
couples	O
who	O
are	O
at	O
risk	O
of	O
conceiving	O
fetuses	O
with	O
severe	O
thalassemia	O
.	O

METHODS	O
:	O
Single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
high-resolution	O
melting	O
(HRM)	O
analysis	O
were	O
used	O
for	O
the	O
identification	O
of	O
a-thalassemia-1	O
Southeast	O
Asian	O
(SEA)	O
and	O
Thai	O
type	O
deletions	O
and	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
obtained	O
using	O
conventional	O
gap-PCR	O
.	O

DNA	O
samples	O
were	O
derived	O
from	O
28	O
normal	O
individuals	O
,	O
11	O
individuals	O
with	O
a-thalassemia-1	O
SEA	O
type	O
deletion	O
,	O
2	O
with	O
a-thalassemia-1	O
Thai	O
type	O
deletion	O
,	O
and	O
2	O
with	O
heterozygous	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
.	O

RESULTS	O
:	O
HRM	O
analysis	O
indicated	O
that	O
the	O
amplified	O
fragments	O
from	O
a-thalassemia-1	O
SEA	O
type	O
deletion	O
,	O
a-thalassemia-1	O
Thai	O
type	O
deletion	O
,	O
b-thalassemia	O
3.5-kb	O
gene	O
deletion	O
,	O
and	O
the	O
wild-type	O
b-globin	O
gene	O
had	O
specific	O
peak	O
heights	O
at	O
mean	O
melting	O
temperature	O
(T(m))	O
values	O
of	O
86.89	O
	O
	O
,	O
85.66	O
	O
	O
,	O
77.24	O
	O
	O
,	O
and	O
74.92	O
	O
	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
using	O
single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
HRM	O
analysis	O
showed	O
100%	O
consistency	O
with	O
those	O
obtained	O
using	O
conventional	O
gap-PCR	O
.	O

CONCLUSIONS	O
:	O
Single-tube	O
multiplex	O
real-time	O
PCR	O
with	O
SYBR	O
Green1	O
and	O
HRM	O
analysis	O
is	O
a	O
potential	O
alternative	O
for	O
routine	O
clinical	O
screening	O
of	O
the	O
common	O
types	O
of	O
a-	O
and	O
b-thalassemia	O
large	O
gene	O
deletions	O
,	O
since	O
it	O
is	O
simple	O
,	O
cost-effective	O
,	O
and	O
highly	O
accurate	O
.	O

Xeroderma	O
pigmentosum	O
variant	O
:	O
complementary	O
molecular	O
approaches	O
to	O
detect	O
a	O
13	O
base	O
pair	O
deletion	O
in	O
the	O
DNA	O
polymerase	O
eta	O
gene	O
.	O

Deficiencies	O
of	O
DNA	O
polymerase	O
eta-an	O
enzyme	O
mediating	O
replication	O
past	O
UV-induced	O
DNA	O
damage-predispose	O
individuals	O
to	O
xeroderma	O
pigmentosum	O
variant	O
(XPV)	O
and	O
result	O
in	O
a	O
high	O
incidence	O
of	O
skin	O
cancers	O
.	O

We	O
designed	O
,	O
developed	O
and	O
assessed	O
several	O
complementary	O
molecular	O
approaches	O
to	O
detect	O
a	O
genetically	O
inherited	O
deletion	O
within	O
DNA	O
polymerase	O
eta	O
.	O

RNA	O
was	O
reverse	O
transcribed	O
from	O
XPV	O
fibroblasts	O
and	O
from	O
normal	O
human	O
cells	O
,	O
and	O
standard	O
polymerase	O
chain	O
reaction	O
(PCR)	O
was	O
conducted	O
on	O
the	O
cDNA	O
targeting	O
a	O
region	O
with	O
a	O
13	O
base	O
pair	O
deletion	O
within	O
the	O
polymerase	O
eta	O
gene	O
.	O

PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
and	O
cycle	O
DNA	O
sequencing	O
.	O

The	O
deletion	O
was	O
found	O
to	O
eliminate	O
a	O
BsrGI	O
restriction	O
site	O
and	O
affected	O
the	O
number	O
of	O
resultant	O
fragments	O
visualized	O
after	O
gel	O
electrophoresis	O
.	O

Cycle	O
sequencing	O
of	O
polymerase	O
eta-specific	O
amplicons	O
from	O
XPV	O
and	O
normal	O
cells	O
provided	O
a	O
second	O
approach	O
for	O
detecting	O
the	O
mutation	O
.	O

Additionally	O
,	O
the	O
use	O
of	O
a	O
fluorescent	O
nucleic	O
acid	O
dye-EvaGreen-in	O
real-time	O
PCR	O
and	O
melt	O
curve	O
analysis	O
distinguished	O
normal	O
and	O
XPV	O
patient-derived	O
amplicons	O
as	O
well	O
as	O
heteroduplexes	O
that	O
represent	O
heterozygotic	O
carriers	O
without	O
the	O
need	O
for	O
high	O
resolution	O
melt	O
analysis-compatible	O
software	O
.	O

Our	O
approaches	O
are	O
easily	O
adaptable	O
by	O
diagnostic	O
laboratories	O
that	O
screen	O
for	O
or	O
verify	O
genetically	O
inherited	O
disorders	O
and	O
identify	O
carriers	O
of	O
a	O
defective	O
gene	O
.	O

C10ORF97	O
is	O
a	O
novel	O
tumor-suppressor	O
gene	O
of	O
non-small-cell	O
lung	O
cancer	O
and	O
a	O
functional	O
variant	O
of	O
this	O
gene	O
increases	O
the	O
risk	O
of	O
non-small-cell	O
lung	O
cancer	O
.	O

In	O
an	O
earlier	O
study	O
we	O
showed	O
that	O
C10ORF97	O
(	O
chromosome-10	O
,	O
open	O
reading	O
frame-97	O
)	O
was	O
expressed	O
in	O
almost	O
all	O
of	O
the	O
tissues	O
and	O
cell	O
lines	O
tested	O
,	O
and	O
that	O
it	O
inhibited	O
the	O
growth	O
of	O
seven	O
tumor	O
cell	O
lines	O
,	O
including	O
two	O
lung	O
carcinoma	O
cell	O
lines	O
(	O
A549	O
and	O
PG	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
C10ORF97	O
is	O
downregulated	O
in	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
tissue	O
compared	O
with	O
normal	O
lung	O
tissue	O
.	O

Overexpression	O
of	O
C10ORF97	O
significantly	O
suppressed	O
human	O
lung	O
carcinoma	O
A549	O
cell	O
growth	O
(	O
proliferation	O
and	O
anchorage-independent	O
growth	O
in	O
soft	O
agar	O
)	O
and	O
motility	O
(	O
migration	O
and	O
adhesion	O
)	O
.	O

This	O
tumor-suppressive	O
function	O
of	O
C10ORF97	O
was	O
also	O
verified	O
in	O
vivo	O
.	O

We	O
further	O
found	O
that	O
C10ORF97	O
caused	O
G(1)	O
arrest	O
of	O
A549	O
cells	O
and	O
modulated	O
the	O
expression	O
level	O
of	O
several	O
cell-cycle	O
regulators	O
(	O
such	O
as	O
CDK2	O
,	O
cyclin-E	O
and	O
p27	O
)	O
.	O

These	O
effects	O
of	O
C10ORF97	O
were	O
mediated	O
by	O
physical	O
association	O
between	O
C10ORF97	O
and	O
Jun-activating	O
domain-binding	O
protein-1	O
(JAB1)	O
,	O
and	O
blocking	O
of	O
JAB1-mediated	O
translocation	O
of	O
p27	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

Together	O
,	O
these	O
results	O
indicated	O
that	O
C10ORF97	O
functions	O
as	O
a	O
novel	O
tumor	O
suppressor	O
by	O
modulating	O
several	O
key	O
G(1)/S-regulatory	O
proteins	O
by	O
interacting	O
with	O
JAB1	O
.	O

These	O
findings	O
led	O
us	O
to	O
hypothesize	O
that	O
a	O
single-nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
C10ORF97	O
gene	O
that	O
affects	O
its	O
expression	O
might	O
be	O
associated	O
with	O
susceptibility	O
to	O
NSCLC	O
.	O

SNP216	O
C>T	B-DNAMutation
rs2297882	B-SNP
in	O
the	O
C10ORF97	O
Kozak	O
sequence	O
was	O
identified	O
,	O
and	O
allele	O
T	O
of	O
SNP216	O
suppressed	O
C10ORF97	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
TT	O
genotype	O
of	O
SNP216	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
NSCLC	O
(	O
adjusted	O
odds	O
ratio=1.73	O
(	O
95%	O
confidence	O
interval	O
:	O
1.33-2.25	O
)	O
,	O
P=4.6	O
	O
	O
10(-5)	O
)	O
.	O

These	O
data	O
indicated	O
that	O
C10ORF97	O
is	O
a	O
tumor	O
suppressor	O
of	O
NSCLC	O
progression	O
and	O
C10ORF97-SNP216	O
may	O
serve	O
as	O
a	O
predictor	O
of	O
NSCLC	O
.	O

MHC	O
region	O
and	O
risk	O
of	O
systemic	O
lupus	O
erythematosus	O
in	O
African	O
American	O
women	O
.	O

The	O
major	O
histocompatibility	O
complex	O
(MHC)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
.	O

Although	O
SLE	O
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
,	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	O
region	O
in	O
relationship	O
to	O
SLE	O
in	O
African	O
Americans	O
.	O

We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	O
region	O
for	O
1,536	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	O
gene	O
in	O
a	O
SLE	O
case-control	O
study	O
(	O
380	O
cases	O
,	O
765	O
age-matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women's	O
Health	O
Study	O
.	O

We	O
also	O
genotyped	O
1,509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O

The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	O
was	O
the	O
rs9271366	B-SNP
(	O
odds	O
ratio	O
,	O
OR	O
=	O
1.70	O
,	O
p	O
=	O
5.6	O
	O
	O
10(-5)	O
)	O
near	O
the	O
HLA-DRB1	O
gene	O
.	O

Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
,	O
rs204890	B-SNP
(	O
OR	O
=	O
1.86	O
,	O
p	O
=	O
1.2	O
	O
	O
10(-4)	O
)	O
,	O
rs2071349	B-SNP
(	O
OR	O
=	O
1.53	O
,	O
p	O
=	O
1.0	O
	O
	O
10(-3)	O
)	O
,	O
and	O
rs2844580	B-SNP
(	O
OR	O
=	O
1.43	O
,	O
p	O
=	O
1.3	O
	O
	O
10(-3)	O
)	O
,	O
to	O
be	O
associated	O
with	O
SLE	O
independent	O
of	O
the	O
rs9271366	B-SNP
SNP	O
.	O

In	O
univariate	O
analysis	O
,	O
the	O
OR	O
for	O
the	O
C4A	O
deletion	O
was	O
1.38	O
,	O
p	O
=	O
0.075	O
,	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1.01	O
,	O
p	O
=	O
0.98	O
.	O

A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high-risk	O
alleles	O
(	O
OR	O
=	O
1.67	O
per	O
high-risk	O
allele	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Our	O
strongest	O
signal	O
,	O
the	O
rs9271366	B-SNP
SNP	O
,	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	O
in	O
a	O
previous	O
Chinese	O
genome-wide	O
association	O
study	O
(GWAS)	O
.	O

In	O
addition	O
,	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	O
were	O
confirmed	O
in	O
our	O
study	O
,	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	O
with	O
European	O
and	O
Chinese	O
subjects	O
.	O

In	O
summary	O
,	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	O
region	O
associated	O
with	O
risk	O
of	O
SLE	O
in	O
African	O
American	O
women	O
.	O

Molecular	O
and	O
clinical	O
analysis	O
of	O
glioblastoma	O
with	O
an	O
oligodendroglial	O
component	O
(GBMO)	O
.	O

The	O
genetic	O
and	O
clinical	O
features	O
of	O
glioblastoma	O
with	O
an	O
oligodendroglial	O
component	O
(GBMO)	O
,	O
pathologically	O
defined	O
as	O
anaplastic	O
oligo-astrocytoma	O
with	O
necrosis	O
,	O
remain	O
unclear	O
.	O

We	O
investigated	O
the	O
correlation	O
between	O
genetic	O
alterations	O
and	O
clinical	O
outcomes	O
in	O
19	O
GBMO	O
patients	O
we	O
have	O
encountered	O
since	O
1997	O
.	O

Using	O
single	O
nucleotide	O
polymorphism	O
oligonucleotide	O
genomic	O
(SNP)	O
microarrays	O
,	O
we	O
analyzed	O
gene	O
amplification	O
,	O
loss	O
of	O
heterozygosity	O
(LOH)	O
,	O
and	O
homozygous	O
deletions	O
in	O
their	O
whole	O
genome	O
.	O

We	O
also	O
analyzed	O
their	O
overall	O
survival	O
(OS)	O
.	O

Pathological	O
studies	O
revealed	O
the	O
presence	O
of	O
calcification	O
in	O
11	O
and	O
of	O
a	O
cyst	O
in	O
9	O
of	O
the	O
19	O
patients	O
.	O

Whole-genome	O
analysis	O
using	O
SNP	O
microarrays	O
revealed	O
LOH	O
of	O
chromosome	O
10	O
in	O
11	O
,	O
EGFR	O
amplification	O
in	O
8	O
,	O
9p21	O
(	O
INK4	O
locus	O
)	O
deletion	O
in	O
12	O
,	O
PDGFR	O
amplification	O
in	O
2	O
,	O
and	O
LOH	O
of	O
1p19q	O
in	O
2	O
patients	O
.	O

Median	O
OS	O
was	O
14	O
	O
months	O
(	O
average	O
22.8	O
	O
months	O
)	O
.	O

The	O
pattern	O
of	O
genetic	O
alterations	O
was	O
similar	O
in	O
GBMO	O
and	O
glioblastoma	O
multiforme	O
(GBM)	O
patients	O
,	O
and	O
the	O
clinical	O
outcomes	O
were	O
similar	O
in	O
GBMO	O
and	O
GBM	O
patients	O
.	O

Exploratory	O
investigation	O
on	O
functional	O
significance	O
of	O
ETS2	O
and	O
SIM2	O
genes	O
in	O
Down	O
syndrome	O
.	O

Trisomy	O
of	O
the	O
21{st}	O
chromosome	O
leads	O
to	O
an	O
over	O
dosage	O
of	O
several	O
regulatory	O
genes	O
in	O
Down	O
syndrome	O
(DS)	O
.	O

Though	O
allelic	O
and	O
genotypic	O
combinations	O
formed	O
between	O
genes	O
are	O
interesting	O
,	O
till	O
date	O
,	O
this	O
particular	O
area	O
has	O
never	O
been	O
explored	O
in	O
DS	O
.	O

In	O
the	O
present	O
investigation	O
four	O
SNPs	O
in	O
two	O
transcription	O
factors	O
,	O
Single	O
minded	O
2	O
(SIM2)	O
and	O
V-ets	O
erythroblastosis	O
virus	O
E26	O
oncogene	O
homolog2	O
(ETS2)	O
,	O
located	O
in	O
the	O
21{st}	O
chromosome	O
were	O
genotyped	O
to	O
understand	O
their	O
role	O
in	O
DS	O
.	O

Genomic	O
DNA	O
of	O
eastern	O
Indian	O
probands	O
with	O
DS	O
(N=132)	O
,	O
their	O
parents	O
(N=209)	O
and	O
ethnically	O
matched	O
controls	O
(N=149)	O
was	O
subjected	O
to	O
PCR-based	O
analyses	O
of	O
functionally	O
important	O
SNPs	O
followed	O
by	O
statistical	O
analyses	O
.	O

ETS2	O
rs461155	B-SNP
showed	O
high	O
heterozygosity	O
in	O
DS	O
.	O

Significantly	O
lower	O
frequency	O
of	O
SIM2	O
C-G	O
haplotype	O
rs2073601	B-SNP
-	O
rs2073416	B-SNP
was	O
noticed	O
in	O
individuals	O
with	O
DS	O
(	O
P	O
value	O
=0.01669	O
)	O
and	O
their	O
fathers	O
(	O
P	O
value=0.01185	O
)	O
.	O

Significantly	O
lower	O
frequency	O
of	O
the	O
A-C-C-G	O
with	O
higher	O
frequency	O
of	O
A-C-A-G	O
haplotypes	O
was	O
also	O
noticed	O
in	O
subjects	O
with	O
DS	O
(	O
P	O
value	O
=0.02089	O
and	O
0.00588	O
respectively	O
)	O
.	O

Data	O
obtained	O
indicate	O
that	O
the	O
rs2073601	B-SNP
'A'	O
allele	O
,	O
responsible	O
for	O
nonsynonymous	O
substitution	O
of	O
leucine	O
to	O
methionine	O
,	O
may	O
have	O
some	O
role	O
in	O
DS	O
in	O
this	O
population	O
.	O

APOE	O
genotype-function	O
relationship	O
:	O
evidence	O
of	O
-491	B-DNAMutation
A/T	I-DNAMutation
promoter	O
polymorphism	O
modifying	O
transcription	O
control	O
but	O
not	O
type	O
2	O
diabetes	O
risk	O
.	O

BACKGROUND	O
:	O
The	O
apolipoprotein	O
E	O
gene	O
(APOE)	O
coding	O
polymorphism	O
modifies	O
the	O
risks	O
of	O
Alzheimer's	O
disease	O
,	O
type	O
2	O
diabetes	O
,	O
and	O
coronary	O
heart	O
disease	O
.	O

Aside	O
from	O
the	O
coding	O
variants	O
,	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
of	O
the	O
APOE	O
promoter	O
has	O
also	O
been	O
shown	O
to	O
modify	O
the	O
risk	O
of	O
Alzheimer's	O
disease	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
In	O
this	O
study	O
we	O
investigate	O
the	O
genotype-function	O
relationship	O
of	O
APOE	O
promoter	O
polymorphism	O
at	O
molecular	O
level	O
and	O
at	O
physiological	O
level	O
:	O
i.e.	O
,	O
in	O
transcription	O
control	O
of	O
the	O
gene	O
and	O
in	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

In	O
molecular	O
studies	O
,	O
the	O
effect	O
of	O
the	O
APOE	O
-491A/T	B-DNAMutation
rs449647	B-SNP
polymorphism	O
on	O
gene	O
transcription	O
was	O
accessed	O
by	O
dual-luciferase	O
reporter	O
gene	O
assays	O
.	O

The	O
-491	B-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
substitution	O
decreased	O
the	O
activity	O
(p<0.05)	O
of	O
the	O
cloned	O
APOE	O
promoter	O
(	O
-1017	O
to	O
+406	O
)	O
.	O

Using	O
the	O
-501	O
to	O
-481	O
nucleotide	O
sequence	O
of	O
the	O
APOE	O
promoter	O
as	O
a	O
'bait'	O
to	O
screen	O
the	O
human	O
brain	O
cDNA	O
library	O
by	O
yeast	O
one-hybrid	O
system	O
yielded	O
ATF4	O
,	O
an	O
endoplasmic	O
reticulum	O
stress	O
response	O
gene	O
,	O
as	O
one	O
of	O
the	O
interacting	O
factors	O
.	O

Electrophoretic-mobility-shift	O
assays	O
(EMSA)	O
and	O
chromatin	O
immuno-precipitation	O
(ChIP)	O
analyses	O
further	O
substantiated	O
the	O
physical	O
interaction	O
between	O
ATF4	O
and	O
the	O
APOE	O
promoter	O
.	O

Over-expression	O
of	O
ATF4	O
stimulated	O
APOE	O
expression	O
whereas	O
siRNA	O
against	O
ATF4	O
suppressed	O
the	O
expression	O
of	O
the	O
gene	O
.	O

However	O
,	O
interaction	O
between	O
APOE	O
promoter	O
and	O
ATF4	O
was	O
not	O
-491A/T-specific	B-DNAMutation
.	O

At	O
physiological	O
level	O
,	O
the	O
genotype-function	O
relationship	O
of	O
APOE	O
promoter	O
polymorphism	O
was	O
studied	O
in	O
type	O
2	O
diabetes	O
.	O

In	O
630	O
cases	O
and	O
595	O
controls	O
,	O
three	O
APOE	O
promoter	O
SNPs	O
-491A/T	B-DNAMutation
,	O
-219G/T	B-DNAMutation
rs405509	B-SNP
,	O
and	O
+113G/C	B-DNAMutation
rs440446	B-SNP
were	O
genotyped	O
and	O
tested	O
for	O
association	O
with	O
type	O
2	O
diabetes	O
in	O
Hong	O
Kong	O
Chinese	O
.	O

No	O
SNP	O
or	O
haplotype	O
association	O
with	O
type	O
2	O
diabetes	O
was	O
detected	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
At	O
molecular	O
level	O
,	O
polymorphism	O
-491A/T	B-DNAMutation
and	O
ATF4	O
elicit	O
independent	O
control	O
of	O
APOE	O
gene	O
expression	O
.	O

At	O
physiological	O
level	O
,	O
no	O
genotype-risk	O
association	O
was	O
detected	O
between	O
the	O
studied	O
APOE	O
promoter	O
SNPs	O
and	O
type	O
2	O
diabetes	O
in	O
Hong	O
Kong	O
Chinese	O
.	O

Resequencing	O
of	O
IRS2	O
reveals	O
rare	O
variants	O
for	O
obesity	O
but	O
not	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

Our	O
objective	O
was	O
to	O
resequence	O
insulin	O
receptor	O
substrate	O
2	O
(IRS2)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity-	O
and	O
diabetes-related	O
traits	O
in	O
Hispanic	O
children	O
.	O

Exonic	O
and	O
intronic	O
segments	O
,	O
5'	O
and	O
3'	O
flanking	O
regions	O
of	O
IRS2	O
(	O
	O
	O
14.5	O
kb	O
)	O
,	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O

Additionally	O
,	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1-Quad	O
BeadChips	O
were	O
analyzed	O
.	O

Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	O
and	O
diabetes-related	O
traits	O
.	O

Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O

A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(MAF)	O
ranging	O
from	O
0.001	O
to	O
0.47	O
.	O

Forty-two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
;	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
,	O
12	O
in	O
introns	O
,	O
28	O
in	O
the	O
3'-UTR	O
,	O
and	O
2	O
in	O
the	O
5'-UTR	O
.	O

Two	O
insertion/deletions	O
(indels)	O
were	O
detected	O
.	O

Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0.001-0.009	O
)	O
were	O
associated	O
with	O
obesity-related	O
traits	O
(	O
P	O
=	O
0.01-0.00002	O
)	O
.	O

SNP	O
10510452_139	O
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0.77-0.86	O
)	O
of	O
influencing	O
BMI	O
,	O
fat	O
mass	O
,	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O

SNP	O
10510452_139	O
contributed	O
between	O
2	O
and	O
4%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O

None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes-related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	O
.	O

Rare	O
but	O
not	O
common	O
IRS2	O
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	O
homeostasis	O
in	O
Hispanic	O
children	O
.	O

A	O
large	O
heterozygous	O
deletion	O
including	O
the	O
entire	O
C1	O
inhibitor	O
gene	O
in	O
a	O
sporadic	O
case	O
of	O
hereditary	O
angio-oedema	O
.	O

C1	O
inhibitor	O
(C1-INH)	O
deficiency	O
[	O
hereditary	O
or	O
acquired	O
angio-oedema	O
(	O
HAE	O
or	O
AAE)	O
]	O
is	O
characterized	O
by	O
recurring	O
episodes	O
of	O
subcutaneous	O
or	O
submucosal	O
oedema	O
.	O

Many	O
different	O
mutations	O
in	O
the	O
C1-INH	O
gene	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
HAE	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
in	O
a	O
Japanese	O
woman	O
with	O
sporadic	O
HAE	O
.	O

Direct	O
sequencing	O
of	O
genomic	O
DNA	O
revealed	O
no	O
point	O
mutation	O
in	O
the	O
C1-INH	O
gene	O
.	O

Quantitative	O
real-time	O
PCR	O
showed	O
that	O
the	O
copy	O
number	O
of	O
the	O
C1-INH	O
gene	O
in	O
the	O
patient	O
was	O
half	O
that	O
of	O
a	O
healthy	O
control	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
650-kbp	O
deletion	O
on	O
the	O
chromosome	O
,	O
which	O
included	O
the	O
C1-INH	O
gene	O
.	O

We	O
evaluated	O
the	O
correlation	O
between	O
the	O
patient's	O
attacks	O
and	O
her	O
coagulation	O
activity	O
.	O

The	O
levels	O
of	O
D-dimer	O
were	O
high	O
during	O
the	O
angio-oedema	O
attacks	O
,	O
and	O
often	O
exceeded	O
the	O
normal	O
range	O
even	O
during	O
remission	O
,	O
thus	O
the	O
level	O
of	O
D-dimer	O
reflected	O
the	O
activity	O
of	O
HAE	O
in	O
this	O
patient	O
.	O

Phenotype	O
of	O
the	O
202	O
adenine	O
deletion	O
in	O
the	O
parkin	O
gene	O
:	O
40	O
years	O
of	O
follow-up	O
.	O

BACKGROUND	O
:	O
We	O
describe	O
the	O
four	O
decades	O
follow-up	O
of	O
14	O
parkin	O
patients	O
belonging	O
to	O
two	O
large	O
eight-generation-long	O
in-bred	O
Muslim-Arab	O
kindreds	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
a	O
single	O
base-pair	O
of	O
adenine	O
deletion	O
at	O
nucleotide	O
202	O
of	O
exon	O
2	O
(202A)	O
of	O
the	O
parkin	O
gene	O
(	O
all	O
homozygous	O
,	O
one	O
heterozygous	O
)	O
.	O

Parkinson's	O
disease	O
onset	O
age	O
was	O
17-68	O
years	O
.	O

Special	O
features	O
were	O
intractable	O
axial	O
symptoms	O
(	O
low	O
back	O
pain	O
,	O
scoliosis	O
,	O
camptocormia	O
,	O
antecollis	O
)	O
,	O
postural	O
tremor	O
,	O
and	O
preserved	O
cognition	O
.	O

CONCLUSIONS	O
:	O
The	O
202A	O
deletion	O
of	O
the	O
parkin	O
gene	O
causes	O
early-onset	O
Parkinson's	O
disease	O
with	O
marked	O
levodopa/STN-DBS-resistant	O
axial	O
features	O
.	O

Postural	O
tremor	O
and	O
preserved	O
cognition	O
,	O
even	O
after	O
40	O
years	O
of	O
disease	O
,	O
were	O
also	O
evident	O
.	O

Two	O
novel	O
mutations	O
of	O
the	O
PAX6	O
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
.	O

PURPOSE	O
:	O
Aniridia	O
(AN)	O
is	O
a	O
rare	O
congenital	O
panocular	O
disorder	O
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	O
box	O
homeotic	O
gene	O
6(PAX6)	O
gene	O
.	O

The	O
PAX6gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	O
segment	O
malformations	O
including	O
Peters	O
anomaly	O
.	O

We	O
studied	O
the	O
PAX6gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroid	O
,	O
or	O
anterior	O
segment	O
malformations	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	O
were	O
examined	O
clinically	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O

Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR-amplified	O
DNA	O
fragments	O
.	O

Multiplex	O
ligation-dependent	O
probe	O
amplification	O
(MLPA)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O

RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	O
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	O
,	O
coloboma	O
of	O
iris	O
and	O
choroids	O
,	O
and	O
the	O
anterior	O
segment	O
malformations	O
including	O
peters	O
anomaly	O
.	O

Sequencing	O
of	O
the	O
PAX6gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing-site	O
mutations	O
c.357-3C>G	B-DNAMutation
p.Ser119fsX	B-ProteinMutation
were	O
identified	O
in	O
the	O
patients	O
of	O
the	O
AN	O
group	O
.	O

A	O
novel	O
missense	O
mutation	O
c.643T>C	B-DNAMutation
p.S216P	B-ProteinMutation
was	O
detected	O
in	O
the	O
anterior	O
segment	O
malformation	O
group	O
.	O

The	O
mutation	O
p.S216P	B-ProteinMutation
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	O
caused	O
the	O
phenotype	O
of	O
Peters	O
anomaly	O
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O

Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6gene	O
and	O
DKFZ	O
p686k1684gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	O
from	O
the	O
AN	O
group	O
.	O

Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	O
of	O
iris	O
and	O
choroid	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6gene	O
.	O

Screening	O
and	O
cell-based	O
assessment	O
of	O
mutations	O
in	O
the	O
Aristaless-related	O
homeobox	O
(ARX)	O
gene	O
.	O

ARX	O
mutations	O
cause	O
a	O
diverse	O
spectrum	O
of	O
human	O
disorders	O
,	O
ranging	O
from	O
severe	O
brain	O
and	O
genital	O
malformations	O
to	O
non-syndromic	O
intellectual	O
disability	O
(ID)	O
.	O

ARX	O
is	O
a	O
transcription	O
factor	O
with	O
multiple	O
domains	O
that	O
include	O
four	O
polyalanine	O
(pA)	O
tracts	O
,	O
the	O
first	O
two	O
of	O
which	O
are	O
frequently	O
expanded	O
by	O
mutations	O
.	O

We	O
progressively	O
screened	O
DNA	O
samples	O
from	O
613	O
individuals	O
with	O
ID	O
initially	O
for	O
the	O
most	O
frequent	O
ARX	O
mutations	O
(	O
c.304ins(GCG)(7)'expansion'	B-DNAMutation
of	O
pA1	O
and	O
c.429_452dup	B-DNAMutation
'dup24bp'	B-DNAMutation
of	O
pA2	O
)	O
.	O

Five	O
hundred	O
samples	O
without	O
pA1	O
or	O
pA2	O
mutations	O
had	O
the	O
entire	O
ARX	O
ORF	O
screened	O
by	O
single	O
stranded	O
polymorphism	O
conformation	O
(SSCP)	O
and/or	O
denaturing	O
high	O
pressure	O
liquid	O
chromatography	O
(dHPLC)	O
analysis	O
.	O

Overall	O
,	O
eight	O
families	O
with	O
six	O
mutations	O
in	O
ARX	O
were	O
identified	O
(1.31%)	O
:	O
five	O
duplication	O
mutations	O
in	O
pA2	O
(0.82%)	O
with	O
three	O
new	O
clinical	O
reports	O
of	O
families	O
with	O
the	O
dup24bp	B-DNAMutation
and	O
two	O
duplications	O
larger	O
than	O
the	O
dup24bp	B-DNAMutation
mutation	O
discovered	O
(	O
dup27bp	B-DNAMutation
,	O
dup33bp	B-DNAMutation
)	O
;	O
and	O
three	O
point	O
mutations	O
(0.6%)	O
,	O
including	O
one	O
novel	O
mutation	O
in	O
the	O
homeodomain	O
c.1074G>T	B-DNAMutation
.	O

Four	O
ultraconserved	O
regions	O
distal	O
to	O
ARX	O
(uc466-469)	O
were	O
also	O
screened	O
in	O
a	O
subset	O
of	O
94	O
patients	O
,	O
with	O
three	O
unique	O
nucleotide	O
changes	O
identified	O
in	O
two	O
(	O
uc466	O
,	O
uc467	O
)	O
.	O

The	O
subcellular	O
localization	O
of	O
full	O
length	O
ARX	O
proteins	O
was	O
assessed	O
for	O
11	O
variants	O
.	O

Protein	O
mislocalization	O
increased	O
as	O
a	O
function	O
of	O
pA2	O
tract	O
length	O
and	O
phenotypic	O
severity	O
,	O
as	O
has	O
been	O
previously	O
suggested	O
for	O
pA1	O
.	O

Similarly	O
,	O
protein	O
mislocalization	O
of	O
the	O
homeodomain	O
mutations	O
also	O
correlated	O
with	O
clinical	O
severity	O
,	O
suggesting	O
an	O
emerging	O
genotype	O
vs	O
cellular	O
phenotype	O
correlation	O
.	O

Variation	O
in	O
genotype	O
and	O
higher	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
causing	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

Sporotrichosis	O
is	O
usually	O
a	O
localized	O
,	O
lymphocutaneous	O
disease	O
,	O
but	O
its	O
disseminated	O
type	O
was	O
rarely	O
reported	O
.	O

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
specific	O
DNA	O
sequence	O
variation	O
and	O
virulence	O
of	O
a	O
strain	O
of	O
Sporothrix	O
schenckii	O
isolated	O
from	O
the	O
lesion	O
of	O
disseminated	O
cutaneous	O
sporotrichosis	O
.	O

We	O
confirmed	O
this	O
strain	O
to	O
be	O
S	O
.	O

schenckii	O
by(	O
	O
)	O
tubulin	O
and	O
chitin	O
synthase	O
gene	O
sequence	O
analysis	O
in	O
addition	O
to	O
the	O
routine	O
mycological	O
and	O
partial	O
ITS	O
and	O
NTS	O
sequencing	O
.	O

We	O
found	O
a	O
10-bp	O
deletion	O
in	O
the	O
ribosomal	O
NTS	O
region	O
of	O
this	O
strain	O
,	O
in	O
reference	O
to	O
the	O
sequence	O
of	O
control	O
strains	O
isolated	O
from	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

After	O
inoculated	O
into	O
immunosuppressed	O
mice	O
,	O
this	O
strain	O
caused	O
more	O
extensive	O
system	O
involvement	O
and	O
showed	O
stronger	O
virulence	O
than	O
the	O
control	O
strain	O
isolated	O
from	O
a	O
fixed	O
cutaneous	O
sporotrichosis	O
.	O

Our	O
study	O
thus	O
suggests	O
that	O
different	O
clinical	O
manifestation	O
of	O
sporotrichosis	O
may	O
be	O
associated	O
with	O
variation	O
in	O
genotype	O
and	O
virulence	O
of	O
the	O
strain	O
,	O
independent	O
of	O
effects	O
due	O
to	O
the	O
immune	O
status	O
of	O
the	O
host	O
.	O

Identification	O
of	O
a	O
novel	O
FBN1	O
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin-1	O
gene	O
(FBN1)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	O
syndrome	O
(MFS)	O
.	O

METHODS	O
:	O
Patients	O
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	O
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4.0.1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
c.3703T>C	B-DNAMutation
change	O
in	O
exon	O
29	O
of	O
FBN1	O
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	O
by	O
proline	O
at	O
codon	O
1235	O
p.S1235P	B-ProteinMutation
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	O
binding	O
epidermal	O
growth	O
factor-like#15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
p.S1235P	B-ProteinMutation
mutation	O
in	O
FBN1	O
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	O
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	O
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	O
syndrome	O
.	O

The	O
57	O
kb	O
deletion	O
in	O
cystinosis	O
patients	O
extends	O
into	O
TRPV1	O
causing	O
dysregulation	O
of	O
transcription	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

BACKGROUND	O
:	O
Cystinosis	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterised	O
by	O
the	O
abnormal	O
accumulation	O
of	O
lysosomal	O
cystine	O
.	O

Mutations	O
in	O
the	O
cystinosin	O
gene	O
(CTNS)	O
represent	O
known	O
causes	O
for	O
the	O
disease	O
.	O

The	O
major	O
cystinosis	O
mutation	O
is	O
a	O
57	O
kb	O
deletion	O
on	O
human	O
chromosome	O
17p13	O
that	O
removes	O
the	O
majority	O
of	O
CTNS	O
and	O
the	O
entire	O
adjacent	O
gene	O
,	O
CARKL/SHPK	O
.	O

OBJECTIVES	O
:	O
In	O
order	O
to	O
identify	O
other	O
genes	O
that	O
may	O
influence	O
the	O
cystinosis	O
pathobiological	O
pathway	O
,	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMC)	O
were	O
collected	O
from	O
cystinosis	O
family	O
members	O
,	O
and	O
DNA	O
and	O
RNA	O
extracted	O
.	O

RESULTS	O
:	O
Using	O
whole	O
genome	O
transcriptional	O
profiling	O
,	O
transient	O
receptor	O
potential	O
vanilloid	O
1	O
(TRPV1)	O
was	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
association	O
with	O
cystinosis	O
.	O

This	O
was	O
verified	O
using	O
TaqMan	O
qRT-PCR	O
.	O

There	O
was	O
a	O
72%	O
reduction	O
in	O
PBMC	O
TRPV1	O
mRNA	O
levels	O
in	O
cystinosis	O
individuals	O
homozygous	O
for	O
the	O
57	O
kb	O
deletion	O
(n=6)	O
compared	O
to	O
unaffected	O
individuals	O
without	O
the	O
deletion	O
(n=6)	O
(p=0.002)	O
.	O

TRPV1	O
is	O
a	O
sensory	O
receptor	O
located	O
on	O
chromosome	O
17p13	O
,	O
adjacent	O
to	O
CARKL/SHPK	O
.	O

It	O
was	O
ascertained	O
that	O
the	O
57	O
kb	O
deletion	O
extends	O
from	O
exon	O
10	O
of	O
CTNS	O
,	O
upstream	O
through	O
CARKL/SHPK	O
,	O
to	O
intron	O
2	O
of	O
TRPV1	O
,	O
thus	O
deleting	O
the	O
first	O
two	O
non-coding	O
exons	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
57	O
kb	O
deletion	O
extends	O
into	O
the	O
TRPV1	O
gene	O
causing	O
dysregulation	O
of	O
transcription	O
in	O
PBMC	O
isolated	O
from	O
cystinosis	O
patients	O
.	O

Strong	O
association	O
of	O
677	B-DNAMutation
C>T	I-DNAMutation
substitution	O
in	O
the	O
MTHFR	O
gene	O
with	O
male	O
infertility--a	O
study	O
on	O
an	O
indian	O
population	O
and	O
a	O
meta-analysis	O
.	O

BACKGROUND	O
:	O
Methylenetetrahydrofolate	O
reductase	O
(MTHFR)	O
is	O
an	O
important	O
enzyme	O
of	O
folate	O
and	O
methionine	O
metabolism	O
,	O
making	O
it	O
crucial	O
for	O
DNA	O
synthesis	O
and	O
methylation	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
MTHFR	O
gene	O
677C>T	B-DNAMutation
polymorphism	O
in	O
infertile	O
male	O
individuals	O
from	O
North	O
India	O
,	O
followed	O
by	O
a	O
meta-analysis	O
on	O
our	O
data	O
and	O
published	O
studies	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
:	O
We	O
undertook	O
genotyping	O
on	O
a	O
total	O
of	O
837	O
individuals	O
including	O
well	O
characterized	O
infertile	O
(N=522)	O
and	O
confirmed	O
fertile	O
(N=315)	O
individuals	O
.	O

The	O
SNP	O
was	O
typed	O
by	O
direct	O
DNA	O
sequencing	O
.	O

Chi	O
square	O
test	O
was	O
done	O
for	O
statistical	O
analysis	O
.	O

Published	O
studies	O
were	O
searched	O
using	O
appropriate	O
keywords	O
.	O

Source	O
of	O
data	O
collection	O
for	O
meta-analysis	O
included	O
'Pubmed'	O
,	O
'Ovid'	O
and	O
'Google	O
Scholar'	O
.	O

Those	O
studies	O
analyzing	O
677C>T	B-DNAMutation
polymorphism	O
in	O
male	O
infertility	O
and	O
presenting	O
all	O
relevant	O
data	O
were	O
included	O
in	O
meta-analysis	O
.	O

The	O
genotype	O
data	O
for	O
infertile	O
subjects	O
and	O
fertile	O
controls	O
was	O
extracted	O
from	O
each	O
study	O
.	O

Chi	O
square	O
test	O
was	O
done	O
to	O
obtain	O
odds	O
ratio	O
(OR)	O
and	O
p-value	O
.	O

Meta-analysis	O
was	O
performed	O
using	O
Comprehensive	O
Meta-analysis	O
software	O
(	O
Version	O
2	O
)	O
.	O

The	O
frequency	O
of	O
mutant	O
(T)	O
allele	O
(p=0.0025)	O
and	O
genotypes	O
(CT+TT)	O
(p=0.0187)	O
was	O
significantly	O
higher	O
in	O
infertile	O
individuals	O
in	O
comparison	O
to	O
fertile	O
controls	O
in	O
our	O
case-control	O
study	O
.	O

The	O
overall	O
summary	O
estimate	O
(OR)	O
for	O
allele	O
and	O
genotype	O
meta-analysis	O
were	O
1.304	O
(p=0.000)	O
,	O
1.310	O
(p=0.000)	O
,	O
respectively	O
,	O
establishing	O
significant	O
association	O
of	O
677C>T	B-DNAMutation
polymorphism	O
with	O
male	O
infertility	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
:	O
677C>T	B-DNAMutation
substitution	O
associated	O
strongly	O
with	O
male	O
infertility	O
in	O
Indian	O
population	O
.	O

Allele	O
and	O
genotype	O
meta-analysis	O
also	O
supported	O
its	O
strong	O
correlation	O
with	O
male	O
infertility	O
,	O
thus	O
establishing	O
it	O
as	O
a	O
risk	O
factor	O
.	O

Angiotensin-converting	O
enzyme	O
(ACE)	O
serum	O
levels	O
and	O
gene	O
polymorphism	O
in	O
Egyptian	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
polymorphism	O
and	O
serum	O
ACE	O
level	O
among	O
Egyptian	O
SLE	O
patients	O
and	O
its	O
relation	O
to	O
disease	O
activity	O
parameters	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
We	O
enrolled	O
50	O
Egyptian	O
female	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
patients	O
and	O
29	O
healthy	O
controls	O
.	O

Measurement	O
of	O
serum	O
ACE	O
level	O
was	O
done	O
using	O
ELISA	O
,	O
and	O
the	O
ACE	O
genotype	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
using	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
.	O

RESULTS	O
:	O
A	O
significant	O
difference	O
was	O
found	O
in	O
ACE	O
genotypes	O
between	O
SLE	O
patients	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
7.84	O
,	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

The	O
frequency	O
of	O
ACE	O
DD	O
versus	O
(	O
DI	O
and	O
II	O
)	O
genotypes	O
was	O
significantly	O
higher	O
in	O
SLE	O
patients	O
compared	O
with	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
5.57	O
,	O
p	O
=	O
0.018	O
and	O
OR	O
for	O
risk	O
of	O
SLE	O
was	O
3.1	O
with	O
95%	O
confidence	O
interval	O
:	O
1.198.06	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
SLE	O
group	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.006	O
)	O
.	O

Subjects	O
with	O
DD	O
genotype	O
had	O
a	O
significantly	O
higher	O
mean	O
level	O
than	O
those	O
with	O
DI	O
(	O
p	O
	O
	O
=	O
	O
	O
0.015	O
)	O
and	O
II	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Lupus	O
nephritis	O
patients	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI	O
and	O
II	O
genotypes	O
compared	O
with	O
lupus	O
patients	O
without	O
nephritis	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.025	O
)	O
and	O
controls	O
(	O
	O
	O
(2)	O
=8.74	O
,	O
p	O
	O
	O
=	O
	O
	O
0.003	O
)	O
.	O

SLE	O
patients	O
with	O
vasculopathy	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
DD	O
versus	O
DI/II	O
genotypes	O
compared	O
with	O
SLE	O
patients	O
without	O
vasculopathy	O
(	O
Fisher's	O
exact	O
test	O
,	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
and	O
controls	O
(	O
	O
(	O
2	O
	O
	O
)=	O
	O
	O
9.84	O
and	O
p	O
	O
	O
=	O
	O
	O
0.002	O
)	O
.	O

Mean	O
serum	O
ACE	O
level	O
was	O
significantly	O
higher	O
in	O
the	O
lupus	O
nephritis	O
and	O
SLE	O
patients	O
with	O
vasculopathy	O
compared	O
with	O
controls	O
(	O
p	O
	O
	O
=	O
	O
	O
0.008	O
,	O
p	O
	O
	O
=	O
	O
	O
0.001	O
,	O
respectively	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
found	O
between	O
serum	O
ACE	O
level	O
and	O
serum	O
creatinine	O
and	O
24	O
	O
	O
h	O
proteinuria	O
(	O
p	O
	O
	O
=	O
	O
	O
0.03	O
,	O
0.009	O
,	O
respectively	O
)	O
.	O

SLE	O
patients	O
with	O
DD	O
genotype	O
had	O
a	O
statistically	O
significant	O
higher	O
mean	O
SLEDAI	O
score	O
than	O
those	O
with	O
(DI/II)	O
genotypes	O
(	O
p	O
	O
	O
=	O
	O
	O
0.02	O
)	O
.	O

Significant	O
positive	O
correlation	O
was	O
found	O
between	O
serum	O
ACE	O
levels	O
and	O
SLEDAI	O
scores	O
(	O
p	O
	O
	O
=	O
	O
	O
0.04	O
)	O
.	O

CONCLUSION	O
:	O
ACE	O
genotype	O
and	O
subsequently	O
serum	O
ACE	O
level	O
could	O
be	O
associated	O
with	O
the	O
disease	O
activity	O
of	O
Egyptian	O
SLE	O
patients	O
;	O
in	O
addition	O
,	O
ACE	O
deletion	O
polymorphism	O
might	O
be	O
used	O
as	O
one	O
of	O
the	O
predictive	O
factors	O
for	O
the	O
activity	O
of	O
SLE	O
.	O

Further	O
studies	O
on	O
a	O
larger	O
number	O
of	O
patients	O
should	O
be	O
done	O
to	O
determine	O
the	O
exact	O
prevalence	O
of	O
ACE	O
gene	O
polymorphism	O
among	O
Egyptian	O
SLE	O
patients	O
.	O

Genotype	O
rs8099917	B-SNP
near	O
the	O
IL28B	O
gene	O
and	O
amino	O
acid	O
substitution	O
at	O
position	O
70	O
in	O
the	O
core	O
region	O
of	O
the	O
hepatitis	O
C	O
virus	O
are	O
determinants	O
of	O
serum	O
apolipoprotein	O
B-100	O
concentration	O
in	O
chronic	O
hepatitis	O
C	O
.	O

The	O
life	O
cycle	O
of	O
the	O
hepatitis	O
C	O
virus	O
(HCV)	O
is	O
closely	O
related	O
to	O
host	O
lipoprotein	O
metabolism	O
.	O

Serum	O
levels	O
of	O
lipid	O
are	O
associated	O
with	O
the	O
response	O
to	O
pegylated	O
interferon	O
plus	O
ribavirin	O
(PEG-IFN/RBV)	O
therapy	O
,	O
while	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
around	O
the	O
human	O
interleukin	O
28B	O
(IL28B)	O
gene	O
locus	O
and	O
amino	O
acid	O
substitutions	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
have	O
been	O
reported	O
to	O
affect	O
the	O
efficacy	O
of	O
PEG-IFN/RBV	O
therapy	O
in	O
chronic	O
hepatitis	O
with	O
HCV	O
genotype	O
1b	O
infection	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
relationship	O
between	O
serum	O
lipid	O
and	O
factors	O
that	O
are	O
able	O
to	O
predict	O
the	O
efficacy	O
of	O
PEG-IFN/RB	O
therapy	O
,	O
with	O
specific	O
focus	O
on	O
apolipoprotein	O
B-100	O
(apoB-100)	O
in	O
148	O
subjects	O
with	O
chronic	O
HCV	O
G1b	O
infection	O
.	O

Our	O
results	O
demonstrated	O
that	O
both	O
the	O
aa	O
70	O
substitution	O
in	O
the	O
core	O
region	O
of	O
the	O
HCV	O
and	O
the	O
rs8099917	B-SNP
SNP	O
located	O
proximal	O
to	O
the	O
IL28B	O
were	O
independent	O
factors	O
in	O
determining	O
serum	O
apoB-100	O
and	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	O
levels	O
.	O

A	O
significant	O
association	O
was	O
noted	O
between	O
higher	O
levels	O
of	O
apoB-100	O
(	O
P	O
=	O
1.1	O
	O
	O
10(-3)	O
)	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
0.02	O
)	O
and	O
the	O
subjects	O
having	O
Arg70	O
.	O

A	O
significant	O
association	O
was	O
also	O
observed	O
between	O
subjects	O
carrying	O
the	O
rs8099917	B-SNP
TT	O
responder	O
genotype	O
and	O
higher	O
levels	O
of	O
apoB-100	O
(	O
P	O
=	O
6.4	O
	O
	O
10(-3)	O
)	O
and	O
LDL	O
cholesterol	O
(	O
P	O
=	O
4.2	O
	O
	O
10(-3)	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
apoB-100	O
and	O
LDL	O
cholesterol	O
are	O
markers	O
of	O
impaired	O
cellular	O
lipoprotein	O
pathways	O
and/or	O
host	O
endogenous	O
interferon	O
response	O
to	O
HCV	O
in	O
chronic	O
HCV	O
infection	O
.	O

In	O
particular	O
,	O
serum	O
apoB-100	O
concentration	O
might	O
be	O
an	O
informative	O
marker	O
for	O
judging	O
changes	O
in	O
HCV-associated	O
intracellular	O
lipoprotein	O
metabolism	O
in	O
patients	O
carrying	O
the	O
rs8099917	B-SNP
responder	O
genotype	O
.	O

SLURP1	O
mutation-impaired	O
T-cell	O
activation	O
in	O
a	O
family	O
with	O
mal	O
de	O
Meleda	O
.	O

BACKGROUND	O
:	O
Mal	O
de	O
Meleda	O
(MDM)	O
is	O
palmoplantar	O
erythrokeratoderma	O
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP-1	O
(	O
lymphocyte	O
antigen	O
6/urokinase-type	O
plasminogen	O
activator	O
receptor	O
related	O
protein-1	O
)	O
.	O

SLURP-1	O
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
(nAchR)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O

In	O
addition	O
,	O
murine	O
studies	O
have	O
shown	O
that	O
nAchR	O
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T-cell	O
function	O
.	O

Among	O
the	O
family	O
members	O
,	O
patients	O
with	O
the	O
homozygous	O
SLURP1	O
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	O
and	O
viral	O
infection	O
,	O
which	O
might	O
link	O
to	O
defective	O
T-cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	O
gene	O
mutation	O
with	O
T-cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	O
.	O

To	O
test	O
that	O
SLURP-1	O
is	O
essential	O
for	O
T-cell	O
activation	O
.	O

METHODS	O
:	O
Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	O
family	O
bearing	O
the	O
G	O
to	O
A	O
substitution	O
in	O
nucleotide	O
256	O
in	O
the	O
SLURP1	O
gene	O
,	O
corresponding	O
to	O
a	O
glycine	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
86	O
G86R	B-ProteinMutation
in	O
the	O
SLURP-1	O
protein	O
.	O

PBMCs	O
from	O
homozygotes	O
and	O
wild-type	O
controls	O
were	O
stimulated	O
with	O
anti-CD3/anti-CD28	O
antibodies	O
and	O
the	O
level	O
of	O
T-cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O

RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP-1	O
G86R	B-ProteinMutation
mutation	O
had	O
defective	O
T-cell	O
activation	O
.	O

This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
	O
5	O
ug	O
mL(-1)	O
recombinant	O
human	O
SLURP-1	O
protein	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
MDM	O
with	O
the	O
homozygous	O
SLURP-1	O
G86R	B-ProteinMutation
mutation	O
may	O
have	O
an	O
impaired	O
T-cell	O
activation	O
.	O

The	O
presence	O
of	O
wild-type	O
SLURP-1	O
is	O
essential	O
for	O
normal	O
T-cell	O
activation	O
.	O

Interstitial	O
deletion	O
of	O
13q14.13-q32.3	O
presenting	O
with	O
Arima	O
syndrome	O
and	O
bilateral	O
retinoblastoma	O
.	O

A	O
patient	O
with	O
a	O
large	O
deletion	O
of	O
the	O
distal	O
part	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
13	O
showed	O
severe	O
psychomotor	O
retardation	O
,	O
a	O
characteristic	O
face	O
,	O
nystagmus	O
,	O
retinopathy	O
,	O
cystic	O
kidney	O
disease	O
,	O
and	O
brain	O
malformation	O
with	O
molar	O
tooth	O
sign	O
and	O
cerebellar	O
vermis	O
hypoplasia	O
,	O
a	O
phenotype	O
typical	O
of	O
Arima	O
syndrome	O
.	O

This	O
patient	O
also	O
had	O
bilateral	O
retinoblastoma	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
and	O
single-nucleotide-polymorphism	O
genotyping	O
microarray	O
demonstrated	O
an	O
interstitial	O
deletion	O
of	O
54	O
Mbp	O
,	O
ranging	O
from	O
13q14.13	O
to	O
13q32.3	O
and	O
involving	O
the	O
RB1	O
gene	O
.	O

This	O
patient	O
is	O
the	O
first	O
case	O
of	O
Arima	O
syndrome	O
,	O
or	O
a	O
Joubert	O
syndrome-related	O
disorder	O
,	O
that	O
showed	O
linkage	O
to	O
chromosome	O
13q	O
.	O

Impact	O
of	O
5,10-methylenetetrahydrofolate	O
reductase	O
gene	O
polymorphism	O
on	O
neural	O
tube	O
defects	O
.	O

OBJECT	O
:	O
Neural	O
tube	O
defects	O
(NTDs)	O
are	O
among	O
the	O
most	O
common	O
congenital	O
malformations	O
worldwide	O
.	O

Their	O
etiology	O
and	O
exact	O
mechanisms	O
of	O
development	O
are	O
incompletely	O
understood	O
.	O

Many	O
enzymes	O
involved	O
in	O
folate	O
metabolism	O
and	O
the	O
genes	O
encoding	O
these	O
enzymes	O
have	O
been	O
studied	O
as	O
candidates	O
in	O
their	O
etiology	O
.	O

A	O
mutation	O
in	O
the	O
methylenetetrahydrofolate	O
reductase	O
(MTHFR)	O
gene--a	O
C-->T	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
677--is	I-DNAMutation
one	O
among	O
them	O
.	O

The	O
mutation	O
results	O
in	O
substitution	O
of	O
alanine	O
by	O
valine	O
at	O
a	O
functionally	O
important	O
site	O
in	O
the	O
enzyme	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
a	O
risk	O
factor	O
for	O
development	O
of	O
NTDs	O
in	O
certain	O
populations	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
role	O
of	O
MTHFR	O
677	B-DNAMutation
C-->T	I-DNAMutation
mutation	O
as	O
a	O
risk	O
factor	O
for	O
NTD	O
in	O
the	O
South	O
Indian	O
population	O
and	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
the	O
genotypes	O
in	O
the	O
affected	O
child	O
and	O
its	O
mother	O
.	O

METHODS	O
:	O
Blood	O
samples	O
were	O
collected	O
from	O
the	O
test	O
and	O
the	O
control	O
groups	O
.	O

The	O
test	O
group	O
consisted	O
of	O
children	O
with	O
NTDs	O
and	O
their	O
mothers	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
apparently	O
healthy	O
controls	O
.	O

MTHFR	O
C677T	B-DNAMutation
polymorphism	O
in	O
the	O
3	O
groups	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
studies	O
.	O

Comparison	O
of	O
polymorphism	O
in	O
the	O
3	O
groups	O
was	O
using	O
the	O
chi-square	O
test	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
prevalence	O
of	O
MTHFR	O
677	B-DNAMutation
C-->T	I-DNAMutation
mutation	O
among	O
the	O
3	O
groups	O
(	O
p	O
=	O
0.002	O
)	O
.	O

The	O
risk	O
conferred	O
by	O
the	O
TT	O
genotype	O
in	O
the	O
child	O
was	O
statistically	O
significant	O
(	O
OR	O
12.625	O
,	O
95%	O
CI	O
1.430-111.465	O
)	O
.	O

In	O
the	O
mothers	O
,	O
however	O
,	O
although	O
there	O
was	O
an	O
increased	O
prevalence	O
of	O
the	O
mutation	O
compared	O
with	O
the	O
control	O
individuals	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.152	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
MTHFR	O
677TT	O
genotype	O
is	O
considered	O
to	O
be	O
a	O
definite	O
risk	O
factor	O
for	O
development	O
of	O
NTDs	O
.	O

It	O
is	O
the	O
TT	O
genotype	O
status	O
of	O
the	O
developing	O
embryo	O
,	O
rather	O
than	O
the	O
TT	O
genotype	O
status	O
of	O
its	O
mother	O
,	O
that	O
is	O
the	O
critical	O
genetic	O
determinant	O
of	O
MTHFR-related	O
NTD	O
risk	O
.	O

Bikunin	O
and	O
a1-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
mutational	O
screening	O
in	O
patients	O
with	O
kidney	O
stones	O
:	O
a	O
case-control	O
study	O
.	O

OBJECTIVE	O
:	O
Bikunin	O
is	O
an	O
inhibitor	O
of	O
kidney	O
stone	O
formation	O
synthesized	O
in	O
the	O
liver	O
together	O
with	O
a(1)-microglobulin	O
from	O
the	O
a(1)-microglobulin/bikunin	O
precursor	O
(AMBP)	O
gene	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
bikunin/AMBP	O
gene	O
polymorphisms	O
and	O
urinary	O
stone	O
formation	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
To	O
analyse	O
the	O
DNA	O
,	O
blood	O
samples	O
were	O
taken	O
from	O
75	O
kidney	O
stone	O
formers	O
who	O
had	O
a	O
familial	O
stone	O
history	O
,	O
35	O
sporadic	O
stone	O
formers	O
and	O
101	O
healthy	O
individuals	O
.	O

Four	O
exons	O
of	O
bikunin	O
gene	O
and	O
five	O
parts	O
of	O
the	O
promoter	O
region	O
of	O
the	O
AMBP	O
gene	O
were	O
screened	O
using	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
The	O
Init-2	O
region	O
of	O
the	O
promoter	O
of	O
AMBP	O
gene	O
had	O
polymorphisms	O
at	O
positions	O
-218	O
and	O
-189	O
nt	O
giving	O
three	O
different	O
genotypes	O
having	O
1,3	O
,	O
2,4	O
and	O
1,2,3,4	O
alleles	O
with	O
frequencies	O
of	O
17.06%	O
,	O
60.19%	O
and	O
22.75%	O
,	O
respectively	O
,	O
in	O
all	O
groups	O
.	O

Therefore	O
,	O
the	O
Init-2	O
region	O
appears	O
to	O
be	O
polymorphic	O
.	O

As	O
a	O
result	O
,	O
the	O
1,3	O
allele	O
has	O
-218G	O
and	O
-189T	O
complying	O
with	O
the	O
reference	O
database	O
sequence	O
,	O
the	O
2,4	O
allele	O
has	O
-218G	O
and	O
T-189C	B-DNAMutation
substitution	O
and	O
the	O
allele	O
1,2,3,4	O
genotype	O
has	O
substitutions	O
at	O
positions	O
G-218C	B-DNAMutation
and	O
T-189C	B-DNAMutation
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
allele	O
distribution	O
between	O
patients	O
and	O
controls	O
.	O

These	O
common	O
alleles	O
exist	O
in	O
the	O
Turkish	O
population	O
independent	O
of	O
stone	O
formation	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
existence	O
of	O
bikunin	O
and	O
AMBP	O
promoter	O
polymorphism	O
.	O

Although	O
the	O
Init-2	O
region	O
of	O
the	O
AMBP	O
gene	O
is	O
the	O
binding	O
site	O
for	O
various	O
transcription	O
factors	O
,	O
the	O
results	O
showed	O
no	O
association	O
between	O
these	O
observed	O
genotypes	O
and	O
stone-forming	O
phenotypes	O
.	O

Novel	O
CRELD1	O
gene	O
mutations	O
in	O
patients	O
with	O
atrioventricular	O
septal	O
defect	O
.	O

BACKGROUND	O
:	O
Atrioventricular	O
septal	O
defects	O
(AVSDs)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
,	O
as	O
autosomal	O
dominant	O
defects	O
,	O
and	O
as	O
sporadically	O
occurring	O
malformations	O
.	O

Consequently	O
,	O
there	O
is	O
genetic	O
heterogeneity	O
,	O
but	O
until	O
recently	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	O
.	O

CRELD1	O
gene	O
,	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	O
.	O

METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	O
with	O
AVSD	O
and	O
200	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O

CRELD1	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
with	O
specific	O
primers	O
.	O

The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	O
and	O
controls	O
.	O

RESULTS	O
:	O
In	O
a	O
patient	O
,	O
a	O
C-to-G	O
transition	O
was	O
identified	O
at	O
nucleotide	O
857	O
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	O
for	O
proline	O
at	O
amino	O
acid	O
286	O
in	O
the	O
first	O
calcium-binding	O
EGF	O
domain	O
.	O

This	O
patient	O
had	O
an	O
isolated	O
partial	O
AVSD	O
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O

Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	O
with	O
a	O
partial	O
AVSD	O
and	O
evidence	O
of	O
Down	O
syndrome	O
.	O

The	O
heterozygous	O
c.973G>A	B-DNAMutation
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	O
for	O
glutamic	O
acid	O
at	O
amino	O
acid	O
325	O
E325K	B-ProteinMutation
in	O
the	O
second	O
calcium-binding	O
EGF	O
domain	O
.	O

CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	O
mutations	O
were	O
identified	O
in	O
the	O
calcium-binding	O
EGF	O
domain	O
in	O
patients	O
with	O
AVSD	O
.	O

CRELD1	O
is	O
likely	O
to	O
be	O
an	O
AVSD-susceptibility	O
gene	O
and	O
CRELD1	O
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	O
defect	O
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O

Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2/CYP11B1	O
locus	O
and	O
postoperative	O
hypertension	O
risk	O
in	O
the	O
patients	O
with	O
aldosterone-producing	O
adenomas	O
.	O

OBJECTIVES	O
:	O
Hypertension	O
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O

Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	O
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	O
synthesis	O
genes	O
(	O
CYP11B2	O
,	O
CYP11B1	O
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
for	O
aldosterone-producing	O
adenomas	O
(APA)	O
.	O

METHODS	O
:	O
Ninety-three	O
patients	O
with	O
APA	O
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	O
.	O

All	O
patients	O
were	O
genotyped	O
for	O
rs1799998	B-SNP
(	O
C-344	B-DNAMutation
T	I-DNAMutation
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	B-SNP
A2718G	B-DNAMutation
within	O
CYP11B2	O
and	O
rs6410	B-SNP
(	O
G22	B-DNAMutation
5A	I-DNAMutation
)	O
,	O
rs6387	B-SNP
A2803G	B-DNAMutation
within	O
CYP11B1	O
.	O

The	O
associations	O
between	O
CYPB11B2/CYP11B1	O
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	O
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O
CYP11B2-CYP11B1	O
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
with	O
APA	O
(	O
P	O
=	O
.006	O
)	O
.	O

Specifically	O
,	O
the	O
rs4539	B-SNP
(AA)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.002	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(AGACT)	O
,	O
H2	O
(AGAWT)	O
,	O
and	O
H3	O
(AGAWC)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	O
(	O
P	O
=	O
.01	O
,	O
0.03	O
,	O
0.005	O
after	O
Bonferroni	O
correction	O
)	O
.	O

Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	O
included	O
duration	O
of	O
hypertension	O
(	O
P	O
<.0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	O
(	O
P	O
=	O
.001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.015	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rs4539	B-SNP
(AA)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	O
for	O
Chinese	O
patients	O
treated	O
by	O
adrenalectomy	O
with	O
APA	O
.	O

DNA	O
polymorphisms	O
at	O
CYP11B2/B1	O
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	O
of	O
patients	O
with	O
APA	O
.	O

The	O
GALT	O
rush	O
:	O
high	O
carrier	O
frequency	O
of	O
an	O
unusual	O
deletion	O
mutation	O
of	O
the	O
GALT	O
gene	O
in	O
the	O
Ashkenazi	O
population	O
.	O

Classic	O
galactosemia	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
galactose	O
metabolism	O
manifesting	O
in	O
the	O
first	O
weeks	O
of	O
life	O
following	O
exposure	O
to	O
a	O
milk-based	O
diet	O
.	O

Despite	O
the	O
benefit	O
of	O
avoidance	O
of	O
lactose	O
,	O
many	O
patients	O
suffer	O
from	O
long-term	O
complications	O
including	O
neurological	O
deficits	O
and	O
ovarian	O
failure	O
.	O

To	O
date	O
,	O
over	O
230	O
mutations	O
have	O
been	O
described	O
in	O
the	O
GALT	O
gene	O
resulting	O
in	O
galactosemia	O
.	O

Recently	O
,	O
an	O
unusual	O
mutation	O
was	O
characterized	O
causing	O
a	O
5.5	O
kb	O
deletion	O
,	O
with	O
a	O
relatively	O
high	O
carrier	O
rate	O
in	O
subjects	O
of	O
Ashkenazi	O
Jewish	O
(AJ)	O
descent	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
carrier	O
frequency	O
of	O
this	O
mutation	O
in	O
the	O
AJ	O
population	O
in	O
Israel	O
.	O

For	O
this	O
purpose	O
we	O
developed	O
a	O
high-throughput	O
methodology	O
to	O
genotype	O
both	O
normal	O
and	O
deleted	O
alleles	O
using	O
a	O
chip-based	O
matrix-assisted	O
laser	O
desorption-time-of-flight	O
(MALDI-TOF)	O
mass	O
spectrometer	O
and	O
Multiplex	O
PCR	O
.	O

DNA	O
samples	O
of	O
760	O
anonymous	O
AJ	O
subjects	O
were	O
submitted	O
for	O
analysis	O
,	O
subsequently	O
detecting	O
six	O
individuals	O
heterozygous	O
for	O
the	O
GALT	O
deletion	O
mutation	O
,	O
giving	O
a	O
carrier	O
frequency	O
of	O
1	O
in	O
127	O
(0.79%)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
provides	O
a	O
basis	O
for	O
genetic	O
screening	O
and	O
prenatal	O
counseling	O
and	O
can	O
potentially	O
reduce	O
the	O
morbidity	O
and	O
mortality	O
associated	O
with	O
delayed	O
diagnosis	O
of	O
galactosemia	O
in	O
this	O
patient	O
population	O
.	O

Characterisation	O
of	O
two	O
novel	O
large	O
F8	O
deletions	O
in	O
patients	O
with	O
severe	O
haemophilia	O
A	O
and	O
factor	O
VIII	O
inhibitors	O
.	O

Large	O
deletions	O
are	O
found	O
in	O
approximately	O
5%	O
of	O
patients	O
with	O
severe	O
haemophilia	O
A	O
,	O
but	O
only	O
a	O
few	O
deletion	O
breakpoints	O
have	O
been	O
characterised	O
precisely	O
so	O
far	O
.	O

In	O
this	O
study	O
we	O
characterised	O
the	O
deletion	O
breakpoints	O
of	O
two	O
patients	O
with	O
severe	O
haemophilia	O
A	O
,	O
large	O
deletions	O
and	O
factor	O
VIII	O
(FVIII)	O
inhibitors	O
,	O
and	O
subsequently	O
established	O
deletion-specific	O
assays	O
for	O
the	O
identification	O
of	O
carriers	O
.	O

Patient	O
1	O
had	O
a	O
deletion	O
of	O
37,410	O
bp	O
comprising	O
exon	O
1	O
and	O
the	O
F8	O
promoter	O
region	O
,	O
and	O
a	O
5	O
bp	O
homology	O
(GGGCC)	O
is	O
present	O
at	O
the	O
chromosomal	O
fusion	O
site	O
.	O

In	O
patient	O
2	O
,	O
a	O
deletion	O
of	O
22,230	O
bp	O
including	O
parts	O
of	O
intron	O
25	O
,	O
exon	O
26	O
and	O
3'-UTR	O
was	O
identified	O
.	O

No	O
homologous	O
repetitive	O
elements	O
were	O
found	O
at	O
the	O
breakpoints	O
.	O

However	O
,	O
both	O
breakpoints	O
were	O
located	O
within	O
long	O
terminal	O
repeats	O
of	O
endogenous	O
retroviruses	O
and	O
the	O
DNA	O
motif	O
TTTAAA	O
-	O
known	O
to	O
be	O
able	O
to	O
bend	O
DNA	O
molecules	O
-	O
was	O
identified	O
at	O
the	O
centromeric	O
breakpoint	O
.	O

By	O
deletion-specific	O
PCR	O
experiments	O
we	O
were	O
able	O
to	O
identify	O
a	O
heterozygous	O
state	O
in	O
mother	O
2	O
(carrier)	O
while	O
mother	O
1	O
presented	O
only	O
with	O
wild-type	O
alleles	O
(non-carrier)	O
.	O

Both	O
deletions	O
are	O
most	O
likely	O
created	O
by	O
DNA	O
double	O
strand	O
breaks	O
and	O
subsequent	O
DNA	O
repair	O
by	O
the	O
non-homologous	O
end	O
joining	O
DNA	O
repair	O
pathway	O
(NHEJ)	O
.	O

The	O
exact	O
identification	O
of	O
the	O
deletion	O
breakpoints	O
provides	O
a	O
reliable	O
diagnostic	O
tool	O
for	O
carrier	O
identification	O
in	O
affected	O
families	O
by	O
means	O
of	O
a	O
deletion-specific	O
PCR	O
.	O

Lack	O
of	O
association	O
of	O
C-C	O
chemokine	O
receptor	O
5	O
/\32	O
deletion	O
status	O
with	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
lupus	O
nephritis	O
,	O
and	O
disease	O
severity	O
.	O

OBJECTIVE	O
:	O
C-C	O
chemokine	O
receptor	O
5	O
(CCR5)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
.	O

A	O
32	O
base-pair	O
(/\32)	O
deletion	O
in	O
the	O
CCR5	O
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O

This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	O
diseases	O
.	O

We	O
investigated	O
whether	O
the	O
/\32	O
deletion	O
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(RA)	O
,	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
,	O
and	O
lupus	O
nephritis	O
(LN)	O
;	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	O
patients	O
,	O
97	O
SLE	O
patients	O
,	O
113	O
LN	O
patients	O
,	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	O
/\32	O
deletion	O
.	O

Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	O
and	O
controls	O
.	O

Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy-Weinberg	O
equilibrium	O
.	O

The	O
genotype	O
frequencies	O
of	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5//\32	O
,	O
/\32//\32	O
:	O
RA	O
18.3%	O
and	O
1.2%	O
,	O
respectively	O
;	O
SLE	O
17.5%	O
and	O
2.1%	O
;	O
LN	O
13.3%	O
and	O
1.8%	O
;	O
controls	O
20.0%	O
and	O
2.8%	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
for	O
lower	O
/\32	O
deletion	O
allele	O
frequency	O
in	O
LN	O
patients	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0.08	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	O
status	O
and	O
disease	O
severity	O
in	O
RA	O
,	O
SLE	O
,	O
or	O
LN	O
.	O

CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	O
cannot	O
be	O
excluded	O
,	O
the	O
CCR5	O
/\32	O
deletion	O
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	O
,	O
SLE	O
,	O
or	O
LN	O
.	O

No	O
significant	O
effect	O
of	O
the	O
/\32	O
deletion	O
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O

A	O
novel	O
mutation	O
in	O
GJA8	O
causing	O
congenital	O
cataract-microcornea	O
syndrome	O
in	O
a	O
Chinese	O
pedigree	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
underlying	O
genetic	O
defect	O
in	O
a	O
four-generation	O
family	O
of	O
Chinese	O
origin	O
with	O
autosomal	O
dominant	O
congenital	O
cataract-microcornea	O
syndrome	O
(CCMC)	O
.	O

METHODS	O
:	O
All	O
individuals	O
in	O
the	O
study	O
underwent	O
a	O
full	O
clinical	O
examination	O
and	O
the	O
details	O
of	O
history	O
were	O
collected	O
.	O

Genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
and	O
the	O
exons	O
of	O
all	O
candidate	O
genes	O
were	O
sequenced	O
.	O

RESULTS	O
:	O
Direct	O
sequencing	O
of	O
the	O
encoding	O
regions	O
of	O
the	O
candidate	O
genes	O
revealed	O
a	O
heterozygous	O
mutation	O
c.592C-->T	B-DNAMutation
in	O
exon	O
2	O
of	O
the	O
gap	O
junction	O
protein	O
,	O
alpha	O
8	O
(GJA8)	O
gene	O
.	O

This	O
mutation	O
was	O
responsible	O
for	O
the	O
familial	O
disorder	O
through	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
arginine	O
to	O
tryptophan	O
at	O
codon	O
198	O
p.R198W	B-ProteinMutation
.	O

This	O
change	O
co-segregated	O
with	O
all	O
affected	O
members	O
of	O
the	O
family	O
,	O
but	O
was	O
not	O
detected	O
either	O
in	O
the	O
non-carrier	O
relatives	O
or	O
in	O
the	O
100	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
is	O
the	O
first	O
to	O
relate	O
p.R198W	B-ProteinMutation
mutation	O
in	O
GJA8	O
with	O
CCMC	O
.	O

The	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
GJA8	O
in	O
associated	O
with	O
congenital	O
cataract	O
and	O
microcornea	O
,	O
and	O
implies	O
that	O
this	O
gene	O
has	O
direct	O
involvement	O
with	O
the	O
development	O
of	O
the	O
lens	O
as	O
well	O
as	O
the	O
other	O
anterior	O
segment	O
of	O
the	O
eye	O
.	O

Alpha2B-adrenergic	O
receptor	O
insertion/deletion	O
polymorphism	O
in	O
women	O
with	O
spontaneous	O
recurrent	O
abortions	O
.	O

AIM	O
:	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
alpha2B-adrenoreceptor	O
insertion/deletion	O
(I/D)	O
polymorphism	O
and	O
recurrent	O
spontaneous	O
abortions	O
(RSA)	O
.	O

METHODS	O
:	O
Genotyping	O
was	O
performed	O
in	O
48	O
women	O
with	O
a	O
history	O
of	O
at	O
least	O
three	O
consecutive	O
spontaneous	O
abortions	O
and	O
96	O
women	O
with	O
at	O
least	O
two	O
live	O
births	O
and	O
no	O
history	O
of	O
pregnancy	O
loss	O
.	O

Peripheral	O
venous	O
puncture	O
,	O
DNA	O
extraction	O
and	O
PCR	O
were	O
used	O
for	O
the	O
research	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotype	O
characters	O
.	O

RESULTS	O
:	O
The	O
distribution	O
of	O
DD	O
,	O
ID	O
and	O
II	O
genotypes	O
of	O
the	O
alpha2B-adrenoreceptor	O
gene	O
was	O
2	O
(4.2%)	O
,	O
19	O
(39.6%)	O
and	O
27	O
(56.2%)	O
in	O
the	O
study	O
group	O
and	O
6	O
(6.5%)	O
,	O
28	O
(30.4%)	O
and	O
58	O
(63%)	O
in	O
the	O
control	O
group	O
,	O
respectively	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
.	O

The	O
presence	O
of	O
the	O
D	O
allele	O
was	O
not	O
associated	O
with	O
RSA	O
(	O
P	O
=	O
0.78	O
,	O
odds	O
ratio	O
=	O
0.88	O
,	O
95%	O
CI	O
=	O
0.47-1.65	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
fall	O
short	O
of	O
showing	O
any	O
association	O
between	O
the	O
presence	O
of	O
the	O
alpha2B	O
D	O
allele	O
and	O
the	O
occurrence	O
of	O
spontaneous	O
abortions	O
in	O
the	O
examined	O
population	O
.	O

Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O

Approximately	O
30%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(PTCs)	O
,	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O

However	O
,	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O

Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(indel)	O
of	O
three	O
nucleotides	O
.	O

We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	O
fibrosis	O
patients	O
homozygous	O
for	O
the	O
E831X	B-ProteinMutation
mutation	O
2623G>T	B-DNAMutation
in	O
the	O
CFTR	O
gene	O
.	O

Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
,	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O

Structure-function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
,	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease-causing	O
UAG	O
stop	O
codon	O
.	O

This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O

This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O

Lack	O
of	O
association	O
between	O
ADRA2B-4825	O
gene	O
insertion/deletion	O
polymorphism	O
and	O
migraine	O
in	O
Chinese	O
Han	O
population	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	O
and	O
the	O
12-nucleotide	O
insertion/deletion	O
(indel)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha(2B)-adrenergic	O
receptor	O
gene	O
(ADRA2B)	O
.	O

METHODS	O
:	O
A	O
case-control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	O
and	O
517	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O

Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	O
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	O
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	O
indel	O
polymorphism	O
at	O
position	O
-4825	O
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	O
subjects	O
.	O

Two	O
novel	O
mutations	O
of	O
the	O
TSH-beta	O
subunit	O
gene	O
underlying	O
congenital	O
central	O
hypothyroidism	O
undetectable	O
in	O
neonatal	O
TSH	O
screening	O
.	O

CONTEXT	O
:	O
Patients	O
with	O
TSH-beta	O
subunit	O
defects	O
and	O
congenital	O
hypothyroidism	O
are	O
missed	O
by	O
TSH-based	O
neonatal	O
screening	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
report	O
the	O
molecular	O
consequences	O
of	O
a	O
novel	O
splice-junction	O
mutation	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
TSH-beta	O
subunit	O
gene	O
found	O
in	O
two	O
patients	O
with	O
congenital	O
central	O
hypothyroidism	O
and	O
conventional	O
treatment-resistant	O
anemia	O
.	O

RESULTS	O
:	O
Patient	O
1	O
had	O
a	O
homozygous	O
G	O
to	O
A	O
nucleotide	O
change	O
at	O
the	O
5'	O
donor	O
splice	O
site	O
of	O
exon/intron	O
2	O
.	O

This	O
resulted	O
in	O
a	O
silent	O
change	O
at	O
codon	O
34	O
of	O
the	O
mature	O
protein	O
.	O

In	O
vitro	O
splicing	O
assays	O
showed	O
that	O
the	O
mutant	O
minigene	O
dramatically	O
affected	O
pre-mRNA	O
processing	O
,	O
causing	O
exon	O
2	O
to	O
be	O
completely	O
skipped	O
.	O

The	O
putative	O
product	O
from	O
a	O
new	O
out-of-frame	O
translational	O
start	O
point	O
in	O
exon	O
3	O
is	O
expected	O
to	O
yield	O
a	O
nonsense	O
25-amino-acid	O
peptide	O
.	O

In	O
patient	O
2	O
,	O
sequence	O
analysis	O
revealed	O
a	O
compound	O
heterozygosis	O
for	O
the	O
already	O
reported	O
313delT	B-DNAMutation
C105Vfs114X	B-ProteinMutation
mutation	O
and	O
for	O
a	O
second	O
novel	O
mutation	O
in	O
exon	O
3	O
,	O
substituting	O
G	O
for	O
A	O
at	O
cDNA	O
nucleotide	O
position	O
323	O
,	O
resulting	O
in	O
a	O
C88Y	B-ProteinMutation
change	O
.	O

This	O
cysteine	O
residue	O
is	O
conserved	O
among	O
all	O
dimeric	O
pituitary	O
and	O
placental	O
glycoprotein	O
hormone-beta	O
subunits	O
.	O

Data	O
from	O
in	O
silico	O
analysis	O
confirmed	O
that	O
the	O
C88Y	B-ProteinMutation
mutation	O
would	O
affect	O
subunit	O
conformation	O
.	O

Indeed	O
,	O
two	O
different	O
bioinformatics	O
approaches	O
,	O
PolyPhen	O
and	O
SIFT	O
analysis	O
,	O
predicted	O
C88Y	B-ProteinMutation
to	O
be	O
a	O
damaging	O
substitution	O
.	O

CONCLUSIONS	O
:	O
In	O
isolated	O
TSH	O
deficiency	O
,	O
the	O
exact	O
molecular	O
diagnosis	O
is	O
mandatory	O
for	O
diagnosis	O
of	O
isolated	O
pituitary	O
deficiency	O
,	O
delineation	O
of	O
prognosis	O
,	O
and	O
genetic	O
counseling	O
.	O

Moreover	O
,	O
diagnosis	O
of	O
central	O
hypothyroidism	O
should	O
be	O
considered	O
in	O
the	O
face	O
of	O
severe	O
infant	O
anemia	O
of	O
uncertain	O
etiology	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
CD18	O
causing	O
leukocyte	O
adhesion	O
deficiency	O
in	O
a	O
Chinese	O
patient	O
.	O

BACKGROUND	O
:	O
Leukocyte	O
adhesion	O
deficiency	O
type	O
1	O
(LAD-1)	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
inherited	O
immunodeficiency	O
disease	O
characterized	O
by	O
recurrent	O
severe	O
bacterial	O
infection	O
,	O
impaired	O
pus	O
formation	O
,	O
poor	O
wound	O
healing	O
,	O
associated	O
with	O
the	O
mutation	O
in	O
the	O
CD18	O
gene	O
responsible	O
for	O
the	O
ability	O
of	O
the	O
leucocytes	O
to	O
migrate	O
from	O
the	O
blood	O
stream	O
towards	O
the	O
site	O
of	O
inflammation	O
.	O

Correct	O
and	O
early	O
diagnosis	O
of	O
LAD-1	O
is	O
vital	O
to	O
the	O
success	O
of	O
treatment	O
and	O
prevention	O
of	O
aggressive	O
infections	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
collect	O
the	O
clinical	O
findings	O
of	O
the	O
disease	O
and	O
to	O
identify	O
the	O
genetic	O
entity	O
.	O

METHODS	O
:	O
CD18	O
expression	O
in	O
the	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
his	O
parents	O
and	O
normal	O
control	O
was	O
measured	O
with	O
flow	O
cytometry	O
.	O

The	O
entire	O
coding	O
regions	O
of	O
the	O
CD18	O
gene	O
were	O
screened	O
with	O
direct	O
sequencing	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
CD18	O
expression	O
level	O
on	O
this	O
patient's	O
leukocyte	O
surface	O
was	O
significantly	O
decreased	O
,	O
with	O
normal	O
level	O
in	O
control	O
group	O
,	O
his	O
father	O
and	O
mother	O
.	O

Gene	O
analysis	O
revealed	O
that	O
this	O
patient	O
had	O
a	O
homozygous	O
c.899A	B-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
missense	O
mutation	O
in	O
exon	O
8	O
of	O
CD18	O
gene	O
,	O
causing	O
the	O
substitution	O
of	O
Asp	O
to	O
Val	O
at	O
the	O
300	O
amino	O
acid	O
.	O

His	O
parents	O
were	O
both	O
heterozygous	O
carriers	O
while	O
no	O
such	O
mutation	O
was	O
found	O
in	O
50	O
normal	O
controls	O
.	O

CONCLUSION	O
:	O
This	O
study	O
disclosed	O
a	O
novel	O
point	O
mutation	O
Asp	B-ProteinMutation
300	I-ProteinMutation
Val	I-ProteinMutation
located	O
in	O
a	O
highly	O
conserved	O
region	O
(HCR)	O
of	O
CD18	O
and	O
confirmed	O
the	O
heterogeneity	O
of	O
the	O
mutations	O
causing	O
LAD-1	O
,	O
indicating	O
it	O
was	O
quite	O
beneficial	O
to	O
establish	O
correct	O
and	O
early	O
diagnosis	O
in	O
children	O
with	O
severe	O
LAD-1	O
.	O

Association	O
study	O
of	O
complement	O
factor	O
H	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
and	O
age-related	O
macular	O
degeneration	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	O
factor	O
H	O
(CFH)	O
,	O
C2/BF	O
,	O
and	O
C3	O
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age-related	O
macular	O
degeneration	O
(AMD)	O
.	O

Genetic	O
variants	O
,	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
in	O
these	O
genes	O
were	O
geno-typed	O
for	O
a	O
case-control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty-eight	O
patients	O
with	O
wet	O
AMD	O
,	O
80	O
patients	O
with	O
soft	O
drusen	O
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O

Seven	O
SNPs	O
in	O
CFH	O
and	O
two	O
SNPs	O
in	O
C2	O
,	O
CFB'	O
,	O
and	O
C3	O
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O

A	O
deletion	O
of	O
84,682	O
base	O
pairs	O
covering	O
the	O
CFHR1	O
and	O
CFHR3	O
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	B-SNP
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-SNP
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-SNP
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-SNP
(	O
P	O
=	O
0.0089	O
)	O
,	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(CATA)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	O
with	O
a	O
P	O
value	O
of	O
0.0005	O
and	O
an	O
odds	O
ratio	O
of	O
0.29	O
(	O
95%	O
confidence	O
interval	O
:	O
0.15-0.60	O
)	O
.	O

Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	B-SNP
and	O
rs1410996	B-SNP
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	O
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O

None	O
of	O
the	O
SNPs	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
drusen	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	O
,	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	O
or	O
drusen	O
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

The	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	O
or	O
drusen	O
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	B-SNP
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-SNP
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-SNP
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-SNP
(	O
P	O
=	O
0.0089	O
)	O
,	O
but	O
not	O
rs7535263	B-SNP
,	O
rs1410996	B-SNP
,	O
or	O
rs2274700	B-SNP
,	O
in	O
CFH	O
were	O
significantly	O
associated	O
with	O
wet	O
AMD	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

This	O
study	O
showed	O
that	O
CFH	O
was	O
more	O
likely	O
to	O
be	O
AMD	O
susceptibility	O
gene	O
at	O
Chr.1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	O
in	O
a	O
white	O
population	O
in	O
C2	O
,	O
CFB	O
,	O
and	O
C3	O
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	O
.	O

4G/5G	O
polymorphism	O
and	O
haplotypes	O
of	O
SERPINE1	O
in	O
atherosclerotic	O
diseases	O
of	O
coronary	O
arteries	O
.	O

We	O
assessed	O
the	O
association	O
between	O
common	O
variation	O
at	O
the	O
SERPINE1	O
(PAI1)	O
locus	O
and	O
myocardial	O
infarction	O
(MI)	O
.	O

Haplotype-tagging	O
polymorphisms	O
,	O
including	O
the	O
4G/5G	O
deletion/insertion	O
polymorphism	O
and	O
seven	O
single	O
nucleotide	O
polymorphisms	O
,	O
were	O
analysed	O
in	O
a	O
German	O
sample	O
containing	O
3,657	O
cases	O
with	O
MI	O
and	O
1,211	O
controls	O
.	O

The	O
association	O
between	O
the	O
4G/5G	O
polymorphism	O
and	O
MI	O
was	O
examined	O
in	O
a	O
meta-analysis	O
of	O
data	O
extracted	O
from	O
32	O
studies	O
(	O
13,267	O
cases/14,716	O
controls	O
)	O
.	O

In	O
addition	O
,	O
the	O
relation	O
between	O
the	O
4G/5G	O
polymorphism	O
and	O
coronary	O
diseases	O
,	O
comprising	O
MI	O
,	O
coronary	O
artery	O
disease	O
,	O
coronary	O
heart	O
disease	O
,	O
or	O
the	O
acute	O
coronary	O
syndrome	O
,	O
was	O
assessed	O
in	O
a	O
combined	O
analysis	O
enclosing	O
43	O
studies	O
(	O
17,278	O
cases/18,039	O
controls	O
)	O
.	O

None	O
of	O
the	O
tagging	O
polymorphisms	O
was	O
associated	O
with	O
MI	O
in	O
the	O
present	O
sample	O
(	O
p	O
<or=	O
0.34	O
)	O
.	O

The	O
adjusted	O
odds	O
ratio	O
(OR)	O
for	O
4G	O
allele	O
carriers	O
was	O
1.02	O
(	O
95%	O
confidence	O
interval	O
[CI]	O
0.87-1.19	O
)	O
compared	O
to	O
the	O
5G5G	O
genotype	O
.	O

None	O
of	O
13	O
common	O
(	O
frequency	O
>1.0%	O
)	O
8-marker	O
haplotypes	O
was	O
related	O
to	O
the	O
risk	O
of	O
MI	O
.	O

In	O
a	O
meta-analysis	O
specifically	O
addressing	O
the	O
association	O
with	O
MI	O
,	O
no	O
elevated	O
risk	O
was	O
found	O
in	O
the	O
carriers	O
of	O
the	O
4G	O
allele	O
(	O
OR	O
1.07	O
,	O
95%	O
CI	O
0.99-1.16	O
;	O
p	O
=	O
0.11	O
)	O
.	O

A	O
more	O
general	O
combined	O
analysis	O
of	O
coronary	O
diseases	O
showed	O
a	O
marginally	O
increased	O
risk	O
in	O
4G	O
allele	O
carriers	O
(	O
OR	O
1.08	O
,	O
95%	O
CI	O
1.00-1.16	O
;	O
p	O
=	O
0.044	O
)	O
.	O

In	O
essence	O
,	O
tagging	O
polymorphisms	O
,	O
including	O
the	O
4G/5G	O
polymorphism	O
,	O
and	O
common	O
haplotypes	O
of	O
the	O
SERPINE1	O
gene	O
region	O
were	O
not	O
associated	O
with	O
MI	O
in	O
a	O
German	O
sample	O
,	O
and	O
no	O
compelling	O
evidence	O
was	O
obtained	O
for	O
a	O
relationship	O
of	O
the	O
4G/5G	O
polymorphism	O
to	O
MI	O
and	O
coronary	O
atherosclerosis	O
in	O
a	O
meta-analysis	O
.	O

Recent	O
nosocomial	O
transmission	O
and	O
genotypes	O
of	O
multidrug-resistant	O
Mycobacterium	O
tuberculosis	O
.	O

SETTING	O
:	O
Multidrug-resistant	O
tuberculosis	O
(MDR-TB)	O
is	O
a	O
serious	O
health	O
problem	O
in	O
Eastern	O
European	O
countries	O
,	O
including	O
Latvia	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
proportion	O
of	O
tuberculosis	O
,	O
including	O
MDR-TB	O
cases	O
,	O
attributable	O
to	O
recent	O
transmission	O
and	O
risk	O
factors	O
associated	O
with	O
clustering	O
.	O

DESIGN	O
:	O
Retrospective	O
nested	O
case-control	O
study	O
.	O

The	O
data	O
set	O
incorporated	O
a	O
wide	O
spectrum	O
of	O
social	O
features	O
,	O
as	O
well	O
as	O
genotypes	O
of	O
Mycobacterium	O
tuberculosis	O
isolates	O
determined	O
by	O
insertion	O
sequence	O
6110	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
PvuII	O
cleaved	O
genomic	O
DNA	O
and	O
spoligotyping	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
non-clustered	O
M	O
.	O

tuberculosis	O
,	O
the	O
Beijing	O
genotype	O
(	O
OR	O
12.15	O
)	O
and	O
multidrug	O
resistance	O
(	O
OR	O
5.61	O
,	O
P	O
<	O
0.01	O
)	O
were	O
associated	O
with	O
clustering	O
.	O

In	O
comparison	O
with	O
clustered	O
drug-susceptible	O
M	O
.	O

tuberculosis	O
,	O
clustering	O
of	O
MDR	O
M	O
.	O

tuberculosis	O
was	O
associated	O
with	O
Beijing	O
genotype	O
(	O
OR	O
41.67	O
)	O
,	O
previous	O
hospitalisation	O
(	O
OR	O
18.33	O
)	O
and	O
previous	O
TB	O
treatment	O
(	O
OR	O
17.68	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Direct	O
epidemiological	O
links	O
in	O
hospitals	O
were	O
found	O
for	O
almost	O
one	O
third	O
(32%)	O
of	O
MDR	O
Beijing	O
cases	O
.	O

CONCLUSIONS	O
:	O
MDR	O
cases	O
were	O
more	O
likely	O
to	O
be	O
found	O
in	O
clusters	O
than	O
drug-susceptible	O
cases	O
(	O
74.0%	O
vs	O
.	O

33.6%	O
)	O
.	O

Recent	O
nosocomial	O
transmission	O
of	O
MDR-TB	O
is	O
an	O
important	O
risk	O
factor	O
for	O
the	O
spread	O
of	O
multiresistance	O
,	O
and	O
is	O
associated	O
with	O
the	O
Beijing	O
genotype	O
.	O

Special	O
attention	O
should	O
be	O
paid	O
to	O
infection	O
control	O
measures	O
in	O
hospitals	O
and	O
ambulatory	O
treatment	O
should	O
be	O
enforced	O
.	O

U87MG	O
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	O
cancer	O
cell	O
line	O
.	O

U87MG	O
is	O
a	O
commonly	O
studied	O
grade	O
IV	O
glioma	O
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1,700	O
publications	O
over	O
four	O
decades	O
.	O

In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	O
genome	O
sequencing	O
,	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50-base	O
mate	O
paired	O
strategy	O
with	O
a	O
1.4kb	O
mean	O
insert	O
library	O
.	O

A	O
total	O
of	O
1,014,984,286	O
mate-end	O
and	O
120,691,623	O
single-end	O
two-base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O

All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
,	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O

The	O
aligned	O
sequence	O
reads	O
and	O
mate-pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
,	O
1,315	O
structural	O
variations	O
(	O
>100	O
bp	O
)	O
,	O
191,743	O
small	O
(	O
<21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(indels)	O
,	O
and	O
2,384,470	O
single	O
nucleotide	O
variations	O
(SNVs)	O
.	O

Among	O
these	O
observations	O
,	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	O
was	O
robustly	O
identified	O
,	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O

Data	O
were	O
compared	O
to	O
219,187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93.83%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99.99%	O
sequence	O
accuracy	O
.	O

Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	O
cell	O
line	O
due	O
to	O
small	O
indels	O
,	O
large	O
deletions	O
,	O
and	O
translocations	O
.	O

In	O
total	O
,	O
512	O
genes	O
were	O
homozygously	O
mutated	O
,	O
including	O
154	O
by	O
SNVs	O
,	O
178	O
by	O
small	O
indels	O
,	O
145	O
by	O
large	O
microdeletions	O
,	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O

Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
,	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O

These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	O
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O

The	O
sequence	O
analysis	O
of	O
U87MG	O
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O

Development	O
and	O
validation	O
of	O
a	O
SYBR	O
Green	O
I-based	O
real-time	O
polymerase	O
chain	O
reaction	O
method	O
for	O
detection	O
of	O
haptoglobin	O
gene	O
deletion	O
in	O
clinical	O
materials	O
.	O

BACKGROUND	O
:	O
Anhaptoglobinemic	O
patients	O
run	O
the	O
risk	O
of	O
severe	O
anaphylactic	O
transfusion	O
reaction	O
because	O
they	O
produce	O
serum	O
haptoglobin	O
(Hp)	O
antibodies	O
.	O

Being	O
homozygous	O
for	O
the	O
Hp	O
gene	O
deletion	O
(HP(del))	O
is	O
the	O
only	O
known	O
cause	O
of	O
congenital	O
anhaptoglobinemia	O
,	O
and	O
clinical	O
diagnosis	O
of	O
HP(del)	O
before	O
transfusion	O
is	O
important	O
to	O
prevent	O
anaphylactic	O
shock	O
.	O

We	O
recently	O
developed	O
a	O
5'-nuclease	O
(TaqMan)	O
real-time	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
A	O
SYBR	O
Green	O
I-based	O
duplex	O
real-time	O
PCR	O
assay	O
using	O
two	O
forward	O
primers	O
and	O
a	O
common	O
reverse	O
primer	O
followed	O
by	O
melting	O
curve	O
analysis	O
was	O
developed	O
to	O
determine	O
HP(del)	O
zygosity	O
in	O
a	O
single	O
tube	O
.	O

In	O
addition	O
,	O
to	O
obviate	O
initial	O
DNA	O
extraction	O
,	O
we	O
examined	O
serially	O
diluted	O
blood	O
samples	O
as	O
PCR	O
templates	O
.	O

RESULTS	O
:	O
Allelic	O
discrimination	O
of	O
HP(del)	O
yielded	O
optimal	O
results	O
at	O
blood	O
sample	O
dilutions	O
of	O
1:64	O
to	O
1:1024	O
.	O

The	O
results	O
from	O
2231	O
blood	O
samples	O
were	O
fully	O
concordant	O
with	O
those	O
obtained	O
by	O
the	O
TaqMan-based	O
real-time	O
PCR	O
method	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
rate	O
of	O
the	O
HP(del)	O
allele	O
by	O
the	O
SYBR	O
Green	O
I-based	O
method	O
is	O
comparable	O
with	O
that	O
using	O
the	O
TaqMan-based	O
method	O
.	O

This	O
method	O
is	O
readily	O
applicable	O
due	O
to	O
its	O
low	O
initial	O
cost	O
and	O
analyzability	O
using	O
economical	O
real-time	O
PCR	O
machines	O
and	O
is	O
suitable	O
for	O
high-throughput	O
analysis	O
as	O
an	O
alternative	O
method	O
for	O
allelic	O
discrimination	O
of	O
HP(del)	O
.	O

Investigation	O
of	O
SERPINE1	O
genetic	O
polymorphism	O
in	O
Macedonian	O
patients	O
with	O
occlusive	O
artery	O
disease	O
and	O
deep	O
vein	O
thrombosis	O
.	O

BACKGROUND	O
:	O
Raised	O
SERPINE1	O
plasma	O
levels	O
are	O
related	O
to	O
a	O
1-bp	O
guanine	O
deletion/insertion	O
(4G5G)	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
SERPINE1	O
(	O
plasminogen	O
activator	O
inhibitor	O
1	O
-	O
PAI1	O
)	O
gene	O
.	O

Evidence	O
suggested	O
that	O
the	O
plasma	O
levels	O
of	O
SERPINE1	O
modulate	O
the	O
risk	O
of	O
coronary	O
artery	O
disease	O
;	O
furthermore	O
,	O
that	O
the	O
4G5G	O
polymorphism	O
affects	O
the	O
expression	O
of	O
the	O
SERPINE1	O
gene	O
.	O

AIM	O
:	O
To	O
analyse	O
association	O
of	O
SERPINE1	O
polymorphism	O
with	O
occlusive	O
artery	O
disease	O
(OAD)	O
and	O
deep	O
venous	O
thrombosis	O
(DVT)	O
in	O
Macedonians	O
in	O
order	O
to	O
investigate	O
its	O
role	O
as	O
a	O
part	O
of	O
candidate	O
genes	O
in	O
different	O
vascular	O
diseases	O
in	O
Macedonians	O
.	O

METHODS	O
:	O
Investigated	O
groups	O
consisted	O
of	O
82	O
healthy	O
patients	O
,	O
75	O
with	O
OAD	O
,	O
and	O
66	O
with	O
DVT	O
.	O

Blood	O
samples	O
were	O
collected	O
after	O
written	O
informed	O
consent	O
was	O
obtained	O
,	O
and	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
.	O

Identification	O
of	O
SERPINE1	O
polymorphism	O
was	O
done	O
with	O
CVD	O
StripAssay	O
(	O
ViennaLab	O
,	O
Labordiagnostica	O
GmbH	O
,	O
Austria	O
)	O
.	O

The	O
population	O
genetics	O
analysis	O
package	O
,	O
PyPop	O
,	O
was	O
used	O
for	O
analysis	O
of	O
the	O
SERPINE1	O
data	O
.	O

Pearson's	O
P-values	O
,	O
crude	O
odds	O
ratio	O
and	O
Wald's	O
95%	O
CI	O
were	O
calculated	O
with	O
Bonferroni	O
corrected	O
p	O
value	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
4G	O
allele	O
for	O
SERPINE1	O
was	O
0.538	O
for	O
DVT	O
,	O
0.555	O
for	O
healthy	O
participants	O
,	O
and	O
0.607	O
for	O
OAD	O
.	O

The	O
frequency	O
of	O
5G	O
allele	O
for	O
SERPINE1	O
was	O
the	O
smallest	O
in	O
patients	O
with	O
OAD	O
(0.393)	O
and	O
was	O
higher	O
in	O
healthy	O
participants	O
(0.445)	O
,	O
and	O
patients	O
with	O
DVT	O
(0.462)	O
.	O

Test	O
of	O
neutrality	O
(Fnd)	O
showed	O
negative	O
value	O
,	O
but	O
was	O
significantly	O
different	O
from	O
0	O
for	O
SERPINE1	O
in	O
healthy	O
participants	O
(	O
p	O
of	O
F	O
=	O
0.041	O
)	O
and	O
in	O
patients	O
with	O
DVT	O
(	O
p	O
of	O
F	O
=	O
0.030	O
)	O
.	O

SERPINE1	O
genotypes	O
in	O
healthy	O
participants	O
and	O
patients	O
with	O
OAD	O
were	O
not	O
in	O
Hardy	O
Weinberg	O
proportions	O
(	O
p	O
=	O
0.019	O
and	O
0.001	O
,	O
respectively	O
)	O
.	O

No	O
association	O
between	O
SERPINE1	O
polymorphisms	O
and	O
OAD	O
or	O
DVT	O
was	O
found	O
.	O

CONCLUSION	O
:	O
There	O
is	O
no	O
significant	O
relationship	O
between	O
SERPINE1	O
polymorphisms	O
and	O
occlusive	O
artery	O
disease	O
or	O
deep	O
venous	O
thrombosis	O
in	O
Macedonian	O
population	O
.	O

A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	O
gene	O
may	O
be	O
associated	O
with	O
essential	O
hypertension	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

BACKGROUND	O
:	O
Mice	O
with	O
defects	O
in	O
the	O
Klotho	O
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	O
.	O

We	O
hypothesised	O
that	O
the	O
G-395A	B-DNAMutation
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
Klotho	O
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	O
Hypertension	O
(EH)	O
.	O

METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G-395A	B-DNAMutation
polymorphism	O
of	O
Klotho	O
is	O
associated	O
with	O
EH	O
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	O
with	O
EH	O
and	O
220	O
non-hypertensive	O
subjects	O
.	O

We	O
also	O
tested	O
whether	O
a	O
G/A	B-DNAMutation
substitution	O
at	O
the	O
G-395A	B-DNAMutation
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual-luciferase	O
reporter	O
assay	O
.	O

RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G-395A	B-DNAMutation
polymorphism	O
between	O
the	O
EH	O
and	O
non-hypertension	O
groups	O
are	O
statistically	O
significant	O
(P=0.032)	O
.	O

There	O
are	O
differential	O
effects	O
of	O
age	O
,	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G-395A	B-DNAMutation
polymorphism	O
with	O
EH	O
;	O
the	O
G-395A	B-DNAMutation
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	O
in	O
subjects	O
over	O
60years	O
old	O
,	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	O
in	O
the	O
-395A	O
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0.593	O
(P=0.024)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O

The	O
dual-luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-395A	O
carrier	O
of	O
a	O
498-bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G-395A	B-DNAMutation
site	O
)	O
upstream	O
of	O
the	O
Klotho	O
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-395G	O
carrier	O
.	O

CONCLUSIONS	O
:	O
The	O
G-395A	B-DNAMutation
polymorphism	O
of	O
the	O
human	O
Klotho	O
gene	O
is	O
associated	O
with	O
EH	O
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O

An	O
intronic	O
polymorphism	O
of	O
IRF4	O
gene	O
influences	O
gene	O
transcription	O
in	O
vitro	O
and	O
shows	O
a	O
risk	O
association	O
with	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
in	O
males	O
.	O

The	O
interferon	O
regulatory	O
factor	O
(IRF)	O
family	O
of	O
DNA-binding	O
proteins	O
regulates	O
expression	O
of	O
interferon-inducible	O
genes	O
with	O
roles	O
in	O
the	O
immune	O
response	O
and	O
carcinogenesis	O
.	O

IRF4	O
is	O
involved	O
in	O
the	O
differentiation	O
of	O
B	O
and	O
T	O
cells	O
and	O
is	O
overexpressed	O
in	O
B-cell	O
malignancies	O
as	O
a	O
result	O
of	O
c-REL	O
(NF-kappaB)	O
hyperactivation	O
.	O

IRF4	O
polymorphisms	O
are	O
associated	O
with	O
susceptibility	O
to	O
chronic	O
lymphoid	O
leukemia	O
(CLL)	O
and	O
non-Hodgkin	O
lymphoma	O
(NHL)	O
.	O

We	O
examined	O
13	O
IRF4	O
SNPs	O
in	O
114	O
cases	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
and	O
388	O
newborn	O
controls	O
from	O
Wales	O
(U.K.)	O
using	O
TaqMan	O
assays	O
.	O

IRF4	O
intron	O
4	O
SNP	O
rs12203592	B-SNP
showed	O
a	O
male-specific	O
risk	O
association	O
(	O
OR=4.4	O
,	O
95%	O
CI=1.5	O
to	O
12.6	O
,	O
P=0.007	O
)	O
.	O

Functional	O
consequences	O
of	O
the	O
C>T	B-DNAMutation
substitution	O
at	O
this	O
SNP	O
were	O
assessed	O
by	O
cell-based	O
reporter	O
assays	O
using	O
three	O
different	O
cell	O
lines	O
.	O

We	O
found	O
a	O
repressive	O
effect	O
of	O
the	O
rs12203592	B-SNP
wildtype	O
allele	O
C	O
on	O
IRF4	O
promoter	O
activity	O
(P<0.001)	O
but	O
no	O
repression	O
by	O
the	O
variant	O
allele	O
in	O
any	O
cell	O
line	O
tested	O
.	O

Thus	O
,	O
homozygosity	O
for	O
the	O
rs12203592	B-SNP
variant	O
allele	O
would	O
result	O
in	O
increased	O
IRF4	O
expression	O
.	O

This	O
increase	O
would	O
be	O
compounded	O
by	O
high	O
levels	O
of	O
NF-kappaB	O
activity	O
in	O
males	O
due	O
to	O
the	O
absence	O
of	O
estrogen	O
.	O

IRF4	O
differs	O
from	O
other	O
IRFs	O
in	O
its	O
anti-interferon	O
activity	O
which	O
interferes	O
with	O
immune	O
surveillance	O
.	O

We	O
propose	O
that	O
a	O
detailed	O
study	O
of	O
IRF4	O
can	O
provide	O
information	O
on	O
the	O
mechanism	O
of	O
the	O
sex	O
effect	O
and	O
the	O
role	O
of	O
immune	O
surveillance	O
in	O
childhood	O
ALL	O
development	O
.	O

A	O
novel	O
insertion	O
mutation	O
in	O
the	O
SEDL	O
gene	O
results	O
in	O
X-linked	O
spondyloepiphyseal	O
dysplasia	O
tarda	O
in	O
a	O
large	O
Chinese	O
pedigree	O
.	O

BACKGROUND	O
:	O
Spondyloepiphyseal	O
dysplasia	O
tarda	O
(SEDT)	O
is	O
an	O
X-chromosome	O
linked	O
primary	O
skeletal	O
dysplasia	O
characterized	O
by	O
a	O
disproportionate	O
short-trunked	O
short	O
stature	O
,	O
dysplasia	O
of	O
the	O
large	O
joints	O
and	O
flattened	O
thoracic	O
and	O
lumber	O
vertebral	O
bodies	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
describe	O
a	O
large	O
Chinese	O
SEDT	O
family	O
with	O
a	O
milder	O
phenotype	O
and	O
describe	O
the	O
molecular	O
and	O
clinical	O
findings	O
.	O

METHODS	O
:	O
Eight	O
affected	O
males	O
of	O
the	O
family	O
were	O
diagnosed	O
with	O
SEDT	O
according	O
to	O
their	O
clinical	O
and	O
radiological	O
features	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
the	O
SEDL	O
gene	O
was	O
performed	O
.	O

RT-PCR	O
experiments	O
on	O
total	O
RNA	O
from	O
blood	O
lymphocytes	O
were	O
performed	O
to	O
confirm	O
the	O
defect	O
on	O
the	O
SEDL	O
gene	O
.	O

A	O
short	O
summary	O
of	O
all	O
currently	O
known	O
SEDL	O
gene	O
mutations	O
is	O
presented	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
revealed	O
that	O
all	O
the	O
affected	O
males	O
carried	O
an	O
insertion	O
mutation	O
c.370-371insA	B-DNAMutation
unreported	O
previously	O
,	O
predicted	O
to	O
result	O
in	O
frameshifts	O
and	O
generate	O
a	O
premature	O
stop	O
codon	O
p.S124fsX127	B-ProteinMutation
.	O

The	O
identical	O
mutation	O
was	O
also	O
observed	O
in	O
a	O
10-year	O
old	O
presymptomatic	O
boy	O
of	O
the	O
family	O
.	O

Eight	O
female	O
carriers	O
had	O
the	O
typical	O
sequencing	O
chromatograms	O
of	O
heterozygotes	O
.	O

CONCLUSIONS	O
:	O
Identification	O
of	O
the	O
novel	O
insertion	O
mutation	O
c.370-371insA	B-DNAMutation
in	O
this	O
SEDT	O
family	O
enables	O
carrier	O
detection	O
and	O
presymptomatic/prenatal	O
diagnosis	O
,	O
but	O
also	O
the	O
detailed	O
molecular	O
and	O
clinical	O
features	O
will	O
be	O
useful	O
for	O
extending	O
the	O
evidence	O
for	O
genetic	O
and	O
phenotypic	O
heterogeneity	O
in	O
SEDT	O
.	O

Congestive	O
heart	O
failure	O
with	O
rhabdomyolysis	O
and	O
acute	O
renal	O
failure	O
in	O
a	O
manifesting	O
female	O
carrier	O
of	O
Duchenne	O
muscular	O
dystrophy	O
with	O
duplication	O
of	O
dystrophin	O
gene	O
.	O

We	O
report	O
a	O
69-year-old	O
woman	O
who	O
presented	O
with	O
dyspnea	O
,	O
orthopnea	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

She	O
also	O
had	O
proximal	O
muscle	O
weakness	O
suggestive	O
of	O
muscle	O
disease	O
.	O

Her	O
symptoms	O
were	O
alleviated	O
by	O
induced	O
dieresis	O
,	O
although	O
there	O
was	O
high-serum	O
creatine	O
kinase	O
.	O

Investigations	O
for	O
any	O
possible	O
etiologies	O
of	O
rhabdomyolysis	O
were	O
all	O
negative	O
.	O

An	O
X-linked	O
recessive	O
muscle	O
disease	O
was	O
highly	O
suspicious	O
in	O
view	O
of	O
the	O
fact	O
that	O
both	O
of	O
her	O
sons	O
had	O
suffered	O
from	O
muscle	O
disease	O
and	O
died	O
of	O
respiratory	O
failure	O
at	O
the	O
ages	O
of	O
22	O
and	O
29	O
,	O
respectively	O
.	O

Her	O
muscle	O
biopsy	O
showed	O
mosaic	O
pattern	O
with	O
dystrophin	O
antibody	O
against	O
amino-terminal	O
,	O
carboxy-terminal	O
,	O
and	O
rod	O
domain	O
.	O

Her	O
DNA	O
study	O
revealed	O
heterozygous	O
duplication	O
at	O
exon	O
1	O
to	O
6	O
of	O
the	O
dystrophin	O
gene	O
as	O
well	O
.	O

Therefore	O
,	O
she	O
is	O
a	O
manifesting	O
carrier	O
of	O
dystrophinopathy	O
who	O
was	O
first	O
diagnosed	O
in	O
late	O
adulthood	O
with	O
congestive	O
heart	O
failure	O
,	O
acute	O
episode	O
of	O
spontaneous	O
rhabdomyolysis	O
,	O
and	O
acute	O
renal	O
failure	O
.	O

Forty-two	O
novel	O
COL7A1	O
mutations	O
and	O
the	O
role	O
of	O
a	O
frequent	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
MMP1	O
promoter	O
in	O
modulation	O
of	O
disease	O
severity	O
in	O
a	O
large	O
European	O
dystrophic	O
epidermolysis	O
bullosa	O
cohort	O
.	O

BACKGROUND	O
:	O
Dystrophic	O
epidermolysis	O
bullosa	O
(DEB)	O
is	O
a	O
severe	O
genetic	O
skin	O
blistering	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
COL7A1	O
,	O
encoding	O
collagen	O
VII	O
.	O

Recently	O
,	O
the	O
MMP1	O
promoter	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
rs1799750	B-SNP
,	O
designated	O
as	O
1G	O
2G	O
,	O
was	O
shown	O
to	O
be	O
involved	O
in	O
modulation	O
of	O
disease	O
severity	O
in	O
patients	O
with	O
recessive	O
DEB	O
(RDEB)	O
,	O
and	O
was	O
proposed	O
as	O
a	O
genetic	O
modifier	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
molecular	O
basis	O
of	O
DEB	O
in	O
103	O
individuals	O
and	O
to	O
replicate	O
the	O
results	O
of	O
the	O
MMP1	O
promoter	O
SNP	O
analysis	O
in	O
an	O
independent	O
patient	O
group	O
,	O
as	O
verification	O
is	O
necessary	O
in	O
such	O
a	O
rare	O
and	O
heterogeneous	O
disorder	O
.	O

METHODS	O
:	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
,	O
we	O
performed	O
COL7A1	O
mutation	O
screening	O
,	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
real-time	O
quantitative	O
PCR	O
.	O

The	O
status	O
of	O
the	O
MMP1	O
SNP	O
was	O
analysed	O
by	O
PCR	O
and	O
restriction	O
enzyme	O
digestion	O
and	O
verified	O
by	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
disclosed	O
42	O
novel	O
COL7A1	O
mutations	O
,	O
including	O
the	O
first	O
large	O
genomic	O
deletion	O
of	O
4	O
kb	O
affecting	O
only	O
the	O
COL7A1	O
gene	O
,	O
and	O
three	O
apparently	O
silent	O
mutations	O
affecting	O
splicing	O
.	O

Even	O
though	O
the	O
frequency	O
of	O
the	O
high-risk	O
allele	O
was	O
increased	O
in	O
patients	O
with	O
RDEB	O
,	O
no	O
statistically	O
significant	O
correlation	O
between	O
disease	O
severity	O
and	O
genotype	O
could	O
be	O
made	O
.	O

Also	O
,	O
no	O
correlation	O
was	O
observed	O
with	O
development	O
of	O
squamous	O
cell	O
carcinoma	O
,	O
a	O
severe	O
complication	O
of	O
DEB	O
.	O

CONCLUSIONS	O
:	O
Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
the	O
MMP1	O
SNP	O
is	O
not	O
the	O
sole	O
disease	O
modifier	O
in	O
different	O
forms	O
of	O
DEB	O
,	O
and	O
other	O
genetic	O
and	O
environmental	O
factors	O
contribute	O
to	O
the	O
clinical	O
phenotype	O
.	O

A	O
combination	O
of	O
defective	O
DNA	O
and	O
protective	O
host	O
factors	O
are	O
found	O
in	O
a	O
set	O
of	O
HIV-1	O
ancestral	O
LTNPs	O
.	O

We	O
studied	O
viral	O
evolution	O
in	O
three	O
HIV-1	O
ancestral	O
patients	O
from	O
a	O
group	O
of	O
LTNPs	O
;	O
although	O
some	O
minor	O
sequences	O
showing	O
viral	O
evolution	O
were	O
detected	O
in	O
all	O
patients	O
,	O
the	O
extremely	O
low	O
viral	O
evolution	O
of	O
their	O
viruses	O
was	O
shown	O
by	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
env	O
sequences	O
.	O

Complete	O
nucleotide	O
sequencing	O
of	O
viral	O
DNA	O
showed	O
the	O
major	O
presence	O
of	O
deletions	O
.	O

In	O
two	O
patients	O
,	O
deletions	O
of	O
1088	O
and	O
228	O
nucleotides	O
mapped	O
to	O
5'	O
LTR-gag	O
region	O
;	O
in	O
the	O
other	O
,	O
a	O
247	O
nucleotide	O
deletion	O
was	O
positioned	O
in	O
pol	O
gene	O
up	O
to	O
the	O
vif	O
ORF	O
.	O

These	O
deleted	O
genomes	O
became	O
dominant	O
during	O
follow	O
up	O
.	O

Patient's	O
viruses	O
displayed	O
13	O
common	O
mutations	O
in	O
conserved	O
residues	O
,	O
from	O
the	O
5'	O
LTR	O
to	O
the	O
nef	O
gene	O
.	O

These	O
mutations	O
provided	O
evidence	O
of	O
a	O
common	O
origin	O
.	O

Regarding	O
host	O
characteristics	O
,	O
one	O
patient	O
had	O
HLA	O
B2705/B5801	O
;	O
another	O
B1402/B5701	O
;	O
whereas	O
a	O
third	O
showed	O
B3901/B4402	O
and	O
was	O
Delta32-CCR5	B-DNAMutation
heterozygous	O
.	O

These	O
HIV	O
controllers	O
presented	O
a	O
combination	O
of	O
deleted	O
viral	O
genomes	O
and	O
host	O
protective	O
factors	O
.	O

Mutation	O
of	O
SYNE-1	O
,	O
encoding	O
an	O
essential	O
component	O
of	O
the	O
nuclear	O
lamina	O
,	O
is	O
responsible	O
for	O
autosomal	O
recessive	O
arthrogryposis	O
.	O

Arthrogryposis	O
multiplex	O
congenita	O
(AMC)	O
is	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
congenital	O
joint	O
contractures	O
caused	O
by	O
reduced	O
fetal	O
movements	O
.	O

AMC	O
has	O
an	O
incidence	O
of	O
1	O
in	O
3000	O
newborns	O
and	O
is	O
genetically	O
heterogeneous	O
.	O

We	O
describe	O
an	O
autosomal	O
recessive	O
form	O
of	O
myogenic	O
AMC	O
in	O
a	O
large	O
consanguineous	O
family	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
bilateral	O
clubfoot	O
,	O
decreased	O
fetal	O
movements	O
,	O
delay	O
in	O
motor	O
milestones	O
,	O
then	O
progressive	O
motor	O
decline	O
after	O
the	O
first	O
decade	O
.	O

Genome-wide	O
linkage	O
analysis	O
revealed	O
a	O
single	O
locus	O
on	O
chromosome	O
6q25	O
with	O
Z(max)	O
=	O
3.55	O
at	O
theta	O
=	O
0.0	O
and	O
homozygosity	O
of	O
the	O
polymorphic	O
markers	O
at	O
this	O
locus	O
in	O
patients	O
.	O

Homozygous	O
A	O
to	O
G	O
nucleotide	O
substitution	O
of	O
the	O
conserved	O
AG	O
splice	O
acceptor	O
site	O
at	O
the	O
junction	O
of	O
intron	O
136	O
and	O
exon	O
137	O
of	O
the	O
SYNE-1	O
gene	O
was	O
found	O
in	O
patients	O
.	O

This	O
mutation	O
results	O
in	O
an	O
aberrant	O
retention	O
of	O
intron	O
136	O
of	O
SYNE-1	O
RNA	O
leading	O
to	O
premature	O
stop	O
codons	O
and	O
the	O
lack	O
of	O
the	O
C-terminal	O
transmembrane	O
domain	O
KASH	O
of	O
nesprin-1	O
,	O
the	O
SYNE-1	O
gene	O
product	O
.	O

Mice	O
lacking	O
the	O
KASH	O
domain	O
of	O
nesprin-1	O
display	O
a	O
myopathic	O
phenotype	O
similar	O
to	O
that	O
observed	O
in	O
patients	O
.	O

Altogether	O
,	O
these	O
data	O
strongly	O
suggest	O
that	O
the	O
splice	O
site	O
mutation	O
of	O
SYNE-1	O
gene	O
found	O
in	O
the	O
family	O
is	O
responsible	O
for	O
AMC	O
.	O

Recent	O
reports	O
have	O
shown	O
that	O
mutations	O
of	O
the	O
SYNE-1	O
gene	O
might	O
be	O
responsible	O
for	O
autosomal	O
recessive	O
adult	O
onset	O
cerebellar	O
ataxia	O
.	O

These	O
data	O
indicate	O
that	O
mutations	O
of	O
nesprin-1	O
which	O
interacts	O
with	O
lamin	O
A/C	O
may	O
lead	O
to	O
at	O
least	O
two	O
distinct	O
human	O
disease	O
phenotypes	O
,	O
myopathic	O
or	O
neurological	O
,	O
a	O
feature	O
similar	O
to	O
that	O
found	O
in	O
laminopathies	O
.	O

Identified	O
hidden	O
genomic	O
changes	O
in	O
mantle	O
cell	O
lymphoma	O
using	O
high-resolution	O
single	O
nucleotide	O
polymorphism	O
genomic	O
array	O
.	O

OBJECTIVE	O
:	O
Mantle	O
cell	O
lymphoma	O
(MCL)	O
is	O
a	O
lymphoma	O
characterized	O
by	O
aberrant	O
activation	O
of	O
CCND1/cyclin	O
D1	O
followed	O
by	O
sequential	O
genetic	O
abnormalities	O
.	O

Genomic	O
abnormalities	O
in	O
MCL	O
have	O
been	O
extensively	O
examined	O
by	O
classical	O
cytogenetics	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
techniques	O
,	O
pointing	O
out	O
a	O
number	O
of	O
alterations	O
in	O
genomic	O
regions	O
that	O
correlate	O
with	O
the	O
neoplastic	O
phenotype	O
and	O
survival	O
.	O

Recently	O
,	O
single	O
nucleotide	O
polymorphism	O
genomic	O
microarrays	O
(SNP-chip)	O
have	O
been	O
developed	O
and	O
used	O
for	O
analysis	O
of	O
cancer	O
genomics	O
.	O

This	O
technique	O
allows	O
detection	O
of	O
genomic	O
changes	O
with	O
higher	O
resolution	O
,	O
including	O
loss	O
of	O
heterozygosity	O
without	O
changes	O
of	O
gene	O
dosage	O
,	O
so-called	O
acquired	O
uniparental	O
disomy	O
(aUPD)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
have	O
examined	O
33	O
samples	O
of	O
MCL	O
(	O
28	O
primary	O
MCL	O
and	O
5	O
cell	O
lines	O
)	O
using	O
the	O
250,000	O
SNP-chip	O
from	O
Affymetrix	O
.	O

RESULTS	O
:	O
Known	O
alterations	O
were	O
confirmed	O
by	O
SNP	O
arrays	O
,	O
including	O
deletion	O
of	O
INK4A/ARF	O
,	O
duplication/amplification	O
of	O
MYC	O
,	O
deletion	O
of	O
ATM	O
,	O
and	O
deletion	O
of	O
TP53	O
.	O

We	O
also	O
identified	O
a	O
duplication/amplification	O
that	O
occurred	O
at	O
13q	O
involving	O
oncogenic	O
microRNA	O
,	O
miR17-92	O
.	O

We	O
found	O
other	O
genomic	O
abnormalities	O
,	O
including	O
duplication/amplification	O
of	O
cyclin	O
D1	O
,	O
del(1p)	O
,	O
del(6q)	O
,	O
dup(3q)	O
and	O
dup(18q)	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
these	O
abnormalities	O
at	O
high	O
resolution	O
,	O
allowing	O
us	O
to	O
narrow	O
the	O
size	O
of	O
the	O
commonly	O
deleted	O
regions	O
,	O
including	O
1p	O
and	O
6q	O
.	O

Our	O
SNP-chip	O
analysis	O
detected	O
a	O
number	O
of	O
aUPD	O
sites	O
,	O
including	O
whole	O
chromosome	O
9	O
aUPD	O
and	O
9p	O
aUPD	O
.	O

We	O
also	O
found	O
an	O
MCL	O
case	O
with	O
19p	O
,	O
leading	O
to	O
homozygous	O
deletion	O
of	O
TNFSF	O
genes	O
.	O

CONCLUSION	O
:	O
SNP-chip	O
analysis	O
detected	O
in	O
MCL	O
very	O
small	O
genomic	O
gains/losses	O
,	O
as	O
well	O
as	O
aUPDs	O
,	O
which	O
could	O
not	O
be	O
detected	O
by	O
more	O
conventional	O
methods	O
.	O

COL3A1	O
2209G>A	B-DNAMutation
is	O
a	O
predictor	O
of	O
pelvic	O
organ	O
prolapse	O
.	O

INTRODUCTION	O
AND	O
HYPOTHESIS	O
:	O
A	O
familial	O
tendency	O
has	O
been	O
demonstrated	O
in	O
the	O
etiology	O
of	O
pelvic	O
organ	O
prolapse	O
(POP)	O
,	O
but	O
the	O
specific	O
genetic	O
defects	O
have	O
not	O
been	O
identified	O
.	O

Type	O
III	O
collagen	O
is	O
an	O
important	O
factor	O
in	O
the	O
repair	O
of	O
connective	O
tissue	O
,	O
and	O
gene	O
polymorphisms	O
may	O
impair	O
the	O
tensile	O
strength	O
.	O

We	O
hypothesized	O
that	O
polymorphisms	O
in	O
the	O
alpha	O
I	O
chain	O
of	O
the	O
type	O
III	O
collagen	O
protein-encoding	O
gene	O
(COL3A1)	O
pose	O
women	O
at	O
risk	O
for	O
POP	O
.	O

METHODS	O
:	O
In	O
this	O
case-control	O
study	O
,	O
the	O
prevalence	O
of	O
type	O
III	O
collagen	O
polymorphisms	O
was	O
compared	O
in	O
women	O
with	O
and	O
without	O
signs	O
and	O
symptoms	O
of	O
POP	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
and	O
two	O
POP	O
patients	O
and	O
102	O
normal	O
parous	O
controls	O
were	O
included	O
.	O

A	O
homozygous	O
single-nucleotide	O
substitution	O
in	O
the	O
coding	O
region	O
of	O
type	O
III	O
collagen	O
(	O
COL3A1	O
2209G>A	B-DNAMutation
,	O
rs1800255	B-SNP
)	O
was	O
identified	O
in	O
27	O
(13%)	O
POP	O
patients	O
and	O
three	O
(3%)	O
controls	O
(	O
odds	O
ratio	O
,	O
5.0	O
;	O
95%	O
confidence	O
interval	O
,	O
1.4-17.1	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
probability	O
of	O
POP	O
was	O
higher	O
in	O
women	O
with	O
COL3A1	O
2209G>A	B-DNAMutation
.	O

This	O
polymorphism	O
showed	O
to	O
be	O
a	O
relevant	O
risk	O
factor	O
for	O
POP	O
.	O

A	O
novel	O
ATP7A	O
gross	O
deletion	O
mutation	O
in	O
a	O
Korean	O
patient	O
with	O
Menkes	O
disease	O
.	O

Menkes	O
disease	O
(	O
MD	O
,	O
MIM	O
309400	O
)	O
is	O
a	O
fatal	O
X-linked	O
recessive	O
disorder	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
ATP7A	O
,	O
a	O
copper-transporting	O
,	O
P-type	O
ATPase	O
.	O

Patients	O
with	O
MD	O
are	O
characterized	O
by	O
progressive	O
hypotonia	O
,	O
seizures	O
,	O
failure	O
to	O
thrive	O
,	O
and	O
death	O
in	O
early	O
childhood	O
.	O

Two	O
Korean	O
patients	O
were	O
diagnosed	O
with	O
Menkes	O
disease	O
by	O
clinical	O
and	O
biochemical	O
findings	O
.	O

We	O
found	O
one	O
missense	O
mutation	O
and	O
one	O
gross	O
deletion	O
in	O
the	O
ATP7A	O
gene	O
in	O
the	O
patients	O
.	O

The	O
missense	O
mutation	O
in	O
Patient	O
1	O
,	O
c.3943G>A	B-DNAMutation
p.G1315R	B-ProteinMutation
in	O
exon	O
20	O
,	O
was	O
identified	O
in	O
a	O
previous	O
report	O
.	O

Patient	O
2	O
had	O
a	O
gross	O
deletion	O
of	O
c.1544-?_2916+?	B-DNAMutation
,	O
which	O
was	O
a	O
novel	O
mutation	O
.	O

The	O
patients'	O
mothers	O
were	O
shown	O
to	O
be	O
carriers	O
of	O
the	O
respective	O
mutations	O
.	O

Prenatal	O
DNA	O
diagnosis	O
in	O
the	O
family	O
of	O
Patient	O
2	O
was	O
successfully	O
performed	O
,	O
showing	O
a	O
male	O
fetus	O
with	O
the	O
wild-type	O
genotype	O
.	O

The	O
gross	O
deletion	O
is	O
the	O
first	O
mutation	O
to	O
be	O
identified	O
in	O
the	O
ATP7A	O
gene	O
in	O
Korean	O
MD	O
patients	O
.	O

We	O
expect	O
that	O
our	O
findings	O
will	O
be	O
helpful	O
in	O
understanding	O
the	O
wide	O
range	O
of	O
genetic	O
variation	O
in	O
ATP7A	O
in	O
Korean	O
MD	O
patients	O
.	O

The	O
first	O
founder	O
DGUOK	O
mutation	O
associated	O
with	O
hepatocerebral	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
.	O

Deoxyguanosine	O
kinase	O
(dGK)	O
deficiency	O
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	O
DNA	O
depletion	O
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	O
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	O
patients	O
.	O

This	O
new	O
DGUOK	O
homozygous	O
mutation	O
c.444-62C>A	B-DNAMutation
was	O
identified	O
in	O
three	O
patients	O
from	O
two	O
North-African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	O
chain	O
deficiencies	O
and	O
mitochondrial	O
DNA	O
depletion	O
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	O
patients	O
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	O
abnormal	O
myelination	O
and	O
moderate	O
hyperintensity	O
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	O
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in-frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	O
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	O
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
)	O
,	O
which	O
span	O
4.6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	O
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	O
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	O
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North-African	O
population	O
.	O

Macular	O
corneal	O
dystrophy	O
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	O
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	O
sulfotransferase	O
gene	O
(CHST6)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	O
corneal	O
dystrophy	O
(MCD)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O

METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O

The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(LM)	O
and	O
an	O
electron	O
microscope	O
(EM)	O
separately	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
,	O
and	O
the	O
coding	O
region	O
of	O
CHST6	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O

RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	O
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O

Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O

The	O
compound	O
heterozygous	O
mutations	O
,	O
c.892C>T	B-DNAMutation
and	O
c.1072T>C	B-DNAMutation
,	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	O
in	O
three	O
patients	O
.	O

The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	O
codon	O
for	O
glutamine	O
at	O
codon	O
298	O
p.Q298X	B-ProteinMutation
and	O
a	O
missense	O
mutation	O
at	O
codon	O
358	O
,	O
tyrosine	O
to	O
histidine	O
p.Y358H	B-ProteinMutation
.	O

The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O

These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O

CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	O
function	O
,	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	O
sulfate	O
(KS)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O

It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	O
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O

Genetic	O
polymorphism	O
in	O
chemokine	O
CCL22	O
and	O
susceptibility	O
to	O
Helicobacter	O
pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Gastric	O
carcinoma	O
is	O
widely	O
considered	O
to	O
be	O
related	O
to	O
Helicobacter	O
pylori	O
infection	O
,	O
and	O
the	O
chemokine	O
(	O
C-C	O
motif	O
)	O
ligand	O
22	O
(CCL22)	O
plays	O
an	O
important	O
role	O
in	O
suppressing	O
immune	O
responses	O
against	O
H	O
.	O

pylori	O
and	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
examined	O
the	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
CCL22	O
gene	O
and	O
the	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

METHODS	O
:	O
Information	O
on	O
SNPs	O
in	O
the	O
CCL22	O
coding	O
region	O
was	O
obtained	O
from	O
the	O
HapMap	O
Project	O
database	O
.	O

Genotypes	O
were	O
determined	O
in	O
a	O
case-control	O
cohort	O
that	O
consisted	O
of	O
1001	O
patients	O
with	O
gastric	O
carcinoma	O
and	O
1066	O
controls	O
,	O
and	O
odds	O
ratios	O
(ORs)	O
and	O
95%	O
confidence	O
intervals	O
(	O
95%	O
CIs	O
)	O
were	O
computed	O
by	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

Serum	O
H	O
.	O

pylori	O
antibody	O
levels	O
were	O
measured	O
by	O
using	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
The	O
16C-->A	B-DNAMutation
SNP	O
(	O
reference	B-SNP
SNP	I-SNP
no	I-SNP
.	I-SNP
4359426	I-SNP
)	O
in	O
exon	O
1	O
of	O
the	O
CCL22	O
gene	O
,	O
which	O
causes	O
a	O
2	O
aspartate	O
(2Asp)	O
to	O
2	O
alanine	O
(2Ala)	O
substitution	O
in	O
the	O
CCL22	O
protein	O
,	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
gastric	O
carcinoma	O
.	O

Individuals	O
who	O
were	O
homozygous	O
for	O
the	O
Ala/Ala	O
genotype	O
had	O
an	O
OR	O
of	O
2.27	O
(	O
95%	O
CI	O
,	O
1.28-4.02	O
)	O
compared	O
with	O
individuals	O
who	O
had	O
the	O
Asp/Asp	O
genotype	O
.	O

Stratification	O
analysis	O
indicated	O
that	O
the	O
association	O
was	O
more	O
pronounced	O
among	O
men	O
(	O
OR	O
,	O
2.64	O
;	O
95%	O
CI	O
,	O
1.29-5.41	O
)	O
and	O
among	O
younger	O
individuals	O
(	O
OR	O
,	O
2.85	O
;	O
95%	O
CI	O
,	O
1.36-5.96	O
)	O
compared	O
with	O
women	O
and	O
older	O
individuals	O
.	O

Moreover	O
,	O
a	O
multiplicative	O
joint	O
effect	O
between	O
the	O
CCL22	O
SNP	O
and	O
H	O
.	O

pylori	O
infection	O
that	O
intensified	O
the	O
risk	O
was	O
observed	O
(	O
OR	O
for	O
the	O
presence	O
of	O
both	O
Ala/Ala	O
genotype	O
and	O
H	O
.	O

pylori	O
infection	O
,	O
18.37	O
;	O
95%	O
CI	O
,	O
2.30-146.67	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
from	O
this	O
study	O
suggested	O
that	O
the	O
CCL22	O
polymorphism	O
is	O
associated	O
with	O
an	O
increase	O
risk	O
of	O
developing	O
H	O
.	O

pylori	O
infection-related	O
gastric	O
carcinoma	O
.	O

Impact	O
of	O
pepsinogen	O
C	O
polymorphism	O
on	O
individual	O
susceptibility	O
to	O
gastric	O
cancer	O
and	O
its	O
precancerous	O
conditions	O
in	O
a	O
Northeast	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Human	O
pepsinogen	O
C	O
(PGC)	O
is	O
an	O
aspartic	O
protease	O
produced	O
specifically	O
by	O
the	O
gastric	O
mucosa	O
,	O
and	O
is	O
considered	O
as	O
a	O
mature	O
marker	O
of	O
gastric	O
epithelium	O
.	O

This	O
study	O
examined	O
the	O
contributions	O
of	O
PGC	O
polymorphisms	O
and	O
the	O
Helicobacter	O
pylori	O
(	O
H	O
.	O

pylori	O
)	O
infection	O
to	O
the	O
risk	O
of	O
gastric	O
cancer	O
(GC)	O
,	O
and	O
its	O
precancerous	O
conditions	O
in	O
a	O
Northeast	O
Chinese	O
population	O
.	O

METHODS	O
:	O
The	O
PGC	O
insertion/deletion	O
polymorphism	O
was	O
evaluated	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
followed	O
by	O
direct	O
DNA	O
sequencing	O
in	O
564	O
cases	O
of	O
GC	O
,	O
atrophic	O
gastritis	O
(AG)	O
,	O
gastric	O
ulcer	O
(GU)	O
and	O
superficial	O
gastritis	O
(	O
as	O
control	O
)	O
.	O

All	O
cases	O
were	O
frequency-matched	O
1:1	O
by	O
gender	O
and	O
age	O
(+/-5)	O
.	O

H	O
.	O

pylori	O
infection	O
was	O
identified	O
by	O
serum	O
anti-H	O
.	O

pylori	O
IgG	O
measurement	O
through	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
Patients	O
with	O
a	O
homozygous	O
PGC	O
allele	O
1	O
genotype	O
had	O
a	O
significant	O
risk	O
of	O
AG	O
[	O
adjusted	O
odds	O
ratio	O
(OR)	O
3.11	O
;	O
95%	O
confidence	O
interval	O
(CI)	O
1.44-6.71	O
]	O
or	O
of	O
GC	O
(	O
OR	O
3.00	O
;	O
95%	O
CI	O
1.38-6.51	O
)	O
,	O
and	O
a	O
significantly	O
elevated	O
risk	O
of	O
intestinal	O
metaplasia	O
(	O
OR	O
1.90	O
,	O
95%	O
CI	O
1.11-3.27	O
)	O
.	O

PGC	O
polymorphism	O
with	O
H	O
.	O

pylori	O
infection	O
increased	O
risk	O
of	O
GU	O
(	O
OR	O
8.69	O
;	O
95%	O
CI	O
1.01-74.69	O
)	O
,	O
and	O
AG	O
(	O
OR	O
11.12	O
;	O
95%	O
CI	O
1.37-90.84	O
)	O
or	O
GC	O
(	O
OR	O
10.61	O
;	O
95%	O
CI	O
1.28-87.79	O
)	O
in	O
a	O
super-multiplicative	O
manner	O
.	O

The	O
S	O
value	O
was	O
5.40	O
,	O
6.48	O
and	O
4.34	O
;	O
and	O
the	O
AP	O
value	O
was	O
72.09	O
,	O
7.00	O
and	O
69.69%	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
PGC	O
gene	O
polymorphism	O
increases	O
an	O
individual's	O
susceptibility	O
to	O
GC	O
and	O
its	O
precancerous	O
conditions	O
.	O

Moreover	O
,	O
the	O
PGC	O
gene	O
polymorphism	O
shows	O
a	O
positive	O
link	O
to	O
H	O
.	O

pylori	O
infection	O
in	O
the	O
development	O
of	O
GC	O
.	O

Three	O
novel	O
IGFALS	O
gene	O
mutations	O
resulting	O
in	O
total	O
ALS	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiency	O
in	O
children	O
of	O
different	O
ethnic	O
origins	O
.	O

BACKGROUND/AIMS	O
:	O
To	O
date	O
,	O
four	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
have	O
been	O
reported	O
.	O

We	O
now	O
describe	O
two	O
children	O
of	O
different	O
ethnic	O
background	O
with	O
total	O
acid-labile	O
subunit	O
(ALS)	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	O
deficiencies	O
resulting	O
from	O
three	O
novel	O
mutations	O
in	O
the	O
IGFALS	O
gene	O
.	O

PATIENTS/METHODS	O
:	O
Serum	O
and	O
DNA	O
of	O
patients	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Case	O
1	O
is	O
a	O
12-year-old	O
boy	O
of	O
Mayan	O
origin	O
.	O

Case	O
2	O
is	O
a	O
5-year-old	O
girl	O
of	O
Jewish/Eastern	O
European	O
(	O
Polish	O
,	O
Russian	O
,	O
Austrian-Hungarian)/Icelandic/European	O
(	O
French	O
,	O
English	O
)	O
ancestry	O
.	O

The	O
reported	O
cases	O
had	O
moderate	O
short	O
stature	O
(	O
-2.91	O
and	O
-2.14	O
SDS	O
,	O
respectively	O
)	O
,	O
nondetectable	O
serum	O
ALS	O
and	O
extremely	O
low	O
serum	O
concentrations	O
of	O
IGF-I	O
and	O
IGFBP-3	O
.	O

Case	O
1	O
harbored	O
a	O
novel	O
homozygous	O
1308_1316	B-DNAMutation
dup9	I-DNAMutation
mutation	O
in	O
a	O
highly	O
conserved	O
leucine-rich	O
repeat	O
(LRR)	O
17	O
motif	O
of	O
exon	O
2	O
,	O
representing	O
an	O
in-frame	O
insertion	O
of	O
3	O
amino	O
acids	O
,	O
LEL	O
.	O

Case	O
2	O
harbored	O
a	O
novel	O
heterozygous	O
C60S	B-ProteinMutation
/	O
L244F	B-ProteinMutation
mutation	O
in	O
exon	O
2	O
,	O
located	O
within	O
a	O
highly	O
conserved	O
LRR	O
1	O
and	O
LRR	O
9	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
identification	O
of	O
additional	O
novel	O
IGFALS	O
mutations	O
,	O
resulting	O
in	O
severe	O
IGF-I/IGFBP-3	O
and	O
ALS	O
deficiencies	O
,	O
supports	O
IGFALS	O
as	O
a	O
candidate	O
gene	O
of	O
the	O
GH/IGF	O
system	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
primary	O
IGF	O
deficiency	O
,	O
and	O
represents	O
an	O
important	O
part	O
of	O
its	O
differential	O
diagnosis	O
.	O

A	O
recessive	O
skeletal	O
dysplasia	O
,	O
SEMD	O
aggrecan	O
type	O
,	O
results	O
from	O
a	O
missense	O
mutation	O
affecting	O
the	O
C-type	O
lectin	O
domain	O
of	O
aggrecan	O
.	O

Analysis	O
of	O
a	O
nuclear	O
family	O
with	O
three	O
affected	O
offspring	O
identified	O
an	O
autosomal-recessive	O
form	O
of	O
spondyloepimetaphyseal	O
dysplasia	O
characterized	O
by	O
severe	O
short	O
stature	O
and	O
a	O
unique	O
constellation	O
of	O
radiographic	O
findings	O
.	O

Homozygosity	O
for	O
a	O
haplotype	O
that	O
was	O
identical	O
by	O
descent	O
between	O
two	O
of	O
the	O
affected	O
individuals	O
identified	O
a	O
locus	O
for	O
the	O
disease	O
gene	O
within	O
a	O
17.4	O
Mb	O
interval	O
on	O
chromosome	O
15	O
,	O
a	O
region	O
containing	O
296	O
genes	O
.	O

These	O
genes	O
were	O
assessed	O
and	O
ranked	O
by	O
cartilage	O
selectivity	O
with	O
whole-genome	O
microarray	O
data	O
,	O
revealing	O
only	O
two	O
genes	O
,	O
encoding	O
aggrecan	O
and	O
chondroitin	O
sulfate	O
proteoglycan	O
4	O
,	O
that	O
were	O
selectively	O
expressed	O
in	O
cartilage	O
.	O

Sequence	O
analysis	O
of	O
aggrecan	O
complementary	O
DNA	O
from	O
an	O
affected	O
individual	O
revealed	O
homozygosity	O
for	O
a	O
missense	O
mutation	O
(	O
c.6799G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
)	O
that	O
predicts	O
a	O
p.D2267N	B-ProteinMutation
amino	O
acid	O
substitution	O
in	O
the	O
C-type	O
lectin	O
domain	O
within	O
the	O
G3	O
domain	O
of	O
aggrecan	O
.	O

The	O
D2267	O
residue	O
is	O
predicted	O
to	O
coordinate	O
binding	O
of	O
a	O
calcium	O
ion	O
,	O
which	O
influences	O
the	O
conformational	O
binding	O
loops	O
of	O
the	O
C-type	O
lectin	O
domain	O
that	O
mediate	O
interactions	O
with	O
tenascins	O
and	O
other	O
extracellular-matrix	O
proteins	O
.	O

Expression	O
of	O
the	O
normal	O
and	O
mutant	O
G3	O
domains	O
in	O
mammalian	O
cells	O
showed	O
that	O
the	O
mutation	O
created	O
a	O
functional	O
N-glycosylation	O
site	O
but	O
did	O
not	O
adversely	O
affect	O
protein	O
trafficking	O
and	O
secretion	O
.	O

Surface-plasmon-resonance	O
studies	O
showed	O
that	O
the	O
mutation	O
influenced	O
the	O
binding	O
and	O
kinetics	O
of	O
the	O
interactions	O
between	O
the	O
aggrecan	O
G3	O
domain	O
and	O
tenascin-C	O
.	O

These	O
findings	O
identify	O
an	O
autosomal-recessive	O
skeletal	O
dysplasia	O
and	O
a	O
significant	O
role	O
for	O
the	O
aggrecan	O
C-type	O
lectin	O
domain	O
in	O
regulating	O
endochondral	O
ossification	O
and	O
,	O
thereby	O
,	O
height	O
.	O

Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	O
muscular	O
dystrophy	O
.	O

BACKGROUND	O
:	O
Oculopharyngeal	O
muscular	O
dystrophy	O
(OPMD)	O
is	O
a	O
late	O
onset	O
autosomal	O
dominant	O
muscle	O
disorder	O
.	O

OPMD	O
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	O
tract	O
in	O
the	O
polyadenylate	O
binding-protein	O
nuclear	O
1	O
(PABPN1)	O
gene	O
.	O

We	O
identified	O
and	O
characterized	O
a	O
PABPN1	O
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	O
.	O

METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	O
family	O
.	O

Genetic	O
alterations	O
in	O
the	O
PABPN1	O
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	O
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	O
gene	O
.	O

The	O
normal	O
(GCG)6(GCA)3GCG	O
sequence	O
was	O
replaced	O
by	O
(GCG)6(GCA)(GCG)4(GCA)3GCG	O
due	O
to	O
an	O
insertion	O
of	O
(GCG)4GCA	O
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	O
subjects	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	O
patients	O
in	O
the	O
literature	O
,	O
an	O
insertion	O
of	O
(GCG)4GCA	O
in	O
the	O
PABPN1	O
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	O
subjects	O
.	O

The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross-over	O
of	O
two	O
PABPN1	O
alleles	O
.	O

Combination	O
of	O
polymorphisms	O
within	O
5'	O
and	O
3'	O
untranslated	O
regions	O
of	O
thymidylate	O
synthase	O
gene	O
modulates	O
survival	O
in	O
5	O
fluorouracil-treated	O
colorectal	O
cancer	O
patients	O
.	O

In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	O
gene	O
on	O
overall	O
and	O
progression-	O
free	O
survival	O
of	O
colorectal	O
cancer	O
(CRC)	O
patients	O
subjected	O
to	O
5FU	O
chemotherapy	O
.	O

A	O
28	O
bp	O
variable	O
number	O
of	O
tandem	O
repeats	O
(VNTR)	O
,	O
a	O
G/C	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
and	O
a	O
deletion	O
of	O
6	O
bp	O
at	O
position	O
1494	O
were	O
studied	O
.	O

The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	O
was	O
also	O
evaluated	O
.	O

A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin-embedded	O
sections	O
from	O
113	O
patients	O
diagnosed	O
of	O
advanced	O
CRC	O
.	O

TS	O
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(PCR)	O
for	O
VNTR	O
and	O
PCR	O
,	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(PCR-RFLP)	O
for	O
SNP	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
.	O

To	O
study	O
the	O
combined	O
effect	O
of	O
TS	O
polymorphisms	O
,	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
genotypes	O
:	O
C_allele	O
6-	O
,	O
C_6+/6+	O
,	O
G_allele6-	O
and	O
G_6+/6+	O
.	O

VNTR	O
and	O
ins/del	B-DNAMutation
6	I-DNAMutation
bp	I-DNAMutation
genotypes	O
varied	O
with	O
tumour	O
anatomical	O
site	O
:	O
2R/2R	O
genotype	O
was	O
rare	O
in	O
left-sided	O
tumours	O
(	O
7.0%	O
vs	O
.	O

26.3%	O
of	O
right-sided	O
and	O
24.1%	O
of	O
rectal	O
cancers	O
;	O
P<0.01	O
)	O
,	O
where	O
the	O
variant	O
allele	O
6-	O
was	O
very	O
frequent	O
(69.0%)	O
.	O

Instead	O
,	O
most	O
patients	O
with	O
right-sided	O
tumours	O
were	O
wild-type	O
homozygous	O
6+/6+	O
(63.9%)	O
(P<0.01)	O
.	O

Heterozygous	O
6+/6-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	O
classified	O
as	O
C	O
(50.0%)	O
and	O
D	O
(76.5%)	O
Dukes	O
stages	O
(P=0.05)	O
.	O

None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression-free	O
survival	O
(PFS)	O
.	O

C_6+/6+	O
and	O
G_6+/6+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P=0.03	O
when	O
compared	O
with	O
each	O
other	O
)	O
,	O
while	O
combinations	O
carrying	O
the	O
allele	O
6-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O

The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	O
was	O
unexpectedly	O
high	O
(59.1%)	O
among	O
patients	O
with	O
the	O
unfavourable	O
G_6+/6+	O
combination	O
.	O

In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	O
expression	O
genotypes	O
G_6+/6+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	O
patients	O
treated	O
with	O
5FU	O
.	O

Genome-wide	O
loss	O
of	O
heterozygosity	O
and	O
uniparental	O
disomy	O
in	O
BRCA1/2-associated	O
ovarian	O
carcinomas	O
.	O

PURPOSE	O
:	O
The	O
importance	O
of	O
the	O
BRCA	O
gene	O
products	O
in	O
maintaining	O
genomic	O
stability	O
led	O
us	O
to	O
hypothesize	O
that	O
BRCA-associated	O
and	O
sporadic	O
ovarian	O
cancers	O
would	O
have	O
distinctive	O
genetic	O
profiles	O
despite	O
similarities	O
in	O
histologic	O
appearance	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
A	O
whole-genome	O
copy	O
number	O
analysis	O
of	O
fresh	O
,	O
frozen	O
,	O
papillary	O
serous	O
ovarian	O
cancer	O
DNA	O
was	O
done	O
using	O
the	O
Affymetrix	O
50K	O
Xba	O
Mapping	O
Array	O
using	O
each	O
patient's	O
normal	O
genomic	O
DNA	O
as	O
the	O
matched	O
control	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
copy	O
number	O
abnormalities	O
were	O
summarized	O
to	O
define	O
regions	O
of	O
amplification	O
,	O
deletion	O
,	O
or	O
uniparental	O
disomy	O
(UPD)	O
,	O
defined	O
as	O
loss	O
of	O
one	O
allele	O
and	O
duplication	O
of	O
the	O
remaining	O
allele	O
.	O

Genomic	O
abnormalities	O
were	O
compared	O
between	O
BRCA-associated	O
and	O
sporadic	O
tumors	O
.	O

RESULTS	O
:	O
We	O
compared	O
6	O
BRCA-associated	O
with	O
14	O
sporadic	O
papillary	O
serous	O
ovarian	O
carcinomas	O
.	O

Genetic	O
instability	O
,	O
measured	O
by	O
percentage	O
of	O
genome	O
altered	O
,	O
was	O
more	O
pronounced	O
in	O
BRCA-associated	O
tumors	O
(	O
median	O
,	O
86.6%	O
;	O
range	O
,	O
54-100%	O
)	O
than	O
sporadic	O
tumors	O
(	O
median	O
,	O
43.6%	O
;	O
range	O
,	O
2-83%	O
;	O
P	O
=	O
0.009	O
)	O
.	O

We	O
used	O
frequency	O
plots	O
to	O
show	O
the	O
proportion	O
of	O
cases	O
affected	O
by	O
each	O
type	O
abnormality	O
at	O
each	O
genomic	O
region	O
.	O

BRCA-associated	O
tumors	O
showed	O
genome-wide	O
loss	O
of	O
heterozygosity	O
primarily	O
due	O
to	O
the	O
occurrence	O
of	O
UPD	O
rather	O
than	O
deletion	O
.	O

UPD	O
was	O
found	O
in	O
100%	O
of	O
the	O
BRCA-associated	O
and	O
50%	O
of	O
the	O
sporadic	O
tumors	O
profiled	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
reports	O
on	O
a	O
previously	O
underappreciated	O
genetic	O
phenomenon	O
of	O
UPD	O
,	O
which	O
occurs	O
frequently	O
in	O
ovarian	O
cancer	O
DNA	O
.	O

We	O
observed	O
distinct	O
genetic	O
patterns	O
between	O
BRCA-associated	O
and	O
sporadic	O
ovarian	O
cancers	O
,	O
suggesting	O
that	O
these	O
papillary	O
serous	O
tumors	O
arise	O
from	O
different	O
molecular	O
pathways	O
.	O

Mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
are	O
not	O
sufficient	O
to	O
cause	O
diffuse	O
mesangial	O
sclerosis	O
.	O

Diffuse	O
mesangial	O
sclerosis	O
occurs	O
as	O
an	O
isolated	O
abnormality	O
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O

Recently	O
,	O
mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
(PLCE1)	O
were	O
found	O
to	O
cause	O
a	O
nonsyndromic	O
,	O
autosomal	O
recessive	O
form	O
of	O
this	O
disease	O
.	O

Here	O
we	O
describe	O
three	O
children	O
from	O
one	O
consanguineous	O
kindred	O
of	O
Pakistani	O
origin	O
with	O
diffuse	O
mesangial	O
sclerosis	O
who	O
presented	O
with	O
congenital	O
or	O
infantile	O
nephrotic	O
syndrome	O
.	O

Homozygous	O
mutations	O
in	O
PLCE1	O
(	O
also	O
known	O
as	O
KIAA1516	O
,	O
PLCE	O
,	O
or	O
NPHS3	O
)	O
were	O
identified	O
following	O
genome-wide	O
mapping	O
of	O
single-nucleotide	O
polymorphisms	O
.	O

All	O
affected	O
children	O
were	O
homozygous	O
for	O
a	O
four-basepair	O
deletion	O
in	O
exon	O
3	O
,	O
which	O
created	O
a	O
premature	O
translational	O
stop	O
codon	O
.	O

Analysis	O
of	O
the	O
asymptomatic	O
father	O
of	O
two	O
of	O
the	O
children	O
revealed	O
that	O
he	O
was	O
also	O
homozygous	O
for	O
the	O
same	O
mutation	O
.	O

We	O
conclude	O
this	O
nonpenetrance	O
may	O
be	O
due	O
to	O
compensatory	O
mutations	O
at	O
a	O
second	O
locus	O
and	O
that	O
mutation	O
within	O
PLCE1	O
is	O
not	O
always	O
sufficient	O
to	O
cause	O
diffuse	O
mesangial	O
sclerosis	O
.	O

Somatic	O
TP53	O
mutation	O
mosaicism	O
in	O
a	O
patient	O
with	O
Li-Fraumeni	O
syndrome	O
.	O

We	O
present	O
a	O
girl	O
who	O
developed	O
adrenocortical	O
adenoma	O
at	O
the	O
age	O
of	O
1	O
year	O
and	O
osteosarcoma	O
at	O
the	O
age	O
of	O
5	O
years	O
.	O

There	O
was	O
no	O
history	O
of	O
cancer	O
in	O
her	O
parents	O
and	O
their	O
relatives	O
.	O

However	O
,	O
both	O
tumors	O
were	O
typical	O
for	O
the	O
Li-Fraumeni	O
syndrome	O
(LFS)	O
,	O
and	O
the	O
patient	O
met	O
criteria	O
for	O
germline	O
TP53	O
mutation	O
testing	O
.	O

A	O
mutation	O
in	O
codon	O
282	O
Arg282Trp	B-ProteinMutation
was	O
identified	O
in	O
her	O
blood	O
lymphocyte	O
genomic	O
DNA	O
.	O

The	O
substitution	O
was	O
found	O
in	O
neither	O
of	O
her	O
parents	O
,	O
which	O
indicated	O
a	O
possibility	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

Unexpectedly	O
,	O
sequencing	O
of	O
the	O
DNA	O
of	O
the	O
patient	O
repeatedly	O
showed	O
allelic	O
imbalance	O
in	O
favor	O
of	O
the	O
normal	O
allele	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
investigate	O
the	O
putative	O
somatic	O
mosaicism	O
in	O
the	O
patient	O
consisting	O
of	O
normal	O
cells	O
and	O
cells	O
heterozygous	O
for	O
the	O
mutation	O
.	O

The	O
imbalance	O
was	O
also	O
examined	O
in	O
two	O
other	O
non-invasively	O
sampled	O
tissues	O
,	O
buccal	O
cells	O
,	O
and	O
cells	O
from	O
the	O
urine	O
sediment	O
,	O
and	O
sequencing	O
was	O
confirmed	O
with	O
two	O
other	O
independent	O
methods	O
.	O

While	O
the	O
findings	O
in	O
blood	O
and	O
the	O
urine	O
sediment	O
were	O
similar	O
,	O
in	O
buccal	O
cells	O
both	O
alleles	O
were	O
present	O
in	O
equal	O
amounts	O
.	O

The	O
allele	O
ratio	O
in	O
lymphocytes	O
was	O
consistent	O
with	O
a	O
mosaic	O
where	O
about	O
2/3	O
of	O
cells	O
carried	O
two	O
normal	O
alleles	O
and	O
only	O
1/3	O
was	O
heterozygous	O
for	O
the	O
mutation	O
.	O

Despite	O
the	O
mosaicism	O
the	O
girl	O
developed	O
two	O
early	O
childhood	O
tumors	O
of	O
mesodermal	O
origin	O
,	O
and	O
her	O
phenotype	O
was	O
thus	O
not	O
milder	O
than	O
that	O
of	O
other	O
germline	O
TP53	O
mutation	O
carriers	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
description	O
of	O
somatic	O
mosaicism	O
for	O
a	O
de	O
novo	O
TP53	O
mutation	O
in	O
LFS	O
.	O

A	O
comprehensive	O
analysis	O
of	O
the	O
CDKN2A	O
gene	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
reveals	O
genomic	O
deletion	O
,	O
copy	O
number	O
neutral	O
loss	O
of	O
heterozygosity	O
,	O
and	O
association	O
with	O
specific	O
cytogenetic	O
subgroups	O
.	O

Inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
CDKN2A	O
,	O
can	O
occur	O
by	O
deletion	O
,	O
methylation	O
,	O
or	O
mutation	O
.	O

We	O
assessed	O
the	O
principal	O
mode	O
of	O
inactivation	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
and	O
frequency	O
in	O
biologically	O
relevant	O
subgroups	O
.	O

Mutation	O
or	O
methylation	O
was	O
rare	O
,	O
whereas	O
genomic	O
deletion	O
occurred	O
in	O
21%	O
of	O
B-cell	O
precursor	O
ALL	O
and	O
50%	O
of	O
T-ALL	O
patients	O
.	O

Single	O
nucleotide	O
polymorphism	O
arrays	O
revealed	O
copy	O
number	O
neutral	O
(CNN)	O
loss	O
of	O
heterozygosity	O
(LOH)	O
in	O
8%	O
of	O
patients	O
.	O

Array-based	O
comparative	O
genomic	O
hybridization	O
demonstrated	O
that	O
the	O
mean	O
size	O
of	O
deletions	O
was	O
14.8	O
Mb	O
and	O
biallelic	O
deletions	O
composed	O
a	O
large	O
and	O
small	O
deletion	O
(	O
mean	O
sizes	O
,	O
23.3	O
Mb	O
and	O
1.4	O
Mb	O
)	O
.	O

Among	O
86	O
patients	O
,	O
only	O
2	O
small	O
deletions	O
were	O
below	O
the	O
resolution	O
of	O
detection	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

Patients	O
with	O
high	O
hyperdiploidy	O
,	O
ETV6-RUNX1	O
,	O
or	O
11q23/MLL	O
rearrangements	O
had	O
low	O
rates	O
of	O
deletion	O
(	O
11%	O
,	O
15%	O
,	O
13%	O
)	O
,	O
whereas	O
patients	O
with	O
t(9;22)	O
,	O
t(1;19)	O
,	O
TLX3	O
,	O
or	O
TLX1	O
rearrangements	O
had	O
higher	O
frequencies	O
(	O
61%	O
,	O
42%	O
,	O
78%	O
,	O
and	O
89%	O
)	O
.	O

In	O
conclusion	O
,	O
CDKN2A	O
deletion	O
is	O
a	O
significant	O
secondary	O
abnormality	O
in	O
childhood	O
ALL	O
strongly	O
correlated	O
with	O
phenotype	O
and	O
genotype	O
.	O

The	O
variation	O
in	O
the	O
incidence	O
of	O
CDKN2A	O
deletions	O
by	O
cytogenetic	O
subgroup	O
may	O
explain	O
its	O
inconsistent	O
association	O
with	O
outcome	O
.	O

CNN	O
LOH	O
without	O
apparent	O
CDKN2A	O
inactivation	O
suggests	O
the	O
presence	O
of	O
other	O
relevant	O
genes	O
in	O
this	O
region	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
enhancing	O
hGR-mediated	O
gene	O
expression	O
.	O

CONTEXT	O
:	O
Interindividual	O
variations	O
in	O
glucocorticoid	O
sensitivity	O
have	O
been	O
associated	O
with	O
manifestations	O
of	O
cortisol	O
excess	O
or	O
deficiency	O
and	O
may	O
be	O
partly	O
explained	O
by	O
polymorphisms	O
in	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
.	O

We	O
studied	O
a	O
43-yr-old	O
female	O
,	O
who	O
presented	O
with	O
manifestations	O
consistent	O
with	O
tissue-selective	O
glucocorticoid	O
hypersensitivity	O
.	O

We	O
detected	O
a	O
novel	O
,	O
single	O
,	O
heterozygous	O
nucleotide	O
(	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1201	I-DNAMutation
(	O
exon	O
2	O
)	O
of	O
the	O
hGR	O
gene	O
,	O
which	O
resulted	O
in	O
aspartic	O
acid	O
to	O
histidine	O
substitution	O
at	O
amino	O
acid	O
position	O
401	O
in	O
the	O
amino-terminal	O
domain	O
of	O
the	O
hGRalpha	O
.	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
of	O
action	O
of	O
the	O
natural	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
.	O

METHODS-RESULTS	O
:	O
Compared	O
with	O
the	O
wild-type	O
hGRalpha	O
,	O
the	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
demonstrated	O
a	O
2.4-fold	O
increase	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid-inducible	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	O
in	O
response	O
to	O
dexamethasone	O
but	O
had	O
similar	O
affinity	O
for	O
the	O
ligand	O
(	O
dissociation	O
constant	O
=	O
6.2	O
+/-	O
0.6	O
vs	O
.	O

6.1	O
+/-	O
0.6	O
nm	O
)	O
and	O
time	O
to	O
nuclear	O
translocation	O
(	O
14.75	O
+/-	O
0.25	O
vs	O
.	O

14.25	O
+/-	O
1.13	O
min	O
)	O
.	O

The	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
did	O
not	O
exert	O
a	O
dominant	O
positive	O
or	O
negative	O
effect	O
upon	O
the	O
wild-type	O
receptor	O
,	O
it	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
glucocorticoid	O
response	O
elements	O
,	O
and	O
displayed	O
a	O
normal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
hGRalphaD401H	B-ProteinMutation
enhances	O
the	O
transcriptional	O
activity	O
of	O
glucocorticoid-responsive	O
genes	O
.	O

The	O
presence	O
of	O
the	O
D401H	B-ProteinMutation
mutation	O
may	O
predispose	O
subjects	O
to	O
obesity	O
,	O
hypertension	O
,	O
and	O
other	O
manifestations	O
of	O
the	O
metabolic	O
syndrome	O
.	O

Novel	O
mutations	O
in	O
the	O
IRF6	O
gene	O
in	O
Brazilian	O
families	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
Syndrome	O
(VWS)	O
is	O
an	O
autosomal	O
craniofacial	O
disorder	O
characterized	O
by	O
lower	O
lip	O
pits	O
and	O
cleft	O
lip	O
and/or	O
palate	O
.	O

Mutations	O
in	O
the	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
VWS	O
.	O

To	O
identify	O
novel	O
IRF6	O
mutations	O
in	O
patients	O
affected	O
by	O
VWS	O
,	O
we	O
screened	O
2	O
Brazilian	O
families	O
,	O
sequencing	O
the	O
entire	O
IRF6-coding	O
region	O
and	O
flanking	O
intronic	O
boundaries	O
.	O

Two	O
novel	O
heterozygous	O
mutations	O
were	O
identified	O
:	O
a	O
frame	O
shift	O
mutation	O
with	O
deletion	O
of	O
G	O
at	O
the	O
nucleotide	O
position	O
520	O
in	O
the	O
exon	O
6	O
520delG	B-DNAMutation
,	O
and	O
a	O
missense	O
single	O
nucleotide	O
substitution	O
from	O
T	O
to	O
A	O
at	O
nucleotide	O
position	O
1135	O
in	O
exon	O
8	O
T1135A	B-DNAMutation
.	O

By	O
using	O
restriction	O
enzyme	O
analysis	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
the	O
lack	O
of	O
similar	O
mutations	O
in	O
unrelated	O
healthy	O
individuals	O
and	O
non-syndromic	O
cleft	O
lip	O
and	O
palate	O
patients	O
.	O

Our	O
results	O
further	O
confirmed	O
that	O
haploinsufficiency	O
of	O
the	O
IRF6	O
gene	O
results	O
in	O
VWS	O
.	O

Genetics	O
of	O
Meesmann	O
corneal	O
dystrophy	O
:	O
a	O
novel	O
mutation	O
in	O
the	O
keratin	O
3	O
gene	O
in	O
an	O
asymptomatic	O
family	O
suggests	O
genotype-phenotype	O
correlation	O
.	O

PURPOSE	O
:	O
Juvenile	O
epithelial	O
corneal	O
dystrophy	O
of	O
Meesmann	O
(	O
MCD	O
,	O
OMIM	O
122100	O
)	O
is	O
a	O
dominantly	O
inherited	O
disorder	O
characterized	O
by	O
fragility	O
of	O
the	O
anterior	O
corneal	O
epithelium	O
and	O
intraepithelial	O
microcyst	O
formation	O
.	O

Although	O
the	O
disease	O
is	O
generally	O
mild	O
and	O
affected	O
individuals	O
are	O
often	O
asymptomatic	O
,	O
some	O
suffer	O
from	O
recurrent	O
erosions	O
leading	O
to	O
lacrimation	O
,	O
photophobia	O
,	O
and	O
deterioration	O
in	O
visual	O
acuity	O
.	O

MCD	O
is	O
caused	O
by	O
mutations	O
in	O
keratin	O
3	O
(KRT3)	O
or	O
keratin	O
12	O
(KRT12)	O
genes	O
,	O
which	O
encode	O
cornea-specific	O
cytoskeletal	O
proteins	O
.	O

Seventeen	O
mutations	O
in	O
KRT12	O
and	O
two	O
in	O
KRT3	O
have	O
been	O
described	O
so	O
far	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
genetic	O
background	O
of	O
MCD	O
in	O
a	O
Polish	O
family	O
.	O

METHODS	O
:	O
We	O
report	O
on	O
a	O
three-generation	O
family	O
with	O
MCD	O
.	O

Epithelial	O
lesions	O
characteristic	O
for	O
MCD	O
were	O
visualized	O
with	O
slit-lamp	O
examination	O
and	O
confirmed	O
by	O
in	O
vivo	O
confocal	O
microscopy	O
.	O

Using	O
genomic	O
DNA	O
as	O
a	O
template	O
,	O
all	O
coding	O
regions	O
of	O
KRT3	O
and	O
KRT12	O
were	O
amplified	O
and	O
sequenced	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
verified	O
with	O
restriction	O
endonuclease	O
digestion	O
.	O

RESULTS	O
:	O
In	O
the	O
proband	O
,	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
product	O
from	O
amplified	O
coding	O
regions	O
of	O
KRT3	O
and	O
KRT12	O
revealed	O
a	O
novel	O
1493A>T	B-DNAMutation
heterozygous	O
missense	O
mutation	O
in	O
exon	O
7	O
of	O
KRT3	O
,	O
which	O
predicts	O
the	O
substitution	O
of	O
glutamic	O
acid	O
for	O
valine	O
at	O
codon	O
498	O
E498V	B-ProteinMutation
.	O

Using	O
PCR-Restriction	O
Fragment	O
Length	O
Polymorphism	O
(RFLP)	O
analysis	O
,	O
the	O
mutation	O
was	O
demonstrated	O
to	O
segregate	O
with	O
the	O
disease	O
(	O
four	O
affected	O
members	O
,	O
three	O
non-affected	O
)	O
and	O
to	O
be	O
absent	O
in	O
100	O
controls	O
from	O
the	O
Polish	O
population	O
,	O
indicating	O
that	O
it	O
is	O
not	O
a	O
common	O
polymorphism	O
.	O

CONCLUSIONS	O
:	O
Location	O
of	O
the	O
E498V	B-ProteinMutation
mutation	O
emphasizes	O
the	O
functional	O
relevance	O
of	O
the	O
highly	O
conserved	O
boundary	O
motifs	O
at	O
the	O
COOH-terminus	O
of	O
the	O
alpha-helical	O
rod	O
domain	O
in	O
keratin	O
3	O
(K3)	O
.	O

Identification	O
of	O
a	O
gain-of-function	O
mutation	O
of	O
the	O
prolactin	O
receptor	O
in	O
women	O
with	O
benign	O
breast	O
tumors	O
.	O

There	O
is	O
currently	O
no	O
known	O
genetic	O
disease	O
linked	O
to	O
prolactin	O
(Prl)	O
or	O
its	O
receptor	O
(PrlR)	O
in	O
humans	O
.	O

Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
,	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl/PrlR	O
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	O
diseases	O
with	O
high	O
proliferative	O
potential	O
.	O

Multiple	O
fibroadenomas	O
(MFA)	O
are	O
benign	O
breast	O
tumors	O
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	O
,	O
including	O
at	O
puberty	O
,	O
when	O
Prl	O
has	O
well-recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O

In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	O
patients	O
and	O
170	O
control	O
subjects	O
,	O
we	O
identified	O
four	O
patients	O
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	O
gene	O
,	O
encoding	O
Ile(146)-->Leu	B-ProteinMutation
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O

This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
PrlR	O
(	O
I146L	B-ProteinMutation
)	O
,	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba/F3	O
,	O
HEK293	O
and	O
MCF-7	O
cells	O
)	O
by	O
Prl-independent	O
(i)	O
PrlR	O
tyrosine	O
phosphorylation	O
,	O
(ii)	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(STAT5)	O
signaling	O
,	O
(iii)	O
transcriptional	O
activity	O
toward	O
a	O
Prl-responsive	O
reporter	O
gene	O
,	O
and	O
(iv)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O

Constitutive	O
activity	O
of	O
PrlR	O
(	O
I146L	B-ProteinMutation
)	O
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	O
was	O
supported	O
by	O
increased	O
STAT5	O
signaling	O
.	O

This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	O
associated	O
with	O
a	O
human	O
disease	O
.	O

Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	O
antagonist	O
,	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	O
,	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O

Genetic	O
variation	O
in	O
an	O
individual	O
human	O
exome	O
.	O

There	O
is	O
much	O
interest	O
in	O
characterizing	O
the	O
variation	O
in	O
a	O
human	O
individual	O
,	O
because	O
this	O
may	O
elucidate	O
what	O
contributes	O
significantly	O
to	O
a	O
person's	O
phenotype	O
,	O
thereby	O
enabling	O
personalized	O
genomics	O
.	O

We	O
focus	O
here	O
on	O
the	O
variants	O
in	O
a	O
person's	O
'exome,'	O
which	O
is	O
the	O
set	O
of	O
exons	O
in	O
a	O
genome	O
,	O
because	O
the	O
exome	O
is	O
believed	O
to	O
harbor	O
much	O
of	O
the	O
functional	O
variation	O
.	O

We	O
provide	O
an	O
analysis	O
of	O
the	O
approximately	O
12,500	O
variants	O
that	O
affect	O
the	O
protein	O
coding	O
portion	O
of	O
an	O
individual's	O
genome	O
.	O

We	O
identified	O
approximately	O
10,400	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
(nsSNPs)	O
in	O
this	O
individual	O
,	O
of	O
which	O
approximately	O
15-20%	O
are	O
rare	O
in	O
the	O
human	O
population	O
.	O

We	O
predict	O
approximately	O
1,500	O
nsSNPs	O
affect	O
protein	O
function	O
and	O
these	O
tend	O
be	O
heterozygous	O
,	O
rare	O
,	O
or	O
novel	O
.	O

Of	O
the	O
approximately	O
700	O
coding	O
indels	O
,	O
approximately	O
half	O
tend	O
to	O
have	O
lengths	O
that	O
are	O
a	O
multiple	O
of	O
three	O
,	O
which	O
causes	O
insertions/deletions	O
of	O
amino	O
acids	O
in	O
the	O
corresponding	O
protein	O
,	O
rather	O
than	O
introducing	O
frameshifts	O
.	O

Coding	O
indels	O
also	O
occur	O
frequently	O
at	O
the	O
termini	O
of	O
genes	O
,	O
so	O
even	O
if	O
an	O
indel	O
causes	O
a	O
frameshift	O
,	O
an	O
alternative	O
start	O
or	O
stop	O
site	O
in	O
the	O
gene	O
can	O
still	O
be	O
used	O
to	O
make	O
a	O
functional	O
protein	O
.	O

In	O
summary	O
,	O
we	O
reduced	O
the	O
set	O
of	O
approximately	O
12,500	O
nonsilent	O
coding	O
variants	O
by	O
approximately	O
8-fold	O
to	O
a	O
set	O
of	O
variants	O
that	O
are	O
most	O
likely	O
to	O
have	O
major	O
effects	O
on	O
their	O
proteins'	O
functions	O
.	O

This	O
is	O
our	O
first	O
glimpse	O
of	O
an	O
individual's	O
exome	O
and	O
a	O
snapshot	O
of	O
the	O
current	O
state	O
of	O
personalized	O
genomics	O
.	O

The	O
majority	O
of	O
coding	O
variants	O
in	O
this	O
individual	O
are	O
common	O
and	O
appear	O
to	O
be	O
functionally	O
neutral	O
.	O

Our	O
results	O
also	O
indicate	O
that	O
some	O
variants	O
can	O
be	O
used	O
to	O
improve	O
the	O
current	O
NCBI	O
human	O
reference	O
genome	O
.	O

As	O
more	O
genomes	O
are	O
sequenced	O
,	O
many	O
rare	O
variants	O
and	O
non-SNP	O
variants	O
will	O
be	O
discovered	O
.	O

We	O
present	O
an	O
approach	O
to	O
analyze	O
the	O
coding	O
variation	O
in	O
humans	O
by	O
proposing	O
multiple	O
bioinformatic	O
methods	O
to	O
hone	O
in	O
on	O
possible	O
functional	O
variation	O
.	O

Genome-wide	O
analysis	O
identifies	O
16q	O
deletion	O
associated	O
with	O
survival	O
,	O
molecular	O
subtypes	O
,	O
mRNA	O
expression	O
,	O
and	O
germline	O
haplotypes	O
in	O
breast	O
cancer	O
patients	O
.	O

Breast	O
carcinomas	O
are	O
characterized	O
by	O
DNA	O
copy	O
number	O
alterations	O
(CNAs)	O
with	O
biological	O
and	O
clinical	O
significance	O
.	O

This	O
explorative	O
study	O
integrated	O
CNA	O
,	O
expression	O
,	O
and	O
germline	O
genotype	O
data	O
of	O
112	O
early-stage	O
breast	O
cancer	O
patients	O
.	O

Recurrent	O
CNAs	O
differed	O
substantially	O
between	O
tumor	O
subtypes	O
classified	O
according	O
to	O
expression	O
pattern	O
.	O

Deletion	O
of	O
16q	O
was	O
overrepresented	O
in	O
Luminal	O
A	O
,	O
and	O
a	O
predictor	O
of	O
good	O
prognosis	O
,	O
both	O
overall	O
and	O
for	O
the	O
nonluminal	O
A	O
subgroups	O
.	O

The	O
deleted	O
region	O
most	O
significantly	O
associated	O
with	O
survival	O
mapped	O
to	O
16q22.2	O
,	O
harboring	O
the	O
genes	O
TXNL4B	O
and	O
DXH38	O
,	O
whose	O
expression	O
was	O
strongly	O
correlated	O
with	O
the	O
deletion	O
.	O

The	O
area	O
most	O
frequently	O
deleted	O
resided	O
on	O
16q23.1	O
,	O
3.5	O
MB	O
downstream	O
of	O
the	O
area	O
most	O
significantly	O
associated	O
with	O
survival	O
,	O
and	O
included	O
the	O
tumor	O
suppressor	O
gene	O
ADAMTS18	O
and	O
the	O
cell	O
recognition	O
gene	O
CNTNAP4	O
.	O

Whole-genome	O
association	O
analysis	O
identified	O
germline	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
their	O
corresponding	O
haplotypes	O
,	O
residing	O
on	O
several	O
different	O
chromosomes	O
,	O
to	O
be	O
associated	O
with	O
deletion	O
of	O
16q	O
.	O

The	O
genes	O
where	O
these	O
SNPs	O
reside	O
encode	O
proteins	O
involved	O
in	O
the	O
extracellular	O
matrix	O
(	O
CHST3	O
and	O
SPOCK2	O
)	O
,	O
in	O
regulation	O
of	O
the	O
cell	O
cycle	O
(	O
JMY	O
,	O
PTPRN2	O
,	O
and	O
Cwf19L2	O
)	O
and	O
chromosome	O
stability	O
(KPNB1)	O
.	O

TNFA	O
-308G>A	B-DNAMutation
in	O
two	O
international	O
population-based	O
cohorts	O
and	O
risk	O
of	O
asthma	O
.	O

Genetic	O
association	O
studies	O
have	O
related	O
the	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
(TNFA)	O
guanine	O
to	O
adenine	O
substitution	O
of	O
nucleotide	O
-308	O
-308G>A	B-DNAMutation
polymorphism	O
to	O
increased	O
risk	O
of	O
asthma	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
whether	O
two	O
single-nucleotide	O
polymorphisms	O
,	O
of	O
TNFA	O
and	O
of	O
the	O
lymphotoxin-alpha	O
gene	O
(LTA)	O
,	O
are	O
associated	O
with	O
asthma	O
,	O
bronchial	O
hyperresponsiveness	O
and	O
atopy	O
in	O
adults	O
,	O
by	O
combining	O
the	O
results	O
of	O
two	O
large	O
population-based	O
multicentric	O
studies	O
and	O
conducting	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

The	O
European	O
Community	O
Respiratory	O
Health	O
Survey	O
(ECRHS)	O
and	O
Swiss	O
Cohort	O
Study	O
on	O
Air	O
Pollution	O
and	O
Lung	O
and	O
Heart	O
Diseases	O
in	O
Adults	O
(SAPALDIA)	O
used	O
comparable	O
protocols	O
,	O
including	O
questionnaires	O
for	O
respiratory	O
symptoms	O
and	O
measures	O
of	O
lung	O
function	O
and	O
atopy	O
.	O

DNA	O
samples	O
from	O
11,136	O
participants	O
were	O
genotyped	O
at	O
TNFA	O
-308	O
and	O
LTA	O
252	O
.	O

Logistic	O
regression	O
employing	O
fixed	O
and	O
random	O
effects	O
models	O
and	O
nonparametric	O
techniques	O
were	O
used	O
.	O

The	O
prevalence	O
of	O
asthma	O
was	O
6%	O
.	O

The	O
TNFA	O
-308G>A	B-DNAMutation
polymorphism	O
was	O
associated	O
with	O
increased	O
asthma	O
prevalence	O
and	O
with	O
bronchial	O
hyperresponsiveness	O
.	O

No	O
consistent	O
association	O
was	O
found	O
for	O
atopy	O
.	O

The	O
LTA	O
252A>G	B-DNAMutation
polymorphism	O
was	O
not	O
associated	O
with	O
any	O
of	O
the	O
outcomes	O
.	O

A	O
meta-analysis	O
of	O
17	O
studies	O
showed	O
an	O
increased	O
asthma	O
risk	O
for	O
the	O
TNFA	O
-308	O
adenine	O
allele	O
.	O

The	O
tumour	O
necrosis	O
factor-alpha	O
gene	O
nucleotide	O
-308	O
polymorphism	O
is	O
associated	O
with	O
a	O
moderately	O
increased	O
risk	O
of	O
asthma	O
and	O
bronchial	O
hyperresponsiveness	O
,	O
but	O
not	O
with	O
atopy	O
.	O

These	O
results	O
are	O
supported	O
by	O
a	O
meta-analysis	O
of	O
previously	O
published	O
studies	O
.	O

A	O
splice	O
site	O
mutation	O
in	O
hERG	O
leads	O
to	O
cryptic	O
splicing	O
in	O
human	O
long	O
QT	O
syndrome	O
.	O

Mutations	O
in	O
the	O
human	O
ether-a-go-go-related	O
gene	O
(hERG)	O
cause	O
type	O
2	O
long	O
QT	O
syndrome	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
pathogenic	O
mechanism	O
of	O
the	O
hERG	O
splice	O
site	O
mutation	O
2398+1G>C	B-DNAMutation
and	O
the	O
genotype-phenotype	O
relationship	O
of	O
mutation	O
carriers	O
in	O
three	O
unrelated	O
kindreds	O
with	O
long	O
QT	O
syndrome	O
.	O

The	O
effect	O
of	O
2398+1G>C	B-DNAMutation
on	O
mRNA	O
splicing	O
was	O
studied	O
by	O
analysis	O
of	O
RNA	O
isolated	O
from	O
lymphocytes	O
of	O
index	O
patients	O
and	O
using	O
minigenes	O
expressed	O
in	O
HEK293	O
cells	O
and	O
neonatal	O
rat	O
ventricular	O
myocytes	O
.	O

RT-PCR	O
analysis	O
revealed	O
that	O
the	O
2398+1G>C	B-DNAMutation
mutation	O
disrupted	O
the	O
normal	O
splicing	O
and	O
activated	O
a	O
cryptic	O
splice	O
donor	O
site	O
in	O
intron	O
9	O
,	O
leading	O
to	O
the	O
inclusion	O
of	O
54	O
nt	O
of	O
the	O
intron	O
9	O
sequence	O
in	O
hERG	O
mRNA	O
.	O

The	O
cryptic	O
splicing	O
resulted	O
in	O
an	O
in-frame	O
insertion	O
of	O
18	O
amino	O
acids	O
in	O
the	O
middle	O
of	O
the	O
cyclic	O
nucleotide	O
binding	O
domain	O
.	O

In	O
patch	O
clamp	O
experiments	O
the	O
splice	O
mutant	O
did	O
not	O
generate	O
hERG	O
current	O
.	O

Western	O
blot	O
and	O
immunostaining	O
studies	O
showed	O
that	O
the	O
mutant	O
expressed	O
an	O
immature	O
form	O
of	O
hERG	O
protein	O
that	O
failed	O
to	O
reach	O
the	O
plasma	O
membrane	O
.	O

Coexpression	O
of	O
the	O
mutant	O
and	O
wild-type	O
channels	O
led	O
to	O
a	O
dominant	O
negative	O
suppression	O
of	O
wild-type	O
channel	O
function	O
by	O
intracellular	O
retention	O
of	O
heteromeric	O
channels	O
.	O

Our	O
results	O
demonstrate	O
that	O
2398+1G>C	B-DNAMutation
activates	O
a	O
cryptic	O
site	O
and	O
generates	O
a	O
full-length	O
hERG	O
protein	O
with	O
an	O
insertion	O
of	O
18	O
amino	O
acids	O
,	O
which	O
leads	O
to	O
a	O
trafficking	O
defect	O
of	O
the	O
mutant	O
channel	O
.	O

Catechol-O-methyltransferase	O
(COMT)	O
gene	O
variants	O
:	O
possible	O
association	O
of	O
the	O
Val158Met	B-ProteinMutation
variant	O
with	O
opiate	O
addiction	O
in	O
Hispanic	O
women	O
.	O

Catechol-O-methyltransferase	O
(COMT)	O
catalyzes	O
the	O
breakdown	O
of	O
catechol	O
neurotransmitters	O
,	O
including	O
dopamine	O
,	O
which	O
plays	O
a	O
prominent	O
role	O
in	O
drug	O
reward	O
.	O

A	O
common	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
G472A	B-DNAMutation
,	O
codes	O
for	O
a	O
Val158Met	B-ProteinMutation
substitution	O
and	O
results	O
in	O
a	O
fourfold	O
down	O
regulation	O
of	O
enzyme	O
activity	O
.	O

We	O
sequenced	O
exon	O
IV	O
of	O
COMT	O
gene	O
in	O
search	O
for	O
novel	O
polymorphisms	O
and	O
then	O
genotyped	O
four	O
out	O
of	O
five	O
identified	O
by	O
direct	O
sequencing	O
,	O
using	O
TaqMan	O
assay	O
on	O
266	O
opioid-dependent	O
and	O
173	O
control	O
subjects	O
.	O

Genotype	O
frequencies	O
of	O
the	O
G472A	B-DNAMutation
SNP	O
varied	O
significantly	O
(	O
P	O
=	O
0.029	O
)	O
among	O
the	O
three	O
main	O
ethnic/cultural	O
groups	O
(	O
Caucasians	O
,	O
Hispanics	O
,	O
and	O
African	O
Americans	O
)	O
.	O

Using	O
a	O
genotype	O
test	O
,	O
we	O
found	O
a	O
trend	O
to	O
point-wise	O
association	O
(	O
P	O
=	O
0.053	O
)	O
of	O
the	O
G472A	B-DNAMutation
SNP	O
in	O
Hispanic	O
subjects	O
with	O
opiate	O
addiction	O
.	O

Further	O
analysis	O
of	O
G472A	B-DNAMutation
genotypes	O
in	O
Hispanic	O
subjects	O
with	O
data	O
stratified	O
by	O
gender	O
identified	O
a	O
point-wise	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
association	O
of	O
G/A	O
and	O
A/A	O
genotypes	O
with	O
opiate	O
addiction	O
in	O
women	O
,	O
but	O
not	O
men	O
.	O

These	O
point-wise	O
significant	O
results	O
are	O
not	O
significant	O
experiment-wise	O
(	O
at	O
P	O
<	O
0.05	O
)	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O

No	O
significant	O
association	O
was	O
found	O
with	O
haplotypes	O
of	O
the	O
three	O
most	O
common	O
SNPs	O
.	O

Linkage	O
disequilibrium	O
patterns	O
were	O
similar	O
for	O
the	O
three	O
ethnic/cultural	O
groups	O
.	O

Histamine-N-methyl	O
transferase	O
polymorphism	O
and	O
risk	O
for	O
migraine	O
.	O

BACKGROUND/OBJECTIVES	O
:	O
Histamine	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
migraine	O
.	O

In	O
the	O
CNS	O
,	O
histamine	O
is	O
almost	O
exclusively	O
metabolized	O
by	O
the	O
polymorphic	O
enzyme	O
histamine	O
N-methyltransferase	O
(HNMT)	O
.	O

The	O
HNMT	O
gene	O
(	O
chromosome	O
2q22.1	O
)	O
,	O
shows	O
diverse	O
single	O
nucleotide	O
polymorphisms	O
.	O

One	O
of	O
these	O
,	O
located	O
in	O
exon	O
4	O
C314T	B-DNAMutation
,	O
causes	O
the	O
amino	O
acid	O
substitution	O
Thr105Ile	B-ProteinMutation
,	O
related	O
to	O
decreased	O
enzyme	O
activity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
between	O
HNMT	O
polymorphism	O
and	O
the	O
risk	O
for	O
migraine	O
.	O

METHODS	O
:	O
We	O
studied	O
the	O
frequency	O
of	O
the	O
HNMT	O
genotypes	O
and	O
allelic	O
variantes	O
in	O
197	O
patients	O
with	O
migraine	O
and	O
245	O
healthy	O
controls	O
using	O
a	O
PCR-RLFP	O
method	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
HNMT	O
genotypes	O
and	O
allelic	O
variants	O
did	O
not	O
differ	O
significantly	O
between	O
migraine	O
patients	O
and	O
controls	O
,	O
and	O
were	O
unrelated	O
with	O
the	O
age	O
of	O
onset	O
of	O
migraine	O
attacks	O
,	O
gender	O
,	O
personal	O
history	O
of	O
allergic	O
diseases	O
,	O
family	O
history	O
of	O
migraine	O
,	O
or	O
presence	O
of	O
aura	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
HNMT	O
polymorphism	O
in	O
not	O
related	O
with	O
the	O
risk	O
for	O
migraine	O
.	O

Mutations	O
in	O
the	O
hairless	O
gene	O
underlie	O
APL	O
in	O
three	O
families	O
of	O
Pakistani	O
origin	O
.	O

BACKGROUND	O
:	O
Atrichia	O
with	O
papular	O
lesions	O
(APL)	O
(OMIM#209500)	O
is	O
a	O
rare	O
autosomal	O
recessively	O
inherited	O
form	O
of	O
irreversible	O
alopecia	O
characterized	O
by	O
papular	O
lesions	O
of	O
keratin-filled	O
cysts	O
on	O
various	O
regions	O
of	O
the	O
body	O
.	O

Males	O
and	O
females	O
are	O
equally	O
affected	O
and	O
present	O
with	O
a	O
distinct	O
pattern	O
of	O
total	O
hair	O
loss	O
on	O
scalp	O
,	O
axilla	O
and	O
body	O
.	O

It	O
begins	O
shortly	O
after	O
birth	O
with	O
the	O
development	O
of	O
hair	O
loss	O
,	O
and	O
patients	O
are	O
normally	O
devoid	O
of	O
eyelashes	O
and	O
eyebrows	O
.	O

Mutations	O
in	O
the	O
hairless	O
(HR)	O
gene	O
have	O
been	O
previously	O
shown	O
to	O
be	O
responsible	O
for	O
APL	O
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	O
,	O
we	O
studied	O
the	O
molecular	O
basis	O
of	O
APL	O
in	O
three	O
unrelated	O
families	O
of	O
Pakistani	O
origin	O
.	O

METHOD	O
:	O
Molecular	O
analysis	O
of	O
the	O
HR	O
genes	O
was	O
performed	O
on	O
genomic	O
DNA	O
from	O
probands	O
and	O
family	O
members	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
of	O
the	O
HR	O
gene	O
in	O
family	O
A	O
revealed	O
a	O
novel	O
homozygous	O
2bp	O
deletion	O
in	O
exon	O
6	O
leading	O
to	O
a	O
frameshift	O
and	O
a	O
downstream	O
premature	O
termination	O
codon	O
in	O
exon	O
8	O
1782-83delAG	B-DNAMutation
.	O

In	O
family	O
B	O
,	O
we	O
identified	O
a	O
novel	O
homozygous	O
deletion	O
of	O
a	O
G	O
nucleotide	O
at	O
the	O
exon	O
15-intron	O
15	O
boundary	O
,	O
termed	O
3097delG	B-DNAMutation
.	O

Family	O
C	O
carries	O
a	O
previously	O
reported	O
missense	O
mutation	O
consisting	O
of	O
an	O
A-to-G	O
transition	O
at	O
nucleotide	O
276	O
resulting	O
in	O
the	O
mutation	O
N970S	B-ProteinMutation
in	O
exon	O
14	O
.	O

CONCLUSION	O
:	O
Two	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
novel	O
mutations	O
in	O
the	O
HR	O
gene	O
and	O
extend	O
the	O
body	O
of	O
evidence	O
implicating	O
the	O
hairless	O
gene	O
family	O
in	O
the	O
pathogenesis	O
of	O
human	O
skin	O
disorders	O
.	O

The	O
one	O
previously	O
reported	O
mutation	O
suggests	O
it	O
may	O
represent	O
a	O
recurrent	O
mutation	O
,	O
or	O
alternatively	O
,	O
an	O
allele	O
that	O
is	O
widely	O
dispersed	O
around	O
the	O
world	O
.	O

Identification	O
of	O
apolipoprotein	O
E	O
Guangzhou	O
(	O
arginine	B-ProteinMutation
150	I-ProteinMutation
proline	I-ProteinMutation
)	O
,	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	O
glomerulopathy	O
.	O

BACKGROUND/AIMS	O
:	O
Lipoprotein	O
glomerulopathy	O
(LPG)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus-like	O
substances	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	O
E	O
(apoE)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	O
,	O
but	O
LPG	O
may	O
not	O
be	O
caused	O
by	O
apoE	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	O
with	O
LPG	O
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
:	O
The	O
apoE	O
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	O
patients	O
was	O
sequenced	O
.	O

The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	O
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18-T	O
vector	O
and	O
then	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	O
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	O
patients	O
and	O
1	O
asymptomatic	O
family	O
member	O
.	O

Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	O
to	O
C	O
point	O
mutation	O
in	O
exon	O
4	O
(	O
base	O
308	O
)	O
of	O
the	O
apoE	O
gene	O
in	O
all	O
patients	O
and	O
the	O
asymptomatic	O
family	O
member	O
.	O

This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	O
residue	O
for	O
arginine	O
residue	O
at	O
position	O
150	O
of	O
apoE	O
.	O

Those	O
patients	O
were	O
all	O
heterozygotes	O
with	O
apoE	O
Guangzhou	O
.	O

One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	O
Guangzhou	O
,	O
although	O
he	O
did	O
not	O
have	O
proteinuria	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	O
(	O
arginine	B-ProteinMutation
150	I-ProteinMutation
proline	I-ProteinMutation
)	O
is	O
a	O
novel	O
apoE	O
variant	O
that	O
etiologically	O
related	O
to	O
LPG	O
.	O

This	O
variant	O
(	O
apoE	O
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	O
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	O
.	O

Single	O
nucleotide	O
polymorphisms	O
in	O
bone	O
turnover-related	O
genes	O
in	O
Koreans	O
:	O
ethnic	O
differences	O
in	O
linkage	O
disequilibrium	O
and	O
haplotype	O
.	O

BACKGROUND	O
:	O
Osteoporosis	O
is	O
defined	O
as	O
the	O
loss	O
of	O
bone	O
mineral	O
density	O
that	O
leads	O
to	O
bone	O
fragility	O
with	O
aging	O
.	O

Population-based	O
case-control	O
studies	O
have	O
identified	O
polymorphisms	O
in	O
many	O
candidate	O
genes	O
that	O
have	O
been	O
associated	O
with	O
bone	O
mass	O
maintenance	O
or	O
osteoporotic	O
fracture	O
.	O

To	O
investigate	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
that	O
are	O
associated	O
with	O
osteoporosis	O
,	O
we	O
examined	O
the	O
genetic	O
variation	O
among	O
Koreans	O
by	O
analyzing	O
81	O
genes	O
according	O
to	O
their	O
function	O
in	O
bone	O
formation	O
and	O
resorption	O
during	O
bone	O
remodeling	O
.	O

METHODS	O
:	O
We	O
resequenced	O
all	O
the	O
exons	O
,	O
splice	O
junctions	O
and	O
promoter	O
regions	O
of	O
candidate	O
osteoporosis	O
genes	O
using	O
24	O
unrelated	O
Korean	O
individuals	O
.	O

Using	O
the	O
common	O
SNPs	O
from	O
our	O
study	O
and	O
the	O
HapMap	O
database	O
,	O
a	O
statistical	O
analysis	O
of	O
deviation	O
in	O
heterozygosity	O
depicted	O
.	O

RESULTS	O
:	O
We	O
identified	O
942	O
variants	O
,	O
including	O
888	O
SNPs	O
,	O
43	O
insertion/deletion	O
polymorphisms	O
,	O
and	O
11	O
microsatellite	O
markers	O
.	O

Of	O
the	O
SNPs	O
,	O
557	O
(63%)	O
had	O
been	O
previously	O
identified	O
and	O
331	O
(37%)	O
were	O
newly	O
discovered	O
in	O
the	O
Korean	O
population	O
.	O

When	O
compared	O
SNPs	O
in	O
the	O
Korean	O
population	O
with	O
those	O
in	O
HapMap	O
database	O
,	O
1%	O
(	O
or	O
less	O
)	O
of	O
SNPs	O
in	O
the	O
Japanese	O
and	O
Chinese	O
subpopulations	O
and	O
20%	O
of	O
those	O
in	O
Caucasian	O
and	O
African	O
subpopulations	O
were	O
significantly	O
differentiated	O
from	O
the	O
Hardy-Weinberg	O
expectations	O
.	O

In	O
addition	O
,	O
an	O
analysis	O
of	O
the	O
genetic	O
diversity	O
showed	O
that	O
there	O
were	O
no	O
significant	O
differences	O
among	O
Korean	O
,	O
Han	O
Chinese	O
and	O
Japanese	O
populations	O
,	O
but	O
African	O
and	O
Caucasian	O
populations	O
were	O
significantly	O
differentiated	O
in	O
selected	O
genes	O
.	O

Nevertheless	O
,	O
in	O
the	O
detailed	O
analysis	O
of	O
genetic	O
properties	O
,	O
the	O
LD	O
and	O
Haplotype	O
block	O
patterns	O
among	O
the	O
five	O
sub-populations	O
were	O
substantially	O
different	O
from	O
one	O
another	O
.	O

CONCLUSION	O
:	O
Through	O
the	O
resequencing	O
of	O
81	O
osteoporosis	O
candidate	O
genes	O
,	O
118	O
unknown	O
SNPs	O
with	O
a	O
minor	O
allele	O
frequency	O
(MAF)	O
>	O
0.05	O
were	O
discovered	O
in	O
the	O
Korean	O
population	O
.	O

In	O
addition	O
,	O
using	O
the	O
common	O
SNPs	O
between	O
our	O
study	O
and	O
HapMap	O
,	O
an	O
analysis	O
of	O
genetic	O
diversity	O
and	O
deviation	O
in	O
heterozygosity	O
was	O
performed	O
and	O
the	O
polymorphisms	O
of	O
the	O
above	O
genes	O
among	O
the	O
five	O
populations	O
were	O
substantially	O
differentiated	O
from	O
one	O
another	O
.	O

Further	O
studies	O
of	O
osteoporosis	O
could	O
utilize	O
the	O
polymorphisms	O
identified	O
in	O
our	O
data	O
since	O
they	O
may	O
have	O
important	O
implications	O
for	O
the	O
selection	O
of	O
highly	O
informative	O
SNPs	O
for	O
future	O
association	O
studies	O
.	O

Novel	O
TULP1	O
mutation	O
causing	O
leber	O
congenital	O
amaurosis	O
or	O
early	O
onset	O
retinal	O
degeneration	O
.	O

PURPOSE	O
:	O
To	O
report	O
a	O
large	O
,	O
consanguineous	O
Algerian	O
family	O
affected	O
with	O
Leber	O
congenital	O
amaurosis	O
(LCA)	O
or	O
early-onset	O
retinal	O
degeneration	O
(EORD)	O
.	O

METHODS	O
:	O
All	O
accessible	O
family	O
members	O
underwent	O
a	O
complete	O
ophthalmic	O
examination	O
,	O
and	O
blood	O
was	O
obtained	O
for	O
DNA	O
extraction	O
.	O

Homozygosity	O
mapping	O
was	O
performed	O
with	O
markers	O
flanking	O
12	O
loci	O
associated	O
with	O
LCA	O
.	O

The	O
15	O
exons	O
of	O
TULP1	O
were	O
sequenced	O
.	O

RESULTS	O
:	O
Seven	O
of	O
30	O
examined	O
family	O
members	O
were	O
affected	O
,	O
including	O
five	O
with	O
EORD	O
and	O
two	O
with	O
LCA	O
.	O

All	O
patients	O
had	O
nystagmus	O
,	O
hemeralopia	O
,	O
mild	O
myopia	O
,	O
and	O
low	O
visual	O
acuity	O
without	O
photophobia	O
.	O

Fundus	O
features	O
were	O
variable	O
among	O
EORD	O
patients	O
:	O
typical	O
spicular	O
retinitis	O
pigmentosa	O
or	O
clumped	O
pigmented	O
retinopathy	O
with	O
age-dependent	O
macular	O
involvement	O
.	O

A	O
salt-and-pepper	O
retinopathy	O
with	O
midperipheral	O
retinal	O
pigment	O
epithelium	O
(RPE)	O
atrophy	O
was	O
present	O
in	O
the	O
older	O
patients	O
with	O
LCA	O
,	O
whereas	O
the	O
retina	O
appeared	O
virtually	O
normal	O
in	O
the	O
younger	O
ones	O
.	O

Both	O
scotopic	O
and	O
photopic	O
electroretinograms	O
were	O
nondetectable	O
.	O

Fundus	O
imaging	O
revealed	O
a	O
perifoveal	O
ring	O
of	O
increased	O
fundus	O
autofluorescence	O
(FAF)	O
in	O
the	O
proband	O
,	O
and	O
optical	O
coherence	O
tomography	O
disclosed	O
a	O
thinned	O
retina	O
,	O
mainly	O
due	O
to	O
photoreceptor	O
loss	O
.	O

Linkage	O
analysis	O
identified	O
a	O
region	O
of	O
homozygosity	O
on	O
chromosome	O
6	O
,	O
region	O
p21.3	O
,	O
and	O
mutation	O
screening	O
revealed	O
a	O
novel	O
6-base	O
in-frame	O
duplication	O
,	O
in	O
the	O
TULP1	O
gene	O
.	O

CONCLUSIONS	O
:	O
Mutation	O
in	O
the	O
TULP1	O
gene	O
is	O
a	O
rare	O
cause	O
of	O
LCA/EORD	O
,	O
with	O
only	O
14	O
mutations	O
reported	O
so	O
far	O
.	O

The	O
observed	O
intrafamilial	O
phenotypic	O
variability	O
could	O
be	O
attributed	O
to	O
disease	O
progression	O
or	O
possibly	O
modifier	O
alleles	O
.	O

This	O
study	O
provides	O
the	O
first	O
description	O
of	O
FAF	O
and	O
quantitative	O
reflectivity	O
profiles	O
in	O
TULP1-related	O
retinopathy	O
.	O

Focal	O
dermal	O
hypoplasia	O
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
,	O
p.E300X	B-ProteinMutation
,	O
in	O
the	O
PORCN	O
gene	O
.	O

BACKGROUND	O
:	O
Focal	O
dermal	O
hypoplasia	O
(FDH)	O
(	O
OMIM	O
305600	O
)	O
is	O
an	O
X-linked	O
dominant	O
disorder	O
of	O
ecto-mesodermal	O
development	O
.	O

Also	O
known	O
as	O
Goltz	O
syndrome	O
,	O
FDH	O
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	O
dermis	O
and	O
variable	O
abnormalities	O
of	O
bone	O
,	O
nails	O
,	O
hair	O
,	O
limbs	O
,	O
teeth	O
and	O
eyes	O
.	O

The	O
molecular	O
basis	O
of	O
FDH	O
involves	O
mutations	O
in	O
the	O
PORCN	O
gene	O
,	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	O
in	O
a	O
2-year-old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	O
,	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
,	O
sparse	O
brittle	O
hair	O
,	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
,	O
dental	O
caries	O
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O

METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	O
gene	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
within	O
exon	O
10	O
(NM_203475.1)	O
,	O
converting	O
a	O
glutamic	O
acid	O
residue	O
(GAA)	O
to	O
a	O
premature	O
termination	O
codon	O
(TAA)	O
.	O

This	O
mutation	O
,	O
designated	O
p.E300X	B-ProteinMutation
,	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O

CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	O
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	O
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O

A	O
novel	O
DFNA5	O
mutation	O
,	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
,	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
causes	O
late-onset	O
non-syndromic	O
hearing	O
loss	O
in	O
a	O
Chinese	O
family	O
.	O

We	O
report	O
here	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
molecular	O
characteristics	O
of	O
a	O
large	O
Chinese	O
family	O
exhibiting	O
non-syndromic	O
,	O
late-onset	O
autosomal	O
dominant	O
sensorineural	O
hearing	O
loss	O
.	O

Clinical	O
evaluation	O
revealed	O
variable	O
phenotypes	O
of	O
hearing	O
loss	O
in	O
terms	O
of	O
severity	O
and	O
age-at-onset	O
of	O
disease	O
in	O
these	O
subjects	O
.	O

Genome-wide	O
linkage	O
analysis	O
mapped	O
the	O
disease	O
gene	O
to	O
the	O
DFNA5	O
locus	O
with	O
a	O
maximum	O
two-point	O
log	O
odds	O
score	O
of	O
5.39	O
at	O
[theta]	O
=	O
0	O
for	O
marker	O
D7S2457	O
.	O

DNA	O
sequencing	O
of	O
DFNA5	O
revealed	O
a	O
novel	O
heterozygous	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
substitution	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(RT-PCR)	O
showed	O
skipping	O
of	O
exon	O
8	O
in	O
the	O
mutant	O
transcript	O
.	O

This	O
mutation	O
faithfully	O
cosegregated	O
with	O
hearing	O
loss	O
in	O
the	O
family	O
.	O

In	O
addition	O
,	O
the	O
mutation	O
was	O
absent	O
in	O
100	O
unrelated	O
control	O
DNA	O
samples	O
of	O
Chinese	O
origin	O
.	O

The	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
mutation	O
is	O
predicted	O
to	O
create	O
a	O
shift	O
in	O
the	O
reading	O
frame	O
and	O
introduce	O
a	O
stop	O
codon	O
at	O
position	O
372	O
,	O
thereby	O
resulting	O
in	O
a	O
prematurely	O
truncated	O
DFNA5	O
protein	O
.	O

Up	O
to	O
date	O
,	O
a	O
total	O
of	O
four	O
mutations	O
in	O
DFNA5	O
have	O
been	O
reported	O
to	O
lead	O
to	O
hearing	O
impairment	O
,	O
all	O
of	O
them	O
result	O
in	O
skipping	O
of	O
exon	O
8	O
at	O
the	O
mRNA	O
level	O
.	O

Our	O
findings	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
DFNA5-associated	O
hearing	O
loss	O
is	O
caused	O
by	O
a	O
very	O
specific	O
gain-of-function	O
mutation	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
helix	O
11	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
gene	O
causing	O
generalized	O
glucocorticoid	O
resistance	O
.	O

BACKGROUND	O
:	O
Generalized	O
glucocorticoid	O
resistance	O
is	O
a	O
rare	O
condition	O
characterized	O
by	O
partial	O
,	O
end-organ	O
insensitivity	O
to	O
glucocorticoids	O
,	O
compensatory	O
elevations	O
in	O
adrenocorticotropic	O
hormone	O
and	O
cortisol	O
secretion	O
,	O
and	O
increased	O
production	O
of	O
adrenal	O
steroids	O
with	O
androgenic	O
and/or	O
mineralocorticoid	O
activity	O
.	O

We	O
have	O
identified	O
a	O
new	O
case	O
of	O
glucocorticoid	O
resistance	O
caused	O
by	O
a	O
novel	O
mutation	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
and	O
studied	O
the	O
molecular	O
mechanisms	O
through	O
which	O
the	O
mutant	O
receptor	O
impairs	O
glucocorticoid	O
signal	O
transduction	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
identified	O
a	O
novel	O
,	O
single	O
,	O
heterozygous	O
nucleotide	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
(	O
exon	O
9alpha	O
)	O
of	O
the	O
hGR	O
gene	O
,	O
which	O
resulted	O
in	O
phenylalanine	O
(F)	O
to	O
leucine	O
(L)	O
substitution	O
at	O
amino	O
acid	O
position	O
737	O
within	O
helix	O
11	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
protein	O
.	O

Compared	O
with	O
the	O
wild-type	O
receptor	O
,	O
the	O
mutant	O
receptor	O
hGRalphaF737L	B-ProteinMutation
demonstrated	O
a	O
significant	O
ligand-exposure	O
time-dependent	O
decrease	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid-inducible	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	O
in	O
response	O
to	O
dexamethasone	O
and	O
displayed	O
a	O
2-fold	O
reduction	O
in	O
the	O
affinity	O
for	O
ligand	O
,	O
a	O
12-fold	O
delay	O
in	O
nuclear	O
translocation	O
,	O
and	O
an	O
abnormal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

The	O
mutant	O
receptor	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
DNA	O
and	O
exerted	O
a	O
dominant-negative	O
effect	O
on	O
the	O
wild-type	O
hGRalpha	O
only	O
after	O
a	O
short	O
duration	O
of	O
exposure	O
to	O
the	O
ligand	O
.	O

CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
hGRalphaF737L	B-ProteinMutation
causes	O
generalized	O
glucocorticoid	O
resistance	O
because	O
of	O
decreased	O
affinity	O
for	O
the	O
ligand	O
,	O
marked	O
delay	O
in	O
nuclear	O
translocation	O
,	O
and/or	O
abnormal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

These	O
findings	O
confirm	O
the	O
importance	O
of	O
the	O
C	O
terminus	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
receptor	O
in	O
conferring	O
transactivational	O
activity	O
.	O

Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	O
cancer	O
varies	O
considerably	O
among	O
individuals	O
,	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	O
oxygen	O
species	O
(ROS)	O
because	O
ROS	O
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0.05	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	O
,	O
SOD1	O
,	O
SOD2	O
,	O
GPX1	O
,	O
GPX4	O
,	O
GSR	O
,	O
TXN	O
,	O
TXN2	O
,	O
TXNRD1	O
,	O
and	O
TXNRD2	O
)	O
and	O
survival	O
in	O
4,470	O
women	O
with	O
breast	O
cancer	O
.	O

RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
GPX4	O
(	O
rs713041	B-SNP
and	O
rs757229	B-SNP
)	O
were	O
associated	O
with	O
all-cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.0041	O
and	O
P	O
=	O
.0035	O
)	O
.	O

These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0.61	O
)	O
.	O

GPX4	O
rs713041	B-SNP
is	O
located	O
near	O
the	O
selenocysteine	O
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	O
3'	O
untranslated	O
region	O
,	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
,	O
with	O
a	O
hazard	O
ratio	O
of	O
1.27	O
per	O
rare	O
allele	O
carried	O
(	O
95%	O
CI	O
,	O
1.13	O
to	O
11.43	O
)	O
.	O

This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	O
stage	O
,	O
grade	O
,	O
or	O
estrogen	O
receptor	O
status	O
.	O

We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
,	O
normal	O
breast	O
,	O
and	O
breast	O
tumors	O
compared	O
with	O
the	O
rare	O
allele	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	O
mRNA	O
across	O
genotypes	O
.	O

CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

Manganese	O
superoxide	O
dismutase	O
(Mn-SOD)	O
gene	O
polymorphisms	O
in	O
urolithiasis	O
.	O

Polymorphism	O
in	O
manganese	O
superoxide	O
dismutase	O
gene	O
(Mn-SOD)	O
is	O
a	O
new	O
approach	O
to	O
identify	O
its	O
probable	O
association	O
with	O
urolithiasis	O
.	O

Oxidative	O
stress	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
stone	O
formation	O
in	O
the	O
renal	O
system	O
.	O

MnSOD	O
is	O
one	O
of	O
the	O
primary	O
enzymes	O
that	O
directly	O
scavenges	O
potential	O
harmful	O
oxidizing	O
species	O
.	O

A	O
valine	O
(Val)	O
to	O
alanine	O
(Ala)	O
substitution	O
at	O
amino	O
acid	O
16	O
,	O
occurring	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
the	O
MnSOD	O
gene	O
,	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urolithiasis	O
risk	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
association	O
of	O
MnSOD	O
gene	O
polymorphism	O
with	O
the	O
risk	O
of	O
urolithiasis	O
.	O

We	O
investigated	O
the	O
MnSOD	O
in	O
66	O
stone-forming	O
adults	O
and	O
72	O
healthy	O
volunteers	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
and	O
genotyping	O
was	O
performed	O
with	O
PCR-based	O
methods	O
.	O

Then	O
PCR	O
products	O
were	O
cut	O
by	O
BsaW1	O
.	O

Products	O
were	O
run	O
on	O
3%	O
agarose	O
gel	O
,	O
246	O
bp	O
regions	O
were	O
1-Ala-9	O
,	O
164	O
and	O
82	O
bp	O
products	O
were	O
determined	O
as	O
2	O
Val-9	O
.	O

Chi-square	O
test	O
was	O
used	O
for	O
comparison	O
between	O
patients	O
and	O
controls	O
.	O

In	O
the	O
control	O
group	O
the	O
homozygote	O
Ala	O
allele	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
patient	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
distribution	O
of	O
Ala/Val	O
and	O
homozygote	O
Val	O
alleles	O
in	O
the	O
patient	O
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

MnSOD	O
genotype	O
determination	O
may	O
provide	O
a	O
tool	O
to	O
identify	O
individuals	O
who	O
are	O
at	O
risk	O
of	O
urolithiasis	O
.	O

This	O
experiment	O
also	O
provides	O
data	O
about	O
antioxidant	O
status	O
and	O
stone	O
formation	O
.	O

A	O
novel	O
"pearl	O
box"	O
cataract	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
connexin	O
46	O
(GJA3)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
undertake	O
mutation	O
screening	O
in	O
the	O
connexin	O
46	O
(GJA3)	O
gene	O
in	O
seven	O
congenital	O
cataract	O
families	O
of	O
Indian	O
origin	O
.	O

METHODS	O
:	O
Seven	O
Indian	O
families	O
with	O
congenital	O
cataract	O
were	O
analyzed	O
by	O
detailed	O
family	O
history	O
and	O
clinical	O
evaluation	O
.	O

Each	O
family	O
had	O
two	O
to	O
five	O
affected	O
members	O
.	O

Mutation	O
screening	O
was	O
carried	O
out	O
in	O
the	O
candidate	O
gene	O
,	O
connexin	O
46	O
(GJA3)	O
,	O
using	O
bidirectional	O
sequencing	O
of	O
amplified	O
products	O
.	O

Segregation	O
of	O
the	O
observed	O
change	O
with	O
the	O
disease	O
phenotype	O
was	O
further	O
tested	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
.	O

RESULTS	O
:	O
Sequencing	O
of	O
the	O
coding	O
region	O
of	O
GJA3	O
showed	O
the	O
presence	O
of	O
a	O
novel	O
,	O
heterozygous	O
C260T	B-DNAMutation
change	O
in	O
one	O
family	O
(CC-472)	O
who	O
had	O
two	O
affected	O
members	O
.	O

The	O
cataract	O
phenotype	O
gave	O
the	O
appearance	O
like	O
a	O
"pearl	O
box"	O
in	O
these	O
two	O
affected	O
individuals	O
of	O
this	O
family	O
.	O

The	O
observed	O
C260T	B-DNAMutation
substitution	O
created	O
a	O
novel	O
restriction	O
enzyme	O
site	O
for	O
NlaIII	O
and	O
resulted	O
in	O
substitution	O
of	O
highly	O
conserved	O
threonine	O
at	O
position	O
87	O
by	O
methionine	O
T87M	B-ProteinMutation
.	O

NlaIII	O
restriction	O
digestion	O
analysis	O
revealed	O
this	O
nucleotide	O
change	O
was	O
not	O
in	O
unaffected	O
members	O
of	O
this	O
family	O
or	O
in	O
100	O
unrelated	O
control	O
subjects	O
(	O
200	O
chromosomes	O
)	O
with	O
the	O
same	O
ethnic	O
background	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
a	O
novel	O
mutation	O
identified	O
in	O
the	O
second	O
transmembrane	O
domain	O
of	O
the	O
connexin	O
46	O
.	O

These	O
findings	O
thus	O
expand	O
the	O
mutation	O
spectrum	O
of	O
the	O
GJA3	O
in	O
association	O
with	O
congenital	O
cataract	O
.	O

Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self-antigens	O
have	O
been	O
associated	O
with	O
Crohn's	O
disease	O
.	O

The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	O
that	O
underlies	O
Crohn's	O
disease	O
,	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	O
.	O

It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	O
immune	O
receptor	O
genes	O
(	O
nucleotide	O
oligomerisation	O
domain	O
(NOD)	O
2/caspase	O
recruitment	O
domain	O
(CARD)	O
15	O
,	O
NOD1/CARD4	O
,	O
TUCAN/CARDINAL/CARD8	O
,	O
Toll-like	O
receptor	O
(TLR)	O
4	O
,	O
TLR2	O
,	O
TLR1	O
and	O
TLR6	O
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
.	O

Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	O
with	O
IBD	O
(	O
874	O
Crohn's	O
disease	O
,	O
259	O
ulcerative	O
colitis	O
,	O
30	O
indeterminate	O
colitis	O
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti-Saccharomyces	O
cerevisiae	O
antibodies	O
(gASCA)	O
IgG	O
,	O
anti-laminaribioside	O
antibodies	O
(ALCA)	O
IgG	O
,	O
anti-chitobioside	O
antibodies	O
(ACCA)	O
IgA	O
,	O
anti-mannobioside	O
antibodies	O
(AMCA)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(Omp)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2/CARD15	O
,	O
TUCAN/CARDINAL/CARD8	O
,	O
NOD1/CARD4	O
,	O
TLR4	O
,	O
TLR1	O
,	O
TLR2	O
and	O
TLR6	O
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
Crohn's	O
disease	O
patients	O
without	O
CARD15	O
mutations	O
,	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	O
variant	O
in	O
Crohn's	O
disease	O
patients	O
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66.1%	O
versus	O
51.5%	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
ALCA	O
positivity	O
(	O
43.3%	O
versus	O
34.9%	O
,	O
p	O
=	O
0.018	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85.7	O
versus	O
51.8	O
ELISA	O
units	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
independent	O
of	O
ileal	O
involvement	O
.	O

A	O
gene	O
dosage	O
effect	O
,	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	O
carrying	O
none	O
,	O
one	O
and	O
two	O
CARD15	O
variants	O
,	O
respectively	O
,	O
was	O
seen	O
for	O
both	O
markers	O
.	O

Similarly	O
,	O
Crohn's	O
disease	O
patients	O
carrying	O
NOD1/CARD4	O
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild-type	O
patients	O
(	O
63.8%	O
versus	O
55.2%	O
,	O
p	O
=	O
0.014	O
)	O
,	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O

An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	O
D299G	B-ProteinMutation
and	O
TLR2	O
P631H	B-ProteinMutation
variants	O
,	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23.4%	O
versus	O
35%	O
,	O
p	O
=	O
0.013	O
)	O
and	O
Omp	O
antibodies	O
(	O
20.5%	O
versus	O
34.6%	O
,	O
p	O
=	O
0.009	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Variants	O
in	O
innate	O
immune	O
receptor	O
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	O
and	O
TLR4	O
variants	O
was	O
observed	O
.	O

These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	O
.	O

Tenomodulin	O
is	O
associated	O
with	O
obesity	O
and	O
diabetes	O
risk	O
:	O
the	O
Finnish	O
diabetes	O
prevention	O
study	O
.	O

We	O
recently	O
showed	O
that	O
long-term	O
weight	O
reduction	O
changes	O
the	O
gene	O
expression	O
profile	O
of	O
adipose	O
tissue	O
in	O
overweight	O
individuals	O
with	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
.	O

One	O
of	O
the	O
responding	O
genes	O
was	O
X-chromosomal	O
tenomodulin	O
(TNMD)	O
,	O
a	O
putative	O
angiogenesis	O
inhibitor	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
associations	O
of	O
individual	O
single	O
nucleotide	O
polymorphisms	O
and	O
haplotypes	O
with	O
adiposity	O
,	O
glucose	O
metabolism	O
,	O
and	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
(T2D)	O
.	O

Seven	O
single	O
nucleotide	O
polymorphisms	O
from	O
two	O
different	O
haploblocks	O
were	O
genotyped	O
from	O
507	O
participants	O
of	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
(DPS)	O
.	O

Sex-specific	O
genotype	O
effects	O
were	O
observed	O
.	O

Three	O
markers	O
of	O
haploblock	O
1	O
were	O
associated	O
with	O
features	O
of	O
adiposity	O
in	O
women	O
(	O
rs5966709	B-SNP
,	O
rs4828037	B-SNP
)	O
and	O
men	O
rs11798018	B-SNP
.	O

Markers	O
rs2073163	B-SNP
and	O
rs1155794	B-SNP
from	O
haploblock	O
2	O
were	O
associated	O
with	O
2-hour	O
plasma	O
glucose	O
levels	O
in	O
men	O
during	O
the	O
3-year	O
follow-up	O
.	O

The	O
same	O
two	O
markers	O
together	O
with	O
rs2073162	B-SNP
associated	O
with	O
the	O
conversion	O
of	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

The	O
risk	O
of	O
developing	O
T2D	O
was	O
approximately	O
2-fold	O
in	O
individuals	O
with	O
genotypes	O
associated	O
with	O
higher	O
2-hour	O
plasma	O
glucose	O
levels	O
;	O
the	O
hazard	O
ratios	O
were	O
2.192	O
(	O
p	O
=	O
0.025	O
)	O
for	O
rs2073162	B-SNP
-A	O
,	O
2.191	O
(	O
p	O
=	O
0.027	O
)	O
for	O
rs2073163	B-SNP
-C	O
,	O
and	O
1.998	O
(	O
p	O
=	O
0.054	O
)	O
for	O
rs1155974	B-SNP
-T	O
.	O

These	O
results	O
suggest	O
that	O
TNMD	O
polymorphisms	O
are	O
associated	O
with	O
adiposity	O
and	O
also	O
with	O
glucose	O
metabolism	O
and	O
conversion	O
from	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

Novel	O
mutations	O
in	O
the	O
ZEB1	O
gene	O
identified	O
in	O
Czech	O
and	O
British	O
patients	O
with	O
posterior	O
polymorphous	O
corneal	O
dystrophy	O
.	O

We	O
describe	O
the	O
search	O
for	O
mutations	O
in	O
six	O
unrelated	O
Czech	O
and	O
four	O
unrelated	O
British	O
families	O
with	O
posterior	O
polymorphous	O
corneal	O
dystrophy	O
(PPCD)	O
;	O
a	O
relatively	O
rare	O
eye	O
disorder	O
.	O

Coding	O
exons	O
and	O
intron/exon	O
boundaries	O
of	O
all	O
three	O
genes	O
(	O
VSX1	O
,	O
COL8A2	O
,	O
and	O
ZEB1/TCF8	O
)	O
previously	O
reported	O
to	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
this	O
disorder	O
were	O
screened	O
by	O
DNA	O
sequencing	O
.	O

Four	O
novel	O
pathogenic	O
mutations	O
were	O
identified	O
in	O
four	O
families	O
;	O
two	O
deletions	O
,	O
one	O
nonsense	O
,	O
and	O
one	O
duplication	O
within	O
exon	O
7	O
in	O
the	O
ZEB1	O
gene	O
located	O
at	O
10p11.2	O
.	O

We	O
also	O
genotyped	O
the	O
Czech	O
patients	O
to	O
test	O
for	O
a	O
founder	O
haplotype	O
and	O
lack	O
of	O
disease	O
segregation	O
with	O
the	O
20p11.2	O
locus	O
we	O
previously	O
described	O
.	O

Although	O
a	O
systematic	O
clinical	O
examination	O
was	O
not	O
performed	O
,	O
our	O
investigation	O
does	O
not	O
support	O
an	O
association	O
between	O
ZEB1	O
changes	O
and	O
self	O
reported	O
non-ocular	O
anomalies	O
.	O

In	O
the	O
remaining	O
six	O
families	O
no	O
disease	O
causing	O
mutations	O
were	O
identified	O
thereby	O
indicating	O
that	O
as	O
yet	O
unidentified	O
gene(s)	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
PPCD	O
.	O

3'	O
Mutation	O
of	O
the	O
APC	O
gene	O
and	O
family	O
history	O
of	O
FAP	O
in	O
a	O
patient	O
with	O
apparently	O
sporadic	O
desmoid	O
tumors	O
.	O

Desmoid	O
tumors	O
may	O
occur	O
sporadically	O
or	O
as	O
part	O
of	O
the	O
extraintestinal	O
manifestations	O
of	O
familial	O
adenomatous	O
polyposis	O
.	O

Different	O
phenotypes	O
have	O
been	O
described	O
and	O
some	O
genotype-phenotype	O
correlations	O
have	O
been	O
raised	O
,	O
associated	O
with	O
different	O
sites	O
of	O
germline	O
mutations	O
in	O
the	O
adenomatous	O
polyposis	O
coli	O
(APC)	O
gene	O
.	O

We	O
report	O
on	O
a	O
42-year-old	O
woman	O
ascertained	O
for	O
a	O
large	O
desmoid	O
tumor	O
of	O
the	O
anterior	O
chest	O
wall	O
with	O
pleural	O
involvement	O
,	O
which	O
persistently	O
recurred	O
despite	O
a	O
decade	O
of	O
treatment	O
including	O
hormone	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
surgery	O
.	O

Spontaneous	O
disappearance	O
of	O
the	O
tumor	O
was	O
later	O
noted	O
after	O
1	O
year	O
without	O
any	O
treatment	O
and	O
confirmed	O
after	O
4	O
years	O
of	O
regular	O
follow-up	O
.	O

Repeated	O
colonoscopies	O
were	O
normal	O
in	O
the	O
proband	O
and	O
DNA	O
sequencing	O
showed	O
a	O
frameshift	O
mutation	O
due	O
to	O
a	O
single	O
adenosine	O
deletion	O
at	O
position	O
5772	O
(	O
codon	O
1924	O
)	O
.	O

This	O
mutation	O
,	O
located	O
in	O
the	O
exon	O
15	O
at	O
the	O
3'	O
end	O
of	O
the	O
APC	O
gene	O
,	O
leads	O
to	O
an	O
unusual	O
and	O
late	O
onset	O
phenotype	O
.	O

The	O
pedigree	O
revealed	O
other	O
isolated	O
or	O
familial	O
adenomatous	O
polyposis-associated	O
cases	O
of	O
desmoid	O
tumors	O
.	O

This	O
family	O
report	O
shows	O
that	O
a	O
molecular	O
analysis	O
of	O
the	O
APC	O
gene	O
should	O
be	O
performed	O
in	O
familial	O
desmoid	O
tumors	O
for	O
accurate	O
genetic	O
counseling	O
and	O
follow-up	O
.	O

Atypical	O
Rothmund-Thomson	O
syndrome	O
in	O
a	O
patient	O
with	O
compound	O
heterozygous	O
mutations	O
in	O
RECQL4	O
gene	O
and	O
phenotypic	O
features	O
in	O
RECQL4	O
syndromes	O
.	O

We	O
describe	O
the	O
natural	O
history	O
of	O
the	O
RTSII	O
phenotype	O
in	O
a	O
7-year-old	O
boy	O
who	O
developed	O
intrauterine	O
and	O
postnatal	O
growth	O
retardation	O
,	O
failure	O
to	O
thrive	O
and	O
persisting	O
diarrhoea	O
.	O

The	O
growth	O
hormone	O
stimulation	O
test	O
identified	O
an	O
isolated	O
growth	O
hormone	O
deficiency	O
.	O

Since	O
infancy	O
,	O
the	O
patient	O
manifested	O
skin	O
lesions	O
characterized	O
by	O
a	O
very	O
mild	O
poikilodermic-like	O
appearance	O
on	O
the	O
cheeks	O
only	O
,	O
widespread	O
caf	O
	O
-au-lait	O
spots	O
and	O
the	O
absence	O
of	O
eyebrows	O
and	O
eyelashes	O
.	O

There	O
was	O
no	O
cataract	O
.	O

Orthopaedic	O
and	O
radiologic	O
work-up	O
identified	O
the	O
absence	O
of	O
thumb	O
anomaly	O
and	O
radial	O
head	O
luxation	O
and	O
patellar	O
hypoplasia	O
.	O

Neurologic	O
,	O
cognitive	O
milestones	O
and	O
intelligence	O
were	O
normal	O
.	O

The	O
cytogenetic	O
work-up	O
did	O
not	O
show	O
any	O
anomaly	O
.	O

Based	O
on	O
this	O
clinical	O
presentation	O
,	O
we	O
carried	O
out	O
a	O
sequencing	O
analysis	O
of	O
the	O
RECQL4	O
gene	O
,	O
which	O
is	O
responsible	O
for	O
Rothmund-Thomson	O
,	O
RAPADILINO	O
and	O
Baller-Gerold	O
syndromes	O
and	O
found	O
a	O
splice	O
site	O
mutation	O
IVS10-1G>A	B-DNAMutation
and	O
a	O
nucleotide	O
substitution	O
in	O
exon	O
12	O
L638P	B-ProteinMutation
.	O

The	O
mother	O
was	O
identified	O
as	O
a	O
carrier	O
for	O
the	O
substitution	O
in	O
exon	O
12	O
and	O
the	O
father	O
for	O
the	O
splice	O
site	O
mutation	O
,	O
respectively	O
.	O

An	O
analysis	O
of	O
the	O
transcripts	O
focused	O
on	O
the	O
RECQL4	O
helicase	O
domain	O
:	O
in	O
the	O
proband	O
only	O
those	O
generated	O
from	O
the	O
maternal	O
L638	O
allele	O
were	O
present	O
.	O

This	O
case	O
report	O
emphasizes	O
the	O
clinical	O
overlap	O
between	O
RAPADILINO	O
and	O
Rothmund-Thomson	O
syndromes	O
within	O
a	O
continuum	O
phenotypic	O
spectrum	O
.	O

The	O
distinctive	O
set	O
of	O
clinical	O
signs	O
displayed	O
by	O
the	O
patient	O
may	O
be	O
accounted	O
for	O
by	O
his	O
unique	O
combination	O
of	O
two	O
different	O
RECQL4	O
mutations	O
.	O

The	O
molecular	O
findings	O
provide	O
information	O
that	O
enhances	O
our	O
comprehension	O
of	O
genotype-phenotype	O
correlations	O
in	O
RECQL4	O
diseases	O
,	O
enables	O
a	O
more	O
precise	O
genetic	O
counseling	O
to	O
the	O
parents	O
and	O
facilitates	O
a	O
more	O
appropriate	O
long-term	O
follow-up	O
to	O
the	O
affected	O
child	O
.	O

Genome-wide	O
analysis	O
of	O
neuroblastomas	O
using	O
high-density	O
single	O
nucleotide	O
polymorphism	O
arrays	O
.	O

BACKGROUND	O
:	O
Neuroblastomas	O
are	O
characterized	O
by	O
chromosomal	O
alterations	O
with	O
biological	O
and	O
clinical	O
significance	O
.	O

We	O
analyzed	O
paired	O
blood	O
and	O
primary	O
tumor	O
samples	O
from	O
22	O
children	O
with	O
high-risk	O
neuroblastoma	O
for	O
loss	O
of	O
heterozygosity	O
(LOH)	O
and	O
DNA	O
copy	O
number	O
change	O
using	O
the	O
Affymetrix	O
10K	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
.	O

FINDINGS	O
:	O
Multiple	O
areas	O
of	O
LOH	O
and	O
copy	O
number	O
gain	O
were	O
seen	O
.	O

The	O
most	O
commonly	O
observed	O
area	O
of	O
LOH	O
was	O
on	O
chromosome	O
arm	O
11q	O
(	O
15/22	O
samples	O
;	O
68%	O
)	O
.	O

Chromosome	O
11q	O
LOH	O
was	O
highly	O
associated	O
with	O
occurrence	O
of	O
chromosome	O
3p	O
LOH	O
:	O
9	O
of	O
the	O
15	O
samples	O
with	O
11q	O
LOH	O
had	O
concomitant	O
3p	O
LOH	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Chromosome	O
1p	O
LOH	O
was	O
seen	O
in	O
one-third	O
of	O
cases	O
.	O

LOH	O
events	O
on	O
chromosomes	O
11q	O
and	O
1p	O
were	O
generally	O
accompanied	O
by	O
copy	O
number	O
loss	O
,	O
indicating	O
hemizygous	O
deletion	O
within	O
these	O
regions	O
.	O

The	O
one	O
exception	O
was	O
on	O
chromosome	O
11p	O
,	O
where	O
LOH	O
in	O
all	O
four	O
cases	O
was	O
accompanied	O
by	O
normal	O
copy	O
number	O
or	O
diploidy	O
,	O
implying	O
uniparental	O
disomy	O
.	O

Gain	O
of	O
copy	O
number	O
was	O
most	O
frequently	O
observed	O
on	O
chromosome	O
arm	O
17q	O
(	O
21/22	O
samples	O
;	O
95%	O
)	O
and	O
was	O
associated	O
with	O
allelic	O
imbalance	O
in	O
six	O
samples	O
.	O

Amplification	O
of	O
MYCN	O
was	O
also	O
noted	O
,	O
and	O
also	O
amplification	O
of	O
a	O
second	O
gene	O
,	O
ALK	O
,	O
in	O
a	O
single	O
case	O
.	O

CONCLUSIONS	O
:	O
This	O
analysis	O
demonstrates	O
the	O
power	O
of	O
SNP	O
arrays	O
for	O
high-resolution	O
determination	O
of	O
LOH	O
and	O
DNA	O
copy	O
number	O
change	O
in	O
neuroblastoma	O
,	O
a	O
tumor	O
in	O
which	O
specific	O
allelic	O
changes	O
drive	O
clinical	O
outcome	O
and	O
selection	O
of	O
therapy	O
.	O

Epstein	O
Barr	O
virus	O
genotypes	O
and	O
LMP-1	O
variants	O
in	O
HIV-infected	O
patients	O
.	O

Two	O
Epstein	O
Barr	O
virus	O
(EBV)	O
genotypes	O
:	O
EBV-1	O
and	O
EBV-2	O
have	O
been	O
described	O
.	O

A	O
30-bp	O
deletion	O
in	O
latent	O
membrane	O
protein-1	O
gene	O
(del-LMP-1)	O
has	O
been	O
identified	O
in	O
various	O
pathologies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
EBV	O
genotypes	O
and	O
30-bp	O
deletion	O
frequency	O
in	O
HIV-infected	O
patients	O
from	O
Argentina	O
.	O

The	O
study	O
was	O
performed	O
on	O
258	O
individuals	O
:	O
Cases	O
:	O
144	O
HIV-infected	O
patients	O
that	O
included	O
:	O
(a)	O
7	O
AIDS	O
patients	O
with	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
(PCNSL)	O
,	O
(b)	O
62	O
AIDS	O
patients	O
,	O
and	O
(c)	O
75	O
asymptomatic	O
HIV-infected	O
patients	O
.	O

Controls	O
:	O
114	O
HIV-negative	O
individuals	O
.	O

EBV	O
genotypes	O
and	O
variants	O
in	O
LMP-1	O
gene	O
were	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)-Southern	O
blot	O
on	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
brain	O
biopsies	O
.	O

In	O
PCNSL	O
,	O
the	O
presence	O
of	O
EBV	O
was	O
confirmed	O
by	O
EBER	O
RNA	O
in	O
situ	O
hybridization	O
,	O
and	O
DNA	O
sequencing	O
of	O
3'	O
end	O
LMP-l	O
gene	O
of	O
PCR	O
products	O
was	O
performed	O
.	O

In	O
HIV-infected	O
patients	O
,	O
EBV-1	O
was	O
detected	O
in	O
48.6%	O
,	O
EBV-2	O
in	O
18.8%	O
,	O
and	O
co-infection	O
with	O
both	O
genotypes	O
in	O
32.6%	O
.	O

In	O
control	O
group	O
,	O
EBV-1	O
was	O
present	O
in	O
74.3%	O
,	O
EBV-2	O
in	O
12.4%	O
,	O
and	O
co-infection	O
in	O
13.3%	O
.	O

Del-LMP-1	O
was	O
found	O
in	O
44.4%	O
of	O
HIV-infected	O
patients	O
samples	O
(	O
20.7%	O
alone	O
and	O
23.7%	O
co-infection	O
with	O
non-deleted	O
form	O
)	O
while	O
it	O
was	O
found	O
in	O
25.3%	O
(	O
6.3%	O
alone	O
and	O
19%	O
with	O
co-infection	O
)	O
in	O
HIV-negative	O
individuals	O
.	O

In	O
HIV-infected	O
patients	O
EBV-2	O
,	O
co-infection	O
and	O
30-bp	O
deletion	O
are	O
more	O
prevalent	O
than	O
in	O
control	O
group	O
.	O

In	O
all	O
,	O
PCNSL	O
brain	O
biopsies	O
samples	O
,	O
del-LMP-1	O
always	O
was	O
detected	O
with	O
EBV-2	O
,	O
but	O
more	O
cases	O
would	O
have	O
to	O
be	O
included	O
to	O
draw	O
definitive	O
conclusions	O
.	O

Retinoblastoma	O
in	O
India	O
:	O
microsatellite	O
analysis	O
and	O
its	O
application	O
in	O
genetic	O
counseling	O
OBJECTIVES	O
:	O
This	O
study	O
was	O
conducted	O
with	O
two	O
objectives	O
.	O

The	O
first	O
was	O
to	O
estimate	O
the	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
(LOH)	O
of	O
the	O
RB1	O
gene	O
as	O
a	O
mechanism	O
in	O
disease	O
causation	O
in	O
tumors	O
of	O
patients	O
from	O
India	O
.	O

The	O
second	O
objective	O
was	O
to	O
employ	O
RB1	O
molecular	O
deletion	O
and	O
microsatellite-based	O
linkage	O
analysis	O
as	O
laboratory	O
tools	O
,	O
while	O
counseling	O
families	O
with	O
a	O
history	O
of	O
retinoblastoma	O
(RB)	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
tumors	O
of	O
54	O
RB	O
patients	O
and	O
their	O
relatives	O
.	O

Eight	O
fluorescent	O
microsatellite	O
markers	O
,	O
both	O
intragenic	O
and	O
flanking	O
the	O
RB1	O
gene	O
,	O
were	O
used	O
.	O

After	O
PCR	O
amplification	O
,	O
samples	O
were	O
run	O
on	O
an	O
ABI	O
PRISM	O
310	O
genetic	O
analyzer	O
for	O
LOH	O
,	O
deletion	O
detection	O
,	O
and	O
haplotype	O
generation	O
.	O

RESULTS	O
:	O
LOH	O
was	O
found	O
in	O
conjunction	O
with	O
tumor	O
formation	O
in	O
72.9%	O
of	O
RB	O
patients	O
(	O
39/54	O
patients	O
;	O
p=0.001	O
;	O
95%	O
CI	O
0.6028	O
,	O
0.8417	O
)	O
;	O
however	O
,	O
we	O
could	O
not	O
associate	O
various	O
other	O
clinical	O
parameters	O
of	O
RB	O
patients	O
with	O
the	O
presence	O
or	O
absence	O
of	O
RB1	O
LOH	O
.	O

Seven	O
germline	O
deletions	O
(	O
13%	O
of	O
RB	O
patients	O
)	O
were	O
identified	O
,	O
and	O
the	O
maternal	O
allele	O
was	O
more	O
frequently	O
lost	O
(p=0.01)	O
.	O

A	O
disease	O
co-segregating	O
haplotype	O
was	O
detected	O
in	O
two	O
hereditary	O
autosomal	O
dominant	O
cases	O
.	O

CONCLUSION	O
:	O
LOH	O
of	O
the	O
RB1	O
gene	O
could	O
play	O
an	O
important	O
role	O
in	O
tumor	O
formation	O
.	O

Large	O
deletions	O
involving	O
RB1	O
were	O
observed	O
,	O
and	O
a	O
disease	O
co-segregating	O
haplotype	O
was	O
used	O
for	O
indirect	O
genetic	O
testing	O
.	O

This	O
is	O
the	O
first	O
report	O
from	O
India	O
where	O
molecular	O
testing	O
has	O
been	O
applied	O
for	O
RB	O
families	O
in	O
conjunction	O
with	O
genetic	O
counseling	O
.	O

In	O
tertiary	O
ophthalmic	O
practice	O
in	O
India	O
,	O
there	O
is	O
an	O
emerging	O
trend	O
towards	O
the	O
application	O
of	O
genetical	O
knowledge	O
in	O
clinical	O
practice	O
.	O

The	O
G51S	B-ProteinMutation
purine	O
nucleoside	O
phosphorylase	O
polymorphism	O
is	O
associated	O
with	O
cognitive	O
decline	O
in	O
Alzheimer's	O
disease	O
patients	O
.	O

Alzheimer's	O
disease	O
(AD)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
,	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
,	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O

Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O

Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
,	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
,	O
apoptosis	O
,	O
and	O
inflammatory	O
responses	O
.	O

These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	O
.	O

In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G/A	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
purine	O
nucleoside	O
phosphorylase	O
(PNP)	O
gene	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	O
to	O
glycine	O
at	O
position	O
51	O
G51S	B-ProteinMutation
,	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	O
patients	O
(n=321)	O
and	O
non-demented	O
control	O
(n=208)	O
.	O

The	O
PNP	O
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O

The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	O
patients	O
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	O
decline	O
during	O
a	O
2-year	O
follow-up	O
.	O

An	O
increased	O
representation	O
of	O
the	O
PNP	O
AA	O
genotype	O
was	O
observed	O
in	O
AD	O
patients	O
with	O
fast	O
cognitive	O
deterioration	O
in	O
comparison	O
with	O
that	O
from	O
patients	O
with	O
slow	O
deterioration	O
rate	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
G51S	B-ProteinMutation
PNP	O
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	O
decline	O
in	O
AD	O
patients	O
,	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	O
disorder	O
.	O

Two	O
sites	O
in	O
the	O
MAPT	O
region	O
confer	O
genetic	O
risk	O
for	O
Guam	O
ALS/PDC	O
and	O
dementia	O
.	O

Unusual	O
forms	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(ALS-G)	O
,	O
Parkinsonism	O
dementia	O
complex	O
(PDC-G)	O
and	O
Guam	O
dementia	O
(GD)	O
are	O
found	O
in	O
Chamorros	O
,	O
the	O
indigenous	O
people	O
of	O
Guam	O
.	O

Neurofibrillary	O
tangles	O
composed	O
of	O
hyperphosphorylated	O
tau	O
are	O
a	O
neuropathologic	O
feature	O
of	O
these	O
closely	O
related	O
disorders	O
.	O

To	O
determine	O
if	O
variation	O
in	O
the	O
gene	O
that	O
encodes	O
microtubule-associated	O
protein	O
tau	O
gene	O
(MAPT)	O
contributes	O
to	O
risk	O
for	O
these	O
disorders	O
,	O
we	O
genotyped	O
nine	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
sites	O
and	O
one	O
insertion/deletion	O
in	O
the	O
5'	O
end	O
of	O
MAPT	O
in	O
54	O
ALS-G	O
,	O
135	O
PDC-G	O
,	O
153	O
GD	O
and	O
258	O
control	O
subjects	O
,	O
all	O
of	O
whom	O
are	O
Chamorros	O
.	O

Variation	O
at	O
three	O
SNPs	O
(	O
sites	O
2	O
,	O
6	O
and	O
9	O
)	O
influenced	O
risk	O
for	O
ALS-G	O
,	O
PDC-G	O
and	O
GD	O
.	O

SNP2	O
acts	O
through	O
a	O
dominant	O
mechanism	O
and	O
is	O
independent	O
of	O
the	O
risk	O
conferred	O
by	O
SNPs	O
6	O
and	O
9	O
,	O
the	O
latter	O
two	O
acting	O
by	O
a	O
recessive	O
mechanism	O
.	O

Persons	O
with	O
the	O
high-risk	O
SNP6	O
and	O
SNP9	O
AC/AC	O
diplotype	O
had	O
an	O
increased	O
risk	O
of	O
3-fold	O
[	O
95%	O
confidence	O
interval	O
(	O
CI)=1.10-8.25	O
]	O
for	O
GD	O
,	O
4-fold	O
(	O
95%	O
CI=1.40-11.64	O
)	O
for	O
PDC-G	O
and	O
6-fold	O
(	O
95%	O
CI=1.44-32.14	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
persons	O
with	O
other	O
diplotypes	O
after	O
adjusting	O
for	O
SNP2	O
.	O

Carriers	O
of	O
the	O
SNP2	O
G	O
allele	O
had	O
an	O
increased	O
risk	O
of	O
1.6-fold	O
(	O
95%	O
CI=1.00-2.62	O
)	O
for	O
GD	O
,	O
2-fold	O
(	O
95%	O
CI=1.28-3.66	O
)	O
for	O
PDC-G	O
,	O
and	O
1.5-fold	O
(	O
95%	O
CI=0.74-3.00	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
non-carriers	O
after	O
adjusting	O
for	O
SNPs	O
6	O
and	O
9	O
.	O

Others	O
have	O
shown	O
that	O
SNP6	O
is	O
also	O
associated	O
with	O
risk	O
for	O
progressive	O
supranuclear	O
palsy	O
.	O

These	O
two	O
independent	O
cis-acting	O
sites	O
presumably	O
influence	O
risk	O
for	O
Guam	O
neuro-degenerative	O
disorders	O
by	O
regulating	O
MAPT	O
expression	O
.	O

A	O
novel	O
mutation	O
E333D	B-ProteinMutation
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
causing	O
resistance	O
to	O
thyroid	O
hormone	O
syndrome	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
(RTH)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	O
hormones	O
(TH)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	O
stimulating	O
hormone	O
(TSH)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	O
.	O

The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
(TRbeta)	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	O
mutation	O
E333D	B-ProteinMutation
located	O
in	O
the	O
large	O
carboxy-terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	O
.	O

The	O
mutation	O
was	O
identified	O
in	O
a	O
22-year-old	O
French	O
woman	O
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	O
.	O

Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	O
(	O
T4	O
:	O
20.8	O
pg/ml	O
(	O
normal	O
,	O
8.5-18)	O
)	O
and	O
triiodothyronine	O
(	O
T3	O
:	O
5.7	O
pg/ml	O
(	O
normal	O
,	O
1.4-4)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	O
level	O
of	O
4.7	O
mU/ml	O
(	O
normal	O
,	O
0.4-4	O
)	O
.	O

Her	O
father	O
and	O
her	O
brother's	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	O
.	O

Direct	O
sequencing	O
of	O
the	O
TRbeta	O
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A>C	B-DNAMutation
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	O
acid	O
333	O
by	O
aspartic	O
acid	O
residue	O
E333D	B-ProteinMutation
.	O

Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	O
mutant	O
were	O
conducted	O
.	O

We	O
found	O
that	O
the	O
E333D	B-ProteinMutation
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	O
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	O
X	O
receptor	O
(RXR)	O
when	O
bound	O
to	O
DNA	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
E333D	B-ProteinMutation
TRbeta	O
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2-	O
and	O
DR4-TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	O
TSHalpha	O
promoter	O
.	O

Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild-type	O
TRbeta	O
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(F2-TRE)	O
and	O
a	O
negative	O
(TSHalpha)	O
promoter	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	B-ProteinMutation
TRbeta	O
mutation	O
is	O
responsible	O
for	O
the	O
RTH	O
phenotype	O
in	O
the	O
proposita's	O
family	O
.	O

Homozygous	O
deletion	O
related	O
to	O
Alu	O
repeats	O
in	O
RLBP1	O
causes	O
retinitis	O
punctata	O
albescens	O
.	O

PURPOSE	O
:	O
Retinitis	O
punctata	O
albescens	O
(RPA)	O
is	O
an	O
infrequently	O
occurring	O
form	O
of	O
autosomal	O
recessive	O
(	O
and	O
rarely	O
dominant	O
)	O
retinal	O
dystrophy	O
featuring	O
early-onset	O
severe	O
night	O
blindness	O
and	O
tiny	O
,	O
dotlike	O
,	O
white	O
deposits	O
in	O
the	O
fundus	O
.	O

RPA	O
is	O
associated	O
mostly	O
with	O
mutations	O
in	O
RLBP1	O
and	O
occasionally	O
in	O
RHO	O
,	O
RDS	O
,	O
and	O
RDH5	O
.	O

In	O
this	O
study	O
,	O
mutations	O
were	O
sought	O
in	O
RLBP1	O
,	O
which	O
encodes	O
the	O
retinol	O
binding	O
protein	O
CRALBP	O
in	O
patients	O
with	O
typical	O
RPA	O
.	O

METHODS	O
:	O
Clinical	O
investigation	O
included	O
funduscopy	O
,	O
visual	O
field	O
testing	O
,	O
electroretinogram	O
recording	O
,	O
and	O
adaptometry	O
.	O

The	O
7	O
coding	O
exons	O
(3-9)	O
of	O
RLBP1	O
and	O
the	O
15th	O
(last)	O
exon	O
of	O
ABDH2	O
were	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

Long-distance	O
PCR	O
and	O
cloning	O
of	O
genomic	O
DNA	O
were	O
performed	O
to	O
characterize	O
the	O
deletion	O
.	O

RESULTS	O
:	O
The	O
study	O
involved	O
a	O
24-year-old	O
Moroccan	O
patient	O
with	O
typical	O
RPA	O
,	O
born	O
of	O
first-cousin	O
parents	O
.	O

He	O
carried	O
a	O
7.36-kb	O
homozygous	O
deletion	O
encompassing	O
the	O
last	O
3	O
exons	O
of	O
RLBP1	O
(	O
7	O
,	O
8	O
,	O
and	O
9	O
)	O
and	O
part	O
of	O
the	O
intergenic	O
region	O
between	O
RLBP1	O
and	O
ABHD2	O
,	O
which	O
lies	O
downstream	O
of	O
RLBP1	O
.	O

This	O
deletion	O
abolishes	O
the	O
retinal	O
binding	O
site	O
of	O
CRALBP	O
.	O

The	O
telomeric	O
breakpoint	O
of	O
the	O
deletion	O
(	O
in	O
RLBP1	O
intron	O
6	O
)	O
is	O
embedded	O
in	O
an	O
Alu	O
element	O
,	O
whereas	O
the	O
centromeric	O
breakpoint	O
(	O
in	O
the	O
intergenic	O
region	O
)	O
lies	O
between	O
two	O
Alu	O
elements	O
placed	O
in	O
the	O
opposite	O
orientation	O
.	O

CONCLUSIONS	O
:	O
Because	O
of	O
the	O
high	O
density	O
of	O
Alu	O
elements	O
in	O
RLBP1	O
,	O
a	O
systematic	O
search	O
should	O
be	O
made	O
for	O
deletions	O
in	O
this	O
gene	O
when	O
one	O
or	O
both	O
alleles	O
lack	O
point	O
mutations	O
,	O
in	O
the	O
case	O
of	O
RPA	O
or	O
flecked	O
retinal	O
dystrophy	O
.	O

Monocyte	O
chemotactic	O
protein-1	O
single	O
nucleotide	O
polymorphisms	O
do	O
not	O
confer	O
susceptibility	O
for	O
the	O
development	O
of	O
adult	O
onset	O
polymyositis/dermatomyositis	O
in	O
UK	O
Caucasians	O
.	O

OBJECTIVES	O
:	O
Polymyositis	O
(PM)	O
and	O
dermatomyositis	O
(DM)	O
form	O
part	O
of	O
the	O
idiopathic	O
inflammatory	O
myopathies	O
(IIMs)	O
.	O

The	O
chemokine	O
monocyte	O
chemotactic	O
protein-1	O
(MCP-1)	O
is	O
expressed	O
at	O
sites	O
of	O
the	O
T	O
cell	O
inflammatory	O
response	O
in	O
the	O
IIMs	O
.	O

We	O
thus	O
investigate	O
whether	O
genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
confer	O
disease	O
susceptibility	O
for	O
the	O
development	O
of	O
PM	O
and	O
DM	O
.	O

METHODS	O
:	O
DNA	O
samples	O
were	O
analysed	O
from	O
a	O
group	O
of	O
195	O
UK	O
Caucasian	O
IIM	O
patients	O
,	O
comprising	O
103	O
PM	O
and	O
92	O
DM	O
.	O

Their	O
results	O
were	O
compared	O
with	O
those	O
of	O
162	O
ethnically	O
matched	O
controls	O
.	O

The	O
polymorphic	O
positions	O
of	O
three	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
one	O
insertion-deletion	O
sequence	O
within	O
regions	O
coding	O
for	O
MCP-1	O
were	O
tested	O
.	O

The	O
SNPs	O
examined	O
were	O
located	O
in	O
intron	O
1	O
(	O
rs2857657	B-SNP
,	O
C/G	B-DNAMutation
)	O
,	O
exon	O
2	O
(	O
rs4586	B-SNP
,	O
A/G	B-DNAMutation
)	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
rs13900	B-SNP
,	O
C/T	B-DNAMutation
)	O
.	O

The	O
insertion-deletion	O
sequence	O
was	O
located	O
in	O
intron	O
1	O
(	O
rs3917887	B-SNP
,	O
AGCTCCTCCTTCTC/-	B-DNAMutation
)	O
.	O

Each	O
SNP	O
was	O
tested	O
for	O
Hardy-Weinberg	O
equilibrium	O
and	O
allelic/genotypic	O
associations	O
.	O

Haplotype	O
frequencies	O
were	O
estimated	O
using	O
the	O
Expectation/Maximization	O
algorithm	O
.	O

RESULTS	O
:	O
There	O
was	O
strong	O
linkage	O
disequilibrium	O
present	O
between	O
three	O
out	O
of	O
these	O
four	O
markers	O
.	O

The	O
majority	O
of	O
controls	O
were	O
in	O
Hardy	O
Weinberg	O
equilibrium	O
.	O

No	O
allelic	O
,	O
genotypic	O
or	O
haplotypic	O
associations	O
were	O
detected	O
when	O
comparing	O
PM	O
or	O
DM	O
cases	O
to	O
controls	O
,	O
or	O
when	O
PM	O
and	O
DM	O
were	O
compared	O
with	O
each	O
other	O
.	O

CONCLUSIONS	O
:	O
Genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
do	O
not	O
demonstrate	O
significant	O
genetic	O
associations	O
with	O
the	O
IIMs	O
,	O
and	O
do	O
not	O
discriminate	O
PM	O
from	O
DM	O
in	O
a	O
UK	O
Caucasian	O
population	O
.	O

Gene	O
polymorphisms	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
venous	O
and	O
arterial	O
thromboembolism	O
:	O
frequency	O
distribution	O
in	O
a	O
healthy	O
German	O
population	O
.	O

Evolvement	O
and	O
progression	O
of	O
cardiovascular	O
diseases	O
affecting	O
the	O
venous	O
and	O
arterial	O
system	O
are	O
influenced	O
by	O
a	O
multitude	O
of	O
environmental	O
and	O
hereditary	O
factors	O
.	O

Many	O
of	O
these	O
hereditary	O
factors	O
consist	O
of	O
defined	O
gene	O
polymorphisms	O
,	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
or	O
insertion-deletion	O
polymorphisms	O
,	O
which	O
directly	O
or	O
indirectly	O
affect	O
the	O
hemostatic	O
system	O
.	O

The	O
frequencies	O
of	O
individual	O
hemostatic	O
gene	O
polymorphisms	O
in	O
different	O
normal	O
populations	O
are	O
well	O
defined	O
.	O

However	O
,	O
descriptions	O
of	O
patterns	O
of	O
genetic	O
variability	O
of	O
a	O
larger	O
extent	O
of	O
different	O
factors	O
of	O
hereditary	O
hypercoagulability	O
in	O
single	O
populations	O
are	O
scarce	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
i	O
)	O
to	O
give	O
a	O
detailed	O
description	O
of	O
the	O
frequencies	O
of	O
factors	O
of	O
hereditary	O
thrombophilia	O
and	O
their	O
combinations	O
in	O
a	O
German	O
population	O
(	O
n	O
=	O
282	O
)	O
and	O
ii	O
)	O
to	O
compare	O
their	O
distributions	O
with	O
those	O
reported	O
for	O
other	O
regions	O
.	O

Variants	O
of	O
coagulation	O
factors	O
[	O
factor	O
V	O
1691G>A	B-DNAMutation
(	O
factor	O
V	O
Leiden	O
)	O
,	O
factor	O
V	O
4070A>G	B-DNAMutation
(	O
factor	O
V	O
HR2	O
haplotype	O
)	O
,	O
factor	O
VII	O
Arg353Gln	B-ProteinMutation
,	O
factor	O
XIII	O
Val34Leu	B-ProteinMutation
,	O
beta-fibrinogen	O
-455G>A	B-DNAMutation
,	O
prothrombin	O
20210G>A	B-DNAMutation
]	O
,	O
coagulation	O
inhibitors	O
[	O
tissue	O
factor	O
pathway	O
inhibitor	O
536C>T	B-DNAMutation
,	O
thrombomodulin	O
127G>A	B-DNAMutation
]	O
,	O
fibrinolytic	O
factors	O
[	O
angiotensin	O
converting	O
enzyme	O
intron	O
16	O
insertion/deletion	O
,	O
factor	O
VII-activating	O
protease	O
1601G>A	B-DNAMutation
(	O
FSAP	O
Marburg	O
I	O
)	O
,	O
plasminogen	O
activator	O
inhibitor	O
1-675	O
insertion/deletion	O
(5G/4G)	O
,	O
tissue	O
plasminogen	O
activator	O
intron	O
h	O
deletion/insertion	O
]	O
,	O
and	O
other	O
factors	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
thromboembolic	O
diseases	O
[	O
apolipoprotein	O
E2/E3/E4	O
,	O
glycoprotein	O
Ia	O
807C>T	B-DNAMutation
,	O
methylenetetrahydrofolate	O
reductase	O
677C>T	B-DNAMutation
]	O
were	O
included	O
.	O

The	O
distribution	O
of	O
glycoprotein	O
Ia	O
807C>T	B-DNAMutation
deviated	O
significantly	O
from	O
the	O
Hardy-Weinberg	O
equilibrium	O
,	O
and	O
a	O
comparison	O
with	O
previously	O
published	O
data	O
indicates	O
marked	O
region	O
and	O
ethnicity	O
dependent	O
differences	O
in	O
the	O
genotype	O
distributions	O
of	O
some	O
other	O
factors	O
.	O

Severe	O
prothrombin	O
deficiency	O
caused	O
by	O
prothrombin-Edmonton	O
R-4Q	B-ProteinMutation
combined	O
with	O
a	O
previously	O
undetected	O
deletion	O
.	O

BACKGROUND	O
:	O
During	O
infancy	O
,	O
a	O
male	O
patient	O
experienced	O
several	O
life-threatening	O
bleeding	O
episodes	O
.	O

Standard	O
coagulation	O
tests	O
revealed	O
that	O
the	O
patient's	O
plasma	O
prothrombin	O
activity	O
was	O
8%	O
,	O
while	O
his	O
father's	O
and	O
mother's	O
levels	O
were	O
74%	O
and	O
62%	O
,	O
respectively	O
.	O

OBJECTIVES	O
:	O
A	O
molecular	O
genetic	O
approach	O
was	O
used	O
to	O
determine	O
the	O
molecular	O
basis	O
of	O
prothrombin	O
deficiency	O
within	O
the	O
family	O
.	O

PATIENT/METHODS	O
:	O
Prothrombin	O
genomic	O
DNA	O
fragments	O
were	O
amplified	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

In	O
addition	O
,	O
liver	O
cDNA	O
fragments	O
were	O
amplified	O
from	O
the	O
patient	O
by	O
using	O
reverse	O
transcription	O
(RT)	O
and	O
PCR	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
DNA	O
fragments	O
were	O
determined	O
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
heterozygous	O
point	O
mutation	O
(	O
g.1755	B-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
,	O
named	O
prothrombin-Edmonton	O
)	O
was	O
detected	O
in	O
the	O
patient	O
and	O
his	O
mother	O
,	O
resulting	O
in	O
the	O
mutation	O
of	O
Arg-4	O
in	O
the	O
prothrombin	O
propeptide	O
to	O
Gln	O
R-4Q	B-ProteinMutation
.	O

RT-PCR	O
analysis	O
of	O
the	O
patient's	O
liver	O
sample	O
demonstrated	O
the	O
presence	O
of	O
two	O
mRNA	O
transcripts	O
that	O
differed	O
by	O
the	O
presence	O
or	O
absence	O
of	O
exon	O
11	O
.	O

Real-time	O
PCR	O
analysis	O
on	O
genomic	O
DNA	O
and	O
cDNA	O
confirmed	O
a	O
deletion	O
g.10435_10809del	B-DNAMutation
in	O
the	O
paternal	O
allele	O
.	O

CONCLUSIONS	O
:	O
The	O
patient	O
has	O
a	O
maternally-inherited	O
point	O
mutation	O
R-4Q	B-ProteinMutation
and	O
a	O
paternally-inherited	O
deletion	O
.	O

By	O
analogy	O
with	O
the	O
previously	O
reported	O
factor	O
IX	O
San	O
Dimas	O
,	O
the	O
R-4Q	B-ProteinMutation
mutation	O
probably	O
causes	O
under-carboxylation	O
of	O
prothrombin	O
and	O
poor	O
cleavage	O
of	O
the	O
propeptide	O
in	O
the	O
hepatocyte	O
.	O

The	O
deletion	O
probably	O
results	O
in	O
a	O
polypeptide	O
that	O
lacks	O
50	O
amino	O
acids	O
from	O
the	O
protease	O
domain	O
;	O
this	O
is	O
likely	O
to	O
impair	O
folding	O
,	O
secretion	O
,	O
stability	O
and/or	O
activity	O
of	O
the	O
truncated	O
prothrombin	O
.	O

The	O
two	O
mutations	O
combine	O
to	O
give	O
the	O
prothrombin	O
deficiency	O
observed	O
in	O
the	O
patient	O
.	O

A	O
novel	O
His158Arg	B-ProteinMutation
mutation	O
in	O
TIMP3	O
causes	O
a	O
late-onset	O
form	O
of	O
Sorsby	O
fundus	O
dystrophy	O
.	O

PURPOSE	O
:	O
To	O
describe	O
the	O
phenotype	O
and	O
genotype	O
of	O
a	O
family	O
with	O
suspected	O
Sorsby	O
fundus	O
dystrophy	O
(SFD)	O
.	O

DESIGN	O
:	O
Case	O
reports	O
and	O
results	O
of	O
deoxyribonucleic	O
acid	O
(DNA)	O
analysis	O
.	O

METHODS	O
:	O
Clinical	O
features	O
were	O
determined	O
by	O
complete	O
ophthalmologic	O
examination	O
or	O
by	O
review	O
of	O
medical	O
records	O
.	O

Mutational	O
analysis	O
of	O
the	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
(TIMP)3	O
gene	O
was	O
performed	O
by	O
DNA	O
resequencing	O
.	O

Biochemical	O
properties	O
of	O
the	O
mutant	O
TIMP3	O
protein	O
were	O
studied	O
,	O
and	O
phylogenetic	O
and	O
molecular	O
modeling	O
analyses	O
of	O
TIMP	O
proteins	O
were	O
performed	O
.	O

RESULTS	O
:	O
Fundi	O
of	O
four	O
affected	O
family	O
members	O
demonstrated	O
active	O
or	O
regressed	O
bilateral	O
choroidal	O
neovascularization	O
,	O
whereas	O
another	O
affected	O
individual	O
displayed	O
severe	O
diffuse	O
pigmentary	O
degeneration	O
associated	O
with	O
nyctalopia	O
characteristic	O
of	O
SFD	O
.	O

Onset	O
of	O
disease	O
occurred	O
in	O
the	O
fifth	O
to	O
seventh	O
decades	O
of	O
life	O
.	O

A	O
heterozygous	O
His158Arg	B-ProteinMutation
mutation	O
was	O
found	O
in	O
seven	O
affected	O
family	O
members	O
and	O
was	O
absent	O
from	O
an	O
unaffected	O
member	O
and	O
98	O
unrelated	O
controls	O
.	O

Bioinformatic	O
analyses	O
indicate	O
that	O
histidine	O
158	O
is	O
an	O
evolutionarily	O
conserved	O
residue	O
in	O
most	O
vertebrate	O
TIMP	O
homologs	O
and	O
predict	O
that	O
substitution	O
by	O
arginine	O
disrupts	O
TIMP3	O
function	O
.	O

The	O
mutant	O
protein	O
appears	O
to	O
be	O
expressed	O
by	O
fibroblasts	O
from	O
an	O
affected	O
family	O
member	O
.	O

Molecular	O
modeling	O
suggests	O
that	O
TIMP3	O
residue	O
158	O
may	O
be	O
part	O
of	O
a	O
protein-protein	O
interaction	O
interface	O
.	O

CONCLUSION	O
:	O
A	O
novel	O
mutation	O
in	O
TIMP3	O
causes	O
a	O
late-onset	O
form	O
of	O
SFD	O
in	O
this	O
family	O
.	O

His158Arg	B-ProteinMutation
is	O
the	O
first	O
reported	O
TIMP3	O
SFD	O
coding	O
sequence	O
mutation	O
that	O
does	O
not	O
create	O
an	O
unpaired	O
cysteine	O
.	O

Further	O
study	O
of	O
this	O
unusual	O
mutation	O
may	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
SFD	O
pathogenesis	O
.	O

Analysis	O
of	O
a	O
missense	O
variant	O
of	O
the	O
human	O
N-formyl	O
peptide	O
receptor	O
that	O
is	O
associated	O
with	O
agonist-independent	O
beta-arrestin	O
association	O
and	O
indices	O
of	O
inflammation	O
.	O

Formyl-Met-Leu-Phe	O
(fMLP)	O
is	O
a	O
potent	O
chemoattractant	O
molecule	O
released	O
from	O
both	O
bacteria	O
and	O
damaged	O
mitochondria	O
that	O
activates	O
fMLP	O
receptors	O
(FPR)	O
leading	O
to	O
neutrophil	O
chemotaxis	O
,	O
degranulation	O
and	O
superoxide	O
production	O
.	O

A	O
common	O
missense	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
human	O
FPR1	O
gene	O
at	O
nucleotide	O
c.32C>T	B-DNAMutation
results	O
in	O
the	O
amino-acid	O
substitution	O
,	O
p.I11T	B-ProteinMutation
,	O
in	O
the	O
FPR1	O
extracellular	O
amino-terminus	O
.	O

The	O
minor	O
(c.32T)	O
allele	O
frequencies	O
were	O
0.25	O
,	O
0.27	O
,	O
0.25	O
,	O
0.15	O
and	O
0.14	O
in	O
healthy	O
Caucasian	O
,	O
African	O
,	O
East	O
Indian	O
,	O
Chinese	O
and	O
Native	O
Canadian	O
individuals	O
,	O
respectively	O
.	O

In	O
subjects	O
homozygous	O
for	O
the	O
p.T11	O
allele	O
,	O
we	O
find	O
elevated	O
serum	O
concentrations	O
of	O
C-reactive	O
protein	O
,	O
increased	O
absolute	O
counts	O
of	O
blood	O
leukocytes	O
and	O
neutrophils	O
,	O
and	O
erythrocyte	O
sedimentation	O
rates	O
.	O

When	O
expressed	O
in	O
HEK	O
293	O
and	O
RBL-2H3	O
cells	O
a	O
substantial	O
proportion	O
of	O
FPR1	O
p.I11T	B-ProteinMutation
variant	O
is	O
retained	O
intracellularly	O
and	O
agonist-independent	O
internalization	O
of	O
the	O
FPR1	O
p.I11T	B-ProteinMutation
variant	O
,	O
but	O
not	O
the	O
wild-type	O
FPR1	O
,	O
is	O
constitutively	O
associated	O
with	O
beta-arrestin2-GFP	O
in	O
vesicles	O
.	O

Moreover	O
,	O
basal	O
N-acetyl-D-glucosaminidase	O
release	O
is	O
increased	O
in	O
primary	O
neutrophils	O
isolated	O
from	O
subjects	O
either	O
heterozygous	O
or	O
homozygous	O
for	O
the	O
FPR1	O
p.T11	O
allele	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
an	O
increased	O
receptor	O
activity	O
and	O
phenotypic	O
expression	O
of	O
increased	O
inflammatory	O
indices	O
in	O
subjects	O
with	O
the	O
p.T11	O
allele	O
.	O

Clinical	O
characterization	O
and	O
evaluation	O
of	O
DYT1	O
gene	O
in	O
Indian	O
primary	O
dystonia	O
patients	O
.	O

OBJECTIVES	O
:	O
Dystonia	O
is	O
a	O
common	O
movement	O
disorder	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
relative	O
distribution	O
of	O
the	O
primary	O
dystonia	O
subtypes	O
and	O
identify	O
mutation	O
(s)	O
in	O
the	O
DYT1	O
gene	O
in	O
Indian	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Primary	O
dystonia	O
patients	O
(	O
n	O
=	O
178	O
)	O
and	O
controls	O
(	O
n	O
=	O
63	O
)	O
,	O
lacking	O
any	O
symptoms	O
of	O
the	O
disease	O
,	O
were	O
recruited	O
for	O
the	O
study	O
from	O
eastern	O
India	O
.	O

The	O
nucleotide	O
variants	O
in	O
the	O
DYT1	O
gene	O
were	O
identified	O
by	O
carrying	O
out	O
polymerase	O
chain	O
reaction	O
,	O
single	O
stranded	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Unlike	O
other	O
reports	O
,	O
pain	O
and/or	O
tremor	O
was	O
more	O
common	O
in	O
our	O
sporadic	O
patients	O
than	O
in	O
familial	O
cases	O
.	O

Three	O
reported	O
and	O
two	O
novel	O
changes	O
were	O
identified	O
in	O
this	O
gene	O
.	O

The	O
homozygous	O
genotype	O
(G,G)	O
for	O
a	O
missense	O
variant	O
(	O
c.646G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
;	O
Asp216His	B-ProteinMutation
)	O
was	O
significantly	O
over-represented	O
in	O
the	O
patients	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
the	O
commonly	O
reported	O
3	O
bp	O
deletion	O
904-906delGAG	B-DNAMutation
was	O
not	O
detected	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
DYT1	O
gene	O
might	O
have	O
a	O
limited	O
role	O
in	O
causation	O
of	O
dystonia	O
in	O
the	O
Indian	O
population	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
in	O
subjects	O
with	O
multiple	O
endocrine	O
neoplasia-1	O
.	O

Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(MEN1)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	O
endocrine	O
and	O
pituitary	O
adenomas	O
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	O
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	O
with	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	O
had	O
primary	O
hyperparathyroidism	O
(PHPT)	O
plus	O
a	O
prolactinoma	O
;	O
three	O
relatives	O
had	O
PHPT	O
only	O
.	O

The	O
index	O
patient	O
in	O
the	O
second	O
family	O
was	O
a	O
46-yr-old	O
woman	O
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	O
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	O
and	O
watery	O
diarrhea	O
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	O
islet	O
cell	O
tumor	O
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	O
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	O
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	O
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	O
to	O
G	O
transition	O
at	O
codon	O
557	O
AAG-->GAG	B-DNAMutation
of	O
exon	O
10	O
of	O
MEN1	O
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	O
by	O
glutamic	O
acid	O
.	O

The	O
Chinese	O
index	O
patient	O
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	O
at	O
codon	O
418	O
of	O
exon	O
9	O
GAC-->TAT	B-DNAMutation
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	O
acid	O
by	O
tyrosine	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O

Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
:	O
the	O
STOP-NIDDM	O
trial	O
.	O

Hepatocyte	O
nuclear	O
factor	O
4alpha	O
(HNF4alpha)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	O
liver	O
and	O
pancreatic	O
islets	O
.	O

We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
of	O
HNF4A	O
,	O
encoding	O
HNF4alpha	O
,	O
influenced	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
subjects	O
of	O
the	O
STOP-NIDDM	O
trial	O
.	O

This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	O
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	O
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O

Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	B-SNP
,	O
rs1884614	B-SNP
,	O
and	O
rs2144908	B-SNP
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D'>0.97	O
,	O
r	O
(	O
2)>0.95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	B-SNP
was	O
included	O
in	O
further	O
analyses	O
.	O

Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	B-SNP
had	O
a	O
1.7-fold	O
elevated	O
risk	O
[	O
95%	O
confidence	O
interval	O
(CI)	O
1.09-2.66	O
;	O
P=0.020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	O
compared	O
to	O
women	O
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	O
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O

No	O
association	O
was	O
found	O
in	O
men	O
.	O

Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	B-SNP
,	O
rs2071197	B-SNP
,	O
and	O
rs3818247	B-SNP
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	O
.	O

Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	O
and	O
their	O
haplotypes	O
predispose	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
female	O
subjects	O
of	O
the	O
STOP-NIDDM	O
study	O
population	O
.	O

Genomic	O
characterization	O
of	O
five	O
deletions	O
in	O
the	O
LDL	O
receptor	O
gene	O
in	O
Danish	O
Familial	O
Hypercholesterolemic	O
subjects	O
.	O

BACKGROUND	O
:	O
Familial	O
Hypercholesterolemia	O
is	O
a	O
common	O
autosomal	O
dominantly	O
inherited	O
disease	O
that	O
is	O
most	O
frequently	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
receptor	O
for	O
low	O
density	O
lipoproteins	O
(LDLR)	O
.	O

Deletions	O
and	O
other	O
major	O
structural	O
rearrangements	O
of	O
the	O
LDLR	O
gene	O
account	O
for	O
approximately	O
5%	O
of	O
the	O
mutations	O
in	O
many	O
populations	O
.	O

METHODS	O
:	O
Five	O
genomic	O
deletions	O
in	O
the	O
LDLR	O
gene	O
were	O
characterized	O
by	O
amplification	O
of	O
mutated	O
alleles	O
and	O
sequencing	O
to	O
identify	O
genomic	O
breakpoints	O
.	O

A	O
diagnostic	O
assay	O
based	O
on	O
duplex	O
PCR	O
for	O
the	O
exon	O
7-8	O
deletion	O
was	O
developed	O
to	O
discriminate	O
between	O
heterozygotes	O
and	O
normals	O
,	O
and	O
bioinformatic	O
analyses	O
were	O
used	O
to	O
identify	O
interspersed	O
repeats	O
flanking	O
the	O
deletions	O
.	O

RESULTS	O
:	O
In	O
one	O
case	O
15	O
bp	O
had	O
been	O
inserted	O
at	O
the	O
site	O
of	O
the	O
deleted	O
DNA	O
,	O
and	O
,	O
in	O
all	O
five	O
cases	O
,	O
Alu	O
elements	O
flanked	O
the	O
sites	O
where	O
deletions	O
had	O
occurred	O
.	O

An	O
assay	O
developed	O
to	O
discriminate	O
the	O
wildtype	O
and	O
the	O
deletion	O
allele	O
in	O
a	O
simple	O
duplex	O
PCR	O
detected	O
three	O
FH	O
patients	O
as	O
heterozygotes	O
,	O
and	O
two	O
individuals	O
with	O
normal	O
lipid	O
values	O
were	O
detected	O
as	O
normal	O
homozygotes	O
.	O

CONCLUSION	O
:	O
The	O
identification	O
of	O
the	O
breakpoints	O
should	O
make	O
it	O
possible	O
to	O
develop	O
specific	O
tests	O
for	O
these	O
mutations	O
,	O
and	O
the	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
role	O
of	O
Alu	O
repeats	O
in	O
intragenic	O
deletions	O
.	O

Ectodermal	O
dysplasia-skin	O
fragility	O
syndrome	O
resulting	O
from	O
a	O
new	O
homozygous	O
mutation	O
,	O
888delC	B-DNAMutation
,	O
in	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
an	O
inherited	O
disorder	O
of	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
,	O
resulting	O
in	O
ectodermal	O
dysplasia-skin	O
fragility	O
syndrome	O
.	O

The	O
affected	O
6-year-old	O
boy	O
had	O
red	O
skin	O
at	O
birth	O
and	O
subsequently	O
developed	O
skin	O
fragility	O
,	O
progressive	O
plantar	O
keratoderma	O
,	O
nail	O
dystrophy	O
,	O
and	O
alopecia	O
.	O

Skin	O
biopsy	O
revealed	O
widening	O
of	O
intercellular	O
spaces	O
in	O
the	O
epidermis	O
and	O
a	O
reduced	O
number	O
of	O
small	O
,	O
poorly	O
formed	O
desmosomes	O
.	O

Mutation	O
analysis	O
of	O
the	O
plakophilin	O
1	O
gene	O
PKP1	O
revealed	O
a	O
homozygous	O
deletion	O
of	O
C	O
at	O
nucleotide	O
888	O
within	O
exon	O
5	O
.	O

This	O
mutation	O
differs	O
from	O
the	O
PKP1	O
gene	O
pathology	O
reported	O
in	O
8	O
previously	O
published	O
individuals	O
with	O
this	O
rare	O
genodermatosis	O
.	O

However	O
,	O
all	O
cases	O
show	O
similar	O
clinical	O
features	O
,	O
highlighting	O
the	O
importance	O
of	O
functional	O
plakophilin	O
1	O
in	O
maintaining	O
desmosomal	O
adhesion	O
in	O
skin	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
this	O
protein	O
in	O
aspects	O
of	O
ectodermal	O
development	O
.	O

Polymorphisms	O
in	O
thymidylate	O
synthase	O
gene	O
and	O
susceptibility	O
to	O
breast	O
cancer	O
in	O
a	O
Chinese	O
population	O
:	O
a	O
case-control	O
analysis	O
.	O

BACKGROUND	O
:	O
Accumulative	O
evidence	O
suggests	O
that	O
low	O
folate	O
intake	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
breast	O
cancer	O
.	O

Polymorphisms	O
in	O
genes	O
involved	O
in	O
folate	O
metabolism	O
may	O
influence	O
DNA	O
methylation	O
,	O
nucleotide	O
synthesis	O
,	O
and	O
thus	O
individual	O
susceptibility	O
to	O
cancer	O
.	O

Thymidylate	O
synthase	O
(TYMS)	O
is	O
a	O
key	O
enzyme	O
that	O
participates	O
in	O
folate	O
metabolism	O
and	O
catalyzes	O
the	O
conversion	O
of	O
dUMP	O
to	O
dTMP	O
in	O
the	O
process	O
of	O
DNA	O
synthesis	O
.	O

Two	O
potentially	O
functional	O
polymorphisms	O
[	O
a	O
28-bp	O
tandem	O
repeat	O
in	O
the	O
TYMS	O
5'-untranslated	O
enhanced	O
region	O
(TSER)	O
and	O
a	O
6-bp	O
deletion/insertion	O
in	O
the	O
TYMS	O
3'-untranslated	O
region	O
(	O
TS	O
3'-UTR)	O
]	O
were	O
suggested	O
to	O
be	O
correlated	O
with	O
alteration	O
of	O
thymidylate	O
synthase	O
expression	O
and	O
associated	O
with	O
cancer	O
risk	O
.	O

METHODS	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
polymorphisms	O
of	O
the	O
TYMS	O
gene	O
are	O
associated	O
with	O
risk	O
of	O
breast	O
cancer	O
,	O
we	O
genotyped	O
these	O
two	O
polymorphisms	O
in	O
a	O
case-control	O
study	O
of	O
432	O
incident	O
cases	O
with	O
invasive	O
breast	O
cancer	O
and	O
473	O
cancer-free	O
controls	O
in	O
a	O
Chinese	O
population	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
the	O
distribution	O
of	O
TS3'-UTR	O
1494del6	B-DNAMutation
genotype	O
frequencies	O
were	O
significantly	O
different	O
between	O
the	O
cases	O
and	O
controls	O
(	O
P	O
=	O
0.026	O
)	O
.	O

Compared	O
with	O
the	O
TS3'-UTR	O
del6/del6	O
wild-type	O
genotype	O
,	O
a	O
significantly	O
reduced	O
risk	O
was	O
associated	O
with	O
the	O
ins6/ins6	O
homozygous	O
variant	O
genotype	O
(	O
adjusted	O
OR	O
=	O
0.58	O
,	O
95%	O
CI	O
=	O
0.35-0.97	O
)	O
but	O
not	O
the	O
del6/ins6	O
genotype	O
(	O
OR	O
=	O
1.09	O
,	O
95%	O
CI	O
=	O
0.82-1.46	O
)	O
.	O

Furthermore	O
,	O
breast	O
cancer	O
risks	O
associated	O
with	O
the	O
TS3'-UTR	O
del6/del6	O
genotype	O
were	O
more	O
evident	O
in	O
older	O
women	O
,	O
postmenopausal	O
subjects	O
,	O
individuals	O
with	O
a	O
younger	O
age	O
at	O
first-live	O
birth	O
and	O
individuals	O
with	O
an	O
older	O
age	O
at	O
menarche	O
.	O

However	O
,	O
there	O
was	O
no	O
evidence	O
for	O
an	O
association	O
between	O
the	O
TSER	O
polymorphism	O
and	O
breast	O
cancer	O
risks	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
TS3'-UTR	O
del6	O
polymorphism	O
may	O
play	O
a	O
role	O
in	O
the	O
etiology	O
of	O
breast	O
cancer	O
.	O

Further	O
larger	O
population-based	O
studies	O
as	O
well	O
as	O
functional	O
evaluation	O
of	O
the	O
variants	O
are	O
warranted	O
to	O
confirm	O
our	O
findings	O
.	O

Insertion/deletion	O
polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
gene	O
in	O
Kawasaki	O
disease	O
.	O

Polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
gene	O
is	O
reported	O
to	O
be	O
associated	O
with	O
ischemic	O
heart	O
disease	O
,	O
hypertrophic	O
cardiomyopathy	O
,	O
and	O
idiopathic	O
dilated	O
cardiomyopathy	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
Kawasaki	O
disease	O
and	O
insertion/deletion	O
polymorphism	O
of	O
ACE	O
gene	O
.	O

Fifty	O
five	O
Kawasaki	O
disease	O
patients	O
and	O
43	O
healthy	O
children	O
were	O
enrolled	O
.	O

ACE	O
genotype	O
was	O
evaluated	O
from	O
each	O
of	O
the	O
subjects'	O
DNA	O
fragments	O
through	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Frequencies	O
of	O
ACE	O
genotypes	O
(	O
DD	O
,	O
ID	O
,	O
II	O
)	O
were	O
12.7%	O
,	O
60.0%	O
,	O
27.3%	O
in	O
Kawasaki	O
group	O
,	O
and	O
41.9%	O
,	O
30.2%	O
,	O
27.9%	O
in	O
control	O
group	O
respectively	O
,	O
indicating	O
low	O
rate	O
of	O
DD	O
and	O
high	O
rate	O
of	O
ID	O
genotype	O
among	O
Kawasaki	O
patients	O
(p<0.01)	O
.	O

Comparing	O
allelic	O
(	O
I	O
,	O
D	O
)	O
frequencies	O
,	O
I	O
allele	O
was	O
more	O
prevalent	O
in	O
Kawasaki	O
group	O
than	O
in	O
control	O
group	O
(	O
57.3%	O
vs	O
.	O

43.0%	O
,	O
p<0.05	O
)	O
.	O

In	O
Kawasaki	O
group	O
,	O
both	O
genotype	O
and	O
allelic	O
frequencies	O
were	O
not	O
statistically	O
different	O
between	O
those	O
with	O
coronary	O
dilatations	O
and	O
those	O
without	O
.	O

ACE	O
gene	O
I/D	O
polymorphism	O
is	O
thought	O
to	O
be	O
associated	O
with	O
Kawasaki	O
disease	O
but	O
not	O
with	O
the	O
development	O
of	O
coronary	O
dilatations	O
.	O

Tumor	O
thymidylate	O
synthase	O
1494del6	B-DNAMutation
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	O
cancer	O
patients	O
receiving	O
fluorouracil-based	O
adjuvant	O
treatment	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	O
thymidylate	O
synthase	O
(TS)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	O
cancer	O
patients	O
receiving	O
adjuvant	O
fluorouracil	O
(FU)	O
-based	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty-nine	O
colorectal	O
cancer	O
patients	O
homogeneously	O
treated	O
with	O
FU	O
plus	O
levamisole	O
or	O
leucovorin	O
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O

TS	O
enhancer	O
region	O
,	O
3R	O
G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
and	O
TS	O
1494del6	B-DNAMutation
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh-frozen	O
normal	O
mucosa	O
and	O
tumor	O
.	O

Mutational	O
analyses	O
of	O
TS	O
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	O
and	O
in	O
18	O
additional	O
metachronic	O
metastases	O
.	O

TS	O
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	O
.	O

Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
,	O
differentiation	O
,	O
and	O
location	O
.	O

RESULTS	O
:	O
Tumor	O
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
26%	O
)	O
showed	O
that	O
the	O
3R/3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[HR]	O
=	O
0.38	O
;	O
95%	O
CI	O
,	O
0.16	O
to	O
0.93	O
;	O
P	O
=	O
.020	O
for	O
the	O
recessive	O
model	O
)	O
.	O

3R	O
G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O

Tumor	O
TS	O
1494del6	B-DNAMutation
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
36%	O
)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
,	O
based	O
on	O
an	O
additive	O
model	O
,	O
HR	O
=	O
0.42	O
;	O
95%	O
CI	O
,	O
0.22	O
to	O
0.82	O
;	O
P	O
=	O
.0034	O
)	O
.	O

Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D'	O
=	O
0.71	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
3R/-6	O
base	O
pair	O
(bp)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R/+6bp	O
(	O
HR	O
=	O
0.42	O
;	O
95%	O
CI	O
,	O
0.20	O
to	O
0.85	O
;	O
P	O
=	O
.017	O
)	O
.	O

No	O
TS	O
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	O
or	O
metastases	O
.	O

TS	O
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O

CONCLUSION	O
:	O
Tumor	O
TS	O
1494del6	B-DNAMutation
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU-based	O
adjuvant	O
treatment	O
of	O
colorectal	O
cancer	O
patients	O
.	O

Genetic	O
variation	O
in	O
the	O
COX-2	O
gene	O
and	O
the	O
association	O
with	O
prostate	O
cancer	O
risk	O
.	O

COX-2	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	O
acid	O
to	O
prostaglandins	O
.	O

The	O
prostaglandins	O
produced	O
by	O
COX-2	O
are	O
involved	O
in	O
inflammation	O
and	O
pain	O
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O

Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
,	O
chemical	O
carcinogen-induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX-2	O
plays	O
a	O
role	O
in	O
human	O
carcinogenesis	O
and	O
is	O
overexpressed	O
in	O
prostate	O
cancer	O
tissue	O
.	O

We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX-2	O
gene	O
are	O
associated	O
with	O
prostate	O
cancer	O
risk	O
.	O

We	O
analyzed	O
a	O
large	O
population-based	O
case-control	O
study	O
,	O
cancer	O
prostate	O
in	O
Sweden	O
(CAPS)	O
consisting	O
of	O
1,378	O
cases	O
and	O
782	O
controls	O
.	O

We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
spanning	O
the	O
entire	O
COX-2	O
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O

Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	O
and	O
control	O
subjects	O
and	O
gene-specific	O
haplotypes	O
were	O
constructed	O
.	O

A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(	O
+3100	B-DNAMutation
T/G	I-DNAMutation
and	O
+8365	B-DNAMutation
C/T	I-DNAMutation
)	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
0.78	O
(	O
95%	O
CI=0.64-0.96	O
)	O
and	O
0.65	O
(	O
95%	O
CI=0.45-0.94	O
)	O
respectively	O
.	O

In	O
the	O
haplotype	O
analysis	O
,	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+3100	B-DNAMutation
T/G	I-DNAMutation
and	O
+8365	B-DNAMutation
C/T	I-DNAMutation
,	O
with	O
a	O
population	O
frequency	O
of	O
3%	O
,	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	O
cancer	O
(	O
p=0.036	O
,	O
global	O
simulated	O
p-value=0.046	O
)	O
.	O

This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	O
is	O
involved	O
in	O
prostate	O
carcinogenesis	O
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX-2	O
gene	O
influence	O
the	O
risk	O
of	O
prostate	O
cancer	O
.	O

A	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-ProteinMutation
,	O
in	O
the	O
mineralocorticoid	O
receptor	O
gene	O
in	O
Japanese	O
hypertensives	O
:	O
its	O
implications	O
for	O
clinical	O
phenotypes	O
.	O

A	O
gain-of-function	O
mutation	O
resulting	O
in	O
the	O
S810L	B-ProteinMutation
amino	O
acid	O
substitution	O
in	O
the	O
hormone-binding	O
domain	O
of	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
,	O
locus	O
symbol	O
NR3C2	O
)	O
is	O
responsible	O
for	O
early-onset	O
hypertension	O
that	O
is	O
exacerbated	O
in	O
pregnancy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
other	O
types	O
of	O
missense	O
mutations	O
in	O
the	O
hormone-binding	O
domain	O
could	O
be	O
implicated	O
in	O
hypertension	O
in	O
Japanese	O
.	O

Here	O
,	O
we	O
screened	O
942	O
Japanese	O
patients	O
with	O
hypertension	O
for	O
the	O
S810L	B-ProteinMutation
mutation	O
in	O
exon	O
6	O
in	O
the	O
MR	O
.	O

We	O
did	O
not	O
identify	O
the	O
S810L	B-ProteinMutation
mutation	O
in	O
our	O
hypertensive	O
population	O
,	O
indicating	O
that	O
S810L	B-ProteinMutation
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
etiology	O
of	O
essential	O
hypertension	O
in	O
Japanese	O
.	O

However	O
,	O
we	O
identified	O
a	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-ProteinMutation
,	O
in	O
three	O
patients	O
in	O
a	O
heterozygous	O
state	O
,	O
in	O
addition	O
to	O
four	O
single	O
nucleotide	O
polymorphisms	O
,	O
including	O
one	O
synonymous	O
mutation	O
L809L	B-ProteinMutation
.	O

The	O
F826Y	B-ProteinMutation
mutation	O
is	O
present	O
in	O
the	O
MR	O
hormone-binding	O
domain	O
and	O
might	O
affect	O
the	O
ligand	O
affinity	O
.	O

The	O
F826Y	B-ProteinMutation
mutation	O
was	O
also	O
identified	O
in	O
13	O
individuals	O
(	O
5	O
hypertensives	O
and	O
8	O
normotensives	O
)	O
in	O
a	O
Japanese	O
general	O
population	O
(n=3,655)	O
.	O

The	O
allele	O
frequency	O
was	O
0.00178	O
.	O

The	O
frequencies	O
of	O
the	O
F826Y	B-ProteinMutation
mutation	O
in	O
the	O
hypertensive	O
population	O
(3/942)	O
and	O
in	O
the	O
hypertensive	O
group	O
(	O
5/	O
1,480	O
)	O
and	O
the	O
normotensive	O
group	O
(8/2,175)	O
in	O
the	O
general	O
population	O
were	O
not	O
significantly	O
different	O
,	O
suggesting	O
that	O
this	O
mutation	O
does	O
not	O
greatly	O
affect	O
hypertension	O
.	O

Although	O
it	O
is	O
unclear	O
at	O
present	O
whether	O
or	O
not	O
the	O
F826Y	B-ProteinMutation
mutation	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
mineralocorticoid	O
receptor	O
activity	O
,	O
this	O
missense	O
mutation	O
may	O
contribute	O
,	O
to	O
some	O
extent	O
,	O
to	O
clinical	O
phenotypes	O
through	O
its	O
effects	O
on	O
MR	O
.	O

Genetic	O
alterations	O
in	O
primary	O
glioblastomas	O
in	O
Japan	O
.	O

Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	O
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	O
from	O
mainly	O
caucasian	O
patients	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	O
in	O
Japanese	O
patients	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	O
mutations	O
in	O
16	O
of	O
73	O
(22%)	O
glioblastomas	O
and	O
PTEN	O
mutations	O
in	O
13	O
of	O
63	O
(21%)	O
cases	O
analyzed	O
.	O

Polymerase	O
chain	O
reaction	O
(PCR)	O
showed	O
EGFR	O
amplification	O
in	O
25	O
of	O
77	O
(32%)	O
cases	O
and	O
p16	O
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(42%)	O
cases	O
.	O

Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(69%)	O
glioblastomas	O
.	O

The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	O
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O

As	O
previously	O
observed	O
for	O
glioblastomas	O
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	O
amplification	O
and	O
p16	O
deletion	O
(p=0.009)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	O
mutations	O
and	O
p16	O
deletion	O
(p=0.049)	O
in	O
glioblastomas	O
in	O
Japan	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	O
patients	O
(p=0.002)	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18-21	O
)	O
of	O
the	O
EGFR	O
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(3%)	O
glioblastomas	O
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(5%)	O
glioblastomas	O
in	O
Switzerland	O
.	O

The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	B-DNAMutation
787	I-DNAMutation
CAG/CAA	I-DNAMutation
(Gln/Gln)	O
in	O
glioblastomas	O
in	O
Japan	O
were	O
G/G	O
(82.4%)	O
,	O
G/A	O
(10.8%)	O
,	O
A/A	O
(6.8%)	O
,	O
corresponding	O
to	O
G	O
0.878	O
versus	O
A	O
0.122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	O
in	O
Switzerland	O
:	O
G/G	O
(27.2%)	O
,	O
G/A	O
(28.4%)	O
,	O
A/A	O
(44.4%)	O
,	O
corresponding	O
to	O
G	O
0.414	O
versus	O
A	O
0.586	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	O
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	O
gene	O
.	O

Evidence	O
for	O
alternative	O
candidate	O
genes	O
near	O
RB1	O
involved	O
in	O
clonal	O
expansion	O
of	O
in	O
situ	O
urothelial	O
neoplasia	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
studies	O
using	O
hypervariable	O
DNA	O
markers	O
on	O
chromosome	O
13	O
and	O
then	O
integrate	O
the	O
recombination-	O
and	O
single-nucleotide	O
polymorphic	O
sites	O
(SNPs)-based	O
deletion	O
maps	O
with	O
the	O
annotated	O
genome	O
sequence	O
.	O

Using	O
bladders	O
resected	O
from	O
patients	O
with	O
invasive	O
urothelial	O
carcinoma	O
,	O
we	O
studied	O
allelic	O
patterns	O
of	O
40	O
microsatellite	O
markers	O
mapping	O
to	O
all	O
regions	O
of	O
chromosome	O
13	O
and	O
79	O
SNPs	O
located	O
within	O
the	O
13q14	O
region	O
containing	O
the	O
RB1	O
gene	O
.	O

A	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
strategy	O
was	O
used	O
to	O
identify	O
the	O
evolution	O
of	O
allelic	O
losses	O
on	O
chromosome	O
13	O
during	O
the	O
progression	O
of	O
bladder	O
neoplasia	O
.	O

Markers	O
mapping	O
to	O
chromosomal	O
regions	O
involved	O
in	O
clonal	O
expansion	O
of	O
preneoplastic	O
intraurothelial	O
lesions	O
were	O
subsequently	O
tested	O
in	O
25	O
tumors	O
and	O
21	O
voided	O
urine	O
samples	O
of	O
patients	O
with	O
bladder	O
cancer	O
.	O

Four	O
clusters	O
of	O
allelic	O
losses	O
mapping	O
to	O
distinct	O
regions	O
of	O
chromosome	O
13	O
were	O
identified	O
.	O

Markers	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
is	O
flanked	O
by	O
D13S263	O
and	O
D13S276	O
,	O
which	O
contains	O
the	O
RB1	O
gene	O
,	O
showed	O
allelic	O
losses	O
associated	O
with	O
early	O
clonal	O
expansion	O
of	O
intraurothelial	O
neoplasia	O
.	O

Such	O
losses	O
could	O
be	O
identified	O
in	O
approximately	O
32%	O
bladder	O
tumor	O
tissue	O
samples	O
and	O
38%	O
of	O
voided	O
urines	O
from	O
patients	O
with	O
bladder	O
cancer	O
.	O

The	O
integration	O
of	O
distribution	O
patterns	O
of	O
clonal	O
allelic	O
losses	O
revealed	O
by	O
the	O
microsatellite	O
markers	O
with	O
those	O
obtained	O
by	O
genotyping	O
of	O
SNPs	O
disclosed	O
that	O
the	O
loss	O
within	O
an	O
approximately	O
4-Mb	O
segment	O
centered	O
around	O
RB1	O
may	O
represent	O
an	O
incipient	O
event	O
in	O
bladder	O
neoplasia	O
.	O

However	O
,	O
the	O
inactivation	O
of	O
RB1	O
occurred	O
later	O
and	O
was	O
associated	O
with	O
the	O
onset	O
of	O
severe	O
dysplasia/carcinoma	O
in	O
situ	O
.	O

Our	O
studies	O
provide	O
evidence	O
for	O
the	O
presence	O
of	O
critical	O
alternative	O
candidate	O
genes	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
are	O
involved	O
in	O
clonal	O
expansion	O
of	O
neoplasia	O
within	O
the	O
bladder	O
antecedent	O
to	O
the	O
inactivation	O
of	O
the	O
RB1	O
gene	O
.	O

Allele-specific	O
amplification	O
in	O
cancer	O
revealed	O
by	O
SNP	O
array	O
analysis	O
.	O

Amplification	O
,	O
deletion	O
,	O
and	O
loss	O
of	O
heterozygosity	O
of	O
genomic	O
DNA	O
are	O
hallmarks	O
of	O
cancer	O
.	O

In	O
recent	O
years	O
a	O
variety	O
of	O
studies	O
have	O
emerged	O
measuring	O
total	O
chromosomal	O
copy	O
number	O
at	O
increasingly	O
high	O
resolution	O
.	O

Similarly	O
,	O
loss-of-heterozygosity	O
events	O
have	O
been	O
finely	O
mapped	O
using	O
high-throughput	O
genotyping	O
technologies	O
.	O

We	O
have	O
developed	O
a	O
probe-level	O
allele-specific	O
quantitation	O
procedure	O
that	O
extracts	O
both	O
copy	O
number	O
and	O
allelotype	O
information	O
from	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
data	O
to	O
arrive	O
at	O
allele-specific	O
copy	O
number	O
across	O
the	O
genome	O
.	O

Our	O
approach	O
applies	O
an	O
expectation-maximization	O
algorithm	O
to	O
a	O
model	O
derived	O
from	O
a	O
novel	O
classification	O
of	O
SNP	O
array	O
probes	O
.	O

This	O
method	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
that	O
is	O
able	O
to	O
(a)	O
determine	O
the	O
generalized	O
genotype	O
of	O
aberrant	O
samples	O
at	O
each	O
SNP	O
site	O
(	O
e.g.	O
,	O
CCCCT	O
at	O
an	O
amplified	O
site	O
)	O
,	O
and	O
(b)	O
infer	O
the	O
copy	O
number	O
of	O
each	O
parental	O
chromosome	O
across	O
the	O
genome	O
.	O

With	O
this	O
method	O
,	O
we	O
are	O
able	O
to	O
determine	O
not	O
just	O
where	O
amplifications	O
and	O
deletions	O
occur	O
,	O
but	O
also	O
the	O
haplotype	O
of	O
the	O
region	O
being	O
amplified	O
or	O
deleted	O
.	O

The	O
merit	O
of	O
our	O
model	O
and	O
general	O
approach	O
is	O
demonstrated	O
by	O
very	O
precise	O
genotyping	O
of	O
normal	O
samples	O
,	O
and	O
our	O
allele-specific	O
copy	O
number	O
inferences	O
are	O
validated	O
using	O
PCR	O
experiments	O
.	O

Applying	O
our	O
method	O
to	O
a	O
collection	O
of	O
lung	O
cancer	O
samples	O
,	O
we	O
are	O
able	O
to	O
conclude	O
that	O
amplification	O
is	O
essentially	O
monoallelic	O
,	O
as	O
would	O
be	O
expected	O
under	O
the	O
mechanisms	O
currently	O
believed	O
responsible	O
for	O
gene	O
amplification	O
.	O

This	O
suggests	O
that	O
a	O
specific	O
parental	O
chromosome	O
may	O
be	O
targeted	O
for	O
amplification	O
,	O
whether	O
because	O
of	O
germ	O
line	O
or	O
somatic	O
variation	O
.	O

An	O
R	O
software	O
package	O
containing	O
the	O
methods	O
described	O
in	O
this	O
paper	O
is	O
freely	O
available	O
at	O
http://genome.dfci.harvard.edu/~tlaframb/PLASQ	O
.	O

Tag/anti-tag	O
liquid-phase	O
primer	O
extension	O
array	O
:	O
a	O
flexible	O
and	O
versatile	O
genotyping	O
platform	O
.	O

This	O
study	O
demonstrates	O
an	O
array-based	O
platform	O
to	O
genotype	O
simultaneously	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
some	O
short	O
insertions/deletions	O
(indels)	O
by	O
the	O
integration	O
of	O
the	O
universal	O
tag/anti-tag	O
(TAT)	O
system	O
,	O
liquid-phase	O
primer	O
extension	O
(LIPEX)	O
,	O
and	O
a	O
novel	O
two-color	O
detection	O
strategy	O
on	O
an	O
array	O
format	O
(TATLIPEXA)	O
.	O

The	O
TAT	O
system	O
permits	O
a	O
universal	O
chip	O
to	O
be	O
used	O
for	O
many	O
applications	O
,	O
and	O
the	O
LIPEX	O
simplifies	O
the	O
sample	O
preparation	O
but	O
improves	O
the	O
sensitivity	O
significantly	O
.	O

More	O
importantly	O
,	O
all	O
SNPs	O
and	O
some	O
short	O
indels	O
can	O
be	O
interrogated	O
in	O
a	O
single	O
reaction	O
with	O
only	O
two	O
fluorescent	O
ddNTPs	O
.	O

The	O
concept	O
of	O
TATLIPEXA	O
is	O
demonstrated	O
for	O
nine	O
SNPs	O
(	O
eight	O
point	O
mutations	O
and	O
one	O
single-base	O
insertion	O
)	O
,	O
and	O
genotypes	O
obtained	O
show	O
a	O
remarkable	O
concordance	O
rate	O
of	O
100%	O
with	O
both	O
DNA	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Moreover	O
,	O
TATLIPEXA	O
is	O
able	O
to	O
provide	O
quantitative	O
information	O
on	O
allele	O
frequency	O
in	O
pooled	O
DNA	O
samples	O
,	O
which	O
could	O
serve	O
as	O
a	O
rapid	O
screening	O
tool	O
for	O
SNPs	O
associated	O
with	O
diseases	O
.	O

The	O
promoter	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
implicated	O
in	O
glaucoma	O
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O

PURPOSE	O
:	O
Nitric	O
oxide	O
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	O
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	O
and	O
non-neurological	O
disorders	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	O
Oxide	O
Synthase	O
,	O
iNOS	O
,	O
and	O
the	O
neuropathological	O
disorder	O
glaucoma	O
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	O
in	O
the	O
world	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	O
and	O
primary	O
open	O
angle	O
glaucoma	O
,	O
POAG	O
,	O
and	O
to	O
find	O
the	O
functional	O
element(s)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion/deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	O
were	O
genotyped	O
in	O
200	O
POAG	O
patients	O
and	O
200	O
age-matched	O
controls	O
.	O

Also	O
,	O
the	O
CCTTT-microsatellite	O
was	O
examined	O
for	O
its	O
protein-binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT-microsatellite	O
,	O
between	O
patients	O
and	O
controls	O
.	O

(CCTTT)14	O
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter-construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	O
patients	O
,	O
while	O
(CCTTT)10	O
and	O
(CCTTT)13	O
were	O
less	O
common	O
.	O

In	O
EMSA	O
,	O
the	O
(CCTTT)14	O
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT-microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	O
with	O
POAG	O
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O

Genetic	O
homogeneity	O
for	O
inherited	O
congenital	O
microcoria	O
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O

PURPOSE	O
:	O
Congenital	O
microcoria	O
is	O
a	O
rare	O
autosomal	O
dominant	O
developmental	O
disorder	O
of	O
the	O
iris	O
associated	O
with	O
myopia	O
and	O
juvenile	O
open	O
angle	O
glaucoma	O
.	O

Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31-q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	O
microcoria	O
(	O
pupils	O
with	O
a	O
diameter	O
<2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31-q32	O
locus	O
.	O

METHODS	O
:	O
Twenty-four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O

Microsatellite	O
markers	O
at	O
13q31-q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O

Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O

RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3.5	O
,	O
4.7	O
,	O
and	O
5.3	O
were	O
found	O
co-incident	O
with	O
consecutive	O
markers	O
D13S154	O
,	O
DCT	O
,	O
and	O
D13S1280	O
.	O

Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6.0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
to	O
chromosomal	O
locus	O
13q31-q32	O
.	O

In	O
addition	O
,	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	O
and	O
glaucoma	O
were	O
screened	O
for	O
glaucoma	O
genes	O
:	O
myocilin	O
(MYOC)	O
,	O
optineurin	O
(OPTN)	O
and	O
CYP1B1	O
.	O

Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
144	B-DNAMutation
G>A	I-DNAMutation
)	O
resulting	O
in	O
a	O
Q48H	B-ProteinMutation
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	O
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	O
patients	O
,	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
(MCOR)	O
to	O
13q31-q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O

When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	O
locus	O
to	O
a	O
6-7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O

The	O
DCT	O
locus	O
,	O
a	O
member	O
of	O
the	O
tyrosinase	O
family	O
involved	O
in	O
pigmentation	O
,	O
maps	O
within	O
this	O
region	O
.	O

Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	O
microcoria	O
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	O
,	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	O
Q48H	B-ProteinMutation
(1q24.3-q25.2)	O
,	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	O
in	O
India	O
.	O

Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	O
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	O
and	O
glaucoma	O
causation	O
.	O

The	O
relationship	O
between	O
microcoria	O
,	O
glaucoma	O
,	O
and	O
the	O
MYOC	O
Q48H	B-ProteinMutation
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O

Segregation	O
of	O
a	O
M404V	B-ProteinMutation
mutation	O
of	O
the	O
p62/sequestosome	O
1	O
(p62/SQSTM1)	O
gene	O
with	O
polyostotic	O
Paget's	O
disease	O
of	O
bone	O
in	O
an	O
Italian	O
family	O
.	O

Mutations	O
of	O
the	O
p62/Sequestosome	O
1	O
gene	O
(p62/SQSTM1)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget's	O
disease	O
of	O
bone	O
(PDB)	O
.	O

We	O
originally	O
described	O
a	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
M404V	B-ProteinMutation
of	O
exon	O
8	O
,	O
in	O
the	O
ubiquitin	O
protein-binding	O
domain	O
of	O
p62/SQSTM1	O
gene	O
in	O
an	O
Italian	O
PDB	O
patient	O
.	O

The	O
collection	O
of	O
data	O
from	O
the	O
patient's	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	O
.	O

Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	B-ProteinMutation
mutation	O
with	O
the	O
polyostotic	O
PDB	O
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O

DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
,	O
4	O
PDB	O
patients	O
and	O
18	O
clinically	O
unaffected	O
members	O
.	O

Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
,	O
four	O
possessed	O
the	O
M404V	B-ProteinMutation
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	O
,	O
except	O
one	O
patient	O
with	O
a	O
single	O
X-ray-assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	O
disease	O
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O

By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
,	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	B-ProteinMutation
mutation	O
,	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	O
phosphatase	O
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
genotype-phenotype	O
correlation	O
between	O
the	O
M404V	B-ProteinMutation
mutation	O
in	O
the	O
p62/SQSTM1	O
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	O
in	O
this	O
family	O
.	O

The	O
high	O
penetrance	O
of	O
the	O
PDB	O
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype-phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62/SQSTM1	O
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	O
.	O

HPRTSardinia	O
:	O
a	O
new	O
point	O
mutation	O
causing	O
HPRT	O
deficiency	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT)	O
deficiency	O
always	O
causing	O
hyperuricemia	O
presents	O
various	O
degrees	O
of	O
neurological	O
manifestations	O
,	O
the	O
most	O
severe	O
which	O
is	O
Lesch-Nyhan	O
syndrome	O
.	O

The	O
HPRT	O
gene	O
is	O
situated	O
in	O
the	O
region	O
Xq26-q27.2	O
and	O
consists	O
of	O
9	O
exons	O
.	O

At	O
least	O
300	O
different	O
mutations	O
at	O
different	O
sites	O
in	O
the	O
HPRT	O
coding	O
region	O
from	O
exon	O
1	O
to	O
exon	O
9	O
have	O
been	O
identified	O
.	O

A	O
new	O
mutation	O
in	O
the	O
HPRT	O
gene	O
has	O
been	O
determined	O
in	O
one	O
patient	O
with	O
complete	O
deficiency	O
of	O
erythrocyte	O
activity	O
,	O
with	O
hyperuricemia	O
and	O
gout	O
but	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Analysis	O
of	O
cultured	O
fibroblasts	O
revealed	O
minimal	O
residual	O
HPRT	O
activity	O
mainly	O
when	O
guanine	O
was	O
the	O
substrate	O
.	O

Genomic	O
DNA	O
sequencing	O
demonstrated	O
patient's	O
mother	O
heterozygosity	O
for	O
the	O
mutation	O
and	O
no	O
mutation	O
in	O
her	O
brother	O
.	O

The	O
mutation	O
consists	O
in	O
a	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
C463T	B-DNAMutation
in	O
exon	O
6	O
,	O
resulting	O
in	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
155	O
P155S	B-ProteinMutation
.	O

This	O
mutation	O
had	O
not	O
been	O
reported	O
previously	O
and	O
has	O
been	O
designated	O
HPRT(Sardinia)	O
.	O

The	O
mutation	O
identified	O
in	O
this	O
patient	O
allows	O
some	O
expression	O
of	O
functional	O
enzyme	O
in	O
nucleated	O
cells	O
such	O
as	O
fibroblasts	O
,	O
indicating	O
that	O
such	O
cell	O
type	O
may	O
add	O
further	O
information	O
to	O
conventional	O
blood	O
analysis	O
.	O

A	O
multicentre	O
survey	O
gathering	O
patients	O
with	O
variant	O
neurological	O
forms	O
could	O
contribute	O
to	O
understand	O
the	O
pathophysiology	O
of	O
the	O
neurobehavioral	O
symptoms	O
of	O
HPRT	O
deficiency	O
.	O

Genetic	O
variation	O
in	O
UCP2	O
(	O
uncoupling	O
protein-2	O
)	O
is	O
associated	O
with	O
energy	O
metabolism	O
in	O
Pima	O
Indians	O
.	O

AIMS/HYPOTHESIS	O
:	O
Uncoupling	O
protein-2	O
(UCP2)	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
insulin	O
secretion	O
and	O
the	O
development	O
of	O
obesity	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
genetic	O
variation	O
in	O
UCP2	O
on	O
type	O
2	O
diabetes	O
and	O
obesity	O
,	O
as	O
well	O
as	O
on	O
metabolic	O
phenotypes	O
related	O
to	O
these	O
diseases	O
,	O
in	O
Pima	O
Indians	O
.	O

METHODS	O
:	O
The	O
coding	O
and	O
untranslated	O
regions	O
of	O
UCP2	O
,	O
and	O
approximately	O
1	O
kb	O
of	O
the	O
5'	O
upstream	O
region	O
,	O
were	O
sequenced	O
in	O
DNA	O
samples	O
taken	O
from	O
83	O
extremely	O
obese	O
Pima	O
Indians	O
who	O
were	O
not	O
first-degree	O
relatives	O
.	O

RESULTS	O
:	O
Five	O
variants	O
were	O
identified	O
:	O
(1)	O
a	O
-866G/A	B-DNAMutation
in	O
the	O
5'	O
upstream	O
region	O
;	O
(2)	O
a	O
G/A	B-DNAMutation
in	O
exon	O
2	O
;	O
(3)	O
a	O
C/T	B-DNAMutation
resulting	O
in	O
an	O
Ala55Val	B-ProteinMutation
substitution	O
in	O
exon	O
4	O
;	O
and	O
(	O
4	O
,	O
5	O
)	O
two	O
insertion/deletions	O
(	O
ins/del	O
;	O
45-bp	O
and	O
3-bp	O
)	O
in	O
the	O
3'	O
untranslated	O
region	O
.	O

Among	O
the	O
83	O
subjects	O
whose	O
DNA	O
was	O
sequenced	O
,	O
the	O
-866G/A	B-DNAMutation
was	O
in	O
complete	O
genotypic	O
concordance	O
with	O
the	O
Ala55Val	B-ProteinMutation
and	O
the	O
3-bp	O
ins/del	O
polymorphism	O
.	O

The	O
G/A	B-DNAMutation
polymorphism	O
in	O
exon	O
2	O
was	O
extremely	O
rare	O
.	O

To	O
capture	O
the	O
common	O
variation	O
in	O
this	O
gene	O
for	O
association	O
analyses	O
,	O
the	O
-866G/A	B-DNAMutation
variant	O
(	O
as	O
a	O
representative	O
of	O
Ala55Val	B-ProteinMutation
and	O
the	O
3-bp	O
ins/del	O
polymorphism	O
)	O
and	O
the	O
45-bp	O
ins/del	O
were	O
also	O
genotyped	O
for	O
864	O
full-blooded	O
Pima	O
Indians	O
.	O

Neither	O
of	O
these	O
variants	O
was	O
associated	O
with	O
type	O
2	O
diabetes	O
or	O
body	O
mass	O
index	O
.	O

However	O
,	O
in	O
a	O
subgroup	O
of	O
185	O
subjects	O
who	O
had	O
undergone	O
detailed	O
metabolic	O
measurements	O
,	O
these	O
variants	O
were	O
associated	O
with	O
24-h	O
energy	O
expenditure	O
as	O
measured	O
in	O
a	O
human	O
metabolic	O
chamber	O
(	O
p=0.007	O
for	O
the	O
45-bp	O
ins/del	O
and	O
p=0.03	O
for	O
the	O
-866G/A	B-DNAMutation
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
family	O
membership	O
,	O
fat-free	O
mass	O
and	O
fat	O
mass	O
)	O
.	O

CONCLUSIONS/INTERPRETATION	O
:	O
Our	O
data	O
indicate	O
that	O
variation	O
in	O
UCP2	O
may	O
play	O
a	O
role	O
in	O
energy	O
metabolism	O
,	O
but	O
this	O
gene	O
does	O
not	O
contribute	O
significantly	O
to	O
the	O
aetiology	O
of	O
type	O
2	O
diabetes	O
and/or	O
obesity	O
in	O
Pima	O
Indians	O
.	O

Association	O
of	O
atopy	O
and	O
eczema	O
with	O
polymorphisms	O
in	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain-IL-2-inducible	O
T-cell	O
kinase	O
gene	O
cluster	O
in	O
chromosome	O
5	O
q	O
33	O
.	O

BACKGROUND	O
:	O
The	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain	O
(TIM)	O
gene	O
family	O
and	O
the	O
gene	O
for	O
IL-2-inducible	O
T-cell	O
kinase	O
(ITK)	O
,	O
located	O
in	O
chromosome	O
5	O
q	O
33	O
and	O
potentially	O
involved	O
in	O
the	O
T-cell	O
proliferation	O
and	O
differentiation	O
,	O
are	O
good	O
candidate	O
genes	O
for	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
assessed	O
the	O
role	O
of	O
polymorphisms	O
in	O
the	O
TIM	O
family	O
genes	O
and	O
ITK	O
in	O
atopy	O
,	O
eczema	O
,	O
and	O
asthma	O
.	O

METHODS	O
:	O
Twenty-one	O
polymorphisms	O
in	O
the	O
TIM-ITK	O
gene	O
cluster	O
were	O
genotyped	O
in	O
564	O
children	O
enrolled	O
in	O
the	O
Tucson	O
Children's	O
Respiratory	O
Study	O
.	O

Skin	O
prick	O
tests	O
to	O
common	O
allergens	O
were	O
performed	O
at	O
age	O
6.1	O
years	O
(n=508)	O
,	O
age	O
10.8	O
years	O
(n=539)	O
,	O
and	O
age	O
16.6	O
years	O
(n=424)	O
.	O

Asthma	O
and	O
eczema	O
were	O
assessed	O
by	O
questionnaire	O
at	O
these	O
3	O
points	O
.	O

Averaged	O
relative	O
risks	O
were	O
estimated	O
.	O

RESULTS	O
:	O
One	O
15-bp	O
insertion/deletion	O
in	O
exon	O
4	O
of	O
TIM	O
1	O
was	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
(	O
relative	O
risk	O
associated	O
with	O
carrying	O
at	O
least	O
1	O
rare	O
allele=1.24	O
[1.07--1.45]	O
,	O
P=.005	O
;	O
and	O
1.43	O
[1.01--2.01]	O
,	O
P=.004	O
,	O
respectively	O
)	O
.	O

The	O
3	O
tested	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
TIM	O
3	O
were	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
.	O

One	O
of	O
them	O
,	O
at	O
position	O
+4259	O
calculated	O
from	O
the	O
translation	O
start	O
site	O
,	O
predicts	O
a	O
putative	O
change	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
,	O
and	O
was	O
the	O
most	O
strongly	O
related	O
to	O
atopy	O
(	O
relative	O
risk=1.28	O
[1.12--1.47]	O
;	O
P=.0003	O
)	O
.	O

SNPs	O
in	O
the	O
5'	O
genomic	O
region	O
in	O
ITK	O
,	O
which	O
show	O
moderate	O
linkage	O
disequilibrium	O
with	O
those	O
in	O
TIM	O
3	O
,	O
had	O
an	O
independent	O
effect	O
on	O
atopy	O
.	O

None	O
of	O
the	O
polymorphisms	O
studied	O
was	O
related	O
to	O
asthma	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
support	O
a	O
potential	O
role	O
for	O
SNPs	O
in	O
TIM	O
1	O
,	O
TIM	O
3	O
,	O
and	O
ITK	O
,	O
independent	O
of	O
each	O
other	O
,	O
in	O
allergic	O
diseases	O
.	O

Carrier	O
frequency	O
of	O
mutation	O
657del5	B-DNAMutation
in	O
the	O
NBS1	O
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	O
with	O
sporadic	O
lymphoid	O
malignancies	O
.	O

Nijmegen	O
breakage	O
syndrome	O
(NBS)	O
is	O
a	O
human	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	O
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	O
and	O
leukemia	O
.	O

Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	O
mutation	O
,	O
657del5	B-DNAMutation
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	O
lymphoid	O
malignancies	O
,	O
and	O
in	O
Polish	O
adults	O
with	O
non-Hodgkin	O
lymphoma	O
(NHL)	O
.	O

In	O
addition	O
,	O
the	O
substitution	O
643C>T	B-DNAMutation
R215W	B-ProteinMutation
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
.	O

In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	O
lymphoid	O
malignancies	O
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	O
.	O

The	O
NBS1	O
mutation	O
657del5	B-DNAMutation
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	O
with	O
ALL	O
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	O
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	O
with	O
Hodgkin	O
lymphoma	O
(HL)	O
.	O

No	O
carriers	O
of	O
the	O
variant	O
R215W	B-ProteinMutation
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O

The	O
relative	O
frequency	O
of	O
the	O
657del5	B-DNAMutation
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6,984	O
controls	O
matched	O
by	O
place	O
of	O
patient	O
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0.006	O
)	O
.	O

In	O
the	O
analyzed	O
population	O
with	O
malignancies	O
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	B-DNAMutation
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1.48-1.85	O
,	O
95%	O
confidence	O
interval	O
1.18-2.65	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	O
with	O
ALL	O
and	O
NHL	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Nonetheless	O
,	O
NBS1	O
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	O
malignancies	O
in	O
childhood	O
and	O
adolescence	O
.	O

Dominant	O
and	O
recessive	O
COL6A1	O
mutations	O
in	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
five	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
patients	O
(	O
two	O
Italians	O
,	O
one	O
Belgian	O
,	O
and	O
two	O
Turks	O
)	O
with	O
a	O
clinical	O
phenotype	O
showing	O
different	O
degrees	O
of	O
severity	O
,	O
all	O
carrying	O
mutations	O
localized	O
in	O
COL6A1	O
.	O

We	O
sequenced	O
the	O
three	O
entire	O
COL6	O
complementary	O
DNA	O
.	O

Three	O
of	O
five	O
patients	O
have	O
recessive	O
mutations	O
:	O
two	O
patients	O
(	O
P1and	O
P3	O
)	O
have	O
homozygous	O
single-nucleotide	O
deletions	O
,	O
one	O
in	O
exon	O
9	O
and	O
one	O
in	O
exon	O
22	O
;	O
one	O
patient	O
(P2)	O
has	O
a	O
homozygous	O
single-nucleotide	O
substitution	O
leading	O
to	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
31	O
.	O

The	O
nonsense	O
mutation	O
of	O
P2	O
also	O
causes	O
a	O
partial	O
skipping	O
of	O
exon	O
31	O
with	O
the	O
formation	O
of	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
32	O
in	O
15%	O
of	O
the	O
total	O
COL6A1	O
messenger	O
RNA	O
.	O

The	O
remaining	O
two	O
patients	O
carry	O
a	O
heterozygous	O
glycine	O
substitution	O
in	O
exons	O
9	O
and	O
10	O
inside	O
the	O
triple-helix	O
region	O
;	O
both	O
are	O
dominant	O
mutations	O
because	O
the	O
missense	O
mutations	O
are	O
absent	O
in	O
the	O
DNA	O
of	O
their	O
respective	O
parents	O
.	O

As	O
for	O
the	O
three	O
homozygous	O
recessive	O
mutations	O
,	O
the	O
apparently	O
healthy	O
consanguineous	O
parents	O
all	O
carry	O
a	O
heterozygous	O
mutated	O
allele	O
.	O

Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
report	O
a	O
genotype-phenotype	O
correlation	O
demonstrating	O
that	O
heterozygous	O
glycine	O
substitutions	O
in	O
the	O
triple-helix	O
domain	O
of	O
COL6A1	O
are	O
dominant	O
and	O
responsible	O
for	O
a	O
milder	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
phenotype	O
,	O
and	O
that	O
recessive	O
mutations	O
in	O
COL6A1	O
correlate	O
with	O
more	O
severe	O
clinical	O
and	O
biochemical	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
phenotypes	O
.	O

A	O
single-nucleotide	O
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
hPER2	O
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O

The	O
PERIOD2	O
(PER2)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
human	O
PER2	O
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	O
sleep	O
phase	O
syndrome	O
(ASPS)	O
.	O

We	O
have	O
investigated	O
three	O
other	O
single-nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	O
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
C-1228T	B-DNAMutation
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5'-untranslated	O
region	O
(5'-UTR)	O
C111G	B-DNAMutation
,	O
and	O
one	O
missense	O
mutation	O
G3853A	B-DNAMutation
causing	O
a	O
glycine	O
to	O
glutamine	O
substitution	O
in	O
the	O
predicted	O
protein	O
.	O

Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n=35	O
for	O
each	O
group	O
)	O
.	O

Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111G	O
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(0.14)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(0.03)	O
(	O
Fisher's	O
exact	O
test	O
,	O
two-sided	O
P	O
value=0.031	O
,	O
odds	O
ratio=5.67	O
)	O
.	O

No	O
significant	O
difference	O
in	O
111G	O
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O

Computer	O
prediction	O
indicated	O
that	O
the	O
C111G	B-DNAMutation
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O

The	O
PER2	O
111G	O
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	O
.	O

Allelic	O
expression	O
imbalance	O
of	O
human	O
mu	O
opioid	O
receptor	O
(OPRM1)	O
caused	O
by	O
variant	O
A118G	B-DNAMutation
.	O

As	O
a	O
primary	O
target	O
for	O
opioid	O
drugs	O
and	O
peptides	O
,	O
the	O
mu	O
opioid	O
receptor	O
(OPRM1)	O
plays	O
a	O
key	O
role	O
in	O
pain	O
perception	O
and	O
addiction	O
.	O

Genetic	O
variants	O
of	O
OPRM1	O
have	O
been	O
implicated	O
in	O
predisposition	O
to	O
drug	O
addiction	O
,	O
in	O
particular	O
the	O
single	O
nucleotide	O
polymorphism	O
A118G	B-DNAMutation
,	O
leading	O
to	O
an	O
N40D	B-ProteinMutation
substitution	O
,	O
with	O
an	O
allele	O
frequency	O
of	O
10-32%	O
,	O
and	O
uncertain	O
functions	O
.	O

We	O
have	O
measured	O
allele-specific	O
mRNA	O
expression	O
of	O
OPRM1	O
in	O
human	O
autopsy	O
brain	O
tissues	O
,	O
using	O
A118G	B-DNAMutation
as	O
a	O
marker	O
.	O

In	O
8	O
heterozygous	O
samples	O
measured	O
,	O
the	O
A118	O
mRNA	O
allele	O
was	O
1.5-2.5-fold	O
more	O
abundant	O
than	O
the	O
G118	O
allele	O
.	O

Transfection	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
of	O
a	O
cDNA	O
representing	O
only	O
the	O
coding	O
region	O
of	O
OPRM1	O
,	O
carrying	O
adenosine	O
,	O
guanosine	O
,	O
cytidine	O
,	O
and	O
thymidine	O
in	O
position	O
118	O
,	O
resulted	O
in	O
1.5-fold	O
lower	O
mRNA	O
levels	O
only	O
for	O
OPRM1-G118	O
,	O
and	O
more	O
than	O
10-fold	O
lower	O
OPRM1	O
protein	O
levels	O
,	O
measured	O
by	O
Western	O
blotting	O
and	O
receptor	O
binding	O
assay	O
.	O

After	O
transfection	O
and	O
inhibition	O
of	O
transcription	O
with	O
actinomycin	O
D	O
,	O
analysis	O
of	O
mRNA	O
turnover	O
failed	O
to	O
reveal	O
differences	O
in	O
mRNA	O
stability	O
between	O
A118	O
and	O
G118	O
alleles	O
,	O
indicating	O
a	O
defect	O
in	O
transcription	O
or	O
mRNA	O
maturation	O
.	O

These	O
results	O
indicate	O
that	O
OPRM1-G118	O
is	O
a	O
functional	O
variant	O
with	O
deleterious	O
effects	O
on	O
both	O
mRNA	O
and	O
protein	O
yield	O
.	O

Clarifying	O
the	O
functional	O
relevance	O
of	O
polymorphisms	O
associated	O
with	O
susceptibility	O
to	O
a	O
complex	O
disorder	O
such	O
as	O
drug	O
addiction	O
provides	O
a	O
foundation	O
for	O
clinical	O
association	O
studies	O
.	O

Identification	O
of	O
a	O
novel	O
WFS1	O
mutation	O
AFF344-345ins	B-ProteinMutation
in	O
Japanese	O
patients	O
with	O
Wolfram	O
syndrome	O
.	O

Wolfram	O
syndrome	O
(WFS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
early	O
onset	O
diabetes	O
mellitus	O
,	O
progressive	O
optic	O
atrophy	O
,	O
sensorineural	O
deafness	O
and	O
diabetes	O
insipidus	O
.	O

Affected	O
individuals	O
may	O
also	O
have	O
renal	O
tract	O
abnormalities	O
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	O
syndromes	O
.	O

WFS1	O
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	O
.	O

We	O
report	O
herein	O
a	O
Japanese	O
family	O
,	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O

In	O
the	O
WFS1	O
gene	O
of	O
these	O
patients	O
,	O
we	O
identified	O
a	O
novel	O
mutation	O
,	O
a	O
nine	O
nucleotide	O
insertion	O
AFF344-345ins	B-ProteinMutation
.	O

In	O
addition	O
,	O
one	O
of	O
these	O
patients	O
had	O
preclinical	O
hypopituitarism	O
,	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	O
.	O

As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
transcriptome	O
analyses	O
of	O
a	O
1.2	O
Mb	O
candidate	O
ovarian	O
cancer	O
tumor	O
suppressor	O
locus	O
region	O
at	O
17q25.1-q25.2	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
was	O
performed	O
in	O
epithelial	O
ovarian	O
cancers	O
(EOC)	O
to	O
further	O
characterize	O
a	O
previously	O
identified	O
candidate	O
tumor	O
suppressor	O
gene	O
(TSG)	O
region	O
encompassing	O
D17S801	O
at	O
chromosomal	O
region	O
17q25.1	O
.	O

LOH	O
of	O
at	O
least	O
one	O
informative	O
marker	O
was	O
observed	O
for	O
100	O
(71%)	O
of	O
140	O
malignant	O
EOC	O
samples	O
in	O
an	O
analysis	O
of	O
6	O
polymorphic	O
markers	O
(cen-D17S1839-D17S785-D17S1817-D17S801-D17S751-D17S722-tel)	O
.	O

The	O
combined	O
LOH	O
analysis	O
revealed	O
a	O
453	O
kilobase	O
(Kb)	O
minimal	O
region	O
of	O
deletion	O
(MRD)	O
bounded	O
by	O
D17S1817	O
and	O
D17S751	O
.	O

Human	O
and	O
mouse	O
genome	O
assemblies	O
were	O
used	O
to	O
resolve	O
marker	O
inconsistencies	O
in	O
the	O
D17S1839-D17S722	O
interval	O
and	O
identify	O
candidates	O
.	O

The	O
region	O
contains	O
32	O
known	O
and	O
strongly	O
predicted	O
genes	O
,	O
9	O
of	O
which	O
overlap	O
the	O
MRD	O
.	O

The	O
reference	O
genomic	O
sequences	O
share	O
nearly	O
identical	O
gene	O
structures	O
and	O
the	O
organization	O
of	O
the	O
region	O
is	O
highly	O
collinear	O
.	O

Although	O
,	O
the	O
region	O
does	O
not	O
show	O
any	O
large	O
internal	O
duplications	O
,	O
a	O
1.5	O
Kb	O
inverted	O
duplicated	O
sequence	O
of	O
87%	O
nucleotide	O
identity	O
was	O
observed	O
in	O
a	O
13	O
Kb	O
region	O
surrounding	O
D17S801	O
.	O

Transcriptome	O
analysis	O
by	O
Affymetrix	O
GeneChip	O
and	O
reverse	O
transcription	O
(RT)-polymerase	O
chain	O
reaction	O
(PCR)	O
methods	O
of	O
3	O
well	O
characterized	O
EOC	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
normal	O
ovarian	O
surface	O
epithelial	O
(NOSE)	O
cells	O
was	O
performed	O
with	O
32	O
candidates	O
spanning	O
D17S1839-D17S722	O
interval	O
.	O

RT-PCR	O
analysis	O
of	O
8	O
known	O
or	O
strongly	O
predicted	O
genes	O
residing	O
in	O
the	O
MRD	O
in	O
10	O
EOC	O
samples	O
,	O
that	O
exhibited	O
LOH	O
of	O
the	O
MRD	O
,	O
identified	O
FLJ22341	O
as	O
a	O
strong	O
candidate	O
TSG	O
.	O

The	O
proximal	O
repeat	O
sequence	O
of	O
D17S801	O
occurs	O
8	O
Kb	O
upstream	O
of	O
the	O
putative	O
promoter	O
region	O
of	O
FLJ22341	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
EOC	O
samples	O
and	O
cell	O
lines	O
identified	O
DKFZP434P0316	O
that	O
maps	O
proximal	O
to	O
the	O
MRD	O
,	O
as	O
a	O
candidate	O
.	O

While	O
Affymetrix	O
technology	O
was	O
useful	O
for	O
initially	O
eliminating	O
less	O
promising	O
candidates	O
,	O
subsequent	O
RT-PCR	O
analysis	O
of	O
well-characterized	O
EOC	O
samples	O
was	O
essential	O
to	O
prioritize	O
TSG	O
candidates	O
for	O
further	O
study	O
.	O

Autosomal	O
dominant	O
inheritance	O
of	O
Williams-Beuren	O
syndrome	O
in	O
a	O
father	O
and	O
son	O
with	O
haploinsufficiency	O
for	O
FKBP6	O
.	O

Williams-Beuren	O
syndrome	O
(WBS)	O
is	O
a	O
neurodevelopmental	O
microdeletion	O
disorder	O
that	O
usually	O
occurs	O
sporadically	O
due	O
to	O
its	O
location	O
within	O
a	O
highly	O
repetitive	O
genomic	O
region	O
that	O
is	O
unstable	O
and	O
prone	O
to	O
unequal	O
cross-over	O
during	O
meiosis	O
.	O

The	O
consequential	O
loss	O
of	O
chromosomal	O
material	O
includes	O
approximately	O
1.5	O
Mb	O
of	O
DNA	O
at	O
7q11.23	O
.	O

Whilst	O
cases	O
of	O
dominant	O
inheritance	O
have	O
been	O
described	O
in	O
the	O
literature	O
,	O
there	O
have	O
been	O
few	O
reports	O
of	O
molecular	O
confirmation	O
and	O
none	O
have	O
carried	O
out	O
detailed	O
genotyping	O
.	O

We	O
describe	O
a	O
Bulgarian	O
father	O
and	O
son	O
with	O
WBS	O
detected	O
by	O
fluorescent	O
in	O
situ	O
hybridisation	O
(	O
with	O
an	O
elastin	O
gene	O
probe	O
)	O
and	O
loss	O
of	O
heterozygosity	O
mapping	O
using	O
microsatellite	O
markers	O
located	O
in	O
the	O
critical	O
region	O
.	O

These	O
individuals	O
appear	O
to	O
have	O
a	O
common	O
WBS	O
heterozygous	O
deletion	O
,	O
confirming	O
the	O
expected	O
dominant	O
transmission	O
and	O
adding	O
to	O
the	O
few	O
familial	O
cases	O
reported	O
.	O

The	O
deletion	O
includes	O
the	O
gene	O
FKBP6	O
which	O
has	O
recently	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
homologous	O
chromosome	O
pairing	O
in	O
meiosis	O
and	O
male	O
fertility	O
in	O
mouse	O
models	O
.	O

Homozygous	O
Fkbp6	O
-/-	O
male	O
mice	O
are	O
infertile	O
and	O
our	O
data	O
suggests	O
that	O
haploinsufficiency	O
for	O
FKBP6	O
does	O
not	O
appear	O
to	O
preclude	O
male	O
fertility	O
in	O
WBS	O
,	O
although	O
male	O
infertility	O
involving	O
this	O
gene	O
has	O
the	O
potential	O
to	O
follow	O
the	O
mouse	O
model	O
as	O
a	O
human	O
autosomal	O
recessive	O
condition	O
.	O

Hb	O
zoeterwoude	O
[	O
beta23(B5)Val-->Ala	B-ProteinMutation
)	O
]	O
:	O
a	O
new	O
beta-globin	O
variant	O
found	O
in	O
association	O
with	O
erythrocytosis	O
.	O

We	O
describe	O
the	O
characterization	O
of	O
a	O
new	O
hemoglobin	O
(Hb)	O
variant	O
found	O
in	O
a	O
77-year-old	O
Dutch	O
woman	O
,	O
suspected	O
of	O
hypoxia-mediated	O
erythrocytosis	O
.	O

The	O
typical	O
blood	O
parameters	O
(	O
Hb	O
17.3	O
g/dL	O
;	O
PCV	O
0.525	O
L/L	O
;	O
RBC	O
5.82	O
x	O
10(12)/L	O
)	O
could	O
not	O
be	O
explained	O
by	O
any	O
of	O
the	O
pathological	O
or	O
physiological	O
conditions	O
causing	O
erythrocytosis	O
.	O

The	O
patient	O
was	O
preventively	O
phlebotomized	O
because	O
of	O
intermittent	O
claudication	O
and	O
erythrocytosis	O
.	O

At	O
the	O
hematological	O
and	O
biochemical	O
levels	O
,	O
no	O
anemia	O
or	O
hemolysis	O
were	O
present	O
and	O
no	O
abnormal	O
Hb	O
fractions	O
were	O
detectable	O
on	O
alkaline	O
electrophoresis	O
or	O
high	O
performance	O
liquid	O
chromatography	O
(HPLC)	O
.	O

Molecular	O
analysis	O
revealed	O
intact	O
alpha-globin	O
genes	O
and	O
a	O
heterozygosity	O
for	O
a	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
of	O
the	O
beta-globin	O
gene	O
,	O
causing	O
a	O
Val-->Ala	B-ProteinMutation
amino	O
acid	O
substitution	O
.	O

The	O
P50	O
measured	O
in	O
full	O
blood	O
indicated	O
that	O
this	O
mutant	O
has	O
an	O
elevated	O
oxygen	O
affinity	O
.	O

This	O
is	O
the	O
fourth	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
23	O
of	O
the	O
beta	O
gene	O
and	O
the	O
second	O
associated	O
with	O
erythrocytosis	O
.	O

Because	O
the	O
family	O
was	O
not	O
available	O
for	O
investigation	O
no	O
information	O
was	O
obtained	O
as	O
to	O
whether	O
the	O
mutation	O
represents	O
a	O
de	O
novo	O
event	O
or	O
was	O
inherited	O
,	O
and	O
might	O
be	O
a	O
more	O
common	O
cause	O
of	O
erythrocytosis	O
in	O
Dutch	O
patients	O
.	O

Considering	O
the	O
relatively	O
high	O
frequency	O
of	O
beta-thalassemia	O
(thal)	O
in	O
the	O
large	O
allochthonous	O
population	O
in	O
The	O
Netherlands	O
,	O
combinations	O
of	O
Hb	O
Zoeterwoude	O
and	O
beta-thal	O
traits	O
may	O
lead	O
to	O
hemizygosity	O
,	O
with	O
severe	O
hypoxia	O
and	O
erythrocytosis	O
from	O
a	O
few	O
months	O
after	O
birth	O
.	O

[	O
Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphisms	O
and	O
coronary	O
risk	O
in	O
a	O
Portuguese	O
population	O
]	O
.	O

BACKGROUND	O
:	O
A	O
family	O
history	O
of	O
coronary	O
heart	O
disease	O
(CHD)	O
is	O
a	O
strong	O
risk	O
marker	O
for	O
the	O
disease	O
,	O
independently	O
of	O
classical	O
risk	O
factors	O
.	O

It	O
could	O
be	O
decoded	O
by	O
recognizing	O
the	O
polymorphisms	O
associated	O
with	O
increased	O
risk	O
.	O

Renin-angiotensin	O
system	O
genes	O
are	O
candidate	O
genes	O
in	O
CHD	O
and	O
the	O
deletion	O
allele	O
of	O
the	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
has	O
been	O
reported	O
as	O
deleterious	O
.	O

However	O
,	O
there	O
is	O
disagreement	O
as	O
to	O
the	O
role	O
of	O
the	O
insertion/deletion	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
in	O
coronary	O
risk	O
.	O

AIM	O
:	O
To	O
evaluate	O
whether	O
ACE	O
gene	O
polymorphisms	O
constitute	O
a	O
CHD	O
risk	O
factor	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
population-based	O
case-control	O
study	O
of	O
301	O
subjects	O
with	O
a	O
history	O
of	O
myocardial	O
infarction	O
or	O
angiographic	O
evidence	O
of	O
coronary	O
heart	O
disease	O
and	O
510	O
age-	O
and	O
gender-matched	O
controls	O
,	O
without	O
CHD	O
,	O
living	O
in	O
a	O
region	O
with	O
high	O
CHD	O
mortality	O
rates	O
.	O

Blood	O
samples	O
were	O
taken	O
,	O
DNA	O
extracted	O
and	O
genotypes	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Amplification	O
products	O
were	O
identified	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

STATISTICAL	O
ANALYSIS	O
:	O
The	O
Data	O
were	O
evaluated	O
by	O
SPSS	O
for	O
Windows	O
,	O
using	O
the	O
Student's	O
t	O
test	O
,	O
the	O
chi-square	O
test	O
,	O
odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
.	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
the	O
DD	O
,	O
ID	O
and	O
II	O
genotype	O
was	O
41.2%	O
,	O
46.3%	O
,	O
12.5%	O
in	O
the	O
cases	O
and	O
28.1%	O
,	O
55.2%	O
and	O
16.7%	O
in	O
the	O
control	O
group	O
.	O

The	O
frequency	O
of	O
the	O
DD	O
genotype	O
was	O
significantly	O
higher	O
in	O
the	O
cases	O
than	O
in	O
the	O
controls	O
(	O
41.2%	O
vs	O
.	O

28.1%	O
,	O
odds	O
ratio	O
1.79	O
,	O
95%	O
CI	O
1.31	O
to	O
2.4	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

By	O
contrast	O
,	O
the	O
ID	O
and	O
II	O
genotypes'	O
prevalence	O
was	O
higher	O
in	O
the	O
control	O
group	O
(	O
55.2%	O
vs	O
.	O

46.3%	O
,	O
p	O
=	O
0.002	O
and	O
16.7	O
vs	O
.	O

12.5%	O
,	O
p	O
=	O
NS	O
,	O
respectively	O
)	O
compared	O
to	O
the	O
case	O
group	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
clearly	O
shows	O
that	O
the	O
ACE	O
DD	O
polymorphism	O
is	O
strongly	O
linked	O
to	O
CHD	O
,	O
and	O
if	O
our	O
data	O
are	O
confirmed	O
in	O
a	O
larger	O
population	O
sample	O
,	O
more	O
aggressive	O
vascular	O
prevention	O
could	O
be	O
justified	O
in	O
patients	O
carrying	O
the	O
DD	O
genotype	O
.	O

DNA	O
repair	O
gene	O
polymorphisms	O
in	O
relation	O
to	O
chromosome	O
aberration	O
frequencies	O
in	O
retired	O
radiation	O
workers	O
.	O

Polymorphic	O
variation	O
in	O
DNA	O
repair	O
genes	O
was	O
examined	O
in	O
a	O
group	O
of	O
retired	O
workers	O
from	O
the	O
British	O
Nuclear	O
Fuels	O
plc	O
facility	O
at	O
Sellafield	O
in	O
relation	O
to	O
previously	O
determined	O
translocation	O
frequencies	O
in	O
peripheral	O
blood	O
lymphocytes	O
.	O

Variation	O
at	O
seven	O
polymorphisms	O
in	O
four	O
genes	O
involved	O
in	O
the	O
base	O
excision	O
repair	O
(	O
XRCC1	O
R194W	B-ProteinMutation
,	O
R399Q	B-ProteinMutation
and	O
a	O
[AC]n	O
microsatellite	O
in	O
the	O
3'	O
UTR	O
)	O
and	O
double	O
strand	O
break	O
repair	O
(	O
XRCC3	O
T241M	B-ProteinMutation
and	O
a	O
[AC]n	O
microsatellite	O
in	O
intron	O
3	O
of	O
XRCC3	O
,	O
XRCC4	O
I134T	B-ProteinMutation
,	O
and	O
a	O
GACTAn	O
microsatellite	O
located	O
120	O
kb	O
5'	O
of	O
XRCC5	O
)	O
pathways	O
was	O
determined	O
for	O
291	O
retired	O
radiation	O
workers	O
who	O
had	O
received	O
cumulative	O
occupational	O
external	O
radiation	O
doses	O
of	O
between	O
0	O
and	O
1873	O
mSv	O
.	O

When	O
the	O
interaction	O
between	O
radiation	O
dose	O
and	O
each	O
DNA	O
repair	O
gene	O
polymorphism	O
was	O
examined	O
in	O
relation	O
to	O
translocation	O
frequency	O
there	O
was	O
no	O
evidence	O
for	O
any	O
of	O
the	O
polymorphisms	O
studied	O
influencing	O
the	O
response	O
to	O
occupational	O
exposure	O
.	O

A	O
positive	O
interaction	O
observed	O
between	O
genotype	O
(	O
individuals	O
with	O
at	O
least	O
one	O
allele	O
>	O
or	O
=20	O
repeat	O
units	O
)	O
at	O
a	O
microsatellite	O
locus	O
in	O
the	O
XRCC3	O
gene	O
and	O
smoking	O
status	O
should	O
be	O
interpreted	O
cautiously	O
because	O
interactions	O
were	O
investigated	O
for	O
seven	O
polymorphisms	O
and	O
two	O
exposures	O
.	O

Nonetheless	O
,	O
further	O
research	O
is	O
warranted	O
to	O
examine	O
whether	O
this	O
DNA	O
repair	O
gene	O
variant	O
might	O
be	O
associated	O
with	O
a	O
sub-optimal	O
repair	O
response	O
to	O
smoking-induced	O
DNA	O
damage	O
and	O
hence	O
an	O
increased	O
frequency	O
of	O
translocations	O
.	O

Primary	O
malignant	O
lymphoma	O
of	O
the	O
brain	O
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	O
tumor	O
suppressor	O
gene	O
.	O

Ten	O
primary	O
central	O
nervous	O
system	O
lymphomas	O
(	O
PCNSL	O
,	O
brain	O
lymphomas	O
)	O
were	O
examined	O
for	O
p14	O
gene	O
exon	O
1beta	O
deletion	O
,	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
,	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot-based	O
methylation	O
assay	O
.	O

In	O
Southern	O
blot	O
analysis	O
,	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
,	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
,	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O

Thus	O
,	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	O
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
,	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O

In	O
addition	O
,	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	O
,	O
we	O
detected	O
a	O
missense	O
mutation	O
L50R	B-ProteinMutation
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O

Methylation	O
of	O
the	O
5'CpG	O
island	O
of	O
the	O
p14	O
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O

Our	O
observation	O
of	O
frequent	O
p14	O
gene	O
abnormalities	O
(90%)	O
and	O
inactivation	O
(40-60%)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	O
lymphoma	O
in	O
which	O
p14	O
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
,	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	O
between	O
PCNSL	O
and	O
systemic	O
lymphoma	O
.	O

Compound	O
heterozygosity	O
for	O
a	O
novel	O
nine-nucleotide	O
deletion	O
and	O
the	O
Asn45Ser	B-ProteinMutation
missense	O
mutation	O
in	O
the	O
glycoprotein	O
IX	O
gene	O
in	O
a	O
patient	O
with	O
Bernard-Soulier	O
syndrome	O
.	O

Bernard-Soulier	O
syndrome	O
(BSS)	O
is	O
a	O
rare	O
inherited	O
bleeding	O
disorder	O
due	O
to	O
quantitative	O
or	O
qualitative	O
abnormalities	O
in	O
the	O
platelet	O
glycoprotein	O
(GP)	O
Ib/IX/V	O
complex	O
,	O
the	O
major	O
von	O
Willebrand	O
factor	O
receptor	O
.	O

The	O
complex	O
comprises	O
four	O
subunits	O
,	O
each	O
encoded	O
by	O
a	O
separate	O
gene	O
.	O

Several	O
mutations	O
have	O
been	O
described	O
for	O
each	O
of	O
the	O
subunits	O
,	O
except	O
for	O
GPV	O
,	O
as	O
a	O
cause	O
of	O
BSS	O
.	O

We	O
describe	O
here	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
a	O
child	O
with	O
BSS	O
.	O

Flow-cytometric	O
analysis	O
of	O
the	O
patient's	O
platelets	O
showed	O
a	O
markedly	O
reduced	O
surface	O
expression	O
of	O
all	O
three	O
glycoproteins	O
of	O
the	O
GPIb/IX/V	O
complex	O
.	O

DNA	O
sequencing	O
analysis	O
showed	O
the	O
patient	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
the	O
GPIX	O
gene	O
,	O
a	O
novel	O
nine-nucleotide	O
deletion	O
starting	O
at	O
position	O
1952	O
of	O
the	O
gene	O
that	O
changes	O
asparagine	O
86	O
for	O
alanine	O
and	O
eliminates	O
amino	O
acids	O
87	O
,	O
88	O
,	O
and	O
89	O
(	O
arginine	O
,	O
threonine	O
,	O
and	O
proline	O
)	O
and	O
a	O
previously	O
reported	O
point	O
mutation	O
that	O
changes	O
the	O
codon	O
asparagine	O
(AAC)	O
for	O
serine	O
(AGC)	O
at	O
residue	O
45	O
.	O

Her	O
mother	O
was	O
heterozygous	O
for	O
the	O
Asn45Ser	B-ProteinMutation
mutation	O
,	O
and	O
her	O
father	O
,	O
for	O
the	O
nine-nucleotide	O
deletion	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
additive	O
effects	O
of	O
both	O
mutations	O
in	O
the	O
GPIX	O
gene	O
are	O
responsible	O
for	O
the	O
BSS	O
phenotype	O
of	O
the	O
patient	O
.	O

Leydig	O
cell	O
hypoplasia	O
due	O
to	O
inactivation	O
of	O
luteinizing	O
hormone	O
receptor	O
by	O
a	O
novel	O
homozygous	O
nonsense	O
truncation	O
mutation	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
.	O

Inactivating	O
mutations	O
in	O
the	O
LH	O
receptor	O
are	O
the	O
predominant	O
cause	O
for	O
male	O
pseudohermaphroditism	O
in	O
subjects	O
with	O
Leydig	O
cell	O
hypoplasia	O
(LCH)	O
.	O

The	O
severity	O
of	O
the	O
mutations	O
,	O
correlates	O
with	O
residual	O
receptor	O
activities	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
presentation	O
of	O
one	O
subject	O
with	O
complete	O
male	O
pseudohermaphroditism	O
and	O
LCH	O
.	O

We	O
identify	O
within	O
the	O
proband	O
and	O
her	O
similarly	O
afflicted	O
sibling	O
a	O
homozygous	O
T	O
to	O
G	O
transversion	O
at	O
nucleotide	O
1836	O
in	O
exon	O
11	O
of	O
the	O
LH/CGR	O
gene	O
.	O

This	O
causes	O
conversion	O
of	O
a	O
tyrosine	O
codon	O
into	O
a	O
stop	O
codon	O
at	O
codon	O
612	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
,	O
resulting	O
in	O
a	O
truncated	O
receptor	O
that	O
lacks	O
a	O
cytoplasmic	O
tail	O
.	O

In	O
vitro	O
,	O
in	O
contrast	O
to	O
cells	O
expressing	O
a	O
normal	O
LHR	O
,	O
cells	O
transfected	O
with	O
the	O
mutant	O
cDNA	O
exhibit	O
neither	O
surface	O
binding	O
of	O
radiolabeled	O
hCG	O
nor	O
cAMP	O
generation	O
.	O

In	O
vitro	O
expression	O
under	O
the	O
control	O
of	O
the	O
LHR	O
signal	O
peptide	O
of	O
either	O
a	O
wild	O
type	O
or	O
mutant	O
LHR-GFP	O
fusion	O
protein	O
shows	O
no	O
differences	O
in	O
receptor	O
cellular	O
localization	O
.	O

In	O
conclusion	O
,	O
the	O
in	O
vitro	O
studies	O
suggest	O
that	O
residues	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
and	O
cytoplasmic	O
tail	O
are	O
important	O
for	O
receptor	O
binding	O
and	O
activation	O
without	O
playing	O
a	O
major	O
role	O
in	O
receptor	O
cellular	O
trafficking	O
.	O

Polymorphic	O
forms	O
of	O
prostate	O
specific	O
antigen	O
and	O
their	O
interaction	O
with	O
androgen	O
receptor	O
trinucleotide	O
repeats	O
in	O
prostate	O
cancer	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	O
specific	O
antigen	O
(PSA)	O
may	O
increase	O
prostate	O
cancer	O
(PC)	O
risk	O
.	O

The	O
PSA	O
gene	O
contains	O
a	O
G/A	B-DNAMutation
substitution	O
in	O
the	O
androgen	O
response	O
element	O
(ARE)	O
1	O
region	O
.	O

The	O
androgen	O
receptor	O
(AR)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	O
risk	O
.	O

The	O
effect	O
on	O
PC	O
risks	O
from	O
PSA	O
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	O
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O

METHODS	O
:	O
One	O
hundred	O
PC	O
patients	O
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	O
prostate	O
hyperplasia	O
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA/ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O

PCR	O
products	O
were	O
cut	O
with	O
Nhe	O
1	O
restriction	O
enzyme	O
to	O
distinguish	O
G/A	B-DNAMutation
alleles	O
.	O

AR/CAG	O
and	O
GGC	O
repeat	O
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA/GG	O
distribution	O
in	O
PC	O
(30%)	O
than	O
either	O
benign	O
prostatic	O
hyperplasia	O
(BPH)	O
(18%)	O
or	O
population	O
controls	O
(16%)	O
(	O
P	O
=	O
0.025	O
)	O
.	O

Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	O
(	O
<	O
65	O
years	O
;	O
42%	O
;	O
P	O
=	O
0.012	O
)	O
.	O

Additionally	O
,	O
when	O
PSA	O
genotype	O
was	O
cross	O
classified	O
with	O
CAG	O
repeat	O
,	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	O
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(	O
<	O
22	O
)	O
CAG/GG	O
genotype	O
(	O
P	O
=	O
0.006	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA/ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	O
especially	O
among	O
younger	O
men	O
.	O

Moreover	O
,	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	O
repeat	O
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	O
disease	O
.	O

Genetic	O
linkage	O
of	O
snowflake	O
vitreoretinal	O
degeneration	O
to	O
chromosome	O
2q36	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
chromosomal	O
location	O
of	O
the	O
gene	O
causing	O
snowflake	O
vitreoretinal	O
degeneration	O
(SVD)	O
,	O
an	O
autosomal	O
dominant	O
retinal	O
degeneration	O
characterized	O
by	O
small	O
yellow-white	O
dots	O
in	O
the	O
retina	O
,	O
fibrillar	O
anomaly	O
of	O
the	O
vitreous	O
humor	O
,	O
and	O
retinal	O
detachment	O
.	O

METHODS	O
:	O
Clinical	O
data	O
were	O
collected	O
on	O
31	O
family	O
members	O
by	O
history	O
and	O
examination	O
.	O

Thirteen	O
family	O
members	O
underwent	O
prospective	O
examination	O
.	O

Genotyping	O
was	O
performed	O
using	O
microsatellite	O
markers	O
spaced	O
at	O
approximately	O
10	O
cM	O
intervals	O
.	O

Two-point	O
and	O
multipoint	O
linkage	O
analysis	O
was	O
performed	O
(	O
FASTLINK	O
version	O
of	O
the	O
MLINK	O
program	O
and	O
the	O
VITESSE	O
algorithm	O
,	O
both	O
available	O
at	O
http://linkage.rockefeller.edu/soft/list.html	O
)	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
amplified	O
genomic	O
DNA	O
and	O
mRNA	O
was	O
performed	O
for	O
candidate	O
gene	O
analysis	O
.	O

RESULTS	O
:	O
The	O
SVD	O
locus	O
was	O
linked	O
to	O
markers	O
in	O
a	O
region	O
of	O
chromosome	O
2q36	O
defined	O
by	O
D2S2158	O
and	O
D2S2202	O
,	O
based	O
on	O
meiotic	O
breakpoint	O
mapping	O
of	O
affected	O
individuals	O
.	O

A	O
maximum	O
two-point	O
lod	O
score	O
of	O
5.5	O
was	O
obtained	O
with	O
marker	O
D2S172	O
at	O
theta	O
;	O
=	O
0	O
within	O
this	O
region	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
all	O
52	O
exons	O
of	O
the	O
COL4A3	O
gene	O
revealed	O
no	O
potentially	O
pathogenic	O
coding	O
sequence	O
variation	O
or	O
evidence	O
for	O
deletion	O
.	O

CONCLUSIONS	O
:	O
The	O
genetic	O
locus	O
for	O
SVD	O
lies	O
in	O
a	O
9	O
Mb	O
region	O
flanked	O
by	O
D2S2158	O
and	O
D2S2202	O
.	O

Localization	O
of	O
SVD	O
to	O
a	O
genomic	O
region	O
distinct	O
from	O
both	O
Wagner	O
disease	O
and	O
the	O
Stickler	O
syndromes	O
indicates	O
that	O
SVD	O
is	O
a	O
distinct	O
genetic	O
entity	O
.	O

The	O
absence	O
of	O
coding	O
sequence	O
variation	O
in	O
the	O
only	O
collagen	O
gene	O
within	O
the	O
disease-region	O
,	O
suggests	O
a	O
novel	O
pathogenesis	O
for	O
vitreoretinal	O
degeneration	O
.	O

Snowflake	O
vitreoretinal	O
degeneration	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
families	O
with	O
fibrillar	O
anomaly	O
of	O
the	O
vitreous	O
.	O

Polymorphisms	O
in	O
the	O
MMP1	O
and	O
MMP3	O
promoter	O
and	O
non-small	O
cell	O
lung	O
carcinoma	O
in	O
North	O
China	O
.	O

Matrix	O
metalloproteinases	O
(MMPs)	O
are	O
proteolytic	O
enzymes	O
that	O
regulate	O
various	O
cell	O
behaviors	O
in	O
cancer	O
biology	O
,	O
via	O
their	O
basic	O
function	O
of	O
degradation	O
of	O
proteins	O
.	O

Genetic	O
variations	O
in	O
several	O
MMP	O
promoters	O
may	O
influence	O
transcription	O
and	O
expression	O
of	O
MMPs	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
effects	O
of	O
the	O
two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
the	O
guanine	O
insertion	O
polymorphism	O
in	O
the	O
MMP1	O
promoter	O
and	O
the	O
adenosine	O
insertion	O
polymorphism	O
in	O
the	O
MMP3	O
promoter	O
,	O
on	O
risk	O
of	O
the	O
development	O
and	O
lymphatic	O
metastasis	O
of	O
non-small	O
cell	O
lung	O
carcinoma	O
(NSCLC)	O
.	O

The	O
MMP1	O
and	O
MMP3	O
SNPs	O
were	O
genotyped	O
by	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
analysis	O
in	O
243	O
NSCLC	O
patients	O
and	O
350	O
control	O
subjects	O
in	O
North	O
China	O
.	O

The	O
overall	O
genotype	O
and	O
allelotype	O
distribution	O
of	O
both	O
the	O
variants	O
in	O
cancer	O
patients	O
and	O
controls	O
was	O
not	O
significantly	O
different	O
(	O
all	O
P	O
values	O
are	O
above	O
0.05	O
)	O
.	O

However	O
,	O
stratification	O
analysis	O
showed	O
that	O
smoking	O
individuals	O
with	O
the	O
MMP3	O
5A	O
allele	O
had	O
a	O
>1.5-fold	O
increased	O
risk	O
to	O
develop	O
NSCLC	O
,	O
compared	O
with	O
those	O
harboring	O
the	O
6A	O
homozygous	O
[	O
the	O
age	O
and	O
gender	O
adjusted	O
odds	O
ratio	O
(OR)	O
=	O
1.68	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
=	O
1.04-2.70	O
]	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
the	O
MMP3	O
5A	O
homozygote	O
in	O
NSCLC	O
patients	O
with	O
lymphatic	O
metastasis	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
lymph	O
node	O
negative	O
ones	O
(	O
5.7	O
versus	O
0%	O
,	O
P	O
=	O
0.04	O
)	O
.	O

Moreover	O
,	O
the	O
MMP	O
1G/5A	O
haplotype	O
significantly	O
increased	O
the	O
risk	O
of	O
lymphatic	O
metastasis	O
(	O
OR	O
=	O
3.36	O
,	O
95%	O
CI	O
=	O
1.42-7.94	O
)	O
,	O
compared	O
with	O
the	O
2G/6A	O
haplotype	O
.	O

The	O
present	O
result	O
suggested	O
that	O
the	O
MMP3	O
promoter	O
polymorphism	O
may	O
modify	O
susceptibility	O
to	O
NSCLC	O
,	O
and	O
the	O
MMP	O
1G/5A	O
haplotype	O
may	O
predicate	O
the	O
risk	O
of	O
lymphatic	O
metastasis	O
of	O
this	O
tumor	O
.	O

Lack	O
of	O
evidence	O
for	O
mutations	O
or	O
deletions	O
in	O
the	O
CDKN2A/p16	O
and	O
CDKN2B/p15	O
genes	O
of	O
Brazilian	O
neuroblastoma	O
patients	O
.	O

Neuroblastoma	O
,	O
the	O
most	O
common	O
extracranial	O
tumor	O
in	O
childhood	O
,	O
has	O
a	O
wide	O
spectrum	O
of	O
clinical	O
and	O
biological	O
features	O
.	O

The	O
loss	O
of	O
heterozygosity	O
within	O
the	O
9p21	O
region	O
has	O
been	O
reported	O
as	O
a	O
prognostic	O
factor	O
.	O

Two	O
tumor	O
suppressor	O
genes	O
located	O
in	O
this	O
region	O
,	O
the	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
(	O
cyclin-dependent	O
kinase	O
inhibitors	O
2B	O
and	O
2A	O
,	O
respectively	O
)	O
genes	O
,	O
play	O
a	O
critical	O
role	O
in	O
cell	O
cycle	O
progression	O
and	O
are	O
considered	O
to	O
be	O
targets	O
for	O
tumor	O
inactivation	O
.	O

We	O
analyzed	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
gene	O
alterations	O
in	O
11	O
patients	O
,	O
who	O
ranged	O
in	O
age	O
from	O
4	O
months	O
to	O
13	O
years	O
(	O
male/female	O
ratio	O
was	O
1.2:1	O
)	O
.	O

The	O
most	O
frequent	O
stage	O
of	O
the	O
tumor	O
was	O
stage	O
IV	O
(50%)	O
,	O
followed	O
by	O
stages	O
II	O
and	O
III	O
(20%)	O
and	O
stage	O
I	O
(10%)	O
.	O

The	O
samples	O
were	O
submitted	O
to	O
the	O
multiplex	O
PCR	O
technique	O
for	O
homozygous	O
deletion	O
analysis	O
and	O
to	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequencing	O
for	O
mutation	O
analysis	O
.	O

All	O
exons	O
of	O
both	O
genes	O
were	O
analyzed	O
,	O
but	O
no	O
deletion	O
was	O
detected	O
.	O

One	O
sample	O
exhibited	O
shift	O
mobility	O
specific	O
for	O
exon	O
2	O
in	O
the	O
CDKN2B/p15	O
gene	O
,	O
not	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Homozygous	O
deletions	O
and	O
mutations	O
are	O
not	O
involved	O
in	O
the	O
inactivation	O
mechanism	O
of	O
the	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
genes	O
in	O
neuroblastoma	O
;	O
however	O
,	O
these	O
two	O
abnormalities	O
do	O
not	O
exclude	O
other	O
inactivation	O
pathways	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
the	O
expression	O
of	O
these	O
genes	O
is	O
altered	O
in	O
this	O
disease	O
.	O

Therefore	O
,	O
other	O
mechanisms	O
of	O
inactivation	O
,	O
such	O
as	O
methylation	O
of	O
promoter	O
region	O
and	O
unproperly	O
function	O
of	O
proteins	O
,	O
may	O
be	O
considered	O
in	O
order	O
to	O
estimate	O
the	O
real	O
contribution	O
of	O
these	O
genes	O
to	O
neuroblastoma	O
genesis	O
or	O
disease	O
progression	O
.	O

Fabry	O
disease	O
female	O
proband	O
with	O
clinical	O
manifestations	O
similar	O
to	O
hypertrophic	O
cardiomyopathy	O
.	O

Fabry's	O
disease	O
is	O
an	O
X-linked	O
inborn	O
error	O
of	O
glycosphingolipid	O
catabolism	O
,	O
resulting	O
from	O
a	O
deficiency	O
in	O
alpha-galactosidase	O
A	O
(	O
alpha-Gal	O
A	O
)	O
.	O

A	O
56-year-old	O
Japanese	O
woman	O
was	O
at	O
first	O
suspected	O
of	O
having	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
patient	O
and	O
her	O
son	O
had	O
alpha-Gal	O
A	O
activity	O
in	O
leukocytes	O
that	O
was	O
remarkably	O
below	O
the	O
limit	O
of	O
controls	O
.	O

DNA	O
analysis	O
of	O
the	O
alpha-Gal	O
A	O
gene	O
revealed	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
19	O
in	O
exon	O
1	O
,	O
resulting	O
in	O
leucine-to-proline	O
substitution	O
.	O

As	O
a	O
result	O
she	O
was	O
confirmed	O
as	O
a	O
classic	O
Fabry	O
heterozygote	O
.	O

Recent	O
advances	O
in	O
enzyme	O
replacement	O
therapy	O
can	O
reverse	O
the	O
storage	O
of	O
glycosphingolipids	O
in	O
Fabry's	O
disease	O
.	O

Thus	O
,	O
in	O
patients	O
with	O
cardiac	O
hypertrophy	O
,	O
it	O
is	O
important	O
to	O
differentiate	O
Fabry's	O
disease	O
from	O
other	O
causes	O
of	O
hypertrophy	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
measure	O
alpha-Gal	O
A	O
activity	O
in	O
all	O
suspected	O
cases	O
and	O
to	O
analyze	O
genetic	O
abnormalities	O
in	O
heterozygotes	O
.	O

Genetic	O
variation	O
in	O
apolipoprotein	O
D	O
and	O
Alzheimer's	O
disease	O
.	O

Apolipoprotein	O
D	O
(apoD)	O
is	O
a	O
lipoprotein-associated	O
glycoprotein	O
,	O
structurally	O
unrelated	O
to	O
apoE	O
,	O
that	O
transports	O
small	O
hydrophobic	O
ligands	O
including	O
cholesterol	O
and	O
sterols	O
.	O

Levels	O
are	O
increased	O
in	O
the	O
hippocampus	O
and	O
CSF	O
of	O
Alzheimer's	O
disease	O
(AD)	O
patients	O
.	O

We	O
tested	O
whether	O
variation	O
in	O
the	O
APOD	O
gene	O
affects	O
AD	O
risk	O
.	O

Four	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
investigated	O
(	O
in	O
map	O
order	O
)	O
:	O
exon	O
2	O
,	O
15T-->C	B-DNAMutation
encodes	O
an	O
amino	O
acid	O
substitution	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
;	O
intron	B-DNAMutation
2	I-DNAMutation
,	I-DNAMutation
-352G-->A	I-DNAMutation
;	O
intron	B-DNAMutation
3	I-DNAMutation
,	I-DNAMutation
+45C-->T	I-DNAMutation
;	O
intron	B-DNAMutation
4	I-DNAMutation
,	I-DNAMutation
+718C-->T	I-DNAMutation
,	O
determined	O
by	O
SNaPshot	O
assay	O
.	O

SNP	O
frequencies	O
for	O
394	O
eastern	O
Finnish	O
AD	O
patients	O
were	O
compared	O
with	O
those	O
found	O
for	O
470	O
control	O
subjects	O
,	O
dividing	O
subjects	O
also	O
into	O
early-onset	O
AD	O
(	O
EOAD	O
;	O
<	O
or	O
=	O
65	O
years	O
)	O
and	O
late-onset	O
AD	O
(	O
LOAD	O
;	O
>65	O
years	O
)	O
groups	O
.	O

The	O
-352G	O
allele	O
was	O
associated	O
with	O
a	O
significant	O
3-fold	O
increase	O
in	O
the	O
risk	O
of	O
EOAD	O
(	O
OR	O
:	O
2.7	O
;	O
95%	O
CI	O
:	O
1.1-6.5	O
)	O
.	O

The	O
-352G	O
containing	O
haplotypes	O
were	O
more	O
common	O
for	O
EOAD	O
cases	O
(	O
TGCC	O
:	O
0.48	O
vs	O
0.41	O
;	O
TGCT	O
:	O
0.08	O
vs	O
0.01	O
(	O
p	O
=	O
0.002	O
)	O
.	O

In	O
the	O
Grade-of-membership	O
analysis	O
,	O
APOD	O
genotype	O
frequencies	O
at	O
each	O
SNP	O
site	O
and	O
disease	O
status	O
were	O
used	O
to	O
construct	O
two	O
latent	O
groups	O
:	O
the	O
affected	O
group	O
carried	O
-352	O
as	O
GG	O
or	O
GA	O
and	O
+45	O
CC	O
,	O
was	O
often	O
women	O
and	O
enriched	O
in	O
APOE	O
epsilon4	O
.	O

Each	O
method	O
suggested	O
that	O
the	O
-352G	O
allele	O
frequency	O
is	O
higher	O
for	O
EOAD	O
in	O
the	O
eastern	O
Finnish	O
population	O
.	O

Genetic	O
analyses	O
and	O
expression	O
studies	O
identified	O
a	O
novel	O
mutation	O
W486C	B-ProteinMutation
as	O
a	O
molecular	O
basis	O
of	O
congenital	O
coagulation	O
factor	O
XII	O
deficiency	O
.	O

We	O
analyzed	O
the	O
factor	O
XII	O
(FXII)	O
gene	O
of	O
a	O
patient	O
with	O
congenital	O
FXII	O
deficiency	O
and	O
identified	O
a	O
novel	O
amino	O
acid	O
substitution	O
W486C	B-ProteinMutation
in	O
the	O
catalytic	O
domain	O
.	O

The	O
proband	O
was	O
an	O
asymptomatic	O
49-year-old	O
Japanese	O
female	O
with	O
abnormal	O
coagulation	O
test	O
,	O
discovered	O
by	O
chance	O
.	O

The	O
FXII	O
activity	O
and	O
antigen	O
level	O
were	O
both	O
under	O
10%	O
,	O
suggesting	O
a	O
cross-reacting	O
material-negative	O
FXII	O
deficiency	O
.	O

Sequence	O
analysis	O
of	O
the	O
proband's	O
FXII	O
gene	O
revealed	O
a	O
homozygous	O
nucleotide	O
substitution	O
G	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
in	O
exon	O
12	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
W486C	B-ProteinMutation
in	O
the	O
catalytic	O
domain	O
.	O

We	O
constructed	O
the	O
mutant	O
FXII	O
cDNA	O
in	O
an	O
expression	O
plasmid	O
vector	O
and	O
transfected	O
it	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
recombinant	O
wild-type	O
FXII	O
antigen	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
by	O
immunoprecipitation	O
assay	O
,	O
but	O
the	O
mutant	O
FXII	O
W486C	B-ProteinMutation
was	O
not	O
observed	O
.	O

On	O
the	O
other	O
hand	O
,	O
both	O
the	O
wild-type	O
FXII	O
and	O
W486C	B-ProteinMutation
cell	O
lysates	O
contained	O
FXII	O
antigen	O
and	O
FXII	O
mRNA	O
,	O
as	O
estimated	O
by	O
western	O
blotting	O
and	O
quantitative	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
W486C	B-ProteinMutation
substitution	O
of	O
FXII	O
impairs	O
intracellular	O
processing	O
of	O
the	O
protein	O
and/or	O
transport	O
system	O
.	O

Lack	O
of	O
major	O
involvement	O
of	O
human	O
uroplakin	O
genes	O
in	O
vesicoureteral	O
reflux	O
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O

BACKGROUND	O
:	O
Primary	O
vesicoureteral	O
reflux	O
(VUR)	O
is	O
a	O
hereditary	O
disorder	O
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O

It	O
affects	O
about	O
1%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	O
diseases	O
.	O

Its	O
associated	O
nephropathy	O
is	O
an	O
important	O
cause	O
of	O
end-stage	O
renal	O
failure	O
in	O
children	O
and	O
adults	O
.	O

Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	O
uroplakin	O
(UP)	O
III	O
gene	O
,	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial-specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
,	O
causes	O
VUR	O
and	O
hydronephrosis	O
.	O

METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	O
genes	O
might	O
play	O
a	O
role	O
in	O
human	O
VUR	O
,	O
we	O
genotyped	O
all	O
four	O
UP	O
genes	O
in	O
76	O
patients	O
with	O
radiologically	O
proven	O
primary	O
VUR	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O

RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
identified	O
,	O
seven	O
of	O
which	O
were	O
missense	O
,	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O

Since	O
healthy	O
relatives	O
of	O
the	O
VUR	O
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	O
,	O
we	O
used	O
a	O
population	O
of	O
90	O
race-matched	O
,	O
healthy	O
individuals	O
,	O
unrelated	O
to	O
the	O
VUR	O
patients	O
,	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O

Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	O
.	O

However	O
,	O
SNP1	O
of	O
UP	O
Ia	O
gene	O
affecting	O
a	O
C	O
to	O
T	O
conversion	O
and	O
an	O
Ala7Val	B-ProteinMutation
change	O
,	O
and	O
SNP7	O
of	O
UP	O
III	O
affecting	O
a	O
C	O
to	O
G	O
conversion	O
and	O
a	O
Pro154Ala	B-ProteinMutation
change	O
,	O
were	O
marginally	O
associated	O
with	O
VUR	O
(	O
both	O
P=	O
0.08	O
)	O
.	O

Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
,	O
in	O
combination	O
with	O
the	O
first	O
set	O
,	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	O
III	O
SNP7	O
in	O
VUR	O
(	O
P=	O
0.036	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs	O
.	O

controls	O
)	O
.	O

CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	O
genes	O
cannot	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	O
in	O
humans	O
,	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O

The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	O
patients	O
,	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	O
III	O
knockout	O
mice	O
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	O
,	O
but	O
also	O
severe	O
hydronephrosis	O
and	O
neonatal	O
death	O
,	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	O
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	O
.	O

Evaluation	O
of	O
the	O
Lys198Asn	B-ProteinMutation
and	O
-134delA	B-DNAMutation
genetic	O
polymorphisms	O
of	O
the	O
endothelin-1	O
gene	O
.	O

Endothelin-1	O
(ET-1)	O
is	O
a	O
potent	O
vasoconstrictor	O
and	O
shows	O
various	O
pharmacological	O
responses	O
.	O

Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ET-1	O
gene	O
(EDN1)	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
blood	O
pressure	O
(BP)	O
.	O

One	O
is	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
,	O
which	O
showed	O
a	O
positive	O
association	O
with	O
BP	O
in	O
overweight	O
people	O
.	O

Another	O
is	O
the	O
3A/4A	O
polymorphism	O
-134delA	B-DNAMutation
located	O
in	O
the	O
5'-untranslated	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
in	O
ET-1	O
in	O
vitro	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
either	O
of	O
the	O
two	O
polymorphisms	O
and	O
the	O
plasma	O
ET-1	O
level	O
.	O

We	O
expressed	O
both	O
the	O
major	O
(Lys-type)	O
and	O
minor	O
type	O
(Asn-type)	O
preproET-1	O
in	O
three	O
different	O
cell	O
lines	O
,	O
and	O
measured	O
the	O
levels	O
of	O
ET-1	O
and	O
big	O
ET-1	O
in	O
the	O
culture	O
supernatant	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
ET-1	O
or	O
big	O
ET-1	O
between	O
the	O
Asn-type	O
and	O
Lys-type	O
transfectant	O
.	O

In	O
the	O
association	O
study	O
,	O
the	O
plasma	O
levels	O
of	O
ET-1	O
in	O
54	O
hypertensive	O
patients	O
having	O
an	O
amino	O
acid	O
substitution	O
from	O
Lys	O
to	O
Asn	O
at	O
position	O
198	O
were	O
not	O
different	O
from	O
those	O
of	O
hypertensives	O
without	O
the	O
substitution	O
.	O

However	O
,	O
we	O
found	O
a	O
significant	O
difference	O
in	O
ET-1	O
levels	O
between	O
individuals	O
with	O
the	O
3A/3A	O
and	O
3A/4A	O
genotypes	O
.	O

Our	O
transient	O
expression	O
study	O
indicates	O
that	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
may	O
not	O
directly	O
affect	O
ET-1	O
and	O
big	O
ET-1	O
production	O
.	O

Another	O
variant	O
in	O
the	O
EDN1	O
gene	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
may	O
be	O
responsible	O
for	O
the	O
association	O
with	O
BP	O
,	O
or	O
the	O
interaction	O
between	O
the	O
EDN1	O
Lys198Asn	B-ProteinMutation
polymorphism	O
and	O
other	O
factors	O
such	O
as	O
obesity	O
may	O
be	O
involved	O
in	O
the	O
mechanisms	O
elevating	O
BP	O
in	O
vivo	O
.	O

Altered	O
replication	O
timing	O
of	O
the	O
HIRA/Tuple1	O
locus	O
in	O
the	O
DiGeorge	O
and	O
Velocardiofacial	O
syndromes	O
.	O

DiGeorge	O
and	O
Velocardiofacial	O
syndromes	O
(DGS/VCFS)	O
are	O
endowed	O
by	O
a	O
similar	O
complex	O
phenotype	O
including	O
cardiovascular	O
,	O
craniofacial	O
,	O
and	O
thymic	O
malformations	O
,	O
and	O
are	O
associated	O
with	O
heterozygous	O
deletions	O
of	O
22q11	O
chromosomal	O
band	O
.	O

The	O
Typically	O
Deleted	O
Region	O
in	O
the	O
22q11.21	O
subband	O
(	O
here	O
called	O
TDR22	O
)	O
is	O
very	O
gene-dense	O
,	O
and	O
the	O
extent	O
of	O
the	O
deletion	O
has	O
been	O
defined	O
precisely	O
in	O
several	O
studies	O
.	O

However	O
,	O
to	O
date	O
there	O
is	O
no	O
evidence	O
for	O
a	O
mechanism	O
of	O
haploinsufficiency	O
that	O
can	O
fully	O
explain	O
the	O
DGS/VCFS	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
candidate	O
gene	O
HIRA/Tuple1	O
mapping	O
on	O
the	O
non-deleted	O
TDR22	O
,	O
in	O
DGS/VCFS	O
subjects	O
presents	O
a	O
delayed	O
replication	O
timing	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cell	O
ratio	O
showing	O
the	O
HIRA/Tuple1	O
locus	O
localised	O
toward	O
the	O
nuclear	O
periphery	O
.	O

It	O
is	O
known	O
that	O
replication	O
timing	O
and	O
nuclear	O
location	O
are	O
generally	O
correlated	O
to	O
the	O
transcription	O
activity	O
of	O
the	O
relative	O
DNA	O
region	O
.	O

We	O
propose	O
that	O
the	O
alteration	O
in	O
the	O
replication/nuclear	O
location	O
pattern	O
of	O
the	O
non-deleted	O
TDR22	O
indicates	O
an	O
altered	O
gene	O
regulation	O
hence	O
an	O
altered	O
transcritpion	O
in	O
DGS/VCFS	O
.	O

Desmin-related	O
myopathy	O
with	O
Mallory	O
body-like	O
inclusions	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
selenoprotein	O
N	O
gene	O
.	O

Desmin-related	O
myopathies	O
(DRMs)	O
are	O
a	O
heterogeneous	O
group	O
of	O
muscle	O
disorders	O
,	O
morphologically	O
defined	O
by	O
intrasarcoplasmic	O
aggregates	O
of	O
desmin	O
.	O

Mutations	O
in	O
the	O
desmin	O
and	O
the	O
alpha-B	O
crystallin	O
genes	O
account	O
for	O
approximately	O
one	O
third	O
of	O
the	O
DRM	O
cases	O
.	O

The	O
genetic	O
basis	O
of	O
the	O
other	O
forms	O
remain	O
unknown	O
,	O
including	O
the	O
early-onset	O
,	O
recessive	O
form	O
with	O
Mallory	O
body-like	O
inclusions	O
(MB-DRMs)	O
,	O
first	O
described	O
in	O
five	O
related	O
German	O
patients	O
.	O

Recently	O
,	O
we	O
identified	O
the	O
selenoprotein	O
N	O
gene	O
(SEPN1)	O
as	O
responsible	O
for	O
SEPN-related	O
myopathy	O
(SEPN-RM)	O
,	O
a	O
unique	O
early-onset	O
myopathy	O
formerly	O
divided	O
in	O
two	O
different	O
nosological	O
categories	O
:	O
rigid	O
spine	O
muscular	O
dystrophy	O
and	O
the	O
severe	O
form	O
of	O
classical	O
multiminicore	O
disease	O
.	O

The	O
finding	O
of	O
Mallory	O
body-like	O
inclusions	O
in	O
two	O
cases	O
of	O
genetically	O
documented	O
SEPN-RM	O
led	O
us	O
to	O
suspect	O
a	O
relationship	O
between	O
MB-DRM	O
and	O
SEPN1	O
.	O

In	O
the	O
original	O
MB-DRM	O
German	O
family	O
,	O
we	O
demonstrated	O
a	O
linkage	O
of	O
the	O
disease	O
to	O
the	O
SEPN1	O
locus	O
(1p36)	O
,	O
and	O
subsequently	O
a	O
homozygous	O
SEPN1	O
deletion	O
(	O
del	B-DNAMutation
92	I-DNAMutation
nucleotide	I-DNAMutation
-19/+73	I-DNAMutation
)	O
in	O
the	O
affected	O
patients	O
.	O

A	O
comparative	O
reevaluation	O
showed	O
that	O
MB-DRM	O
and	O
SEPN-RM	O
share	O
identical	O
clinical	O
features	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
MB-DRM	O
should	O
be	O
categorized	O
as	O
SEPN-RM	O
.	O

These	O
findings	O
substantiate	O
the	O
molecular	O
heterogeneity	O
of	O
DRM	O
,	O
expand	O
the	O
morphological	O
spectrum	O
of	O
SEPN-RM	O
,	O
and	O
implicate	O
a	O
necessary	O
reassessment	O
of	O
the	O
nosological	O
boundaries	O
in	O
early-onset	O
myopathies	O
.	O

CRYBA3/A1	O
gene	O
mutation	O
associated	O
with	O
suture-sparing	O
autosomal	O
dominant	O
congenital	O
nuclear	O
cataract	O
:	O
a	O
novel	O
phenotype	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
defect	O
leading	O
to	O
the	O
congenital	O
nuclear	O
cataract	O
affecting	O
a	O
large	O
five-generation	O
Swiss	O
family	O
.	O

METHODS	O
:	O
Family	O
history	O
and	O
clinical	O
data	O
were	O
recorded	O
.	O

The	O
phenotype	O
was	O
documented	O
by	O
both	O
slit	O
lamp	O
and	O
Scheimpflug	O
photography	O
.	O

One	O
cortical	O
lens	O
was	O
evaluated	O
by	O
electron	O
microscopy	O
after	O
cataract	O
extraction	O
.	O

Lenticular	O
phenotyping	O
and	O
genotyping	O
were	O
performed	O
independently	O
with	O
short	O
tandem	O
repeat	O
polymorphism	O
.	O

Linkage	O
analysis	O
was	O
performed	O
,	O
and	O
candidate	O
genes	O
were	O
PCR	O
amplified	O
and	O
screened	O
for	O
mutations	O
on	O
both	O
strands	O
using	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Affected	O
individuals	O
had	O
a	O
congenital	O
nuclear	O
lactescent	O
cataract	O
in	O
both	O
eyes	O
.	O

Linkage	O
was	O
observed	O
on	O
chromosome	O
17	O
for	O
DNA	O
marker	O
D17S1857	O
(	O
lod	O
score	O
:	O
3.44	O
at	O
theta	O
=	O
0	O
)	O
.	O

Direct	O
sequencing	O
of	O
CRYBA3/A1	O
,	O
which	O
maps	O
to	O
the	O
vicinity	O
,	O
revealed	O
an	O
in-frame	O
3-bp	O
deletion	O
in	O
exon	O
4	O
279delGAG	B-DNAMutation
.	O

This	O
mutation	O
involved	O
a	O
deletion	O
of	O
glycine-91	O
,	O
cosegregated	O
in	O
all	O
affected	O
individuals	O
,	O
and	O
was	O
not	O
observed	O
in	O
unaffected	O
individuals	O
or	O
in	O
250	O
normal	O
control	O
subjects	O
from	O
the	O
same	O
ethnic	O
background	O
.	O

Electron	O
microscopy	O
showed	O
that	O
cortical	O
lens	O
fiber	O
morphology	O
was	O
normal	O
.	O

CONCLUSIONS	O
:	O
The	O
DeltaG91	B-ProteinMutation
mutation	O
in	O
CRYBA3/A1	O
is	O
associated	O
with	O
an	O
autosomal	O
dominant	O
congenital	O
nuclear	O
lactescent	O
cataract	O
.	O

A	O
splice	O
mutation	O
IVS3+1G/A	B-DNAMutation
in	O
this	O
gene	O
has	O
been	O
reported	O
in	O
a	O
zonular	O
cataract	O
with	O
sutural	O
opacities	O
.	O

These	O
results	O
indicate	O
phenotypic	O
heterogeneity	O
related	O
to	O
mutations	O
in	O
this	O
gene	O
.	O

A	O
first	O
Taiwanese	O
Chinese	O
family	O
of	O
type	O
2B	O
von	O
Willebrand	O
disease	O
with	O
R1306W	B-ProteinMutation
mutation	O
.	O

Clinical	O
,	O
laboratory	O
and	O
genetic	O
defect	O
of	O
a	O
Taiwanese	O
family	O
with	O
type	O
2B	O
von	O
Willebrand	O
disease	O
(VWD)	O
were	O
studied	O
.	O

The	O
proband	O
was	O
a	O
55-year-old	O
woman	O
who	O
gave	O
birth	O
to	O
two	O
daughters	O
and	O
one	O
son	O
aged	O
30	O
,	O
29	O
and	O
27	O
,	O
respectively	O
.	O

All	O
had	O
abnormal	O
mucocutaneous	O
bleedings	O
since	O
their	O
childhood	O
.	O

In	O
proband	O
,	O
PT	O
,	O
PTT	O
and	O
platelet	O
count	O
were	O
normal	O
;	O
template	O
bleeding	O
time	O
was	O
14	O
min	O
;	O
VIII:C	O
was	O
51%	O
,	O
von	O
Willebrand	O
factor	O
antigen	O
(VWF:Ag)	O
,	O
42%	O
and	O
von	O
Willerand	O
factor	O
ristocetin-cofactor	O
(	O
VWF:RCo	O
,	O
15%	O
)	O
;	O
ristocetin-induced	O
platelet	O
aggregation	O
(RIPA)	O
at	O
0.3	O
and	O
0.6	O
mg/ml	O
of	O
ristocetin	O
was	O
16%	O
and	O
68%	O
,	O
respectively	O
.	O

The	O
enhanced	O
response	O
to	O
ristocetin	O
was	O
identified	O
to	O
be	O
in	O
plasma	O
,	O
not	O
in	O
platelet	O
itself	O
,	O
by	O
mixing	O
studies	O
.	O

Analysis	O
of	O
von	O
Willebrand	O
factor	O
(VWF)	O
multimer	O
of	O
plasma	O
but	O
not	O
of	O
platelets	O
showed	O
absence	O
of	O
high-molecular	O
weight	O
(HMW)	O
multimer	O
.	O

All	O
three	O
children	O
had	O
similar	O
laboratory	O
findings	O
.	O

Exon	O
28	O
of	O
VWF	O
gene	O
was	O
amplified	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
sequenced	O
.	O

The	O
proband	O
and	O
three	O
children	O
were	O
all	O
found	O
to	O
be	O
heterozygous	O
for	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
3916	O
resulting	O
in	O
Arg	B-ProteinMutation
1306	I-ProteinMutation
Trp	I-ProteinMutation
R1306W	B-ProteinMutation
substitution	O
.	O

This	O
mutation	O
in	O
the	O
glycoprotein	O
Ib	O
(GPIb)-binding	O
site	O
has	O
been	O
found	O
to	O
increase	O
the	O
affinity	O
of	O
plasma	O
VWF	O
for	O
platelets	O
,	O
and	O
thus	O
cause	O
loss	O
of	O
HMW	O
multimers	O
and	O
often	O
thrombocytopenia	O
.	O

In	O
conclusion	O
,	O
a	O
first	O
report	O
of	O
type	O
2B	O
VWD	O
in	O
a	O
Taiwanese	O
Chinese	O
family	O
who	O
show	O
R1306W	B-ProteinMutation
mutation	O
in	O
VWF	O
gene	O
was	O
described	O
.	O

Comparison	O
of	O
sequential	O
cytomegalovirus	O
isolates	O
in	O
a	O
patient	O
with	O
lymphoma	O
and	O
failing	O
antiviral	O
therapy	O
.	O

BACKGROUND	O
:	O
Long-term	O
anti-cytomegalovirus	O
(CMV)	O
treatments	O
in	O
immunocompromised	O
patients	O
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O

Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	O
isolates	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	O
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain-specific	O
variability	O
in	O
a	O
patient	O
with	O
non-Hodgkin's	O
lymphoma	O
in	O
whom	O
successive	O
anti-CMV	O
treatments	O
failed	O
.	O

STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	O
isolates	O
collected	O
from	O
one	O
patient	O
during	O
a	O
2-year	O
follow-up	O
period	O
were	O
retrospectively	O
analysed	O
.	O

In	O
parallel	O
,	O
we	O
used	O
glycoprotein	O
B	O
(gB)	O
genotyping	O
,	O
and	O
a-	O
and	O
UL10-13-sequence	O
analysis	O
to	O
study	O
CMV	O
interstrain	O
variability	O
.	O

RESULTS	O
:	O
The	O
patient	O
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	O
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O

Resistance	O
to	O
ganciclovir	O
,	O
cidofovir	O
and	O
foscarnet	O
was	O
successively	O
detected	O
during	O
the	O
follow-up	O
period	O
.	O

UL97	O
protein	O
kinase	O
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	O
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
,	O
and	O
then	O
at	O
position	O
594	O
.	O

Decreased	O
sensitivity	O
to	O
foscarnet	O
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495K	B-ProteinMutation
in	O
DNA	O
polymerase	O
,	O
whereas	O
cross-resistance	O
to	O
ganciclovir	O
and	O
cidofovir	O
was	O
due	O
to	O
the	O
L501I	B-ProteinMutation
substitution	O
.	O

CONCLUSIONS	O
:	O
The	O
CMV	O
isolates	O
obtained	O
from	O
our	O
patient	O
were	O
complex	O
mixtures	O
of	O
strains	O
.	O

Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O

Molecular	O
analysis	O
of	O
acute	O
intermittent	O
porphyria	O
:	O
mutation	O
screening	O
in	O
20	O
patients	O
in	O
Germany	O
reveals	O
11	O
novel	O
mutations	O
.	O

Acute	O
intermittent	O
porphyria	O
(AIP)	O
is	O
a	O
very	O
rare	O
autosomal	O
dominant	O
disorder	O
with	O
low	O
penetrance	O
.	O

Mutations	O
in	O
the	O
gene	O
of	O
the	O
porphobilinogen	O
deaminase	O
(PBG-D)	O
,	O
also	O
called	O
hydroxymethylbilane	O
synthase	O
(HMBS)	O
,	O
cause	O
a	O
partial	O
deficiency	O
of	O
this	O
enzyme	O
of	O
the	O
heme	O
biosynthetic	O
pathway	O
.	O

Overstimulation	O
of	O
heme	O
biosynthesis	O
causes	O
clinical	O
symptoms	O
.	O

Because	O
of	O
the	O
variability	O
of	O
the	O
symptoms	O
,	O
diagnosis	O
is	O
often	O
delayed	O
.	O

Using	O
two	O
approaches	O
for	O
genetic	O
analysis	O
,	O
first	O
in	O
a	O
stepwise	O
manner	O
,	O
then	O
sequencing	O
extensive	O
parts	O
of	O
the	O
gene	O
,	O
the	O
screening	O
of	O
the	O
DNA	O
of	O
20	O
unrelated	O
individuals	O
revealed	O
20	O
different	O
mutations	O
,	O
11	O
of	O
which	O
had	O
not	O
been	O
reported	O
previously	O
.	O

The	O
novel	O
mutations	O
affected	O
intron	O
1	O
(	O
33	B-DNAMutation
+	I-DNAMutation
2	I-DNAMutation
T-->C	I-DNAMutation
)	O
,	O
exon	O
5	O
(	O
181	B-DNAMutation
G-->C	I-DNAMutation
)	O
,	O
intron	O
6	O
(	O
267-61	B-DNAMutation
del	I-DNAMutation
8	I-DNAMutation
bp	I-DNAMutation
)	O
,	O
intron	O
7	O
(	O
345-1	B-DNAMutation
G-->C	I-DNAMutation
)	O
,	O
intron	O
9	O
(	O
498	B-DNAMutation
+	I-DNAMutation
15	I-DNAMutation
G-->T	I-DNAMutation
and	O
499-13	B-DNAMutation
Delta-14	I-DNAMutation
bp	I-DNAMutation
indel	I-DNAMutation
TGA	I-DNAMutation
)	O
,	O
intron	O
13	O
(	O
825	B-DNAMutation
+	I-DNAMutation
1	I-DNAMutation
G-->C	I-DNAMutation
and	O
825	B-DNAMutation
+	I-DNAMutation
2	I-DNAMutation
T-->C	I-DNAMutation
)	O
,	O
exon	O
15	O
(	O
962	B-DNAMutation
G-A	I-DNAMutation
,	O
1067	B-DNAMutation
del	I-DNAMutation
A	I-DNAMutation
and	O
1067-1068	B-DNAMutation
ins	I-DNAMutation
5	I-DNAMutation
bp	I-DNAMutation
)	O
.	O

The	O
other	O
nine	O
mutations	O
detected	O
affected	O
intron	O
14	O
,	O
exons	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
(3x)	O
and	O
12	O
.	O

In	O
the	O
majority	O
of	O
AIP	O
patients	O
,	O
the	O
genotype	O
does	O
not	O
predict	O
phenotypic	O
expression	O
.	O

Since	O
the	O
sudden	O
manifestation	O
of	O
the	O
disease	O
maybe	O
prevented	O
by	O
early	O
diagnosis	O
,	O
identification	O
of	O
AIP	O
gene	O
carriers	O
is	O
the	O
best	O
preventive	O
measure	O
.	O

This	O
was	O
performed	O
in	O
five	O
families	O
,	O
revealing	O
10	O
additional	O
AIP	O
gene	O
carriers	O
.	O

Identification	O
of	O
the	O
Kna/Knb	O
polymorphism	O
and	O
a	O
method	O
for	O
Knops	O
genotyping	O
.	O

BACKGROUND	O
:	O
DNA	O
mutations	O
resulting	O
in	O
the	O
McCoy	O
and	O
Swain-Langley	O
polymorphisms	O
have	O
been	O
identified	O
on	O
complement	O
receptor	O
1	O
(CR1)-a	O
ligand	O
for	O
rosetting	O
of	O
Plasmodium	O
falciparum-infected	O
RBCs	O
.	O

The	O
molecular	O
identification	O
of	O
the	O
Kna/Knb	O
polymorphism	O
was	O
sought	O
to	O
develop	O
a	O
genotyping	O
method	O
for	O
use	O
in	O
the	O
study	O
of	O
the	O
Knops	O
blood	O
group	O
and	O
malaria	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
CR1	O
deletion	O
constructs	O
were	O
used	O
in	O
inhibition	O
studies	O
of	O
anti-Kna	O
.	O

PCR	O
amplification	O
of	O
Exon	O
29	O
was	O
followed	O
by	O
DNA	O
sequencing	O
.	O

A	O
PCR-RFLP	O
was	O
developed	O
with	O
NdeI	O
,	O
BsmI	O
,	O
and	O
MfeI	O
for	O
the	O
detection	O
of	O
Kna/Knb	O
,	O
McCa/McCb	O
,	O
and	O
Sl1/Sl2	O
,	O
respectively	O
.	O

Knops	O
phenotypes	O
were	O
determined	O
with	O
standard	O
serologic	O
techniques	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
310	O
Malian	O
persons	O
were	O
phenotyped	O
for	O
Kna	O
with	O
200	O
(64%)	O
Kn(a+)	O
and	O
110	O
(36%)	O
Kn(a-)	O
.	O

Many	O
of	O
the	O
Kn(a-)	O
exhibited	O
the	O
Knops-null	O
phenotype	O
,	O
that	O
is	O
,	O
Helgeson	O
.	O

The	O
Kna/b	O
DNA	O
polymorphism	O
was	O
identified	O
as	O
a	O
V1561M	B-ProteinMutation
mutation	O
with	O
allele	O
frequencies	O
of	O
Kna	O
(V1561)	O
0.9	O
and	O
Knb	O
(M1561)	O
0.1	O
.	O

CONCLUSION	O
:	O
The	O
high	O
frequency	O
(18%)	O
of	O
Knb	O
in	O
West	O
African	O
persons	O
suggests	O
that	O
it	O
is	O
not	O
solely	O
a	O
Caucasian	O
trait	O
.	O

Furthermore	O
,	O
because	O
of	O
the	O
high	O
incidence	O
of	O
heterozygosity	O
as	O
well	O
as	O
amorphs	O
,	O
accurate	O
Knops	O
typing	O
of	O
donors	O
of	O
African	O
descent	O
is	O
best	O
accomplished	O
by	O
a	O
combination	O
of	O
molecular	O
and	O
serologic	O
techniques	O
.	O

Two	O
novel	O
severe	O
mutations	O
in	O
the	O
pancreatic	O
secretory	O
trypsin	O
inhibitor	O
gene	O
(SPINK1)	O
cause	O
familial	O
and/or	O
hereditary	O
pancreatitis	O
.	O

Mutations	O
in	O
the	O
serine	O
protease	O
inhibitor	O
Kazal	O
type	O
1	O
gene	O
(SPINK1)	O
encoding	O
pancreatic	O
secretory	O
trypsin	O
inhibitor	O
(PSTI)	O
have	O
recently	O
been	O
found	O
to	O
be	O
associated	O
with	O
chronic	O
pancreatitis	O
.	O

Nevertheless	O
,	O
knowledge	O
of	O
severe	O
mutations	O
is	O
particularly	O
scarce	O
,	O
both	O
in	O
terms	O
of	O
number	O
and	O
in	O
the	O
extent	O
of	O
clinical	O
information	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
expand	O
the	O
known	O
spectrum	O
of	O
such	O
mutations	O
.	O

46	O
unrelated	O
families	O
,	O
each	O
including	O
at	O
least	O
two	O
pancreatitis	O
patients	O
and	O
carrying	O
neither	O
cationic	O
trypsinogen	O
(PRSS1)	O
mutations	O
nor	O
the	O
frequent	O
SPINK1	O
N34S	B-ProteinMutation
mutation	O
,	O
participated	O
in	O
this	O
study	O
.	O

The	O
four	O
exons	O
and	O
their	O
flanking	O
sequences	O
of	O
the	O
SPINK1	O
gene	O
were	O
screened	O
by	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
analysis	O
(DHPLC)	O
;	O
and	O
mutations	O
were	O
identified	O
by	O
direct	O
sequencing	O
.	O

A	O
heterozygous	O
microdeletion	O
mutation	O
c.27delC	B-DNAMutation
,	O
which	O
occurs	O
within	O
a	O
symmetric	O
element	O
,	O
was	O
identified	O
in	O
two	O
families	O
.	O

In	O
one	O
family	O
,	O
c.27delC	B-DNAMutation
showed	O
segregation	O
with	O
the	O
disease	O
across	O
two	O
generations	O
,	O
with	O
a	O
penetrance	O
of	O
up	O
to	O
75%	O
.	O

But	O
in	O
the	O
other	O
family	O
,	O
however	O
,	O
the	O
same	O
mutation	O
manifested	O
as	O
a	O
low-penetrance	O
susceptibility	O
factor	O
.	O

In	O
addition	O
,	O
a	O
novel	O
heterozygous	O
splicing	O
mutation	O
,	O
c.87+1G>A	B-DNAMutation
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
was	O
found	O
in	O
one	O
family	O
with	O
familial	O
pancreatitis	O
.	O

Our	O
results	O
also	O
helped	O
to	O
resolve	O
the	O
sharply	O
differing	O
views	O
about	O
PSTI's	O
role	O
in	O
pancreatitis	O
.	O

A	O
novel	O
two	O
nucleotide	O
deletion	O
in	O
the	O
apolipoprotein	O
A-I	O
gene	O
,	O
apoA-I	O
Shinbashi	O
,	O
associated	O
with	O
high	O
density	O
lipoprotein	O
deficiency	O
,	O
corneal	O
opacities	O
,	O
planar	O
xanthomas	O
,	O
and	O
premature	O
coronary	O
artery	O
disease	O
.	O

Familial	O
HDL	O
deficiency	O
(FHD)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
lipoprotein	O
disorder	O
.	O

We	O
describe	O
a	O
novel	O
genetic	O
variant	O
of	O
the	O
apolipoprotein	O
A-I	O
(apoA-I)	O
gene	O
resulting	O
in	O
FHD	O
.	O

The	O
proband	O
is	O
a	O
51-year-old	O
woman	O
who	O
was	O
hospitalized	O
due	O
to	O
severe	O
heart	O
failure	O
.	O

Her	O
plasma	O
HDL-cholesterol	O
(C)	O
and	O
apoA-I	O
concentrations	O
were	O
0.08mmol/l	O
and	O
1mg/dl	O
,	O
respectively	O
.	O

She	O
exhibited	O
corneal	O
opacities	O
and	O
planar	O
xanthomas	O
on	O
eyelids	O
and	O
elbows	O
.	O

Coronary	O
angiography	O
demonstrated	O
extensive	O
obstructions	O
in	O
two	O
major	O
vessels	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
the	O
patient's	O
apoA-I	O
gene	O
revealed	O
a	O
homozygosity	O
for	O
a	O
GC	O
deletion	O
between	O
5	O
GC	O
repeats	O
in	O
exon	O
4	O
,	O
creating	O
a	O
frameshift	O
and	O
a	O
stop	O
codon	O
at	O
residue	O
178	O
.	O

We	O
designated	O
this	O
mutation	O
as	O
apoA-I	O
Shinbashi	O
.	O

The	O
proband's	O
father	O
,	O
son	O
,	O
and	O
daughter	O
were	O
found	O
to	O
be	O
heterozygous	O
for	O
this	O
mutation	O
and	O
their	O
HDL-C	O
and	O
apoA-I	O
levels	O
were	O
about	O
half	O
of	O
normal	O
levels	O
,	O
demonstrating	O
a	O
gene	O
dosage	O
effect	O
.	O

The	O
father	O
underwent	O
coronary	O
bypass	O
surgery	O
at	O
age	O
of	O
70	O
years	O
.	O

Lecithin-cholesterol	O
acyltransferase	O
(LCAT)	O
activity	O
was	O
decreased	O
by	O
63%	O
in	O
the	O
homozygote	O
and	O
31%	O
in	O
heterozygotes	O
,	O
respectively	O
.	O

This	O
new	O
case	O
of	O
apoA-I	O
deficiency	O
,	O
apoA-I	O
Shinbashi	O
,	O
is	O
the	O
first	O
case	O
involving	O
a	O
single	O
gene	O
defect	O
of	O
the	O
apoA-I	O
gene	O
to	O
develop	O
all	O
the	O
characteristics	O
for	O
apoA-I	O
deficiency	O
,	O
including	O
premature	O
coronary	O
heart	O
disease	O
.	O

Gonadal	O
mosaicism	O
in	O
severe	O
Pallister-Hall	O
syndrome	O
.	O

Pallister-Hall	O
syndrome	O
(	O
PHS	O
,	O
MIM	O
#146510	O
)	O
is	O
characterized	O
by	O
central	O
and	O
postaxial	O
polydactyly	O
,	O
hypothalamic	O
hamartoma	O
(HH)	O
,	O
bifid	O
epiglottis	O
,	O
imperforate	O
anus	O
,	O
renal	O
abnormalities	O
,	O
and	O
pulmonary	O
segmentation	O
anomalies	O
.	O

It	O
is	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
.	O

Here	O
,	O
we	O
describe	O
a	O
family	O
with	O
two	O
affected	O
children	O
manifesting	O
severe	O
PHS	O
with	O
mental	O
retardation	O
,	O
behavioral	O
problems	O
,	O
and	O
intractable	O
seizures	O
.	O

Both	O
parents	O
are	O
healthy	O
,	O
with	O
normal	O
intelligence	O
,	O
and	O
have	O
no	O
malformations	O
on	O
physical	O
,	O
laryngoscopic	O
,	O
and	O
cranial	O
MRI	O
exam	O
.	O

The	O
atypical	O
presentation	O
of	O
these	O
children	O
and	O
the	O
absence	O
of	O
parental	O
manifestations	O
suggested	O
an	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
or	O
gonadal	O
mosaicism	O
.	O

Sequencing	O
of	O
GLI3	O
revealed	O
a	O
two	O
nucleotide	O
deletion	O
in	O
exon	O
15	O
c.3385_3386delTT	B-DNAMutation
predicting	O
a	O
frameshift	O
and	O
premature	O
stop	O
at	O
codon	O
1129	O
p.F1129X	B-ProteinMutation
in	O
the	O
children	O
while	O
both	O
parents	O
have	O
wild	O
type	O
alleles	O
.	O

Genotyping	O
with	O
GLI3	O
intragenic	O
markers	O
revealed	O
that	O
both	O
children	O
inherited	O
the	O
abnormal	O
allele	O
from	O
their	O
mother	O
thus	O
supporting	O
gonadal	O
mosaicism	O
as	O
the	O
underlying	O
mechanism	O
of	O
inheritance	O
(	O
paternity	O
was	O
confirmed	O
)	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
gonadal	O
mosaicism	O
in	O
PHS	O
.	O

The	O
severe	O
CNS	O
manifestations	O
of	O
these	O
children	O
are	O
reminiscent	O
of	O
children	O
with	O
non-syndromic	O
HH	O
who	O
often	O
have	O
progressive	O
mental	O
retardation	O
with	O
behavioral	O
problems	O
and	O
intractable	O
seizures	O
.	O

We	O
conclude	O
that	O
the	O
phenotypic	O
spectrum	O
of	O
PHS	O
can	O
include	O
severe	O
CNS	O
manifestations	O
and	O
that	O
recurrence	O
risks	O
for	O
PHS	O
should	O
include	O
a	O
proviso	O
for	O
gonadal	O
mosaicism	O
,	O
though	O
the	O
frequency	O
cannot	O
be	O
calculated	O
from	O
a	O
single	O
case	O
report	O
.	O

Published	O
2003	O
Wiley-Liss	O
,	O
Inc	O
.	O

High-resolution	O
deletion	O
mapping	O
of	O
15q13.2-q21.1	O
in	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
.	O

Deletions	O
found	O
in	O
several	O
types	O
of	O
human	O
tumor	O
,	O
including	O
carcinomas	O
of	O
the	O
colorectum	O
,	O
breast	O
,	O
and	O
lung	O
,	O
suggest	O
the	O
presence	O
of	O
a	O
potential	O
tumor	O
suppressor	O
gene(s)	O
on	O
chromosome	O
15	O
.	O

Common	O
regions	O
of	O
deletion	O
in	O
these	O
tumors	O
are	O
at	O
15q15	O
and	O
15q21	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
loss	O
of	O
heterozygosity	O
(LOH)	O
on	O
chromosome	O
15	O
to	O
ascertain	O
its	O
potential	O
involvement	O
in	O
the	O
development	O
and	O
progression	O
of	O
transitional	O
cell	O
carcinoma	O
(TCC)	O
of	O
the	O
bladder	O
.	O

A	O
panel	O
of	O
26	O
polymorphic	O
markers	O
,	O
spanning	O
15q12-15q22	O
,	O
were	O
used	O
to	O
map	O
regions	O
of	O
LOH	O
in	O
51	O
TCCs	O
.	O

LOH	O
was	O
found	O
for	O
at	O
least	O
one	O
marker	O
in	O
the	O
region	O
15q14-15q15.3	O
in	O
20	O
of	O
51	O
(39%)	O
tumors	O
.	O

Deletion	O
mapping	O
defined	O
two	O
minimum	O
regions	O
of	O
deletion	O
:	O
a	O
distal	O
region	O
between	O
the	O
markers	O
D15S514	O
and	O
D15S537	O
at	O
15q15.1-15q15.3	O
(	O
estimated	O
as	O
3	O
Mb	O
)	O
and	O
a	O
more	O
proximal	O
region	O
between	O
the	O
markers	O
D15S971	O
and	O
D15S1042	O
at	O
15q14	O
(	O
estimated	O
as	O
1.1	O
Mb	O
)	O
.	O

Analysis	O
of	O
a	O
panel	O
of	O
33	O
bladder	O
tumor	O
cell	O
lines	O
revealed	O
regions	O
of	O
contiguous	O
homozygosity	O
for	O
markers	O
in	O
15q15	O
,	O
indicating	O
likely	O
LOH	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
mitotic	O
recombination	O
is	O
the	O
predicted	O
mechanism	O
of	O
LOH	O
in	O
two	O
of	O
these	O
.	O

These	O
regions	O
of	O
LOH	O
on	O
15q	O
may	O
contain	O
tumor	O
suppressor	O
genes	O
the	O
loss	O
or	O
inactivation	O
of	O
which	O
is	O
associated	O
with	O
TCC	O
development	O
.	O

The	O
DNA	O
repair	O
gene	O
RAD51	O
at	O
15q15.1	O
represents	O
a	O
candidate	O
15q	O
tumor	O
suppressor	O
gene	O
.	O

Expression	O
analysis	O
of	O
rad51	O
protein	O
in	O
tumor	O
cell	O
lines	O
revealed	O
variable	O
levels	O
of	O
expression	O
but	O
no	O
significant	O
loss	O
of	O
expression	O
in	O
cell	O
lines	O
with	O
likely	O
15q	O
LOH	O
.	O

Muscle	O
glycogenosis	O
and	O
mitochondrial	O
hepatopathy	O
in	O
an	O
infant	O
with	O
mutations	O
in	O
both	O
the	O
myophosphorylase	O
and	O
deoxyguanosine	O
kinase	O
genes	O
.	O

OBJECTIVES	O
:	O
To	O
document	O
2	O
apparently	O
incongruous	O
clinical	O
disorders	O
occurring	O
in	O
the	O
same	O
infant	O
:	O
congenital	O
myopathy	O
with	O
myophosphorylase	O
deficiency	O
(	O
McArdle	O
disease	O
)	O
and	O
mitochondrial	O
hepatopathy	O
with	O
liver	O
failure	O
and	O
mitochondrial	O
DNA	O
depletion	O
.	O

METHODS	O
:	O
An	O
infant	O
girl	O
born	O
to	O
consanguineous	O
Moroccan	O
parents	O
had	O
severe	O
congenital	O
hypotonia	O
and	O
hepatomegaly	O
,	O
developed	O
liver	O
failure	O
,	O
and	O
died	O
at	O
5	O
months	O
of	O
age	O
.	O

We	O
studied	O
muscle	O
and	O
liver	O
biopsy	O
specimens	O
histochemically	O
and	O
biochemically	O
,	O
and	O
we	O
sequenced	O
the	O
whole	O
coding	O
regions	O
of	O
the	O
deoxyguanosine	O
kinase	O
(dGK)	O
and	O
myophosphorylase	O
(PYGM)	O
genes	O
.	O

RESULTS	O
:	O
Muscle	O
biopsy	O
specimens	O
showed	O
subsarcolemmal	O
glycogen	O
accumulation	O
and	O
negative	O
histochemical	O
reaction	O
for	O
phosphorylase	O
.	O

Liver	O
biopsy	O
specimens	O
showed	O
micronodular	O
cirrhosis	O
and	O
massive	O
mitochondrial	O
proliferation	O
.	O

Biochemical	O
analysis	O
showed	O
phosphorylase	O
deficiency	O
in	O
muscle	O
and	O
cytochrome	O
c	O
oxidase	O
deficiency	O
in	O
liver	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
missense	O
G-to-A	O
mutation	O
at	O
codon	O
456	O
in	O
exon	O
11	O
of	O
PYGM	O
,	O
as	O
well	O
as	O
a	O
homozygous	O
4-base	O
pair	O
GATT	O
duplication	O
(	O
nucleotides	O
763-766	O
)	O
in	O
exon	O
6	O
of	O
dGK	O
,	O
which	O
produces	O
a	O
frame	O
shift	O
and	O
a	O
premature	O
TGA	O
stop	O
codon	O
at	O
nucleotides	O
766	O
to	O
768	O
,	O
resulting	O
in	O
a	O
truncated	O
255-amino	O
acid	O
protein	O
.	O

Both	O
mutations	O
were	O
absent	O
in	O
100	O
healthy	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
further	O
expand	O
the	O
genetic	O
heterogeneity	O
in	O
patients	O
with	O
McArdle	O
disease	O
;	O
confirm	O
the	O
strong	O
relationship	O
between	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
,	O
liver	O
involvement	O
,	O
and	O
dGK	O
mutations	O
;	O
and	O
suggest	O
that	O
genetic	O
"double	O
trouble"	O
should	O
be	O
considered	O
in	O
patients	O
with	O
unusual	O
severe	O
phenotypes	O
.	O

Association	O
of	O
microsomal	O
epoxide	O
hydrolase	O
polymorphisms	O
and	O
lung	O
cancer	O
risk	O
.	O

Microsomal	O
epoxide	O
hydrolase	O
(mEH)	O
plays	O
a	O
dual	O
role	O
in	O
the	O
detoxification	O
and	O
activation	O
of	O
tobacco	O
procarcinogens	O
.	O

Two	O
polymorphisms	O
affecting	O
enzyme	O
activity	O
have	O
been	O
described	O
in	O
the	O
exons	O
3	O
and	O
4	O
of	O
the	O
mEH	O
gene	O
,	O
which	O
result	O
in	O
the	O
substitution	O
of	O
amino	O
acids	O
histidine	O
to	O
tyrosine	O
at	O
residue	O
113	O
,	O
and	O
arginine	O
to	O
histidine	O
at	O
residue	O
139	O
,	O
respectively	O
.	O

We	O
performed	O
a	O
hospital-based	O
case-control	O
study	O
consisting	O
of	O
277	O
newly	O
diagnosed	O
lung	O
cancer	O
patients	O
and	O
496	O
control	O
subjects	O
to	O
investigate	O
a	O
possible	O
association	O
between	O
these	O
two	O
polymorphisms	O
and	O
lung	O
cancer	O
risk	O
.	O

The	O
polymorphisms	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction/restriction	O
fragment	O
length	O
polymorphism	O
and	O
TaqMan	O
assay	O
using	O
DNA	O
from	O
peripheral	O
white	O
blood	O
cells	O
.	O

Logistic	O
regression	O
was	O
performed	O
to	O
calculate	O
odds	O
ratios	O
(ORs)	O
,	O
confidence	O
limits	O
(CL)	O
and	O
to	O
control	O
for	O
possible	O
confounders	O
.	O

The	O
exon	O
3	O
polymorphism	O
of	O
the	O
mEH	O
gene	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
risk	O
of	O
lung	O
cancer	O
.	O

The	O
adjusted	O
OR	O
,	O
calculated	O
relative	O
to	O
subjects	O
with	O
the	O
Tyr113/Tyr113	O
wild	O
type	O
,	O
for	O
the	O
His113/His113	O
genotype	O
was	O
0.38	O
(	O
95%	O
CL	O
0.20-0.75	O
)	O
.	O

An	O
analysis	O
according	O
to	O
histological	O
subtypes	O
revealed	O
a	O
statistically	O
significant	O
association	O
for	O
adenocarcinomas	O
;	O
the	O
adjusted	O
OR	O
for	O
the	O
His113/His113	O
genotype	O
was	O
0.40	O
(	O
95%	O
CL	O
0.17-0.94	O
)	O
.	O

In	O
contrast	O
,	O
no	O
relationship	O
between	O
the	O
exon	O
4	O
polymorphism	O
and	O
lung	O
cancer	O
risk	O
was	O
found	O
.	O

The	O
adjusted	O
OR	O
,	O
calculated	O
relative	O
to	O
the	O
His139/His139	O
wild	O
type	O
,	O
was	O
for	O
the	O
Arg139/Arg139	O
genotype	O
1.83	O
(0.76-4.44)	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
genetically	O
reduced	O
mEH	O
activity	O
may	O
be	O
protective	O
against	O
lung	O
cancer	O
.	O

Detection	O
of	O
PHKA2	O
gene	O
mutation	O
in	O
four	O
Japanese	O
patients	O
with	O
hepatic	O
phosphorylase	O
kinase	O
deficiency	O
.	O

We	O
analyzed	O
the	O
PHKA2	O
gene	O
in	O
four	O
Japanese	O
families	O
with	O
hepatic	O
phosphorylase	O
kinase	O
(PhK)	O
deficiency	O
.	O

Mutational	O
analysis	O
of	O
PHKA2	O
cDNA	O
was	O
performed	O
by	O
reverse-transcribed	O
polymerase	O
chain	O
reaction	O
(RT-PCR)	O
and	O
direct	O
sequencing	O
,	O
and	O
each	O
mutation	O
was	O
confirmed	O
on	O
the	O
genomic	O
DNA	O
.	O

In	O
boys	O
with	O
low	O
erythrocyte	O
PhK	O
activity	O
(	O
i.e.	O
,	O
x-linked	O
liver	O
glycogenosis	O
[XLG]	O
type	O
I	O
)	O
,	O
deletion	O
of	O
exon	O
2	O
(	O
splice	O
site	O
mutation	O
of	O
79-1	B-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
)	O
or	O
nonsense	O
mutation	O
of	O
Q1169X	B-ProteinMutation
or	O
R497X	B-ProteinMutation
was	O
identified	O
.	O

However	O
,	O
missense	O
mutation	O
of	O
R295C	B-ProteinMutation
was	O
identified	O
in	O
one	O
boy	O
with	O
normal	O
erythrocyte	O
PhK	O
activity	O
(	O
i.e.	O
,	O
XLG	O
type	O
II	O
)	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
100	O
control	O
alleles	O
,	O
and	O
was	O
considered	O
responsible	O
for	O
presentation	O
of	O
the	O
XLG	O
type	O
II	O
phenotype	O
.	O

Excluding	O
Q1169X	B-ProteinMutation
,	O
all	O
mutations	O
detected	O
in	O
this	O
study	O
represented	O
novel	O
mutations	O
.	O

All	O
mothers	O
were	O
found	O
to	O
be	O
heterozygous	O
carriers	O
of	O
the	O
mutations	O
.	O

Gene	O
analysis	O
was	O
confirmed	O
to	O
represent	O
a	O
useful	O
procedure	O
for	O
diagnosing	O
XLG	O
type	O
II	O
,	O
for	O
which	O
liver	O
biopsy	O
had	O
previously	O
been	O
required	O
to	O
detect	O
hepatic	O
PhK	O
deficiency	O
.	O

Mutation	O
analysis	O
of	O
SLC7A9	O
in	O
cystinuria	O
patients	O
in	O
Sweden	O
.	O

Cystinuria	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
increased	O
urinary	O
excretion	O
of	O
cystine	O
and	O
dibasic	O
amino	O
acids	O
,	O
which	O
cause	O
recurrent	O
stone	O
formation	O
in	O
affected	O
individuals	O
.	O

Three	O
subtypes	O
of	O
cystinuria	O
have	O
been	O
described	O
(	O
type	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
:	O
type	O
I	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SLC3A1	O
gene	O
,	O
whereas	O
nontype	O
I	O
(	O
II	O
and	O
III	O
)	O
has	O
been	O
associated	O
with	O
SLC7A9	O
mutations	O
.	O

Of	O
the	O
53	O
patients	O
reported	O
in	O
our	O
previous	O
work	O
,	O
patients	O
that	O
showed	O
SLC7A9	O
mutations	O
in	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
screening	O
and/or	O
either	O
lacked	O
or	O
showed	O
heterozygosity	O
for	O
SLC3A1	O
mutations	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

The	O
entire	O
coding	O
region	O
and	O
the	O
exon/intron	O
boundaries	O
of	O
the	O
SLC7A9	O
gene	O
were	O
analyzed	O
by	O
means	O
of	O
both	O
SSCP	O
and	O
DNA	O
sequencing	O
in	O
16	O
patients	O
,	O
all	O
but	O
one	O
of	O
which	O
were	O
clinically	O
diagnosed	O
as	O
homozygous	O
cystinurics	O
.	O

Three	O
novel	O
SLC7A9	O
mutations	O
were	O
identified	O
in	O
the	O
patient	O
group	O
:	O
two	O
missense	O
mutations	O
(	O
P261L	B-ProteinMutation
and	O
V330M	B-ProteinMutation
)	O
,	O
and	O
one	O
single	O
base-pair	O
deletion	O
(	O
1009	B-DNAMutation
delA	I-DNAMutation
)	O
.	O

We	O
also	O
detected	O
the	O
previously	O
reported	O
A182T	B-ProteinMutation
and	O
nine	O
novel	O
polymorphisms	O
in	O
the	O
patients	O
.	O

Mutations	O
V330M	B-ProteinMutation
and	O
1009delA	B-DNAMutation
occurred	O
on	O
different	O
alleles	O
in	O
one	O
individual	O
,	O
and	O
we	O
suggest	O
that	O
these	O
mutations	O
cause	O
cystinuria	O
in	O
this	O
patient	O
.	O

One	O
patient	O
that	O
was	O
homozygously	O
mutated	O
in	O
the	O
SLC3A1	O
gene	O
carried	O
the	O
third	O
novel	O
mutation	O
P261L	B-ProteinMutation
.	O

We	O
conclude	O
that	O
SLC3A1	O
is	O
still	O
the	O
major	O
disease	O
gene	O
among	O
Swedish	O
cystinuria	O
patients	O
,	O
with	O
only	O
a	O
minor	O
contribution	O
of	O
SLC7A9	O
mutations	O
as	O
the	O
genetic	O
basis	O
of	O
cystinuria	O
.	O

The	O
absence	O
of	O
SLC3A1	O
and	O
SLC7A9	O
mutations	O
in	O
a	O
substantial	O
proportion	O
of	O
the	O
patients	O
implies	O
that	O
mutations	O
in	O
parts	O
of	O
the	O
genes	O
that	O
were	O
not	O
analyzed	O
may	O
be	O
present	O
,	O
as	O
well	O
as	O
large	O
deletions	O
that	O
escape	O
detection	O
by	O
the	O
methods	O
used	O
.	O

However	O
,	O
our	O
results	O
raise	O
the	O
question	O
of	O
whether	O
other	O
,	O
as	O
yet	O
unknown	O
genes	O
,	O
may	O
also	O
be	O
involved	O
in	O
cystinuria	O
.	O

A	O
cluster	O
of	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
caused	O
by	O
three	O
newly	O
identified	O
DLL3	O
mutations	O
segregating	O
in	O
a	O
small	O
village	O
.	O

In	O
1982	O
,	O
one	O
of	O
us	O
reported	O
a	O
cluster	O
of	O
eight	O
individuals	O
affected	O
by	O
spondylocostal	O
dysostosis	O
(	O
SD	O
,	O
MIM	O
277300	O
)	O
in	O
four	O
nuclear	O
families	O
indigenous	O
to	O
a	O
village	O
from	O
eastern	O
Switzerland	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
molecular	O
basis	O
for	O
this	O
cluster	O
was	O
segregation	O
of	O
a	O
single	O
mutation	O
in	O
the	O
DLL3	O
gene	O
,	O
recently	O
linked	O
to	O
SD	O
.	O

Marker	O
haplotypes	O
around	O
the	O
DLL3	O
locus	O
contradicted	O
this	O
hypothesis	O
as	O
three	O
different	O
haplotypes	O
were	O
seen	O
in	O
affected	O
individuals	O
,	O
but	O
sequence	O
analysis	O
showed	O
that	O
three	O
unreported	O
DLL3	O
mutations	O
were	O
segregating	O
:	O
a	O
duplication	O
of	O
17	O
bp	O
in	O
exon	O
8	O
c.1285-1301dup	B-DNAMutation
,	O
a	O
single-nucleotide	O
deletion	O
in	O
exon	O
5	O
c.615delC	B-DNAMutation
,	O
and	O
a	O
R238X	B-ProteinMutation
nonsense	O
mutation	O
in	O
exon	O
6	O
.	O

Contrary	O
to	O
our	O
initial	O
assumption	O
of	O
a	O
single	O
allele	O
segregating	O
in	O
this	O
small	O
community	O
,	O
three	O
different	O
pathogenic	O
alleles	O
were	O
observed	O
,	O
with	O
a	O
putative	O
founder	O
mutation	O
occurring	O
at	O
the	O
homozygous	O
state	O
but	O
also	O
compounding	O
with	O
,	O
and	O
thus	O
revealing	O
,	O
two	O
other	O
independent	O
mutations	O
.	O

As	O
all	O
three	O
mutations	O
predict	O
truncation	O
of	O
the	O
DLL3	O
protein	O
and	O
loss	O
of	O
the	O
membrane-attaching	O
domain	O
,	O
the	O
results	O
confirm	O
that	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
represents	O
the	O
null	O
phenotype	O
of	O
DLL3	O
,	O
with	O
remarkable	O
phenotypic	O
consistency	O
across	O
families	O
.	O

A	O
"null	O
allele"	O
mutation	O
is	O
responsible	O
for	O
erythropoietic	O
protoporphyria	O
in	O
an	O
Israeli	O
patient	O
who	O
underwent	O
liver	O
transplantation	O
:	O
relationships	O
among	O
biochemical	O
,	O
clinical	O
,	O
and	O
genetic	O
parameters	O
.	O

Mutations	O
in	O
the	O
human	O
ferrochelatase	O
gene	O
(FECH)	O
are	O
the	O
primary	O
cause	O
of	O
the	O
inborn	O
disorder	O
erythropoietic	O
protoporphyria	O
(EPP)	O
.	O

While	O
the	O
majority	O
of	O
the	O
EPP	O
patients	O
exhibit	O
only	O
photosensitivity	O
,	O
a	O
small	O
percentage	O
of	O
patients	O
(	O
approximately	O
2%	O
)	O
develop	O
liver	O
complications	O
in	O
addition	O
to	O
the	O
cutaneous	O
symptoms	O
.	O

In	O
this	O
study	O
,	O
the	O
FECH	O
gene	O
of	O
an	O
Israeli	O
EPP	O
patient	O
who	O
suffered	O
from	O
EPP-related	O
liver	O
complications	O
was	O
sequenced	O
.	O

A	O
splicing	O
defect	O
IVS10+1	B-DNAMutation
,	I-DNAMutation
g-->t	I-DNAMutation
,	O
which	O
is	O
known	O
to	O
cause	O
the	O
deletion	O
of	O
exon	O
10	O
,	O
was	O
identified	O
in	O
the	O
index	O
patient	O
as	O
well	O
as	O
in	O
his	O
symptomatic	O
older	O
sister	O
and	O
his	O
asymptomatic	O
mother	O
.	O

Like	O
the	O
other	O
12	O
known	O
FECH	O
mutations	O
associated	O
with	O
liver	O
complications	O
,	O
IVS10+1	B-DNAMutation
,	I-DNAMutation
g-->t	I-DNAMutation
is	O
a	O
"null-allele"	O
mutation	O
.	O

Although	O
the	O
two	O
siblings	O
with	O
overt	O
EPP	O
share	O
an	O
identical	O
genotype	O
with	O
respect	O
to	O
both	O
the	O
mutation	O
on	O
one	O
FECH	O
allele	O
and	O
three	O
intragenic	O
single	O
nucleotide	O
polymorphisms	O
,	O
-251G	B-DNAMutation
,	O
IVS1-23T	B-DNAMutation
,	O
and	O
IVS3-48C	B-DNAMutation
on	O
the	O
other	O
allele	O
,	O
the	O
sister	O
of	O
the	O
index	O
patient	O
has	O
so	O
far	O
shown	O
no	O
signs	O
of	O
liver	O
involvement	O
,	O
suggesting	O
that	O
additional	O
factors	O
might	O
account	O
for	O
the	O
liver	O
disease	O
in	O
EPP	O
.	O

A	O
novel	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
(	O
P450	O
17alpha-hydroxylase	O
)	O
gene	O
leading	O
to	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Mutations	O
in	O
the	O
CYP17	O
gene	O
impair	O
steroid	O
biosynthesis	O
in	O
the	O
adrenals	O
and	O
gonads	O
and	O
often	O
cause	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
,	O
leading	O
to	O
amenorrhea	O
,	O
sexual	O
infantilism	O
,	O
and	O
hypokalemic	O
low	O
aldosterone	O
hypertension	O
.	O

Several	O
CYP17	O
mutations	O
resulting	O
in	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
have	O
been	O
reported	O
previously	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
a	O
novel	O
CYP17	O
mutation	O
from	O
the	O
molecular	O
analysis	O
of	O
a	O
Korean	O
patient	O
with	O
primary	O
amenorrhea	O
with	O
a	O
46,XX	O
karyotype	O
,	O
and	O
hypokalemic	O
hypertension	O
.	O

We	O
sequenced	O
all	O
8	O
exons	O
of	O
the	O
CYP17	O
gene	O
that	O
were	O
amplified	O
from	O
patient's	O
genomic	O
DNA	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
found	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
structural	O
gene	O
;	O
a	O
1-base	O
deletion	O
and	O
a	O
1-base	O
transversion	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
,	O
leading	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
(	O
1-417	O
amino	O
acids	O
)	O
,	O
and	O
a	O
3-base	O
deletion	O
(	O
TCC	O
,	O
either	O
350-351	O
or	O
351-352	O
codon	O
)	O
in	O
the	O
other	O
allele	O
.	O

Restriction	O
enzyme	O
digestion	O
analysis	O
of	O
patient's	O
and	O
parental	O
DNA	O
showed	O
that	O
the	O
1-base	O
deletion	O
and	O
the	O
3-base	O
deletion	O
are	O
inherited	O
from	O
mother	O
and	O
father	O
,	O
respectively	O
.	O

Here	O
we	O
conclude	O
that	O
these	O
novel	O
compound	O
heterozygous	O
mutations	O
might	O
account	O
for	O
the	O
patient's	O
clinical	O
manifestations	O
of	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Haplotypes	O
extending	O
across	O
ACE	O
are	O
associated	O
with	O
Alzheimer's	O
disease	O
.	O

Numerous	O
genes	O
have	O
been	O
implicated	O
in	O
Alzheimer's	O
disease	O
(AD)	O
,	O
but	O
,	O
with	O
the	O
exception	O
of	O
a	O
demonstrated	O
association	O
with	O
the	O
epsilon	O
4	O
allele	O
of	O
APOE	O
,	O
findings	O
have	O
not	O
been	O
consistently	O
replicated	O
across	O
populations	O
.	O

One	O
of	O
the	O
most	O
widely	O
studied	O
is	O
the	O
gene	O
for	O
angiotensin	O
I	O
converting	O
enzyme	O
(	O
ACE	O
)	O
.	O

A	O
meta-analysis	O
of	O
published	O
data	O
on	O
a	O
common	O
Alu	O
indel	O
polymorphism	O
in	O
ACE	O
was	O
performed	O
which	O
indicated	O
highly	O
significant	O
association	O
of	O
the	O
insertion	O
allele	O
with	O
AD	O
(	O
OR	O
1.30	O
;	O
95%	O
CI	O
1.19	O
-	O
1.41	O
;	O
P=4	O
x	O
10(-8)	O
)	O
.	O

To	O
further	O
explore	O
the	O
influence	O
of	O
ACE	O
on	O
AD	O
,	O
several	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
genotyped	O
in	O
five	O
independent	O
populations	O
represented	O
by	O
over	O
3100	O
individuals	O
.	O

Analyses	O
based	O
upon	O
single	O
markers	O
and	O
haplotypes	O
revealed	O
strong	O
evidence	O
of	O
association	O
in	O
case-control	O
models	O
and	O
also	O
in	O
a	O
model	O
examining	O
the	O
influence	O
of	O
variation	O
in	O
ACE	O
upon	O
cerebrospinal	O
fluid	O
levels	O
of	O
amyloid	O
beta42	O
peptide	O
(Abeta42)	O
.	O

The	O
most	O
significant	O
evidence	O
for	O
association	O
with	O
AD	O
was	O
found	O
for	O
an	O
SNP	O
,	O
A-262T	B-DNAMutation
,	O
located	O
in	O
the	O
ACE	O
promoter	O
(	O
OR	O
1.64	O
;	O
95%	O
CI	O
1.33	O
-1.94	O
;	O
P=2	O
x	O
10(-5)	O
)	O
.	O

Estimates	O
of	O
population	O
attributable	O
risk	O
for	O
the	O
common	O
allele	O
of	O
this	O
SNP	O
suggest	O
that	O
it	O
,	O
or	O
an	O
allele	O
in	O
tight	O
linkage	O
disequilibrium	O
(LD)	O
with	O
it	O
,	O
may	O
contribute	O
to	O
as	O
much	O
as	O
35%	O
of	O
AD	O
in	O
the	O
general	O
population	O
.	O

Results	O
support	O
a	O
model	O
whereby	O
decreased	O
ACE	O
activity	O
may	O
influence	O
AD	O
susceptibility	O
by	O
a	O
mechanism	O
involving	O
beta-amyloid	O
metabolism	O
.	O

Identification	O
of	O
new	O
polymorphisms	O
in	O
the	O
CACNA1S	O
gene	O
.	O

We	O
identified	O
four	O
novel	O
polymorphisms	O
in	O
the	O
CACNA1S	O
gene	O
that	O
encodes	O
the	O
alpha1-subunit	O
of	O
the	O
dihydropyridine	O
receptor	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
associated	O
with	O
two	O
genetic	O
diseases	O
:	O
malignant	O
hyperthermia	O
and	O
hypokalemic	O
periodic	O
paralysis	O
.	O

The	O
nucleotide	O
substitutions	O
c2403T	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
and	O
c5398T	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
did	O
not	O
result	O
in	O
amino	O
acid	O
replacement	O
,	O
the	O
nucleotide	O
substitution	O
c4475C	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
caused	O
the	O
replacement	O
of	O
the	O
Ala1492	O
with	O
an	O
Asp	O
residue	O
and	O
an	O
A	O
insertion	O
was	O
identified	O
in	O
intron	O
36	O
.	O

By	O
using	O
methods	O
based	O
on	O
digestion	O
with	O
restriction	O
enzymes	O
we	O
calculated	O
the	O
frequencies	O
of	O
these	O
novel	O
polymorphisms	O
,	O
as	O
well	O
as	O
heterozygosity	O
,	O
in	O
normal	O
subjects	O
from	O
southern	O
Italy	O
.	O

Association	O
of	O
an	O
IL-1A	O
3'UTR	O
polymorphism	O
with	O
end-stage	O
renal	O
disease	O
and	O
IL-1	O
alpha	O
expression	O
.	O

BACKGROUND	O
:	O
We	O
evaluated	O
polymorphisms	O
in	O
the	O
interleukin-1	O
alpha	O
3'-untranslated	O
region	O
(	O
IL-1A	O
3'[UTR]	O
)	O
for	O
association	O
with	O
type	O
2	O
diabetes-associated	O
(DM)	O
and	O
nondiabetic-associated	O
(non-DM)	O
end-stage	O
renal	O
disease	O
(ESRD)	O
in	O
two	O
ethnic	O
groups	O
.	O

METHODS	O
:	O
IL-1A	O
3'UTR	O
polymorphisms	O
were	O
identified	O
by	O
alignment	O
of	O
overlapping	O
human	O
expressed	O
sequence	O
tags	O
(ESTs)	O
.	O

Sequence	O
ambiguities	O
were	O
experimentally	O
confirmed	O
and	O
variants	O
genotyped	O
to	O
test	O
for	O
association	O
with	O
ESRD	O
in	O
75	O
unrelated	O
Caucasians	O
with	O
DM	O
ESRD	O
,	O
95	O
unrelated	O
Caucasian	O
controls	O
and	O
,	O
in	O
a	O
parallel	O
study	O
,	O
92	O
unrelated	O
African	O
Americans	O
with	O
type	O
2	O
DM	O
ESRD	O
,	O
95	O
unrelated	O
African	O
Americans	O
with	O
non-DM	O
ESRD	O
,	O
and	O
86	O
unrelated	O
African	O
American	O
controls	O
.	O

IL-1A	O
3'	O
UTR	O
genotype	O
and	O
lipopolysaccharide	O
(LPS)-stimulated	O
IL-1	O
alpha	O
protein	O
levels	O
were	O
measured	O
in	O
healthy	O
Caucasians	O
(	O
N	O
=	O
112	O
)	O
and	O
African	O
Americans	O
(	O
N	O
=	O
101	O
)	O
to	O
evaluate	O
association	O
between	O
genotype	O
and	O
protein	O
level	O
.	O

RESULTS	O
:	O
A	O
polymorphism	O
in	O
the	O
3'	O
UTR	O
of	O
the	O
human	O
IL-1A	O
gene	O
was	O
associated	O
with	O
ESRD	O
and	O
IL-1	O
alpha	O
protein	O
expression	O
.	O

The	O
polymorphism	O
consists	O
of	O
two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
an	O
insertion/deletion	O
generating	O
four	O
different	O
haplotypes	O
:	O
TN7TTCAA	O
,	O
AN7TTCAA	O
,	O
TN7TTCAG	O
and	O
an	O
allele	O
deleted	O
for	O
four	O
internal	O
bases	O
,	O
TN7(delTTCA)A	B-DNAMutation
.	O

The	O
4	O
bp	O
deletion	O
allele	O
,	O
TN7(delTTCA)A	B-DNAMutation
,	O
was	O
significantly	O
less	O
common	O
among	O
Caucasian	O
DM	O
ESRD	O
and	O
African	O
American	O
non-DM	O
ESRD	O
patients	O
(	O
recessive	O
model	O
;	O
P	O
=	O
0.0364	O
and	O
P	O
=	O
0.0293	O
,	O
respectively	O
)	O
.	O

In	O
vitro	O
,	O
this	O
polymorphism	O
is	O
associated	O
with	O
the	O
amount	O
of	O
IL-1	O
alpha	O
protein	O
synthesized	O
in	O
LPS-stimulated	O
lymphocytes	O
from	O
healthy	O
subjects	O
(	O
P	O
=	O
0.0013	O
,	O
additive	O
model	O
)	O
,	O
with	O
the	O
TN7(delTTCA)A	B-DNAMutation
haplotype	O
associated	O
with	O
higher	O
levels	O
of	O
stimulated	O
IL-1	O
alpha	O
.	O

CONCLUSION	O
:	O
The	O
association	O
of	O
the	O
TN7(delTTCA)A	B-DNAMutation
haplotype	O
with	O
higher	O
levels	O
of	O
IL-1	O
alpha	O
expression	O
and	O
reduced	O
risk	O
for	O
ESRD	O
is	O
consistent	O
with	O
involvement	O
of	O
cytokines	O
in	O
risk	O
for	O
developing	O
nephropathy	O
.	O

The	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
gene	O
in	O
non	O
syndromic	O
hearing	O
loss	O
school	O
children	O
.	O

Recently	O
,	O
molecular	O
testing	O
for	O
GJB2	O
mutations	O
has	O
become	O
the	O
standard	O
of	O
care	O
for	O
the	O
diagnosis	O
of	O
patients	O
with	O
non	O
syndromic	O
hearing	O
impairment	O
of	O
unknown	O
cause	O
.	O

The	O
aims	O
of	O
this	O
study	O
are	O
to	O
determine	O
the	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
and	O
to	O
report	O
the	O
variation	O
of	O
mutations	O
in	O
deaf	O
students	O
who	O
have	O
heterozygous	O
GJB2	O
.	O

This	O
retrospective	O
study	O
was	O
conducted	O
at	O
Universiti	O
Kebangsaan	O
Malaysia	O
Medical	O
Center	O
(UKMMC)	O
.	O

Data	O
was	O
collected	O
from	O
previous	O
files	O
and	O
records	O
from	O
Tissue	O
Engineering	O
and	O
Human	O
Genetic	O
Research	O
Group	O
Laboratory	O
.	O

Approval	O
from	O
Ethical	O
Committee	O
was	O
obtained	O
prior	O
to	O
the	O
study	O
.	O

A	O
total	O
of	O
138	O
students	O
have	O
been	O
screened	O
in	O
previous	O
studies	O
in	O
UKMMC	O
for	O
the	O
presence	O
of	O
GJB2	O
mutations	O
as	O
a	O
cause	O
for	O
hearing	O
loss	O
.	O

Thirty	O
four	O
of	O
the	O
138	O
subjects	O
have	O
GJB2	O
mutations	O
;	O
2	O
showed	O
homozygous	O
mutations	O
whereas	O
another	O
32	O
were	O
heterozygous	O
for	O
GJB2	O
gene	O
mutation	O
.	O

Only	O
31	O
DNA	O
samples	O
of	O
students	O
presented	O
with	O
sensorineural	O
hearing	O
loss	O
with	O
heterozygous	O
mutation	O
in	O
GJB2	O
gene	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
sequencing	O
results	O
obtained	O
were	O
analyzed	O
.	O

The	O
degree	O
of	O
hearing	O
loss	O
of	O
those	O
students	O
with	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
mutation	O
will	O
be	O
discussed	O
.	O

Five	O
out	O
of	O
31	O
subjects	O
(16.2%)	O
have	O
mutations	O
in	O
their	O
GJB6	O
gene	O
,	O
suggesting	O
a	O
digenic	O
inheritance	O
of	O
GJB2/GJB6	O
mutation	O
.	O

In	O
total	O
,	O
four	O
novel	O
mutations	O
were	O
identified	O
;	O
E137D	B-ProteinMutation
(n=1)	O
,	O
R32Q	B-ProteinMutation
(n=1)	O
,	O
E101K	B-ProteinMutation
(n=1)	O
and	O
Y156H	B-ProteinMutation
(n=1)	O
and	O
one	O
mutation	O
deletion	O
;	O
366delT	B-DNAMutation
(n=1)	O
.	O

All	O
students	O
with	O
association	O
GJB2	O
mutation	O
and	O
GJB6	O
showed	O
severe	O
to	O
profound	O
hearing	O
loss	O
in	O
both	O
ears	O
.	O

Interestingly	O
this	O
study	O
not	O
detected	O
the	O
large	O
deletion	O
of	O
342	O
kb	O
in	O
GJB6	O
gene	O
suggesting	O
that	O
the	O
mutation	O
is	O
very	O
rare	O
in	O
this	O
region	O
compared	O
to	O
certain	O
parts	O
of	O
the	O
world	O
.	O

Homozygously	O
deleted	O
gene	O
DACH1	O
regulates	O
tumor-initiating	O
activity	O
of	O
glioma	O
cells	O
.	O

Loss	O
or	O
reduction	O
in	O
function	O
of	O
tumor	O
suppressor	O
genes	O
contributes	O
to	O
tumorigenesis	O
.	O

Here	O
,	O
by	O
allelic	O
DNA	O
copy	O
number	O
analysis	O
using	O
single-nucleotide	O
polymorphism	O
genotyping	O
array	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
homozygous	O
deletion	O
in	O
glioblastoma	O
multiformes	O
at	O
chromosome	O
13q21	O
,	O
where	O
DACH1	O
gene	O
is	O
located	O
.	O

We	O
found	O
decreased	O
cell	O
proliferation	O
of	O
a	O
series	O
of	O
glioma	O
cell	O
lines	O
by	O
forced	O
expression	O
of	O
DACH1	O
.	O

We	O
then	O
generated	O
U87TR-Da	O
glioma	O
cells	O
,	O
where	O
DACH1	O
expression	O
could	O
be	O
activated	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
doxycycline	O
.	O

Both	O
ex	O
vivo	O
cellular	O
proliferation	O
and	O
in	O
vivo	O
growth	O
of	O
s.c	O
.	O

transplanted	O
tumors	O
in	O
mice	O
are	O
reduced	O
in	O
U87TR-Da	O
cells	O
with	O
DACH1	O
expression	O
(U87-DACH1-high)	O
,	O
compared	O
with	O
DACH1-nonexpressing	O
U87TR-Da	O
cells	O
(U87-DACH1-low)	O
.	O

U87-DACH1-low	O
cells	O
form	O
spheroids	O
with	O
CD133	O
and	O
Nestin	O
expression	O
in	O
serum-free	O
medium	O
but	O
U87-DACH1-high	O
cells	O
do	O
not	O
.	O

Compared	O
with	O
spheroid-forming	O
U87-DACH1-low	O
cells	O
,	O
adherent	O
U87-DACH1-high	O
cells	O
display	O
lower	O
tumorigenicity	O
,	O
indicating	O
DACH1	O
decreases	O
the	O
number	O
of	O
tumor-initiating	O
cells	O
.	O

Gene	O
expression	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
reveal	O
that	O
fibroblast	O
growth	O
factor	O
2	O
(FGF2/bFGF)	O
is	O
transcriptionally	O
repressed	O
by	O
DACH1	O
,	O
especially	O
in	O
cells	O
cultured	O
in	O
serum-free	O
medium	O
.	O

Exogenous	O
bFGF	O
rescues	O
spheroid-forming	O
activity	O
and	O
tumorigenicity	O
of	O
the	O
U87-DACH1-high	O
cells	O
,	O
suggesting	O
that	O
loss	O
of	O
DACH1	O
increases	O
the	O
number	O
of	O
tumor-initiating	O
cells	O
through	O
transcriptional	O
activation	O
of	O
bFGF	O
.	O

These	O
results	O
illustrate	O
that	O
DACH1	O
is	O
a	O
distinctive	O
tumor	O
suppressor	O
,	O
which	O
does	O
not	O
only	O
suppress	O
growth	O
of	O
tumor	O
cells	O
but	O
also	O
regulates	O
bFGF-mediated	O
tumor-initiating	O
activity	O
of	O
glioma	O
cells	O
.	O

PTCH1	O
gene	O
mutations	O
in	O
exon	O
17	O
and	O
loss	O
of	O
heterozygosity	O
on	O
D9S180	O
microsatellite	O
in	O
sporadic	O
and	O
inherited	O
human	O
basal	O
cell	O
carcinomas	O
.	O

BACKGROUND	O
:	O
Basal	O
cell	O
carcinomas	O
(BCCs)	O
are	O
the	O
most	O
frequent	O
human	O
cancer	O
that	O
results	O
from	O
malignant	O
transformation	O
of	O
basal	O
cells	O
in	O
the	O
epidermis	O
.	O

Gorlin	O
syndrome	O
is	O
a	O
rare	O
inherited	O
autosomal	O
dominant	O
disease	O
that	O
predisposes	O
with	O
multiple	O
BCCs	O
and	O
other	O
birth	O
defects	O
.	O

Both	O
sporadic	O
and	O
inherited	O
BCCs	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
tumor	O
suppressor	O
gene	O
PTCH1	O
,	O
but	O
there	O
is	O
still	O
uncertainty	O
on	O
the	O
role	O
of	O
its	O
homolog	O
PTCH2	O
.	O

OBJECTIVES	O
:	O
To	O
search	O
for	O
mutations	O
and	O
genomic	O
instability	O
in	O
sporadic	O
and	O
inherited	O
BCCs	O
.	O

METHODS	O
:	O
DNA	O
obtained	O
from	O
leukocytes	O
and	O
tumor	O
cells	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
regarding	O
five	O
exons	O
of	O
PTCH1	O
and	O
PTCH2	O
and	O
neighboring	O
microsatellites	O
.	O

Exons	O
were	O
sequenced	O
and	O
compared	O
with	O
the	O
GenBank	O
database	O
.	O

RESULTS	O
:	O
Only	O
D9S180	O
,	O
of	O
six	O
microsatellites	O
,	O
showed	O
loss	O
of	O
heterozygosity	O
in	O
three	O
BCCs	O
(	O
two	O
sporadic	O
and	O
one	O
inherited	O
)	O
.	O

One	O
sporadic	O
BCC	O
presented	O
the	O
mutation	O
g.2885G>C	B-DNAMutation
in	O
exon	O
17	O
of	O
PTCH1	O
,	O
which	O
predicts	O
the	O
substitution	O
p.R962T	B-ProteinMutation
in	O
an	O
external	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
the	O
leukocytes	O
and	O
tumor	O
cells	O
of	O
one	O
patient	O
with	O
Gorlin	O
syndrome	O
showed	O
the	O
mutation	O
g.2839T>G	B-DNAMutation
in	O
the	O
same	O
exon	O
and	O
gene	O
,	O
which	O
predicts	O
a	O
p.E947stop	B-ProteinMutation
and	O
truncated	O
protein	O
.	O

All	O
control	O
and	O
tumor	O
samples	O
presented	O
IVS9	B-DNAMutation
+	I-DNAMutation
217T	I-DNAMutation
in	O
intron	O
9	O
of	O
PTCH1	O
.	O

CONCLUSION	O
:	O
Mutations	O
found	O
in	O
the	O
PTCH1	O
gene	O
and	O
neighboring	O
repetitive	O
sequences	O
may	O
have	O
contributed	O
to	O
the	O
development	O
of	O
the	O
studied	O
BCCs	O
.	O

Chasing	O
the	O
ubiquitous	O
RET	O
proto-oncogene	O
in	O
South	O
African	O
MEN2	O
families--implications	O
for	O
the	O
surgeon	O
.	O

The	O
RET	O
proto-oncogene	O
(	O
REarranged	O
during	O
Transfection	O
;	O
RET	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
causation	O
of	O
many	O
thyroid	O
tumours	O
.	O

Germline	O
RET	O
proto-oncogene	O
missense	O
mutations	O
have	O
been	O
clearly	O
linked	O
to	O
medullary	O
thyroid	O
carcinoma	O
(MTC)	O
and	O
the	O
inherited	O
cancer	O
syndrome	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
(	O
MEN2A	O
,	O
MEN2B	O
)	O
.	O

METHODS	O
:	O
We	O
investigated	O
a	O
cohort	O
of	O
MEN2-related	O
patients	O
referred	O
to	O
Tygerberg	O
Hospital	O
,	O
W	O
Cape	O
(2003-2009)	O
.	O

The	O
study	O
cohort	O
was	O
divided	O
into	O
three	O
groups	O
based	O
on	O
pathology	O
(	O
viz	O
.	O

MEN/MTC	O
,	O
phaeochromocytoma	O
,	O
and	O
a	O
miscellaneous	O
group	O
of	O
MEN	O
pathologies	O
)	O
.	O

Families	O
with	O
identified	O
high-risk	O
factors	O
were	O
recalled	O
.	O

Serum	O
calcitonin	O
levels	O
were	O
monitored	O
where	O
indicated	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
by	O
standard	O
techniques	O
and	O
polymerase	O
chain	O
reaction	O
(PCR)	O
products	O
screened	O
for	O
RET	O
gene	O
variations	O
by	O
heteroduplex	O
single-strand	O
duplication	O
techniques	O
(	O
heteroduplex	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
)	O
being	O
validated	O
with	O
automated	O
sequencing	O
techniques	O
showing	O
conformational	O
variants	O
in	O
acrylamide	O
gel	O
.	O

RESULTS	O
:	O
We	O
screened	O
40	O
persons	O
,	O
male/female	O
ratio	O
1:1.5	O
.	O

Three	O
ethnic	O
groups	O
were	O
represented	O
(	O
white	O
(12)	O
,	O
black	O
(11)	O
and	O
mixed	O
race	O
(	O
17	O
)	O
)	O
.	O

Nine	O
were	O
index	O
MTC	O
cases	O
,	O
5	O
phaeochromocytoma	O
,	O
3	O
Hirschsprung's	O
disease-MEN	O
associations	O
and	O
2	O
miscellaneous	O
(	O
1	O
neuroblastoma	O
,	O
1	O
intestinal	O
neuronal	O
dysplasia	O
)	O
,	O
while	O
1	O
fell	O
into	O
the	O
MEN2B	O
category	O
.	O

The	O
remaining	O
19	O
were	O
unaffected	O
relatives	O
screened	O
for	O
carrier	O
status	O
,	O
among	O
whom	O
afamilial	O
recurrence	O
was	O
observed	O
in	O
7	O
.	O

On	O
genetic	O
testing	O
,	O
an	O
RET	O
point	O
mutation	O
at	O
the	O
high-risk	O
634	O
cysteine	O
allele	O
was	O
identified	O
in	O
11	O
cases	O
.	O

A	O
further	O
cysteine	O
radical	O
mutation	O
at	O
the	O
620	O
position	O
was	O
related	O
to	O
MEN2	O
in	O
3	O
families	O
plus	O
1	O
other	O
family	O
referred	O
from	O
elsewhere	O
.	O

Other	O
less-recognised	O
gene	O
variations	O
were	O
detected	O
throughout	O
the	O
RET	O
gene	O
in	O
70%	O
of	O
cases	O
and	O
included	O
the	O
691	O
position	O
on	O
codon	O
11	O
(	O
11	O
cases	O
)	O
;	O
the	O
432	O
position	O
(	O
4	O
cases	O
,	O
1	O
homozygous	O
)	O
intronic	O
mutations	O
on	O
exon	O
4	O
(	O
1	O
case	O
)	O
;	O
and	O
an	O
IVS19-37G/C	B-DNAMutation
and	O
a	O
D1017N	B-ProteinMutation
variation	O
in	O
exon	O
19	O
in	O
2	O
MEN	O
families	O
.	O

Fifteen	O
MTC	O
patients	O
have	O
had	O
thyroidectomies	O
,	O
of	O
which	O
2	O
were	O
prophylactic	O
(	O
C-cell	O
hyperplasia	O
;	O
early	O
occult	O
MTC	O
)	O
.	O

A	O
further	O
3	O
are	O
awaiting	O
prophylactic	O
surgery	O
.	O

CONCLUSION	O
:	O
RET	O
gene	O
mutation	O
carries	O
a	O
risk	O
of	O
MEN2	O
and	O
MTC	O
in	O
all	O
ethnic	O
groups	O
in	O
South	O
Africa	O
.	O

Prophylactic	O
surgery	O
may	O
prevent	O
MTC	O
,	O
so	O
genetic	O
screening	O
is	O
important	O
to	O
identify	O
and	O
treat	O
high-risk	O
patients	O
.	O

Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	O
in	O
a	O
kindred	O
with	O
anemia	O
,	O
hyperuricemia	O
,	O
and	O
CKD	O
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	O
(REN)	O
cause	O
renal	O
tubular	O
dysgenesis	O
,	O
which	O
is	O
characterized	O
by	O
death	O
in	O
utero	O
due	O
to	O
kidney	O
failure	O
and	O
pulmonary	O
hypoplasia	O
.	O

The	O
phenotype	O
resembles	O
the	O
fetopathy	O
caused	O
by	O
angiotensin-converting	O
enzyme	O
inhibitor	O
or	O
angiotensin	O
receptor	O
blocker	O
intake	O
during	O
pregnancy	O
.	O

Recently	O
,	O
heterozygous	O
REN	O
mutations	O
were	O
shown	O
to	O
result	O
in	O
early-onset	O
hyperuricemia	O
,	O
anemia	O
,	O
and	O
chronic	O
kidney	O
disease	O
(CKD)	O
.	O

To	O
date	O
,	O
only	O
3	O
different	O
heterozygous	O
REN	O
mutations	O
have	O
been	O
published	O
.	O

We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	O
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	O
and	O
CKD	O
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	O
(uromodulin)	O
and	O
HNF1B	O
(	O
hepatocyte	O
nuclear	O
factor	O
1b	O
)	O
genes	O
.	O

We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	O
to	O
cytosine	O
mutation	O
at	O
position	O
28	O
in	O
the	O
REN	O
complementary	O
DNA	O
,	O
corresponding	O
to	O
a	O
tryptophan	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
10	O
,	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c.28T>C	B-DNAMutation
;	O
p.W10R	B-ProteinMutation
)	O
.	O

On	O
this	O
basis	O
,	O
we	O
conclude	O
that	O
REN	O
mutations	O
are	O
rare	O
events	O
in	O
patients	O
with	O
CKD	O
.	O

Within	O
the	O
kindred	O
,	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	O
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	O
,	O
hyperuricemia	O
,	O
and	O
CKD	O
.	O

Anemia	O
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O

Because	O
all	O
heterozygous	O
REN	O
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
,	O
screening	O
of	O
the	O
REN	O
gene	O
for	O
patients	O
with	O
CKD	O
with	O
hyperuricemia	O
and	O
anemia	O
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
,	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O

Detection	O
of	O
possible	O
restriction	O
sites	O
for	O
type	O
II	O
restriction	O
enzymes	O
in	O
DNA	O
sequences	O
.	O

In	O
order	O
to	O
make	O
a	O
step	O
forward	O
in	O
the	O
knowledge	O
of	O
the	O
mechanism	O
operating	O
in	O
complex	O
polygenic	O
disorders	O
such	O
as	O
diabetes	O
and	O
obesity	O
,	O
this	O
paper	O
proposes	O
a	O
new	O
algorithm	O
(	O
PRSD	O
-possible	O
restriction	O
site	O
detection	O
)	O
and	O
its	O
implementation	O
in	O
Applied	O
Genetics	O
software	O
.	O

This	O
software	O
can	O
be	O
used	O
for	O
in	O
silico	O
detection	O
of	O
potential	O
(hidden)	O
recognition	O
sites	O
for	O
endonucleases	O
and	O
for	O
nucleotide	O
repeats	O
identification	O
.	O

The	O
recognition	O
sites	O
for	O
endonucleases	O
may	O
result	O
from	O
hidden	O
sequences	O
through	O
deletion	O
or	O
insertion	O
of	O
a	O
specific	O
number	O
of	O
nucleotides	O
.	O

Tests	O
were	O
conducted	O
on	O
DNA	O
sequences	O
downloaded	O
from	O
NCBI	O
servers	O
using	O
specific	O
recognition	O
sites	O
for	O
common	O
type	O
II	O
restriction	O
enzymes	O
introduced	O
in	O
the	O
software	O
database	O
(	O
n	O
=	O
126	O
)	O
.	O

Each	O
possible	O
recognition	O
site	O
indicated	O
by	O
the	O
PRSD	O
algorithm	O
implemented	O
in	O
Applied	O
Genetics	O
was	O
checked	O
and	O
confirmed	O
by	O
NEBcutter	O
V2.0	O
and	O
Webcutter	O
2.0	O
software	O
.	O

In	O
the	O
sequence	O
NG_008724.1	O
(	O
which	O
includes	O
63632	O
nucleotides	O
)	O
we	O
found	O
a	O
high	O
number	O
of	O
potential	O
restriction	O
sites	O
for	O
ECO	O
R1	O
that	O
may	O
be	O
produced	O
by	O
deletion	O
(	O
n	O
=	O
43	O
sites	O
)	O
or	O
insertion	O
(	O
n	O
=	O
591	O
sites	O
)	O
of	O
one	O
nucleotide	O
.	O

The	O
second	O
module	O
of	O
Applied	O
Genetics	O
has	O
been	O
designed	O
to	O
find	O
simple	O
repeats	O
sizes	O
with	O
a	O
real	O
future	O
in	O
understanding	O
the	O
role	O
of	O
SNPs	O
(	O
Single	O
Nucleotide	O
Polymorphisms	O
)	O
in	O
the	O
pathogenesis	O
of	O
the	O
complex	O
metabolic	O
disorders	O
.	O

We	O
have	O
tested	O
the	O
presence	O
of	O
simple	O
repetitive	O
sequences	O
in	O
five	O
DNA	O
sequence	O
.	O

The	O
software	O
indicated	O
exact	O
position	O
of	O
each	O
repeats	O
detected	O
in	O
the	O
tested	O
sequences	O
.	O

Future	O
development	O
of	O
Applied	O
Genetics	O
can	O
provide	O
an	O
alternative	O
for	O
powerful	O
tools	O
used	O
to	O
search	O
for	O
restriction	O
sites	O
or	O
repetitive	O
sequences	O
or	O
to	O
improve	O
genotyping	O
methods	O
.	O

Carboxy-terminal	O
sequence	O
variation	O
of	O
LMP1	O
gene	O
in	O
Epstein-Barr-virus-associated	O
mononucleosis	O
and	O
tumors	O
from	O
Serbian	O
patients	O
.	O

Seven	O
strains	O
of	O
Epstein-Barr	O
virus	O
(EBV)	O
are	O
defined	O
based	O
on	O
C-terminal	O
sequence	O
variations	O
of	O
the	O
latent	O
membrane	O
protein	O
1	O
(LMP1)	O
.	O

Some	O
strains	O
,	O
especially	O
those	O
with	O
a	O
30-bp	O
deletion	O
,	O
are	O
thought	O
to	O
be	O
related	O
to	O
tumorigenic	O
activity	O
and	O
geographical	O
localization	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
different	O
LMP1	O
strains	O
and	O
to	O
investigate	O
sequence	O
variation	O
in	O
the	O
C-terminal	O
region	O
of	O
LMP1	O
in	O
Serbian	O
isolates	O
.	O

This	O
study	O
included	O
53	O
EBV-DNA-positive	O
plasma	O
and	O
tissue	O
block	O
samples	O
from	O
patients	O
with	O
mononucleosis	O
syndrome	O
,	O
renal	O
transplantation	O
,	O
and	O
tumors	O
,	O
mostly	O
nasopharyngeal	O
carcinoma	O
.	O

The	O
sequence	O
of	O
the	O
506-bp	O
fragment	O
of	O
LMP1	O
	O
	O
C	O
terminus	O
was	O
used	O
for	O
phylogenetic	O
analyses	O
and	O
identification	O
of	O
LMP1	O
strains	O
,	O
deletions	O
,	O
and	O
mutations	O
.	O

The	O
majority	O
of	O
isolates	O
were	O
non-deleted	O
(66%)	O
,	O
and	O
the	O
rest	O
had	O
30-bp	O
,	O
rare	O
69-bp	O
,	O
or	O
yet	O
unknown	O
27-bp	O
deletions	O
,	O
which	O
were	O
not	O
related	O
to	O
malignant	O
or	O
non-malignant	O
isolate	O
origin	O
.	O

However	O
,	O
the	O
majority	O
of	O
69-bp	O
deletion	O
isolates	O
were	O
derived	O
from	O
patients	O
with	O
nasopharyngeal	O
carcinoma	O
.	O

Less	O
than	O
five	O
33-bp	O
repeats	O
were	O
found	O
in	O
the	O
majority	O
of	O
non-deleted	O
isolates	O
(68.6%)	O
,	O
whereas	O
most	O
69-bp	O
deletion	O
isolates	O
(75%)	O
had	O
five	O
or	O
six	O
repeats	O
.	O

Serbian	O
isolates	O
were	O
assigned	O
to	O
four	O
LMP1	O
strains	O
:	O
B95-8	O
(32.1%)	O
,	O
China	O
1	O
(24.5%)	O
,	O
North	O
Carolina	O
(	O
NC	O
;	O
18.9%	O
)	O
,	O
and	O
Mediterranean	O
(	O
Med	O
;	O
24.5%	O
)	O
.	O

In	O
NC	O
isolates	O
,	O
three	O
new	O
mutations	O
unique	O
for	O
this	O
strain	O
were	O
identified	O
.	O

EBV	O
EBNA2	O
genotypes	O
1	O
and	O
2	O
were	O
both	O
found	O
,	O
with	O
dominance	O
of	O
genotype	O
1	O
(90.7%)	O
.	O

This	O
study	O
demonstrated	O
noticeable	O
geographical-associated	O
characteristics	O
in	O
the	O
LMP1	O
C	O
terminus	O
of	O
investigated	O
isolates	O
.	O

Roles	O
of	O
G1359A	O
polymorphism	O
of	O
the	O
cannabinoid	O
receptor	O
gene	O
(CNR1)	O
on	O
weight	O
loss	O
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O

BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
1359	B-DNAMutation
G/A	I-DNAMutation
)	O
of	O
the	O
CB1	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	O
to	O
A	O
at	O
nucleotide	O
position	O
1359	O
in	O
codon	O
435	O
(Thr)	O
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O

Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O

OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(G1359A)	O
of	O
CB1	O
receptor	O
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	O
loss	O
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	O
patients	O
.	O

DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	O
with	O
obesity	O
was	O
analyzed	O
.	O

Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	O
and	O
A1359A	O
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	O
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O

Results	O
:	O
Forty	O
seven	O
patients	O
(50%)	O
had	O
the	O
genotype	O
G1359G	O
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(50%)	O
patients	O
G1359A	O
(	O
41	O
patients	O
,	O
43.6%	O
)	O
or	O
A1359A	O
(	O
6	O
patients	O
,	O
6.4%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O

In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O

In	O
mutant	O
type	O
group	O
,	O
resistin	O
(	O
4.15	O
	O
	O
	O
1.7	O
ng/ml	O
vs	O
.	O

3.90	O
	O
	O
	O
2.1	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
,	O
leptin	O
(	O
78.4	O
	O
	O
	O
69	O
ng/ml	O
vs	O
66.2	O
	O
	O
	O
32	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
and	O
IL-6	O
(	O
1.40	O
	O
	O
	O
1.9	O
pg/ml	O
vs	O
0.81	O
	O
	O
	O
1.5	O
pg/ml	O
:	O
P	O
<	O
0.05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(A1359)	O
with	O
a	O
decrease	O
of	O
resistin	O
,	O
leptin	O
and	O
interleukin-6	O
secondary	O
to	O
weight	O
loss	O
.	O

Large	O
contiguous	O
gene	O
deletions	O
in	O
Sj	O
	O
gren-Larsson	O
syndrome	O
.	O

Sj	O
	O
gren-Larsson	O
syndrome	O
(SLS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
spasticity	O
and	O
mutations	O
in	O
the	O
ALDH3A2	O
gene	O
for	O
fatty	O
aldehyde	O
dehydrogenase	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	O
aldehyde	O
to	O
fatty	O
acid	O
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	O
patients	O
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	O
patients	O
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	O
locus	O
on	O
17p11.2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24-year-old	O
SLS	O
female	O
was	O
homozygous	O
for	O
a	O
352-kb	O
deletion	O
involving	O
ALDH3A2	O
and	O
4	O
contiguous	O
genes	O
including	O
ALDH3A1	O
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	O
disease	O
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	O
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19-month-old	O
female	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1.44-Mb	O
contiguous	O
gene	O
deletion	O
and	O
a	O
missense	O
mutation	O
(	O
c.407C>T	B-DNAMutation
,	O
P136L	B-ProteinMutation
)	O
in	O
ALDH3A2	O
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	O
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	O
with	O
SLS	O
and	O
other	O
inborn	O
errors	O
of	O
metabolism	O
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O

OPA1	O
mutations	O
in	O
Japanese	O
patients	O
suspected	O
to	O
have	O
autosomal	O
dominant	O
optic	O
atrophy	O
.	O

PURPOSE	O
:	O
To	O
report	O
three	O
types	O
of	O
heterozygous	O
mutations	O
in	O
the	O
OPA1	O
gene	O
in	O
five	O
patients	O
from	O
three	O
families	O
with	O
autosomal	O
dominant	O
optic	O
atrophy	O
(	O
ADOA	O
,	O
MIM#165500	O
)	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
of	O
the	O
peripheral	O
blood	O
.	O

For	O
mtDNA	O
,	O
mutations	O
were	O
examined	O
at	O
positions	O
11778	O
,	O
3460	O
and	O
14484	O
.	O

For	O
the	O
OPA1	O
gene	O
,	O
the	O
exons	O
were	O
amplified	O
by	O
PCR	O
and	O
mutations	O
were	O
detected	O
by	O
restriction	O
enzymes	O
or	O
the	O
dye	O
terminator	O
method	O
.	O

RESULTS	O
:	O
We	O
detected	O
three	O
types	O
of	O
OPA1	O
mutation	O
but	O
no	O
mtDNA	O
mutations	O
.	O

In	O
the	O
OPA1	O
gene	O
,	O
heterozygous	O
frameshift	O
mutations	O
from	O
codon	O
903	O
due	O
to	O
a	O
four-base	O
pair	O
deletion	O
in	O
exon	O
27	O
were	O
detected	O
in	O
three	O
patients	O
from	O
one	O
family	O
(	O
c.2708_2711delTTAG	B-DNAMutation
,	O
p.V903GfsX905	B-ProteinMutation
)	O
.	O

A	O
heterozygous	O
mutation	O
due	O
to	O
a	O
three-base	O
pair	O
deletion	O
in	O
exon	O
17	O
,	O
leading	O
to	O
a	O
one-amino	O
acid	O
deletion	O
(	O
c.1618_1620delACT	B-DNAMutation
,	O
p.T540del	B-ProteinMutation
)	O
,	O
and	O
a	O
heterozygous	O
mutation	O
due	O
to	O
a	O
one-base	O
substitution	O
in	O
exon	O
11	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
c.1084G>T	B-DNAMutation
,	O
p.E362X	B-ProteinMutation
)	O
,	O
were	O
detected	O
in	O
sporadic	O
cases	O
.	O

CONCLUSION	O
:	O
OPA1	O
mutations	O
existed	O
in	O
three	O
Japanese	O
families	O
with	O
ADOA	O
.	O

After	O
a	O
detailed	O
clinical	O
assessment	O
of	O
the	O
proband	O
,	O
the	O
screening	O
of	O
the	O
OPA1	O
gene	O
may	O
be	O
helpful	O
for	O
precise	O
diagnosis	O
of	O
ADOA	O
,	O
provided	O
the	O
relevant	O
information	O
of	O
the	O
family	O
members	O
is	O
limited	O
.	O

Interleukin-17F	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	O
immune	O
thrombocytopenia	O
.	O

INTRODUCTION	O
:	O
IL-17F	O
is	O
a	O
novel	O
inflammatory	O
cytokine	O
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	O
diseases	O
.	O

We	O
investigated	O
the	O
association	O
between	O
chronic	O
ITP	O
and	O
the	O
frequency	O
of	O
the	O
single-nucleotide	O
polymorphism	O
rs763780	B-SNP
7488T/C	B-DNAMutation
,	O
which	O
causes	O
a	O
His-to-Arg	O
substitution	O
at	O
amino	O
acid	O
161	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	O
(	O
men/women	O
,	O
40/62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	O
ITP	O
and	O
188	O
healthy	O
controls	O
(	O
men/women	O
,	O
78/110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O

Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
technique	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	O
with	O
chronic	O
ITP	O
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL-17F	O
7488CC	O
genotype	O
(	O
0%	O
vs	O
.	O

4.8%	O
,	O
P<0.05	O
)	O
.	O

The	O
number	O
of	O
IL-17F	O
7488C	O
alleles	O
among	O
the	O
patients	O
with	O
chronic	O
ITP	O
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8.7%	O
vs	O
.	O

15.2%	O
OR=0.48	O
,	O
95%CI=0.27-0.84	O
,	O
P=0.016	O
)	O
.	O

Furthermore	O
,	O
patients	O
with	O
the	O
IL-17F	O
7488TT	O
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	O
state	O
(	O
platelet	O
count<10	O
10(9)	O
/L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL-17F	O
7488TC	O
genotype	O
(	O
20.9%	O
vs	O
.	O

0%	O
,	O
P=0.04	O
)	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL-17F	O
7488	O
T	O
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	O
ITP	O
,	O
suggesting	O
a	O
role	O
for	O
IL-17F	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
ITP	O
.	O

Loss-of-function	O
mutations	O
in	O
PTPN11	O
cause	O
metachondromatosis	O
,	O
but	O
not	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

Metachondromatosis	O
(MC)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
incompletely	O
penetrant	O
combined	O
exostosis	O
and	O
enchondromatosis	O
tumor	O
syndrome	O
.	O

MC	O
is	O
clinically	O
distinct	O
from	O
other	O
multiple	O
exostosis	O
or	O
multiple	O
enchondromatosis	O
syndromes	O
and	O
is	O
unlinked	O
to	O
EXT1	O
and	O
EXT2	O
,	O
the	O
genes	O
responsible	O
for	O
autosomal	O
dominant	O
multiple	O
osteochondromas	O
(MO)	O
.	O

To	O
identify	O
a	O
gene	O
for	O
MC	O
,	O
we	O
performed	O
linkage	O
analysis	O
with	O
high-density	O
SNP	O
arrays	O
in	O
a	O
single	O
family	O
,	O
used	O
a	O
targeted	O
array	O
to	O
capture	O
exons	O
and	O
promoter	O
sequences	O
from	O
the	O
linked	O
interval	O
in	O
16	O
participants	O
from	O
11	O
MC	O
families	O
,	O
and	O
sequenced	O
the	O
captured	O
DNA	O
using	O
high-throughput	O
parallel	O
sequencing	O
technologies	O
.	O

DNA	O
capture	O
and	O
parallel	O
sequencing	O
identified	O
heterozygous	O
putative	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
in	O
4	O
of	O
the	O
11	O
families	O
.	O

Sanger	O
sequence	O
analysis	O
of	O
PTPN11	O
coding	O
regions	O
in	O
a	O
total	O
of	O
17	O
MC	O
families	O
identified	O
mutations	O
in	O
10	O
of	O
them	O
(	O
5	O
frameshift	O
,	O
2	O
nonsense	O
,	O
and	O
3	O
splice-site	O
mutations	O
)	O
.	O

Copy	O
number	O
analysis	O
of	O
sequencing	O
reads	O
from	O
a	O
second	O
targeted	O
capture	O
that	O
included	O
the	O
entire	O
PTPN11	O
gene	O
identified	O
an	O
additional	O
family	O
with	O
a	O
15	O
kb	O
deletion	O
spanning	O
exon	O
7	O
of	O
PTPN11	O
.	O

Microdissected	O
MC	O
lesions	O
from	O
two	O
patients	O
with	O
PTPN11	O
mutations	O
demonstrated	O
loss-of-heterozygosity	O
for	O
the	O
wild-type	O
allele	O
.	O

We	O
next	O
sequenced	O
PTPN11	O
in	O
DNA	O
samples	O
from	O
54	O
patients	O
with	O
the	O
multiple	O
enchondromatosis	O
disorders	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
,	O
but	O
found	O
no	O
coding	O
sequence	O
PTPN11	O
mutations	O
.	O

We	O
conclude	O
that	O
heterozygous	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
are	O
a	O
frequent	O
cause	O
of	O
MC	O
,	O
that	O
lesions	O
in	O
patients	O
with	O
MC	O
appear	O
to	O
arise	O
following	O
a	O
"second	O
hit,"	O
that	O
MC	O
may	O
be	O
locus	O
heterogeneous	O
since	O
1	O
familial	O
and	O
5	O
sporadically	O
occurring	O
cases	O
lacked	O
obvious	O
disease-causing	O
PTPN11	O
mutations	O
,	O
and	O
that	O
PTPN11	O
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

The	O
TREX1	O
exonuclease	O
R114H	B-ProteinMutation
mutation	O
in	O
Aicardi-Gouti	O
	O
res	O
syndrome	O
and	O
lupus	O
reveals	O
dimeric	O
structure	O
requirements	O
for	O
DNA	O
degradation	O
activity	O
.	O

Mutations	O
in	O
the	O
TREX1	O
gene	O
cause	O
Aicardi-Gouti	O
	O
res	O
syndrome	O
(AGS)	O
and	O
are	O
linked	O
to	O
the	O
autoimmune	O
disease	O
systemic	O
lupus	O
erythematosus	O
.	O

The	O
TREX1	O
protein	O
is	O
a	O
dimeric	O
3'	O
DNA	O
exonuclease	O
that	O
degrades	O
DNA	O
to	O
prevent	O
inappropriate	O
immune	O
activation	O
.	O

One	O
of	O
the	O
most	O
common	O
TREX1	O
mutations	O
,	O
R114H	B-ProteinMutation
,	O
causes	O
AGS	O
as	O
a	O
homozygous	O
and	O
compound	O
heterozygous	O
mutation	O
and	O
is	O
found	O
as	O
a	O
heterozygous	O
mutation	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

The	O
TREX1	O
proteins	O
containing	O
R114H	B-ProteinMutation
and	O
the	O
insertion	O
mutations	O
aspartate	O
at	O
position	O
201	O
D201ins	B-ProteinMutation
and	O
alanine	O
at	O
position	O
124	O
A124ins	B-ProteinMutation
,	O
found	O
in	O
compound	O
heterozygous	O
AGS	O
with	O
R114H	B-ProteinMutation
,	O
were	O
prepared	O
and	O
the	O
DNA	O
degradation	O
activities	O
were	O
tested	O
.	O

The	O
homodimer	O
TREX1(	O
R114H	B-ProteinMutation
/	O
R114H	B-ProteinMutation
)	O
exhibits	O
a	O
23-fold	O
reduced	O
single-stranded	O
DNA	O
(ssDNA)	O
exonuclease	O
activity	O
relative	O
to	O
TREX1(WT)	O
.	O

The	O
TREX1(	O
D201ins	B-ProteinMutation
/	O
D201ins	B-ProteinMutation
)	O
and	O
TREX1(	O
A124ins	B-ProteinMutation
/	O
A124ins	B-ProteinMutation
)	O
exhibit	O
more	O
than	O
10,000-fold	O
reduced	O
ssDNA	O
degradation	O
activities	O
.	O

However	O
,	O
the	O
TREX1(	O
R114H	B-ProteinMutation
/	O
D201ins	B-ProteinMutation
)	O
and	O
TREX1(	O
R114H	B-ProteinMutation
/	O
A124ins	B-ProteinMutation
)	O
compound	O
heterodimers	O
exhibit	O
activities	O
10-fold	O
greater	O
than	O
the	O
TREX1(	O
R114H	B-ProteinMutation
/	O
R114H	B-ProteinMutation
)	O
homodimer	O
during	O
ssDNA	O
and	O
double-stranded	O
DNA	O
(dsDNA)	O
degradation	O
.	O

These	O
higher	O
levels	O
of	O
activities	O
measured	O
in	O
the	O
TREX1(	O
R114H	B-ProteinMutation
/	O
D201ins	B-ProteinMutation
)	O
and	O
TREX1(	O
R114H	B-ProteinMutation
/	O
A124ins	B-ProteinMutation
)	O
compound	O
heterodimers	O
are	O
attributed	O
to	O
Arg-114	O
residues	O
of	O
TREX1(	O
D201ins	B-ProteinMutation
)	O
and	O
TREX1(	O
A124ins	B-ProteinMutation
)	O
positioned	O
at	O
the	O
dimer	O
interface	O
contributing	O
to	O
the	O
active	O
sites	O
of	O
the	O
opposing	O
TREX1(	O
R114H	B-ProteinMutation
)	O
protomer	O
.	O

This	O
interpretation	O
is	O
further	O
supported	O
by	O
exonuclease	O
activities	O
measured	O
for	O
TREX1	O
enzymes	O
containing	O
R114A	B-ProteinMutation
and	O
R114K	B-ProteinMutation
mutations	O
.	O

These	O
biochemical	O
data	O
provide	O
direct	O
evidence	O
for	O
TREX1	O
residues	O
in	O
one	O
protomer	O
contributing	O
to	O
DNA	O
degradation	O
catalyzed	O
in	O
the	O
opposing	O
protomer	O
and	O
help	O
to	O
explain	O
the	O
dimeric	O
TREX1	O
structure	O
required	O
for	O
full	O
catalytic	O
competency	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
glutathione-S-transferase	O
P1	O
gene	O
(GSTP1)	O
and	O
susceptibility	O
to	O
prostate	O
cancer	O
in	O
the	O
Kashmiri	O
population	O
.	O

Glutathione-S-transferase	O
P1	O
(GSTP1)	O
is	O
a	O
critical	O
enzyme	O
of	O
the	O
phase	O
II	O
detoxification	O
pathway	O
.	O

One	O
of	O
the	O
common	O
functional	O
polymorphisms	O
of	O
GSTP1	O
is	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
which	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
Ile105Val	B-ProteinMutation
at	O
the	O
substrate	O
binding	O
site	O
of	O
GSTP1	O
and	O
reduces	O
catalytic	O
activity	O
of	O
GSTP1	O
.	O

To	O
investigate	O
the	O
GSTP1	O
Ile105Val	B-ProteinMutation
genotype	O
frequency	O
in	O
prostate	O
cancer	O
cases	O
in	O
the	O
Kashmiri	O
population	O
,	O
we	O
designed	O
a	O
case-control	O
study	O
,	O
in	O
which	O
50	O
prostate	O
cancer	O
cases	O
and	O
45	O
benign	O
prostate	O
hyperplasia	O
cases	O
were	O
studied	O
for	O
GSTP1	O
Ile105Val	B-ProteinMutation
polymorphism	O
,	O
compared	O
to	O
80	O
controls	O
taken	O
from	O
the	O
general	O
population	O
,	O
employing	O
the	O
PCR-RFLP	O
technique	O
.	O

We	O
found	O
the	O
frequency	O
of	O
the	O
three	O
different	O
genotypes	O
of	O
GSTP1	O
Ile105Val	B-ProteinMutation
in	O
our	O
ethnic	O
Kashmir	O
population	O
,	O
i.e.	O
,	O
Ile/Ile	O
,	O
Ile/Val	O
and	O
Val/Val	O
,	O
to	O
be	O
52.4	O
,	O
33.3	O
and	O
14.3%	O
among	O
prostate	O
cancer	O
cases	O
,	O
48.5	O
,	O
37.5	O
and	O
14%	O
among	O
benign	O
prostate	O
hyperplasia	O
cases	O
and	O
73.8	O
,	O
21.3	O
and	O
5%	O
in	O
the	O
control	O
population	O
,	O
respectively	O
.	O

There	O
was	O
a	O
significant	O
association	O
between	O
the	O
GSTP1	O
Ile/Val	O
genotype	O
and	O
the	O
advanced	O
age	O
group	O
among	O
the	O
cases	O
.	O

We	O
conclude	O
that	O
GSTP1	O
Ile/Val	O
polymorphism	O
is	O
involved	O
in	O
the	O
risk	O
of	O
prostate	O
cancer	O
development	O
in	O
our	O
population	O
.	O

Identification	O
of	O
LIPH	O
gene	O
mutation	O
in	O
a	O
consanguineous	O
family	O
segregating	O
the	O
woolly	O
hair/hypotrichosis	O
phenotype	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
the	O
disease	O
causing	O
gene	O
in	O
a	O
four	O
generation	O
consanguineous	O
family	O
in	O
which	O
eleven	O
family	O
members	O
were	O
suffering	O
from	O
Woolly	O
hair/hypotrichosis	O
phenotype	O
.	O

METHODS	O
:	O
Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
identify	O
the	O
disease-causing	O
gene	O
in	O
this	O
family	O
.	O

Genomic	O
DNA	O
of	O
all	O
the	O
available	O
family	O
members	O
was	O
genotyped	O
for	O
the	O
microsatellite	O
markers	O
for	O
all	O
the	O
known	O
woolly	O
hair/hypotrichosis	O
loci.Automated	O
DNA	O
sequencing	O
of	O
the	O
candidate	O
gene	O
was	O
performed	O
to	O
identify	O
the	O
disease-causing	O
mutation	O
.	O

RESULTS	O
:	O
By	O
using	O
homozygosity	O
linkage	O
analysis	O
we	O
have	O
mapped	O
the	O
family	O
on	O
chromosome	O
3q27.3	O
with	O
a	O
two	O
point	O
LOD	O
score	O
of	O
4.04	O
,	O
Mutation	O
screening	O
of	O
the	O
LIPH	O
gene	O
revealed	O
a	O
homozygous	O
c.659_660delTA	B-DNAMutation
deletion	O
mutation	O
segregating	O
with	O
the	O
disease	O
phenotype	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
the	O
c.659_660delTA	B-DNAMutation
mutation	O
in	O
the	O
LIPH	O
gene	O
cause	O
autosomal	O
recessive	O
WH/hypotrichosis	O
phenotype	O
in	O
this	O
family	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
in	O
several	O
Pakistani	O
and	O
Guyanese	O
families	O
suggesting	O
a	O
founder	O
mutation	O
in	O
the	O
LIPH	O
gene	O
in	O
Indo-Pak	O
sub-continent	O
.	O

Familial	O
glucocorticoid	O
receptor	O
haploinsufficiency	O
by	O
non-sense	O
mediated	O
mRNA	O
decay	O
,	O
adrenal	O
hyperplasia	O
and	O
apparent	O
mineralocorticoid	O
excess	O
.	O

Primary	O
glucocorticoid	O
resistance	O
(	O
OMIM	O
138040	O
)	O
is	O
a	O
rare	O
hereditary	O
disease	O
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	O
action	O
,	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	O
receptor	O
(GR)	O
.	O

Investigation	O
of	O
adrenal	O
incidentalomas	O
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
)	O
,	O
prone	O
to	O
cortisol	O
resistance	O
,	O
bilateral	O
adrenal	O
hyperplasia	O
,	O
arterial	O
hypertension	O
and	O
hypokalemia	O
.	O

This	O
phenotype	O
exacerbated	O
over	O
time	O
,	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p.R469[R,X]	B-ProteinMutation
reported	O
to	O
date	O
for	O
the	O
GR	O
,	O
replacing	O
an	O
arginine	O
(CGA)	O
by	O
a	O
stop	O
(TGA)	O
at	O
amino-acid	O
469	O
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA-binding	O
domain	O
of	O
the	O
receptor	O
.	O

In	O
vitro	O
,	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50-kDa	O
GR	O
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
,	O
devoid	O
of	O
hormone-dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O

In	O
the	O
proband's	O
fibroblasts	O
,	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O

The	O
absence	O
of	O
detectable	O
mutated	O
GR	O
mRNA	O
was	O
accompanied	O
by	O
a	O
50%	O
reduction	O
in	O
wild	O
type	O
GR	O
transcript	O
and	O
protein	O
.	O

This	O
reduced	O
GR	O
expression	O
leads	O
to	O
a	O
significantly	O
below-normal	O
induction	O
of	O
glucocorticoid-induced	O
target	O
genes	O
,	O
FKBP5	O
in	O
fibroblasts	O
.	O

We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	O
signaling	O
dysfunction	O
involved	O
GR	O
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	O
transcript	O
through	O
a	O
nonsense-mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine-treated	O
propositus'	O
fibroblasts	O
.	O

GR	O
haploinsufficiency	O
leads	O
to	O
hypertension	O
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	O
receptor	O
by	O
elevated	O
cortisol	O
rather	O
than	O
to	O
increased	O
mineralocorticoid	O
production	O
reported	O
in	O
primary	O
glucocorticoid	O
resistance	O
.	O

Indeed	O
,	O
apparent	O
mineralocorticoid	O
excess	O
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone-tetrahydrocortisol	O
ratio	O
in	O
affected	O
patients	O
,	O
revealing	O
reduced	O
glucocorticoid	O
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b-hydroxysteroid	O
dehydrogenase	O
type	O
2	O
,	O
a	O
GR	O
regulated	O
gene	O
.	O

We	O
propose	O
thus	O
that	O
GR	O
haploinsufficiency	O
compromises	O
glucocorticoid	O
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	O
,	O
incidentally	O
revealed	O
bilateral	O
adrenal	O
hyperplasia	O
and	O
mineralocorticoid-independent	O
hypertension	O
.	O

cAMP	O
sensitivity	O
of	O
HCN	O
pacemaker	O
channels	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
autonomic	O
rate	O
control	O
.	O

BACKGROUND	O
:	O
HCN	O
channels	O
activate	O
the	O
pacemaker	O
current	O
I(f)	O
,	O
which	O
is	O
thought	O
to	O
contribute	O
significantly	O
to	O
generation	O
and	O
regulation	O
of	O
heart	O
rhythm	O
.	O

HCN4	O
represents	O
the	O
dominant	O
isotype	O
in	O
the	O
sinoatrial	O
node	O
and	O
binding	O
of	O
cAMP	O
was	O
suggested	O
to	O
be	O
necessary	O
for	O
autonomic	O
heart	O
rate	O
regulation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
insertion	O
of	O
13	O
nucleotides	O
in	O
exon	O
6	O
of	O
the	O
HCN4	O
gene	O
leading	O
to	O
a	O
truncated	O
cyclic	O
nucleotide-binding	O
domain	O
was	O
identified	O
in	O
a	O
45-year-old	O
woman	O
with	O
sinus	O
bradycardia	O
.	O

Biophysical	O
properties	O
determined	O
by	O
whole-cell	O
patch-clamp	O
recording	O
of	O
HEK293	O
cells	O
demonstrated	O
that	O
mutant	O
subunits	O
(HCN4-695X)	O
were	O
insensitive	O
to	O
cAMP	O
.	O

Heteromeric	O
channels	O
composed	O
of	O
wild-type	O
and	O
mutant	O
subunits	O
failed	O
to	O
respond	O
to	O
cAMP-like	O
homomeric	O
mutant	O
channels	O
,	O
indicating	O
a	O
dominant-negative	O
suppression	O
of	O
cAMP-induced	O
channel	O
activation	O
by	O
mutant	O
subunits	O
.	O

Pedigree	O
analysis	O
identified	O
7	O
additional	O
living	O
carriers	O
showing	O
similar	O
clinical	O
phenotypes	O
,	O
that	O
is	O
,	O
sinus	O
node	O
dysfunction	O
with	O
mean	O
resting	O
heart	O
rate	O
of	O
45.9	O
	O
4.6	O
bpm	O
(n=8)	O
compared	O
with	O
66.5	O
	O
9.1	O
bpm	O
of	O
unaffected	O
relatives	O
(	O
n=6	O
;	O
P<0.01	O
)	O
.	O

Clinical	O
evaluation	O
revealed	O
no	O
ischemic	O
or	O
structural	O
heart	O
disease	O
in	O
any	O
family	O
member	O
.	O

Importantly	O
,	O
mutant	O
carriers	O
exhibited	O
normal	O
heart	O
rate	O
variance	O
and	O
full	O
ability	O
to	O
accelerate	O
heart	O
rate	O
under	O
physical	O
activity	O
or	O
pharmacological	O
stimulation	O
.	O

Moreover	O
,	O
mutant	O
carriers	O
displayed	O
distinctive	O
sinus	O
arrhythmias	O
and	O
premature	O
beats	O
linked	O
to	O
adrenergic	O
stress	O
.	O

CONCLUSIONS	O
:	O
In	O
humans	O
,	O
cAMP	O
responsiveness	O
of	O
I(f)	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
maximum	O
heart	O
rate	O
,	O
heart	O
rate	O
variability	O
,	O
or	O
chronotropic	O
competence	O
.	O

Furthermore	O
,	O
cAMP-activated	O
I(f)	O
may	O
stabilize	O
heart	O
rhythm	O
during	O
chronotropic	O
response	O
.	O

A	O
novel	O
homozygous	O
splice	O
site	O
mutation	O
in	O
COL7A1	O
in	O
a	O
Chinese	O
patient	O
with	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
and	O
squamous	O
cell	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(RDEB)	O
is	O
an	O
inherited	O
blistering	O
skin	O
disorder	O
caused	O
by	O
mutations	O
in	O
COL7A1	O
gene	O
encoding	O
type	O
VII	O
collagen	O
,	O
the	O
major	O
component	O
of	O
anchoring	O
fibrils	O
in	O
the	O
dermo-epidermal	O
junction	O
.	O

The	O
development	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
(SCC)	O
is	O
one	O
of	O
the	O
most	O
serious	O
complications	O
of	O
this	O
disease	O
.	O

We	O
report	O
herein	O
a	O
Chinese	O
patient	O
with	O
the	O
severe	O
generalized	O
subtype	O
of	O
RDEB	O
(	O
RDEB-sev	O
gen	O
)	O
complicated	O
by	O
SCC	O
.	O

METHODS	O
:	O
Skin	O
biopsies	O
were	O
examined	O
for	O
histology	O
,	O
basement	O
membrane	O
ultrastructure	O
,	O
and	O
type	O
VII	O
collagen	O
expression	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
blood	O
samples	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
automated	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
patient's	O
skin	O
revealed	O
an	O
undetectable	O
expression	O
of	O
type	O
VII	O
collagen	O
polypeptides	O
in	O
the	O
basement	O
membrane	O
zone	O
.	O

Mutation	O
analysis	O
identified	O
a	O
novel	O
splice	O
site	O
mutation	O
in	O
intron	O
64	O
IVS64+5g->a	B-DNAMutation
of	O
COL7A1	O
gene	O
,	O
which	O
resulted	O
in	O
an	O
in-frame	O
deletion	O
of	O
exon	O
64	O
in	O
both	O
alleles	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
contributes	O
to	O
the	O
expanding	O
database	O
of	O
COL7A1	O
mutations	O
and	O
emphasizes	O
the	O
need	O
to	O
elucidate	O
the	O
underlying	O
genetic	O
mechanisms	O
associated	O
with	O
the	O
increased	O
incidence	O
of	O
SCC	O
in	O
RDEB	O
patients	O
.	O

Molecular	O
diagnosis	O
of	O
46,XY	O
DSD	O
and	O
identification	O
of	O
a	O
novel	O
8	O
nucleotide	O
deletion	O
in	O
exon	O
1	O
of	O
the	O
SRD5A2	O
gene	O
.	O

Phenotypic	O
presentation	O
of	O
46,XY	O
DSD	O
depends	O
on	O
the	O
underlying	O
defects	O
.	O

Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O

Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O

Mutational	O
analysis	O
of	O
androgen	O
receptor	O
(AR)	O
and	O
SRD5A2	O
genes	O
was	O
performed	O
in	O
29	O
patients	O
with	O
46,XY	O
DSD	O
,	O
by	O
PCR-SSCP	O
.	O

The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O

Interestingly	O
,	O
six	O
patients	O
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle/nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	O
gene	O
.	O

In	O
five	O
patients	O
p.R246Q	B-ProteinMutation
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g.80_87delT	B-DNAMutation
CGCGAAG	I-DNAMutation
p.A27fsX132	B-ProteinMutation
and	O
p.R246Q	B-ProteinMutation
.	O

Another	O
patient	O
with	O
isolated	O
micropenis	O
harbored	O
a	O
heterozygous	O
p.G196S	B-ProteinMutation
missense	O
mutation	O
.	O

No	O
AR	O
gene	O
mutation	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
p.R246Q	B-ProteinMutation
mutation	O
is	O
common	O
amongst	O
patients	O
with	O
SRD5A2	O
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O

Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	O
gene	O
in	O
a	O
patient	O
with	O
severe	O
hypospadias	O
.	O

A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers-Danlos	O
Syndrome	O
,	O
vascular	O
type	O
by	O
high-resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers-Danlos	O
syndrome	O
,	O
vascular	O
type	O
(vEDS)	O
(	O
MIM	O
#130050	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
type	O
III	O
procollagen	O
gene	O
(COL3A1)	O
mutations	O
.	O

Most	O
COL3A1	O
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient-derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High-resolution	O
melting	O
curve	O
analysis	O
(hrMCA)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post-PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost-effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	O
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	O
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	O
patients	O
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	O
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	O
mutations	O
,	O
including	O
one	O
deletion	O
c.2187delA	B-DNAMutation
and	O
one	O
nonsense	O
mutation	O
c.2992C>T	B-DNAMutation
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(SAG)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding-region	O
SNPs	O
(	O
rs1800255	B-SNP
:	O
G>A	B-DNAMutation
,	O
rs1801184	B-SNP
:	O
T>C	B-DNAMutation
,	O
and	O
rs2271683	B-SNP
:	O
A>G	B-DNAMutation
)	O
in	O
COL3A1	O
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	O
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype-phenotype	O
correlation	O
in	O
COL3A1	O
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O

Identification	O
of	O
a	O
frameshift	O
mutation	O
in	O
Osterix	O
in	O
a	O
patient	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

Osteogenesis	O
imperfecta	O
,	O
or	O
"brittle	O
bone	O
disease,"	O
is	O
a	O
type	O
I	O
collagen-related	O
condition	O
associated	O
with	O
osteoporosis	O
and	O
increased	O
risk	O
of	O
bone	O
fractures	O
.	O

Using	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
approach	O
,	O
we	O
have	O
identified	O
a	O
homozygous	O
single	O
base	O
pair	O
deletion	O
c.1052delA	B-DNAMutation
in	O
SP7/Osterix	O
(OSX)	O
in	O
an	O
Egyptian	O
child	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

The	O
clinical	O
findings	O
from	O
this	O
patient	O
include	O
recurrent	O
fractures	O
,	O
mild	O
bone	O
deformities	O
,	O
delayed	O
tooth	O
eruption	O
,	O
normal	O
hearing	O
,	O
and	O
white	O
sclera	O
.	O

OSX	O
encodes	O
a	O
transcription	O
factor	O
containing	O
three	O
Cys2-His2	O
zinc-finger	O
DNA-binding	O
domains	O
at	O
its	O
C	O
terminus	O
,	O
which	O
,	O
in	O
mice	O
,	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
bone	O
formation	O
.	O

The	O
frameshift	O
caused	O
by	O
the	O
c.1052delA	B-DNAMutation
deletion	O
removes	O
the	O
last	O
81	O
amino	O
acids	O
of	O
the	O
protein	O
,	O
including	O
the	O
third	O
zinc-finger	O
motif	O
.	O

This	O
finding	O
adds	O
another	O
locus	O
to	O
the	O
spectrum	O
of	O
genes	O
associated	O
with	O
osteogenesis	O
imperfecta	O
and	O
reveals	O
that	O
SP7/OSX	O
also	O
plays	O
a	O
key	O
role	O
in	O
human	O
bone	O
development	O
.	O

A	O
Taiwanese	O
boy	O
with	O
congenital	O
generalized	O
lipodystrophy	O
caused	O
by	O
homozygous	O
Ile262fs	B-ProteinMutation
mutation	O
in	O
the	O
BSCL2	O
gene	O
.	O

Congenital	O
generalized	O
lipodystrophy	O
(CGL)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disease	O
that	O
is	O
characterized	O
by	O
a	O
near-complete	O
absence	O
of	O
adipose	O
tissue	O
from	O
birth	O
or	O
early	O
infancy	O
.	O

Mutations	O
in	O
the	O
BSCL2	O
gene	O
are	O
known	O
to	O
result	O
in	O
CGL2	O
,	O
a	O
more	O
severe	O
phenotype	O
than	O
CGL1	O
,	O
with	O
earlier	O
onset	O
,	O
more	O
extensive	O
fat	O
loss	O
and	O
biochemical	O
changes	O
,	O
more	O
severe	O
intellectual	O
impairment	O
,	O
and	O
more	O
severe	O
cardiomyopathy	O
.	O

We	O
report	O
a	O
3-month-old	O
Taiwanese	O
boy	O
with	O
initial	O
presentation	O
of	O
a	O
lack	O
of	O
subcutaneous	O
fat	O
,	O
prominent	O
musculature	O
,	O
generalized	O
eruptive	O
xanthomas	O
,	O
and	O
extreme	O
hypertriglyceridemia	O
.	O

Absence	O
of	O
mechanical	O
adipose	O
tissue	O
in	O
the	O
orbits	O
and	O
scalp	O
was	O
revealed	O
by	O
head	O
magnetic	O
resonance	O
imaging	O
.	O

Hepatomegaly	O
was	O
noticed	O
,	O
and	O
histological	O
examination	O
of	O
a	O
liver	O
biopsy	O
specimen	O
suggested	O
severe	O
hepatic	O
steatosis	O
and	O
periportal	O
necrosis	O
.	O

However	O
,	O
echocardiography	O
indicated	O
no	O
sign	O
of	O
cardiomyopathy	O
and	O
he	O
showed	O
no	O
distinct	O
intellectual	O
impairment	O
that	O
interfered	O
with	O
daily	O
life	O
.	O

About	O
1	O
year	O
later	O
,	O
abdominal	O
computed	O
tomography	O
revealed	O
enlargement	O
of	O
kidneys	O
.	O

He	O
had	O
a	O
homozygous	O
insertion	O
of	O
a	O
nucleotide	O
,	O
783insG	B-DNAMutation
(	O
Ile262fs	B-ProteinMutation
mutation	O
)	O
,	O
in	O
exon	O
7	O
of	O
the	O
BSCL2	O
gene	O
.	O

We	O
reviewed	O
the	O
genotype	O
of	O
CGL	O
cases	O
from	O
Japan	O
,	O
India	O
,	O
China	O
and	O
Taiwan	O
,	O
and	O
found	O
that	O
BSCL2	O
is	O
a	O
major	O
causative	O
gene	O
for	O
CGL	O
in	O
Asian	O
.	O

8q24	O
allelic	O
imbalance	O
and	O
MYC	O
gene	O
copy	O
number	O
in	O
primary	O
prostate	O
cancer	O
.	O

Four	O
independent	O
regions	O
within	O
8q24	O
near	O
the	O
MYC	O
gene	O
are	O
associated	O
with	O
risk	O
for	O
prostate	O
cancer	O
(Pca)	O
.	O

Here	O
,	O
we	O
investigated	O
allelic	O
imbalance	O
(AI)	O
at	O
8q24	O
risk	O
variants	O
and	O
MYC	O
gene	O
DNA	O
copy	O
number	O
(CN)	O
in	O
27	O
primary	O
Pcas	O
.	O

Heterozygotes	O
were	O
observed	O
in	O
24	O
of	O
27	O
patients	O
at	O
one	O
or	O
more	O
8q24	O
markers	O
and	O
27%	O
of	O
the	O
loci	O
exhibited	O
AI	O
in	O
tumor	O
DNA	O
.	O

The	O
8q24	O
risk	O
alleles	O
were	O
preferentially	O
favored	O
in	O
the	O
tumors	O
.	O

Increased	O
MYC	O
gene	O
CN	O
was	O
observed	O
in	O
33%	O
of	O
tumors	O
,	O
and	O
the	O
co-existence	O
of	O
increased	O
MYC	O
gene	O
CN	O
with	O
AI	O
at	O
risk	O
loci	O
was	O
observed	O
in	O
86%	O
(	O
P<0.004	O
exact	O
binomial	O
test	O
)	O
of	O
the	O
informative	O
tumors	O
.	O

No	O
AI	O
was	O
observed	O
in	O
tumors	O
,	O
which	O
did	O
not	O
reveal	O
increased	O
MYC	O
gene	O
CN	O
.	O

Higher	O
Gleason	O
score	O
was	O
associated	O
with	O
tumors	O
exhibiting	O
AI	O
(P=0.04)	O
and	O
also	O
with	O
increased	O
MYC	O
gene	O
CN	O
(P=0.02)	O
.	O

Our	O
results	O
suggest	O
that	O
AI	O
at	O
8q24	O
and	O
increased	O
MYC	O
gene	O
CN	O
may	O
both	O
be	O
related	O
to	O
high	O
Gleason	O
score	O
in	O
Pca	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
these	O
two	O
somatic	O
alterations	O
may	O
be	O
due	O
to	O
the	O
same	O
preferential	O
chromosomal	O
duplication	O
event	O
during	O
prostate	O
tumorigenesis	O
.	O

Lack	O
of	O
p16	O
gene	O
mutations	O
in	O
gastric	O
cancers	O
in	O
Kashmir	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
The	O
focus	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
frequencies	O
of	O
homozygous	O
deletions	O
and	O
mutations	O
of	O
p16	O
gene	O
in	O
gastric	O
carcinomas	O
in	O
the	O
Kashmiri	O
population	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
84	O
gastric	O
carcinoma	O
patients	O
were	O
screened	O
by	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
technique	O
and	O
later	O
by	O
DNA	O
sequencing	O
to	O
detect	O
mutations	O
of	O
the	O
p16	O
gene	O
.	O

Also	O
PCR	O
was	O
applied	O
further	O
to	O
further	O
detect	O
any	O
homozygous	O
deletions	O
.	O

RESULTS	O
:	O
SSCP	O
and	O
DNA	O
sequencing	O
performed	O
encompassing	O
all	O
the	O
three	O
exons	O
of	O
p16	O
gene	O
could	O
not	O
detect	O
any	O
mutations	O
in	O
any	O
ofl	O
84	O
cases	O
.	O

Though	O
we	O
could	O
observe	O
mobility	O
shifts	O
in	O
SSCP	O
of	O
two	O
samples	O
,	O
subsequent	O
DNA	O
sequencing	O
did	O
not	O
show	O
any	O
mutation	O
.	O

Further	O
PCR	O
could	O
not	O
detect	O
any	O
homozygous	O
deletion	O
in	O
P16	O
in	O
any	O
case	O
.	O

CONCLUSION	O
:	O
Though	O
Kashmir	O
is	O
a	O
high	O
incidence	O
area	O
of	O
gastric	O
carcinomas	O
,	O
p16gene	O
mutations	O
/or	O
deletions	O
do	O
not	O
appear	O
to	O
be	O
involved	O
.	O

Clinical	O
and	O
genetic	O
characterization	O
of	O
manifesting	O
carriers	O
of	O
DMD	O
mutations	O
.	O

Manifesting	O
carriers	O
of	O
DMD	O
gene	O
mutations	O
may	O
present	O
diagnostic	O
challenges	O
,	O
particularly	O
in	O
the	O
absence	O
of	O
a	O
family	O
history	O
of	O
dystrophinopathy	O
.	O

We	O
review	O
the	O
clinical	O
and	O
genetic	O
features	O
in	O
15	O
manifesting	O
carriers	O
identified	O
among	O
860	O
subjects	O
within	O
the	O
United	O
Dystrophinopathy	O
Project	O
,	O
a	O
large	O
clinical	O
dystrophinopathy	O
cohort	O
whose	O
members	O
undergo	O
comprehensive	O
DMD	O
mutation	O
analysis	O
.	O

We	O
defined	O
manifesting	O
carriers	O
as	O
females	O
with	O
significant	O
weakness	O
,	O
excluding	O
those	O
with	O
only	O
myalgias/cramps	O
.	O

DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
used	O
to	O
study	O
X-chromosome	O
inactivation	O
patterns	O
.	O

Among	O
these	O
manifesting	O
carriers	O
,	O
age	O
at	O
symptom	O
onset	O
ranged	O
from	O
2	O
to	O
47	O
years	O
.	O

Seven	O
had	O
no	O
family	O
history	O
and	O
eight	O
had	O
male	O
relatives	O
with	O
Duchenne	O
muscular	O
dystrophy	O
(DMD)	O
.	O

Clinical	O
severity	O
among	O
the	O
manifesting	O
carriers	O
varied	O
from	O
a	O
DMD-like	O
progression	O
to	O
a	O
very	O
mild	O
Becker	O
muscular	O
dystrophy-like	O
phenotype	O
.	O

Eight	O
had	O
exonic	O
deletions	O
or	O
duplications	O
and	O
six	O
had	O
point	O
mutations	O
.	O

One	O
patient	O
had	O
two	O
mutations	O
(	O
an	O
exonic	O
deletion	O
and	O
a	O
splice	O
site	O
mutation	O
)	O
,	O
consistent	O
with	O
a	O
heterozygous	O
compound	O
state	O
.	O

The	O
X-chromosome	O
inactivation	O
pattern	O
was	O
skewed	O
toward	O
non-random	O
in	O
four	O
out	O
of	O
seven	O
informative	O
deletions	O
or	O
duplications	O
but	O
was	O
random	O
in	O
all	O
cases	O
with	O
nonsense	O
mutations	O
.	O

We	O
present	O
the	O
results	O
of	O
DMD	O
mutation	O
analysis	O
in	O
this	O
manifesting	O
carrier	O
cohort	O
,	O
including	O
the	O
first	O
example	O
of	O
a	O
presumably	O
compound	O
heterozygous	O
DMD	O
mutation	O
.	O

Our	O
results	O
demonstrate	O
that	O
improved	O
molecular	O
diagnostic	O
methods	O
facilitate	O
the	O
identification	O
of	O
DMD	O
mutations	O
in	O
manifesting	O
carriers	O
,	O
and	O
confirm	O
the	O
heterogeneity	O
of	O
mutational	O
mechanisms	O
as	O
well	O
as	O
the	O
wide	O
spectrum	O
of	O
phenotypes	O
.	O

Detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	O
cancer	O
patients	O
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	O
EGFR	O
status	O
and	O
response	O
to	O
EGFR	O
inhibitors	O
.	O

AIMS	O
:	O
EGFR	O
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR-targeted	O
therapy	O
in	O
lung	O
cancer	O
.	O

However	O
,	O
standard	O
EGFR	O
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	O
tissue	O
,	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(Sequenom)	O
with	O
a	O
mutant-enriched	O
PCR	O
(ME-PCR)	O
to	O
detect	O
EGFR	O
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	O
with	O
lung	O
cancer	O
.	O

METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	O
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	O
Exon	O
19	O
deletion	O
and	O
EGFR	O
L858R	B-ProteinMutation
mutation	O
.	O

Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	O
mutation	O
status	O
obtained	O
in	O
tumor	O
DNA	O
(	O
18/31	O
EGFR	O
mutant	O
)	O
.	O

The	O
relationship	O
of	O
EGFR	O
mutation	O
status	O
in	O
tumor	O
and/or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O

RESULTS	O
:	O
The	O
EGFR	O
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	O
in	O
61%	O
of	O
patients	O
(19/31)	O
.	O

By	O
mass	O
spectrometry	O
genotyping	O
,	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5/14	O
EGFR	O
Exon	O
19	O
deletions	O
and	O
3/4	O
EGFR	O
L858R	B-ProteinMutation
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	O
.	O

Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	O
tissue	O
.	O

Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME-PCR	O
.	O

For	O
patients	O
treated	O
with	O
erlotinib	O
,	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	O
mutation	O
in	O
plasma	O
and/or	O
tumor	O
tissue	O
(p=0.002)	O
,	O
with	O
the	O
two	O
patients	O
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME-PCR	O
is	O
feasible	O
.	O

A	O
positive	O
EGFR	O
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	O
EGFR	O
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR-targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	O
with	O
insufficient	O
or	O
unavailable	O
tumor	O
specimens	O
.	O

Recombinant	O
phenotyping	O
of	O
cytomegalovirus	O
sequence	O
variants	O
detected	O
after	O
200	O
or	O
100	O
days	O
of	O
valganciclovir	O
prophylaxis	O
.	O

BACKGROUND	O
:	O
In	O
a	O
phase	O
III	O
controlled	O
trial	O
IMproved	O
Protection	O
Against	O
Cytomegalovirus	O
in	O
Transplantation	O
(IMPACT)	O
comparing	O
200	O
with	O
100	O
days	O
of	O
valganciclovir	O
prophylaxis	O
in	O
318	O
cytomegalovirus	O
D+/R-	O
kidney	O
transplant	O
recipients	O
,	O
an	O
equal	O
number	O
of	O
patients	O
(	O
n=3	O
per	O
arm	O
)	O
had	O
known	O
ganciclovir	O
resistance	O
mutations	O
detected	O
during	O
viral	O
breakthrough	O
.	O

In	O
addition	O
,	O
many	O
other	O
viral	O
sequence	O
variants	O
were	O
observed	O
that	O
were	O
of	O
unknown	O
significance	O
for	O
ganciclovir	O
resistance	O
.	O

Recombinant	O
phenotyping	O
was	O
performed	O
to	O
determine	O
whether	O
the	O
previously	O
uncharacterized	O
genotypic	O
changes	O
affected	O
ganciclovir	O
susceptibility	O
,	O
especially	O
in	O
those	O
receiving	O
the	O
longer	O
duration	O
of	O
prophylaxis	O
.	O

METHODS	O
:	O
Sequences	O
encoding	O
individual	O
amino	O
acid	O
substitutions	O
in	O
the	O
UL97	O
kinase	O
or	O
UL54	O
DNA	O
polymerase	O
gene	O
were	O
transferred	O
by	O
recombination	O
into	O
a	O
cloned	O
cytomegalovirus	O
laboratory	O
strain	O
,	O
followed	O
by	O
reporter-based	O
yield	O
reduction	O
phenotypic	O
assay	O
of	O
the	O
resulting	O
virus	O
for	O
ganciclovir	O
susceptibility	O
.	O

RESULTS	O
:	O
Twenty-six	O
uncharacterized	O
amino	O
acid	O
substitutions	O
were	O
detected	O
,	O
2	O
in	O
UL97	O
and	O
24	O
in	O
UL54	O
.	O

All	O
10	O
substitutions	O
in	O
the	O
200-day	O
arm	O
and	O
9	O
of	O
17	O
substitutions	O
in	O
the	O
100-day	O
arm	O
(	O
prioritized	O
based	O
on	O
location	O
and	O
conservation	O
)	O
were	O
selected	O
for	O
phenotyping	O
;	O
one	O
substitution	O
was	O
detected	O
in	O
both	O
subsets	O
.	O

Results	O
were	O
generated	O
for	O
nine	O
of	O
ten	O
200-day	O
and	O
eight	O
of	O
nine	O
100-day	O
substitutions	O
,	O
with	O
no	O
substitution	O
demonstrating	O
a	O
significant	O
reduction	O
in	O
ganciclovir	O
susceptibility	O
.	O

The	O
two	O
remaining	O
amino	O
acid	O
substitutions	O
,	O
both	O
in	O
UL54	O
,	O
were	O
not	O
evaluated	O
because	O
of	O
poor	O
viral	O
viability	O
.	O

CONCLUSION	O
:	O
Phenotypic	O
evaluation	O
of	O
previously	O
uncharacterized	O
viral	O
genotypes	O
in	O
the	O
200-day	O
valganciclovir	O
prophylaxis	O
group	O
showed	O
no	O
evidence	O
of	O
an	O
increased	O
incidence	O
of	O
genotypic	O
ganciclovir	O
resistance	O
when	O
compared	O
with	O
those	O
in	O
the	O
100-day	O
prophylaxis	O
group	O
.	O

Monoallelic	O
thyroid	O
peroxidase	O
gene	O
mutation	O
in	O
a	O
patient	O
with	O
congenital	O
hypothyroidism	O
with	O
total	O
iodide	O
organification	O
defect	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
genetic	O
defect	O
of	O
a	O
patient	O
with	O
dyshormonogenetic	O
congenital	O
hypothyroidisms	O
(CH)	O
with	O
total	O
iodide	O
organification	O
defect	O
(TIOD)	O
.	O

A	O
male	O
child	O
diagnosed	O
with	O
CH	O
during	O
neonatal	O
screening	O
.	O

Laboratory	O
tests	O
confirmed	O
the	O
permanent	O
and	O
severe	O
CH	O
with	O
TIOD	O
(	O
99%	O
perchlorate	O
release	O
)	O
.	O

The	O
coding	O
sequence	O
of	O
TPO	O
,	O
DUOX2	O
,	O
and	O
DUOXA2	O
genes	O
and	O
2957	O
base	O
pairs	O
(bp)	O
of	O
the	O
TPO	O
promoter	O
were	O
sequenced	O
.	O

Molecular	O
analysis	O
of	O
patient's	O
DNA	O
identified	O
the	O
heterozygous	O
duplication	O
GGCC	O
c.1186_1187insGGCC	B-DNAMutation
in	O
exon	O
8	O
of	O
the	O
TPO	O
gene	O
.	O

No	O
additional	O
mutation	O
was	O
detected	O
either	O
in	O
the	O
TPO	O
gene	O
,	O
TPO	O
promoter	O
,	O
DUOX2	O
or	O
DUOXA2	O
genes	O
.	O

We	O
have	O
described	O
a	O
patient	O
with	O
a	O
clear	O
TIOD	O
causing	O
severe	O
goitrous	O
CH	O
due	O
to	O
a	O
monoallelic	O
TPO	O
mutation	O
.	O

A	O
plausible	O
explanation	O
for	O
the	O
association	O
between	O
an	O
autosomal	O
recessive	O
disorder	O
with	O
a	O
single	O
TPO-mutated	O
allele	O
is	O
the	O
presence	O
of	O
monoallelic	O
TPO	O
expression	O
.	O

The	O
M235T	B-ProteinMutation
polymorphism	O
of	O
the	O
angiotensinogen	O
gene	O
in	O
South	O
Indian	O
patients	O
of	O
hypertrophic	O
cardiomyopathy	O
.	O

INTRODUCTION	O
:	O
Hypertrophic	O
cardiomyopathy	O
(HCM)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	O
disease	O
with	O
a	O
diverse	O
clinical	O
course	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	B-DNAMutation
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	O
(AGT)	O
gene	O
with	O
HCM	O
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

Subjects	O
and	O
methods	O
.	O

One-hundred	O
and	O
fifty	O
HCM	O
(	O
90	O
sporadic	O
hypertrophic	O
cardiomyopathy	O
[SHCM]	O
and	O
60	O
familial	O
hypertrophic	O
cardiomyopathy	O
[	O
FHCM	O
]	O
)	O
patients	O
and	O
165	O
age-	O
and	O
sex-matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	O
and	O
left	O
ventricular	O
hypertrophy	O
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	O
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	O
to	O
threonine	O
substitution	O
at	O
codon	O
235	O
M235T	B-ProteinMutation
of	O
exon	O
2	O
,	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	O
.	O

RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0.04	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0.003	O
)	O
between	O
the	O
SHCM	O
patients	O
and	O
controls	O
.	O

The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	O
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	O
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	O
.	O

Atypical	O
GH	O
insensitivity	O
syndrome	O
and	O
severe	O
insulin-like	O
growth	O
factor-I	O
deficiency	O
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	O
receptor	O
,	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O

BACKGROUND/AIMS	O
:	O
GH	O
insensitivity	O
and	O
IGF	O
deficiency	O
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	O
receptor	O
(GHR)	O
.	O

We	O
describe	O
a	O
4-year-old	O
child	O
with	O
modest	O
growth	O
failure	O
and	O
normal	O
serum	O
concentrations	O
of	O
GH-binding	O
protein	O
(GHBP)	O
,	O
but	O
clinical	O
evidence	O
of	O
GH	O
insensitivity	O
.	O

METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-4	O
SD	O
,	O
elevated	O
serum	O
GH	O
concentrations	O
,	O
abnormally	O
low	O
serum	O
IGF-I	O
and	O
IGFBP-3	O
concentrations	O
and	O
normal	O
GHBP	O
concentrations	O
.	O

DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	O
,	O
including	O
a	O
previously	O
reported	O
R211H	B-ProteinMutation
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
899dupC	B-DNAMutation
,	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O

Treatment	O
with	O
recombinant	O
DNA-derived	O
IGF-I	O
resulted	O
in	O
growth	O
acceleration	O
.	O

CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	O
can	O
result	O
in	O
GH	O
insensitivity	O
and	O
IGF	O
deficiency	O
,	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	O
.	O

The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	O
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	O
,	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	O
concentrations	O
.	O

Alteration	O
in	O
the	O
gene	O
encoding	O
protein	O
tyrosine	O
phosphatase	O
nonreceptor	O
type	O
6	O
(PTPN6/SHP1)	O
may	O
contribute	O
to	O
neutrophilic	O
dermatoses	O
.	O

We	O
have	O
found	O
a	O
B2	O
repeat	O
insertion	O
in	O
the	O
gene	O
encoding	O
protein	O
tyrosine	O
phosphatase	O
nonreceptor	O
type	O
6	O
(PTPN6)	O
in	O
a	O
mouse	O
that	O
developed	O
a	O
skin	O
disorder	O
with	O
clinical	O
and	O
histopathological	O
features	O
resembling	O
those	O
seen	O
in	O
human	O
neutrophilic	O
dermatoses	O
.	O

Neutrophilic	O
dermatoses	O
are	O
a	O
group	O
of	O
complex	O
heterogeneous	O
autoinflammatory	O
diseases	O
that	O
all	O
demonstrate	O
excessive	O
neutrophil	O
infiltration	O
of	O
the	O
skin	O
.	O

Therefore	O
,	O
we	O
tested	O
the	O
cDNA	O
and	O
genomic	O
DNA	O
sequences	O
of	O
PTPN6	O
from	O
patients	O
with	O
Sweet's	O
syndrome	O
(SW)	O
and	O
pyoderma	O
gangrenosum	O
and	O
found	O
numerous	O
novel	O
splice	O
variants	O
in	O
different	O
combinations	O
.	O

Isoforms	O
resulting	O
from	O
deletions	O
of	O
exons	O
2	O
,	O
5	O
,	O
11	O
,	O
and	O
15	O
and	O
retention	O
of	O
intron	O
1	O
or	O
5	O
were	O
the	O
most	O
common	O
in	O
a	O
patients	O
with	O
a	O
familial	O
case	O
of	O
SW	O
,	O
who	O
had	O
a	O
neonatal	O
onset	O
of	O
an	O
inflammatory	O
disorder	O
with	O
skin	O
lesions	O
and	O
a	O
biopsy	O
specimen	O
consistent	O
with	O
SW	O
.	O

These	O
isoforms	O
were	O
associated	O
with	O
a	O
heterozygous	O
E441G	B-ProteinMutation
mutation	O
and	O
a	O
heterozygous	O
1.7-kbp	O
deletion	O
in	O
the	O
promoter	O
region	O
of	O
the	O
PTPN6	O
gene	O
.	O

Although	O
full-length	O
PTPN6	O
was	O
detected	O
in	O
all	O
other	O
patients	O
with	O
either	O
pyoderma	O
gangrenosum	O
or	O
SW	O
,	O
it	O
was	O
always	O
associated	O
with	O
splice	O
variants	O
:	O
a	O
partial	O
deletion	O
of	O
exon	O
4	O
with	O
the	O
complete	O
deletion	O
of	O
exon	O
5	O
,	O
alterations	O
that	O
were	O
not	O
detected	O
in	O
healthy	O
controls	O
.	O

The	O
defect	O
in	O
transcriptional	O
regulation	O
of	O
the	O
hematopoietic	O
PTPN6	O
appears	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
certain	O
subsets	O
of	O
the	O
heterogeneous	O
group	O
of	O
neutrophilic	O
dermatoses	O
.	O

Novel	O
and	O
recurrent	O
TRPV4	O
mutations	O
and	O
their	O
association	O
with	O
distinct	O
phenotypes	O
within	O
the	O
TRPV4	O
dysplasia	O
family	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
TRPV4	O
,	O
a	O
gene	O
that	O
encodes	O
a	O
Ca(2+)	O
permeable	O
non-selective	O
cation	O
channel	O
,	O
have	O
recently	O
been	O
found	O
in	O
a	O
spectrum	O
of	O
skeletal	O
dysplasias	O
that	O
includes	O
brachyolmia	O
,	O
spondylometaphyseal	O
dysplasia	O
,	O
Kozlowski	O
type	O
(SMDK)	O
and	O
metatropic	O
dysplasia	O
(MD)	O
.	O

Only	O
a	O
total	O
of	O
seven	O
missense	O
mutations	O
were	O
detected	O
,	O
however	O
.	O

The	O
full	O
spectrum	O
of	O
TRPV4	O
mutations	O
and	O
their	O
phenotypes	O
remained	O
unclear	O
.	O

OBJECTIVES	O
AND	O
METHODS	O
:	O
To	O
examine	O
TRPV4	O
mutation	O
spectrum	O
and	O
phenotype-genotype	O
association	O
,	O
we	O
searched	O
for	O
TRPV4	O
mutations	O
by	O
PCR-direct	O
sequencing	O
from	O
genomic	O
DNA	O
in	O
22	O
MD	O
and	O
20	O
SMDK	O
probands	O
.	O

RESULTS	O
:	O
TRPV4	O
mutations	O
were	O
found	O
in	O
all	O
but	O
one	O
MD	O
subject	O
.	O

In	O
total	O
,	O
19	O
different	O
heterozygous	O
mutations	O
were	O
identified	O
in	O
41	O
subjects	O
;	O
two	O
were	O
recurrent	O
and	O
17	O
were	O
novel	O
.	O

In	O
MD	O
,	O
a	O
recurrent	O
P799L	B-ProteinMutation
mutation	O
was	O
identified	O
in	O
nine	O
subjects	O
,	O
as	O
well	O
as	O
10	O
novel	O
mutations	O
including	O
F471del	B-ProteinMutation
,	O
the	O
first	O
deletion	O
mutation	O
of	O
TRPV4	O
.	O

In	O
SMDK	O
,	O
a	O
recurrent	O
R594H	B-ProteinMutation
mutation	O
was	O
identified	O
in	O
12	O
subjects	O
and	O
seven	O
novel	O
mutations	O
.	O

An	O
association	O
between	O
the	O
position	O
of	O
mutations	O
and	O
the	O
disease	O
phenotype	O
was	O
also	O
observed	O
.	O

Thus	O
,	O
P799	O
in	O
exon	O
15	O
is	O
a	O
hot	O
codon	O
for	O
MD	O
mutations	O
,	O
as	O
four	O
different	O
amino	O
acid	O
substitutions	O
have	O
been	O
observed	O
at	O
this	O
codon	O
;	O
while	O
R594	O
in	O
exon	O
11	O
is	O
a	O
hotspot	O
for	O
SMDK	O
mutations	O
.	O

CONCLUSION	O
:	O
The	O
TRPV4	O
mutation	O
spectrum	O
in	O
MD	O
and	O
SMDK	O
,	O
which	O
showed	O
genotype-phenotype	O
correlation	O
and	O
potential	O
functional	O
significance	O
of	O
mutations	O
that	O
are	O
non-randomly	O
distributed	O
over	O
the	O
gene	O
,	O
was	O
presented	O
in	O
this	O
study	O
.	O

The	O
results	O
would	O
help	O
diagnostic	O
laboratories	O
establish	O
efficient	O
screening	O
strategies	O
for	O
genetic	O
diagnosis	O
of	O
the	O
TRPV4	O
dysplasia	O
family	O
diseases	O
.	O

Association	O
of	O
obesity	O
risk	O
SNPs	O
in	O
PCSK1	O
with	O
insulin	O
sensitivity	O
and	O
proinsulin	O
conversion	O
.	O

BACKGROUND	O
:	O
Prohormone	O
convertase	O
1	O
is	O
involved	O
in	O
maturation	O
of	O
peptides	O
.	O

Rare	O
mutations	O
in	O
gene	O
PCSK1	O
,	O
encoding	O
this	O
enzyme	O
,	O
cause	O
childhood	O
obesity	O
and	O
abnormal	O
glucose	O
homeostasis	O
with	O
elevated	O
proinsulin	O
concentrations	O
.	O

Common	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
within	O
this	O
gene	O
,	O
rs6232	B-SNP
and	O
rs6235	B-SNP
,	O
are	O
associated	O
with	O
obesity	O
.	O

We	O
studied	O
whether	O
these	O
SNPs	O
influence	O
the	O
prediabetic	O
traits	O
insulin	O
resistance	O
,	O
beta-cell	O
dysfunction	O
,	O
or	O
glucose	O
intolerance	O
.	O

METHODS	O
:	O
We	O
genotyped	O
1498	O
German	O
subjects	O
for	O
SNPs	O
rs6232	B-SNP
and	O
rs6235	B-SNP
within	O
PCSK1	O
.	O

The	O
subjects	O
were	O
metabolically	O
characterized	O
by	O
oral	O
glucose	O
tolerance	O
test	O
with	O
glucose	O
,	O
insulin	O
,	O
proinsulin	O
,	O
and	O
C-peptide	O
measurements	O
.	O

A	O
subgroup	O
of	O
512	O
subjects	O
underwent	O
a	O
hyperinsulinemic-euglycemic	O
clamp	O
.	O

RESULTS	O
:	O
The	O
minor	O
allele	O
frequencies	O
were	O
25.8%	O
for	O
SNP	O
rs6235	B-SNP
and	O
6.0%	O
for	O
rs6232	B-SNP
.	O

After	O
adjustment	O
for	O
sex	O
and	O
age	O
,	O
we	O
found	O
no	O
association	O
of	O
SNPs	O
rs6235	B-SNP
and	O
rs6232	B-SNP
with	O
BMI	O
or	O
other	O
weight-related	O
traits	O
(	O
all	O
p	O
>or=	O
0.07	O
)	O
.	O

Both	O
minor	O
alleles	O
,	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
BMI	O
and	O
insulin	O
sensitivity	O
were	O
associated	O
with	O
elevated	O
AUCproinsulin	O
and	O
AUCproinsulin/AUCinsulin	O
(	O
rs6235	B-SNP
:	O
p(additive)	O
model	O
<or=	O
0.009	O
,	O
effect	O
sizes	O
8/8%	O
,	O
rs6232	B-SNP
:	O
pdominant	O
model	O
<or=	O
0.01	O
,	O
effect	O
sizes	O
10/21%	O
)	O
.	O

Insulin	O
secretion	O
was	O
not	O
affected	O
by	O
the	O
variants	O
(	O
different	O
secretion	O
parameters	O
,	O
all	O
p	O
>or=	O
0.08	O
)	O
.	O

The	O
minor	O
allele	O
of	O
SNP	O
rs6232	B-SNP
was	O
additionally	O
associated	O
with	O
15%	O
higher	O
OGTT-derived	O
and	O
19%	O
higher	O
clamp-derived	O
insulin	O
sensitivity	O
(	O
pdom	O
<or=	O
0.0047	O
)	O
,	O
4.5%	O
lower	O
HOMAIR	O
(	O
pdom	O
=	O
0.02	O
)	O
and	O
3.5%	O
lower	O
120-min	O
glucose	O
(	O
pdom	O
=	O
0.0003	O
)	O
independently	O
of	O
BMI	O
and	O
proinsulin	O
conversion	O
.	O

SNP	O
rs6235	B-SNP
was	O
not	O
associated	O
with	O
parameters	O
of	O
glucose	O
metabolism	O
.	O

CONCLUSIONS	O
:	O
Like	O
rare	O
mutations	O
in	O
PCSK1	O
,	O
the	O
more	O
common	O
variants	O
tested	O
determine	O
glucose-stimulated	O
proinsulin	O
conversion	O
,	O
but	O
not	O
insulin	O
secretion	O
.	O

In	O
addition	O
,	O
rs6232	B-SNP
,	O
encoding	O
the	O
amino	O
acid	O
exchange	O
N221D	B-ProteinMutation
,	O
influences	O
insulin	O
sensitivity	O
and	O
glucose	O
homeostasis	O
.	O

Correlation	O
between	O
thymidylate	O
synthase	O
gene	O
variants	O
,	O
RNA	O
and	O
protein	O
levels	O
in	O
primary	O
colorectal	O
adenocarcinomas	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
thymidylate	O
synthase	O
(TS)	O
genotype	O
,	O
mRNA	O
and	O
protein	O
levels	O
in	O
primary	O
colorectal	O
adenocarcinoma	O
,	O
and	O
to	O
examine	O
the	O
correlation	O
between	O
microsatellite	O
instability	O
(MSI)	O
and	O
TS	O
expression	O
.	O

The	O
TS	O
genotype	O
of	O
68	O
patients	O
with	O
colorectal	O
cancer	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
tumour	O
tissue	O
.	O

The	O
TS	O
mRNA	O
levels	O
in	O
tumour	O
tissue	O
were	O
measured	O
by	O
reverse-transcription	O
PCR	O
,	O
and	O
TS	O
protein	O
levels	O
and	O
MSI	O
status	O
were	O
assessed	O
using	O
immunohistochemistry	O
.	O

Significantly	O
higher	O
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
in	O
patients	O
with	O
the	O
TS	O
3R/3R	O
versus	O
the	O
2R/2R	O
and	O
2R/3R	O
genotypes	O
.	O

There	O
was	O
no	O
correlation	O
between	O
TS	O
single	O
nucleotide	O
polymorphism	O
and	O
TS	O
expression	O
.	O

Individuals	O
homozygous	O
for	O
the	O
six	O
base-pair	O
insertion	O
in	O
the	O
3'-untranslated	O
region	O
had	O
significantly	O
higher	O
TS	O
mRNA	O
levels	O
than	O
heterozygous	O
and	O
homozygous	O
wild	O
type	O
individuals	O
.	O

The	O
TS	O
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
higher	O
in	O
microsatellite	O
unstable	O
tumours	O
compared	O
with	O
microsatellite	O
stable	O
tumours	O
.	O

There	O
was	O
a	O
significant	O
association	O
between	O
the	O
number	O
of	O
TS	O
enhancer	O
region	O
repeats	O
(	O
in	O
blood	O
)	O
and	O
intratumoural	O
TS	O
mRNA	O
and	O
protein	O
levels	O
.	O

A	O
larger	O
case	O
series	O
investigating	O
the	O
role	O
of	O
TS	O
gene	O
polymorphisms	O
as	O
predictors	O
of	O
sensitivity	O
to	O
5-fluorouracil-based	O
chemotherapy	O
is	O
required	O
.	O

A	O
functional	O
polymorphism	O
in	O
the	O
disrupted-in	O
schizophrenia	O
1	O
gene	O
is	O
associated	O
with	O
chronic	O
fatigue	O
syndrome	O
.	O

AIMS	O
:	O
Disrupted-in	O
schizophrenia	O
1	O
(DISC1)	O
,	O
identified	O
in	O
a	O
pedigree	O
with	O
a	O
familial	O
psychosis	O
with	O
the	O
chromosome	O
translocation	O
(1:11)	O
,	O
is	O
a	O
putative	O
susceptibility	O
gene	O
for	O
psychoses	O
such	O
as	O
schizophrenia	O
and	O
major	O
depressive	O
disorder	O
(MDD)	O
.	O

Patients	O
with	O
chronic	O
fatigue	O
syndrome	O
(CFS)	O
report	O
having	O
continuous	O
severe	O
fatigue	O
and	O
many	O
overlapping	O
symptoms	O
with	O
MDD	O
;	O
however	O
,	O
the	O
mechanism	O
and	O
effective	O
treatment	O
of	O
CFS	O
are	O
still	O
unclear	O
.	O

We	O
focused	O
on	O
the	O
overlapping	O
symptoms	O
between	O
CFS	O
and	O
MDD	O
and	O
performed	O
an	O
association	O
study	O
of	O
the	O
functional	O
single-nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
DISC1	O
gene	O
with	O
CFS	O
.	O

MAIN	O
METHODS	O
:	O
Venous	O
blood	O
was	O
drawn	O
from	O
CFS	O
patients	O
and	O
controls	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
whole	O
blood	O
according	O
to	O
standard	O
procedures	O
.	O

Ser704Cys	B-ProteinMutation
DISC1	O
SNP	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
5'-exonuclease	O
allelic	O
discrimination	O
assay	O
.	O

KEY	O
FINDINGS	O
:	O
We	O
found	O
that	O
the	O
Cys704	O
allele	O
of	O
Ser704Cys	B-ProteinMutation
SNP	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
CFS	O
development	O
compared	O
with	O
the	O
Ser704	O
allele	O
.	O

SIGNIFICANCE	O
:	O
DISC1	O
Ser704Cys	B-ProteinMutation
might	O
be	O
a	O
functional	O
variant	O
that	O
affects	O
one	O
of	O
the	O
mechanisms	O
implicated	O
in	O
the	O
biology	O
of	O
CFS	O
.	O

Some	O
patients	O
with	O
CFS	O
showed	O
a	O
phenotype	O
similar	O
to	O
that	O
of	O
patients	O
with	O
MDD	O
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
biological	O
mechanism	O
,	O
because	O
this	O
study	O
is	O
of	O
a	O
rather	O
preliminary	O
nature	O
.	O

Despite	O
the	O
variety	O
of	O
patients	O
with	O
CFS	O
,	O
DISC1	O
Ser704Cys	B-ProteinMutation
has	O
an	O
association	O
with	O
CFS	O
,	O
which	O
may	O
also	O
suggest	O
that	O
DISC1	O
plays	O
a	O
central	O
role	O
in	O
the	O
induction	O
of	O
various	O
psychiatric	O
diseases	O
.	O

Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
.	O

Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p.R315X	B-ProteinMutation
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
(ARSB)	O
gene	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O

Patient	O
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	O
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c.899-1142del	B-DNAMutation
.	O

As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	O
gene	O
.	O

This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g.99367-102002del	B-DNAMutation
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O

We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O

The	O
six-nucleotide	O
deletion/insertion	O
variant	O
in	O
the	O
CASP8	O
promoter	O
region	O
is	O
inversely	O
associated	O
with	O
risk	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

Caspase	O
8	O
(CASP8)	O
is	O
an	O
apoptosis-related	O
cysteine	O
peptidase	O
involved	O
in	O
the	O
death	O
receptor	O
pathway	O
and	O
likely	O
in	O
the	O
mitochondrial	O
pathway	O
.	O

A	O
CASP8	O
promoter	O
region	O
six-nucleotide	O
deletion/insertion	O
(	O
-652	B-DNAMutation
6N	I-DNAMutation
ins/del	I-DNAMutation
)	O
variant	O
and	O
a	O
coding	O
region	O
D302H	B-ProteinMutation
polymorphism	O
are	O
reportedly	O
important	O
in	O
cancer	O
development	O
,	O
but	O
no	O
reported	O
study	O
has	O
assessed	O
the	O
associations	O
of	O
these	O
genetic	O
variations	O
with	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
.	O

In	O
a	O
hospital-based	O
study	O
of	O
non-Hispanic	O
whites	O
,	O
we	O
genotyped	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
and	O
302H	O
variants	O
in	O
1,023	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(SCCHN)	O
and	O
1,052	O
cancer-free	O
controls	O
.	O

Crude	O
and	O
adjusted	O
odds	O
ratios	O
(OR)	O
and	O
95%	O
confidence	O
intervals	O
(CI)	O
were	O
estimated	O
using	O
unconditional	O
logistic	O
regression	O
models	O
.	O

The	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
variant	O
genotypes	O
or	O
haplotypes	O
were	O
inversely	O
associated	O
with	O
SCCHN	O
risk	O
(	O
adjusted	O
OR	O
,	O
0.70	O
;	O
95%	O
CI	O
,	O
0.57-0.85	O
for	O
the	O
ins/del	O
+	O
del/del	O
genotypes	O
compared	O
with	O
the	O
ins/ins	O
genotype	O
;	O
adjusted	O
OR	O
,	O
0.73	O
;	O
95%	O
CI	O
,	O
0.55-0.97	O
for	O
the	O
del-D	O
haplotype	O
compared	O
with	O
the	O
ins-D	O
haplotype	O
)	O
.	O

Furthermore	O
,	O
the	O
number	O
of	O
the	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
(	O
but	O
not	O
302H	O
)	O
variant	O
allele	O
tended	O
to	O
correlate	O
with	O
increased	O
levels	O
of	O
camptothecin-induced	O
p53-mediated	O
apoptosis	O
in	O
T	O
lymphocytes	O
from	O
170	O
cancer-free	O
controls	O
.	O

We	O
concluded	O
that	O
the	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
variant	O
allele	O
may	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
SCCHN	O
in	O
non-Hispanic	O
white	O
populations	O
.	O

Further	O
validation	O
by	O
population-based	O
case-control	O
studies	O
and	O
rigorous	O
mechanistic	O
studies	O
is	O
warranted	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
and	O
angiotensin	O
type	O
1	O
receptor	O
A1166C	B-DNAMutation
polymorphisms	O
as	O
genetic	O
risk	O
factors	O
in	O
benign	O
prostatic	O
hyperplasia	O
and	O
prostate	O
cancer	O
.	O

INTRODUCTION	O
:	O
Prostate	O
cancer	O
is	O
one	O
of	O
the	O
most	O
common	O
malignant	O
neoplasias	O
in	O
developed	O
countries	O
.	O

In	O
2003	O
,	O
6,536	O
new	O
cases	O
and	O
4,602	O
related	O
deaths	O
were	O
reported	O
in	O
Mexico	O
.	O

The	O
renin-angiotensin	O
system	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
prostate	O
cancer	O
pathology	O
.	O

Two	O
previous	O
studies	O
investigated	O
the	O
association	O
of	O
prostate	O
cancer	O
with	O
the	O
insertion/deletion	O
(I/D)	O
polymorphism	O
in	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
;	O
both	O
studies	O
reported	O
an	O
association	O
between	O
prostate	O
cancer	O
and	O
the	O
DD	O
genotype	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
searching	O
for	O
an	O
association	O
of	O
prostate	O
cancer	O
and	O
benign	O
prostatic	O
hyperplasia	O
with	O
the	O
I/D	O
polymorphism	O
in	O
the	O
ACE	O
gene	O
and	O
the	O
A1166C	B-DNAMutation
polymorphism	O
in	O
the	O
angiotensin	O
type	O
1	O
receptor	O
(AGT1R)	O
gene	O
and	O
at	O
comparing	O
allele	O
frequencies	O
between	O
both	O
groups	O
and	O
the	O
general	O
population	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
20	O
samples	O
from	O
individuals	O
with	O
a	O
prostate	O
cancer	O
diagnosis	O
and	O
from	O
20	O
samples	O
from	O
individuals	O
with	O
a	O
benign	O
prostatic	O
hyperplasia	O
diagnosis	O
.	O

Genotyping	O
was	O
performed	O
by	O
PCR-RFLP	O
analysis	O
.	O

Polymorphism	O
frequency	O
results	O
obtained	O
for	O
the	O
test	O
groups	O
were	O
compared	O
with	O
the	O
frequencies	O
in	O
66	O
individuals	O
from	O
the	O
general	O
population	O
,	O
which	O
were	O
previously	O
obtained	O
at	O
the	O
same	O
molecular	O
medicine	O
laboratory	O
in	O
the	O
context	O
of	O
other	O
studies	O
.	O

RESULTS	O
:	O
The	O
comparative	O
analysis	O
of	O
the	O
three	O
groups	O
revealed	O
significant	O
differences	O
for	O
allele	O
frequencies	O
in	O
the	O
two	O
genes	O
in	O
patients	O
groups	O
(	O
prostate	O
cancer	O
and	O
benign	O
prostatic	O
hyperplasia	O
)	O
versus	O
the	O
general	O
population	O
.	O

The	O
D	O
allele	O
in	O
the	O
ACE	O
gene	O
was	O
closely	O
associated	O
with	O
a	O
significant	O
higher	O
risk	O
of	O
developing	O
both	O
benign	O
prostatic	O
hyperplasia	O
(	O
odds	O
ratio	O
[OR]=21.87	O
;	O
95%	O
confidence	O
interval	O
[	O
CI]=2.314-206.479	O
)	O
or	O
prostate	O
cancer	O
(	O
OR=31.66	O
;	O
95%	O
CI=0.091-1.272	O
)	O
,	O
and	O
the	O
AGT1R	O
A1166	O
allele	O
in	O
the	O
homozygote	O
state	O
was	O
identified	O
as	O
a	O
risk	O
genotype	O
for	O
benign	O
prostatic	O
hyperplasia	O
(OR=56.07)	O
.	O

CONCLUSIONS	O
:	O
Genotypes	O
in	O
ACE	O
and	O
AGT1R	O
polymorphisms	O
could	O
be	O
considered	O
as	O
genetic	O
risk	O
markers	O
for	O
benign	O
prostatic	O
hyperplasia	O
or	O
prostate	O
cancer	O
.	O

Molecular	O
analysis	O
of	O
gamma-globin	O
promoters	O
,	O
HS-111	O
and	O
3'HS1	O
,	O
in	O
beta-thalassemia	O
intermedia	O
patients	O
associated	O
with	O
high	O
levels	O
of	O
Hb	O
F	O
.	O

The	O
nucleotide	O
(nt)	O
variations	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gamma-globin	O
genes	O
,	O
HS-111	O
and	O
3'HS1	O
regions	O
,	O
were	O
studied	O
in	O
Iranian	O
patients	O
with	O
beta-thalassemia	O
intermedia	O
(beta-TI)	O
,	O
beta-thalassemia	O
major	O
(beta-TM)	O
and	O
healthy	O
individuals	O
.	O

Of	O
the	O
five	O
nt	O
variations	O
at	O
the	O
5'	O
end	O
of	O
the	O
(A)gamma-globin	O
gene	O
,	O
-369	B-DNAMutation
(C>G)	I-DNAMutation
,	O
-611	B-DNAMutation
(-T)	I-DNAMutation
and	O
-603/604	B-DNAMutation
(GA>AG)	I-DNAMutation
were	O
found	O
in	O
all	O
samples	O
,	O
whereas	O
-588	B-DNAMutation
(A>G)	I-DNAMutation
and	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
were	O
found	O
at	O
different	O
frequencies	O
in	O
the	O
studied	O
groups	O
.	O

Therefore	O
,	O
the	O
-369	O
,	O
-611	O
and	O
-603/604	O
variations	O
were	O
considered	O
common	O
mutations	O
in	O
this	O
population	O
,	O
and	O
the	O
difference	O
with	O
respect	O
to	O
the	O
-AAGC	O
deletion	O
was	O
not	O
significant	O
.	O

However	O
,	O
the	O
A	O
allele	O
of	O
the	O
-588	O
variation	O
and	O
[+]	O
allele	O
of	O
the	O
XmnI	O
polymorphism	O
were	O
more	O
frequent	O
in	O
beta-TI	O
patients	O
,	O
especially	O
those	O
who	O
had	O
the	O
IVS-II-1(G>A)	B-DNAMutation
/	O
IVS-II-1(G>A)	B-DNAMutation
genotype	O
.	O

The	O
+	O
allele	O
of	O
XmnI	O
also	O
had	O
complete	O
correlation	O
with	O
the	O
A	O
allele	O
of	O
-588	O
variation	O
.	O

The	O
HS-111	O
(	O
-21	O
A	O
)	O
variation	O
also	O
showed	O
association	O
with	O
beta-TI	O
patients	O
who	O
had	O
high	O
levels	O
of	O
Hb	O
F	O
.	O

Bearing	O
in	O
mind	O
that	O
the	O
-588	O
variation	O
lies	O
within	O
the	O
postulated	O
adult-specific	O
silencer	O
region	O
and	O
that	O
the	O
majority	O
of	O
beta-TI	O
patients	O
had	O
allele	O
A	O
,	O
then	O
it	O
can	O
be	O
envisaged	O
that	O
this	O
allele	O
could	O
have	O
a	O
role	O
in	O
altering	O
the	O
repressor	O
function	O
at	O
this	O
region	O
.	O

Therefore	O
,	O
the	O
A	O
allele	O
of	O
-588	O
,	O
[+]	O
allele	O
of	O
XmnI	O
and	O
HS-111	O
(	O
-21	O
A	O
)	O
variation	O
are	O
useful	O
genetic	O
markers	O
to	O
differentiate	O
between	O
beta-TM	O
and	O
beta-TI	O
patients	O
.	O

However	O
,	O
these	O
nt	O
changes	O
alone	O
may	O
not	O
be	O
the	O
only	O
elements	O
raising	O
the	O
level	O
of	O
Hb	O
F	O
,	O
other	O
regulatory	O
and	O
modifying	O
factors	O
also	O
play	O
a	O
role	O
in	O
Hb	O
F	O
production	O
.	O

Multiple	O
trichoepitheliomas--a	O
novel	O
mutation	O
in	O
the	O
CYLD	O
gene	O
.	O

BACKGROUND	O
:	O
Trichoepitheliomas	O
are	O
benign	O
neoplasms	O
with	O
follicular	O
differentiation	O
.	O

They	O
may	O
present	O
as	O
a	O
solitary	O
lesion	O
or	O
as	O
multiple	O
lesions	O
.	O

Multiple	O
trichoepitheliomas	O
are	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
within	O
families	O
,	O
with	O
both	O
variable	O
penetrance	O
and	O
expressivity	O
.	O

Recent	O
investigations	O
support	O
that	O
mutations	O
in	O
CYLD	O
,	O
the	O
gene	O
affected	O
in	O
familial	O
cylindromatosis	O
as	O
well	O
as	O
in	O
Brooke-Spiegler	O
syndrome	O
,	O
are	O
also	O
responsible	O
for	O
multiple	O
trichoepitheliomas	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
report	O
the	O
case	O
of	O
a	O
9-year-old	O
African	O
girl	O
with	O
multiple	O
facial	O
trichoepitheliomas	O
in	O
whom	O
a	O
mutation	O
in	O
the	O
CYLD	O
gene	O
was	O
hypothesised	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
genomic	O
DNA	O
extraction	O
from	O
the	O
peripheral	O
blood	O
,	O
a	O
molecular	O
analysis	O
of	O
the	O
CYLD	O
gene	O
was	O
performed	O
by	O
PCR	O
,	O
DHPLC	O
and	O
automated	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
mutation	O
in	O
exon	O
18	O
of	O
the	O
CYLD	O
gene	O
c.2449delT	B-DNAMutation
was	O
identified	O
,	O
with	O
a	O
deletion	O
of	O
one	O
nucleotide	O
resulting	O
in	O
a	O
premature	O
translational	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
831	O
on	O
the	O
affected	O
allele	O
(	O
p.Cys817Valfs	B-ProteinMutation
X15	I-ProteinMutation
)	O
.	O

CONCLUSIONS	O
:	O
The	O
predominating	O
tumours	O
define	O
the	O
classification	O
of	O
these	O
three	O
entities	O
.	O

Nevertheless	O
,	O
studies	O
suggest	O
that	O
they	O
can	O
simply	O
represent	O
phenotypic	O
variations	O
of	O
the	O
same	O
disease	O
spectrum	O
,	O
sharing	O
common	O
genetic	O
mutations	O
.	O

FGFR4	O
Gly388Arg	B-ProteinMutation
polymorphism	O
and	O
prostate	O
cancer	O
risk	O
in	O
Scottish	O
men	O
.	O

Fibroblast	O
growth	O
factor	O
receptor	O
4	O
(FGFR4)	O
,	O
a	O
member	O
of	O
the	O
fibroblast	O
growth	O
receptor	O
family	O
,	O
was	O
recently	O
reported	O
to	O
be	O
more	O
abundantly	O
expressed	O
in	O
malignant	O
than	O
benign	O
prostate	O
cells	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
at	O
position	O
388	O
of	O
the	O
FGFR4	O
amino-acid	O
sequence	O
results	O
in	O
the	O
substitution	O
of	O
glycine	O
(Gly)	O
with	O
arginine	O
(Arg)	O
and	O
higher	O
frequency	O
of	O
the	O
ArgArg	O
genotype	O
was	O
previously	O
found	O
in	O
prostate	O
cancer	O
patients	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
blood	O
drawn	O
from	O
399	O
prostate	O
cancer	O
patients	O
,	O
150	O
BPH	O
patients	O
and	O
294	O
healthy	O
community	O
controls	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
carried	O
out	O
and	O
single	O
nucleotide	O
polymorphisms	O
of	O
FGFR4	O
were	O
identified	O
by	O
restriction	O
enzyme	O
digestion	O
.	O

No	O
overall	O
association	O
is	O
detectable	O
between	O
the	O
Arg	O
allele	O
and	O
increased	O
prostate	O
cancer	O
risk	O
.	O

Subgroup	O
analysis	O
shows	O
a	O
higher	O
incidence	O
of	O
the	O
heterozygous	O
ArgGly	O
genotype	O
in	O
cancer	O
cases	O
than	O
in	O
the	O
combined	O
group	O
of	O
BPH	O
and	O
controls	O
(P<0.05)	O
;	O
this	O
difference	O
is	O
statistically	O
significant	O
between	O
cancer	O
and	O
BPH	O
patients	O
but	O
not	O
between	O
cancer	O
cases	O
and	O
community	O
controls	O
.	O

The	O
single	O
nucleotide	O
polymorphism	O
Gly(388)Arg	B-ProteinMutation
in	O
FGFR4	O
is	O
not	O
associated	O
with	O
increased	O
risk	O
of	O
prostate	O
cancer	O
in	O
Scottish	O
men	O
.	O

This	O
observation	O
is	O
in	O
contrast	O
with	O
results	O
from	O
two	O
previous	O
studies	O
conducted	O
in	O
the	O
USA	O
and	O
Japan	O
.	O

Polymorphisms	O
in	O
the	O
FOXP3	O
gene	O
in	O
Han	O
Chinese	O
psoriasis	O
patients	O
.	O

BACKGROUND	O
:	O
Psoriasis	O
is	O
a	O
common	O
dermatological	O
disorder	O
,	O
in	O
which	O
autoimmunity	O
plays	O
an	O
important	O
role	O
.	O

CD4(+)CD25(+)	O
regulatory	O
T	O
cells	O
(T-regs)	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	O
diseases	O
.	O

T-regs	O
express	O
the	O
fork	O
head/winged	O
helix	O
transcription	O
factor	O
,	O
FOXP3	O
,	O
which	O
appears	O
to	O
be	O
of	O
key	O
importance	O
in	O
the	O
development	O
and	O
function	O
of	O
T-regs	O
.	O

Studies	O
have	O
found	O
that	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
FOXP3	O
gene	O
contribute	O
to	O
susceptibility	O
to	O
some	O
autoimmune	O
disorders	O
.	O

However	O
,	O
information	O
about	O
FOXP3	O
gene	O
in	O
psoriasis	O
is	O
limited	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
evaluated	O
the	O
association	O
between	O
FOXP3	O
gene	O
SNPs	O
and	O
susceptibility	O
to	O
psoriasis	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
In	O
a	O
hospital-based	O
case-control	O
study	O
,	O
524	O
patients	O
with	O
psoriasis	O
and	O
549	O
psoriasis-free	O
controls	O
were	O
recruited	O
according	O
to	O
age	O
and	O
gender	O
.	O

We	O
investigated	O
four	O
SNPs	O
in	O
the	O
FOXP3	O
gene	O
(	O
-6054	B-DNAMutation
,	I-DNAMutation
deletion/ATT	I-DNAMutation
;	O
-3279	B-DNAMutation
,	I-DNAMutation
A/C	I-DNAMutation
;	O
-924	B-DNAMutation
,	I-DNAMutation
A/G	I-DNAMutation
;	O
IVS9+459	B-DNAMutation
,	I-DNAMutation
A/G	I-DNAMutation
)	O
in	O
psoriatic	O
patients	O
,	O
and	O
assessed	O
allele	O
and	O
genotype	O
frequencies	O
in	O
psoriatic	O
patients	O
(	O
237	O
females	O
,	O
287	O
males	O
)	O
and	O
normal	O
controls	O
(	O
272	O
females	O
,	O
277	O
males	O
)	O
.	O

The	O
polymorphisms	O
were	O
genotyped	O
using	O
the	O
PCR	O
sequence-specific	O
primer	O
(PCR-SSP)	O
technique	O
and	O
PCR-restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
increased	O
risk	O
of	O
psoriasis	O
was	O
associated	O
with	O
the	O
FOXP3	O
-3279	O
AC	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1.32	O
;	O
95%	O
CI	O
,	O
1.01-1.74	O
)	O
and	O
the	O
combined	O
AC+AA	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1.38	O
;	O
95%	O
CI	O
,	O
1.07-1.78	O
)	O
,	O
compared	O
with	O
the	O
-3279	O
CC	O
genotype	O
.	O

We	O
also	O
found	O
that	O
an	O
increased	O
risk	O
of	O
psoriasis	O
was	O
associated	O
with	O
the	O
FOXP3	O
IVS9+459	O
GG	O
genotype	O
(	O
adjusted	O
OR	O
,	O
2.24	O
;	O
95%	O
CI	O
,	O
1.41-3.58	O
)	O
.	O

However	O
,	O
the	O
combined	O
GA+GG	O
genotype	O
showed	O
no	O
such	O
tendency	O
(	O
adjusted	O
OR=1.28	O
;	O
95%	O
CI	O
,	O
1.00-1.64	O
)	O
,	O
compared	O
with	O
the	O
IVS9+459	O
AA	O
genotype	O
.	O

There	O
was	O
no	O
evidence	O
of	O
an	O
increased	O
risk	O
associated	O
with	O
the	O
FOXP3-6054	B-DNAMutation
deletion/ATT	I-DNAMutation
or	O
FOXP3-924	B-DNAMutation
A/G	I-DNAMutation
genotype	O
.	O

In	O
combined	O
genotype	O
analyses	O
,	O
the	O
FOXP3-3279	O
AC+AA	O
genotype	O
was	O
more	O
obviously	O
associated	O
in	O
males	O
(	O
adjusted	O
OR=1.60	O
,	O
95%	O
CI=1.11-2.31	O
)	O
and	O
severe	O
psoriasis	O
patients	O
(	O
PASI	O
score	O
>20	O
;	O
adjusted	O
OR=1.97	O
,	O
95%	O
CI=1.41-2.75	O
)	O
.	O

Meanwhile	O
,	O
the	O
FOXP3	O
IVS9+459	O
GA+GG	O
genotype	O
was	O
also	O
associated	O
with	O
severe	O
psoriasis	O
patients	O
(	O
adjusted	O
OR=1.69	O
,	O
95%	O
CI=1.21-2.36	O
)	O
.	O

CONCLUSIONS	O
:	O
FOXP3	O
polymorphisms	O
appear	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
psoriasis	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O

A	O
LDR-PCR	O
approach	O
for	O
multiplex	O
polymorphisms	O
genotyping	O
of	O
severely	O
degraded	O
DNA	O
with	O
fragment	O
sizes	O
<100	O
bp	O
.	O

Reducing	O
amplicon	O
sizes	O
has	O
become	O
a	O
major	O
strategy	O
for	O
analyzing	O
degraded	O
DNA	O
typical	O
of	O
forensic	O
samples	O
.	O

However	O
,	O
amplicon	O
sizes	O
in	O
current	O
mini-short	O
tandem	O
repeat-polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
mini-sequencing	O
assays	O
are	O
still	O
not	O
suitable	O
for	O
analysis	O
of	O
severely	O
degraded	O
DNA	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
multiplex	O
typing	O
method	O
that	O
couples	O
ligase	O
detection	O
reaction	O
with	O
PCR	O
that	O
can	O
be	O
used	O
to	O
identify	O
single	O
nucleotide	O
polymorphisms	O
and	O
small-scale	O
insertion/deletions	O
in	O
a	O
sample	O
of	O
severely	O
fragmented	O
DNA	O
.	O

This	O
method	O
adopts	O
thermostable	O
ligation	O
for	O
allele	O
discrimination	O
and	O
subsequent	O
PCR	O
for	O
signal	O
enhancement	O
.	O

In	O
this	O
study	O
,	O
four	O
polymorphic	O
loci	O
were	O
used	O
to	O
assess	O
the	O
ability	O
of	O
this	O
technique	O
to	O
discriminate	O
alleles	O
in	O
an	O
artificially	O
degraded	O
sample	O
of	O
DNA	O
with	O
fragment	O
sizes	O
<100	O
bp	O
.	O

Our	O
results	O
showed	O
clear	O
allelic	O
discrimination	O
of	O
single	O
or	O
multiple	O
loci	O
,	O
suggesting	O
that	O
this	O
method	O
might	O
aid	O
in	O
the	O
analysis	O
of	O
extremely	O
degraded	O
samples	O
in	O
which	O
allelic	O
drop	O
out	O
of	O
larger	O
fragments	O
is	O
observed	O
.	O

A	O
MANBA	O
mutation	O
resulting	O
in	O
residual	O
beta-mannosidase	O
activity	O
associated	O
with	O
severe	O
leukoencephalopathy	O
:	O
a	O
possible	O
pseudodeficiency	O
variant	O
.	O

BACKGROUND	O
:	O
beta-Mannosidosis	O
(	O
OMIM	O
248510	O
)	O
is	O
a	O
rare	O
inborn	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
the	O
deficient	O
activity	O
of	O
beta-mannosidase	O
,	O
an	O
enzyme	O
encoded	O
by	O
a	O
single	O
gene	O
(MANBA)	O
located	O
on	O
chromosome	O
4q22-25	O
.	O

To	O
date	O
,	O
only	O
20	O
cases	O
of	O
this	O
autosomal	O
recessive	O
disorder	O
have	O
been	O
described	O
and	O
14	O
different	O
MANBA	O
mutations	O
were	O
incriminated	O
in	O
the	O
disease	O
.	O

These	O
are	O
all	O
null	O
mutations	O
or	O
missense	O
mutations	O
that	O
abolish	O
beta-mannosidase	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
molecular	O
defect	O
of	O
a	O
new	O
case	O
of	O
beta-mannosidosis	O
,	O
presenting	O
with	O
a	O
severe	O
neurological	O
disorder	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
of	O
the	O
patient	O
to	O
allow	O
MANBA	O
sequencing	O
.	O

The	O
identified	O
mutation	O
was	O
engineered	O
by	O
site-directed	O
mutagenesis	O
and	O
the	O
mutant	O
protein	O
was	O
expressed	O
through	O
transient	O
transfection	O
in	O
HEK293T	O
cells	O
.	O

The	O
beta-mannosidase	O
expression	O
and	O
activity	O
were	O
respectively	O
assessed	O
by	O
Western	O
blot	O
and	O
fluorometric	O
assay	O
in	O
both	O
leukocytes	O
and	O
HEK293T	O
cells	O
.	O

RESULTS	O
:	O
A	O
missense	O
disease-associated	O
mutation	O
,	O
c.1922G>A	B-DNAMutation
p.Arg641His	B-ProteinMutation
,	O
was	O
identified	O
for	O
which	O
the	O
patient	O
was	O
homozygous	O
.	O

In	O
contrast	O
to	O
previously	O
described	O
missense	O
mutations	O
,	O
this	O
substitution	O
does	O
not	O
totally	O
abrogate	O
the	O
enzyme	O
activity	O
but	O
led	O
to	O
a	O
residual	O
activity	O
of	O
about	O
7%	O
in	O
the	O
patient's	O
leukocytes	O
,	O
11%	O
in	O
lymphoblasts	O
and	O
14%	O
in	O
plasma	O
.	O

Expression	O
studies	O
in	O
transfected	O
cells	O
also	O
resulted	O
in	O
7%	O
residual	O
activity	O
.	O

CONCLUSION	O
:	O
Correlations	O
between	O
MANBA	O
mutations	O
,	O
residual	O
activity	O
of	O
beta-mannosidase	O
and	O
the	O
severity	O
of	O
the	O
ensuing	O
neurological	O
disorder	O
are	O
discussed	O
.	O

Whether	O
the	O
c.1922G>A	B-DNAMutation
mutation	O
is	O
responsible	O
for	O
a	O
yet	O
undescribed	O
pseudodeficiency	O
of	O
beta-mannosidase	O
is	O
also	O
discussed	O
.	O

Screening	O
of	O
the	O
LIX1	O
gene	O
in	O
Japanese	O
and	O
Malaysian	O
patients	O
with	O
SMA	O
and/or	O
SMA-like	O
disorder	O
.	O

BACKGROUND	O
:	O
The	O
majority	O
of	O
spinal	O
muscular	O
atrophy	O
(SMA)	O
patients	O
showed	O
homozygous	O
deletion	O
or	O
other	O
mutations	O
of	O
SMN1	O
.	O

However	O
,	O
the	O
genetic	O
etiology	O
of	O
a	O
significant	O
number	O
of	O
SMA	O
patients	O
has	O
not	O
been	O
clarified	O
.	O

Recently	O
,	O
mutation	O
in	O
the	O
gene	O
underlying	O
cat	O
SMA	O
,	O
limb	O
expression	O
1	O
(LIX1)	O
,	O
has	O
been	O
reported	O
.	O

Similarity	O
in	O
clinical	O
and	O
pathological	O
features	O
of	O
cat	O
and	O
human	O
SMA	O
may	O
give	O
an	O
insight	O
into	O
possible	O
similarity	O
of	O
the	O
genetic	O
etiology	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
for	O
a	O
mutation	O
in	O
LIX1	O
using	O
direct	O
DNA	O
sequencing	O
in	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
who	O
retained	O
SMN1	O
.	O

A	O
total	O
of	O
33	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
of	O
which	O
22	O
were	O
Japanese	O
and	O
11	O
were	O
Malaysians	O
.	O

All	O
these	O
patients	O
possessed	O
at	O
least	O
two	O
copies	O
of	O
SMN1	O
.	O

RESULTS	O
:	O
We	O
did	O
not	O
identify	O
any	O
pathogenic	O
mutations	O
in	O
the	O
coding	O
regions	O
or	O
splice	O
sites	O
of	O
LIX1	O
in	O
the	O
patients	O
.	O

In	O
addition	O
,	O
we	O
described	O
a	O
polymorphism	O
within	O
LIX1	O
intron	O
3	O
,	O
c.387+107A>T	B-DNAMutation
.	O

We	O
found	O
that	O
A-allele	O
is	O
significantly	O
more	O
frequent	O
in	O
SMA	O
patients	O
compared	O
to	O
normal	O
individuals	O
.	O

CONCLUSION	O
:	O
Molecular	O
genetic	O
analysis	O
of	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
suggests	O
that	O
LIX1	O
is	O
not	O
associated	O
with	O
the	O
development	O
of	O
their	O
disorders	O
.	O

However	O
,	O
the	O
number	O
of	O
patients	O
analyzed	O
in	O
this	O
study	O
was	O
very	O
limited	O
,	O
and	O
a	O
larger	O
study	O
with	O
bigger	O
sample	O
size	O
is	O
needed	O
to	O
confirm	O
this	O
result	O
.	O

Single	O
nucleotide	O
polymorphism	O
discovery	O
in	O
TBX1	O
in	O
individuals	O
with	O
and	O
without	O
22q11.2	O
deletion	O
syndrome	O
.	O

BACKGROUND	O
:	O
Children	O
with	O
22q11.2	O
deletion	O
syndrome	O
(22q11.2DS)	O
have	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
.	O

TBX1	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
gene	O
for	O
some	O
of	O
the	O
features	O
in	O
this	O
condition	O
.	O

Polymorphisms	O
in	O
the	O
nondeleted	O
TBX1	O
,	O
which	O
may	O
affect	O
the	O
function	O
of	O
the	O
sole	O
TBX1	O
gene	O
in	O
individuals	O
with	O
the	O
22q11.2DS	O
,	O
may	O
be	O
a	O
key	O
to	O
understanding	O
the	O
phenotypic	O
variability	O
among	O
individuals	O
with	O
a	O
shared	O
deletion	O
.	O

Comprehensive	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
by	O
resequencing	O
candidate	O
genes	O
can	O
identify	O
genetic	O
variants	O
that	O
influence	O
a	O
given	O
phenotype	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
characterize	O
the	O
sequence	O
variability	O
in	O
TBX1	O
by	O
identifying	O
all	O
common	O
SNPs	O
in	O
this	O
gene	O
.	O

METHODS	O
:	O
We	O
resequenced	O
TBX1	O
in	O
29	O
children	O
with	O
a	O
documented	O
22q11.2	O
deletion	O
and	O
95	O
nondeleted	O
,	O
healthy	O
individuals	O
.	O

We	O
estimated	O
allele	O
frequencies	O
,	O
performed	O
tagSNP	O
selection	O
,	O
and	O
inferred	O
haplotypes	O
.	O

We	O
also	O
compared	O
SNP	O
frequencies	O
between	O
22q11.2DS	O
and	O
control	O
samples	O
.	O

RESULTS	O
:	O
We	O
identified	O
355	O
biallelic	O
markers	O
among	O
the	O
190	O
chromosomes	O
resequenced	O
in	O
the	O
control	O
panel	O
.	O

The	O
vast	O
majority	O
of	O
the	O
markers	O
identified	O
were	O
SNPs	O
(	O
n	O
=	O
331	O
)	O
,	O
and	O
the	O
remainder	O
indels	O
(	O
n	O
=	O
24	O
)	O
.	O

We	O
did	O
not	O
identify	O
SNPs	O
or	O
indels	O
in	O
the	O
cis-	O
regulatory	O
element	O
(	O
FOX-binding	O
site	O
)	O
upstream	O
of	O
TBX1	O
.	O

In	O
children	O
with	O
22q11.2DS	O
we	O
detected	O
187	O
biallelic	O
markers	O
,	O
six	O
of	O
which	O
were	O
indels	O
.	O

Four	O
of	O
the	O
seven	O
coding	O
SNPs	O
identified	O
in	O
the	O
controls	O
were	O
identified	O
in	O
children	O
with	O
22q11.2DS	O
.	O

CONCLUSIONS	O
:	O
This	O
comprehensive	O
SNP	O
discovery	O
data	O
can	O
be	O
used	O
to	O
select	O
SNPs	O
to	O
genotype	O
for	O
future	O
association	O
studies	O
assessing	O
the	O
role	O
of	O
TBX1	O
and	O
phenotypic	O
variability	O
in	O
individuals	O
with	O
22q11.2DS	O
.	O

Matriptase-2	O
mutations	O
in	O
iron-refractory	O
iron	O
deficiency	O
anemia	O
patients	O
provide	O
new	O
insights	O
into	O
protease	O
activation	O
mechanisms	O
.	O

Mutations	O
leading	O
to	O
abrogation	O
of	O
matriptase-2	O
proteolytic	O
activity	O
in	O
humans	O
are	O
associated	O
with	O
an	O
iron-refractory	O
iron	O
deficiency	O
anemia	O
(IRIDA)	O
due	O
to	O
elevated	O
hepcidin	O
levels	O
.	O

Here	O
we	O
describe	O
two	O
novel	O
heterozygous	O
mutations	O
within	O
the	O
matriptase-2	O
(TMPRSS6)	O
gene	O
of	O
monozygotic	O
twin	O
girls	O
exhibiting	O
an	O
IRIDA	O
phenotype	O
.	O

The	O
first	O
is	O
the	O
frameshift	O
mutation	O
P686fs	B-ProteinMutation
caused	O
by	O
the	O
insertion	O
of	O
the	O
four	O
nucleotides	O
CCCC	O
in	O
exon	O
16	O
2172_2173insCCCC	B-DNAMutation
that	O
is	O
predicted	O
to	O
terminate	O
translation	O
before	O
the	O
catalytic	O
serine	O
.	O

The	O
second	O
mutation	O
is	O
the	O
di-nucleotide	O
substitution	O
c.467C>A	B-DNAMutation
and	O
c.468C>T	B-DNAMutation
in	O
exon	O
3	O
that	O
causes	O
the	O
missense	O
mutation	O
A118D	B-ProteinMutation
in	O
the	O
SEA	O
domain	O
of	O
the	O
extracellular	O
stem	O
region	O
of	O
matriptase-2	O
.	O

Functional	O
analysis	O
of	O
both	O
variant	O
matriptase-2	O
proteases	O
has	O
revealed	O
that	O
they	O
lead	O
to	O
ineffective	O
suppression	O
of	O
hepcidin	O
transcription	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
A118D	B-ProteinMutation
SEA	O
domain	O
mutation	O
causes	O
an	O
intra-molecular	O
structural	O
imbalance	O
that	O
impairs	O
matriptase-2	O
activation	O
.	O

Collectively	O
,	O
these	O
results	O
extend	O
the	O
pattern	O
of	O
TMPRSS6	O
mutations	O
associated	O
with	O
IRIDA	O
and	O
functionally	O
demonstrate	O
that	O
mutations	O
affecting	O
protease	O
regions	O
other	O
than	O
the	O
catalytic	O
domain	O
may	O
have	O
a	O
profound	O
impact	O
in	O
the	O
regulatory	O
role	O
of	O
matriptase-2	O
during	O
iron	O
deficiency	O
.	O

Serotonin	O
transporter	O
gene	O
polymorphic	O
element	O
5-HTTLPR	O
increases	O
the	O
risk	O
of	O
sporadic	O
Parkinson's	O
disease	O
in	O
Italy	O
.	O

Parkinson's	O
disease	O
(PD)	O
is	O
a	O
neurodegenerative	O
disorder	O
causing	O
muscular	O
rigidity	O
,	O
resting	O
tremor	O
and	O
bradykinesia	O
.	O

We	O
conducted	O
an	O
association	O
study	O
assessing	O
how	O
PD	O
risk	O
in	O
Italy	O
was	O
influenced	O
by	O
the	O
serotonin	O
transporter	O
gene	O
(SLC6A4)	O
polymorphic	O
region	O
5-HTTLPR	O
,	O
consisting	O
of	O
an	O
insertion/deletion	O
(	O
long	O
allele-L/short	O
allele-S	O
)	O
of	O
43	O
bp	O
in	O
the	O
SLC6A4	O
promoter	O
region	O
.	O

The	O
SLC6A4	O
promoter	O
single	O
nucleotide	O
polymorphism	O
rs25531	B-SNP
A-->G	B-DNAMutation
was	O
evaluated	O
too	O
.	O

We	O
collected	O
837	O
independent	O
subjects	O
(	O
393	O
PD	O
,	O
444	O
controls	O
)	O
.	O

An	O
association	O
between	O
the	O
5-HTTLPR	O
polymorphism	O
and	O
risk	O
of	O
PD	O
(	O
S/S	O
genotype	O
OR	O
[	O
95%	O
CI	O
]	O
:	O
1.7[1.2-2.5]	O
,	O
p	O
=	O
0.002	O
)	O
was	O
found	O
.	O

The	O
rs25531	B-SNP
and	O
the	O
haplotype	O
5-HTTLPR/	O
rs25531	B-SNP
did	O
not	O
associate	O
with	O
risk	O
of	O
PD	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
5-HTTLPR	O
polymorphic	O
element	O
within	O
the	O
SLC6A4	O
promoter	O
may	O
govern	O
the	O
genetic	O
risk	O
of	O
PD	O
in	O
Italians	O
.	O

Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	O
patients	O
.	O

Asthma	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
airways	O
.	O

Several	O
candidate	O
genes	O
have	O
been	O
identified	O
with	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
including	O
the	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
gene	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
frequency	O
of	O
an	O
ACE	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	O
patients	O
and	O
to	O
determine	O
its	O
impact	O
on	O
clinical	O
parameters	O
and	O
disease	O
severity	O
.	O

Ninety-seven	O
asthmatic	O
patients	O
(	O
M/F	O
25/72	O
,	O
mean	O
age	O
39	O
+/-	O
13	O
years	O
)	O
and	O
96	O
healthy	O
subjects	O
(	O
M/F	O
26/70	O
,	O
mean	O
age	O
38	O
+/-	O
12	O
years	O
)	O
were	O
included	O
.	O

At	O
baseline	O
,	O
all	O
participants	O
completed	O
a	O
questionnaire	O
on	O
demographics	O
,	O
symptoms	O
,	O
triggering	O
factors	O
,	O
severity	O
of	O
asthma	O
,	O
and	O
the	O
presence	O
of	O
atopism	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
all	O
patients	O
and	O
genomic	O
DNA	O
was	O
isolated	O
.	O

The	O
frequency	O
of	O
the	O
ACE	O
genotypes	O
(	O
I	O
=	O
insertion	O
and	O
D	O
=	O
deletion	O
)	O
among	O
asthmatics	O
and	O
controls	O
were	O
compared	O
:	O
asthmatics	O
showed	O
a	O
40.2%	O
prevalence	O
of	O
the	O
DD	O
genotype	O
(	O
n	O
=	O
39	O
)	O
,	O
ID	O
was	O
45.4%	O
(	O
n	O
=	O
44	O
)	O
,	O
and	O
II	O
was	O
14.4%	O
(	O
n	O
=	O
14.4	O
)	O
.	O

In	O
the	O
control	O
subjects	O
,	O
the	O
frequency	O
of	O
DD	O
was	O
18.8%	O
(	O
n	O
=	O
18	O
)	O
,	O
ID	O
was	O
50%	O
(	O
n	O
=	O
48	O
)	O
and	O
II	O
was	O
31.3%	O
(	O
n	O
=	O
30	O
)	O
.	O

The	O
DD	O
ACE	O
genotype	O
was	O
significantly	O
more	O
frequent	O
in	O
asthmatics	O
compared	O
with	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Asthmatics	O
with	O
the	O
ID	O
ACE	O
genotype	O
showed	O
a	O
higher	O
frequency	O
of	O
drug	O
allergies	O
,	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.08	O
)	O
.	O

Asthmatics	O
with	O
the	O
DD	O
genotype	O
appeared	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
asthmatic	O
episode	O
exacerbations	O
due	O
to	O
viral	O
infections	O
,	O
but	O
again	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.08	O
)	O
.	O

Patients	O
with	O
mild	O
or	O
moderate-severe	O
asthma	O
had	O
similar	O
frequencies	O
of	O
these	O
mutations	O
.	O

We	O
found	O
a	O
higher	O
frequency	O
of	O
the	O
ACE	O
DD	O
gene	O
mutation	O
in	O
Turkish	O
asthmatic	O
patients	O
compared	O
with	O
non-asthmatics	O
,	O
suggesting	O
that	O
this	O
ACE	O
gene	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
asthma	O
but	O
does	O
not	O
increase	O
the	O
severity	O
of	O
the	O
disease	O
.	O

The	O
role	O
of	O
the	O
CCR5	O
Delta32	B-DNAMutation
polymorphism	O
in	O
abdominal	O
aortic	O
aneurysms	O
.	O

BACKGROUND	O
:	O
C-C	O
chemokine	O
receptor	O
5	O
(CCR5)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O

Abdominal	O
aortic	O
aneurysms	O
(AAA)	O
may	O
arise	O
as	O
the	O
result	O
of	O
a	O
chronic	O
inflammatory	O
process	O
which	O
is	O
influenced	O
by	O
genetic	O
predisposition	O
.	O

The	O
CCR5	O
gene	O
is	O
associated	O
with	O
a	O
32	O
base	O
pair	O
deletion	O
(	O
the	O
Delta32	B-DNAMutation
polymorphism	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
CCR5	O
Delta32	B-DNAMutation
polymorphism	O
in	O
the	O
development	O
of	O
AAA	O
.	O

METHODS	O
:	O
A	O
case-control	O
study	O
was	O
conducted	O
including	O
285	O
patients	O
with	O
AAA	O
and	O
273	O
control	O
subjects	O
.	O

A	O
blood	O
sample	O
was	O
taken	O
from	O
each	O
individual	O
and	O
DNA	O
was	O
extracted	O
.	O

CCR5	O
genotype	O
was	O
determined	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Flow	O
cytometry	O
was	O
used	O
to	O
investigate	O
the	O
biological	O
activity	O
of	O
the	O
Delta32	B-DNAMutation
polymorphism	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
AAA	O
and	O
the	O
control	O
group	O
in	O
relation	O
to	O
the	O
Delta32	B-DNAMutation
allele	O
frequency	O
(	O
AAA	O
group	O
10%	O
,	O
control	O
group	O
=	O
12%	O
,	O
P	O
=	O
0.82	O
,	O
chi-squared	O
analysis	O
)	O
.	O

Genotype	O
analysis	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
(	O
AAA	O
vs	O
.	O

controls	O
,	O
wild-type	O
homozygotes	O
=	O
82%	O
vs	O
.	O

77%	O
,	O
heterozygotes	O
=	O
16%	O
vs	O
.	O

21%	O
,	O
vs	O
.	O

Delta32	B-DNAMutation
homozygotes	O
=	O
2%	O
and	O
2%	O
,	O
respectively	O
,	O
P	O
=	O
0.33	O
,	O
chi-squared	O
analysis	O
)	O
.	O

The	O
polymorphism	O
was	O
shown	O
to	O
be	O
biologically	O
active	O
with	O
the	O
number	O
of	O
Delta32	B-DNAMutation
alleles	O
correlating	O
with	O
cell	O
expression	O
of	O
ccr5	O
as	O
detected	O
with	O
flow	O
cytometry	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
the	O
ccr5	O
Delta32	B-DNAMutation
is	O
a	O
biologically	O
active	O
genetic	O
polymorphism	O
;	O
however	O
,	O
there	O
is	O
no	O
association	O
between	O
this	O
polymorphism	O
and	O
AAA	O
.	O

Marked	O
high	O
density	O
lipoprotein	O
deficiency	O
due	O
to	O
apolipoprotein	O
A-I	O
Tomioka	O
(	O
codon	O
138	O
deletion	O
)	O
.	O

We	O
report	O
a	O
novel	O
apolipoprotein	O
A-I	O
(apoA-I)	O
mutation	O
identified	O
in	O
a	O
64-year-old	O
patient	O
with	O
marked	O
plasma	O
high	O
density	O
lipoprotein	O
(HDL)	O
cholesterol	O
(	O
4	O
mg/dl	O
)	O
and	O
apoA-I	O
(5mg/dl)	O
deficiency	O
,	O
prior	O
myocardial	O
infarction	O
,	O
and	O
moderate	O
corneal	O
opacities	O
.	O

Coronary	O
angiography	O
revealed	O
extensive	O
atherosclerosis	O
in	O
all	O
three	O
major	O
vessels	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
the	O
proband	O
revealed	O
a	O
homozygous	O
novel	O
deletion	O
of	O
two	O
successive	O
adenine	O
residues	O
in	O
codon	O
138	O
in	O
the	O
apoA-I	O
gene	O
,	O
resulting	O
in	O
a	O
frameshift	O
mutation	O
at	O
amino	O
acid	O
residues	O
138-178	O
,	O
which	O
we	O
have	O
designated	O
as	O
apoA-I	O
Tomioka	O
.	O

His	O
elder	O
brother	O
was	O
also	O
homozygous	O
for	O
apoA-I	O
Tomioka	O
with	O
marked	O
HDL	O
cholesterol	O
and	O
apoA-I	O
deficiency	O
,	O
but	O
had	O
no	O
clinical	O
evidence	O
of	O
coronary	O
heart	O
disease	O
.	O

Other	O
family	O
members	O
including	O
three	O
siblings	O
and	O
two	O
sons	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
and	O
had	O
approximately	O
50%	O
of	O
normal	O
plasma	O
HDL	O
cholesterol	O
,	O
and	O
apoA-I	O
.	O

Analysis	O
of	O
apoA-I-containing	O
HDL	O
particles	O
by	O
two-dimensional	O
gel	O
electrophoresis	O
revealed	O
undetectable	O
apoA-I	O
HDL	O
particles	O
in	O
the	O
homozygotes	O
,	O
while	O
in	O
heterozygotes	O
,	O
the	O
mean	O
concentrations	O
of	O
apoA-I	O
in	O
large	O
alpha-1	O
and	O
very	O
small	O
prebeta-1	O
HDL	O
subpopulations	O
were	O
significantly	O
decreased	O
at	O
about	O
35%	O
of	O
normal	O
.	O

Thus	O
,	O
apoA-I	O
Tomioka	O
,	O
a	O
novel	O
deletion	O
mutation	O
in	O
codon	O
138	O
of	O
the	O
apoA-I	O
gene	O
,	O
is	O
the	O
causative	O
defect	O
in	O
this	O
case	O
of	O
HDL	O
deficiency	O
.	O

Correlation	O
of	O
polymorphism	O
of	O
the	O
coding	O
region	O
of	O
glutathione	O
S-	O
transferase	O
M1	O
to	O
susceptibility	O
of	O
nasopharyngeal	O
carcinoma	O
in	O
South	O
China	O
population	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Glutathione	O
S-transferase	O
M1	O
(GSTM1)	O
deficiency	O
may	O
increase	O
the	O
risk	O
of	O
nasopharyngeal	O
carcinoma	O
(NPC)	O
.	O

This	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
of	O
the	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
coding	O
region	O
of	O
GSTM1	O
gene	O
to	O
NPC	O
susceptibility	O
in	O
southern	O
China	O
population	O
.	O

METHODS	O
:	O
In	O
total	O
239	O
NPC	O
patients	O
and	O
286	O
age-matched	O
healthy	O
controls	O
were	O
entered	O
into	O
the	O
study	O
.	O

Among	O
them	O
,	O
225	O
out	O
of	O
239	O
NPC	O
patients	O
and	O
273	O
out	O
of	O
286	O
controls	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

SNP	O
screening	O
of	O
all	O
exons	O
,	O
relevant	O
intron-exon	O
boundaries	O
,	O
and	O
the	O
promoter	O
region	O
of	O
GSTM1	O
,	O
in	O
total	O
4739bp	O
,	O
was	O
performed	O
by	O
PCR	O
direct	O
sequencing	O
.	O

The	O
loci	O
T1270533G	B-DNAMutation
and	O
C1256088C	O
were	O
selected	O
for	O
the	O
case-control	O
study	O
using	O
the	O
tetra-Primer	O
ARMS-PCR	O
,	O
as	O
well	O
as	O
the	O
sequencing	O
method	O
.	O

RESULTS	O
:	O
In	O
total	O
29	O
SNPs	O
of	O
GSTM1	O
were	O
identified	O
by	O
sequencing	O
.	O

Missense	O
mutation	O
occurred	O
in	O
the	O
polymorphic	O
loci	O
of	O
T1270533G	B-DNAMutation
and	O
C1256088C	O
.	O

However	O
,	O
no	O
evident	O
relationships	O
between	O
the	O
variants	O
of	O
T1270533G	B-DNAMutation
and	O
clinical	O
phenotypes	O
of	O
NPC	O
were	O
observed	O
in	O
the	O
NPC	O
group	O
and	O
healthy	O
control	O
group	O
(	O
OR	O
=	O
0.170	O
,	O
95%CI	O
=	O
0.95-0.306	O
for	O
homozygote	O
TT	O
)	O
.	O

The	O
deletion	O
frequency	O
of	O
C1256088C	O
was	O
45%	O
(45/100)	O
for	O
NPC	O
patients	O
and	O
42%	O
(42/100)	O
for	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphism	O
of	O
T1270533G	B-DNAMutation
does	O
not	O
affect	O
the	O
detoxification	O
function	O
of	O
GSTM1	O
.	O

The	O
T1270533G	B-DNAMutation
locus	O
has	O
no	O
apparent	O
association	O
with	O
genetic	O
susceptibility	O
to	O
NPC	O
in	O
the	O
southern	O
China	O
population	O
.	O

The	O
loss	O
rate	O
of	O
C1256088C	O
is	O
high	O
in	O
this	O
study	O
.	O

High-resolution	O
genomic	O
copy	O
number	O
profiling	O
of	O
glioblastoma	O
multiforme	O
by	O
single	O
nucleotide	O
polymorphism	O
DNA	O
microarray	O
.	O

Glioblastoma	O
multiforme	O
(GBM)	O
is	O
an	O
extremely	O
malignant	O
brain	O
tumor	O
.	O

To	O
identify	O
new	O
genomic	O
alterations	O
in	O
GBM	O
,	O
genomic	O
DNA	O
of	O
tumor	O
tissue/explants	O
from	O
55	O
individuals	O
and	O
6	O
GBM	O
cell	O
lines	O
were	O
examined	O
using	O
single	O
nucleotide	O
polymorphism	O
DNA	O
microarray	O
(SNP-Chip)	O
.	O

Further	O
gene	O
expression	O
analysis	O
relied	O
on	O
an	O
additional	O
56	O
GBM	O
samples	O
.	O

SNP-Chip	O
results	O
were	O
validated	O
using	O
several	O
techniques	O
,	O
including	O
quantitative	O
PCR	O
(Q-PCR)	O
,	O
nucleotide	O
sequencing	O
,	O
and	O
a	O
combination	O
of	O
Q-PCR	O
and	O
detection	O
of	O
microsatellite	O
markers	O
for	O
loss	O
of	O
heterozygosity	O
with	O
normal	O
copy	O
number	O
[	O
acquired	O
uniparental	O
disomy	O
(	O
AUPD	O
)	O
]	O
.	O

Whole	O
genomic	O
DNA	O
copy	O
number	O
in	O
each	O
GBM	O
sample	O
was	O
profiled	O
by	O
SNP-Chip	O
.	O

Several	O
signaling	O
pathways	O
were	O
frequently	O
abnormal	O
.	O

Either	O
the	O
p16(INK4A)/p15(INK4B)-CDK4/6-pRb	O
or	O
p14(ARF)-MDM2/4-p53	O
pathways	O
were	O
abnormal	O
in	O
89%	O
(	O
49	O
of	O
55	O
)	O
of	O
cases	O
.	O

Simultaneous	O
abnormalities	O
of	O
both	O
pathways	O
occurred	O
in	O
84%	O
(	O
46	O
of	O
55	O
)	O
samples	O
.	O

The	O
phosphoinositide	O
3-kinase	O
pathway	O
was	O
altered	O
in	O
71%	O
(	O
39	O
of	O
55	O
)	O
GBMs	O
either	O
by	O
deletion	O
of	O
PTEN	O
or	O
amplification	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
and/or	O
vascular	O
endothelial	O
growth	O
factor	O
receptor/platelet-derived	O
growth	O
factor	O
receptor	O
alpha	O
.	O

Deletion	O
of	O
chromosome	O
6q26-27	O
often	O
occurred	O
(	O
16	O
of	O
55	O
samples	O
)	O
.	O

The	O
minimum	O
common	O
deleted	O
region	O
included	O
PARK2	O
,	O
PACRG	O
,	O
QKI	O
,	O
and	O
PDE10A	O
genes	O
.	O

Further	O
reverse	O
transcription	O
Q-PCR	O
studies	O
showed	O
that	O
PARK2	O
expression	O
was	O
decreased	O
in	O
another	O
collection	O
of	O
GBMs	O
at	O
a	O
frequency	O
of	O
61%	O
(	O
34	O
of	O
56	O
)	O
of	O
samples	O
.	O

The	O
1p36.23	O
region	O
was	O
deleted	O
in	O
35%	O
(	O
19	O
of	O
55	O
)	O
of	O
samples	O
.	O

Notably	O
,	O
three	O
samples	O
had	O
homozygous	O
deletion	O
encompassing	O
this	O
site	O
.	O

Also	O
,	O
a	O
novel	O
internal	O
deletion	O
of	O
a	O
putative	O
tumor	O
suppressor	O
gene	O
,	O
LRP1B	O
,	O
was	O
discovered	O
causing	O
an	O
aberrant	O
protein	O
.	O

AUPDs	O
occurred	O
in	O
58%	O
(	O
32	O
of	O
55	O
)	O
of	O
the	O
GBM	O
samples	O
and	O
five	O
of	O
six	O
GBM	O
cell	O
lines	O
.	O

A	O
common	O
AUPD	O
was	O
found	O
at	O
chromosome	O
17p13.3-12	O
(	O
included	O
p53	O
gene	O
)	O
in	O
13	O
of	O
61	O
samples	O
and	O
cell	O
lines	O
.	O

Single-strand	O
conformational	O
polymorphism	O
and	O
nucleotide	O
sequencing	O
showed	O
that	O
9	O
of	O
13	O
of	O
these	O
samples	O
had	O
homozygous	O
p53	O
mutations	O
,	O
suggesting	O
that	O
mitotic	O
recombination	O
duplicated	O
the	O
abnormal	O
p53	O
gene	O
,	O
probably	O
providing	O
a	O
growth	O
advantage	O
to	O
these	O
cells	O
.	O

A	O
significantly	O
shortened	O
survival	O
time	O
was	O
found	O
in	O
patients	O
with	O
13q14	O
(RB)	O
deletion	O
or	O
17p13.1	O
(p53)	O
deletion/AUPD	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
this	O
technique	O
is	O
a	O
rapid	O
,	O
robust	O
,	O
and	O
inexpensive	O
method	O
to	O
profile	O
genome-wide	O
abnormalities	O
in	O
GBM	O
.	O

A	O
large	O
Swiss	O
family	O
with	O
Bernard-Soulier	O
syndrome	O
-	O
Correlation	O
phenotype	O
and	O
genotype	O
.	O

Bernard-Soulier	O
syndrome	O
(BSS)	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
inherited	O
bleeding	O
disorder	O
associated	O
with	O
thrombocytopenia	O
,	O
thrombocytopathy	O
and	O
giant	O
platelets	O
.	O

BSS	O
is	O
caused	O
by	O
genetic	O
alterations	O
of	O
the	O
glycoprotein	O
(GP)	O
Ib/V/IX	O
complex	O
.	O

We	O
report	O
on	O
a	O
large	O
Swiss	O
family	O
of	O
whom	O
four	O
family	O
members	O
suffer	O
from	O
BSS	O
.	O

Here	O
,	O
a	O
homozygous	O
missense	O
mutation	O
in	O
position	O
1829	O
(A(R)G)	O
of	O
the	O
GPIX	O
gene	O
constituting	O
a	O
N45S	B-ProteinMutation
substitution	O
is	O
the	O
cause	O
for	O
the	O
bleeding	O
symptoms	O
.	O

A	O
total	O
of	O
38	O
family	O
members	O
within	O
two	O
generations	O
were	O
analyzed	O
regarding	O
the	O
N45S	B-ProteinMutation
mutation	O
by	O
DNA	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

The	O
laboratory	O
parameters	O
which	O
are	O
characteristically	O
for	O
BSS	O
such	O
as	O
platelet	O
count	O
,	O
platelet	O
volume	O
and	O
the	O
expression	O
of	O
CD42a	O
(GPIX)	O
,	O
CD42b	O
(GPIbalpha)	O
and	O
CD41	O
(GPIIb)	O
were	O
measured	O
for	O
all	O
38	O
individuals	O
.	O

The	O
four	O
homozygous	O
patients	O
showed	O
bleeding	O
symptoms	O
,	O
thrombocytopenia	O
and	O
giant	O
platelets	O
.	O

In	O
these	O
patients	O
,	O
the	O
expression	O
of	O
CD42a	O
(GPIX)	O
,	O
CD42b	O
(GPIbalpha)	O
was	O
diminished	O
.	O

Interestingly	O
,	O
the	O
intensity	O
of	O
the	O
bleeding	O
symptoms	O
of	O
the	O
4	O
homozygous	O
family	O
members	O
seemed	O
to	O
vary	O
although	O
they	O
carry	O
the	O
same	O
mutation	O
.	O

The	O
24	O
heterozygous	O
carriers	O
did	O
not	O
differ	O
significantly	O
from	O
their	O
10	O
wildtype	O
family	O
members	O
regarding	O
bleeding	O
symptoms	O
and	O
laboratory	O
analysis	O
.	O

Identification	O
and	O
molecular	O
characterization	O
of	O
six	O
novel	O
mutations	O
in	O
the	O
UDP-N-acetylglucosamine-1-phosphotransferase	O
gamma	O
subunit	O
(GNPTG)	O
gene	O
in	O
patients	O
with	O
mucolipidosis	O
III	O
gamma	O
.	O

Mucolipidosis	O
type	O
III	O
(MLIII)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
affecting	O
lysosomal	O
hydrolase	O
trafficking	O
.	O

In	O
a	O
study	O
of	O
10	O
patients	O
from	O
seven	O
families	O
with	O
a	O
clinical	O
phenotype	O
and	O
enzymatic	O
diagnosis	O
of	O
MLIII	O
,	O
six	O
novel	O
GNPTG	O
gene	O
mutations	O
were	O
identified	O
.	O

These	O
included	O
missense	O
p.T286M	B-ProteinMutation
and	O
nonsense	O
p.W111X	B-ProteinMutation
mutations	O
and	O
a	O
transition	O
in	O
the	O
obligate	O
AG-dinucleotide	O
of	O
the	O
intron	O
8	O
acceptor	O
splice	O
site	O
c.610-2A>G	B-DNAMutation
.	O

Three	O
microdeletions	O
were	O
also	O
identified	O
,	O
two	O
of	O
which	O
(	O
c.611delG	B-DNAMutation
and	O
c.640_667del28	B-DNAMutation
)	O
were	O
located	O
within	O
the	O
coding	O
region	O
whereas	O
one	O
c.609+28_610-16del	B-DNAMutation
was	O
located	O
entirely	O
within	O
intron	O
8	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
c.610-2A>G	B-DNAMutation
transition	O
demonstrated	O
that	O
the	O
change	O
altered	O
splicing	O
,	O
leading	O
to	O
the	O
production	O
of	O
two	O
distinct	O
aberrantly	O
spliced	O
forms	O
,	O
viz	O
.	O

the	O
skipping	O
of	O
exon	O
9	O
p.G204_K247del	B-ProteinMutation
or	O
the	O
retention	O
of	O
introns	O
8	O
and	O
9	O
p.G204VfsX28	B-ProteinMutation
.	O

RT-PCR	O
analysis	O
,	O
performed	O
on	O
a	O
patient	O
homozygous	O
for	O
the	O
intronic	O
deletion	O
c.609+28_610-16del	B-DNAMutation
,	O
failed	O
to	O
detect	O
any	O
GNPTG	O
RNA	O
transcripts	O
.	O

To	O
determine	O
whether	O
c.609+28_610-16del	B-DNAMutation
allele-derived	O
transcripts	O
were	O
subject	O
to	O
nonsense-mediated	O
mRNA	O
decay	O
(NMD)	O
,	O
patient	O
fibroblasts	O
were	O
incubated	O
with	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

An	O
RT-PCR	O
fragment	O
retaining	O
43	O
bp	O
of	O
intron	O
8	O
was	O
consistently	O
detected	O
suggesting	O
that	O
the	O
33-bp	O
genomic	O
deletion	O
had	O
elicited	O
NMD	O
.	O

Quantitative	O
real-time	O
PCR	O
and	O
GNPTG	O
western	O
blot	O
analysis	O
confirmed	O
that	O
the	O
homozygous	O
microdeletion	O
p.G204VfsX17	B-ProteinMutation
had	O
elicited	O
NMD	O
resulting	O
in	O
failure	O
to	O
synthesize	O
GNPTG	O
protein	O
.	O

Analysis	O
of	O
the	O
sequences	O
surrounding	O
the	O
microdeletion	O
breakpoints	O
revealed	O
either	O
intrinsic	O
repetitivity	O
of	O
the	O
deleted	O
region	O
or	O
short	O
direct	O
repeats	O
adjacent	O
to	O
the	O
breakpoint	O
junctions	O
.	O

This	O
is	O
consistent	O
with	O
these	O
repeats	O
having	O
mediated	O
the	O
microdeletions	O
via	O
replication	O
slippage	O
and	O
supports	O
the	O
view	O
that	O
the	O
mutational	O
spectrum	O
of	O
the	O
GNPTG	O
gene	O
is	O
strongly	O
influenced	O
by	O
the	O
properties	O
of	O
the	O
local	O
DNA	O
sequence	O
environment	O
.	O

Pure	O
monosomy	O
and	O
pure	O
trisomy	O
of	O
13q21.2-31.1	O
consequent	O
to	O
a	O
familial	O
insertional	O
translocation	O
:	O
exclusion	O
of	O
PCDH9	O
as	O
the	O
responsible	O
gene	O
for	O
autosomal	O
dominant	O
auditory	O
neuropathy	O
(AUNA1)	O
.	O

Insertional	O
translocations	O
(IT)	O
are	O
rare	O
structural	O
rearrangements	O
.	O

Offspring	O
of	O
IT	O
balanced	O
carriers	O
are	O
at	O
high	O
risk	O
to	O
have	O
either	O
pure	O
partial	O
trisomy	O
or	O
monosomy	O
for	O
the	O
inserted	O
segment	O
as	O
manifested	O
by	O
"pure"	O
phenotypes	O
.	O

We	O
describe	O
an	O
IT	O
between	O
chromosomes	O
3	O
and	O
13	O
segregating	O
in	O
a	O
three-generation	O
pedigree	O
.	O

Short	O
tandem	O
repeat	O
(STR)	O
segregation	O
analysis	O
and	O
array-comparative	O
genomic	O
hybridization	O
were	O
used	O
to	O
define	O
the	O
IT	O
as	O
a	O
25.1	O
Mb	O
segment	O
spanning	O
13q21.2-q31.1	O
.	O

The	O
phenotype	O
of	O
pure	O
monosomy	O
included	O
deafness	O
,	O
duodenal	O
stenosis	O
,	O
developmental	O
and	O
growth	O
delay	O
,	O
vertebral	O
anomalies	O
,	O
and	O
facial	O
dysmorphisms	O
;	O
the	O
trisomy	O
was	O
manifested	O
by	O
only	O
minor	O
dysmorphisms	O
.	O

As	O
the	O
AUNA1	O
deafness	O
locus	O
on	O
13q14-21	O
overlaps	O
the	O
IT	O
in	O
the	O
PCDH9	O
(protocadherin-9)	O
gene	O
region	O
,	O
PCDH9	O
was	O
investigated	O
as	O
a	O
candidate	O
gene	O
for	O
deafness	O
in	O
both	O
families	O
.	O

Genotyping	O
of	O
STRs	O
and	O
single	O
nucleotide	O
polymorphisms	O
defined	O
the	O
AUNA1	O
breakpoint	O
as	O
35	O
kb	O
5'	O
to	O
PCDH9	O
,	O
with	O
a	O
2.4	O
Mb	O
area	O
of	O
overlap	O
with	O
the	O
IT	O
.	O

DNA	O
sequencing	O
of	O
coding	O
regions	O
in	O
the	O
AUNA1	O
family	O
and	O
in	O
the	O
retained	O
homologue	O
chromosome	O
in	O
the	O
monosomic	O
patient	O
revealed	O
no	O
mutations	O
.	O

We	O
conclude	O
that	O
AUNA1	O
deafness	O
does	O
not	O
share	O
a	O
common	O
etiology	O
with	O
deafness	O
associated	O
with	O
monosomy	O
13q21.2-q31.3	O
;	O
deafness	O
may	O
result	O
from	O
monosomy	O
of	O
PCHD9	O
or	O
another	O
gene	O
in	O
the	O
IT	O
,	O
as	O
has	O
been	O
demonstrated	O
in	O
contiguous	O
gene	O
deletion	O
syndromes	O
.	O

Precise	O
characterization	O
of	O
the	O
breakpoints	O
of	O
the	O
translocated	O
region	O
is	O
useful	O
to	O
identify	O
which	O
genes	O
may	O
be	O
contributing	O
to	O
the	O
phenotype	O
,	O
either	O
through	O
haploinsufficiency	O
or	O
extra	O
dosage	O
effects	O
,	O
in	O
order	O
to	O
define	O
genotype-phenotype	O
correlations	O
.	O

A	O
simple	O
multiplex	O
real-time	O
PCR	O
methodology	O
for	O
the	O
SMN1	O
gene	O
copy	O
number	O
quantification	O
.	O

Spinal	O
muscular	O
atrophy	O
(SMA)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
,	O
in	O
about	O
95%	O
of	O
SMA	O
cases	O
,	O
by	O
homozygous	O
deletion	O
of	O
the	O
survival	O
motor	O
neuron	O
1	O
(SMN1)	O
gene	O
or	O
its	O
conversion	O
to	O
the	O
highly	O
homologous	O
SMN2	O
gene	O
.	O

The	O
molecular	O
diagnosis	O
of	O
SMA	O
is	O
usually	O
carried	O
out	O
by	O
a	O
PCR-Restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
approach	O
.	O

However	O
,	O
this	O
approach	O
is	O
not	O
useful	O
for	O
identification	O
of	O
healthy	O
deletion	O
carriers	O
.	O

TaqMan	O
technology	O
is	O
one	O
of	O
the	O
most	O
reliable	O
and	O
widely	O
adopted	O
techniques	O
for	O
the	O
SMN1	O
copy	O
number	O
evaluation	O
.	O

However	O
,	O
several	O
limitations	O
of	O
this	O
technique	O
have	O
been	O
described	O
.	O

Particularly	O
,	O
DNA	O
extraction	O
methods	O
and	O
accurate	O
template	O
quantification	O
have	O
been	O
shown	O
to	O
be	O
critical	O
for	O
reliable	O
results	O
.	O

In	O
this	O
work	O
,	O
we	O
set	O
up	O
a	O
reliable	O
,	O
highly	O
reproducible	O
,	O
and	O
easy-to-perform	O
TaqMan	O
technology-based	O
protocol	O
to	O
obtain	O
the	O
SMN1	O
gene	O
copy	O
number	O
assessment	O
.	O

We	O
demonstrate	O
that	O
PCR	O
amplification	O
of	O
both	O
target	O
gene	O
and	O
reference	O
gene	O
in	O
the	O
same	O
reaction	O
mix	O
,	O
instead	O
of	O
separated	O
mixes	O
,	O
greatly	O
reduces	O
reported	O
criticisms	O
of	O
simplex	O
TaqMan	O
technology	O
.	O

The	O
multiplex	O
real-time	O
PCR	O
we	O
describe	O
allows	O
interlaboratory	O
samples	O
and	O
data	O
exchange	O
,	O
without	O
the	O
need	O
to	O
equalize	O
the	O
DNA	O
isolation	O
technique	O
.	O

Further	O
,	O
the	O
protocol	O
described	O
below	O
requires	O
fewer	O
replica	O
tests	O
than	O
the	O
simplex	O
methodology	O
does	O
,	O
leading	O
to	O
reduced	O
overall	O
cost	O
for	O
the	O
diagnostic	O
assay	O
.	O

Phosphatidylinositol	O
3-kinase	O
p85alpha	O
regulatory	O
subunit	O
gene	O
Met326Ile	B-ProteinMutation
polymorphism	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

BACKGROUND	O
:	O
Insulin	O
resistance	O
is	O
a	O
core	O
feature	O
of	O
polycystic	O
ovary	O
syndrome	O
(PCOS)	O
.	O

Phosphatidylinositol	O
(PI)	O
3-kinase	O
is	O
an	O
important	O
enzyme	O
in	O
the	O
early	O
insulin	O
signaling	O
cascade	O
and	O
plays	O
a	O
key	O
role	O
in	O
insulin-mediated	O
glucose	O
transport	O
.	O

In	O
its	O
regulatory	O
subunit	O
,	O
p85alpha	O
,	O
there	O
is	O
a	O
common	O
amino	O
acid	O
substitution	O
(	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
)	O
,	O
and	O
this	O
amino	O
acid	O
may	O
be	O
crucial	O
for	O
the	O
function	O
of	O
the	O
p85alpha	O
regulatory	O
subunit	O
and	O
PI3-kinase	O
.	O

METHODS	O
:	O
Analysis	O
of	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
was	O
carried	O
out	O
on	O
DNA	O
samples	O
from	O
256	O
PCOS	O
patients	O
and	O
283	O
controls	O
.	O

Clinical	O
and	O
biochemical	O
profiles	O
of	O
participants	O
were	O
also	O
compared	O
.	O

RESULTS	O
:	O
The	O
genotype	O
distribution	O
of	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
in	O
the	O
PCOS	O
group	O
was	O
not	O
different	O
from	O
that	O
of	O
the	O
controls	O
(	O
Met326Met	O
/	O
Met326Ile	B-ProteinMutation
/	O
Ile326Ile	O
rates	O
were	O
73.4%/23.4%/3.2%	O
and	O
70.3%/26.1%/3.6%	O
for	O
the	O
PCOS	O
and	O
control	O
groups	O
,	O
respectively	O
,	O
P	O
=	O
0.72	O
)	O
.	O

The	O
PCOS	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
presence	O
of	O
the	O
variant	O
326Ile	O
allele	O
.	O

Compared	O
with	O
those	O
carrying	O
at	O
least	O
one	O
variant	O
326Ile	O
allele	O
,	O
carriers	O
with	O
the	O
Met326Met	O
genotype	O
had	O
higher	O
serum	O
17-hydroxyprogesterone	O
(17-OHP)	O
{1.1	O
[	O
95%	O
confidence	O
interval	O
(CI)	O
1.1-1.3	O
]	O
ng/ml	O
in	O
those	O
with	O
the	O
Met326Met	O
genotype	O
versus	O
0.8	O
(	O
95%	O
CI	O
0.7-1.0	O
)	O
ng/ml	O
in	O
those	O
with	O
Ile326Ile	O
and	O
Met326Ile	B-ProteinMutation
genotypes	O
,	O
P	O
=	O
0.0073}	O
and	O
free	O
testosterone	O
levels	O
[	O
1.2	O
(	O
95%	O
CI	O
1.1-1.4	O
)	O
pg/ml	O
for	O
Met326Met	O
genotype	O
versus	O
0.9	O
(	O
95%	O
CI	O
0.6-1.3	O
)	O
pg/ml	O
for	O
Ile326Ile	O
and	O
Met326Ile	B-ProteinMutation
genotypes	O
,	O
P	O
=	O
0.038	O
]	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
PI3-kinase	O
gene	O
Met326Ile	B-ProteinMutation
polymorphism	O
may	O
not	O
be	O
a	O
major	O
determinant	O
for	O
the	O
development	O
of	O
PCOS	O
,	O
but	O
it	O
may	O
modulate	O
the	O
concentrations	O
of	O
serum	O
17-OHP	O
or	O
free	O
testosterone	O
in	O
PCOS	O
patients	O
.	O

Identification	O
of	O
newly	O
polymorphic	O
intron	O
40	O
markers	O
of	O
the	O
von	O
Willebrand	O
factor	O
gene	O
in	O
a	O
Japanese	O
population	O
.	O

We	O
investigated	O
a	O
region	O
of	O
repetitive	O
DNA	O
located	O
in	O
intron	O
40	O
of	O
the	O
von	O
Willebrand	O
factor	O
(vWF)	O
gene	O
(	O
nucleotides	O
[nt]	O
1639-2404	O
;	O
i.e.	O
,	O
F8VWF	O
)	O
.	O

We	O
identified	O
13	O
alleles	O
and	O
33	O
genotypes	O
in	O
49	O
unrelated	O
Japanese	O
individuals	O
.	O

The	O
heterozygosity	O
of	O
the	O
region	O
was	O
0.897	O
.	O

Direct	O
sequence	O
analyses	O
revealed	O
five	O
single-base	O
substitutions	O
,	O
one	O
tetranucleotide	O
(TTAT)	O
insertion	O
,	O
and	O
seven	O
short	O
tandem	O
repeats	O
(STRs)	O
in	O
the	O
intron	O
;	O
four	O
of	O
the	O
STRs	O
and	O
one	O
single-base	O
substitution	O
had	O
been	O
reported	O
previously	O
.	O

The	O
four	O
new	O
base	O
substitutions	O
we	O
identified	O
were	O
1849T>A	B-DNAMutation
,	O
2122C>T	B-DNAMutation
,	O
2180C>T	B-DNAMutation
,	O
and	O
2192C>T	B-DNAMutation
.	O

The	O
novel	O
TTAT	O
tetranucleotide	O
was	O
inserted	O
between	O
nt	O
2057	O
and	O
2058	O
.	O

The	O
three	O
newly	O
identified	O
STRs	O
were	O
1978(TATC)(1-2)	B-DNAMutation
,	O
2193(ATCT)(5-13)	B-DNAMutation
,	O
and	O
2234(TGTA)(5-7)	B-DNAMutation
.	O

The	O
five	O
single-base	O
substitutions	O
and	O
the	O
TTAT	O
insertion	O
were	O
identified	O
only	O
with	O
3'	O
downstream	O
of	O
vWA	O
allele	O
14	O
.	O

Neurofibromin	O
1	O
(NF1)	O
defects	O
are	O
common	O
in	O
human	O
ovarian	O
serous	O
carcinomas	O
and	O
co-occur	O
with	O
TP53	O
mutations	O
.	O

Ovarian	O
serous	O
carcinoma	O
(OSC)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	O
epithelial	O
malignancy	O
.	O

Mutations	O
of	O
TP53	O
and	O
dysfunction	O
of	O
the	O
Brca1	O
and/or	O
Brca2	O
tumor-suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	O
,	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well-established	O
tumor-suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O

Using	O
a	O
genome-wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	O
,	O
we	O
identified	O
two	O
tumors	O
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	O
gene	O
.	O

Subsequently	O
,	O
18	O
ovarian	O
carcinoma-derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	O
were	O
evaluated	O
for	O
NF1	O
alterations	O
.	O

Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	O
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
,	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
,	O
NF1	O
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and/or	O
aberrant	O
splicing	O
of	O
NF1	O
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	O
expression	O
.	O

Similarly	O
,	O
NF1	O
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(22%)	O
of	O
41	O
primary	O
OSCs	O
.	O

As	O
expected	O
,	O
tumors	O
and	O
cell	O
lines	O
with	O
NF1	O
defects	O
lacked	O
mutations	O
in	O
KRAS	O
or	O
BRAF	O
but	O
showed	O
Ras	O
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	O
(	O
primary	O
tumors	O
)	O
or	O
increased	O
levels	O
of	O
GTP-bound	O
Ras	O
(	O
cell	O
lines	O
)	O
.	O

The	O
TP53	O
tumor-suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	O
with	O
documented	O
NF1	O
mutation	O
,	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor-suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	O
carcinomas	O
with	O
serous	O
differentiation	O
.	O

The	O
influence	O
of	O
interstitial	O
collagenase-1	O
genotype	O
polymorphism	O
on	O
colorectal	O
cancer	O
risk	O
in	O
Iranian	O
population	O
.	O

Interstitial	O
collagenase-1	O
degrades	O
a	O
variety	O
of	O
extracellular	O
matrix	O
components	O
.	O

A	O
single	O
guanine	O
insertion	O
polymorphism	O
in	O
the	O
promoter	O
has	O
been	O
found	O
that	O
influences	O
on	O
the	O
transcription	O
and	O
expression	O
level	O
of	O
the	O
gene	O
.	O

It	O
is	O
suggested	O
that	O
this	O
polymorphism	O
may	O
enhance	O
susceptibility	O
to	O
some	O
types	O
of	O
cancer	O
.	O

Therefore	O
,	O
this	O
case-control	O
study	O
evaluated	O
the	O
association	O
of	O
this	O
genotype	O
polymorphism	O
with	O
susceptibility	O
to	O
initiation	O
and	O
invasion	O
of	O
colorectal	O
cancer	O
.	O

For	O
this	O
reason	O
,	O
whole	O
blood	O
samples	O
were	O
obtained	O
from	O
150	O
CRC	O
patients	O
and	O
100	O
control	O
subjects	O
in	O
Tehran	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
and	O
genotyped	O
by	O
PCR-RFLP	O
method	O
.	O

We	O
showed	O
that	O
2G	O
allele	O
and	O
2G/2G	O
genotype	O
had	O
higher	O
frequencies	O
in	O
patients	O
(	O
60%	O
and	O
39%	O
,	O
respectively	O
)	O
than	O
in	O
controls	O
(	O
47%	O
and	O
23%	O
,	O
respectively	O
)	O
.	O

The	O
CRC	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
with	O
metastasis	O
(M+)	O
and	O
without	O
metastasis	O
(M-)	O
groups	O
.	O

The	O
2G	O
allele	O
was	O
more	O
frequent	O
in	O
M+	O
group	O
compared	O
with	O
control	O
group	O
.	O

However	O
,	O
no	O
significantly	O
difference	O
was	O
observed	O
between	O
M-group	O
and	O
control	O
(	O
chi(2	O
)	O
=	O
0.48	O
,	O
P	O
=	O
0.78	O
for	O
2G/2G	O
genotype	O
)	O
.	O

Further	O
stratification	O
analyses	O
showed	O
that	O
only	O
gender	O
(	O
OR	O
=	O
2.58	O
,	O
95%	O
CI	O
=	O
0.89-7.52	O
for	O
women	O
and	O
OR	O
=	O
4.12	O
,	O
95%	O
CI	O
=	O
1.62-10.42	O
for	O
men	O
)	O
and	O
smoking	O
(	O
OR	O
=	O
3.03	O
,	O
95%	O
CI	O
=	O
1.28-7.16	O
for	O
non-smokers	O
and	O
OR	O
=	O
4.09	O
,	O
95%	O
CI	O
=	O
1.18-4.15	O
for	O
smoker	O
)	O
may	O
modify	O
the	O
risk	O
of	O
colorectal	O
invasion	O
related	O
to	O
2G/2G	O
genotype	O
.	O

Furthermore	O
,	O
individual	O
with	O
2G/2G	O
genotype	O
seems	O
to	O
spread	O
metastasis	O
,	O
3	O
years	O
earlier	O
than	O
those	O
who	O
were	O
1G/1G	O
and	O
1G/2G	O
.	O

In	O
conclusion	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
present	O
epidemiological	O
study	O
for	O
the	O
first	O
time	O
indicates	O
the	O
relationship	O
of	O
2G/2G	O
genotype	O
polymorphism	O
with	O
invasion	O
risk	O
of	O
colorectal	O
cancer	O
in	O
subgroups	O
of	O
gender	O
and	O
smoking	O
,	O
especially	O
in	O
smoker	O
men	O
.	O

A	O
case	O
of	O
Bernard-Soulier	O
Syndrome	O
due	O
to	O
a	O
homozygous	O
four	O
bases	O
deletion	O
(TGAG)	O
of	O
GPIbalpha	O
gene	O
:	O
lack	O
of	O
GPIbalpha	O
but	O
absence	O
of	O
bleeding	O
.	O

More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	O
with	O
Bernard-Soulier	O
Syndrome	O
(BSS)	O
,	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and/or	O
expression	O
of	O
GPIbalpha	O
.	O

Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
,	O
such	O
as	O
bleeding	O
,	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O

We	O
describe	O
in	O
a	O
BSS	O
patient	O
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	O
(TGAG)	O
in	O
the	O
gpIbalpha	O
gene	O
coding	O
sequence	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O

In	O
the	O
propositus	O
,	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10(9)	O
platelets/L	O
)	O
,	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	O
was	O
absent	O
.	O

Propositus'	O
parents	O
are	O
consanguineous	O
.	O

His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	O
(	O
108	O
x	O
10(9)/L	O
and	O
120	O
x	O
10(9)/L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister's	O
referred	O
normal	O
platelet	O
counts	O
.	O

The	O
surface	O
expression	O
of	O
GPIbalpha	O
was	O
practically	O
undetectable	O
by	O
flow-cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	O
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O

Proband's	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four-base-pair	O
deletion	O
(TGAG)	O
,	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
,	O
leading	O
to	O
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	O
codon	O
after	O
11	O
novel	O
amino	O
acids	O
.	O

The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	O
TGAG	O
deletion	O
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O

Surprisingly	O
,	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	O
tendency	O
.	O

Is	O
the	O
European	O
spatial	O
distribution	O
of	O
the	O
HIV-1-resistant	O
CCR5-Delta32	B-DNAMutation
allele	O
formed	O
by	O
a	O
breakdown	O
of	O
the	O
pathocenosis	O
due	O
to	O
the	O
historical	O
Roman	O
expansion	O
.	O

We	O
studied	O
the	O
possible	O
effects	O
of	O
the	O
expansion	O
of	O
ancient	O
Mediterranean	O
civilizations	O
during	O
the	O
five	O
centuries	O
before	O
and	O
after	O
Christ	O
on	O
the	O
European	O
distribution	O
of	O
the	O
mutant	O
allele	O
for	O
the	O
chemokine	O
receptor	O
gene	O
CCR5	O
which	O
has	O
a	O
32-bp	O
deletion	O
CCR5-Delta32	B-DNAMutation
.	O

There	O
is	O
a	O
strong	O
evidence	O
for	O
the	O
unitary	O
origin	O
of	O
the	O
CCR5-Delta32	B-DNAMutation
mutation	O
,	O
this	O
it	O
is	O
found	O
principally	O
in	O
Europe	O
and	O
Western	O
Asia	O
,	O
with	O
generally	O
a	O
north-south	O
downhill	O
cline	O
frequency	O
.	O

Homozygous	O
carriers	O
of	O
this	O
mutation	O
show	O
a	O
resistance	O
to	O
HIV-1	O
infection	O
and	O
a	O
slower	O
progression	O
towards	O
AIDS	O
.	O

However	O
,	O
HIV	O
has	O
clearly	O
emerged	O
too	O
recently	O
to	O
have	O
been	O
the	O
selective	O
force	O
on	O
CCR5	O
.	O

Our	O
analyses	O
showed	O
strong	O
negative	O
correlations	O
in	O
Europe	O
between	O
the	O
allele	O
frequency	O
and	O
two	O
historical	O
parameters	O
,	O
i.e	O
.	O

the	O
first	O
colonization	O
dates	O
by	O
the	O
great	O
ancient	O
Mediterranean	O
civilizations	O
,	O
and	O
the	O
distances	O
from	O
the	O
Northern	O
frontiers	O
of	O
the	O
Roman	O
Empire	O
in	O
its	O
greatest	O
expansion	O
.	O

Moreover	O
,	O
other	O
studies	O
have	O
shown	O
that	O
the	O
deletion	O
frequencies	O
in	O
both	O
German	O
Bronze	O
Age	O
and	O
Swedish	O
Neolithic	O
populations	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
corresponding	O
modern	O
populations	O
,	O
and	O
this	O
deletion	O
has	O
been	O
found	O
in	O
ancient	O
DNA	O
of	O
around	O
7000	O
years	O
ago	O
,	O
suggesting	O
that	O
in	O
the	O
past	O
,	O
the	O
deletion	O
frequency	O
could	O
have	O
been	O
relatively	O
high	O
in	O
European	O
populations	O
.	O

In	O
addition	O
,	O
in	O
West	O
Nile	O
virus	O
pathogenesis	O
,	O
CCR5	O
plays	O
an	O
antimicrobial	O
role	O
showing	O
that	O
host	O
genetic	O
factors	O
are	O
highly	O
pathogen-specific	O
.	O

Our	O
results	O
added	O
to	O
all	O
these	O
previous	O
data	O
suggest	O
that	O
the	O
actual	O
European	O
allele	O
frequency	O
distribution	O
might	O
not	O
be	O
due	O
to	O
genes	O
spreading	O
,	O
but	O
to	O
a	O
negative	O
selection	O
resulting	O
in	O
the	O
spread	O
of	O
pathogens	O
principally	O
during	O
Roman	O
expansion	O
.	O

Indeed	O
,	O
as	O
gene	O
flows	O
from	O
colonizers	O
to	O
European	O
native	O
populations	O
were	O
extremely	O
low	O
,	O
the	O
mutational	O
changes	O
might	O
be	O
associated	O
with	O
vulnerability	O
to	O
imported	O
infections	O
.	O

To	O
date	O
,	O
the	O
nature	O
of	O
the	O
parasites	O
remains	O
unknown	O
;	O
however	O
,	O
zoonoses	O
could	O
be	O
incriminated	O
.	O

Expanding	O
clinical	O
spectrum	O
of	O
non-autoimmune	O
hyperthyroidism	O
due	O
to	O
an	O
activating	O
germline	O
mutation	O
,	O
p.M453T	B-ProteinMutation
,	O
in	O
the	O
thyrotropin	O
receptor	O
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non-autoimmune	O
hyperthyroidism	O
(NAH)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	O
receptor	O
(TSHR)	O
gene	O
.	O

PATIENTS	O
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O

Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O

GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	O
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	O
to	O
C	O
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	O
gene	O
c.1358T-->C	B-DNAMutation
resulting	O
in	O
the	O
substitution	O
of	O
methionine	O
(ATG)	O
by	O
threonine	O
(ACG)	O
at	O
codon	O
453	O
p.M453T	B-ProteinMutation
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O

They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O

In	O
addition	O
to	O
hyperthyroidism	O
,	O
ventriculomegaly	O
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Ventriculomegaly	O
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	O
because	O
of	O
an	O
activating	O
TSHR	O
germline	O
mutation	O
.	O

In	O
addition	O
,	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
,	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O

Identification	O
of	O
rifampin-resistant	O
genotypes	O
in	O
Mycobacterium	O
tuberculosis	O
by	O
PCR-reverse	O
dot	O
blot	O
hybridization	O
.	O

A	O
PCR-reverse	O
dot	O
blot	O
hybridization	O
(RDBH)	O
assay	O
was	O
developed	O
for	O
rapid	O
identification	O
of	O
rifampin	O
(RFP)-resistant	O
genotypes	O
in	O
Mycobacterium	O
tuberculosis	O
clinical	O
isolates	O
.	O

The	O
assay	O
used	O
the	O
rpoB	O
gene	O
as	O
target	O
and	O
was	O
used	O
to	O
evaluate	O
148	O
clinical	O
isolates	O
(	O
97	O
RFP-resistant	O
isolates	O
and	O
51	O
RFP-susceptible	O
isolates	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
isolates	O
were	O
subjected	O
to	O
DNA	O
sequencing	O
and	O
conventional	O
drug	O
susceptibility	O
test	O
.	O

One	O
hundred	O
and	O
forty	O
one	O
(95.3%)	O
and	O
136	O
(91.9%)	O
of	O
the	O
148	O
strains	O
were	O
correctly	O
identified	O
by	O
DNA	O
sequencing	O
and	O
RDBH	O
assay	O
,	O
respectively	O
.	O

None	O
of	O
the	O
51	O
RFP-susceptible	O
isolates	O
examined	O
had	O
alterations	O
in	O
rpoB	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
DNA	O
sequencing	O
were	O
92.8%	O
and	O
100%	O
,	O
and	O
the	O
positive	O
predictive	O
value	O
(PPV)	O
and	O
negative	O
predictive	O
value	O
(NPV)	O
were	O
100%	O
and	O
87.9%	O
,	O
respectively	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
RDBH	O
assay	O
were	O
87.6%	O
and	O
100%	O
,	O
and	O
the	O
PPV	O
and	O
NPV	O
were	O
100%	O
and	O
81.0%	O
,	O
respectively	O
.	O

Codons	O
531	O
and	O
526	O
of	O
the	O
rpoB	O
were	O
found	O
to	O
be	O
the	O
most	O
common	O
sites	O
of	O
nucleotide	O
substitutions	O
.	O

Mutations	O
at	O
codons	O
511	O
,	O
513	O
,	O
515	O
,	O
516	O
,	O
517	O
,	O
518	O
,	O
and	O
533	O
were	O
also	O
found	O
.	O

There	O
were	O
two-codon	O
mutations	O
in	O
four	O
isolates	O
.	O

No	O
deletion	O
and	O
insertion	O
was	O
found	O
in	O
the	O
rpoB	O
gene	O
.	O

These	O
results	O
indicate	O
that	O
the	O
RDBH	O
assay	O
is	O
a	O
rapid	O
,	O
simple	O
,	O
and	O
reliable	O
method	O
for	O
routine	O
identification	O
of	O
RFP	O
resistance	O
in	O
M	O
.	O

tuberculosis	O
.	O

Molecular	O
and	O
clinical	O
characterization	O
of	O
a	O
novel	O
SCN5A	O
mutation	O
associated	O
with	O
atrioventricular	O
block	O
and	O
dilated	O
cardiomyopathy	O
.	O

BACKGROUND	O
:	O
Increased	O
susceptibility	O
to	O
dilated	O
cardiomyopathy	O
has	O
been	O
observed	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
SCN5A	O
gene	O
,	O
but	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
and	O
characterized	O
,	O
both	O
in	O
vitro	O
and	O
clinically	O
,	O
an	O
SCN5A	O
mutation	O
associated	O
with	O
familial	O
progressive	O
atrioventricular	O
block	O
of	O
adult	O
onset	O
and	O
dilated	O
cardiomyopathy	O
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Among	O
32	O
family	O
members	O
,	O
5	O
were	O
initially	O
diagnosed	O
with	O
atrioventricular	O
block	O
after	O
age	O
30	O
;	O
4	O
were	O
studied	O
,	O
3	O
of	O
whom	O
later	O
developed	O
dilated	O
cardiomyopathy	O
.	O

We	O
found	O
a	O
heterozygous	O
single-nucleotide	O
mutation	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
A1180V	B-ProteinMutation
in	O
all	O
studied	O
patients	O
and	O
in	O
6	O
other	O
younger	O
unaffected	O
members	O
but	O
not	O
in	O
200	O
control	O
chromosomes	O
.	O

When	O
expressed	O
with	O
the	O
beta1	O
subunit	O
,	O
the	O
mutated	O
channels	O
exhibited	O
a	O
-4.5-mV	O
shift	O
of	O
inactivation	O
with	O
slower	O
recovery	O
leading	O
to	O
a	O
rate-dependent	O
Na(+)	O
current	O
reduction	O
and	O
a	O
moderate	O
increase	O
in	O
late	O
Na(+)	O
current	O
.	O

Clinical	O
study	O
revealed	O
that	O
although	O
QRS	O
duration	O
decreased	O
with	O
increasing	O
heart	O
rate	O
in	O
noncarrier	O
family	O
members	O
,	O
this	O
change	O
was	O
blunted	O
in	O
unaffected	O
carriers	O
whose	O
ECG	O
and	O
heart	O
function	O
were	O
normal	O
.	O

Resting	O
corrected	O
QT	O
interval	O
of	O
unaffected	O
carriers	O
was	O
significantly	O
longer	O
than	O
that	O
of	O
noncarriers	O
,	O
even	O
though	O
it	O
was	O
still	O
within	O
the	O
normal	O
range	O
.	O

CONCLUSIONS	O
:	O
A1180V	B-ProteinMutation
expresses	O
a	O
mild	O
Na(+)	O
channel	O
phenotype	O
in	O
vitro	O
and	O
a	O
corresponding	O
clinical	O
phenotype	O
in	O
unaffected	O
mutation	O
carriers	O
,	O
implying	O
that	O
A1180V	B-ProteinMutation
caused	O
structural	O
heart	O
disease	O
in	O
affected	O
carriers	O
by	O
disturbing	O
Na(+)	O
influx	O
and	O
,	O
hence	O
,	O
cellular	O
Na(+)	O
homeostasis	O
.	O

The	O
high	O
penetrance	O
of	O
A1180V	B-ProteinMutation
suggests	O
this	O
phenotype	O
as	O
a	O
high	O
risk	O
factor	O
for	O
dilated	O
cardiomyopathy	O
with	O
preceding	O
atrioventricular	O
block	O
.	O

Anticipation	O
in	O
familial	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
with	O
R124C	B-ProteinMutation
mutation	O
in	O
the	O
TGFBI	O
(BIGH3)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
,	O
ophthalmic	O
,	O
and	O
genetic	O
characteristics	O
for	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
(LCDI)	O
in	O
a	O
Chilean	O
family	O
.	O

METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
,	O
color	O
cornea	O
photography	O
,	O
applanation	O
tonography	O
,	O
and	O
fundoscopy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
.	O

Exon	O
4	O
of	O
the	O
transforming	O
growth	O
factor-induced	O
gene	O
(TGFBI)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
,	O
R124C	B-ProteinMutation
,	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O

We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
,	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	O
restriction	O
enzyme	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O

RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	O
corneal	O
dystrophy	O
.	O

Six	O
participants	O
demonstrated	O
LCD1	O
in	O
both	O
eyes	O
,	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O

Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3-42	O
years	O
old	O
)	O
.	O

Moreover	O
,	O
in	O
this	O
family	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O

Visual	O
acuity	O
varied	O
from	O
1.0	O
to	O
0.13	O
.	O

Two	O
patients	O
,	O
ages	O
69	O
and	O
44	O
years	O
old	O
,	O
demonstrated	O
a	O
degree	O
of	O
severity	O
"Bad"	O
according	O
to	O
best-corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O

The	O
exon	O
4	O
sequence	O
of	O
TGFBI	O
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single-nucleotide	O
mutation	O
,	O
C417T	B-DNAMutation
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
R124C	B-ProteinMutation
in	O
the	O
encoded	O
TGF-induced	O
protein	O
.	O

Using	O
PCR-RFLP	O
,	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
R124C	B-ProteinMutation
mutation	O
in	O
TGFBI	O
cosegregated	O
with	O
LCD	O
type	O
I	O
in	O
the	O
investigated	O
family	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	O
type	O
I	O
in	O
Chilean	O
patients	O
.	O

The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O

Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
and	O
the	O
NAD(P)H:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
in	O
patients	O
who	O
developed	O
anthracycline-related	O
congestive	O
heart	O
failure	O
after	O
childhood	O
cancer	O
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	O
as	O
part	O
of	O
cancer	O
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	O
heart	O
failure	O
(CHF)	O
.	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline-related	O
CHF	O
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	O
(	O
in	O
particular	O
,	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
and	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
.	O

METHODS	O
:	O
A	O
nested	O
case-control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	O
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	O
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	O
with	O
CHF	O
(cases)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	O
(NQO1*2)	O
and	O
CBR3	O
(	O
the	O
CBR3	O
valine	O
[V]	O
to	O
methionine	O
[M]	O
substitution	O
at	O
position	O
244	O
[	O
V244M	B-ProteinMutation
]	O
)	O
.	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	O
isoforms	O
(	O
CBR3	O
V244	O
and	O
CBR3	O
M244	O
)	O
and	O
the	O
anthracycline	O
substrate	O
doxorubicin	O
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1*2	O
and	O
CBR3	O
V244M	B-ProteinMutation
)	O
and	O
the	O
risk	O
of	O
CHF	O
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1*2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
(	O
odds	O
ratio	O
[OR]	O
,	O
1.04	O
;	O
P=.97	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	O
(	O
OR	O
,	O
8.16	O
;	O
P=.056	O
for	O
G/G	O
vs	O
A/A	O
;	O
OR	O
,	O
5.44	O
;	O
P=.092	O
for	O
G/A	O
vs	O
A/A	O
)	O
.	O

In	O
line	O
,	O
recombinant	O
CBR3	O
V244	O
(	O
G	O
allele	O
)	O
synthesized	O
2.6-fold	O
more	O
cardiotoxic	O
doxorubicinol	O
per	O
unit	O
of	O
time	O
than	O
CBR3	O
M244	O
(	O
A	O
allele	O
;	O
CBR3	O
V244	O
[	O
8.26+/-3.57	O
nmol/hour.mg	O
]	O
vs	O
CBR3	O
M244	O
[	O
3.22+/-0.67	O
nmol/hour.mg	O
]	O
;	O
P=.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
among	O
childhood	O
cancer	O
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	O
anthracycline	O
alcohol	O
metabolites	O
.	O

Larger	O
confirmatory	O
case-control	O
studies	O
are	O
warranted	O
.	O

Association	O
between	O
promoter	O
-1607	O
polymorphism	O
of	O
MMP1	O
and	O
lumbar	O
disc	O
disease	O
in	O
Southern	O
Chinese	O
.	O

BACKGROUND	O
:	O
Matrix	O
metalloproteinases	O
(MMPs)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O

A	O
SNP	O
for	O
guanine	O
insertion/deletion	O
G/D	B-DNAMutation
,	O
the	O
-1607	O
promoter	O
polymorphism	O
,	O
of	O
the	O
MMP1	O
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O

Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	O
.	O

METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O

DDD	O
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman's	O
classification	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O

Association	O
and	O
Hardy-Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi-square	O
test	O
and	O
Mann-Whitney	O
U	O
test	O
.	O

RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
and	O
DDD	O
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O

D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.027	O
,	O
odds	O
ratio	O
=	O
1.41	O
with	O
95%	O
CI	O
=	O
1.04-1.90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.046	O
,	O
odds	O
ratio	O
=	O
1.50	O
with	O
95%	O
CI	O
=	O
1.01-2.24	O
)	O
.	O

Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0.035	O
,	O
odds	O
ratio	O
=	O
1.617	O
with	O
95%	O
CI	O
=	O
1.033-2.529	O
;	O
allelic	O
:	O
p	O
value	O
=	O
0.033	O
,	O
odds	O
ratio	O
=	O
1.445	O
with	O
95%	O
CI	O
=	O
1.029-2.029	O
)	O
.	O

Disc	O
bulge	O
,	O
annular	O
tears	O
and	O
the	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O

CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	O
allele	O
for	O
the	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
are	O
about	O
1.5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	O
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O

Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O

Disc	O
bulge	O
,	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O

Association	O
between	O
gynecomastia	O
and	O
aromatase	O
(CYP19)	O
polymorphisms	O
.	O

OBJECTIVE	O
:	O
Aromatase	O
cytochrome	O
P45019	O
(CYP19)	O
is	O
a	O
key	O
enzyme	O
in	O
estrogen	O
biosynthesis	O
,	O
and	O
polymorphisms	O
within	O
its	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
estrogen-dependent	O
diseases	O
.	O

Enhanced	O
estrogen	O
stimulation	O
of	O
breast	O
tissue	O
in	O
men	O
may	O
lead	O
to	O
gynecomastia	O
.	O

We	O
assessed	O
whether	O
intron	O
4	O
(TTTA)n	O
repeat	O
and	O
TCT	O
deletion/insertion	O
polymorphisms	O
and	O
an	O
exon	O
10	O
(3'-UTR)	O
C/T	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
of	O
CYP19	O
are	O
associated	O
with	O
gynecomastia	O
.	O

DESIGN/METHODS	O
:	O
We	O
performed	O
a	O
genetic	O
association	O
study	O
of	O
100	O
patients	O
referred	O
to	O
the	O
endocrinological	O
outpatient	O
clinic	O
with	O
breast	O
glandular	O
tissue	O
enlargement	O
confirmed	O
by	O
clinical	O
and	O
ultrasound	O
examinations	O
and	O
99	O
healthy	O
volunteers	O
without	O
gynecomastia	O
.	O

Microsatellite	O
(TTTA)n	O
and	O
insertion/deletion	O
polymorphisms	O
were	O
studied	O
using	O
capillary	O
electrophoresis	O
,	O
and	O
the	O
C/T	B-DNAMutation
polymorphism	O
in	O
the	O
3'-UTR	O
was	O
analyzed	O
using	O
the	O
TaqMan	O
assay	O
.	O

RESULTS	O
:	O
Significantly	O
increased	O
risk	O
of	O
gynecomastia	O
was	O
found	O
in	O
subjects	O
carrying	O
a	O
CYP19	O
exon	O
10	O
T	O
allele	O
that	O
was	O
previously	O
related	O
to	O
the	O
high	O
aromatase	O
activity	O
.	O

Frequency	O
of	O
the	O
TT	O
genotype	O
was	O
significantly	O
higher	O
in	O
patients	O
when	O
compared	O
with	O
controls	O
(	O
40.6	O
vs	O
26.3%	O
;	O
TT	O
versus	O
CT	O
and	O
CC	O
genotypes	O
;	O
P(c)<0.05	O
)	O
.	O

We	O
found	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
alleles	O
of	O
studied	O
polymorphic	O
loci	O
.	O

T	O
allele	O
in	O
the	O
3'-UTR	O
was	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
long	O
alleles	O
of	O
the	O
intron	O
4	O
polymorphism	O
,	O
mainly	O
(TTTA)11	O
.	O

However	O
,	O
our	O
findings	O
did	O
not	O
show	O
significant	O
correlation	O
of	O
alleles	O
having	O
more	O
than	O
nine	O
TTTA	O
repeats	O
with	O
gynecomastia	O
.	O

CONCLUSIONS	O
:	O
The	O
CYP19	O
polymorphisms	O
might	O
contribute	O
to	O
the	O
incidence	O
of	O
gynecomastia	O
,	O
but	O
further	O
studies	O
in	O
larger	O
groups	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	O
adenomas	O
.	O

OBJECTIVE	O
:	O
Pituitary	O
adenomas	O
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O

Pituitary	O
adenoma	O
predisposition	O
(PAP)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	O
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenomas	O
.	O

DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	O
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O

PATIENTS	O
:	O
A	O
population-based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenoma	O
patients	O
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	O
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
in-frame	O
deletion	O
Y248del	B-ProteinMutation
c.742_744delTAC	B-DNAMutation
was	O
identified	O
in	O
one	O
GH-secreting	O
adenoma	O
patient	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
of	O
tumour	O
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild-type	O
allele	O
.	O

First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O

CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non-GH-secreting	O
adenoma	O
patients	O
,	O
germline	O
AIP	O
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH-secreting	O
tumours	O
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O

The	O
present	O
study	O
reports	O
the	O
AIP	O
mutation	O
analysis	O
results	O
on	O
patients	O
of	O
a	O
single	O
ethnic	O
origin	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	O
in	O
paediatric	O
pituitary	O
adenomas	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	O
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
in	O
the	O
Japanese	O
population	O
.	O

OBJECTIVES	O
:	O
Interferon	O
regulatory	O
factor	O
5	O
(IRF5)	O
is	O
a	O
member	O
of	O
the	O
IRF	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
.	O

Polymorphisms	O
in	O
the	O
IRF5	O
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythaematosus	O
(SLE)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
,	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	O
diseases	O
is	O
still	O
uncertain	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	O
in	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(RA)	O
in	O
Japanese	O
subjects	O
.	O

METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
a	O
CGGGG	O
insertion-deletion	O
polymorphism	O
in	O
the	O
IRF5	O
gene	O
.	O

We	O
performed	O
2	O
sets	O
of	O
case-control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	O
with	O
RA	O
and	O
658	O
controls	O
;	O
second	O
set	O
:	O
1112	O
patients	O
with	O
RA	O
and	O
940	O
controls	O
)	O
,	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	O
leukocyte	O
antigen	O
(HLA)-DRB1	O
shared	O
epitope	O
(SE)	O
status	O
.	O

We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O

RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	B-SNP
A	O
allele	O
with	O
RA	O
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(OR)	O
1.22	O
,	O
95%	O
CI	O
1.09	O
to	O
1.35	O
,	O
p<0.001	O
in	O
the	O
combined	O
analysis	O
)	O
.	O

When	O
the	O
patients	O
were	O
stratified	O
by	O
the	O
SE	O
,	O
the	O
rs729302	B-SNP
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
(	O
OR	O
1.50	O
,	O
95%	O
CI	O
1.17	O
to	O
1.92	O
,	O
p	O
=	O
0.001	O
)	O
as	O
compared	O
with	O
patients	O
carrying	O
the	O
SE	O
(	O
OR	O
1.11	O
,	O
95%	O
CI	O
0.93	O
to	O
1.33	O
,	O
p	O
=	O
0.24	O
)	O
.	O

In	O
both	O
sets	O
,	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	O
susceptibility	O
,	O
but	O
rs729302	B-SNP
was	O
significantly	O
associated	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	O
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	O
,	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
.	O

Functional	O
inactivation	O
of	O
the	O
WTX	O
gene	O
is	O
not	O
a	O
frequent	O
event	O
in	O
Wilms'	O
tumors	O
.	O

For	O
many	O
years	O
the	O
precise	O
genetic	O
etiology	O
of	O
the	O
majority	O
of	O
Wilms'	O
tumors	O
has	O
remained	O
unexplained	O
.	O

Recently	O
,	O
the	O
WTX	O
gene	O
,	O
mapped	O
to	O
chromosome	O
Xq11.1	O
,	O
has	O
been	O
reported	O
to	O
be	O
lost	O
or	O
mutated	O
in	O
approximately	O
one-third	O
of	O
Wilms'	O
tumors	O
.	O

Moreover	O
,	O
in	O
female	O
cases	O
,	O
the	O
somatically	O
inactivated	O
alleles	O
were	O
found	O
to	O
invariantly	O
derive	O
from	O
the	O
active	O
chromosome	O
X	O
.	O

Consequently	O
,	O
WTX	O
has	O
been	O
proposed	O
as	O
a	O
'one-hit'	O
tumor	O
suppressor	O
gene	O
.	O

To	O
provide	O
further	O
insights	O
on	O
the	O
contribution	O
of	O
WTX	O
to	O
the	O
development	O
of	O
the	O
disease	O
,	O
we	O
have	O
examined	O
102	O
Wilms'	O
tumors	O
,	O
obtained	O
from	O
43	O
male	O
and	O
57	O
female	O
patients	O
.	O

Quantitative	O
PCR	O
analyses	O
detected	O
WTX	O
deletions	O
in	O
5	O
of	O
45	O
(11%)	O
tumors	O
from	O
males	O
,	O
whereas	O
loss	O
of	O
heterozygosity	O
at	O
WTX-linked	O
microsatellites	O
was	O
observed	O
in	O
9	O
tumors	O
from	O
50	O
informative	O
females	O
(19%)	O
.	O

However	O
,	O
in	O
the	O
latter	O
group	O
,	O
using	O
a	O
combination	O
of	O
HUMARA	O
assay	O
and	O
bisulfite-modified	O
DNA	O
sequencing	O
,	O
we	O
found	O
that	O
the	O
deletion	O
affected	O
the	O
active	O
chromosome	O
X	O
only	O
in	O
two	O
cases	O
(4%)	O
.	O

Sequence	O
analyses	O
detected	O
an	O
inactivating	O
somatic	O
mutation	O
of	O
WTX	O
in	O
a	O
single	O
tumor	O
,	O
in	O
which	O
a	O
strongly	O
reduced	O
expression	O
of	O
the	O
mutant	O
allele	O
respect	O
to	O
the	O
wild-type	O
allele	O
was	O
observed	O
,	O
a	O
finding	O
not	O
consistent	O
with	O
its	O
localization	O
on	O
the	O
active	O
chromosome	O
X	O
.	O

Overall	O
,	O
a	O
functional	O
somatic	O
nullizygosity	O
of	O
the	O
WTX	O
gene	O
was	O
ascertained	O
only	O
in	O
seven	O
of	O
the	O
Wilms'	O
tumors	O
included	O
in	O
the	O
study	O
(	O
approximately	O
7%	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
previously	O
reported	O
estimates	O
on	O
the	O
proportion	O
of	O
Wilms'	O
tumors	O
due	O
to	O
WTX	O
alterations	O
should	O
be	O
reconsidered	O
.	O

Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
in	O
patients	O
with	O
anophthalmia/microphthalmia	O
.	O

PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
have	O
been	O
reported	O
in	O
patients	O
with	O
anophthalmia	O
and/or	O
microphthalmia	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
34	O
anophthalmic/microphthalmic	O
patient	O
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	O
and	O
CHX10	O
.	O

METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(CSGE)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	O
and	O
CHX10	O
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
)	O
,	O
five	O
unaffected	O
family	O
members	O
,	O
and	O
80	O
healthy	O
controls	O
.	O

Patient	O
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O

Base	O
pair	O
changes	O
in	O
SOX2	O
and	O
CHX10	O
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	O
samples	O
.	O

RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	O
were	O
identified	O
in	O
this	O
cohort	O
.	O

Mutation	O
c.310	B-DNAMutation
G>T	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Glu104X	I-ProteinMutation
)	O
,	O
found	O
in	O
one	O
patient	O
,	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(HMG)	O
DNA-binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	O
acid	O
to	O
a	O
stop	O
codon	O
.	O

The	O
second	O
mutation	O
,	O
noted	O
in	O
two	O
affected	O
siblings	O
,	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c.549delC	B-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Pro184ArgfsX19	I-ProteinMutation
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O

The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O

In	O
addition	O
,	O
a	O
novel	O
nucleotide	O
substitution	O
c.*557G>A	B-DNAMutation
was	O
identified	O
in	O
the	O
3'-untranslated	O
region	O
in	O
one	O
patient	O
.	O

The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O

A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c	B-DNAMutation
.	I-DNAMutation
*469	I-DNAMutation
C>A	I-DNAMutation
,	O
SNP	O
rs11915160	B-SNP
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	O
.	O

Screening	O
of	O
CHX10	O
identified	O
two	O
synonymous	O
sequence	O
variants	O
,	O
c.471	B-DNAMutation
C>T	I-DNAMutation
(	O
p.Ser157Ser	B-ProteinMutation
,	O
rs35435463	B-SNP
)	O
and	O
c.579	B-DNAMutation
G>A	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Gln193Gln	I-ProteinMutation
,	O
novel	O
SNP	O
)	O
,	O
and	O
one	O
non-synonymous	O
sequence	O
variant	O
,	O
c.871	B-DNAMutation
G>A	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Asp291Asn	I-ProteinMutation
,	O
novel	O
SNP	O
)	O
.	O

The	O
non-synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
,	O
suggesting	O
non-causality	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	O
in	O
ocular	O
development	O
.	O

Loss	O
of	O
SOX2	O
function	O
results	O
in	O
severe	O
eye	O
malformation	O
.	O

CHX10	O
was	O
not	O
implicated	O
with	O
microphthalmia/anophthalmia	O
in	O
our	O
patient	O
cohort	O
.	O

Co-inheritance	O
of	O
a	O
PKD1	O
mutation	O
and	O
homozygous	O
PKD2	O
variant	O
:	O
a	O
potential	O
modifier	O
in	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(ADPKD)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
polycystins	O
1	O
(PC1)	O
and	O
2	O
(PC2)	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
inherited	O
renal	O
diseases	O
,	O
affecting	O
~1	O
:	O
1000	O
Caucasians	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
Greek	O
ADPKD	O
patients	O
with	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
assay	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
patient	O
homozygous	O
for	O
a	O
nucleotide	O
change	O
c.1445T	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
,	O
resulting	O
in	O
a	O
novel	O
homozygous	O
substitution	O
of	O
the	O
non-polar	O
hydrophobic	O
phenylalanine	O
to	O
the	O
polar	O
hydrophilic	O
cysteine	O
in	O
exon	O
6	O
at	O
codon	O
482	O
p.F482C	B-ProteinMutation
of	O
the	O
PKD2	O
gene	O
and	O
a	O
de-novo	O
PKD1	O
splice-site	O
variant	O
IVS21-2delAG	B-DNAMutation
.	O

We	O
did	O
not	O
find	O
this	O
PKD2	O
variant	O
in	O
a	O
screen	O
of	O
280	O
chromosomes	O
of	O
healthy	O
subjects	O
,	O
supporting	O
its	O
pathogenicity	O
.	O

The	O
proband's	O
parents	O
did	O
not	O
have	O
the	O
PKD1	O
mutation	O
.	O

Real-time	O
PCR	O
of	O
the	O
PKD2	O
transcript	O
from	O
a	O
skin	O
biopsy	O
revealed	O
20-fold	O
higher	O
expression	O
in	O
the	O
patient	O
than	O
in	O
a	O
healthy	O
subject	O
and	O
was	O
higher	O
in	O
the	O
patient's	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
than	O
in	O
those	O
of	O
her	O
heterozygote	O
daughter	O
and	O
a	O
healthy	O
subject	O
.	O

The	O
greater	O
gene	O
expression	O
was	O
also	O
supported	O
by	O
Western	O
blotting	O
.	O

Inner	O
medullar	O
collecting	O
duct	O
(IMCD)	O
cells	O
transfected	O
with	O
the	O
mutant	O
PKD2	O
mouse	O
gene	O
presented	O
a	O
perinuclear	O
and	O
diffuse	O
cytoplasmic	O
localization	O
compared	O
with	O
the	O
wild	O
type	O
ER	O
localization	O
.	O

Patch-clamping	O
of	O
PBMCs	O
from	O
the	O
p.F482C	B-ProteinMutation
homozygous	O
and	O
heterozygous	O
subjects	O
revealed	O
lower	O
polycystin-2	O
channel	O
function	O
than	O
in	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
for	O
the	O
first	O
time	O
a	O
patient	O
with	O
ADPKD	O
who	O
is	O
heterozygous	O
for	O
a	O
de	O
novo	O
PKD1	O
variant	O
and	O
homozygous	O
for	O
a	O
novel	O
PKD2	O
mutation	O
.	O

A	O
human	O
phospholamban	O
promoter	O
polymorphism	O
in	O
dilated	O
cardiomyopathy	O
alters	O
transcriptional	O
regulation	O
by	O
glucocorticoids	O
.	O

Depressed	O
calcium	O
handling	O
by	O
the	O
sarcoplasmic	O
reticulum	O
(SR)	O
Ca-ATPase	O
and	O
its	O
regulator	O
phospholamban	O
(PLN)	O
is	O
a	O
key	O
characteristic	O
of	O
human	O
and	O
experimental	O
heart	O
failure	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
increases	O
in	O
the	O
relative	O
levels	O
of	O
PLN	O
to	O
Ca-ATPase	O
in	O
failing	O
hearts	O
and	O
resulting	O
inhibition	O
of	O
Ca	O
sequestration	O
during	O
diastole	O
,	O
impairs	O
contractility	O
.	O

Here	O
,	O
we	O
identified	O
a	O
genetic	O
variant	O
in	O
the	O
PLN	O
promoter	O
region	O
,	O
which	O
increases	O
its	O
expression	O
and	O
may	O
serve	O
as	O
a	O
genetic	O
modifier	O
in	O
dilated	O
cardiomyopathy	O
(DCM)	O
.	O

The	O
variant	O
AF177763.1:g.203A>C	B-DNAMutation
(	O
at	O
position	O
-36	O
bp	O
relative	O
to	O
the	O
PLN	O
transcriptional	O
start	O
site	O
)	O
was	O
found	O
only	O
in	O
the	O
heterozygous	O
form	O
in	O
1	O
out	O
of	O
296	O
normal	O
subjects	O
and	O
in	O
22	O
out	O
of	O
381	O
cardiomyopathy	O
patients	O
(	O
heart	O
failure	O
at	O
age	O
of	O
18-44	O
years	O
,	O
ejection	O
fraction=22+/-9%	O
)	O
.	O

In	O
vitro	O
analysis	O
,	O
using	O
luciferase	O
as	O
a	O
reporter	O
gene	O
in	O
rat	O
neonatal	O
cardiomyocytes	O
,	O
indicated	O
that	O
the	O
PLN-variant	O
increased	O
activity	O
by	O
24%	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Furthermore	O
,	O
the	O
g.203A>C	B-DNAMutation
substitution	O
altered	O
the	O
specific	O
sequence	O
of	O
the	O
steroid	O
receptor	O
for	O
the	O
glucocorticoid	O
nuclear	O
receptor	O
(GR)/transcription	O
factor	O
in	O
the	O
PLN	O
promoter	O
,	O
resulting	O
in	O
enhanced	O
binding	O
to	O
the	O
mutated	O
DNA	O
site	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
g.203A>C	B-DNAMutation
genetic	O
variant	O
in	O
the	O
human	O
PLN	O
promoter	O
may	O
contribute	O
to	O
depressed	O
contractility	O
and	O
accelerate	O
functional	O
deterioration	O
in	O
heart	O
failure	O
.	O

Cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
is	O
strictly	O
associated	O
with	O
mutations	O
in	O
KCNV2	O
.	O

PURPOSE	O
:	O
Cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
(CDSRR)	O
is	O
a	O
retinal	O
disorder	O
characterized	O
by	O
reduced	O
visual	O
acuity	O
,	O
color	O
vision	O
defects	O
,	O
and	O
specific	O
alterations	O
of	O
ERG	O
responses	O
that	O
feature	O
elevated	O
scotopic	O
b-wave	O
amplitudes	O
at	O
high	O
luminance	O
intensities	O
.	O

Mutations	O
in	O
PDE6H	O
and	O
in	O
KCNV2	O
have	O
been	O
described	O
in	O
CDSRR	O
.	O

A	O
combined	O
clinical	O
and	O
genetic	O
study	O
was	O
conducted	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
CDSRR	O
,	O
to	O
substantiate	O
these	O
prior	O
RESULTS	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
<AbstractText	O
Label="METHODS"	O
NlmCategory="METHODS">Seventeen	O
patients	O
from	O
13	O
families	O
underwent	O
a	O
detailed	O
ophthalmic	O
examination	O
including	O
color	O
vision	O
testing	O
,	O
Goldmann	O
visual	O
fields	O
,	O
fundus	O
photography	O
,	O
Ganzfeld	O
and	O
multifocal	O
ERGs	O
,	O
and	O
optical	O
coherence	O
tomography	O
.	O

The	O
coding	O
sequences	O
and	O
flanking	O
intron/UTR	O
sequences	O
of	O
PDE6C	O
and	O
KCNV2	O
were	O
screened	O
for	O
mutations	O
by	O
means	O
of	O
DHPLC	O
and	O
direct	O
DNA	O
sequencing	O
of	O
PCR-amplified	O
genomic	O
DNA	O
.	O

results	O
.	O

Whereas	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
PDE6H	O
gene	O
,	O
mutations	O
in	O
KCNV2	O
were	O
identified	O
in	O
all	O
patients	O
,	O
in	O
either	O
the	O
homozygous	O
or	O
compound	O
heterozygous	O
state	O
.	O

Ten	O
of	O
the	O
11	O
identified	O
mutations	O
were	O
novel	O
,	O
including	O
three	O
missense	O
and	O
six	O
truncating	O
mutations	O
and	O
one	O
gross	O
deletion	O
.	O

The	O
mutations	O
concordantly	O
segregate	O
in	O
all	O
available	O
families	O
according	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

The	O
CDSRR	O
phenotype	O
was	O
associated	O
with	O
reduced	O
visual	O
acuity	O
of	O
variable	O
degree	O
and	O
color	O
vision	O
defects	O
.	O

Macular	O
defects	O
ranging	O
from	O
mild	O
pigmentary	O
changes	O
to	O
distinct	O
foveal	O
atrophy	O
were	O
present	O
in	O
nine	O
patients	O
.	O

Progression	O
of	O
the	O
disease	O
was	O
observed	O
in	O
only	O
three	O
of	O
seven	O
patients	O
with	O
follow-up	O
data	O
.	O

CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
is	O
tightly	O
linked	O
with	O
mutations	O
in	O
KCNV2	O
.	O

SnoRNA	O
U50	O
is	O
a	O
candidate	O
tumor-suppressor	O
gene	O
at	O
6q14.3	O
with	O
a	O
mutation	O
associated	O
with	O
clinically	O
significant	O
prostate	O
cancer	O
.	O

Deletion	O
of	O
chromosome	O
6q14-q22	O
is	O
common	O
in	O
multiple	O
human	O
cancers	O
including	O
prostate	O
cancer	O
,	O
and	O
chromosome	O
6	O
transferred	O
into	O
cancer	O
cells	O
induces	O
senescence	O
and	O
reduces	O
cell	O
growth	O
,	O
tumorigenicity	O
and	O
metastasis	O
,	O
indicating	O
the	O
existence	O
of	O
one	O
or	O
more	O
tumor-suppressor	O
genes	O
in	O
6q	O
.	O

To	O
identify	O
the	O
6q	O
tumor-suppressor	O
gene	O
,	O
we	O
first	O
narrowed	O
the	O
common	O
region	O
of	O
deletion	O
to	O
a	O
2.5	O
Mb	O
interval	O
at	O
6q14-15	O
.	O

Of	O
the	O
11	O
genes	O
located	O
in	O
this	O
minimal	O
deletion	O
region	O
and	O
expressed	O
in	O
normal	O
prostates	O
,	O
only	O
snoRNA	O
U50	O
was	O
mutated	O
,	O
demonstrated	O
transcriptional	O
downregulation	O
and	O
inhibited	O
colony	O
formation	O
in	O
prostate	O
cancer	O
cells	O
.	O

The	O
mutation	O
,	O
a	O
homozygous	O
2	O
bp	O
(TT)	O
deletion	O
,	O
was	O
found	O
in	O
two	O
of	O
30	O
prostate	O
cancer	O
cell	O
lines/xenografts	O
and	O
nine	O
of	O
89	O
localized	O
prostate	O
cancers	O
(	O
eleven	O
of	O
119	O
or	O
9%	O
cancers	O
)	O
.	O

Two	O
of	O
89	O
(2%)	O
patients	O
with	O
prostate	O
cancer	O
also	O
showed	O
the	O
same	O
mutation	O
in	O
their	O
germline	O
DNA	O
,	O
but	O
none	O
of	O
104	O
cancer-free	O
control	O
men	O
did	O
.	O

The	O
homozygous	O
deletion	O
abolished	O
U50	O
function	O
in	O
a	O
colony	O
formation	O
assay	O
.	O

Analysis	O
of	O
1371	O
prostate	O
cancer	O
cases	O
and	O
1371	O
matched	O
control	O
men	O
from	O
a	O
case-control	O
study	O
nested	O
in	O
a	O
prospective	O
cohort	O
showed	O
that	O
,	O
although	O
a	O
germline	O
heterozygous	O
genotype	O
of	O
the	O
deletion	O
was	O
detected	O
in	O
both	O
patients	O
and	O
controls	O
at	O
similar	O
frequencies	O
,	O
the	O
homozygosity	O
of	O
the	O
deletion	O
was	O
significantly	O
associated	O
with	O
clinically	O
significant	O
prostate	O
cancer	O
(	O
odds	O
ratio	O
2.9	O
;	O
95%	O
confidence	O
interval	O
1.17-7.21	O
)	O
.	O

These	O
findings	O
establish	O
snoRNA	O
U50	O
as	O
a	O
reasonable	O
candidate	O
for	O
the	O
6q	O
tumor-suppressor	O
gene	O
in	O
prostate	O
cancer	O
and	O
likely	O
in	O
other	O
types	O
of	O
cancers	O
.	O

Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood-onset	O
systemic	O
lupus	O
erythematosus	O
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O

OBJECTIVE	O
:	O
Childhood-onset	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	O
for	O
genetic	O
study	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	O
,	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	O
with	O
childhood-onset	O
SLE	O
and	O
both	O
of	O
their	O
parents	O
.	O

METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
,	O
a	O
platform	O
of	O
9,412	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
from	O
1,204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O

Molecular	O
inversion	O
probes	O
and	O
high-throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O

Seven	O
hundred	O
fifty	O
three	O
subjects	O
,	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood-onset	O
SLE	O
families	O
,	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(TDT)	O
and	O
multitest	O
corrections	O
.	O

RESULTS	O
:	O
Family-based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	O
with	O
a	O
N673S	B-ProteinMutation
polymorphism	O
in	O
the	O
P-selectin	O
gene	O
(SELP)	O
(	O
P	O
=	O
5.74	O
x	O
10(-6)	O
)	O
and	O
a	O
C203S	B-ProteinMutation
polymorphism	O
in	O
the	O
interleukin-1	O
receptor-associated	O
kinase	O
1	O
gene	O
(IRAK1)	O
(	O
P	O
=	O
9.58	O
x	O
10(-6)	O
)	O
.	O

These	O
2	O
SNPs	O
had	O
a	O
false	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<0.05	O
,	O
and	O
therefore	O
a	O
>95%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O

Furthermore	O
,	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<0.5	O
,	O
suggesting	O
association	O
with	O
SLE	O
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O

These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	O
(Fas)	O
and	O
IRF5	O
,	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	O
pathogenesis	O
.	O

CONCLUSION	O
:	O
SELP	O
and	O
IRAK1	O
were	O
identified	O
as	O
novel	O
SLE-associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
,	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	O
.	O

The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O

Screening	O
of	O
Iranian	O
thalassemic	O
families	O
for	O
the	O
most	O
common	O
deletions	O
of	O
the	O
beta-globin	O
gene	O
cluster	O
.	O

Deltabeta-thalassemia	O
(thal)	O
is	O
a	O
disorder	O
,	O
characterized	O
by	O
increased	O
levels	O
of	O
fetal	O
hemoglobin	O
(	O
Hb	O
F	O
)	O
in	O
adult	O
life	O
.	O

A	O
considerable	O
number	O
of	O
deletions	O
of	O
variable	O
size	O
and	O
position	O
in	O
the	O
beta-globin	O
gene	O
cluster	O
are	O
associated	O
with	O
the	O
clinical	O
manifestation	O
of	O
deltabeta-thal	O
.	O

In	O
this	O
study	O
we	O
have	O
determined	O
the	O
presence	O
of	O
the	O
eight	O
most	O
common	O
deletions	O
in	O
Iranian	O
patients	O
.	O

Thirty-two	O
patients	O
from	O
19	O
families	O
were	O
referred	O
to	O
the	O
Kariminejad-Najmabadi	O
Pathology	O
and	O
Genetics	O
Center	O
,	O
Tehran	O
,	O
Iran	O
(	O
a	O
private	O
genetics	O
center	O
)	O
,	O
within	O
the	O
past	O
3	O
years	O
with	O
elevated	O
levels	O
of	O
Hb	O
F	O
and	O
low	O
mean	O
corpuscular	O
volume	O
(MCV)	O
.	O

After	O
obtaining	O
their	O
informed	O
consent	O
,	O
DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
by	O
the	O
salting-out	O
method	O
.	O

Detection	O
of	O
eight	O
deletions	O
was	O
performed	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

These	O
deletions	O
included	O
the	O
hereditary	O
persistence	O
of	O
fetal	O
Hb	O
(HPFH)	O
1	O
(Black)	O
and	O
3	O
(Indian)	O
,	O
Spanish	O
(	O
-114	O
kb	O
)	O
,	O
Sicilian	O
(	O
-13,377	O
bp	O
)	O
,	O
Chinese	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
(	O
-100	O
kb	O
)	O
,	O
Asian-Indian	O
inversion-deletion	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
,	O
and	O
the	O
Turkish	O
form	O
of	O
inversion-deletion	O
(deltabeta)(0)-thal	O
,	O
as	O
well	O
as	O
the	O
Hbs	O
Lepore	O
,	O
which	O
are	O
characterized	O
by	O
unequal	O
crossovers	O
between	O
the	O
delta-	O
and	O
beta-globin	O
genes	O
.	O

We	O
found	O
the	O
Sicilian	O
(	O
-13,377	O
bp	O
)	O
and	O
Hb	O
Lepore	O
deletions	O
as	O
well	O
as	O
the	O
Asian-Indian	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
in	O
11	O
(57.89%)	O
,	O
three	O
(15.78%)	O
and	O
five	O
(26.31%)	O
families	O
,	O
respectively	O
.	O

None	O
of	O
the	O
aforementioned	O
deletions	O
were	O
found	O
in	O
one	O
of	O
the	O
patients	O
.	O

This	O
is	O
the	O
first	O
study	O
of	O
the	O
deletions	O
involved	O
in	O
deltabeta-thal	O
in	O
Iranian	O
patients	O
.	O

Our	O
study	O
highlights	O
the	O
importance	O
of	O
detecting	O
these	O
mutations	O
for	O
prenatal	O
diagnosis	O
carrier	O
detection	O
and	O
genotype/phenotype	O
prediction	O
.	O

Clinical	O
and	O
molecular	O
characterization	O
of	O
Italian	O
patients	O
affected	O
by	O
Cohen	O
syndrome	O
.	O

Cohen	O
syndrome	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
with	O
variability	O
in	O
the	O
clinical	O
manifestations	O
,	O
characterized	O
by	O
developmental	O
delay	O
,	O
visual	O
disability	O
,	O
facial	O
dysmorphisms	O
and	O
intermittent	O
neutropenia	O
.	O

We	O
described	O
a	O
cohort	O
of	O
10	O
patients	O
affected	O
by	O
Cohen	O
syndrome	O
from	O
nine	O
Italian	O
families	O
ranging	O
from	O
5	O
to	O
52	O
years	O
at	O
assessment	O
.	O

Characteristic	O
age	O
related	O
facial	O
changes	O
were	O
well	O
documented	O
.	O

Visual	O
anomalies	O
,	O
namely	O
retinopathy	O
and	O
myopia	O
,	O
were	O
present	O
in	O
9/10	O
patients	O
(	O
retinopathy	O
in	O
9/10	O
and	O
myopia	O
in	O
8/10	O
)	O
.	O

Truncal	O
obesity	O
has	O
been	O
described	O
in	O
all	O
patients	O
older	O
than	O
6	O
years	O
(8/8)	O
.	O

DNA	O
samples	O
from	O
all	O
patients	O
were	O
analyzed	O
for	O
mutations	O
in	O
COH1	O
by	O
DHPLC	O
.	O

We	O
detected	O
15	O
COH1	O
alterations	O
most	O
of	O
them	O
were	O
truncating	O
mutations	O
,	O
only	O
one	O
being	O
a	O
missense	O
change	O
.	O

Partial	O
gene	O
deletions	O
have	O
been	O
found	O
in	O
two	O
families	O
.	O

Most	O
mutations	O
were	O
private	O
.	O

Two	O
were	O
already	O
reported	O
in	O
the	O
literature	O
just	O
once	O
.	O

A	O
single	O
base	O
deletion	O
leading	O
to	O
p.T3708fs3769	B-ProteinMutation
,	O
never	O
reported	O
before	O
,	O
was	O
found	O
in	O
three	O
apparently	O
unrelated	O
families	O
deriving	O
from	O
a	O
restricted	O
area	O
of	O
the	O
Veneto's	O
lowland	O
,	O
between	O
Padova	O
town	O
and	O
Tagliamento	O
river	O
,	O
in	O
heterozygous	O
state	O
.	O

Given	O
the	O
geographical	O
conformation	O
of	O
this	O
region	O
,	O
which	O
is	O
neither	O
geographically	O
or	O
culturally	O
isolated	O
,	O
a	O
recent	O
origin	O
of	O
the	O
mutation	O
could	O
be	O
hypothesized	O
.	O

Skewed	O
X	O
inactivation	O
in	O
an	O
X	O
linked	O
nystagmus	O
family	O
resulted	O
from	O
a	O
novel	O
,	O
p.R229G	B-ProteinMutation
,	O
missense	O
mutation	O
in	O
the	O
FRMD7	O
gene	O
.	O

AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	O
defect	O
of	O
a	O
large	O
Turkish	O
X	O
linked	O
nystagmus	O
(NYS)	O
family	O
.	O

METHODS	O
:	O
Both	O
Xp11	O
and	O
Xq26	O
loci	O
were	O
tested	O
by	O
linkage	O
analysis	O
.	O

The	O
12	O
exons	O
and	O
intron-exon	O
junctions	O
of	O
the	O
FRMD7	O
gene	O
were	O
screened	O
by	O
direct	O
sequencing	O
.	O

X	O
chromosome	O
inactivation	O
analysis	O
was	O
performed	O
by	O
enzymatic	O
predigestion	O
of	O
DNA	O
with	O
a	O
methylation-sensitive	O
enzyme	O
,	O
followed	O
by	O
PCR	O
of	O
the	O
polymorphic	O
CAG	O
repeat	O
of	O
the	O
androgen	O
receptor	O
gene	O
.	O

RESULTS	O
:	O
The	O
family	O
contained	O
162	O
individuals	O
,	O
among	O
whom	O
28	O
had	O
NYS	O
.	O

Linkage	O
analysis	O
confirmed	O
the	O
Xq26	O
locus	O
.	O

A	O
novel	O
missense	O
c.686C>G	B-DNAMutation
mutation	O
,	O
which	O
causes	O
the	O
substitution	O
of	O
a	O
conserved	O
arginine	O
at	O
amino	O
acid	O
position	O
229	O
by	O
glycine	O
p.R229G	B-ProteinMutation
in	O
exon	O
8	O
of	O
the	O
FRMD7	O
gene	O
,	O
was	O
observed	O
.	O

This	O
change	O
was	O
not	O
documented	O
in	O
120	O
control	O
individuals	O
.	O

The	O
clinical	O
findings	O
in	O
a	O
female	O
who	O
was	O
homozygous	O
for	O
the	O
mutation	O
were	O
not	O
different	O
from	O
those	O
of	O
affected	O
heterozygous	O
females	O
.	O

Skewed	O
X	O
inactivation	O
was	O
remarkable	O
in	O
the	O
affected	O
females	O
of	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
p.R229G	B-ProteinMutation
mutation	O
in	O
the	O
FRMD7	O
gene	O
causes	O
the	O
NYS	O
phenotype	O
,	O
and	O
skewed	O
X	O
inactivation	O
influences	O
the	O
manifestation	O
of	O
the	O
disease	O
in	O
X	O
linked	O
NYS	O
females	O
.	O

Polymorphic	O
MLH1	O
and	O
risk	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	O
lymphoma	O
,	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	O
.	O

Cytotoxicity	O
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(MMR)	O
system	O
.	O

Loss	O
of	O
MLH1	O
,	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
,	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	O
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O

We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	O
(	O
position	O
-93	O
,	O
rs1800734	B-SNP
)	O
modifies	O
the	O
risk	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
.	O

METHODS	O
:	O
133	O
patients	O
who	O
developed	O
cancer	O
following	O
chemotherapy	O
and/or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)	O
,	O
420	O
patients	O
diagnosed	O
with	O
de	O
novo	O
myeloid	O
leukaemia	O
,	O
242	O
patients	O
diagnosed	O
with	O
primary	O
Hodgkin	O
lymphoma	O
,	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	O
-93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O

Odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
for	O
cancer	O
risk	O
by	O
MLH1	O
-93	O
polymorphism	O
status	O
,	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
,	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	O
-93	O
variant	O
was	O
higher	O
in	O
patients	O
who	O
developed	O
therapy	O
related	O
acute	O
myeloid	O
leukaemia	O
(t-AML)	O
(	O
75.0%	O
,	O
n	O
=	O
12	O
)	O
or	O
breast	O
cancer	O
(	O
53.3%	O
.	O

n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
compared	O
to	O
patients	O
without	O
previous	O
methylating	O
exposure	O
(	O
t-AML	O
,	O
30.4%	O
,	O
n	O
=	O
69	O
;	O
breast	O
cancer	O
patients	O
,	O
27.2%	O
,	O
n	O
=	O
22	O
)	O
.	O

The	O
MLH1	O
-93	O
variant	O
allele	O
was	O
also	O
over-represented	O
in	O
t-AML	O
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	O
cases	O
(	O
36.9%	O
,	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36.3%	O
,	O
n	O
=	O
952	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t-AML	O
(	O
odds	O
ratio	O
5.31	O
,	O
95%	O
confidence	O
interval	O
1.40	O
to	O
20.15	O
)	O
,	O
but	O
only	O
in	O
patients	O
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	O
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
.	O

However	O
,	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	O
PAX9	O
causes	O
oligodontia	O
.	O

PAX9	O
and	O
MSX1	O
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	O
and	O
syndromic	O
oligodontia	O
,	O
respectively	O
.	O

We	O
screened	O
one	O
family	O
with	O
nonsyndromic	O
oligodontia	O
for	O
mutations	O
in	O
PAX9	O
and	O
MSX1	O
.	O

Single	O
stranded	O
conformational	O
polymorphism	O
(SSCP)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139T	B-DNAMutation
transition	O
in	O
PAX9	O
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O

There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	O
.	O

The	O
C139T	B-DNAMutation
mutation	O
,	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	O
by	O
a	O
tryptophan	O
R47W	B-ProteinMutation
in	O
the	O
N-terminal	O
subdomain	O
,	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	O
paired	O
domain	O
.	O

To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	O
phenotype	O
caused	O
by	O
this	O
mutation	O
,	O
we	O
analyzed	O
the	O
binding	O
of	O
wild-type	O
and	O
mutant	O
PAX9	O
paired	O
domain	O
protein	O
to	O
double-stranded	O
DNA	O
targets	O
.	O

The	O
R47W	B-ProteinMutation
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O

Role	O
of	O
homozygous	O
DC-SIGNR	O
5/5	O
tandem	O
repeat	O
polymorphism	O
in	O
HIV-1	O
exposed	O
seronegative	O
North	O
Indian	O
individuals	O
.	O

Despite	O
multiple	O
sexual	O
exposures	O
to	O
HIV-1	O
virus	O
,	O
some	O
individuals	O
remain	O
HIV-1	O
seronegative	O
.	O

Although	O
several	O
genetic	O
factors	O
have	O
been	O
related	O
to	O
HIV-1	O
resistance	O
,	O
the	O
homozygosity	O
for	O
a	O
mutation	O
in	O
CCR5	O
gene	O
(	O
the	O
32-bp	O
deletion	O
,	O
i.e.	O
,	O
CCR5-Delta32	B-DNAMutation
allele	O
)	O
is	O
presently	O
considered	O
the	O
most	O
relevant	O
one	O
.	O

The	O
C-type	O
lectins	O
,	O
DC-SIGN	O
(	O
present	O
on	O
dendritic	O
cells	O
and	O
macrophages	O
)	O
and	O
DC-SIGNR	O
(	O
present	O
on	O
endothelial	O
cells	O
in	O
liver	O
and	O
lymph	O
nodes	O
)	O
efficiently	O
bind	O
and	O
transmit	O
HIV-1	O
to	O
susceptible	O
cell	O
in	O
trans	O
,	O
thereby	O
augmenting	O
the	O
infection	O
.	O

A	O
potential	O
association	O
of	O
the	O
DC-SIGN	O
and	O
DC-SIGNR	O
neck	O
domain	O
repeat	O
polymorphism	O
and	O
risk	O
of	O
HIV-1	O
infection	O
is	O
currently	O
under	O
debate	O
.	O

To	O
determine	O
the	O
influence	O
of	O
host	O
genetic	O
factors	O
on	O
HIV-1	O
resistance	O
,	O
we	O
conducted	O
genetic	O
risk	O
association	O
study	O
in	O
HIV-1-exposed	O
seronegative	O
(	O
n	O
=	O
47	O
)	O
individuals	O
,	O
HIV-1	O
seronegative	O
(	O
n	O
=	O
262	O
)	O
healthy	O
control	O
,	O
and	O
HIV-1-infected	O
seropositive	O
patients	O
(	O
n	O
=	O
168	O
)	O
for	O
polymorphism	O
in	O
neck	O
domain	O
of	O
DC-SIGN	O
and	O
DC-SIGNR	O
genes	O
.	O

The	O
DC-SIGN	O
and	O
DC-SIGNR	O
genotypes	O
were	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
method	O
in	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
and	O
confirmed	O
by	O
sequencing	O
.	O

Fisher	O
exact	O
or	O
chi	O
(2)	O
test	O
was	O
used	O
for	O
static	O
analysis	O
.	O

DC-SIGN	O
genotype	O
and	O
allele	O
distribution	O
was	O
fairly	O
similar	O
in	O
HIV-1-exposed	O
seronegative	O
,	O
HIV-1	O
seropositive	O
,	O
and	O
HIV-1	O
seronegative	O
control	O
.	O

There	O
was	O
no	O
statistical	O
significance	O
in	O
the	O
differences	O
in	O
the	O
distribution	O
of	O
DC-SIGN	O
genotypes	O
.	O

A	O
total	O
of	O
13	O
genotypes	O
were	O
found	O
in	O
DC-SIGNR	O
neck	O
repeat	O
region	O
polymorphism	O
.	O

Among	O
all	O
the	O
genotypes	O
,	O
only	O
5/5	O
homozygous	O
showed	O
significant	O
reduced	O
risk	O
of	O
HIV-1	O
infection	O
in	O
HIV-1-exposed	O
seronegative	O
individuals	O
(	O
p	O
=	O
0.009	O
)	O
.	O

A	O
unique	O
genotype	O
8/5	O
heterozygous	O
was	O
also	O
found	O
in	O
HIV-1	O
seropositive	O
individual	O
,	O
which	O
is	O
not	O
reported	O
elsewhere	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
(	O
ACE	O
I/D	O
)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(AT1R)	O
gene	O
polymorphism	O
and	O
its	O
association	O
with	O
preeclampsia	O
in	O
Chinese	O
women	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
whether	O
polymorphisms	O
of	O
angiotensin	O
converting	O
enzyme	O
gene	O
(ACE)	O
and	O
angiotensin	O
II	O
receptor	O
type	O
1	O
gene	O
(AT1R)	O
are	O
associated	O
with	O
etiology	O
of	O
preeclampsia	O
and	O
renal	O
impact	O
in	O
women	O
with	O
preeclampsia	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
133	O
patients	O
with	O
preeclampsia	O
and	O
105	O
healthy	O
pregnant	O
women	O
.	O

The	O
I/D	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
was	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
,	O
and	O
the	O
A1166C	B-DNAMutation
polymorphism	O
of	O
the	O
AT(1)R	O
gene	O
was	O
additionally	O
assessed	O
by	O
DdeI	O
digestion	O
.	O

The	O
level	O
of	O
proteinuria	O
,	O
fasting	O
serum	O
urea	O
,	O
creatinine	O
and	O
uric	O
acid	O
were	O
investigated	O
according	O
to	O
different	O
genotypes	O
of	O
ACE	O
and	O
AT1R	O
genes	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
genotypes	O
of	O
the	O
ACE	O
gene	O
and	O
the	O
AT1R	O
gene	O
was	O
similar	O
in	O
preeclampsia	O
and	O
normal	O
pregnancy	O
.	O

DD	O
and	O
ID	O
genotype	O
predominated	O
in	O
patients	O
with	O
severe	O
proteinuria	O
,	O
as	O
well	O
as	O
increased	O
serum	O
urea	O
and	O
uric	O
acid	O
.	O

Serum	O
creatinine	O
was	O
also	O
increased	O
,	O
but	O
no	O
significant	O
difference	O
was	O
found	O
among	O
three	O
genotypes	O
.	O

The	O
level	O
of	O
proteinuria	O
,	O
serum	O
uric	O
acid	O
,	O
urea	O
,	O
and	O
creatinine	O
did	O
not	O
vary	O
between	O
different	O
AT1R	O
genotypes	O
.	O

Compared	O
with	O
patients	O
without	O
renal	O
dysfunction	O
,	O
the	O
frequency	O
of	O
DD	O
and	O
ID	O
genotypes	O
of	O
ACE	O
gene	O
was	O
much	O
higher	O
in	O
those	O
with	O
renal	O
dysfunction	O
,	O
but	O
AC	O
and	O
CC	O
genotypes	O
of	O
AT1R	O
gene	O
were	O
not	O
.	O

CONCLUSION	O
:	O
We	O
found	O
no	O
association	O
of	O
the	O
two	O
gene	O
polymorphisms	O
with	O
preeclampsia	O
.	O

However	O
,	O
ACE	O
gene	O
I/D	O
polymorphisms	O
were	O
associated	O
with	O
the	O
severe	O
proteinuria	O
and	O
renal	O
dysfunction	O
seen	O
in	O
preeclampsia	O
.	O

Preeclampsia	O
patients	O
carrying	O
the	O
D	O
allele	O
may	O
be	O
susceptible	O
to	O
renal	O
dysfunction	O
.	O

An	O
improved	O
tetra-primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	O
G380R	B-ProteinMutation
mutation	O
responsible	O
for	O
achondroplasia	O
.	O

Achondroplasia	O
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	O
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1/7500	O
.	O

In	O
more	O
than	O
98%	O
of	O
cases	O
,	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	O
to	O
A	O
or	O
G	O
to	O
C	O
substitution	O
at	O
nucleotide	O
position	O
1138	O
p.G380R	B-ProteinMutation
of	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(FGFR3)	O
gene	O
.	O

We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra-primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
c.1138G>A	B-DNAMutation
and	O
c.1138G>C	B-DNAMutation
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
c.1138G>A	B-DNAMutation
mutation	O
.	O

Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild-type	O
alleles	O
.	O

The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
,	O
3	O
known	O
patients	O
with	O
achondroplasia	O
,	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	O
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
c.1138G>A	B-DNAMutation
mutation	O
by	O
PCR-RFLP	O
.	O

We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O

Our	O
tetra-primer	O
PCR	O
assay	O
is	O
sensitive	O
,	O
low-cost	O
,	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	O
p.G380R	B-ProteinMutation
genotyping	O
,	O
which	O
could	O
be	O
used	O
even	O
in	O
"low-tech"	O
laboratories	O
.	O

Association	O
study	O
between	O
Gilles	O
de	O
la	O
Tourette	O
Syndrome	O
and	O
two	O
genes	O
in	O
the	O
Robo-Slit	O
pathway	O
located	O
in	O
the	O
chromosome	O
11q24	O
linked/associated	O
region	O
.	O

Gilles	O
de	O
la	O
Tourette	O
Syndrome	O
(GTS)	O
is	O
an	O
inherited	O
neuropsychiatric	O
disorder	O
characterized	O
by	O
the	O
presence	O
of	O
motor	O
and	O
phonic	O
tics	O
.	O

Previous	O
genetic	O
studies	O
have	O
identified	O
linkage	O
and	O
association	O
between	O
GTS	O
and	O
the	O
11q24	O
chromosomal	O
region	O
.	O

We	O
selected	O
for	O
study	O
,	O
within	O
this	O
region	O
,	O
two	O
possible	O
susceptibility	O
genes	O
for	O
GTS	O
,	O
the	O
ROBO3	O
and	O
ROBO4	O
genes	O
.	O

These	O
two	O
genes	O
were	O
selected	O
because	O
of	O
the	O
recent	O
identification	O
of	O
SLITRK1	O
as	O
a	O
potential	O
susceptibility	O
gene	O
for	O
GTS	O
based	O
on	O
a	O
translocation	O
breakpoint	O
and	O
the	O
further	O
finding	O
of	O
two	O
mutations	O
in	O
the	O
SLITRK1	O
gene	O
in	O
three	O
patients	O
with	O
GTS	O
.	O

While	O
thus	O
far	O
,	O
the	O
SLITRK1	O
gene	O
appears	O
to	O
account	O
for	O
only	O
a	O
few	O
cases	O
of	O
GTS	O
,	O
these	O
findings	O
,	O
if	O
confirmed	O
,	O
point	O
to	O
other	O
genes	O
in	O
these	O
pathways	O
that	O
may	O
contribute	O
to	O
GTS	O
.	O

Based	O
on	O
this	O
,	O
we	O
examined	O
two	O
genes	O
in	O
the	O
Slit-Robo	O
pathway	O
involved	O
in	O
cell	O
migration	O
,	O
axonal	O
pathfinding	O
,	O
and/or	O
neuronal	O
differentiation	O
because	O
of	O
their	O
location	O
in	O
11q24	O
,	O
a	O
region	O
previously	O
identified	O
as	O
linked	O
and	O
associated	O
with	O
GTS	O
.	O

We	O
selected	O
six	O
haplotype	O
tagging	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
for	O
ROBO3	O
and	O
four	O
for	O
ROBO4	O
and	O
genotyped	O
them	O
in	O
our	O
sample	O
of	O
trios	O
and	O
sibpair	O
families	O
diagnosed	O
with	O
GTS	O
.	O

Based	O
on	O
155	O
nuclear	O
families	O
with	O
255	O
affected	O
children	O
,	O
we	O
did	O
not	O
find	O
evidence	O
for	O
association	O
between	O
GTS	O
and	O
either	O
the	O
ROBO3	O
or	O
ROBO4	O
genes	O
.	O

Thus	O
,	O
these	O
two	O
genes	O
are	O
unlikely	O
to	O
be	O
the	O
susceptibility	O
genes	O
contributing	O
to	O
GTS	O
on	O
11q24	O
.	O

Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	O
.	O

Mutations	O
in	O
the	O
GJB2	O
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	O
hearing	O
impairment	O
in	O
Europe	O
.	O

Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O

Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	O
impairment	O
.	O

Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	O
gene	O
)	O
patients	O
with	O
hearing	O
impairment	O
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	O
and	O
GJB3	O
)	O
and	O
in	O
the	O
5'	O
non-coding	O
region	O
of	O
GJB2	O
including	O
the	O
splice	O
sites	O
.	O

Eleven	O
out	O
of	O
47	O
GJB2-heterozygous	O
patients	O
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-3170G>A	B-DNAMutation
in	O
the	O
5'UTR	O
region	O
of	O
GJB2	O
.	O

One	O
out	O
of	O
these	O
11	O
patients	O
showed	O
homozygous	O
-3170G>A	B-DNAMutation
genotype	O
in	O
combination	O
with	O
p.R127H	B-ProteinMutation
.	O

Next	O
to	O
the	O
GJB2	O
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	O
[Delta(GJB6-D13S1830)]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	O
[	O
c.357C>T	B-DNAMutation
,	O
c.798C>T	B-DNAMutation
and	O
c.94C>T	B-DNAMutation
(	O
p.R32W	B-ProteinMutation
)	O
]	O
which	O
are	O
unlikely	O
disease-causing	O
.	O

Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-3170G>A	B-DNAMutation
mutation	O
(	O
in	O
addition	O
to	O
c.35delG	B-DNAMutation
)	O
in	O
patients	O
with	O
hearing	O
impairment	O
.	O

Characterisation	O
of	O
a	O
large	O
complex	O
intragenic	O
re-arrangement	O
in	O
the	O
FVII	O
gene	O
(F7)	O
avoiding	O
misdiagnosis	O
in	O
inherited	O
factor	O
VII	O
deficiency	O
.	O

Inherited	O
factor	O
VII	O
(FVII)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
bleeding	O
disorder	O
mostly	O
caused	O
by	O
point	O
mutations	O
.	O

Large	O
genomic	O
re-arrangements	O
at	O
F7	O
locus	O
could	O
account	O
for	O
a	O
fraction	O
of	O
mutant	O
alleles	O
that	O
remain	O
unidentified	O
after	O
DNA	O
sequencing	O
,	O
because	O
they	O
escape	O
conventional	O
polymerase	O
chain	O
reaction	O
(PCR)-based	O
techniques	O
.	O

We	O
report	O
the	O
first	O
systematic	O
screening	O
of	O
F7	O
for	O
large	O
re-arrangements	O
,	O
by	O
semi-quantitative	O
multiplex	O
PCR	O
of	O
fluorescent	O
fragments	O
targeting	O
the	O
9	O
exons	O
and	O
the	O
promoter	O
region	O
.	O

A	O
well-characterised	O
cohort	O
of	O
43	O
unrelated	O
patients	O
either	O
apparently	O
homozygous	O
for	O
a	O
F7	O
point	O
mutation	O
or	O
carrying	O
at	O
least	O
one	O
unidentified	O
F7	O
mutant	O
allele	O
participated	O
in	O
this	O
study	O
.	O

Two	O
large	O
F7	O
re-arrangements	O
were	O
identified	O
in	O
two	O
FVII-deficient	O
pedigrees	O
,	O
including	O
a	O
discontinuous	O
deletion	O
involving	O
two	O
distinct	O
portions	O
of	O
F7	O
whose	O
proximal	O
and	O
distal	O
end	O
junctions	O
were	O
characterised	O
.	O

A	O
simple	O
and	O
efficient	O
method	O
for	O
the	O
routine	O
detection	O
of	O
gross	O
alterations	O
of	O
F7	O
,	O
which	O
accounted	O
for	O
2.3%	O
of	O
mutant	O
alleles	O
in	O
our	O
sample	O
,	O
is	O
now	O
available	O
in	O
inherited	O
FVII	O
deficiency	O
.	O

This	O
test	O
should	O
complement	O
conventional	O
PCR-based	O
techniques	O
not	O
only	O
in	O
unsolved	O
cases	O
,	O
but	O
also	O
where	O
inheritance	O
pattern	O
analysis	O
is	O
not	O
achievable	O
.	O

A	O
novel	O
IRF6	O
nonsense	O
mutation	O
Y67X	B-ProteinMutation
in	O
a	O
German	O
family	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
syndrome	O
(VWS)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	O
orofacial	O
cleft	O
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	O
lip	O
and	O
palate	O
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	O
pits	O
,	O
cleft	O
lip	O
and	O
cleft	O
palate	O
,	O
and	O
hypodontia	O
.	O

VWS	O
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	O
gene	O
in	O
exons	O
2-9	O
have	O
been	O
found	O
in	O
VWS	O
patients	O
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	O
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	O
gene	O
.	O

All	O
5	O
patients	O
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c.201C>A	B-DNAMutation
changing	O
the	O
tyrosine	O
codon	O
at	O
amino	O
acid	O
position	O
67	O
into	O
a	O
stop	O
codon	O
p.Y67X	B-ProteinMutation
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad-interferon	O
regulatory	O
factor-binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	O
transcription	O
factors	O
.	O

Subfertility	O
in	O
mice	O
harboring	O
a	O
mutation	O
in	O
betaB2-crystallin	O
.	O

PURPOSE	O
:	O
betaB2-crystallin	O
is	O
one	O
of	O
the	O
most	O
abundant	O
proteins	O
of	O
the	O
adult	O
ocular	O
lens	O
of	O
mammals	O
although	O
it	O
is	O
expressed	O
at	O
lower	O
levels	O
in	O
several	O
extralenticular	O
locations	O
.	O

While	O
mutations	O
in	O
betaB2-crystallin	O
are	O
known	O
to	O
result	O
in	O
lens	O
opacities	O
,	O
alterations	O
in	O
tissues	O
besides	O
the	O
lens	O
have	O
not	O
been	O
previously	O
investigated	O
in	O
these	O
mutants	O
.	O

Since	O
we	O
found	O
mice	O
harboring	O
the	O
Crybb2Phil	O
mutation	O
bred	O
poorly	O
,	O
here	O
we	O
assess	O
the	O
contribution	O
of	O
betaB2-crystallin	O
to	O
mouse	O
fertility	O
and	O
determine	O
the	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
.	O

METHODS	O
:	O
The	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
was	O
analyzed	O
by	O
rt-PCR	O
,	O
western	O
blotting	O
,	O
and	O
immunohistochemistry	O
.	O

The	O
fecundity	O
of	O
wildtype	O
and	O
Crybb2Phil	O
mice	O
was	O
analyzed	O
by	O
quantitative	O
fertility	O
testing	O
.	O

The	O
morphology	O
of	O
testes	O
and	O
ovaries	O
was	O
assessed	O
by	O
hematoxylin	O
and	O
eosin	O
staining	O
.	O

RESULTS	O
:	O
In	O
the	O
mouse	O
testis	O
,	O
betaB2-crystallin	O
mRNA	O
is	O
found	O
at	O
low	O
levels	O
at	O
birth	O
,	O
but	O
its	O
expression	O
upregulates	O
in	O
this	O
tissue	O
as	O
the	O
testis	O
is	O
primed	O
to	O
initiate	O
spermatogenesis	O
.	O

Western	O
blotting	O
detected	O
betaB2-crystallin	O
protein	O
in	O
sperm	O
obtained	O
from	O
mice	O
,	O
cattle	O
,	O
and	O
humans	O
while	O
immunolocalization	O
detected	O
this	O
protein	O
in	O
developing	O
sperm	O
from	O
the	O
spermatocyte	O
stage	O
onward	O
.	O

Male	O
and	O
female	O
mice	O
homozygous	O
for	O
a	O
12	O
nucleotide	O
inframe	O
deletion	O
mutation	O
in	O
betaB2-crystallin	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
derived	O
background	O
due	O
to	O
defects	O
in	O
egg	O
and	O
sperm	O
production	O
.	O

However	O
,	O
mice	O
harboring	O
the	O
same	O
mutation	O
on	O
the	O
C57Bl/6	O
genetic	O
background	O
did	O
not	O
exhibit	O
any	O
defects	O
in	O
reproductive	O
function	O
.	O

CONCLUSIONS	O
:	O
betaB2-crystallin	O
is	O
expressed	O
in	O
developing	O
and	O
mature	O
sperm	O
and	O
mice	O
of	O
both	O
sexes	O
harboring	O
the	O
Philly	O
mutation	O
in	O
the	O
betaB2-crystallin	O
gene	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
genetic	O
background	O
.	O

While	O
these	O
data	O
are	O
suggestive	O
of	O
a	O
role	O
for	O
betaB2-crystallin	O
in	O
fertility	O
,	O
definitive	O
determination	O
of	O
this	O
will	O
await	O
the	O
creation	O
of	O
a	O
betaB2-crystallin	O
null	O
mouse	O
.	O

Monitoring	O
the	O
isochromosome	O
i(7)(q10)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
by	O
real-time	O
quantitative	O
PCR	O
.	O

Clonal	O
chromosome	O
anomalies	O
may	O
be	O
found	O
in	O
the	O
bone	O
marrow	O
(BM)	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
,	O
who	O
are	O
at	O
risk	O
to	O
develop	O
myelodysplastic	O
syndromes	O
and/or	O
acute	O
myeloid	O
leukemias	O
.	O

In	O
particular	O
,	O
an	O
isochromosome	O
i(7)(q10)	O
is	O
frequent	O
,	O
and	O
is	O
usually	O
monitored	O
by	O
chromosome	O
analyses	O
.	O

We	O
tested	O
an	O
approach	O
by	O
real-time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(RQ-PCR)	O
on	O
a	O
chromosome	O
7	O
polymorphism	O
.	O

Five	O
DNA	O
samples	O
of	O
2	O
Shwachman	O
syndrome	O
patients	O
with	O
clonal	O
i(7)(q10)	O
in	O
the	O
BM	O
were	O
used	O
.	O

Both	O
were	O
heterozygous	O
for	O
the	O
diallelic	O
indel	O
polymorphism	O
MID1064	O
,	O
which	O
maps	O
in	O
7q35	O
.	O

The	O
percentage	O
of	O
i(7)(q10)-positive	O
cells	O
was	O
extrapolated	O
from	O
the	O
ratio	O
of	O
the	O
2	O
alleles	O
measured	O
by	O
means	O
of	O
an	O
allele-specific	O
RQ-PCR	O
assay	O
.	O

The	O
results	O
were	O
compared	O
with	O
cytogenetic	O
analyses	O
on	O
the	O
same	O
material	O
used	O
for	O
RQ-PCR	O
.	O

In	O
1	O
patient	O
,	O
the	O
RQ-PCR	O
results	O
matched	O
well	O
with	O
those	O
of	O
chromosome	O
analyses	O
,	O
whereas	O
in	O
the	O
other	O
one	O
RQ-PCR	O
showed	O
that	O
around	O
40%	O
of	O
the	O
BM	O
cells	O
were	O
abnormal	O
,	O
while	O
they	O
resulted	O
to	O
be	O
nearly	O
80%	O
with	O
conventional	O
monitoring	O
assays	O
.	O

As	O
the	O
results	O
obtained	O
by	O
RQ-PCR	O
refer	O
to	O
the	O
DNA	O
of	O
around	O
128,000	O
BM	O
cells	O
,	O
our	O
method	O
proved	O
to	O
be	O
feasible	O
and	O
more	O
efficient	O
in	O
the	O
quantitative	O
evaluation	O
of	O
the	O
i(7)(q10)-positive	O
clone	O
than	O
conventional	O
ones	O
.	O

DFF45/ICAD	O
restores	O
cisplatin-induced	O
nuclear	O
fragmentation	O
but	O
not	O
DNA	O
cleavage	O
in	O
DFF45-deficient	O
neuroblastoma	O
cells	O
.	O

We	O
have	O
previously	O
defined	O
a	O
homozygously	O
deleted	O
region	O
at	O
chromosome	O
1p36.2-p36.3	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
,	O
NB-1	O
and	O
NB-C201	O
,	O
and	O
identified	O
six	O
genes	O
including	O
DFF45/ICAD	O
within	O
this	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
NB-C201	O
cells	O
are	O
much	O
more	O
resistant	O
to	O
various	O
genotoxic	O
stresses	O
such	O
as	O
cisplatin	O
(CDDP)	O
than	O
CHP134	O
and	O
SH-SY5Y	O
cells	O
that	O
do	O
not	O
have	O
the	O
homozygous	O
deletion	O
.	O

To	O
examine	O
a	O
role(s)	O
of	O
DFF45	O
in	O
the	O
regulation	O
of	O
apoptosis	O
in	O
response	O
to	O
CDDP	O
,	O
we	O
have	O
established	O
stably	O
DFF45-expressing	O
NB-C201	O
cell	O
clones	O
(	O
DFF45-1	O
and	O
DFF45-3	O
)	O
and	O
a	O
control	O
cell	O
clone	O
(NB-C201-C)	O
using	O
a	O
retrovirus-mediated	O
gene	O
transfer	O
.	O

In	O
contrast	O
to	O
NB-C201-C	O
cells	O
,	O
DFF45-3	O
cells	O
displayed	O
apoptotic	O
nuclear	O
fragmentation	O
in	O
response	O
to	O
CDDP	O
.	O

Although	O
CDDP-induced	O
proteolytic	O
cleavage	O
of	O
procaspase-3	O
and	O
DFF45	O
in	O
DFF45-3	O
cells	O
,	O
we	O
could	O
not	O
detect	O
a	O
typical	O
apoptotic	O
DNA	O
fragmentation	O
.	O

Additionally	O
,	O
deletion	O
analysis	O
revealed	O
that	O
C-terminal	O
region	O
of	O
DFF45	O
is	O
required	O
for	O
inducing	O
nuclear	O
fragmentation	O
.	O

Unexpectedly	O
,	O
(	O
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	O
bromide	O
(MTT)	O
assays	O
demonstrated	O
that	O
DFF45	O
has	O
undetectable	O
effect	O
on	O
CDDP	O
sensitivity	O
of	O
NB-C201	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
present	O
results	O
suggest	O
that	O
DFF45/DFF40	O
system	O
may	O
be	O
sufficient	O
for	O
CDDP-induced	O
nuclear	O
fragmentation	O
but	O
not	O
DNA	O
cleavage	O
.	O

Molecular	O
analysis	O
of	O
the	O
CYP2F1	O
gene	O
:	O
identification	O
of	O
a	O
frequent	O
non-functional	O
allelic	O
variant	O
.	O

The	O
CYP2F1	O
is	O
a	O
human	O
cytochrome	O
P450	O
that	O
is	O
selectively	O
expressed	O
in	O
lung	O
tissue	O
and	O
involved	O
in	O
the	O
metabolism	O
of	O
various	O
pneumotoxicants	O
with	O
potential	O
carcinogenic	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
first	O
systematic	O
investigation	O
of	O
the	O
genetic	O
polymorphism	O
of	O
this	O
enzyme	O
.	O

We	O
analyzed	O
the	O
nucleotidic	O
sequence	O
of	O
the	O
CYP2F1	O
gene	O
in	O
DNA	O
samples	O
from	O
90	O
French	O
Caucasians	O
consisting	O
in	O
44	O
patients	O
with	O
lung	O
cancer	O
and	O
46	O
control	O
individuals	O
,	O
using	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
PCR	O
products	O
(PCR-SSCP)	O
.	O

We	O
identified	O
24	O
novel	O
mutations	O
distributed	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gene	O
,	O
as	O
well	O
as	O
in	O
the	O
coding	O
regions	O
and	O
their	O
flanking	O
intronic	O
sequences	O
.	O

In	O
addition	O
to	O
the	O
wild-type	O
CYP2F1*1	O
allele	O
,	O
seven	O
allelic	O
variant	O
,	O
CYP2F1*2A	O
,	O
*2B	O
,	O
*3	O
,	O
*4	O
,	O
*5A	O
,	O
*5B	O
and	O
*6	O
,	O
were	O
characterized	O
.	O

The	O
most	O
frequent	O
allelic	O
variant	O
,	O
CYP2F1*2A	O
(25.6%)	O
,	O
harbors	O
a	O
combination	O
of	O
9	O
mutations	O
,	O
including	O
2	O
missense	O
mutations	O
(	O
Asp218Asn	B-ProteinMutation
and	O
Gln266His	B-ProteinMutation
)	O
and	O
a	O
1-bp	O
insertion	O
c.14_15insC	B-DNAMutation
that	O
creates	O
a	O
premature	O
stop	O
codon	O
in	O
exon	O
2	O
,	O
probably	O
leading	O
to	O
the	O
synthesis	O
of	O
a	O
severely	O
truncated	O
protein	O
with	O
no	O
catalytic	O
activity	O
.	O

The	O
identification	O
of	O
around	O
7%	O
of	O
homozygotes	O
for	O
the	O
frameshift	O
mutation	O
in	O
our	O
Caucasian	O
population	O
suggests	O
the	O
existence	O
of	O
an	O
interindividual	O
variation	O
of	O
the	O
CYP2F1	O
activity	O
and	O
,	O
consequently	O
,	O
the	O
possibility	O
of	O
interindividual	O
differences	O
in	O
the	O
toxic	O
response	O
to	O
some	O
pneumotoxicants	O
and	O
in	O
the	O
susceptibility	O
to	O
certain	O
chemically	O
induced	O
diseases	O
.	O

However	O
,	O
our	O
preliminary	O
results	O
did	O
not	O
show	O
any	O
evidence	O
that	O
the	O
CYP2F1	O
genetic	O
polymorphism	O
has	O
implications	O
in	O
the	O
pathogenesis	O
of	O
lung	O
cancer	O
.	O

Human	O
TBX1	O
missense	O
mutations	O
cause	O
gain	O
of	O
function	O
resulting	O
in	O
the	O
same	O
phenotype	O
as	O
22q11.2	O
deletions	O
.	O

Deletion	O
22q11.2	O
syndrome	O
is	O
the	O
most	O
frequent	O
known	O
microdeletion	O
syndrome	O
and	O
is	O
associated	O
with	O
a	O
highly	O
variable	O
phenotype	O
,	O
including	O
DiGeorge	O
and	O
Shprintzen	O
(velocardiofacial)	O
syndromes	O
.	O

Although	O
haploinsufficiency	O
of	O
the	O
T-box	O
transcription	O
factor	O
gene	O
TBX1	O
is	O
thought	O
to	O
cause	O
the	O
phenotype	O
,	O
to	O
date	O
,	O
only	O
four	O
different	O
point	O
mutations	O
in	O
TBX1	O
have	O
been	O
reported	O
in	O
association	O
with	O
six	O
of	O
the	O
major	O
features	O
of	O
22q11.2	O
deletion	O
syndrome	O
.	O

Although	O
,	O
for	O
the	O
two	O
truncating	O
mutations	O
,	O
loss	O
of	O
function	O
was	O
previously	O
shown	O
,	O
the	O
pathomechanism	O
of	O
the	O
missense	O
mutations	O
remains	O
unknown	O
.	O

We	O
report	O
a	O
novel	O
heterozygous	O
missense	O
mutation	O
,	O
H194Q	B-ProteinMutation
,	O
in	O
a	O
familial	O
case	O
of	O
Shprintzen	O
syndrome	O
and	O
show	O
that	O
this	O
and	O
the	O
two	O
previously	O
reported	O
missense	O
mutations	O
result	O
in	O
gain	O
of	O
function	O
,	O
possibly	O
through	O
stabilization	O
of	O
the	O
protein	O
dimer	O
DNA	O
complex	O
.	O

We	O
therefore	O
conclude	O
that	O
TBX1	O
gain-of-function	O
mutations	O
can	O
result	O
in	O
the	O
same	O
phenotypic	O
spectrum	O
as	O
haploinsufficiency	O
caused	O
by	O
loss-of-function	O
mutations	O
or	O
deletions	O
.	O

A	O
possible	O
bichromatid	O
mutation	O
in	O
a	O
male	O
gamete	O
giving	O
rise	O
to	O
a	O
female	O
mosaic	O
for	O
two	O
different	O
mutations	O
in	O
the	O
X-linked	O
gene	O
WAS	O
.	O

In	O
genetic	O
disorders	O
caused	O
by	O
point	O
mutations	O
or	O
small	O
frameshift	O
mutations	O
,	O
affected	O
members	O
of	O
the	O
same	O
family	O
are	O
expected	O
to	O
have	O
the	O
same	O
mutation	O
in	O
the	O
causative	O
gene	O
.	O

We	O
have	O
recently	O
evaluated	O
a	O
family	O
in	O
which	O
this	O
was	O
not	O
the	O
case	O
.	O

Maternal	O
cousins	O
with	O
Wiskott-Aldrich	O
syndrome	O
(	O
WAS	O
;	O
MIM	O
301000	O
)	O
had	O
two	O
different	O
but	O
contiguous	O
single	O
base	O
pair	O
deletions	O
in	O
WAS	O
.	O

The	O
proband	O
had	O
an	O
A	O
deletion	O
in	O
codon	O
242	O
in	O
exon	O
7	O
of	O
WAS	O
;	O
his	O
two	O
cousins	O
had	O
a	O
C	O
deletion	O
in	O
codon	O
241	O
.	O

The	O
mother	O
of	O
the	O
proband	O
was	O
heterozygous	O
for	O
the	O
A	O
deletion	O
allele	O
,	O
but	O
her	O
three	O
sisters	O
,	O
including	O
the	O
mother	O
of	O
the	O
affected	O
cousins	O
,	O
were	O
heterozygous	O
for	O
the	O
C	O
deletion	O
.	O

Both	O
deletions	O
occurred	O
on	O
the	O
haplotype	O
from	O
the	O
unaffected	O
maternal	O
great-grandfather	O
.	O

The	O
maternal	O
grandmother	O
,	O
who	O
was	O
a	O
carrier	O
of	O
WAS	O
,	O
based	O
on	O
a	O
non-random	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
in	O
T	O
cells	O
,	O
was	O
mosaic	O
for	O
both	O
deletions	O
.	O

These	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
mutations	O
originating	O
in	O
a	O
male	O
gamete	O
with	O
different	O
mutations	O
on	O
the	O
two	O
strands	O
of	O
DNA	O
,	O
a	O
bichromatid	O
mutation	O
.	O

A	O
novel	O
mutation	O
at	O
the	O
DFNA36	O
hearing	O
loss	O
locus	O
reveals	O
a	O
critical	O
function	O
and	O
potential	O
genotype-phenotype	O
correlation	O
for	O
amino	O
acid-572	O
of	O
TMC1	O
.	O

We	O
ascertained	O
a	O
North	O
American	O
Caucasian	O
family	O
(LMG248)	O
segregating	O
autosomal	O
dominant	O
,	O
non-syndromic	O
,	O
post-lingual	O
,	O
progressive	O
sensorineural	O
hearing	O
loss	O
.	O

The	O
hearing	O
loss	O
begins	O
in	O
the	O
second	O
decade	O
of	O
life	O
and	O
initially	O
affects	O
high	O
frequencies	O
.	O

It	O
progresses	O
to	O
profound	O
deafness	O
at	O
all	O
frequencies	O
by	O
the	O
fourth	O
or	O
fifth	O
decade	O
.	O

The	O
phenotype	O
co-segregates	O
with	O
short-tandem	O
repeat	O
markers	O
flanking	O
the	O
TMC1	O
gene	O
at	O
the	O
DFNA36	O
locus	O
on	O
chromosome	O
9q31-q21	O
.	O

The	O
affected	O
individuals	O
carry	O
a	O
novel	O
missense	O
substitution	O
,	O
p.D572H	B-ProteinMutation
c.G1714C	B-DNAMutation
,	O
of	O
the	O
TMC1	O
gene	O
.	O

This	O
mutation	O
is	O
at	O
the	O
same	O
nucleotide	O
and	O
amino	O
acid	O
position	O
as	O
the	O
only	O
other	O
reported	O
DFNA36	O
mutation	O
,	O
p.D572N	B-ProteinMutation
c.G1714A	B-DNAMutation
.	O

Our	O
observations	O
implicate	O
a	O
critical	O
function	O
for	O
amino	O
acid-572	O
for	O
wild-type	O
TMC1	O
function	O
or	O
the	O
pathogenesis	O
of	O
DFNA36	O
hearing	O
loss	O
.	O

The	O
slower	O
progression	O
of	O
hearing	O
loss	O
associated	O
with	O
p.D572H	B-ProteinMutation
,	O
in	O
comparison	O
with	O
that	O
caused	O
by	O
p.D572N	B-ProteinMutation
,	O
may	O
reflect	O
a	O
correlation	O
of	O
DFNA36	O
phenotype	O
with	O
TMC1	O
genotype	O
.	O

Cytochrome	O
p4501A1	O
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	O
cancer	O
.	O

CYP1A1	O
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	O
cancer	O
.	O

To	O
evaluate	O
this	O
phenomenon	O
,	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	O
to	O
G	O
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	B-ProteinMutation
and	O
T3801C	B-DNAMutation
at	O
3'UTR	O
)	O
of	O
CYP1A1	O
gene	O
in	O
prostate	O
cancer	O
were	O
analyzed	O
in	O
a	O
case-control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O

The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1/m1	O
genotype	O
at	O
3'UTR	O
of	O
CYP1A1	O
gene	O
(	O
OR-4.64	O
;	O
95%CI	O
=	O
1.51-14.86	O
;	O
P	O
<	O
0.01	O
)	O
whereas	O
the	O
CYP1A1	O
Ile/Val	O
genotype	O
(w2/m2)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	O
cancer	O
(	O
OR-0.17	O
;	O
95%CI	O
=	O
0.02-0.89	O
;	O
P=0.03	O
)	O
.	O

A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	O
grade	O
showed	O
the	O
w1/m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
;	O
however	O
the	O
tumor	O
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O

Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1/m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2/m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	O
cancer	O
.	O

Multipoint	O
interphase	O
FISH	O
in	O
childhood	O
T-acute	O
lymphoblastic	O
leukemia	O
detects	O
subpopulations	O
that	O
carry	O
different	O
chromosome	O
3	O
aberrations	O
.	O

We	O
examined	O
chromosome	O
3	O
in	O
32	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
bone	O
marrow	O
samples	O
.	O

Using	O
interphase	O
multipoint	O
FISH	O
(mp-FISH)	O
,	O
which	O
was	O
developed	O
by	O
our	O
group	O
,	O
with	O
42	O
chromosome	O
3-specific	O
probes	O
,	O
we	O
detected	O
clonal	O
chromosome	O
3	O
aberrations	O
in	O
4	O
T-cell	O
ALL	O
(T-ALL)	O
cases	O
.	O

Four	O
out	O
of	O
seven	O
T-ALL	O
cases	O
carried	O
3q	O
trisomies	O
.	O

One	O
T-ALL	O
case	O
carried	O
either	O
trisomy	O
3	O
(	O
in	O
15%	O
of	O
the	O
cells	O
)	O
or	O
a	O
23-megabase	O
(Mb)	O
3p13	O
approximately	O
p12	O
deletion	O
in	O
a	O
different	O
subpopulation	O
of	O
cells	O
of	O
32%	O
.	O

Another	O
T-ALL	O
case	O
had	O
either	O
3q	O
trisomy	O
in	O
11%	O
or	O
a	O
12-Mb	O
3p12	O
approximately	O
p13	O
deletion	O
in	O
19%	O
of	O
the	O
cells	O
.	O

The	O
deletions	O
were	O
overlapping	O
.	O

In	O
both	O
cases	O
,	O
the	O
majority	O
of	O
the	O
bone	O
marrow	O
cells	O
(	O
47	O
and	O
70%	O
,	O
respectively	O
)	O
were	O
normal	O
chromosome	O
3	O
disomics	O
.	O

The	O
interstitial	O
deletions	O
detected	O
harbor	O
a	O
known	O
homozygous	O
deletion	O
region	O
between	O
72.6	O
and	O
78.8	O
Mb	O
,	O
which	O
has	O
been	O
described	O
in	O
lung	O
and	O
breast	O
tumors	O
and	O
contains	O
the	O
DUTT1/ROBO1	O
tumor	O
suppressor	O
gene	O
.	O

These	O
deletions	O
detected	O
by	O
mp-FISH	O
would	O
have	O
remained	O
unnoticed	O
by	O
conventional	O
cytogenetics	O
and	O
multiplex	O
FISH	O
,	O
as	O
well	O
as	O
by	O
current	O
methods	O
based	O
on	O
total	O
tumor	O
DNA	O
analysis	O
such	O
as	O
comparative	O
genomic	O
hybridization	O
(CGH)	O
,	O
array	O
CGH	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(LOH)	O
.	O

Single-base	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
6	O
c.671G>A	B-DNAMutation
,	O
resulting	O
in	O
the	O
skipping	O
of	O
exon	O
6	O
,	O
and	O
exons	O
6	O
and	O
7	O
in	O
human	O
succinyl-CoA:3-ketoacid	O
CoA	O
transferase	O
(SCOT)	O
gene	O
.	O

Succinyl-CoA:3-ketoacid	O
CoA	O
transferase	O
(	O
SCOT	O
,	O
EC	O
2.8.3.5	O
)	O
is	O
the	O
key	O
enzyme	O
for	O
ketone	O
body	O
utilization	O
.	O

Hereditary	O
SCOT	O
deficiency	O
(	O
MIM	O
245050	O
)	O
causes	O
episodes	O
of	O
severe	O
ketoacidosis	O
.	O

We	O
identified	O
a	O
homozygous	O
point	O
mutation	O
c.671G>A	B-DNAMutation
,	O
which	O
is	O
a	O
single-base	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
6	O
,	O
in	O
a	O
Turkish	O
patient	O
(GS12)	O
with	O
SCOT	O
deficiency	O
.	O

This	O
point	O
mutation	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
6	O
,	O
and	O
exons	O
6	O
and	O
7	O
in	O
human	O
SCOT	O
genes	O
.	O

To	O
understand	O
why	O
the	O
c.671G>A	B-DNAMutation
causes	O
exons	O
6	O
and	O
7	O
skipping	O
,	O
nuclear	O
RNA	O
was	O
separated	O
from	O
cytoplasmic	O
RNA	O
and	O
both	O
were	O
analyzed	O
by	O
RT-PCR	O
.	O

In	O
nuclear	O
RNA	O
,	O
SCOT	O
mRNA	O
with	O
exon	O
6	O
skipping	O
was	O
predominant	O
and	O
mRNA	O
with	O
exons	O
6	O
and	O
7	O
skipping	O
was	O
hardly	O
detected	O
,	O
whereas	O
the	O
latter	O
became	O
one	O
of	O
major	O
mRNA	O
species	O
in	O
cytoplasmic	O
RNA	O
.	O

This	O
discrepancy	O
was	O
interpreted	O
as	O
follows	O
:	O
exon	O
6	O
skipping	O
causes	O
a	O
frameshift	O
and	O
nonsense-mediated	O
RNA	O
decay	O
in	O
the	O
cytosol	O
,	O
so	O
mRNA	O
with	O
exon	O
6	O
skipping	O
was	O
unstable	O
.	O

On	O
the	O
other	O
hand	O
,	O
SCOT	O
mRNA	O
with	O
exons	O
6	O
and	O
7	O
is	O
a	O
minor	O
transcript	O
but	O
it	O
retains	O
the	O
reading-frame	O
and	O
is	O
stable	O
in	O
cytosol	O
.	O

As	O
a	O
result	O
,	O
the	O
latter	O
mRNA	O
is	O
more	O
abundant	O
under	O
steady-state	O
conditions	O
as	O
compared	O
to	O
the	O
former	O
mRNA	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	O
protein-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
.	O

BACKGROUND	O
:	O
Meningococcal	O
disease	O
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	O
meningitidis	O
.	O

Surfactant	O
protein	O
(SP)-A	O
and	O
SP-D	O
are	O
pattern-recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	O
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	O
.	O

Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O

METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP-A1	O
,	O
SP-A2	O
,	O
and	O
SP-D	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	O
with	O
microbiologically	O
proven	O
meningococcal	O
disease	O
,	O
including	O
18	O
patients	O
who	O
died	O
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP-A2	O
increased	O
the	O
risk	O
of	O
meningococcal	O
disease	O
(	O
odds	O
ratio	O
[OR]	O
,	O
7.4	O
;	O
95%	O
confidence	O
interval	O
[CI]	O
,	O
1.3-42.4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0.3	O
;	O
95%	O
CI	O
,	O
0.1-0.97	O
)	O
.	O

An	O
analysis	O
of	O
the	O
multiple	O
single-nucleotide	O
polymorphisms	O
in	O
SP-A	O
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	O
(	O
in	O
1A1	O
)	O
rather	O
than	O
glutamine	O
(	O
in	O
1A5	O
)	O
at	O
amino	O
acid	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	O
disease	O
(	O
OR	O
,	O
6.7	O
;	O
95%	O
CI	O
,	O
1.4-31.5	O
)	O
.	O

Carriage	O
of	O
alleles	O
encoding	O
lysine	O
at	O
residue	O
223	O
was	O
found	O
in	O
61%	O
of	O
patients	O
who	O
died	O
,	O
compared	O
with	O
35%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2.9	O
;	O
95%	O
CI	O
,	O
1.1-7.7	O
)	O
.	O

Genetic	O
variation	O
of	O
SP-A1	O
and	O
SP-D	O
was	O
not	O
associated	O
with	O
meningococcal	O
disease	O
.	O

CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	O
with	O
lysine	O
at	O
residue	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
of	O
SP-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	O
.	O

Nucleotide	O
change	O
of	O
codon	O
38	O
in	O
the	O
X	O
gene	O
of	O
hepatitis	O
B	O
virus	O
genotype	O
C	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
hepatocellular	O
carcinoma	O
.	O

BACKGROUND/AIMS	O
:	O
The	O
hepatitis	O
B	O
virus	O
(HBV)	O
genotype	O
C	O
is	O
associated	O
with	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
(HCC)	O
.	O

In	O
addition	O
,	O
the	O
HBV	O
X	O
gene	O
,	O
which	O
encodes	O
the	O
pleiotropic	O
transactivator	O
HBx	O
,	O
has	O
also	O
been	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
nucleotide	O
changes	O
in	O
the	O
X	O
gene	O
of	O
genotype	O
C	O
are	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

METHODS/RESULTS	O
:	O
We	O
sequenced	O
the	O
X	O
gene	O
in	O
age-	O
and	O
sex-matched	O
39	O
HBV-infected	O
patients	O
with	O
HCC	O
and	O
36	O
HBV-infected	O
patients	O
without	O
HCC	O
.	O

A	O
novel	O
nucleotide	O
change	O
that	O
resulted	O
in	O
a	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
38	O
in	O
HBx	O
(	O
codon-38	O
change	O
)	O
was	O
preferentially	O
found	O
in	O
patients	O
with	O
HCC	O
.	O

Then	O
,	O
sera	O
were	O
collected	O
from	O
a	O
new	O
group	O
of	O
age-	O
and	O
sex-matched	O
52	O
patients	O
with	O
HCC	O
and	O
51	O
patients	O
without	O
HCC	O
.	O

In	O
this	O
cohort	O
also	O
,	O
the	O
codon-38	O
change	O
was	O
associated	O
with	O
HCC	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
the	O
prevalence	O
of	O
the	O
codon-38	O
change	O
was	O
significantly	O
associated	O
with	O
HCC	O
in	O
all	O
patients	O
(	O
P=0.001	O
,	O
odds	O
ratio	O
:	O
4.89	O
)	O
.	O

CONCLUSION	O
:	O
The	O
codon-38	O
change	O
in	O
genotype	O
C	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
HCC	O
and	O
may	O
serve	O
as	O
a	O
useful	O
molecular	O
marker	O
for	O
predicting	O
the	O
clinical	O
outcomes	O
in	O
patients	O
infected	O
with	O
HBV	O
.	O

No	O
independent	O
role	O
of	O
the	O
-1123	B-DNAMutation
G>C	I-DNAMutation
and+2740	B-DNAMutation
A>G	I-DNAMutation
variants	O
in	O
the	O
association	O
of	O
PTPN22	O
with	O
type	O
1	O
diabetes	O
and	O
juvenile	O
idiopathic	O
arthritis	O
in	O
two	O
Caucasian	O
populations	O
.	O

INTRODUCTION	O
:	O
The	O
PTPN22	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
T	O
cell	O
response	O
.	O

Its	O
+1858C>T	B-DNAMutation
R620W	B-ProteinMutation
polymorphism	O
has	O
been	O
shown	O
to	O
associate	O
with	O
a	O
risk	O
for	O
multiple	O
autoimmune	O
diseases	O
,	O
including	O
type	O
1	O
diabetes	O
(T1D)	O
and	O
juvenile	O
idiopathic	O
arthritis	O
(JIA)	O
.	O

The	O
minor	O
(susceptibility)	O
allele	O
is	O
absent	O
in	O
Asian	O
populations	O
,	O
but	O
a	O
recent	O
study	O
suggested	O
an	O
independent	O
involvement	O
of	O
another	O
polymorphism	O
located	O
within	O
the	O
promoter	O
-1123	O
nucleotides	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O

AIMS	O
:	O
We	O
aimed	O
to	O
analyse	O
the	O
association	O
of	O
three	O
PTPN22	O
polymorphisms	O
in	O
two	O
distinct	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
(	O
with	O
T1D	O
and	O
with	O
JIA	O
)	O
and	O
Azeri	O
(	O
with	O
T1D	O
)	O
.	O

METHODS	O
:	O
The	O
single	O
nucleotide	O
polymorphisms	O
(SNP)	O
at	O
positions	O
-1123	O
rs2488457	B-SNP
,	O
+1858	O
(	O
rs2476601	B-SNP
,	O
the	O
R620W	B-ProteinMutation
substitution	O
)	O
,	O
and	O
+2740	O
rs1217412	B-SNP
were	O
genotyped	O
using	O
TaqMan	O
assays	O
in	O
372	O
subjects	O
with	O
childhood-onset	O
T1D	O
,	O
130	O
subjects	O
with	O
JIA	O
,	O
and	O
400	O
control	O
subjects	O
of	O
Czech	O
origin	O
,	O
and	O
in	O
160	O
subjects	O
with	O
T1D	O
and	O
271	O
healthy	O
controls	O
of	O
Azeri	O
origin	O
.	O

RESULTS	O
:	O
In	O
the	O
Czechs	O
,	O
all	O
three	O
SNPs	O
were	O
in	O
a	O
tight	O
linkage	O
disequlibrium	O
,	O
while	O
in	O
the	O
Azeri	O
,	O
the	O
linkage	O
disequlibrium	O
was	O
limited	O
to	O
between	O
the	O
promoter	O
and	O
3'-UTR	O
polymorphism	O
,	O
D'(-1123	O
,	O
+2740)=0.99	O
,	O
r(2)=0.72	O
.	O

Haplotype	O
reconstruction	O
via	O
the	O
expectation-maximization	O
algorithm	O
showed	O
in	O
both	O
populations	O
that	O
only	O
the	O
haplotype	O
containing	O
the	O
minor	O
(W)	O
allele	O
at	O
codon	O
620	O
was	O
associated	O
with	O
T1D	O
(	O
OR=2.26	O
,	O
95%	O
CI	O
1.68-3.02	O
in	O
Czechs	O
,	O
OR=14.8	O
,	O
95%	O
CI	O
2.0-651	O
in	O
Azeri	O
)	O
or	O
JIA	O
(	O
OR=2.43	O
,	O
95%	O
CI	O
1.66-3.56	O
in	O
Czechs	O
)	O
.	O

The	O
haplotypes	O
having	O
the	O
wild-type	O
(R)	O
allele	O
at	O
codon	O
620	O
and	O
minor	O
alleles	O
at	O
-1123	O
and/or	O
+2740	O
were	O
neutral	O
as	O
to	O
the	O
risk	O
of	O
autoimmune	O
conditions	O
in	O
both	O
populations	O
.	O

CONCLUSIONS	O
:	O
In	O
two	O
different	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
and	O
the	O
Azeri	O
,	O
no	O
independent	O
contribution	O
can	O
be	O
detected	O
either	O
of	O
the	O
-1123	O
promoter	O
SNP	O
or	O
the	O
+2740	O
3'-UTR	O
SNP	O
,	O
and	O
only	O
the	O
minor	O
allele	O
at	O
PTPN22	O
codon	O
620	O
contributes	O
to	O
the	O
risk	O
of	O
autoimmunity	O
.	O

Mutations	O
in	O
the	O
NDP	O
gene	O
:	O
contribution	O
to	O
Norrie	O
disease	O
,	O
familial	O
exudative	O
vitreoretinopathy	O
and	O
retinopathy	O
of	O
prematurity	O
.	O

BACKGROUND	O
:	O
To	O
examine	O
the	O
contribution	O
of	O
mutations	O
within	O
the	O
Norrie	O
disease	O
(NDP)	O
gene	O
to	O
the	O
clinically	O
similar	O
retinal	O
diseases	O
Norrie	O
disease	O
,	O
X-linked	O
familial	O
exudative	O
vitreoretinopathy	O
(FEVR)	O
,	O
Coat's	O
disease	O
and	O
retinopathy	O
of	O
prematurity	O
(ROP)	O
.	O

METHODS	O
:	O
A	O
dataset	O
comprising	O
13	O
Norrie-FEVR	O
,	O
one	O
Coat's	O
disease	O
,	O
31	O
ROP	O
patients	O
and	O
90	O
ex-premature	O
babies	O
of	O
<32	O
weeks'	O
gestation	O
underwent	O
an	O
ophthalmologic	O
examination	O
and	O
were	O
screened	O
for	O
mutations	O
within	O
the	O
NDP	O
gene	O
by	O
direct	O
DNA	O
sequencing	O
,	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
or	O
gel	O
electrophoresis	O
.	O

Controls	O
were	O
only	O
screened	O
using	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
and	O
gel	O
electrophoresis	O
.	O

Confirmation	O
of	O
mutations	O
identified	O
was	O
obtained	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Evidence	O
for	O
two	O
novel	O
mutations	O
in	O
the	O
NDP	O
gene	O
was	O
presented	O
:	O
Leu103Val	B-ProteinMutation
in	O
one	O
FEVR	O
patient	O
and	O
His43Arg	B-ProteinMutation
in	O
monozygotic	O
twin	O
Norrie	O
disease	O
patients	O
.	O

Furthermore	O
,	O
a	O
previously	O
described	O
14-bp	O
deletion	O
located	O
in	O
the	O
5'	O
unstranslated	O
region	O
of	O
the	O
NDP	O
gene	O
was	O
detected	O
in	O
three	O
cases	O
of	O
regressed	O
ROP	O
.	O

A	O
second	O
heterozygotic	O
14-bp	O
deletion	O
was	O
detected	O
in	O
an	O
unaffected	O
ex-premature	O
girl	O
.	O

Only	O
two	O
of	O
the	O
13	O
Norrie-FEVR	O
index	O
cases	O
had	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
with	O
deafness	O
and	O
mental	O
retardation	O
.	O

CONCLUSION	O
:	O
Two	O
novel	O
mutations	O
within	O
the	O
coding	O
region	O
of	O
the	O
NDP	O
gene	O
were	O
found	O
,	O
one	O
associated	O
with	O
a	O
severe	O
disease	O
phenotypes	O
of	O
Norrie	O
disease	O
and	O
the	O
other	O
with	O
FEVR	O
.	O

A	O
deletion	O
within	O
the	O
non-coding	O
region	O
was	O
associated	O
with	O
only	O
mild-regressed	O
ROP	O
,	O
despite	O
the	O
presence	O
of	O
low	O
birthweight	O
,	O
prematurity	O
and	O
exposure	O
to	O
oxygen	O
.	O

In	O
full-term	O
children	O
with	O
retinal	O
detachment	O
only	O
15%	O
appear	O
to	O
have	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
and	O
this	O
is	O
important	O
for	O
counselling	O
parents	O
on	O
the	O
possible	O
long-term	O
outcome	O
.	O

Intronic	O
deletions	O
in	O
the	O
SLC34A3	O
gene	O
cause	O
hereditary	O
hypophosphatemic	O
rickets	O
with	O
hypercalciuria	O
.	O

CONTEXT	O
:	O
Hereditary	O
hypophosphatemic	O
rickets	O
with	O
hypercalciuria	O
(HHRH)	O
is	O
a	O
rare	O
metabolic	O
disorder	O
,	O
characterized	O
by	O
hypophosphatemia	O
and	O
rickets/osteomalacia	O
with	O
increased	O
serum	O
1,25-dihydroxyvitamin	O
D	O
[1,25-(OH)(2)D]	O
resulting	O
in	O
hypercalciuria	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
,	O
which	O
encodes	O
sodium-phosphate	O
cotransporter	O
type	O
IIc	O
,	O
are	O
responsible	O
for	O
the	O
occurrence	O
of	O
HHRH	O
.	O

DESIGN	O
AND	O
SETTING	O
:	O
Mutation	O
analysis	O
of	O
exons	O
and	O
adjacent	O
introns	O
in	O
the	O
SLC34A3	O
gene	O
was	O
conducted	O
at	O
an	O
academic	O
research	O
laboratory	O
and	O
medical	O
center	O
.	O

PATIENTS	O
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Members	O
of	O
two	O
unrelated	O
families	O
with	O
HHRH	O
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Two	O
affected	O
siblings	O
in	O
one	O
family	O
were	O
homozygous	O
for	O
a	O
101-bp	O
deletion	O
in	O
intron	O
9	O
.	O

Haplotype	O
analysis	O
of	O
the	O
SLC34A3	O
locus	O
in	O
the	O
family	O
showed	O
that	O
the	O
two	O
deletions	O
are	O
on	O
different	O
haplotypes	O
.	O

An	O
unrelated	O
individual	O
with	O
HHRH	O
was	O
a	O
compound	O
heterozygote	O
for	O
an	O
85-bp	O
deletion	O
in	O
intron	O
10	O
and	O
a	O
G-to-A	O
substitution	O
at	O
the	O
last	O
nucleotide	O
in	O
exon	O
7	O
.	O

The	O
intron	O
9	O
deletion	O
(	O
and	O
likely	O
the	O
other	O
two	O
mutations	O
)	O
identified	O
in	O
this	O
study	O
causes	O
aberrant	O
RNA	O
splicing	O
.	O

Sequence	O
analysis	O
of	O
the	O
deleted	O
regions	O
revealed	O
the	O
presence	O
of	O
direct	O
repeats	O
of	O
homologous	O
sequences	O
.	O

CONCLUSION	O
:	O
HHRH	O
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
.	O

Haplotype	O
analysis	O
suggests	O
that	O
the	O
two	O
intron	O
9	O
deletions	O
arose	O
independently	O
.	O

The	O
identification	O
of	O
three	O
independent	O
deletions	O
in	O
introns	O
9	O
and	O
10	O
suggests	O
that	O
the	O
SLC34A3	O
gene	O
may	O
be	O
susceptible	O
to	O
unequal	O
crossing	O
over	O
because	O
of	O
sequence	O
misalignment	O
during	O
meiosis	O
.	O

DNA	O
damage	O
and	O
repair	O
in	O
gastric	O
cancer--a	O
correlation	O
with	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
polymorphisms	O
.	O

The	O
cell's	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	O
induction	O
,	O
promotion	O
and	O
progression	O
.	O

Both	O
the	O
mutagens'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
,	O
including	O
DNA	O
repair	O
genes	O
.	O

The	O
hOGG1	O
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	O
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O

Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
,	O
which	O
can	O
contribute	O
to	O
stomach	O
cancer	O
.	O

In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	O
peroxide	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	O
cancer	O
patients	O
and	O
30	O
healthy	O
individuals	O
.	O

The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
:	O
a	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
of	O
the	O
hOGG1	O
gene	O
producing	O
a	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
(	O
the	O
Ser326Cys	B-ProteinMutation
polymorphism	O
)	O
and	O
a	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
5'-untranslated	O
region	O
)	O
of	O
the	O
RAD51	O
gene	O
(	O
the	O
G135C	B-DNAMutation
polymorphism	O
)	O
.	O

DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	O
III	O
(Nth)	O
and	O
formamidopyrimidine-DNA	O
glycosylase	O
(Fpg)	O
,	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O

The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O

We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	O
cancer	O
occurrence	O
,	O
impaired	O
DNA	O
repair	O
in	O
human	O
lymphocytes	O
and	O
the	O
G/C	O
genotype	O
of	O
the	O
G135C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
.	O

Moreover	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	O
cancer	O
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	B-ProteinMutation
polymorphism	O
of	O
the	O
hOGG1	O
gene	O
and	O
gastric	O
cancer	O
,	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and/or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O

Therefore	O
,	O
our	O
result	O
suggest	O
that	O
the	O
G135C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
be	O
linked	O
with	O
gastric	O
cancer	O
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or/and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O

Genotyping	O
of	O
five	O
chinese	O
patients	O
with	O
17alpha-hydroxylase	O
deficiency	O
diagnosed	O
through	O
high-performance	O
liquid	O
chromatography	O
serum	O
adrenal	O
profile	O
:	O
identification	O
of	O
two	O
novel	O
CYP17	O
mutations	O
.	O

CONTEXT	O
:	O
17alpha-Hydroxylase	O
deficiency	O
is	O
a	O
rare	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
caused	O
by	O
CYP17	O
gene	O
mutations	O
.	O

OBJECTIVE	O
:	O
Five	O
Chinese	O
patients	O
with	O
17alpha-hydroxylase	O
deficiency	O
were	O
genotyped	O
.	O

PATIENTS	O
:	O
The	O
five	O
patients	O
derived	O
from	O
four	O
families	O
living	O
in	O
Shandong	O
Province	O
,	O
China	O
.	O

The	O
diagnosis	O
of	O
17alpha-hydroxylase	O
deficiency	O
was	O
initially	O
established	O
through	O
HPLC	O
serum	O
adrenal	O
profiles	O
in	O
Qilu	O
Hospital	O
,	O
China	O
,	O
from	O
1983-1993	O
.	O

RESULTS	O
:	O
Three	O
CYP17	O
gene	O
mutations	O
were	O
identified	O
from	O
these	O
patients	O
.	O

Among	O
them	O
,	O
V311fs	B-ProteinMutation
and	O
Y329fs	B-ProteinMutation
are	O
two	O
novel	O
frame-shifting	O
mutations	O
.	O

V311fs	B-ProteinMutation
is	O
an	O
8-bp	O
nucleotide	O
(TTAAATGG)	O
deletion	O
in	O
exon	O
5	O
.	O

Y329fs	B-ProteinMutation
is	O
a	O
deletion-insertion	O
combined	O
mutation	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
in	O
exon	O
6	O
.	O

Two	O
homozygotes	O
for	O
Y329fs	B-ProteinMutation
and	O
one	O
compound	O
heterozygote	O
for	O
Y329fs	B-ProteinMutation
and	O
V311fs	B-ProteinMutation
were	O
identified	O
from	O
three	O
different	O
families	O
.	O

Two	O
homozygous	O
sisters	O
for	O
the	O
D487_S488_F489	O
deletion	O
were	O
identified	O
.	O

CONCLUSION	O
:	O
The	O
results	O
confirmed	O
the	O
diagnostic	O
value	O
of	O
the	O
HPLC	O
serum	O
adrenal	O
profile	O
for	O
17alpha-hydroxylase	O
deficiency	O
.	O

The	O
D487_S488_F489	O
deletion	O
had	O
been	O
identified	O
in	O
two	O
previously	O
genotyped	O
Chinese	O
families	O
.	O

In	O
our	O
present	O
study	O
,	O
a	O
third	O
Chinese	O
family	O
with	O
this	O
mutation	O
was	O
identified	O
,	O
suggesting	O
that	O
this	O
mutation	O
is	O
a	O
prevalent	O
CYP17	O
mutation	O
in	O
the	O
Chinese	O
population	O
.	O

The	O
identification	O
of	O
Y329fs	B-ProteinMutation
mutation	O
in	O
addition	O
to	O
three	O
previously	O
identified	O
mutations	O
at	O
codon	O
329	O
suggests	O
that	O
codon	O
329	O
is	O
an	O
unstable	O
point	O
of	O
the	O
CYP17	O
gene	O
.	O

The	O
mutations	O
identified	O
from	O
our	O
five	O
patients	O
appear	O
to	O
be	O
random	O
,	O
but	O
the	O
recurrence	O
of	O
the	O
Y329fs	B-ProteinMutation
mutation	O
may	O
be	O
attributed	O
to	O
a	O
founder	O
effect	O
.	O

Our	O
studies	O
suggest	O
that	O
17alpha-hydroxylase	O
deficiency	O
may	O
not	O
be	O
rare	O
in	O
the	O
Chinese	O
population	O
.	O

A	O
novel	O
multidrug-resistance	O
protein	O
2	O
gene	O
mutation	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
primary	O
biliary	O
cirrhosis	O
and	O
pruritus	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
characterized	O
by	O
the	O
substitution	O
of	O
valine	O
for	O
glutamate	O
V1188E	B-ProteinMutation
in	O
exon	O
25	O
of	O
the	O
multidrug	O
resistance	O
protein	O
2	O
gene	O
was	O
found	O
in	O
a	O
group	O
of	O
patients	O
with	O
primary	O
biliary	O
cirrhosis	O
.	O

This	O
heterozygous	O
mutation	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
pruritus	O
.	O

Genetic	O
heterogeneity	O
of	O
the	O
GLDC	O
gene	O
in	O
28	O
unrelated	O
patients	O
with	O
glycine	O
encephalopathy	O
.	O

Glycine	O
encephalopathy	O
,	O
or	O
nonketotic	O
hyperglycinaemia	O
(	O
NKH	O
;	O
Mckusick	O
238300	O
)	O
is	O
a	O
severe	O
autosomal	O
recessive	O
disease	O
due	O
to	O
a	O
defect	O
in	O
the	O
glycine	O
cleavage	O
system	O
(GCS)	O
,	O
which	O
is	O
a	O
complex	O
of	O
four	O
subunits	O
:	O
P-	O
,	O
T-	O
,	O
H-	O
and	O
L-proteins	O
.	O

A	O
P-protein	O
(	O
glycine	O
decarboxylase	O
or	O
GLDC	O
)	O
deficiency	O
was	O
reported	O
in	O
about	O
80%	O
of	O
NKH	O
patients	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
of	O
the	O
GLDC	O
gene	O
in	O
28	O
unrelated	O
patients	O
with	O
neonatal	O
NKH	O
using	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
(DHPLC)	O
and	O
sequencing	O
.	O

Forty	O
different	O
gene	O
alterations	O
were	O
identified	O
,	O
confirming	O
the	O
large	O
molecular	O
heterogeneity	O
of	O
the	O
GLDC	O
gene	O
.	O

Eighteen	O
alterations	O
were	O
clearly	O
disease-causing	O
:	O
two	O
large	O
deletions	O
,	O
four	O
one-base	O
deletions	O
(	O
c.28delC	B-DNAMutation
,	O
c.1175delC	B-DNAMutation
,	O
c.2186delC	B-DNAMutation
,	O
c.2422delA	B-DNAMutation
)	O
,	O
one	O
1-base	O
insertion	O
c.1002_1003insT	B-DNAMutation
,	O
one	O
4-base	O
insertion	O
c.1285_1286insCAAA	B-DNAMutation
,	O
one	O
insertion/deletion	O
c.2153_2155delinsTCCTGGTTTA	B-DNAMutation
,	O
five	O
nonsense	O
mutations	O
(	O
p.E153X	B-ProteinMutation
,	O
p.R236X	B-ProteinMutation
,	O
p.E270X	B-ProteinMutation
,	O
p.R337X	B-ProteinMutation
,	O
p.R424X	B-ProteinMutation
)	O
and	O
four	O
splice	O
site	O
mutations	O
(	O
c.861+1G	B-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
,	O
c.1402-1C	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
,	O
c.2316-1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
,	O
c.2919+1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
.	O

Additionally	O
,	O
we	O
identified	O
one	O
intronic	O
mutation	O
outside	O
the	O
consensus	O
splice	O
sites	O
(	O
c.2838+5G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
and	O
21	O
nucleotide	O
substitutions	O
leading	O
to	O
amino	O
acid	O
change	O
(	O
including	O
three	O
previously	O
described	O
mutations	O
:	O
p.T269M	B-ProteinMutation
,	O
p.R461Q	B-ProteinMutation
,	O
p.G771R	B-ProteinMutation
)	O
,	O
the	O
pathogenicity	O
of	O
which	O
should	O
be	O
confirmed	O
by	O
expression	O
studies	O
(	O
p.S132W	B-ProteinMutation
,	O
p.Y138F	B-ProteinMutation
,	O
p.G171A	B-ProteinMutation
,	O
p.T187K	B-ProteinMutation
,	O
p.R212K	B-ProteinMutation
,	O
p.T269M	B-ProteinMutation
,	O
p.R373W	B-ProteinMutation
,	O
p.I440N	B-ProteinMutation
,	O
p.R461Q	B-ProteinMutation
,	O
p.N533Y	B-ProteinMutation
,	O
p.C644F	B-ProteinMutation
,	O
p.H651R	B-ProteinMutation
,	O
p.V705M	B-ProteinMutation
,	O
p.N732K	B-ProteinMutation
,	O
p.G771R	B-ProteinMutation
,	O
p.H775R	B-ProteinMutation
,	O
p.T830M	B-ProteinMutation
,	O
p.A841P	B-ProteinMutation
,	O
p.D880V	B-ProteinMutation
,	O
p.S957P	B-ProteinMutation
and	O
p.R966G	B-ProteinMutation
)	O
.	O

Mutation	O
analysis	O
allowed	O
us	O
to	O
identify	O
sequence	O
alterations	O
in	O
both	O
alleles	O
for	O
19	O
patients	O
and	O
in	O
one	O
allele	O
for	O
7	O
patients	O
One	O
patient	O
was	O
carrying	O
three	O
mutations	O
(	O
p.Y138F	B-ProteinMutation
,	O
p.T269M	B-ProteinMutation
and	O
p.E153X	B-ProteinMutation
)	O
and	O
one	O
patient	O
was	O
carrying	O
two	O
amino	O
acid	O
substitutions	O
on	O
the	O
same	O
allele	O
(	O
p.V705M	B-ProteinMutation
and	O
p.R212K	B-ProteinMutation
)	O
and	O
an	O
unidentified	O
mutation	O
on	O
the	O
other	O
allele	O
.	O

No	O
mutation	O
could	O
be	O
found	O
in	O
two	O
patients	O
,	O
suggesting	O
possible	O
defects	O
in	O
the	O
H-protein	O
or	O
gene	O
alterations	O
that	O
could	O
not	O
be	O
identified	O
by	O
our	O
technique	O
.	O

The	O
potential	O
use	O
of	O
genotype	O
determination	O
for	O
prenatal	O
diagnosis	O
is	O
emphasized	O
.	O

Genetic	O
investigation	O
of	O
the	O
TSPYL1	O
gene	O
in	O
sudden	O
infant	O
death	O
syndrome	O
.	O

BACKGROUND	O
:	O
Sudden	O
infant	O
death	O
syndrome	O
(SIDS)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	O
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O

Recently	O
,	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	O
infant	O
death	O
with	O
dysgenesis	O
of	O
the	O
testes	O
syndrome	O
(SIDDT)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	O
gene	O
.	O

PURPOSE	O
:	O
The	O
study's	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	O
in	O
SIDS	O
.	O

METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	O
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O

RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
,	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O

No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	O
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O

In	O
one	O
female	O
patient	O
a	O
p.F366L	B-ProteinMutation
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
,	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O

A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
,	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
,	O
cannot	O
be	O
ruled	O
out	O
completely	O
.	O

Because	O
SIDDT	O
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	O
mutations	O
,	O
this	O
heterozygous	O
exchange	O
cannot	O
solely	O
explain	O
the	O
sudden	O
death	O
in	O
this	O
child	O
.	O

The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	O
457_458insG	B-DNAMutation
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O

CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	O
gene	O
and	O
SIDS	O
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O

Genetic	O
analysis	O
of	O
TSPYL1	O
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	O
without	O
dysgenesis	O
of	O
the	O
testes	O
.	O

Indirect	O
CFTR	O
mutation	O
identification	O
by	O
PCR/OLA	O
anomalous	O
electropherograms	O
.	O

Mutations	O
of	O
CFTR	O
gene	O
are	O
responsible	O
for	O
cystic	O
fibrosis	O
(CF)	O
and	O
other	O
clinical	O
conditions	O
such	O
as	O
congenital	O
absence	O
of	O
the	O
vas	O
deferens	O
(CAVD)	O
,	O
chronic	O
pancreatitis	O
(IP)	O
,	O
and	O
idiopathic	O
disseminated	O
bronchiectasis	O
(DBE)	O
classified	O
as	O
CFTR-related	O
disorders	O
.	O

The	O
PCR/OLA	O
assay	O
is	O
designed	O
to	O
detect	O
31	O
known	O
mutations	O
including	O
the	O
24	O
most	O
common	O
CF	O
mutations	O
worldwide	O
,	O
as	O
identified	O
by	O
the	O
CF	O
Consortium	O
.	O

In	O
order	O
to	O
define	O
the	O
CFTR	O
genotype	O
a	O
series	O
of	O
1812	O
individuals	O
from	O
central-southern	O
Italy	O
with	O
and	O
without	O
CF	O
manifestations	O
were	O
screened	O
by	O
using	O
the	O
PCR/OLA	O
assay	O
.	O

Here	O
we	O
report	O
the	O
description	O
of	O
five	O
cases	O
of	O
anomalous	O
electropherograms	O
obtained	O
after	O
PCR/OLA	O
analysis	O
,	O
that	O
led	O
to	O
the	O
identification	O
,	O
in	O
the	O
homozygous	O
state	O
,	O
of	O
two	O
point	O
mutations	O
(	O
D110H	B-ProteinMutation
and	O
S589N	B-ProteinMutation
)	O
not	O
included	O
in	O
the	O
assay	O
test	O
panel	O
,	O
a	O
large	O
gene	O
deletion	O
CFTRdel14b_17b	B-DNAMutation
,	O
and	O
an	O
exonic	O
polymorphism	O
(	O
c.4002A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
)	O
.	O

Haplotype	O
and	O
real	O
time	O
PCR	O
analysis	O
were	O
also	O
performed	O
in	O
the	O
subject	O
carrying	O
the	O
large	O
CFTR	O
deletion	O
.	O

The	O
study	O
demonstrates	O
that	O
the	O
PCR/OLA	O
assay	O
,	O
besides	O
being	O
an	O
efficient	O
and	O
user-friendly	O
method	O
to	O
screen	O
known	O
mutations	O
in	O
the	O
CFTR	O
gene	O
,	O
may	O
also	O
function	O
as	O
a	O
mutation/polymorphism-scanning	O
assay	O
,	O
at	O
least	O
for	O
certain	O
nucleotide	O
changes	O
located	O
in	O
some	O
critical	O
regions	O
of	O
the	O
gene	O
.	O

Congenital	O
disorder	O
of	O
glycosylation	O
Ic	O
due	O
to	O
a	O
de	O
novo	O
deletion	O
and	O
an	O
hALG-6	O
mutation	O
.	O

We	O
describe	O
a	O
new	O
cause	O
of	O
congenital	O
disorder	O
of	O
glycosylation-Ic	O
(CDG-Ic)	O
in	O
a	O
young	O
girl	O
with	O
a	O
rather	O
mild	O
CDG	O
phenotype	O
.	O

Her	O
cells	O
accumulated	O
lipid-linked	O
oligosaccharides	O
lacking	O
three	O
glucose	O
residues	O
,	O
and	O
sequencing	O
of	O
the	O
ALG6	O
gene	O
showed	O
what	O
initially	O
appeared	O
to	O
be	O
a	O
homozygous	O
novel	O
point	O
mutation	O
338G>A	B-DNAMutation
.	O

However	O
,	O
haplotype	O
analysis	O
showed	O
that	O
the	O
patient	O
does	O
not	O
carry	O
any	O
paternal	O
DNA	O
markers	O
extending	O
33kb	O
in	O
the	O
telomeric	O
direction	O
from	O
the	O
ALG6	O
region	O
,	O
and	O
microsatellite	O
analysis	O
extended	O
the	O
abnormal	O
region	O
to	O
at	O
least	O
2.5Mb	O
.	O

We	O
used	O
high-resolution	O
karyotyping	O
to	O
confirm	O
a	O
deletion	O
(10-12Mb)	O
[del(1)(p31.2p32.3)]	O
and	O
found	O
no	O
structural	O
abnormalities	O
in	O
the	O
father	O
,	O
suggesting	O
a	O
de	O
novo	O
event	O
.	O

Our	O
findings	O
extend	O
the	O
causes	O
of	O
CDG	O
to	O
larger	O
DNA	O
deletions	O
and	O
identify	O
the	O
first	O
Japanese	O
CDG-Ic	O
mutation	O
.	O

A	O
novel	O
single-nucleotide	O
substitution	O
,	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
,	O
in	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
associated	O
with	O
allergic	O
diseases	O
.	O

Cysteinyl	O
leukotrienes	O
(cysLTs)	O
play	O
important	O
roles	O
in	O
bronchial	O
asthma	O
,	O
and	O
can	O
mediate	O
bronchial	O
smooth	O
muscle	O
constriction	O
and	O
increase	O
mucous	O
secretion	O
,	O
vascular	O
permeability	O
and	O
cellular	O
infiltration	O
.	O

We	O
identified	O
a	O
novel	O
heterozygous	O
single-nucleotide	O
substitution	O
10G>A	B-DNAMutation
(	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
)	O
in	O
the	O
first	O
exon	O
of	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
(LTC4S)	O
.	O

This	O
substitution	O
was	O
detected	O
in	O
5	O
of	O
141	O
allergic	O
patients	O
,	O
but	O
not	O
in	O
110	O
nonallergic	O
subjects	O
.	O

There	O
was	O
a	O
difference	O
in	O
the	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
frequency	O
between	O
the	O
allergic	O
patients	O
and	O
nonallergic	O
subjects	O
(	O
Fisher's	O
exact	O
test	O
,	O
p=0.0460	O
)	O
.	O

The	O
five	O
patients	O
with	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
had	O
allergic	O
diseases	O
such	O
as	O
bronchial	O
asthma	O
and/or	O
allergic	O
dermatitis	O
.	O

Furthermore	O
,	O
a	O
familial	O
analysis	O
of	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
revealed	O
a	O
link	O
with	O
allergic	O
diseases	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
in	O
the	O
LTC4S	O
might	O
be	O
associated	O
with	O
allergic	O
diseases	O
.	O

A	O
genetic	O
analysis	O
of	O
serotonergic	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
in	O
migraine	O
using	O
a	O
DNA	O
pooling	O
approach	O
.	O

Migraine	O
is	O
a	O
common	O
debilitating	O
primary	O
headache	O
disorder	O
with	O
significant	O
mental	O
,	O
physical	O
and	O
social	O
health	O
implications	O
.	O

The	O
brain	O
neurotransmitter	O
5-hydroxytryptamine	O
(	O
5-HT	O
;	O
serotonin	O
)	O
is	O
involved	O
in	O
nociceptive	O
pathways	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
migraine	O
.	O

With	O
few	O
genetic	O
studies	O
investigating	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
governing	O
the	O
rate	O
of	O
5-HT	O
activity	O
and	O
their	O
relationship	O
to	O
migraine	O
,	O
it	O
was	O
the	O
objective	O
of	O
this	O
study	O
to	O
assess	O
genetic	O
variants	O
within	O
the	O
human	O
tryptophan	O
hydroxylase	O
(TPH)	O
,	O
amino	O
acid	O
decarboxylase	O
(AADC)	O
and	O
monoamine	O
oxidase	O
A	O
(MAOA)	O
genes	O
in	O
migraine	O
susceptibility	O
.	O

This	O
objective	O
was	O
undertaken	O
using	O
a	O
high-throughput	O
DNA	O
pooling	O
experimental	O
design	O
,	O
which	O
proved	O
to	O
be	O
a	O
very	O
accurate	O
,	O
sensitive	O
and	O
specific	O
method	O
of	O
estimating	O
allele	O
frequencies	O
for	O
single	O
nucleotide	O
polymorphism	O
,	O
insertion	O
deletion	O
and	O
variable	O
number	O
tandem	O
repeat	O
loci	O
.	O

Application	O
of	O
DNA	O
pooling	O
to	O
a	O
wide	O
array	O
of	O
genetic	O
loci	O
provides	O
greater	O
scope	O
in	O
the	O
assessment	O
of	O
population-based	O
genetic	O
association	O
study	O
designs	O
.	O

Despite	O
the	O
application	O
of	O
this	O
high-throughput	O
genotyping	O
method	O
,	O
negative	O
results	O
from	O
the	O
two-stage	O
DNA	O
pooling	O
design	O
used	O
to	O
screen	O
loci	O
within	O
the	O
TPH	O
,	O
AADC	O
and	O
MAOA	O
genes	O
did	O
not	O
support	O
their	O
role	O
in	O
migraine	O
susceptibility	O
.	O

A	O
Cys	B-ProteinMutation
23-Ser	I-ProteinMutation
23	I-ProteinMutation
substitution	O
in	O
the	O
5-HT(2C)	O
receptor	O
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	O
affective	O
disorder	O
:	O
an	O
Austrian-Canadian	O
collaborative	O
study	O
.	O

Most	O
females	O
with	O
seasonal	O
affective	O
disorder	O
(SAD)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	O
gain	O
when	O
depressed	O
.	O

The	O
serotonin	O
2C	O
receptor	O
(5-HT(2C))	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O

A	O
5-HT(2C)	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
)	O
within	O
the	O
5-HT(2C)	O
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5-HT(2C)	O
function	O
.	O

We	O
hypothesized	O
that	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	O
.	O

Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	O
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	O
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
.	O

Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	O
with	O
atypical	O
features	O
.	O

In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	O
and	O
controls	O
(p=0.044)	O
and	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
was	O
associated	O
with	O
weight	O
(p=0.039)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p=0.038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(p=0.031)	O
.	O

All	O
values	O
were	O
highest	O
in	O
Cys/Cys	O
,	O
intermediate	O
in	O
Cys/Ser	O
,	O
and	O
lowest	O
in	O
Ser/Ser	O
carriers	O
.	O

In	O
Canadian	O
patients	O
,	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(p=0.046)	O
,	O
with	O
lowest	O
values	O
in	O
Ser/Ser	O
carriers	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	O
,	O
and	O
the	O
gene-dose	O
effect-like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O

Two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
form	O
Chinese	O
sex	O
reversal	O
XY	O
females	O
.	O

The	O
SRY	O
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O

SRY	O
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG-box	O
motif	O
(	O
high-mobility	O
group-box	O
)	O
,	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O

Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	O
are	O
among	O
the	O
known	O
causes	O
of	O
XY	O
sex	O
reversal	O
.	O

Here	O
,	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	O
who	O
presented	O
with	O
46,XY	O
sex	O
reversal	O
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(ORF)	O
of	O
SRY	O
gene	O
.	O

DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O

A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	O
gene	O
was	O
amplified	O
,	O
using	O
primers	O
XES-2	O
and	O
XES-7	O
.	O

The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm-T	O
vectors	O
,	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377-3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O

PCR-restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O

In	O
two	O
patients,de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O

An	O
A	O
was	O
replaced	O
by	O
a	O
G	O
in	O
codon	O
38	O
upstream	O
of	O
the	O
5'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	O
gene	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	O
by	O
glycine	O
.	O

Another	O
heterozygous	O
T	O
to	O
A	O
transition	O
at	O
the	O
nucleotide	O
position	O
+387	O
which	O
encodes	O
for	O
a	O
Tyrosine	O
(Tyr)	O
instead	O
of	O
a	O
Term	O
,	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild-type	O
sequence	O
.	O

These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR-restrict	O
enzyme	O
method	O
.	O

As	O
demonstrated	O
by	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
analysis,homology	O
search	O
,	O
and	O
review	O
of	O
the	O
literature	O
,	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	O
gene	O
nucleotide	O
substitutions	O
(missense/nonsense)	O
to	O
45	O
.	O

These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	O
reversal,not	O
only	O
inside	O
the	O
HMG-box	O
but	O
also	O
outside	O
the	O
HMG-box	O
.	O

The	O
two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	O
with	O
46,XY	O
female	O
sex	O
reversal	O
.	O

Successful	O
therapy	O
with	O
argatroban	O
for	O
superior	O
mesenteric	O
vein	O
thrombosis	O
in	O
a	O
patient	O
with	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
38-year-old	O
woman	O
was	O
admitted	O
with	O
superior	O
mesenteric	O
vein	O
(SMV)	O
thrombosis	O
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O

The	O
plasma	O
antithrombin	O
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	O
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O

However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	O
inhibitor	O
,	O
argatroban	O
.	O

Family	O
studies	O
of	O
antithrombin	O
activity	O
revealed	O
that	O
she	O
had	O
type	O
I	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	O
(	O
single	O
nucleotide	O
T	O
insertion	O
at	O
7916	O
and	O
7917	O
,	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O

Argatroban	O
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	O
antithrombin	O
deficiency	O
with	O
SMV	O
thrombosis	O
.	O

Mild	O
glycine	O
encephalopathy	O
(NKH)	O
in	O
a	O
large	O
kindred	O
due	O
to	O
a	O
silent	O
exonic	O
GLDC	O
splice	O
mutation	O
.	O

BACKGROUND	O
:	O
Classic	O
neonatal-onset	O
glycine	O
encephalopathy	O
(GE)	O
is	O
devastating	O
and	O
life	O
threatening	O
.	O

Milder	O
,	O
later	O
onset	O
variants	O
have	O
been	O
reported	O
but	O
were	O
usually	O
sporadic	O
and	O
incompletely	O
defined	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
clinical	O
and	O
biochemical	O
phenotype	O
and	O
molecular	O
basis	O
of	O
mild	O
GE	O
in	O
nine	O
children	O
from	O
a	O
consanguineous	O
Israeli	O
Bedouin	O
kindred	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
screened	O
for	O
GLDC	O
,	O
AMT	O
,	O
and	O
GCSH	O
gene	O
mutations	O
.	O

GLDC	O
expression	O
in	O
lymphoblasts	O
was	O
studied	O
by	O
Northern	O
blot	O
and	O
reverse	O
transcriptase	O
PCR	O
analysis	O
.	O

RESULTS	O
:	O
Clinical	O
features	O
included	O
hypotonia	O
,	O
abnormal	O
movements	O
,	O
convulsions	O
,	O
and	O
moderate	O
mental	O
retardation	O
with	O
relative	O
sparing	O
of	O
gross	O
motor	O
function	O
,	O
activities	O
of	O
daily	O
living	O
skills	O
,	O
and	O
receptive	O
language	O
.	O

Aggression	O
and	O
irritability	O
were	O
prominent	O
.	O

CSF-to-plasma	O
glycine	O
ratio	O
was	O
mildly	O
to	O
moderately	O
elevated	O
.	O

All	O
nine	O
patients	O
were	O
homozygous	O
and	O
their	O
parents	O
heterozygous	O
for	O
a	O
novel	O
,	O
translationally	O
silent	O
GLDC	O
exon	O
22	O
transversion	O
c.2607C>A	B-DNAMutation
.	O

Lymphoblast	O
GLDC	O
mRNA	O
levels	O
were	O
considerably	O
reduced	O
.	O

Three	O
aberrantly	O
spliced	O
cDNA	O
species	O
were	O
identified	O
:	O
exon	O
22	O
and	O
exon	O
22	O
to	O
23	O
skipping	O
,	O
and	O
insertion	O
of	O
an	O
87-base	O
pair	O
cryptic	O
exon	O
.	O

Homozygosity	O
for	O
c.2607C>A	B-DNAMutation
was	O
also	O
identified	O
in	O
an	O
unrelated	O
but	O
haplotypically	O
identical	O
patient	O
with	O
an	O
unusually	O
favorable	O
outcome	O
despite	O
severe	O
neonatal-onset	O
GE	O
.	O

Mutation	O
analysis	O
enabled	O
prenatal	O
diagnosis	O
of	O
three	O
unaffected	O
and	O
one	O
affected	O
pregnancies	O
.	O

CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
this	O
kindred	O
led	O
to	O
missplicing	O
and	O
reduced	O
GLDC	O
(	O
glycine	O
decarboxylase	O
)	O
expression	O
.	O

The	O
4	O
to	O
6%	O
of	O
normally	O
spliced	O
GLDC	O
mRNA	O
in	O
the	O
patients	O
may	O
account	O
for	O
their	O
relatively	O
favorable	O
clinical	O
outcome	O
compared	O
with	O
patients	O
with	O
classic	O
glycine	O
encephalopathy	O
.	O

Activating	O
mutation	O
in	O
the	O
tyrosine	O
kinase	O
JAK2	O
in	O
polycythemia	O
vera	O
,	O
essential	O
thrombocythemia	O
,	O
and	O
myeloid	O
metaplasia	O
with	O
myelofibrosis	O
.	O

Polycythemia	O
vera	O
(PV)	O
,	O
essential	O
thrombocythemia	O
(ET)	O
,	O
and	O
myeloid	O
metaplasia	O
with	O
myelofibrosis	O
(MMM)	O
are	O
clonal	O
disorders	O
arising	O
from	O
hematopoietic	O
progenitors	O
.	O

An	O
internet-based	O
protocol	O
was	O
used	O
to	O
collect	O
clinical	O
information	O
and	O
biological	O
specimens	O
from	O
patients	O
with	O
these	O
diseases	O
.	O

High-throughput	O
DNA	O
resequencing	O
identified	O
a	O
recurrent	O
somatic	O
missense	O
mutation	O
JAK2V617F	O
in	O
granulocyte	O
DNA	O
samples	O
of	O
121	O
of	O
164	O
PV	O
patients	O
,	O
of	O
which	O
41	O
had	O
homozygous	O
and	O
80	O
had	O
heterozygous	O
mutations	O
.	O

Molecular	O
and	O
cytogenetic	O
analyses	O
demonstrated	O
that	O
homozygous	O
mutations	O
were	O
due	O
to	O
duplication	O
of	O
the	O
mutant	O
allele	O
.	O

JAK2V617F	O
was	O
also	O
identified	O
in	O
granulocyte	O
DNA	O
samples	O
from	O
37	O
of	O
115	O
ET	O
and	O
16	O
of	O
46	O
MMM	O
patients	O
,	O
but	O
was	O
not	O
observed	O
in	O
269	O
normal	O
individuals	O
.	O

In	O
vitro	O
analysis	O
demonstrated	O
that	O
JAK2V617F	O
is	O
a	O
constitutively	O
active	O
tyrosine	O
kinase	O
.	O

Severe	O
growth	O
hormone	O
insensitivity	O
resulting	O
from	O
total	O
absence	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5b	O
.	O

CONTEXT	O
:	O
The	O
central	O
clinical	O
feature	O
of	O
GH	O
insensitivity	O
(GHI)	O
is	O
severe	O
growth	O
failure	O
associated	O
with	O
elevated	O
serum	O
concentrations	O
of	O
GH	O
and	O
abnormally	O
low	O
serum	O
levels	O
of	O
IGF-I	O
.	O

GHI	O
can	O
be	O
the	O
result	O
of	O
an	O
abnormality	O
in	O
the	O
GH	O
receptor	O
or	O
aberrancies	O
downstream	O
of	O
the	O
GH	O
receptor	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
GH-IGF-I	O
axis	O
in	O
a	O
young	O
female	O
GHI	O
subject	O
who	O
presented	O
with	O
a	O
height	O
of	O
114	O
cm	O
(	O
-7.8	O
sd	O
score	O
)	O
at	O
age	O
16.4	O
yr	O
.	O

PATIENT	O
:	O
The	O
subject	O
,	O
from	O
a	O
consanguineous	O
pedigree	O
,	O
had	O
circulating	O
levels	O
of	O
GH	O
and	O
GH-binding	O
protein	O
that	O
were	O
normal	O
to	O
elevated	O
,	O
whereas	O
IGF-I	O
(	O
7.2	O
ng/ml	O
;	O
normal	O
,	O
242-600	O
)	O
,	O
IGF-binding	O
protein-3	O
(	O
543	O
ng/ml	O
;	O
normal	O
,	O
2500-4800	O
)	O
,	O
and	O
acid-labile	O
subunit	O
(	O
1.22	O
microg/ml	O
;	O
normal	O
,	O
5.6-16	O
)	O
levels	O
were	O
abnormally	O
low	O
and	O
failed	O
to	O
increase	O
during	O
an	O
IGF-I	O
generation	O
test	O
.	O

DESIGN	O
:	O
Dermal	O
fibroblast	O
cultures	O
were	O
established	O
with	O
the	O
consent	O
of	O
the	O
patient	O
and	O
family	O
.	O

Immunoblot	O
analysis	O
of	O
cell	O
lysates	O
and	O
DNA	O
sequencing	O
of	O
her	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5b	O
(STAT5b)	O
,	O
a	O
critical	O
intermediate	O
of	O
the	O
GH-IGF-I	O
axis	O
,	O
were	O
performed	O
.	O

RESULTS	O
:	O
Sequencing	O
of	O
the	O
STAT5b	O
gene	O
revealed	O
a	O
novel	O
homozygous	O
insertion	O
of	O
a	O
single	O
nucleotide	O
in	O
exon	O
10	O
.	O

The	O
insertion	O
resulted	O
in	O
a	O
frame	O
shift	O
,	O
leading	O
to	O
early	O
protein	O
termination	O
and	O
consequent	O
lack	O
of	O
immunodetectable	O
STAT5b	O
protein	O
.	O

CONCLUSION	O
:	O
The	O
identification	O
of	O
a	O
second	O
case	O
of	O
severe	O
growth	O
failure	O
associated	O
with	O
STAT5b	O
mutation	O
implicates	O
a	O
unique	O
and	O
critical	O
role	O
for	O
STAT5b	O
in	O
GH	O
stimulation	O
of	O
IGF-I	O
gene	O
expression	O
and	O
statural	O
growth	O
.	O

Association	O
of	O
sporadic	O
chondrocalcinosis	O
with	O
a	O
-4-basepair	O
G-to-A	O
transition	O
in	O
the	O
5'-untranslated	O
region	O
of	O
ANKH	O
that	O
promotes	O
enhanced	O
expression	O
of	O
ANKH	O
protein	O
and	O
excess	O
generation	O
of	O
extracellular	O
inorganic	O
pyrophosphate	O
.	O

OBJECTIVE	O
:	O
Certain	O
mutations	O
in	O
ANKH	O
,	O
which	O
encodes	O
a	O
multiple-pass	O
transmembrane	O
protein	O
that	O
regulates	O
inorganic	O
pyrophosphate	O
(PPi)	O
transport	O
,	O
are	O
linked	O
to	O
autosomal-dominant	O
familial	O
chondrocalcinosis	O
.	O

This	O
study	O
investigated	O
the	O
potential	O
for	O
ANKH	O
sequence	O
variants	O
to	O
promote	O
sporadic	O
chondrocalcinosis	O
.	O

METHODS	O
:	O
ANKH	O
variants	O
identified	O
by	O
genomic	O
sequencing	O
were	O
screened	O
for	O
association	O
with	O
chondrocalcinosis	O
in	O
128	O
patients	O
with	O
severe	O
sporadic	O
chondrocalcinosis	O
or	O
pseudogout	O
and	O
in	O
ethnically	O
matched	O
healthy	O
controls	O
.	O

The	O
effects	O
of	O
specific	O
variants	O
on	O
expression	O
of	O
common	O
markers	O
were	O
evaluated	O
by	O
in	O
vitro	O
transcription/translation	O
.	O

The	O
function	O
of	O
these	O
variants	O
was	O
studied	O
in	O
transfected	O
human	O
immortalized	O
CH-8	O
articular	O
chondrocytes	O
.	O

RESULTS	O
:	O
Sporadic	O
chondrocalcinosis	O
was	O
associated	O
with	O
a	O
G-to-A	O
transition	O
in	O
the	O
ANKH	O
5'-untranslated	O
region	O
(5'-UTR)	O
at	O
4	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
(	O
in	O
homozygotes	O
of	O
the	O
minor	O
allele	O
,	O
genotype	O
relative	O
risk	O
6.0	O
,	O
P	O
=	O
0.0006	O
;	O
overall	O
genotype	O
association	O
P	O
=	O
0.02	O
)	O
.	O

This	O
-4-bp	O
transition	O
,	O
as	O
well	O
as	O
2	O
mutations	O
previously	O
linked	O
with	O
familial	O
and	O
sporadic	O
chondrocalcinosis	O
(	O
+14	O
bp	O
C-to-T	O
and	O
C-terminal	O
GAG	O
deletion	O
,	O
respectively	O
)	O
,	O
but	O
not	O
the	O
French	O
familial	O
chondrocalcinosis	O
kindred	O
143-bp	O
T-to-C	O
mutation	O
,	O
increased	O
reticulocyte	O
ANKH	O
transcription/ANKH	O
translation	O
in	O
vitro	O
.	O

Transfection	O
of	O
complementary	O
DNA	O
for	O
both	O
the	O
wild-type	O
ANKH	O
and	O
the	O
-4-bp	O
ANKH	O
protein	O
variant	O
promoted	O
increased	O
extracellular	O
PPi	O
in	O
CH-8	O
cells	O
,	O
but	O
unexpectedly	O
,	O
these	O
ANKH	O
mutants	O
had	O
divergent	O
effects	O
on	O
the	O
expression	O
of	O
extracellular	O
PPi	O
and	O
the	O
chondrocyte	O
hypertrophy	O
marker	O
,	O
type	O
X	O
collagen	O
.	O

CONCLUSION	O
:	O
A	O
subset	O
of	O
sporadic	O
chondrocalcinosis	O
appears	O
to	O
be	O
heritable	O
via	O
a	O
-4-bp	O
G-to-A	O
ANKH	O
5'-UTR	O
transition	O
that	O
up-regulates	O
expression	O
of	O
ANKH	O
and	O
extracellular	O
PPi	O
in	O
chondrocyte	O
cells	O
.	O

Distinct	O
ANKH	O
mutations	O
associated	O
with	O
heritable	O
chondrocalcinosis	O
may	O
promote	O
disease	O
by	O
divergent	O
effects	O
on	O
extracellular	O
PPi	O
and	O
chondrocyte	O
hypertrophy	O
,	O
which	O
is	O
likely	O
to	O
mediate	O
differences	O
in	O
the	O
clinical	O
phenotypes	O
and	O
severity	O
of	O
the	O
disease	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
in	O
gastric	O
cancer	O
correlates	O
with	O
the	O
angiotensin	O
I-converting	O
enzyme	O
gene	O
insertion/deletion	O
polymorphism	O
.	O

PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	O
I-converting	O
enzyme	O
(ACE)	O
on	O
gastric	O
cancer	O
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	O
cancer	O
progression	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O

Amplified	O
ACE	O
gene	O
fragments	O
were	O
separated	O
on	O
agarose	O
gels	O
.	O

D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190-	O
or	O
490-bp	O
fragments	O
,	O
respectively	O
.	O

Local	O
expression	O
of	O
ACE	O
was	O
investigated	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Twenty-four	O
of	O
113	O
(21%)	O
gastric	O
cancer	O
patients	O
had	O
the	O
II	O
,	O
57	O
(51%)	O
the	O
ID	O
,	O
and	O
32	O
(28%)	O
the	O
DD	O
genotype	O
.	O

The	O
distribution	O
of	O
the	O
ACE	O
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	O
without	O
gastric	O
cancer	O
.	O

However	O
,	O
the	O
ACE	O
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	O
node	O
metastases	O
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(UICC)	O
tumor	O
stage	O
.	O

Patients	O
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	O
node	O
metastases	O
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	O
stage	O
(	O
P	O
=	O
0.01	O
)	O
than	O
patients	O
with	O
the	O
DD	O
genotype	O
.	O

No	O
correlation	O
was	O
found	O
between	O
tumor	O
type	O
,	O
tumor	O
location	O
,	O
local	O
tumor	O
growth	O
,	O
distant	O
metastases	O
,	O
and	O
the	O
ACE	O
genotype	O
.	O

The	O
expression	O
of	O
ACE	O
in	O
gastric	O
cancer	O
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	O
.	O

ACE	O
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(100%)	O
specimens	O
and	O
by	O
tumor	O
cells	O
in	O
56	O
(56%)	O
specimens	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	O
is	O
expressed	O
locally	O
in	O
gastric	O
cancer	O
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O

Identification	O
of	O
novel	O
type	O
VII	O
collagen	O
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch/German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	O
collagen	O
gene	O
leading	O
to	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
,	O
Hallopeau-Siemens	O
variant	O
(HS-RDEB)	O
.	O

The	O
maternal	O
mutation	O
is	O
a	O
single	O
base	O
pair	O
deletion	O
of	O
a	O
cytosine	O
nucleotide	O
in	O
exon	O
26	O
,	O
designated	O
3472delC	B-DNAMutation
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(PTC)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O

The	O
paternal	O
mutation	O
is	O
a	O
G-->A	B-DNAMutation
transition	O
located	O
at	O
the	O
5'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
IVS51	B-DNAMutation
+	I-DNAMutation
1G-->A	I-DNAMutation
.	O

This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out-of-frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O

To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS-RDEB	O
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O

Adult	O
onset	O
metachromatic	O
leukodystrophy	O
without	O
electroclinical	O
peripheral	O
nervous	O
system	O
involvement	O
:	O
a	O
new	O
mutation	O
in	O
the	O
ARSA	O
gene	O
.	O

BACKGROUND	O
:	O
Metachromatic	O
leukodystrophy	O
(MLD)	O
is	O
a	O
lysosomal	O
storage	O
disease	O
caused	O
by	O
the	O
deficiency	O
of	O
arylsulfatase	O
A	O
(ARSA)	O
.	O

Clinically	O
,	O
the	O
disease	O
is	O
heterogeneous	O
with	O
respect	O
to	O
the	O
age	O
of	O
onset	O
,	O
affection	O
of	O
peripheral	O
and	O
central	O
nervous	O
systems	O
,	O
and	O
progression	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
mutations	O
in	O
the	O
ARSA	O
gene	O
of	O
a	O
patient	O
with	O
adult-onset	O
MLD	O
with	O
no	O
signs	O
of	O
peripheral	O
polyneuropathy	O
and	O
to	O
emphasize	O
the	O
clinical	O
,	O
neuroradiologic	O
,	O
neuropathologic	O
,	O
and	O
genetic	O
features	O
of	O
the	O
disease	O
.	O

DESIGN	O
:	O
Case	O
study	O
of	O
a	O
patient	O
clinically	O
presenting	O
with	O
rapidly	O
progressive	O
dementia	O
and	O
behavioral	O
abnormalities	O
.	O

We	O
report	O
the	O
findings	O
of	O
clinical	O
evaluation	O
and	O
neurophysiologic	O
and	O
neuropathologic	O
studies	O
of	O
peripheral	O
nerves	O
;	O
we	O
also	O
performed	O
DNA	O
sequence	O
analysis	O
,	O
transfections	O
,	O
metabolic	O
labeling	O
,	O
and	O
immunoprecipitation	O
of	O
mutant	O
ARSA	O
polypeptides	O
.	O

SETTING	O
:	O
Genetic	O
research	O
and	O
clinical	O
unit	O
,	O
university	O
hospital	O
.	O

RESULTS	O
:	O
Genetic	O
analysis	O
revealed	O
homozygosity	O
for	O
a	O
novel	O
mutation	O
in	O
exon	O
3	O
of	O
ARSA	O
F219V	B-ProteinMutation
.	O

This	O
substitution	O
leads	O
to	O
a	O
misfolded	O
unstable	O
enzyme	O
with	O
a	O
specific	O
activity	O
less	O
than	O
1%	O
of	O
normal	O
.	O

There	O
were	O
no	O
clinical	O
or	O
neurophysiologic	O
signs	O
of	O
peripheral	O
nervous	O
system	O
dysfunction	O
.	O

Typical	O
neuropathologic	O
signs	O
for	O
MLD	O
were	O
absent	O
from	O
nerve	O
biopsy	O
specimens	O
.	O

CONCLUSIONS	O
:	O
This	O
novel	O
mutation	O
is	O
associated	O
with	O
progressive	O
psychocognitive	O
impairment	O
without	O
clinical	O
or	O
electrophysiologic	O
signs	O
and	O
only	O
minor	O
morphologic	O
signs	O
of	O
peripheral	O
nerve	O
affection	O
.	O

The	O
F219V	B-ProteinMutation
substitution	O
causes	O
reduction	O
in	O
enzyme	O
activity	O
to	O
an	O
extent	O
unexpected	O
for	O
an	O
adult	O
patient	O
with	O
MLD	O
.	O

Parkin	O
mutations	O
and	O
early-onset	O
parkinsonism	O
in	O
a	O
Taiwanese	O
cohort	O
.	O

BACKGROUND	O
:	O
Loss	O
of	O
function	O
of	O
the	O
parkin	O
gene	O
(PRKN)	O
is	O
the	O
predominant	O
genetic	O
cause	O
of	O
juvenile	O
and	O
early-onset	O
parkinsonism	O
in	O
Japan	O
,	O
Europe	O
,	O
and	O
the	O
United	O
States	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
PRKN	O
mutations	O
in	O
Taiwanese	O
(	O
ethnic	O
Chinese	O
)	O
patients	O
with	O
early-onset	O
parkinsonism	O
and	O
to	O
explore	O
genotype-phenotype	O
correlations	O
.	O

DESIGN	O
:	O
Clinical	O
assessment	O
included	O
medical	O
,	O
neurologic	O
,	O
and	O
psychiatric	O
evaluation	O
.	O

Genomic	O
DNA	O
sequencing	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
were	O
performed	O
to	O
identify	O
PRKN	O
mutations	O
.	O

Gene	O
expression	O
was	O
examined	O
in	O
patient	O
lymphoblastoid	O
cell	O
lines	O
,	O
in	O
which	O
PRKN	O
mutations	O
were	O
identified	O
.	O

PATIENTS	O
:	O
Forty-one	O
Taiwanese	O
patients	O
with	O
early-onset	O
parkinsonism	O
(	O
aged	O
<50	O
years	O
at	O
onset	O
)	O
.	O

RESULTS	O
:	O
Four	O
of	O
41	O
probands	O
had	O
PRKN	O
mutations	O
.	O

One	O
proband	O
had	O
compound	O
heterozygous	O
mutations	O
,	O
with	O
a	O
PRKN	O
exon	O
2	O
deletion	O
and	O
an	O
exon	O
7	O
G284R	B-ProteinMutation
substitution	O
.	O

The	O
phenotype	O
resembled	O
typical	O
Parkinson	O
disease	O
.	O

Three	O
patients	O
were	O
mutation	O
carriers	O
.	O

One	O
proband	O
had	O
PRKN	O
exon	O
2	O
and	O
exon	O
3	O
deletions	O
in	O
the	O
same	O
allele	O
.	O

However	O
,	O
this	O
patient's	O
phenotype	O
was	O
that	O
of	O
classic	O
"parkin-proven"	O
autosomal	O
recessive	O
juvenile	O
parkinsonism	O
,	O
characterized	O
by	O
symmetrical	O
foot	O
dystonia	O
at	O
onset	O
,	O
gait	O
disturbance	O
,	O
diurnal	O
change	O
,	O
and	O
very	O
slow	O
progression	O
.	O

The	O
2	O
remaining	O
carriers	O
had	O
novel	O
heterozygous	O
exon	O
11	O
R396G	B-ProteinMutation
substitutions	O
.	O

Patients	O
with	O
PRKN	O
mutations	O
were	O
younger	O
at	O
onset	O
than	O
those	O
without	O
mutations	O
,	O
and	O
they	O
required	O
a	O
lower	O
dose	O
of	O
levodopa	O
despite	O
longer	O
disease	O
duration	O
.	O

CONCLUSIONS	O
:	O
Mutations	O
in	O
PRKN	O
are	O
a	O
rare	O
cause	O
of	O
early-onset	O
parkinsonism	O
in	O
Taiwanese	O
individuals	O
.	O

The	O
overall	O
mutation	O
frequency	O
,	O
adjusted	O
for	O
age	O
at	O
onset	O
,	O
was	O
comparable	O
with	O
that	O
reported	O
for	O
white	O
cohorts	O
;	O
however	O
,	O
the	O
point	O
mutations	O
identified	O
seem	O
to	O
be	O
population	O
specific	O
.	O

TGFBI	O
gene	O
mutations	O
causing	O
lattice	O
and	O
granular	O
corneal	O
dystrophies	O
in	O
Indian	O
patients	O
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
TGFBI	O
gene	O
in	O
Indian	O
patients	O
with	O
lattice	O
corneal	O
dystrophy	O
(LCD)	O
or	O
granular	O
corneal	O
dystrophy	O
(GCD)	O
and	O
to	O
look	O
for	O
genotype-phenotype	O
correlations	O
.	O

METHODS	O
:	O
Thirty-seven	O
unrelated	O
patients	O
were	O
studied	O
,	O
18	O
with	O
LCD	O
and	O
19	O
with	O
GCD	O
.	O

The	O
diagnosis	O
of	O
LCD	O
or	O
GCD	O
was	O
made	O
on	O
the	O
basis	O
of	O
clinical	O
and/or	O
histopathological	O
evaluation	O
.	O

Exons	O
and	O
flanking	O
intron	O
sequences	O
of	O
the	O
TGFBI	O
gene	O
were	O
amplified	O
by	O
PCR	O
with	O
specific	O
primers	O
.	O

PCR	O
products	O
were	O
screened	O
by	O
the	O
method	O
of	O
single-strand	O
conformation	O
polymorphism	O
followed	O
by	O
sequencing	O
.	O

Mutations	O
were	O
confirmed	O
by	O
screening	O
at	O
least	O
100	O
unrelated	O
normal	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Mutations	O
were	O
identified	O
in	O
14	O
of	O
18	O
patients	O
with	O
LCD	O
and	O
in	O
all	O
19	O
patients	O
with	O
GCD	O
.	O

In	O
LCD	O
,	O
three	O
novel	O
heterozygous	O
mutations	O
found	O
were	O
glycine-594-valine	B-ProteinMutation
Gly594Val	B-ProteinMutation
in	O
2	O
of	O
18	O
patients	O
,	O
valine-539-aspartic	B-ProteinMutation
acid	O
Val539Asp	B-ProteinMutation
in	O
1	O
patient	O
,	O
and	O
deletion	O
of	O
valine	O
624	O
,	O
valine	O
625	O
Val624-Val625del	B-ProteinMutation
in	O
1	O
patient	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
Arg124Cys	B-ProteinMutation
was	O
found	O
in	O
8	O
of	O
18	O
patients	O
and	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
His626Arg	B-ProteinMutation
in	O
2	O
of	O
18	O
patients	O
.	O

Atypical	O
clinical	O
features	O
for	O
LCD	O
were	O
noted	O
in	O
patients	O
with	O
the	O
Gly594Val	B-ProteinMutation
and	O
Val624-Val625del	B-ProteinMutation
mutations	O
.	O

In	O
GCD	O
,	O
18	O
patients	O
with	O
GCD	O
type	O
I	O
had	O
a	O
mutation	O
of	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
Arg555Trp	B-ProteinMutation
and	O
1	O
patient	O
with	O
GCD	O
type	O
III	O
(	O
Reis-Bucklers	O
dystrophy	O
)	O
,	O
had	O
the	O
Arg124Leu	B-ProteinMutation
mutation	O
.	O

Seven	O
novel	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
also	O
found	O
,	O
of	O
which	O
a	O
change	O
of	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
Leu269Phe	B-ProteinMutation
was	O
found	O
in	O
12	O
of	O
18	O
patients	O
with	O
the	O
Arg555Trp	B-ProteinMutation
mutation	O
.	O

CONCLUSIONS	O
:	O
Arg124Cys	B-ProteinMutation
and	O
Arg555Trp	B-ProteinMutation
appear	O
to	O
be	O
the	O
predominant	O
mutations	O
causing	O
LCD	O
and	O
GCD	O
,	O
respectively	O
,	O
in	O
the	O
population	O
studied	O
.	O

The	O
novel	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
associated	O
with	O
distinct	O
phenotypes	O
.	O

Two	O
new	O
beta-chain	O
variants	O
:	O
Hb	O
Tripoli	O
[beta26(B8)Glu-->Ala]	B-ProteinMutation
and	O
Hb	O
Tizi-Ouzou	O
[beta29(B11)Gly-->Ser]	B-ProteinMutation
.	O

Two	O
new	O
beta-globin	O
chain	O
variants	O
:	O
Hb	O
Tripoli	O
:	O
codon	B-DNAMutation
26	I-DNAMutation
,	I-DNAMutation
GAG-->GCG	I-DNAMutation
[beta26(B8)Glu-->Ala]	B-ProteinMutation
and	O
Hb	O
Tizi-Ouzou	O
:	O
codon	B-DNAMutation
29	I-DNAMutation
,	I-DNAMutation
GGC-->AGC	I-DNAMutation
[beta29(B11)Gly-->Ser]	B-ProteinMutation
are	O
described	O
on	O
the	O
first	O
exon	O
of	O
the	O
beta-globin	O
gene	O
.	O

The	O
two	O
variants	O
are	O
characterized	O
by	O
DNA	O
sequencing	O
and	O
mass	O
spectrometry	O
(MS)	O
.	O

Hematological	O
abnormalities	O
were	O
found	O
in	O
the	O
two	O
carriers	O
.	O

The	O
presence	O
of	O
microcytosis	O
and	O
hypochromia	O
is	O
explained	O
by	O
an	O
additional	O
homozygous	O
3.7	O
kb	O
alpha(+)	O
thalassemic	O
deletion	O
for	O
the	O
carrier	O
of	O
Hb	O
Tizi-Ouzou	O
.	O

Hb	O
Tizi-Ouzou	O
showed	O
a	O
slight	O
instability	O
in	O
vitro	O
.	O

The	O
same	O
hematological	O
abnormalities	O
associated	O
with	O
anemia	O
are	O
difficult	O
to	O
explain	O
for	O
Hb	O
Tripoli's	O
carrier	O
in	O
the	O
absence	O
of	O
an	O
alpha-globin	O
genes	O
abnormality	O
and	O
could	O
suggest	O
a	O
possible	O
abnormal	O
splicing	O
.	O

CD72	O
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	O
systemic	O
lupus	O
erythematosus	O
through	O
epistatic	O
interaction	O
with	O
FCGR2B	O
.	O

We	O
previously	O
reported	O
association	O
of	O
FCGR2B-Ile232Thr	B-ProteinMutation
with	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
in	O
three	O
Asian	O
populations	O
.	O

Because	O
polymorphism	O
of	O
CD72	O
,	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
,	O
was	O
associated	O
with	O
murine	O
SLE	O
,	O
we	O
identified	O
human	O
CD72	O
polymorphisms	O
,	O
tested	O
their	O
association	O
with	O
SLE	O
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	O
in	O
the	O
Japanese	O
(	O
160	O
SLE	O
,	O
277	O
controls	O
)	O
,	O
Thais	O
(	O
87	O
SLE	O
,	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	O
members	O
)	O
.	O

Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O

The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*1	O
and	O
*2	O
,	O
respectively	O
)	O
.	O

Although	O
association	O
with	O
susceptibility	O
to	O
SLE	O
was	O
not	O
detected	O
,	O
the	O
*1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	O
among	O
the	O
Japanese	O
patients	O
(P=0.024)	O
.	O

RT-PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(AS)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS-7	O
transfectants	O
.	O

The	O
ratio	O
of	O
AS/common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*2/*2	O
genotype	O
when	O
compared	O
with	O
*1/*1	O
(P=0.000038)	O
or	O
*1/*2	O
(P=0.0085)	O
genotypes	O
.	O

Using	O
the	O
two	O
Asian	O
cohorts	O
,	O
significant	O
association	O
of	O
FCGR2B-232Thr/Thr	O
with	O
SLE	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72-*1/*1	O
genotype	O
(	O
OR	O
4.63	O
,	O
95%	O
CI	O
1.47-14.6	O
,	O
P=0.009	O
versus	O
FCGR2B-232Ile/Ile	O
plus	O
CD72-*2/*2	O
)	O
.	O

Minigene	O
assays	O
demonstrated	O
that	O
the	O
13-nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O

The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
,	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane-distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
,	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72(c)	O
allele	O
associated	O
with	O
murine	O
SLE	O
.	O

These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72-*2	O
allele	O
decreases	O
risk	O
for	O
human	O
SLE	O
conferred	O
by	O
FCGR2B-232Thr	O
,	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	O
.	O

Features	O
of	O
epidermolysis	O
bullosa	O
simplex	O
due	O
to	O
mutations	O
in	O
the	O
ectodomain	O
of	O
type	O
XVII	O
collagen	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
COL17A1	O
,	O
coding	O
for	O
type	O
XVII	O
collagen	O
,	O
cause	O
junctional	O
epidermolysis	O
bullosa	O
with	O
an	O
ultrastructural	O
plane	O
of	O
cleavage	O
through	O
the	O
lamina	O
lucida	O
of	O
the	O
epidermal	O
basement	O
membrane	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
COL17A1	O
mutations	O
in	O
a	O
child	O
with	O
reduced	O
type	O
XVII	O
collagen	O
expression	O
and	O
intraepidermal	O
blister	O
formation	O
.	O

PATIENT	O
AND	O
METHODS	O
:	O
Protein	O
expression	O
and	O
level	O
of	O
tissue	O
separation	O
were	O
studied	O
by	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

The	O
mutations	O
were	O
identified	O
by	O
analysing	O
the	O
patient's	O
DNA	O
and	O
mRNA	O
.	O

RESULTS	O
:	O
Immunofluorescence	O
microscopy	O
performed	O
on	O
nonlesional	O
skin	O
demonstrated	O
absence	O
of	O
the	O
type	O
XVII	O
collagen	O
endodomain	O
and	O
presence	O
,	O
although	O
reduced	O
,	O
of	O
the	O
shed	O
ectodomain	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
plane	O
of	O
cleavage	O
was	O
through	O
the	O
basal	O
cells	O
,	O
not	O
through	O
the	O
lamina	O
lucida	O
.	O

Two	O
heterozygous	O
mutations	O
were	O
identified	O
in	O
COL17A1	O
:	O
a	O
new	O
3'-acceptor	O
splice-site	O
mutation	O
in	O
intron	O
21	O
1877-2A-->C	B-DNAMutation
,	O
and	O
a	O
deletion	O
in	O
exon	O
48	O
3432delT	B-DNAMutation
.	O

The	O
splice-site	O
mutation	O
in	O
intron	O
21	O
results	O
in	O
alternative	O
transcripts	O
of	O
which	O
two	O
are	O
in-frame	O
,	O
with	O
deletions	O
of	O
the	O
first	O
nine	O
codons	O
of	O
exon	O
22	O
and	O
the	O
entire	O
exon	O
22	O
,	O
respectively	O
.	O

By	O
Western	O
blot	O
analysis	O
,	O
a	O
type	O
XVII	O
collagen	O
molecule	O
was	O
detected	O
that	O
was	O
slightly	O
smaller	O
than	O
normal	O
.	O

CONCLUSIONS	O
:	O
Occasionally	O
mutations	O
in	O
the	O
COL17A1	O
gene	O
may	O
result	O
in	O
split	O
levels	O
suggesting	O
epidermolysis	O
bullosa	O
simplex	O
rather	O
than	O
junctional	O
epidermolysis	O
bullosa	O
.	O

Deletion	O
of	O
mouse	O
rad9	O
causes	O
abnormal	O
cellular	O
responses	O
to	O
DNA	O
damage	O
,	O
genomic	O
instability	O
,	O
and	O
embryonic	O
lethality	O
.	O

The	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
rad9	O
gene	O
promotes	O
cell	O
survival	O
through	O
activation	O
of	O
cell	O
cycle	O
checkpoints	O
induced	O
by	O
DNA	O
damage	O
.	O

Mouse	O
embryonic	O
stem	O
cells	O
with	O
a	O
targeted	O
deletion	O
of	O
Mrad9	O
,	O
the	O
mouse	O
ortholog	O
of	O
this	O
gene	O
,	O
were	O
created	O
to	O
evaluate	O
its	O
function	O
in	O
mammals	O
.	O

Mrad9(-/-)	O
cells	O
demonstrated	O
a	O
marked	O
increase	O
in	O
spontaneous	O
chromosome	O
aberrations	O
and	O
HPRT	O
mutations	O
,	O
indicating	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
.	O

These	O
cells	O
were	O
also	O
extremely	O
sensitive	O
to	O
UV	O
light	O
,	O
gamma	O
rays	O
,	O
and	O
hydroxyurea	O
,	O
and	O
heterozygotes	O
were	O
somewhat	O
sensitive	O
to	O
the	O
last	O
two	O
agents	O
relative	O
to	O
Mrad9(+/+)	O
controls	O
.	O

Mrad9(-/-)	O
cells	O
could	O
initiate	O
but	O
not	O
maintain	O
gamma-ray-induced	O
G(2)	O
delay	O
and	O
retained	O
the	O
ability	O
to	O
delay	O
DNA	O
synthesis	O
rapidly	O
after	O
UV	O
irradiation	O
,	O
suggesting	O
that	O
checkpoint	O
abnormalities	O
contribute	O
little	O
to	O
the	O
radiosensitivity	O
observed	O
.	O

Ectopic	O
expression	O
of	O
Mrad9	O
or	O
human	O
HRAD9	O
complemented	O
Mrad9(-/-)	O
cell	O
defects	O
,	O
indicating	O
that	O
the	O
gene	O
has	O
radioresponse	O
and	O
genomic	O
maintenance	O
functions	O
that	O
are	O
evolutionarily	O
conserved	O
.	O

Mrad9(+/-)	O
mice	O
were	O
generated	O
,	O
but	O
heterozygous	O
intercrosses	O
failed	O
to	O
yield	O
Mrad9(-/-)	O
pups	O
,	O
since	O
embryos	O
died	O
at	O
midgestation	O
.	O

Furthermore	O
,	O
Mrad9(-/-)	O
mouse	O
embryo	O
fibroblasts	O
were	O
not	O
viable	O
.	O

These	O
investigations	O
establish	O
Mrad9	O
as	O
a	O
key	O
mammalian	O
genetic	O
element	O
of	O
pathways	O
that	O
regulate	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
,	O
maintenance	O
of	O
genomic	O
integrity	O
,	O
and	O
proper	O
embryonic	O
development	O
.	O

Genetics	O
of	O
endometriosis	O
:	O
a	O
role	O
for	O
the	O
progesterone	O
receptor	O
gene	O
polymorphism	O
PROGINS	O
.	O

OBJECTIVE	O
:	O
Endometriosis	O
is	O
a	O
steroid-dependent	O
disease	O
with	O
a	O
particular	O
genetic	O
background	O
,	O
but	O
the	O
locations	O
of	O
possible	O
genomic	O
aberrations	O
are	O
still	O
poorly	O
clarified	O
.	O

We	O
have	O
investigated	O
the	O
potential	O
association	O
between	O
endometriosis	O
and	O
the	O
PROGINS	O
306	O
base	O
pair	O
insertion	O
polymorphism	O
in	O
intron	O
G	O
of	O
the	O
progesterone	O
receptor	O
(PR)	O
gene	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
segregate	O
with	O
this	O
disease	O
.	O

DESIGN	O
:	O
In	O
a	O
case-control	O
study	O
,	O
we	O
examined	O
the	O
PROGINS	O
polymorphism	O
of	O
the	O
progesterone	O
receptor	O
gene	O
in	O
131	O
Italian	O
women	O
affected	O
by	O
endometriosis	O
diagnosed	O
according	O
to	O
published	O
criteria	O
for	O
the	O
definition	O
of	O
the	O
definite	O
disease	O
.	O

Control	O
subjects	O
were	O
represented	O
by	O
127	O
Italian	O
women	O
without	O
laparoscopic	O
evidence	O
of	O
the	O
disease	O
.	O

MEASUREMENTS	O
:	O
Peripheral	O
blood	O
samples	O
,	O
DNA	O
extraction	O
and	O
polymerase	O
chain	O
reaction	O
(PCR)	O
were	O
used	O
to	O
genotype	O
women	O
for	O
the	O
presence	O
of	O
the	O
PROGINS	O
polymorphism	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
PROGINS	O
genotypes	O
between	O
patients	O
with	O
and	O
without	O
endometriosis	O
.	O

The	O
frequency	O
of	O
the	O
PROGINS	O
allele	O
T2	O
was	O
17.2%	O
and	O
11%	O
,	O
respectively	O
,	O
in	O
affected	O
women	O
and	O
in	O
controls	O
[	O
odds	O
ratio	O
(OR)	O
=	O
1.7	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
1.0-2.8	O
]	O
.	O

This	O
association	O
was	O
stronger	O
in	O
patients	O
with	O
more	O
severe	O
forms	O
of	O
endometriosis	O
,	O
such	O
as	O
an	O
infiltrating	O
disease	O
or	O
a	O
disease	O
characterized	O
by	O
severe	O
pelvic	O
adhesions	O
(	O
OR	O
2.4	O
,	O
95%	O
CI	O
1.2-4.8	O
;	O
and	O
OR	O
2.7	O
,	O
95%	O
CI	O
1.4-5.3	O
,	O
respectively	O
)	O
.	O

Combination	O
of	O
the	O
results	O
from	O
an	O
earlier	O
study	O
and	O
the	O
current	O
data	O
indicates	O
that	O
carrying	O
the	O
allele	O
variant	O
T2	O
is	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
the	O
risk	O
of	O
developing	O
endometriosis	O
(	O
OR	O
2.0	O
,	O
95%	O
CI	O
1.3-2.9	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
further	O
support	O
the	O
idea	O
that	O
the	O
PROGINS	O
polymorphism	O
of	O
the	O
progesterone	O
receptor	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
endometriosis	O
.	O

Mre11	O
deficiency	O
in	O
Arabidopsis	O
is	O
associated	O
with	O
chromosomal	O
instability	O
in	O
somatic	O
cells	O
and	O
Spo11-dependent	O
genome	O
fragmentation	O
during	O
meiosis	O
.	O

The	O
Mre11/Rad50/Nbs1	O
complex	O
is	O
involved	O
in	O
many	O
aspects	O
of	O
chromosome	O
metabolism	O
.	O

Aberrant	O
function	O
of	O
the	O
complex	O
is	O
associated	O
with	O
defects	O
in	O
the	O
DNA	O
checkpoint	O
,	O
double-strand	O
break	O
repair	O
,	O
meiosis	O
,	O
and	O
telomere	O
maintenance	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
the	O
consequences	O
of	O
Mre11	O
dysfunction	O
for	O
the	O
stability	O
of	O
mitotic	O
and	O
meiotic	O
chromosomes	O
in	O
Arabidopsis	O
thaliana	O
.	O

Although	O
plants	O
homozygous	O
for	O
a	O
T-DNA	O
insertion	O
in	O
a	O
conserved	O
region	O
of	O
the	O
MRE11	O
gene	O
are	O
viable	O
,	O
they	O
exhibit	O
growth	O
defects	O
and	O
are	O
infertile	O
.	O

Analysis	O
of	O
mitotic	O
chromosomes	O
prepared	O
from	O
the	O
mutant	O
plants	O
revealed	O
abundant	O
dicentric	O
chromosomes	O
and	O
chromosomal	O
fragments	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
showed	O
that	O
anaphase	O
bridges	O
are	O
often	O
formed	O
by	O
homologous	O
chromosome	O
arms	O
.	O

The	O
frequency	O
of	O
chromosome	O
fusions	O
was	O
not	O
reduced	O
in	O
mre11	O
ku70	O
double	O
mutants	O
,	O
suggesting	O
that	O
plants	O
possess	O
DNA	O
end-joining	O
activities	O
independent	O
of	O
the	O
Ku70/80	O
and	O
Mre11	O
complexes	O
.	O

Cytogenetic	O
examination	O
of	O
pollen	O
mother	O
cells	O
revealed	O
massive	O
chromosome	O
fragmentation	O
and	O
the	O
absence	O
of	O
synapsis	O
in	O
the	O
initial	O
stages	O
of	O
meiosis	O
.	O

The	O
fragmentation	O
was	O
substantially	O
suppressed	O
in	O
mre11	O
spo11-1	O
double	O
mutants	O
,	O
indicating	O
that	O
Mre11	O
is	O
required	O
for	O
repair	O
but	O
not	O
for	O
the	O
induction	O
of	O
Spo11-dependent	O
meiotic	O
DNA	O
breaks	O
in	O
Arabidopsis	O
.	O

Severe	O
form	O
of	O
thyroid	O
hormone	O
resistance	O
in	O
a	O
patient	O
with	O
homozygous/hemizygous	O
mutation	O
of	O
T3	O
receptor	O
gene	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
syndrome	O
(RTH)	O
is	O
a	O
rare	O
disorder	O
,	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Patients	O
with	O
RTH	O
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	O
or	O
rarely	O
with	O
hypothyroidism	O
.	O

Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
receptor	O
beta	O
gene	O
(TR-beta)	O
.	O

We	O
present	O
a	O
patient	O
with	O
RTH	O
found	O
to	O
be	O
homo-/hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR-beta	O
gene	O
.	O

The	O
single	O
nucleotide	O
substitution	O
I280S	B-ProteinMutation
1123T-->G	B-DNAMutation
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

The	O
I280S	B-ProteinMutation
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	O
.	O

The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	O
intellectual	O
development	O
,	O
hyperkinetic	O
behaviour	O
,	O
tachycardia	O
,	O
hearing	O
and	O
visual	O
impairment	O
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	B-ProteinMutation
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR-beta	O
.	O

Microevolution	O
between	O
paired	O
antral	O
and	O
paired	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
recovered	O
from	O
individual	O
patients	O
.	O

Sequence	O
variations	O
located	O
at	O
the	O
signal	O
sequence	O
and	O
mid-region	O
within	O
the	O
vacA	O
gene	O
,	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
,	O
the	O
indel	O
motifs	O
at	O
the	O
3'-end	O
of	O
the	O
cag	O
pathogenicity	O
island	O
and	O
the	O
regions	O
upstream	O
of	O
the	O
vacA	O
and	O
ribA	O
genes	O
were	O
determined	O
by	O
PCR	O
in	O
19	O
paired	O
antral	O
or	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
obtained	O
at	O
the	O
same	O
endoscopic	O
session	O
,	O
and	O
three	O
antral	O
pairs	O
taken	O
sequentially	O
.	O

Random	O
amplification	O
of	O
polymorphic	O
DNA	O
(RAPD)-PCR	O
and	O
fluorescent	O
amplified	O
fragment	O
length	O
polymorphism	O
(FAFLP)-PCR	O
fingerprinting	O
were	O
applied	O
to	O
these	O
paired	O
clinical	O
isolates	O
.	O

The	O
FAFLP-PCR	O
profiles	O
generated	O
were	O
phylogenetically	O
analysed	O
.	O

For	O
the	O
22	O
paired	O
isolates	O
there	O
were	O
no	O
differences	O
within	O
pairs	O
at	O
five	O
of	O
the	O
genetic	O
loci	O
studied	O
.	O

However	O
,	O
six	O
pairs	O
of	O
isolates	O
(27%)	O
,	O
of	O
which	O
four	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
showed	O
differences	O
in	O
the	O
numbers	O
of	O
repeats	O
located	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
.	O

RAPD-PCR	O
fingerprinting	O
showed	O
that	O
16	O
(73%)	O
pairs	O
,	O
nine	O
of	O
which	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
possessed	O
identical	O
profiles	O
,	O
while	O
six	O
(27%)	O
displayed	O
distinctly	O
different	O
profiles	O
,	O
indicating	O
mixed	O
infections	O
.	O

Three	O
of	O
the	O
six	O
pairs	O
showing	O
differences	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
yielded	O
identical	O
RAPD-PCR	O
fingerprints	O
.	O

FAFLP-PCR	O
fingerprinting	O
and	O
phylogenetic	O
analysis	O
revealed	O
that	O
all	O
16	O
pairs	O
that	O
displayed	O
identical	O
RAPD-PCR	O
profiles	O
had	O
highly	O
similar	O
,	O
but	O
not	O
identical	O
,	O
fingerprints	O
,	O
demonstrating	O
that	O
these	O
pairs	O
were	O
ancestrally	O
related	O
but	O
had	O
undergone	O
minor	O
genomic	O
alterations	O
.	O

Two	O
antrum	O
and	O
corpus	O
pairs	O
of	O
isolates	O
,	O
within	O
the	O
latter	O
group	O
,	O
were	O
isolates	O
obtained	O
from	O
two	O
siblings	O
from	O
the	O
same	O
family	O
.	O

This	O
analysis	O
demonstrated	O
that	O
each	O
sibling	O
was	O
colonized	O
by	O
ancestrally	O
related	O
strains	O
that	O
exhibited	O
differences	O
in	O
vacA	O
genotype	O
characteristics	O
.	O

A	O
novel	O
arginine	O
substitution	O
mutation	O
in	O
1A	O
domain	O
and	O
a	O
novel	O
27	O
bp	O
insertion	O
mutation	O
in	O
2B	O
domain	O
of	O
keratin	O
12	O
gene	O
associated	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

AIM	O
:	O
To	O
determine	O
the	O
disease	O
causing	O
gene	O
defects	O
in	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
of	O
domains	O
1A	O
and	O
2B	O
of	O
the	O
keratin	O
3	O
(K3)	O
and	O
keratin	O
12	O
(K12)	O
genes	O
from	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Novel	O
mutations	O
of	O
the	O
K12	O
gene	O
were	O
identified	O
in	O
both	O
patients	O
.	O

In	O
one	O
patient	O
a	O
heterozygous	O
point	O
mutation	O
(	O
429A-->C	B-DNAMutation
=	O
Arg135Ser	B-ProteinMutation
)	O
was	O
found	O
in	O
the	O
1A	O
domain	O
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
digestion	O
.	O

In	O
the	O
second	O
patient	O
a	O
heterozygous	O
27	O
bp	O
duplication	O
was	O
found	O
inserted	O
in	O
the	O
2B	O
domain	O
at	O
nucleotide	O
position	O
1222	O
1222ins27	B-DNAMutation
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
gel	O
electrophoresis	O
.	O

The	O
mutations	O
were	O
not	O
present	O
in	O
unaffected	O
controls	O
.	O

CONCLUSION	O
:	O
Novel	O
K12	O
mutations	O
were	O
linked	O
to	O
Meesmann's	O
corneal	O
dystrophy	O
in	O
two	O
different	O
patients	O
.	O

A	O
missense	O
mutation	O
replacing	O
a	O
highly	O
conserved	O
arginine	O
residue	O
in	O
the	O
beginning	O
of	O
the	O
helix	O
initiation	O
motif	O
was	O
found	O
in	O
one	O
patient	O
,	O
and	O
an	O
insertion	O
mutation	O
,	O
consisting	O
of	O
a	O
duplication	O
of	O
27	O
nucleotides	O
,	O
was	O
found	O
before	O
the	O
helix	O
termination	O
motif	O
in	O
the	O
other	O
.	O

A	O
new	O
but	O
frequent	O
mutation	O
of	O
apoB-100-apoB	O
His3543Tyr	B-ProteinMutation
.	O

ApolipoproteinB	O
100	O
(apoB-100)	O
is	O
an	O
important	O
component	O
of	O
atherogenic	O
lipoproteins	O
such	O
as	O
LDL	O
and	O
serves	O
as	O
a	O
ligand	O
for	O
the	O
LDL-receptor	O
.	O

Familial	O
defective	O
apolipoproteinB	O
100	O
(FDB)	O
is	O
caused	O
by	O
a	O
R3500Q	B-ProteinMutation
mutation	O
of	O
the	O
apoB	O
gene	O
and	O
results	O
in	O
decreased	O
binding	O
of	O
LDL	O
to	O
the	O
LDL-receptor	O
.	O

So	O
far	O
FDB	O
is	O
the	O
most	O
frequent	O
and	O
best	O
studied	O
alteration	O
of	O
apoB-100	O
.	O

Apart	O
from	O
this	O
,	O
three	O
other	O
apoB	O
mutations	O
,	O
R3500W	B-ProteinMutation
,	O
R3531C	B-ProteinMutation
and	O
R3480W	B-ProteinMutation
,	O
affecting	O
binding	O
to	O
the	O
LDL-receptor	O
are	O
known	O
to	O
date	O
.	O

We	O
screened	O
the	O
apoB	O
gene	O
segment	O
of	O
codons	O
3448-3561	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
analysis	O
in	O
a	O
total	O
of	O
853	O
consecutively	O
sampled	O
German	O
patients	O
undergoing	O
diagnostic	O
coronary	O
angiography	O
for	O
suspected	O
CAD	O
.	O

By	O
this	O
,	O
a	O
new	O
single	O
base	O
mutation	O
was	O
detected	O
and	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

The	O
mutation	O
,	O
CAC(3543)TAC	B-DNAMutation
results	O
in	O
a	O
His3543Tyr	B-ProteinMutation
substitution	O
in	O
apoB-100	O
H3543Y	B-ProteinMutation
.	O

The	O
prevalence	O
of	O
heterozygotes	O
for	O
H3543Y	B-ProteinMutation
in	O
the	O
study	O
population	O
was	O
0.47%	O
compared	O
to	O
0.12%	O
for	O
the	O
known	O
Arg	B-ProteinMutation
3500	I-ProteinMutation
Gln	I-ProteinMutation
R3500Q	B-ProteinMutation
mutation	O
.	O

In	O
conclusion	O
,	O
the	O
new	O
mutation	O
is	O
four	O
times	O
more	O
frequent	O
than	O
"classical"	O
FDB	O
and	O
thus	O
appears	O
to	O
be	O
the	O
most	O
common	O
apoB	O
mutation	O
in	O
Germany	O
.	O

POLG	O
mutations	O
associated	O
with	O
Alpers'	O
syndrome	O
and	O
mitochondrial	O
DNA	O
depletion	O
.	O

Alpers'	O
syndrome	O
is	O
a	O
fatal	O
neurogenetic	O
disorder	O
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	O
,	O
developmental	O
mitochondrial	O
DNA	O
depletion	O
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	O
polymerase	O
gamma	O
(POLG)	O
catalytic	O
activity	O
,	O
refractory	O
seizures	O
,	O
neurodegeneration	O
,	O
and	O
liver	O
disease	O
.	O

In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers'	O
syndrome	O
,	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	O
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	B-ProteinMutation
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	B-DNAMutation
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	B-ProteinMutation
substitution	O
in	O
POLG	O
,	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O

Identification	O
of	O
three	O
F5	O
gene	O
mutations	O
associated	O
with	O
inherited	O
coagulation	O
factor	O
V	O
deficiency	O
in	O
two	O
Chinese	O
pedigrees	O
.	O

To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	O
factor	O
V	O
(FV)	O
deficiency	O
.	O

A	O
37-year-old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18-month-old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	O
coagulation	O
FV	O
deficiency	O
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	O
activity	O
and	O
antigen	O
.	O

All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O

The	O
homozygous	O
deletion	O
IVS8	B-DNAMutation
-2A>G	I-DNAMutation
was	O
identified	O
in	O
the	O
F5	O
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(cDNA)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O

The	O
insertion	O
introduced	O
eight	O
additional	O
amino	O
acids	O
(AA)	O
into	O
the	O
FV	O
protein	O
.	O

Two	O
heterozygous	O
mutations	O
of	O
F5	O
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O

The	O
2238-9del	B-DNAMutation
AG	I-DNAMutation
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	O
AA	O
and	O
the	O
substitution	O
of	O
G6410	B-DNAMutation
by	I-DNAMutation
T	I-DNAMutation
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	B-ProteinMutation
.	O

Three	O
F5	O
gene	O
mutations	O
,	O
IVS8	B-DNAMutation
-2A>G	I-DNAMutation
,	O
2238-9del	B-DNAMutation
AG	I-DNAMutation
and	O
G6410T	B-DNAMutation
,	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	O
FV	O
deficiency	O
,	O
respectively	O
.	O

Four	O
novel	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
gene	O
in	O
Japanese	O
patients	O
with	O
Gitelman's	O
syndrome	O
.	O

BACKGROUND	O
:	O
Gitelman's	O
syndrome	O
(GS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
(NCCT)	O
gene	O
.	O

To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O

It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population-specific	O
distribution	O
of	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	O
gene	O
of	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	O
with	O
GS	O
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O

A	O
mutation	O
analysis	O
of	O
the	O
NCCT	O
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction-amplified	O
DNA	O
products	O
.	O

In	O
patients	O
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O

Five	O
of	O
them	O
[	O
c.185C>T	B-DNAMutation
Thr60Met	B-ProteinMutation
,	O
c.1712C>T	B-DNAMutation
Ala569Val	B-ProteinMutation
,	O
c.1930C>T	B-DNAMutation
Arg642Cys	B-ProteinMutation
,	O
c.2552T>A	B-DNAMutation
Leu849His	B-ProteinMutation
and	O
c.1932delC	B-DNAMutation
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	O
,	O
but	O
not	O
in	O
GS	O
patients	O
from	O
other	O
ethnic	O
groups	O
.	O

The	O
remaining	O
four	O
mutations	O
[	O
c.7A>T	B-DNAMutation
Met1Leu	B-ProteinMutation
,	O
c.1181_1186+20del26	B-DNAMutation
,	O
c.1811_1812delAT	B-DNAMutation
and	O
IVS16+1G>A	B-DNAMutation
]	O
were	O
novel	O
.	O

In	O
cDNA	O
derived	O
from	O
a	O
patient	O
with	O
c.1181_1186+20del26	B-DNAMutation
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O

In	O
cDNA	O
derived	O
from	O
patients	O
with	O
IVS16+1G>A	B-DNAMutation
,	O
an	O
additional	O
96	O
bp	O
insertion	O
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O

Six	O
out	O
of	O
seven	O
patients	O
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
Japanese	O
GS	O
patients	O
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O

Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	O
gene	O
exon	O
4	O
in	O
a	O
male	O
pseudohermaphrodite	O
patient	O
of	O
Chinese	O
origin	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5-alpha-reductase	O
type	O
2	O
gene	O
(SRD5A2)	O
analysis	O
in	O
a	O
male	O
pseudohermaphrodite	O
(MPH)	O
patient	O
with	O
normal	O
testosterone	O
(T)	O
production	O
and	O
normal	O
androgen	O
receptor	O
(AR)	O
gene	O
coding	O
sequences	O
.	O

A	O
patient	O
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
,	O
a	O
46,XY	O
karyotype	O
,	O
and	O
normal	O
T	O
secretion	O
under	O
human	O
chorionic	O
gonadotropin	O
(hCG)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O

Exons	O
1-8	O
of	O
the	O
AR	O
gene	O
and	O
exons	O
1-5	O
of	O
the	O
SRD5A2	O
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O

AR	O
gene	O
coding	O
sequences	O
were	O
normal	O
.	O

SRD5A2	O
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
,	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	O
nucleotide	O
deletion	O
,	O
which	O
predicts	O
a	O
frameshift	O
mutation	O
from	O
codon	O
219	O
,	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
,	O
where	O
the	O
substitution	O
of	O
guanine	O
(CGA)	O
by	O
adenine	O
(CAA)	O
predicts	O
a	O
glutamine	O
replacement	O
of	O
arginine	O
R227Q	B-ProteinMutation
.	O

Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O

The	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	O
mutations	O
,	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O

The	O
patient	O
showed	O
an	O
R227Q	B-ProteinMutation
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	O
patients	O
,	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
,	O
Tdel219	B-DNAMutation
.	O

Testis	O
morphology	O
showed	O
that	O
,	O
during	O
early	O
infancy	O
,	O
the	O
5-alpha-reductase	O
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O

Single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
the	O
FMR1	O
gene	O
in	O
autistic	O
and	O
mentally	O
retarded	O
children	O
in	O
Japan	O
.	O

Fragile	O
X	O
syndrome	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	O
retardation	O
in	O
males	O
,	O
and	O
patients	O
with	O
fragile	O
X	O
syndrome	O
occasionally	O
develop	O
autism	O
.	O

It	O
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
the	O
trinucleotide	O
repeat	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
FMR1	O
gene	O
,	O
but	O
in	O
a	O
small	O
number	O
of	O
patients	O
deletions	O
and	O
point	O
mutations	O
have	O
been	O
identified	O
.	O

We	O
screened	O
all	O
17	O
exons	O
of	O
the	O
FMR1	O
gene	O
for	O
mutations	O
in	O
90	O
autistic	O
or	O
mentally	O
retarded	O
children	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)-single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
.	O

No	O
mutations	O
were	O
found	O
in	O
76	O
male	O
patients	O
.	O

However	O
,	O
one	O
female	O
patient	O
was	O
heterozygous	O
for	O
a	O
normal	O
allele	O
and	O
a	O
mutant	O
allele	O
with	O
an	O
A	O
to	O
C	O
substitution	O
at	O
nucleotide	O
879	O
in	O
exon	O
9	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
50	O
controls	O
.	O

Reverse	O
transcription-PCR	O
revealed	O
that	O
a	O
large	O
proportion	O
of	O
the	O
mutant	O
transcripts	O
were	O
spliced	O
aberrantly	O
,	O
causing	O
premature	O
termination	O
of	O
the	O
protein	O
synthesis	O
.	O

Although	O
uncommon	O
,	O
point	O
mutations	O
in	O
the	O
FMR1	O
gene	O
may	O
be	O
a	O
cause	O
of	O
autism	O
and	O
mental	O
retardation	O
in	O
Japanese	O
patients	O
.	O

Expression	O
mapping	O
at	O
12p12-13	O
in	O
advanced	O
prostate	O
carcinoma	O
.	O

We	O
have	O
previously	O
mapped	O
a	O
putative	O
prostate	O
cancer	O
tumor-suppressor	O
gene	O
to	O
a	O
1-2	O
Mb	O
region	O
of	O
12p12-13	O
.	O

Initial	O
work	O
to	O
identify	O
the	O
tumor	O
suppressor	O
at	O
this	O
locus	O
focused	O
on	O
candidates	O
previously	O
implicated	O
in	O
malignancy	O
;	O
however	O
,	O
mutational	O
and	O
methylation	O
analyses	O
failed	O
to	O
identify	O
significant	O
genomic	O
events	O
.	O

An	O
alternative	O
approach	O
is	O
to	O
use	O
expression	O
analysis	O
to	O
prioritize	O
the	O
genes	O
within	O
the	O
region	O
of	O
interest	O
.	O

This	O
experimental	O
design	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
tumor-suppressor	O
genes	O
demonstrate	O
decreased	O
expression	O
in	O
tumors	O
compared	O
to	O
normals	O
.	O

Herein	O
,	O
we	O
narrow	O
the	O
region	O
of	O
interest	O
using	O
deletion	O
mapping	O
data	O
and	O
employ	O
expression	O
analysis	O
to	O
prioritize	O
the	O
genes	O
in	O
the	O
minimal	O
deleted	O
region	O
.	O

Highly	O
informative	O
polymorphic	O
markers	O
spanning	O
our	O
region	O
were	O
used	O
to	O
assess	O
for	O
loss	O
of	O
heterozygosity	O
in	O
99	O
tumor	O
and	O
normal	O
DNA	O
pairs	O
.	O

The	O
minimal	O
region	O
of	O
deletion	O
was	O
determined	O
to	O
be	O
approximately	O
500	O
kb	O
bounded	O
by	O
D12S391	O
and	O
A002Q26	O
.	O

Publically	O
available	O
databases	O
place	O
7	O
genes	O
within	O
this	O
minimal	O
deletion	O
region	O
.	O

An	O
additional	O
3	O
genes	O
lie	O
just	O
outside	O
this	O
minimal	O
deletion	O
region	O
and	O
could	O
possibly	O
be	O
inactivated	O
by	O
deletion	O
of	O
promoter	O
,	O
3'-untranslated	O
region	O
sequences	O
or	O
alternative	O
splice	O
variants	O
.	O

Relative	O
levels	O
of	O
expression	O
of	O
these	O
10	O
candidate	O
genes	O
were	O
determined	O
in	O
6	O
normal	O
prostates	O
,	O
5	O
local	O
prostate	O
tumors	O
,	O
9	O
prostate	O
lymph	O
node	O
metastases	O
,	O
6	O
prostate	O
cancer	O
cell	O
lines	O
and	O
12	O
prostate	O
cancer	O
xenografts	O
using	O
quantitative	O
RT-PCR	O
.	O

DUSP16	O
,	O
FLJ10298	O
and	O
BCLG	O
were	O
significantly	O
downregulated	O
in	O
both	O
clinical	O
tumors	O
and	O
cultured	O
prostate	O
cancer	O
tissue	O
,	O
indicating	O
that	O
one	O
or	O
all	O
may	O
be	O
critical	O
to	O
initiation	O
or	O
progression	O
of	O
prostate	O
carcinoma	O
.	O

The	O
Arg753GLn	B-ProteinMutation
polymorphism	O
of	O
the	O
human	O
toll-like	O
receptor	O
2	O
gene	O
in	O
tuberculosis	O
disease	O
.	O

Toll-like	O
receptor	O
2	O
(TLR2)	O
,	O
a	O
member	O
of	O
the	O
Toll-like	O
receptor	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
recognition	O
of	O
,	O
and	O
subsequent	O
immune	O
response	O
activation	O
against	O
,	O
mycobacteria	O
.	O

The	O
genetic	O
polymorphism	O
of	O
TLR2	O
(	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
(	O
Arg753Gln	B-ProteinMutation
)	O
)	O
has	O
been	O
associated	O
with	O
a	O
negative	O
influence	O
on	O
TLR2	O
function	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
determine	O
the	O
innate	O
host	O
response	O
to	O
mycobacteria	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
Arg753Gln	B-ProteinMutation
single	O
nucleotide	O
polymorphism	O
of	O
the	O
TLR2	O
gene	O
in	O
tuberculosis	O
(TB)	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

A	O
retrospective	O
case/control	O
study	O
was	O
carried	O
out	O
.	O

The	O
Arg753Gln	B-ProteinMutation
polymorphism	O
of	O
the	O
TLR2	O
gene	O
was	O
studied	O
in	O
151	O
TB	O
patients	O
compared	O
to	O
116	O
ethnically	O
and	O
age-matched	O
healthy	O
control	O
subjects	O
.	O

The	O
TLR2	O
polymorphism	O
(	O
adenine	O
(A)	O
allele	O
)	O
was	O
observed	O
in	O
17.9	O
and	O
7.7%	O
of	O
TB	O
patients	O
and	O
controls	O
,	O
respectively	O
.	O

When	O
the	O
ratios	O
of	O
the	O
three	O
genotypes	O
were	O
compared	O
between	O
the	O
two	O
groups	O
,	O
the	O
AA	O
genotype	O
was	O
found	O
to	O
be	O
more	O
significantly	O
associated	O
with	O
TB	O
.	O

Allele	O
frequencies	O
for	O
guanine	O
(G)	O
and	O
A	O
were	O
found	O
to	O
be	O
0.95	O
and	O
0.05	O
in	O
the	O
control	O
group	O
and	O
0.86	O
and	O
0.14	O
in	O
the	O
TB	O
patient	O
group	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
developing	O
TB	O
disease	O
was	O
increased	O
6.04-	O
and	O
1.60-fold	O
for	O
carriers	O
of	O
the	O
AA	O
and	O
GA	O
genotypes	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
suggest	O
that	O
the	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
polymorphism	O
of	O
the	O
Toll-like	O
receptor	O
2	O
gene	O
influences	O
the	O
risk	O
of	O
developing	O
tuberculosis	O
.	O

Homozygous	O
deletions	O
within	O
the	O
11q13	O
cervical	O
cancer	O
tumor-suppressor	O
locus	O
in	O
radiation-induced	O
,	O
neoplastically	O
transformed	O
human	O
hybrid	O
cells	O
.	O

Studies	O
on	O
nontumorigenic	O
and	O
tumorigenic	O
human	O
cell	O
hybrids	O
derived	O
from	O
the	O
fusion	O
of	O
HeLa	O
(	O
a	O
cervical	O
cancer	O
cell	O
line	O
)	O
with	O
GM00077	O
(	O
a	O
normal	O
skin	O
fibroblast	O
cell	O
line	O
)	O
have	O
demonstrated	O
"functional"	O
tumor-suppressor	O
activity	O
on	O
chromosome	O
11	O
.	O

It	O
has	O
been	O
shown	O
that	O
several	O
of	O
the	O
neoplastically	O
transformed	O
radiation-induced	O
hybrid	O
cells	O
called	O
GIMs	O
(	O
gamma	O
ray	O
induced	O
mutants	O
)	O
,	O
isolated	O
from	O
the	O
nontumorigenic	O
CGL1	O
cells	O
,	O
have	O
lost	O
one	O
copy	O
of	O
the	O
fibroblast	O
chromosome	O
11	O
.	O

We	O
hypothesized	O
,	O
therefore	O
,	O
that	O
the	O
remaining	O
copy	O
of	O
the	O
gene	O
might	O
be	O
mutated	O
in	O
the	O
cytogenetically	O
intact	O
copy	O
of	O
fibroblast	O
chromosome	O
11	O
.	O

Because	O
a	O
cervical	O
cancer	O
tumor	O
suppressor	O
locus	O
has	O
been	O
localized	O
to	O
chromosome	O
band	O
11q13	O
,	O
we	O
performed	O
deletion-mapping	O
analysis	O
of	O
eight	O
different	O
GIMs	O
using	O
a	O
total	O
of	O
32	O
different	O
polymorphic	O
and	O
microsatellite	O
markers	O
on	O
the	O
long	O
arm	O
(	O
q	O
arm	O
)	O
of	O
chromosome	O
11	O
.	O

Four	O
irradiated	O
,	O
nontumorigenic	O
hybrid	O
cell	O
lines	O
,	O
called	O
CONs	O
,	O
were	O
also	O
analyzed	O
.	O

Allelic	O
deletion	O
was	O
ascertained	O
by	O
the	O
loss	O
of	O
a	O
fibroblast	O
allele	O
in	O
the	O
hybrid	O
cell	O
lines	O
.	O

The	O
analysis	O
confirmed	O
the	O
loss	O
of	O
a	O
fibroblast	O
chromosome	O
11	O
in	O
five	O
of	O
the	O
GIMs	O
.	O

Further	O
,	O
homozygous	O
deletion	O
(	O
complete	O
loss	O
)	O
of	O
chromosome	O
band	O
11q13	O
band	O
sequences	O
,	O
including	O
that	O
of	O
D11S913	O
,	O
was	O
observed	O
in	O
two	O
of	O
the	O
GIMs	O
.	O

Detailed	O
mapping	O
with	O
genomic	O
sequences	O
localized	O
the	O
homozygous	O
deletion	O
to	O
a	O
5.7-kb	O
interval	O
between	O
EST	O
AW167735	O
and	O
EST	O
F05086	O
.	O

Southern	O
blot	O
hybridization	O
using	O
genomic	O
DNA	O
probes	O
from	O
the	O
D11S913	O
locus	O
confirmed	O
the	O
existence	O
of	O
homozygous	O
deletion	O
in	O
the	O
two	O
GIM	O
cell	O
lines	O
.	O

Additionally	O
,	O
PCR	O
analysis	O
showed	O
a	O
reduction	O
in	O
signal	O
intensity	O
for	O
a	O
marker	O
mapped	O
31	O
kb	O
centromeric	O
of	O
D11S913	O
in	O
four	O
other	O
GIMs	O
.	O

Finally	O
,	O
Northern	O
blot	O
hybridization	O
with	O
the	O
genomic	O
probes	O
revealed	O
the	O
presence	O
of	O
a	O
novel	O
>15-kb	O
transcript	O
in	O
six	O
of	O
the	O
GIMs	O
.	O

These	O
transcripts	O
were	O
not	O
observed	O
in	O
the	O
nontumorigenic	O
hybrid	O
cell	O
lines	O
.	O

Because	O
the	O
chromosome	O
11q13	O
band	O
deletions	O
in	O
the	O
tumorigenic	O
hybrid	O
cell	O
lines	O
overlapped	O
with	O
the	O
minimal	O
deletion	O
in	O
cervical	O
cancer	O
,	O
the	O
data	O
suggest	O
that	O
the	O
same	O
gene	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
cervical	O
cancer	O
and	O
in	O
radiation-induced	O
carcinogenesis	O
.	O

We	O
propose	O
that	O
a	O
gene	O
localized	O
in	O
proximity	O
to	O
the	O
homozygous	O
deletion	O
is	O
the	O
candidate	O
tumor-suppressor	O
gene	O
.	O

Structural	O
and	O
biochemical	O
basis	O
for	O
novel	O
mutations	O
in	O
homozygous	O
Israeli	O
maple	O
syrup	O
urine	O
disease	O
patients	O
:	O
a	O
proposed	O
mechanism	O
for	O
the	O
thiamin-responsive	O
phenotype	O
.	O

Maple	O
syrup	O
urine	O
disease	O
(MSUD)	O
results	O
from	O
mutations	O
affecting	O
different	O
subunits	O
of	O
the	O
mitochondrial	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
seven	O
novel	O
mutations	O
in	O
MSUD	O
patients	O
from	O
Israel	O
.	O

These	O
include	O
C219W-alpha	B-ProteinMutation
(	O
TGC	O
to	O
TGG	O
)	O
in	O
the	O
E1alpha	O
subunit	O
;	O
H156Y-beta	B-ProteinMutation
(	O
CAT	O
to	O
TAT	O
)	O
,	O
V69G-beta	B-ProteinMutation
(	O
GTT	O
to	O
GGT	O
)	O
,	O
IVS	B-DNAMutation
9	I-DNAMutation
del[-7:-4]	I-DNAMutation
,	O
and	O
1109	B-DNAMutation
ins	I-DNAMutation
8bp	I-DNAMutation
(	O
exon	O
10	O
)	O
in	O
the	O
E1beta	O
subunit	O
;	O
and	O
H391R	B-ProteinMutation
(	O
CAC	O
to	O
CGC	O
)	O
and	O
S133stop	B-ProteinMutation
(	O
TCA	O
to	O
TGA	O
)	O
affecting	O
the	O
E2	O
subunit	O
of	O
the	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

Recombinant	O
E1	O
proteins	O
carrying	O
the	O
C219W-alpha	B-ProteinMutation
or	O
H156Y-beta	B-ProteinMutation
mutation	O
show	O
no	O
catalytic	O
activity	O
with	O
defective	O
subunit	O
assembly	O
and	O
reduced	O
binding	O
affinity	O
for	O
cofactor	O
thiamin	O
diphosphate	O
.	O

The	O
mutant	O
E1	O
harboring	O
the	O
V69G-beta	B-ProteinMutation
substitution	O
cannot	O
be	O
expressed	O
,	O
suggesting	O
aberrant	O
folding	O
caused	O
by	O
this	O
mutation	O
.	O

These	O
E1	O
mutations	O
are	O
ubiquitously	O
associated	O
with	O
the	O
classic	O
phenotype	O
in	O
homozygous-affected	O
patients	O
.	O

The	O
H391R	B-ProteinMutation
substitution	O
in	O
the	O
E2	O
subunit	O
abolishes	O
the	O
key	O
catalytic	O
residue	O
that	O
functions	O
as	O
a	O
general	O
base	O
in	O
the	O
acyltransfer	O
reaction	O
,	O
resulting	O
in	O
a	O
completely	O
inactive	O
E2	O
component	O
.	O

However	O
,	O
wild-type	O
E1	O
activity	O
is	O
enhanced	O
by	O
E1	O
binding	O
to	O
this	O
full-length	O
mutant	O
E2	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
the	O
augmented	O
E1	O
activity	O
is	O
responsible	O
for	O
robust	O
thiamin	O
responsiveness	O
in	O
homozygous	O
patients	O
carrying	O
the	O
H391R	B-ProteinMutation
E2	O
mutation	O
and	O
that	O
the	O
presence	O
of	O
a	O
full-length	O
mutant	O
E2	O
is	O
diagnostic	O
of	O
this	O
MSUD	O
phenotype	O
.	O

The	O
present	O
results	O
offer	O
a	O
structural	O
and	O
biochemical	O
basis	O
for	O
these	O
novel	O
mutations	O
and	O
will	O
facilitate	O
DNA-based	O
diagnosis	O
for	O
MSUD	O
in	O
the	O
Israeli	O
population	O
.	O

Haplotypes	O
and	O
DNA	O
sequence	O
variation	O
within	O
and	O
surrounding	O
the	O
transthyretin	O
gene	O
:	O
genotype-phenotype	O
correlations	O
in	O
familial	O
amyloid	O
polyneuropathy	O
V30M	B-ProteinMutation
in	O
Portugal	O
and	O
Sweden	O
.	O

Familial	O
amyloid	O
polyneuropathy	O
(FAP)	O
is	O
a	O
lethal	O
autosomal	O
dominant	O
disorder	O
in	O
which	O
fibrils	O
derived	O
from	O
mutant	O
forms	O
of	O
transthyretin	O
(TTR)	O
,	O
the	O
normal	O
plasma	O
carrier	O
of	O
thyroxine	O
(T(4))	O
and	O
retinol-binding	O
protein	O
,	O
are	O
deposited	O
in	O
tissues	O
.	O

Over	O
80	O
TTR	O
sequence	O
variants	O
are	O
associated	O
with	O
FAP	O
,	O
but	O
the	O
amino-acid	O
substitutions	O
alone	O
do	O
not	O
completely	O
explain	O
the	O
variability	O
in	O
disease	O
penetrance	O
,	O
pathology	O
and	O
clinical	O
course	O
.	O

To	O
analyze	O
the	O
factors	O
possibly	O
contributing	O
to	O
this	O
phenotypic	O
variability	O
,	O
we	O
characterized	O
the	O
variations	O
within	O
the	O
wild-type	O
and	O
mutant	O
Val30Met	B-ProteinMutation
TTR	O
genes	O
and	O
their	O
flanking	O
sequences	O
by	O
performing	O
extended	O
microsatellite	O
haplotype	O
analyses	O
,	O
sequencing	O
and	O
single-nucleotide	O
polymorphism	O
haplotyping	O
of	O
genomic	O
DNA	O
from	O
Portuguese	O
and	O
Swedish	O
carriers	O
of	O
V30M	B-ProteinMutation
.	O

We	O
identified	O
10	O
new	O
polymorphisms	O
in	O
the	O
TTR	O
untranslated	O
regions	O
,	O
eight	O
resulting	O
from	O
single-base	O
substitutions	O
and	O
two	O
arising	O
from	O
insertion/deletions	O
in	O
dinucleotide	O
repeat	O
sequences	O
.	O

The	O
data	O
suggest	O
that	O
the	O
onset	O
of	O
symptoms	O
of	O
FAP	O
V30M	B-ProteinMutation
may	O
be	O
modulated	O
by	O
an	O
interval	O
downstream	O
of	O
TTR	O
on	O
the	O
accompanying	O
noncarrier	O
chromosome	O
(	O
defined	O
by	O
microsatellites	O
D18S457	O
and	O
D18S456	O
)	O
,	O
but	O
not	O
by	O
the	O
immediately	O
5'-	O
and	O
3'-flanking	O
sequences	O
of	O
TTR	O
.	O

During	O
the	O
course	O
of	O
these	O
studies	O
,	O
we	O
also	O
encountered	O
the	O
first	O
instance	O
in	O
which	O
the	O
previously	O
described	O
intragenic	O
haplotype	O
III	O
may	O
be	O
associated	O
with	O
V30M	B-ProteinMutation
FAP	O
in	O
the	O
Portuguese	O
population	O
.	O

Germline	O
deletions	O
of	O
EXO1	O
do	O
not	O
cause	O
colorectal	O
tumors	O
and	O
lesions	O
which	O
are	O
null	O
for	O
EXO1	O
do	O
not	O
have	O
microsatellite	O
instability	O
.	O

Exonuclease	O
1	O
(EXO1)	O
is	O
a	O
candidate	O
gene	O
for	O
colorectal	O
tumor	O
susceptibility	O
because	O
it	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
mismatch	O
repair	O
.	O

There	O
have	O
been	O
several	O
studies	O
investigating	O
the	O
role	O
of	O
EXO1	O
in	O
mismatch	O
repair	O
but	O
few	O
investigating	O
its	O
role	O
in	O
causing	O
clinical	O
disease	O
.	O

In	O
one	O
recent	O
study	O
,	O
germline	O
variants	O
of	O
EXO1	O
were	O
reported	O
to	O
be	O
associated	O
with	O
predisposition	O
to	O
colorectal	O
cancer	O
in	O
families	O
with	O
phenotypes	O
similar	O
to	O
hereditary	O
nonpolyposis	O
colon	O
cancer	O
(HNPCC)	O
.	O

We	O
recently	O
identified	O
nine	O
individuals	O
from	O
two	O
British	O
families	O
with	O
multiple	O
cutaneous	O
and	O
uterine	O
leiomyomatosis	O
with	O
independently	O
arising	O
heterozygous	O
germline	O
deletions	O
of	O
1q42.3	O
approximately	O
q43	O
encompassing	O
not	O
only	O
FH	O
,	O
the	O
multiple	O
leiomyomatosis-associated	O
gene	O
,	O
but	O
also	O
several	O
flanking	O
genes	O
,	O
including	O
EXO1	O
.	O

We	O
investigated	O
these	O
families	O
for	O
any	O
indication	O
of	O
predisposition	O
to	O
colorectal	O
cancer	O
or	O
other	O
HNPCC	O
spectrum	O
cancers	O
by	O
means	O
of	O
detailed	O
questionnaires	O
,	O
interviews	O
,	O
and	O
examination	O
of	O
EXO1-null	O
skin	O
leiomyomata	O
for	O
microsatellite	O
instability	O
(MSI)	O
.	O

No	O
individual	O
in	O
these	O
families	O
had	O
developed	O
colorectal	O
cancer	O
or	O
known	O
colorectal	O
adenomas	O
,	O
and	O
none	O
had	O
any	O
symptoms	O
warranting	O
gastrointestinal	O
or	O
other	O
investigation	O
.	O

EXO1-null	O
tumors	O
showed	O
no	O
evidence	O
of	O
MSI	O
.	O

This	O
study	O
questions	O
the	O
functional	O
significance	O
of	O
previously	O
reported	O
variants	O
of	O
EXO1	O
reported	O
in	O
HNPCC-like	O
families	O
and	O
suggests	O
that	O
in	O
humans	O
there	O
may	O
be	O
other	O
as	O
yet	O
undiscovered	O
proteins	O
that	O
have	O
exonuclease	O
function	O
overlapping	O
with	O
that	O
of	O
EXO1	O
in	O
DNA	O
mismatch	O
repair	O
.	O

Also	O
of	O
interest	O
is	O
the	O
absence	O
of	O
phenotypic	O
abnormality	O
apart	O
from	O
multiple	O
leiomyomatosis	O
in	O
any	O
deletion	O
carrier	O
even	O
though	O
the	O
adjacent	O
genes	O
RGS7	O
,	O
KMO	O
,	O
CHML	O
,	O
and	O
OPN3	O
were	O
also	O
deleted	O
.	O

Beta-thalassemia	O
in	O
association	O
with	O
a	O
new	O
delta-chain	O
hemoglobin	O
variant	O
[delta116(g18)Arg-->Leu]	B-ProteinMutation
:	O
implications	O
for	O
carrier	O
screening	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
describe	O
a	O
complicated	O
genetic	O
counseling	O
and	O
prenatal	O
diagnostic	O
case	O
involving	O
an	O
East	O
Indian	O
couple	O
that	O
had	O
lost	O
two	O
consecutive	O
pregnancies	O
.	O

Hemoglobinopathy	O
screening	O
was	O
conducted	O
to	O
investigate	O
the	O
possibility	O
of	O
Hb	O
Bart's	O
hydrops	O
fetalis	O
or	O
Hb	O
H	O
hydrops	O
fetalis	O
.	O

The	O
initial	O
work-up	O
indicated	O
that	O
alpha-thalassemia	O
was	O
not	O
a	O
contributing	O
factor	O
,	O
with	O
both	O
parents	O
being	O
carriers	O
of	O
single	O
gene	O
deletions	O
(-alpha(3.7)/alphaalpha)	O
.	O

However	O
,	O
the	O
Hb	O
electrophoresis	O
results	O
indicated	O
that	O
the	O
couple	O
might	O
be	O
at	O
risk	O
for	O
having	O
children	O
with	O
Hb	O
E/Hb	O
Lepore	O
disease	O
.	O

Subsequent	O
DNA	O
testing	O
demonstrated	O
that	O
the	O
father	O
carried	O
the	O
Hb	O
E	O
mutation	O
,	O
but	O
failed	O
to	O
confirm	O
that	O
the	O
mother	O
carries	O
the	O
Hb	O
Lepore	O
deletion	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
mother	O
was	O
heterozygous	O
for	O
a	O
common	O
East	O
Indian	O
beta(0)-thalassemia	O
mutation	O
,	O
yet	O
had	O
a	O
normal	O
level	O
of	O
Hb	O
A(2)	O
.	O

The	O
mother	O
also	O
carried	O
a	O
previously	O
unreported	O
missense	O
mutation	O
of	O
the	O
delta-globin	O
gene	O
,	O
in	O
cis	O
with	O
the	O
beta(0)-thalassemia	O
mutation	O
,	O
which	O
gave	O
rise	O
to	O
the	O
minor	O
Hb	O
variant	O
originally	O
misidentified	O
as	O
Hb	O
Lepore	O
.	O

This	O
case	O
illustrates	O
the	O
importance	O
of	O
comprehensive	O
molecular	O
analyses	O
for	O
accurate	O
assessment	O
of	O
genetic	O
risks	O
for	O
hemoglobinopathy	O
syndromes	O
.	O

Novel	O
polypyrimidine	O
variation	O
(	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
)	O
in	O
ABCA1	O
causes	O
exon	O
skipping	O
and	O
contributes	O
to	O
HDL	O
cholesterol	O
deficiency	O
in	O
a	O
family	O
with	O
premature	O
coronary	O
disease	O
.	O

Recent	O
studies	O
have	O
implicated	O
mutations	O
in	O
the	O
ATP-binding	O
cassette	O
transporter	O
A1	O
,	O
ABCA1	O
,	O
as	O
a	O
cause	O
of	O
Tangier	O
disease	O
(TD)	O
and	O
familial	O
hypoalphalipoproteinemia	O
(FHA)	O
.	O

We	O
investigated	O
a	O
proband	O
with	O
very	O
low	O
levels	O
of	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
,	O
6	O
mg/dL	O
)	O
and	O
a	O
history	O
of	O
premature	O
coronary	O
heart	O
disease	O
(CHD)	O
.	O

Sequencing	O
of	O
the	O
ABCA1	O
gene	O
revealed	O
2	O
distinct	O
variants	O
.	O

The	O
first	O
mutation	O
was	O
a	O
G5947A	B-DNAMutation
substitution	O
R1851Q	B-ProteinMutation
.	O

The	O
second	O
mutation	O
was	O
a	O
single-nucleotide	O
deletion	O
of	O
thymidine	O
in	O
a	O
polypyrimidine	O
tract	O
located	O
33	O
to	O
46	O
bps	O
upstream	O
to	O
the	O
start	O
of	O
exon	O
47	O
.	O

This	O
mutation	O
does	O
not	O
involve	O
the	O
3'	O
acceptor	O
splice	O
site	O
and	O
is	O
outside	O
the	O
lariat	O
branchpoint	O
sequence	O
(	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
)	O
.	O

Amplification	O
of	O
cDNA	O
obtained	O
in	O
cultured	O
fibroblasts	O
of	O
the	O
proband	O
and	O
affected	O
family	O
member	O
revealed	O
an	O
abnormally	O
spliced	O
cDNA	O
sequence	O
with	O
skipping	O
of	O
exon	O
47	O
.	O

These	O
variants	O
were	O
not	O
identified	O
in	O
over	O
400	O
chromosomes	O
of	O
healthy	O
whites	O
.	O

Compound	O
heterozygotes	O
(n=4)	O
exhibited	O
the	O
lowest	O
HDL-C	O
(	O
11+/-5	O
mg/dL	O
)	O
and	O
ApoA-I	O
(	O
35+/-15	O
mg/dL	O
)	O
compared	O
with	O
wild-type	O
(n=25)	O
(	O
HDL-C	O
51+/-14	O
mg/dL	O
;	O
ApoA-I	O
133+/-21	O
mg/dL	O
)	O
(P<0.0005)	O
or	O
subjects	O
affected	O
with	O
either	O
R1851Q	B-ProteinMutation
(n=6)	O
(	O
HDL-C	O
36+/-8	O
;	O
ApoA-I	O
117+/-19	O
)	O
or	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
(n=5)	O
(	O
HDL-C	O
31+9	O
;	O
ApoA-I	O
115+28	O
(P<0.01)	O
.	O

These	O
data	O
suggest	O
that	O
polypyrimidine	O
tract	O
variation	O
may	O
represent	O
a	O
novel	O
mechanism	O
for	O
altered	O
splicing	O
and	O
exon	O
skipping	O
that	O
is	O
independent	O
of	O
traditional	O
intronic	O
variants	O
as	O
previously	O
identified	O
in	O
acceptor/donor	O
splice	O
regions	O
or	O
the	O
lariat	O
branchpoint	O
domain	O
.	O

Frequency	O
of	O
polymorphisms	O
of	O
genes	O
coding	O
for	O
HIV-1	O
co-receptors	O
CCR5	O
and	O
CCR2	O
in	O
a	O
Brazilian	O
population	O
.	O

Entry	O
of	O
human	O
immunodeficiency	O
type	O
1	O
virus	O
(HIV-1)	O
into	O
target	O
cells	O
requires	O
both	O
CD(4)and	O
one	O
of	O
the	O
chemokine	O
receptors	O
.	O

Viruses	O
predominantly	O
use	O
one	O
,	O
or	O
occasionally	O
both	O
,	O
of	O
the	O
major	O
co-receptors	O
CCR5	O
and	O
CXCR4	O
,	O
although	O
other	O
receptors	O
,	O
including	O
CCR2B	O
and	O
CCR3	O
,	O
function	O
as	O
minor	O
co-receptors	O
.	O

A	O
32-nucleotide	O
deletion	O
(D32)	O
within	O
the	O
b-chemokine	O
receptor	O
5	O
gene	O
(CCR5)	O
has	O
been	O
described	O
in	O
subjects	O
who	O
remain	O
uninfected	O
despite	O
extensive	O
exposition	O
to	O
HIV-1	O
.	O

The	O
heterozygous	O
genotype	O
delays	O
disease	O
progression	O
.	O

This	O
allele	O
is	O
common	O
among	O
Caucasians	O
,	O
but	O
has	O
not	O
been	O
found	O
in	O
people	O
of	O
African	O
or	O
Asian	O
ancestry	O
.	O

A	O
more	O
common	O
transition	O
involving	O
a	O
valine	O
to	O
isoleucine	O
switch	O
in	O
transmembrane	O
domain	O
I	O
of	O
CCR2B	O
(64I)	O
,	O
with	O
unknown	O
functional	O
consequences	O
,	O
was	O
found	O
to	O
delay	O
disease	O
progression	O
but	O
not	O
to	O
reduce	O
infection	O
risk	O
.	O

As	O
the	O
Brazilian	O
population	O
consists	O
of	O
a	O
mixture	O
of	O
several	O
ethnic	O
groups	O
,	O
we	O
decided	O
to	O
examine	O
the	O
genotype	O
frequency	O
of	O
these	O
polymorphisms	O
in	O
this	O
country	O
.	O

There	O
were	O
11.5%	O
CCR5	O
heterozygotes	O
among	O
the	O
HIV-1	O
infected	O
population	O
and	O
12.5%	O
among	O
uninfected	O
individuals	O
,	O
similar	O
to	O
data	O
from	O
North	O
America	O
and	O
Western	O
Europe	O
.	O

The	O
prevalence	O
of	O
CCR2-64I	O
homozygotes	O
and	O
heterozygotes	O
was	O
0.06	O
and	O
15.2%	O
,	O
respectively	O
,	O
also	O
similar	O
to	O
what	O
is	O
known	O
for	O
North	O
America	O
and	O
Western	O
Europe	O
.	O

Progressive	O
decline	O
of	O
vasopressin	O
secretion	O
in	O
familial	O
autosomal	O
dominant	O
neurohypophyseal	O
diabetes	O
insipidus	O
presenting	O
a	O
novel	O
mutation	O
in	O
the	O
vasopressin-neurophysin	O
II	O
gene	O
.	O

OBJECTIVE	O
:	O
Familial	O
autosomal	O
dominant	O
neurohypophyseal	O
diabetes	O
insipidus	O
(FNDI)	O
is	O
a	O
rare	O
form	O
of	O
central	O
diabetes	O
insipidus	O
(DI)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
vasopressin-neurophysin	O
II	O
(AVP-NPII)	O
gene	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
AVP	O
secretion	O
over	O
time	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
AVP-NPII	O
gene	O
in	O
a	O
Brazilian	O
family	O
with	O
FNDI	O
.	O

SUBJECTS	O
AND	O
DESIGN	O
:	O
Four	O
affected	O
members	O
and	O
one	O
nonaffected	O
member	O
from	O
one	O
Brazilian	O
family	O
with	O
FNDI	O
were	O
studied	O
.	O

The	O
diagnosis	O
of	O
central	O
DI	O
was	O
established	O
by	O
fluid	O
deprivation	O
test	O
and	O
hypertonic	O
saline	O
infusion	O
.	O

Two	O
affected	O
members	O
were	O
assessed	O
twice	O
within	O
a	O
6-year	O
interval	O
.	O

For	O
molecular	O
analysis	O
,	O
genomic	O
DNA	O
was	O
extracted	O
and	O
the	O
AVP-NPII	O
gene	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O

RESULTS	O
:	O
The	O
functional	O
assessment	O
of	O
patients	O
with	O
FNDI	O
over	O
time	O
confirmed	O
a	O
progressive	O
loss	O
in	O
AVP	O
secretion	O
.	O

Two	O
patients	O
were	O
first	O
diagnosed	O
as	O
partial	O
central	O
DI	O
and	O
,	O
several	O
years	O
later	O
,	O
they	O
developed	O
severe	O
central	O
DI	O
.	O

Sequencing	O
analysis	O
revealed	O
a	O
heterozygous	O
new	O
point	O
mutation	O
in	O
the	O
nucleotide	O
1892	O
in	O
the	O
coding	O
sequence	O
for	O
neurophysin-II	O
of	O
the	O
AVP-NPII	O
gene	O
1892G>C	B-DNAMutation
predicting	O
an	O
amino	O
acid	O
substitution	O
A68P	B-ProteinMutation
in	O
all	O
affected	O
members	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
demonstrate	O
a	O
gradual	O
vasopressinergic	O
deficiency	O
due	O
to	O
a	O
novel	O
mutation	O
in	O
the	O
AVP-NPII	O
gene	O
in	O
a	O
Brazilian	O
family	O
with	O
FNDI	O
.	O

The	O
accumulation	O
of	O
A68P	B-ProteinMutation
mutated	O
precursor	O
might	O
have	O
a	O
cytotoxicity	O
effect	O
,	O
leading	O
to	O
a	O
gradual	O
death	O
of	O
magnocellular	O
neurones	O
,	O
and	O
a	O
progressive	O
decline	O
in	O
AVP	O
secretion	O
.	O

Congenital	O
hypothyroidism	O
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
sodium/iodide	O
symporter	O
protein	O
.	O

OBJECTIVE	O
:	O
Iodide	O
transport	O
defect	O
(ITD)	O
is	O
a	O
rare	O
disorder	O
characterised	O
by	O
an	O
inability	O
of	O
the	O
thyroid	O
to	O
maintain	O
an	O
iodide	O
gradient	O
across	O
the	O
basolateral	O
membrane	O
of	O
thyroid	O
follicular	O
cells	O
,	O
that	O
often	O
results	O
in	O
congenital	O
hypothyroidism	O
.	O

When	O
present	O
the	O
defect	O
is	O
also	O
found	O
in	O
the	O
salivary	O
glands	O
and	O
gastric	O
mucosa	O
and	O
it	O
has	O
been	O
shown	O
to	O
arise	O
from	O
abnormalities	O
of	O
the	O
sodium/iodide	O
symporter	O
(NIS)	O
.	O

PATIENT	O
:	O
We	O
describe	O
a	O
woman	O
with	O
hypothyroidism	O
identified	O
at	O
the	O
3rd	O
month	O
of	O
life	O
.	O

The	O
diagnosis	O
of	O
ITD	O
was	O
suspected	O
because	O
of	O
nodular	O
goitre	O
,	O
and	O
little	O
if	O
any	O
iodide	O
uptake	O
by	O
the	O
thyroid	O
and	O
salivary	O
glands	O
.	O

Treatment	O
with	O
iodide	O
partially	O
corrected	O
the	O
hypothyroidism	O
;	O
however	O
,	O
long-term	O
substitution	O
therapy	O
with	O
L-thyroxine	O
was	O
started	O
.	O

MEASUREMENTS	O
:	O
Thyroid	O
radioiodide	O
uptake	O
was	O
only	O
1.4%	O
and	O
0.3%	O
at	O
1	O
and	O
24	O
h	O
after	O
the	O
administration	O
of	O
recombinant	O
human	O
TSH	O
.	O

The	O
saliva	O
to	O
plasma	O
I-	O
ratio	O
was	O
1.1	O
indicating	O
that	O
the	O
inability	O
of	O
the	O
thyroid	O
gland	O
to	O
concentrate	O
I-	O
was	O
also	O
present	O
in	O
the	O
salivary	O
glands	O
.	O

RESULTS	O
:	O
Analysis	O
of	O
the	O
patient's	O
NIS	O
gene	O
revealed	O
a	O
15	O
nucleotide	O
(nt)	O
deletion	O
of	O
the	O
coding	O
sequence	O
(	O
nt	O
1314	O
through	O
nt	O
1328	O
)	O
and	O
the	O
insertion	O
of	O
15	O
nt	O
duplicating	O
the	O
first	O
15	O
nt	O
of	O
the	O
adjacent	O
intron	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
this	O
insertion/deletion	O
,	O
while	O
both	O
consanguineous	O
parents	O
were	O
heterozygous	O
.	O

This	O
deletion	O
predicts	O
the	O
production	O
of	O
a	O
protein	O
lacking	O
the	O
five	O
terminal	O
amino	O
acids	O
of	O
exon	O
XI	O
(439-443)	O
which	O
are	O
located	O
in	O
the	O
6th	O
intracellular	O
loop	O
.	O

COS-7	O
cells	O
transfected	O
with	O
a	O
vector	O
expressing	O
the	O
mutant	O
del-(439-443)	B-DNAMutation
NIS	O
failed	O
to	O
concentrate	O
iodide	O
,	O
suggesting	O
that	O
the	O
mutation	O
was	O
the	O
direct	O
cause	O
of	O
the	O
ITD	O
in	O
this	O
patient	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
we	O
describe	O
the	O
first	O
Italian	O
case	O
of	O
congenital	O
hypothyroidism	O
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
NIS	O
gene	O
.	O

Cdx-2	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
determines	O
susceptibility	O
to	O
fracture	O
in	O
the	O
elderly	O
.	O

A	O
Cdx-2	O
binding	O
site	O
polymorphism	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
was	O
reported	O
.	O

In	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
study	O
in	O
2848	O
elderly	O
whites	O
,	O
we	O
found	O
the	O
A-allele	O
to	O
be	O
associated	O
with	O
decreased	O
fracture	O
risk	O
.	O

Our	O
findings	O
expand	O
previous	O
similar	O
findings	O
in	O
a	O
Japanese	O
study	O
to	O
whites	O
and	O
show	O
a	O
relationship	O
with	O
fracture	O
risk	O
of	O
this	O
functional	O
polymorphism	O
.	O

INTRODUCTION	O
:	O
A	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
within	O
a	O
binding	O
site	O
of	O
the	O
intestinal-specific	O
transcription	O
factor	O
Cdx-2	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
(VDR)	O
gene	O
was	O
previously	O
reported	O
.	O

It	O
was	O
found	O
to	O
modulate	O
the	O
transcription	O
of	O
the	O
hVDR	O
gene	O
and	O
to	O
be	O
associated	O
with	O
decreased	O
bone	O
mineral	O
density	O
in	O
a	O
small	O
group	O
of	O
postmenopausal	O
Japanese	O
women	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
VDR	O
Cdx-2	O
genotype	O
and	O
risk	O
of	O
fracture	O
.	O

METHODS	O
:	O
We	O
first	O
determined	O
the	O
location	O
of	O
this	O
SNP	O
in	O
the	O
VDR	O
gene	O
by	O
sequencing	O
analysis	O
,	O
and	O
we	O
developed	O
an	O
allele-specific	O
multiplex	O
polymerase	O
chain	O
reaction	O
test	O
to	O
determine	O
the	O
Cdx-2	O
genotype	O
.	O

We	O
then	O
performed	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
analysis	O
in	O
a	O
large	O
epidemiological	O
cohort	O
of	O
2848	O
Dutch	O
white	O
men	O
and	O
women	O
,	O
>	O
or	O
=	O
55	O
years	O
old	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
The	O
location	O
of	O
the	O
G	O
to	O
A	O
substitution	O
was	O
found	O
in	O
the	O
promoter	O
region	O
of	O
exon	O
le	O
(le-G-1739A)	O
of	O
the	O
VDR	O
gene	O
.	O

By	O
comparing	O
the	O
frequency	O
of	O
the	O
A-allele	O
in	O
eight	O
different	O
ethnic	O
groups	O
,	O
we	O
observed	O
a	O
negative	O
correlation	O
between	O
prevalence	O
of	O
the	O
A-allele	O
and	O
published	O
hip	O
fracture	O
incidence	O
rates	O
in	O
these	O
ethnic	O
groups	O
(	O
p	O
=	O
0.006	O
for	O
men	O
and	O
p	O
=	O
0.02	O
for	O
women	O
)	O
,	O
suggesting	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
fracture	O
risk	O
.	O

Subsequently	O
,	O
in	O
the	O
association	O
study	O
,	O
the	O
A-allele	O
(	O
population	O
frequency	O
19%	O
)	O
was	O
observed	O
to	O
have	O
a	O
protective	O
effect	O
on	O
occurrence	O
of	O
osteoporotic	O
fractures	O
,	O
especially	O
for	O
nonvertebral	O
fracture	O
in	O
women	O
(	O
relative	O
risk	O
of	O
AA	O
versus	O
GG	O
genotype	O
is	O
0.2	O
;	O
95%	O
CI	O
,	O
0.05-0.8	O
)	O
.	O

This	O
effect	O
remained	O
after	O
adjustment	O
for	O
age	O
,	O
weight	O
,	O
and	O
bone	O
mineral	O
density	O
.	O

We	O
conclude	O
that	O
the	O
A-allele	O
of	O
the	O
VDR	O
Cdx-2	O
polymorphism	O
is	O
present	O
in	O
whites	O
,	O
albeit	O
at	O
low	O
frequency	O
,	O
and	O
show	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
risk	O
of	O
fracture	O
.	O

A	O
glycine	O
to	O
aspartic	O
acid	O
substitution	O
of	O
COL2A1	O
in	O
a	O
family	O
with	O
the	O
Strudwick	O
variant	O
of	O
spondyloepimetaphyseal	O
dysplasia	O
.	O

BACKGROUND	O
:	O
Spondyloepimetaphyseal	O
dysplasia	O
(SEMD)	O
is	O
one	O
of	O
a	O
clinically	O
heterogeneous	O
group	O
of	O
skeletal	O
disorders	O
,	O
characterized	O
by	O
defective	O
growth	O
and	O
modelling	O
of	O
the	O
spine	O
and	O
long	O
bones	O
.	O

Common	O
clinical	O
features	O
include	O
disproportionate	O
short	O
stature	O
,	O
malformed	O
vertebrae	O
and	O
abnormal	O
epiphyses	O
or	O
metaphyses	O
.	O

Some	O
cases	O
have	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
COL2A1	O
gene	O
.	O

AIM	O
:	O
To	O
determine	O
whether	O
the	O
autosomal	O
dominant	O
Strudwick-type	O
SEMD	O
in	O
a	O
three-generation	O
family	O
,	O
showing	O
specific	O
phenotypical	O
features	O
such	O
as	O
chest	O
deformity	O
,	O
limb	O
shortening	O
,	O
myopia	O
and	O
early-onset	O
degenerative	O
osteoarthrosis	O
,	O
might	O
be	O
caused	O
by	O
a	O
novel	O
COL2A1	O
mutation	O
.	O

DESIGN	O
:	O
Genetic	O
testing	O
and	O
clinical	O
examination	O
of	O
family	O
members	O
.	O

METHODS	O
:	O
Direct	O
sequencing	O
of	O
PCR-amplified	O
genomic	O
DNA	O
from	O
the	O
COL2A1	O
gene	O
.	O

RESULTS	O
:	O
A	O
point	O
mutation	O
within	O
exon	O
20	O
of	O
the	O
COL2A1	O
gene	O
was	O
identified	O
that	O
substituted	O
a	O
glycine	O
for	O
an	O
aspartic	O
acid	O
residue	O
at	O
codon	O
262	O
.	O

DISCUSSION	O
:	O
All	O
previously	O
reported	O
autosomal	O
dominant	O
mutations	O
causing	O
SEMD	O
have	O
substituted	O
an	O
obligate	O
glycine	O
within	O
the	O
triple	O
helix	O
,	O
in	O
particular	O
at	O
codons	O
292	O
,	O
304	O
and	O
709	O
in	O
the	O
three	O
reported	O
Strudwick-type	O
patients	O
.	O

Additionally	O
,	O
a	O
recurrent	O
glycine	O
substitution	O
at	O
codon	O
154	O
has	O
been	O
identified	O
in	O
two	O
unrelated	O
Finnish	O
cases	O
with	O
radiological	O
features	O
consistent	O
with	O
the	O
Strudwick	O
subtype	O
.	O

Our	O
sixth	O
helical	O
glycine	O
substitution	O
extends	O
the	O
mutational	O
spectrum	O
and	O
genotype/phenotype	O
correlations	O
of	O
Strudwick-type	O
SEMD	O
.	O

Genetic	O
polymorphisms	O
of	O
renin-angiotensin	O
system	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

Genes	O
of	O
the	O
renin-angiotensin	O
system	O
(RAS)	O
are	O
involved	O
in	O
the	O
progression	O
of	O
renal	O
failure	O
.	O

Among	O
them	O
,	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
,	O
angiotensinogen	O
(AGT)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(AT1R)	O
genes	O
are	O
of	O
particular	O
interest	O
.	O

We	O
examined	O
polymorphisms	O
of	O
these	O
three	O
genes	O
for	O
association	O
with	O
the	O
development	O
of	O
interstitial	O
nephritis	O
and	O
progression	O
to	O
end-stage	O
renal	O
failure	O
.	O

The	O
allele	O
frequency	O
and	O
genotype	O
distribution	O
were	O
compared	O
in	O
90	O
patients	O
with	O
interstitial	O
nephritis	O
and	O
200	O
healthy	O
controls	O
.	O

DNA	O
samples	O
were	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

We	O
did	O
not	O
find	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
insertion/deletion	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
.	O

An	O
involvement	O
of	O
M235T	B-ProteinMutation
polymorphism	O
of	O
the	O
AGT	O
gene	O
in	O
renal	O
disease	O
was	O
observed	O
in	O
our	O
study	O
.	O

The	O
frequency	O
of	O
the	O
T	O
allele	O
was	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
32%	O
vs	O
.	O

24%	O
)	O
.	O

In	O
the	O
A1166C	B-DNAMutation
AT1R	O
polymorphism	O
the	O
homozygous	O
CC	O
genotype	O
was	O
also	O
more	O
frequent	O
in	O
interstitial	O
nephritis	O
patients	O
(	O
7%	O
vs	O
.	O

3.5%	O
)	O
.	O

In	O
patients	O
carrying	O
the	O
C	O
allele	O
,	O
an	O
average	O
time	O
to	O
ESRD	O
was	O
significantly	O
shorter	O
than	O
in	O
subjects	O
with	O
the	O
AA	O
genotype	O
.	O

Our	O
study	O
shows	O
the	O
association	O
of	O
the	O
AGT	O
and	O
AT1R	O
gene	O
polymorphisms	O
with	O
the	O
development	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

The	O
C	O
allele	O
of	O
the	O
A1166C	B-DNAMutation
polymorphism	O
appears	O
to	O
be	O
a	O
risk	O
factor	O
for	O
faster	O
disease	O
progression	O
.	O

Epidemiology	O
of	O
tuberculosis	O
on	O
Gran	O
Canaria	O
:	O
a	O
4	O
year	O
population	O
study	O
using	O
traditional	O
and	O
molecular	O
approaches	O
.	O

BACKGROUND	O
:	O
In	O
recent	O
years	O
several	O
population	O
based	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
have	O
shown	O
a	O
higher	O
rate	O
of	O
recent	O
transmission	O
of	O
tuberculosis	O
than	O
previously	O
thought	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
transmission	O
patterns	O
of	O
tuberculosis	O
and	O
the	O
potential	O
causes	O
of	O
recent	O
transmission	O
on	O
the	O
island	O
of	O
Gran	O
Canaria	O
(Spain)	O
.	O

METHODS	O
:	O
The	O
strains	O
of	O
all	O
patients	O
diagnosed	O
with	O
tuberculosis	O
confirmed	O
by	O
culture	O
between	O
1	O
January	O
1993	O
and	O
31	O
December	O
1996	O
were	O
typed	O
by	O
RFLP	O
using	O
the	O
insertion	O
sequence	O
IS6110	O
.	O

A	O
cluster	O
was	O
defined	O
as	O
two	O
or	O
more	O
isolates	O
with	O
an	O
identical	O
RFLP	O
pattern	O
.	O

Epidemiological	O
linkage	O
through	O
contact	O
tracing	O
was	O
investigated	O
.	O

RESULTS	O
:	O
Of	O
the	O
total	O
of	O
719	O
patients	O
,	O
153	O
(21.3%)	O
were	O
excluded	O
because	O
there	O
was	O
inadequate	O
bacterial	O
DNA	O
for	O
genotyping	O
(n=129)	O
or	O
the	O
isolates	O
of	O
Mycobacterium	O
tuberculosis	O
had	O
less	O
than	O
five	O
copies	O
of	O
IS6110	O
(n=24)	O
.	O

The	O
isolates	O
from	O
409	O
patients	O
(72.3%)	O
were	O
grouped	O
into	O
78	O
different	O
clusters	O
with	O
an	O
estimated	O
58.5%	O
of	O
the	O
cases	O
being	O
due	O
to	O
recent	O
transmission	O
.	O

Young	O
age	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
clustering	O
.	O

Only	O
in	O
147	O
(35.9%)	O
of	O
the	O
409	O
patients	O
belonging	O
to	O
a	O
cluster	O
could	O
an	O
epidemiological	O
link	O
be	O
found	O
.	O

111	O
patients	O
(19.6%)	O
were	O
identified	O
as	O
having	O
had	O
previous	O
contact	O
with	O
a	O
tuberculosis	O
patient	O
and	O
81	O
of	O
them	O
(72.9%)	O
belonged	O
to	O
a	O
cluster	O
.	O

The	O
three	O
largest	O
clusters	O
included	O
75	O
,	O
49	O
and	O
20	O
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Recent	O
transmission	O
is	O
frequent	O
among	O
patients	O
with	O
tuberculosis	O
on	O
Gran	O
Canaria	O
and	O
could	O
be	O
associated	O
with	O
certain	O
aspects	O
of	O
control	O
measures	O
.	O

Some	O
of	O
the	O
clusters	O
described	O
in	O
the	O
study	O
could	O
be	O
due	O
to	O
the	O
prevalence	O
of	O
particular	O
strains	O
of	O
M	O
tuberculosis	O
on	O
the	O
island	O
.	O

Spectrum	O
of	O
mutations	O
in	O
the	O
arylsulfatase	O
A	O
gene	O
in	O
a	O
Canadian	O
DNA	O
collection	O
including	O
two	O
novel	O
frameshift	O
mutations	O
,	O
a	O
new	O
missense	O
mutation	O
C488R	B-ProteinMutation
and	O
an	O
MLD	O
mutation	O
R84Q	B-ProteinMutation
in	O
cis	O
with	O
a	O
pseudodeficiency	O
allele	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
in	O
the	O
human	O
arylsulfatase	O
A	O
gene	O
in	O
three	O
patients	O
with	O
MLD	O
,	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
.	O

An	O
insertion	O
,	O
2590_2591insCCCC	B-DNAMutation
in	O
exon	O
8	O
and	O
a	O
deletion	O
,	O
752_758delGCCGGCC	B-DNAMutation
,	O
in	O
exon	O
3	O
will	O
both	O
result	O
in	O
frameshifts	O
.	O

A	O
mutation	O
in	O
exon	O
8	O
,	O
2566T-->C	B-DNAMutation
,	O
results	O
in	O
a	O
missense	O
mutation	O
C488R	B-ProteinMutation
,	O
disrupting	O
an	O
unusual	O
cysteine-knot	O
at	O
the	O
C-terminal	O
end	O
of	O
the	O
protein	O
.	O

All	O
three	O
mutations	O
are	O
heterozygous	O
with	O
previously	O
documented	O
mutations	O
.	O

A	O
previously	O
reported	O
mutation	O
,	O
R84Q	B-ProteinMutation
was	O
identified	O
on	O
a	O
pseudodeficiency	O
allele	O
.	O

These	O
mutations	O
are	O
part	O
of	O
a	O
heterogeneous	O
spectrum	O
of	O
mutations	O
found	O
in	O
a	O
collection	O
of	O
DNA	O
samples	O
from	O
MLD	O
patients	O
from	O
across	O
Canada	O
and	O
the	O
USA	O
.	O

The	O
molecular	O
basis	O
for	O
the	O
thalassaemias	O
in	O
Sri	O
Lanka	O
.	O

The	O
beta-globin	O
gene	O
mutations	O
and	O
the	O
alpha-globin	O
genes	O
of	O
620	O
patients	O
with	O
the	O
phenotype	O
of	O
severe	O
to	O
moderate	O
thalassaemia	O
from	O
seven	O
centres	O
in	O
Sri	O
Lanka	O
were	O
analysed	O
.	O

Twenty-four	O
beta-globin	O
gene	O
mutations	O
were	O
identified	O
,	O
three	O
accounting	O
for	O
84.5%	O
of	O
the	O
1240	O
alleles	O
studied	O
:	O
IVSI-5	B-DNAMutation
(G-->C)	I-DNAMutation
56.2%	O
;	O
IVSI-1	B-DNAMutation
(G-->A)	I-DNAMutation
15.2%	O
;	O
and	O
haemoglobin	O
E	O
(	O
codon	B-DNAMutation
(CD)26	I-DNAMutation
GAG-->GAA	I-DNAMutation
)	O
13.1%	O
.	O

Three	O
new	O
mutations	O
were	O
found	O
;	O
a	O
13-bp	O
deletion	O
removing	O
the	O
last	O
nucleotide	O
in	O
CD6	O
to	O
CD10	O
inclusively	O
,	O
IVSI-129	B-DNAMutation
(A-->C)	I-DNAMutation
in	O
the	O
consensus	O
splice	O
site	O
,	O
and	O
a	O
frame	O
shift	O
,	O
CD55	O
(-A)	O
.	O

The	O
allele	O
frequency	O
of	O
alpha+	O
thalassaemia	O
was	O
6.5%	O
and	O
1.1%	O
for	O
-alpha3.7	O
and	O
-alpha4.2	O
deletions	O
respectively	O
.	O

Non-deletion	O
alpha-thalassaemia	O
was	O
not	O
observed	O
.	O

Triplicate	O
or	O
quadruplicate	O
alpha-globin	O
genes	O
were	O
unusually	O
common	O
.	O

In	O
1.5%	O
of	O
cases	O
it	O
was	O
impossible	O
to	O
identify	O
beta-thalassaemia	O
alleles	O
,	O
but	O
in	O
Kurunegala	O
detailed	O
family	O
studies	O
led	O
to	O
an	O
explanation	O
for	O
the	O
severe	O
thalassaemia	O
phenotype	O
in	O
every	O
case	O
,	O
including	O
a	O
previously	O
unreported	O
instance	O
of	O
homozygosity	O
for	O
a	O
quadruplicated	O
alpha-globin	O
gene	O
together	O
with	O
beta-thalassaemia	O
trait	O
.	O

These	O
findings	O
have	O
implications	O
for	O
the	O
control	O
of	O
thalassaemia	O
in	O
high-frequency	O
populations	O
with	O
complex	O
ethnic	O
histories	O
.	O

Pacemaker	O
channel	O
dysfunction	O
in	O
a	O
patient	O
with	O
sinus	O
node	O
disease	O
.	O

The	O
cardiac	O
pacemaker	O
current	O
I(f)	O
is	O
a	O
major	O
determinant	O
of	O
diastolic	O
depolarization	O
in	O
sinus	O
nodal	O
cells	O
and	O
has	O
a	O
key	O
role	O
in	O
heartbeat	O
generation	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
some	O
forms	O
of	O
"idiopathic"	O
sinus	O
node	O
dysfunction	O
(SND)	O
are	O
related	O
to	O
inherited	O
dysfunctions	O
of	O
cardiac	O
pacemaker	O
ion	O
channels	O
.	O

In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
1-bp	O
deletion	O
1631delC	B-DNAMutation
in	O
exon	O
5	O
of	O
the	O
human	O
HCN4	O
gene	O
was	O
detected	O
in	O
a	O
patient	O
with	O
idiopathic	O
SND	O
.	O

The	O
mutant	O
HCN4	O
protein	O
(HCN4-573X)	O
had	O
a	O
truncated	O
C-terminus	O
and	O
lacked	O
the	O
cyclic	O
nucleotide-binding	O
domain	O
.	O

COS-7	O
cells	O
transiently	O
transfected	O
with	O
HCN4-573X	O
cDNA	O
indicated	O
normal	O
intracellular	O
trafficking	O
and	O
membrane	O
integration	O
of	O
HCN4-573X	O
subunits	O
.	O

Patch-clamp	O
experiments	O
showed	O
that	O
HCN4-573X	O
channels	O
mediated	O
I(f)-like	O
currents	O
that	O
were	O
insensitive	O
to	O
increased	O
cellular	O
cAMP	O
levels	O
.	O

Coexpression	O
experiments	O
showed	O
a	O
dominant-negative	O
effect	O
of	O
HCN4-573X	O
subunits	O
on	O
wild-type	O
subunits	O
.	O

These	O
data	O
indicate	O
that	O
the	O
cardiac	O
I(f)	O
channels	O
are	O
functionally	O
expressed	O
but	O
with	O
altered	O
biophysical	O
properties	O
.	O

Taken	O
together	O
,	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
in	O
vitro	O
data	O
provide	O
a	O
likely	O
explanation	O
for	O
the	O
patient's	O
sinus	O
bradycardia	O
and	O
the	O
chronotropic	O
incompetence	O
.	O

Genetic	O
changes	O
and	O
expression	O
of	O
the	O
mannose	O
6-phosphate/insulin-like	O
growth	O
factor	O
II	O
receptor	O
gene	O
in	O
human	O
hepatitis	O
B	O
virus-associated	O
hepatocellular	O
carcinoma	O
.	O

It	O
was	O
reported	O
that	O
60-70%	O
of	O
hepatitis	O
B	O
virus	O
(HBV)-negative	O
hepatocellular	O
carcinoma	O
(HCC)	O
had	O
loss	O
of	O
heterozygosity	O
(LOH)	O
at	O
the	O
mannose	O
6-phosphate/insulin-like	O
growth	O
factor	O
II	O
receptor	O
(M6P/IGF2R)	O
locus	O
and	O
this	O
gene	O
was	O
mutated	O
in	O
55%	O
of	O
these	O
patients	O
with	O
LOH	O
.	O

In	O
this	O
study	O
,	O
genomic	O
DNA	O
from	O
29	O
pairs	O
of	O
HBV-positive	O
HCC	O
and	O
corresponding	O
non-tumor	O
tissues	O
was	O
used	O
to	O
analyze	O
LOH	O
at	O
the	O
M6P/IGF2R	O
locus	O
and	O
single	O
deoxyguanosine	O
deletion	O
in	O
this	O
gene	O
by	O
PCR	O
.	O

Total	O
RNA	O
from	O
19	O
of	O
the	O
29	O
patients	O
was	O
utilized	O
to	O
determine	O
a	O
192	O
bp	O
insert	O
in	O
the	O
M6P/IGF2R	O
mRNA	O
and	O
expression	O
of	O
this	O
gene	O
by	O
RT-PCR	O
.	O

Twenty-eight	O
of	O
29	O
(97%)	O
HBV-positive	O
HCC	O
were	O
found	O
to	O
be	O
informative	O
at	O
the	O
M6P/IGF2R	O
locus	O
but	O
LOH	O
at	O
this	O
region	O
was	O
only	O
detected	O
in	O
4/28	O
(14%)	O
informative	O
patients	O
.	O

Neither	O
single	O
deoxyguanosine	O
deletion	O
in	O
this	O
gene	O
nor	O
192	O
bp	O
insert	O
in	O
its	O
mRNA	O
occurred	O
in	O
these	O
patients	O
.	O

Compared	O
with	O
corresponding	O
non-tumor	O
tissues	O
,	O
expression	O
of	O
the	O
M6P/IGF2R	O
mRNA	O
was	O
decreased	O
in	O
13/19	O
(68%)	O
HBV-positive	O
HCC	O
tissues	O
,	O
suggesting	O
that	O
M6P/IGF2R	O
may	O
be	O
involved	O
in	O
HBV-associated	O
hepatocarcinogenesis	O
by	O
the	O
regulation	O
of	O
its	O
expression	O
level	O
.	O

In	O
the	O
development	O
of	O
HBV-associated	O
HCC	O
,	O
M6P/IGF2R	O
mutation	O
may	O
not	O
be	O
a	O
major	O
agent	O
.	O

NRAMP1	O
genetic	O
polymorphisms	O
as	O
a	O
risk	O
factor	O
of	O
tuberculous	O
pleurisy	O
.	O

SETTING	O
:	O
Nrampl	O
encoded	O
by	O
the	O
NRAMP1	O
gene	O
influences	O
the	O
phagolysosomal	O
function	O
of	O
alveolar	O
macrophage	O
against	O
Mycobacterium	O
tuberculosis	O
.	O

Genetic	O
polymorphisms	O
of	O
NRAMP1	O
affect	O
innate	O
host	O
resistance	O
through	O
the	O
defective	O
production	O
and	O
function	O
of	O
Nrampl	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
this	O
relationship	O
,	O
the	O
NRAMP1	O
polymorphisms	O
in	O
patients	O
with	O
tuberculous	O
pleurisy	O
were	O
determined	O
.	O

DESIGN	O
:	O
Pleural	O
biopsy	O
proven	O
56	O
patients	O
were	O
designated	O
to	O
the	O
pleurisy	O
group	O
and	O
45	O
healthy	O
adults	O
were	O
designated	O
to	O
the	O
healthy	O
control	O
group	O
.	O

Three	O
NRAMP1	O
polymorphisms	O
such	O
as	O
single	O
nucleotide	O
change	O
in	O
intron	O
4(469	B-DNAMutation
+	I-DNAMutation
14G/C	I-DNAMutation
,	O
INT4	O
)	O
,	O
a	O
non-conservative	O
single-base	O
substitution	O
at	O
codon	O
543(D543N)	B-ProteinMutation
and	O
TGTG	O
deletion	O
in	O
the	O
3'	O
untranslated	O
region	O
(	O
1729	B-DNAMutation
+	I-DNAMutation
55del4	I-DNAMutation
,	O
3'UTR	O
)	O
were	O
determined	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
mutant	O
genotypes	O
of	O
INT4	O
and	O
3'UTR	O
were	O
significantly	O
high	O
in	O
the	O
pleurisy	O
group	O
(	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.02	O
)	O
,	O
but	O
the	O
frequencies	O
of	O
D543N	B-ProteinMutation
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Odds	O
ratios	O
(OR)	O
,	O
which	O
are	O
a	O
comparison	O
of	O
the	O
wild	O
with	O
the	O
mutant	O
genotype	O
,	O
were	O
8.02	O
(	O
95%CI	O
2.42	O
approximately	O
26.57	O
)	O
for	O
INT4	O
and	O
5.73	O
(	O
95%CI	O
1.14	O
approximately	O
28.92	O
)	O
for	O
3'UTR	O
which	O
were	O
statistically	O
significant	O
.	O

In	O
the	O
combined	O
analysis	O
of	O
the	O
INT4	O
and	O
3'UTR	O
,	O
the	O
ORs	O
were	O
6.00	O
(	O
95%CI	O
1.46	O
approximately	O
24.64	O
)	O
for	O
GC/++	O
genotype	O
and	O
14.00	O
(	O
95%CI	O
1.61	O
approximately	O
121.75	O
)	O
for	O
GC/+del	O
when	O
compared	O
with	O
GG/++	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
The	O
NRAMP1	O
genetic	O
polymorphisms	O
,	O
especially	O
INT4	O
and	O
3'UTR	O
,	O
were	O
closely	O
related	O
to	O
tuberculous	O
pleurisy	O
.	O

A	O
novel	O
CACNA1F	O
mutation	O
in	O
a	O
french	O
family	O
with	O
the	O
incomplete	O
type	O
of	O
X-linked	O
congenital	O
stationary	O
night	O
blindness	O
.	O

PURPOSE	O
:	O
To	O
describe	O
a	O
French	O
family	O
with	O
the	O
incomplete	O
type	O
of	O
X-linked	O
congenital	O
stationary	O
night	O
blindness	O
(CSNB2)	O
associated	O
with	O
a	O
novel	O
mutation	O
in	O
the	O
retina-specific	O
calcium	O
channel	O
alpha(1)	O
subunit	O
gene	O
(CACNA1F)	O
.	O

DESIGN	O
:	O
Interventional	O
case	O
report	O
.	O

METHODS	O
:	O
Two	O
family	O
members	O
with	O
a	O
history	O
of	O
nonprogressive	O
night	O
blindness	O
and	O
subnormal	O
visual	O
acuity	O
were	O
clinically	O
examined	O
and	O
the	O
genotype	O
determined	O
by	O
molecular	O
genetic	O
analysis	O
.	O

RESULT	O
:	O
Both	O
patients	O
had	O
clinical	O
manifestations	O
characteristic	O
of	O
CSNB2	O
.	O

Electrophysiologically	O
,	O
we	O
found	O
a	O
predominant	O
reduction	O
of	O
the	O
ERG	O
B-wave	O
in	O
the	O
maximal	O
response	O
.	O

Both	O
rod	O
and	O
cone	O
function	O
were	O
subnormal	O
,	O
with	O
the	O
latter	O
tending	O
to	O
be	O
more	O
attenuated	O
.	O

We	O
identified	O
a	O
C	O
deletion	O
at	O
nucleotide	O
position	O
4548	O
,	O
resulting	O
in	O
a	O
frameshift	O
with	O
a	O
predicted	O
premature	O
termination	O
at	O
codon	O
1524	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
and	O
genetic	O
study	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
CACNA1F	O
gene	O
adds	O
further	O
support	O
to	O
the	O
contention	O
that	O
CSNB2	O
represents	O
a	O
genetically	O
distinct	O
retinal	O
disorder	O
of	O
a	O
calcium	O
channel	O
.	O

Analysis	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
RAD51	O
gene	O
in	O
breast	O
cancer	O
.	O

The	O
breast	O
cancer	O
suppressor	O
proteins	O
BRCA1	O
and	O
BRCA2	O
interact	O
with	O
RAD51	O
,	O
a	O
protein	O
essential	O
for	O
maintaining	O
genomic	O
stability	O
by	O
playing	O
a	O
central	O
role	O
in	O
homology-dependent	O
recombinational	O
repair	O
of	O
the	O
DNA	O
double-strand	O
breaks	O
.	O

Therefore	O
,	O
genetic	O
variability	O
in	O
the	O
RAD51	O
gene	O
may	O
contribute	O
to	O
the	O
appearance	O
and/or	O
progression	O
of	O
breast	O
cancer	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
5'-	O
untranslated	O
region	O
of	O
RAD51	O
(	O
a	O
G	O
to	O
C	O
substitution	O
at	O
position	O
135	O
,	O
the	O
G/C	B-DNAMutation
polymorphism	O
)	O
is	O
reported	O
to	O
modulate	O
breast	O
cancer	O
risk	O
.	O

We	O
investigated	O
the	O
distribution	O
of	O
genotypes	O
and	O
frequency	O
of	O
alleles	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
in	O
breast	O
cancer	O
.	O

Tumor	O
tissues	O
were	O
obtained	O
from	O
postmenopausal	O
women	O
with	O
node-negative	O
and	O
node-positive	O
breast	O
carcinoma	O
with	O
uniform	O
tumor	O
size	O
.	O

Blood	O
samples	O
from	O
age	O
matched	O
healthy	O
women	O
served	O
as	O
control	O
.	O

The	O
G/C	B-DNAMutation
polymorphism	O
was	O
determined	O
by	O
PCR-based	O
MvaI	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

The	O
distribution	O
of	O
the	O
genotypes	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
did	O
not	O
differ	O
significantly	O
(	O
P	O
>	O
0.05	O
)	O
from	O
those	O
predicted	O
by	O
the	O
Hardy-Weinberg	O
distribution	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
genotype	O
distribution	O
and	O
allele	O
frequencies	O
between	O
node-positive	O
and	O
node-negative	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
distributions	O
of	O
the	O
genotypes	O
in	O
subgroups	O
assigned	O
to	O
histological	O
grades	O
according	O
to	O
Scarf-Bloom-Richardson	O
criteria	O
and	O
the	O
distribution	O
predicted	O
by	O
Hardy-Weinberg	O
equilibrium	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Our	O
study	O
implies	O
that	O
the	O
G/C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
not	O
be	O
directly	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
breast	O
cancer	O
and	O
so	O
it	O
may	O
not	O
be	O
useful	O
as	O
an	O
independent	O
marker	O
in	O
this	O
disease	O
.	O

Mutation	O
analysis	O
of	O
DMBT1	O
in	O
glioblastoma	O
,	O
medulloblastoma	O
and	O
oligodendroglial	O
tumors	O
.	O

DMBT1	O
has	O
been	O
implicated	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
10q	O
for	O
brain	O
,	O
gastrointestinal	O
and	O
lung	O
cancer	O
.	O

Homozygous	O
deletion	O
and	O
lack	O
of	O
expression	O
are	O
2	O
known	O
mechanisms	O
for	O
inactivating	O
DMBT1	O
.	O

We	O
evaluated	O
whether	O
somatic	O
mutation	O
,	O
which	O
represents	O
a	O
major	O
inactivation	O
mechanism	O
for	O
most	O
tumor	O
suppressor	O
genes	O
,	O
occurs	O
in	O
the	O
DMBT1	O
gene	O
.	O

A	O
total	O
of	O
102	O
primary	O
brain	O
tumors	O
,	O
consisting	O
of	O
25	O
glioblastoma	O
multiforme	O
,	O
24	O
medulloblastoma	O
and	O
53	O
oligodendroglial	O
tumors	O
,	O
were	O
analyzed	O
by	O
conformation-sensitive	O
gel	O
electrophoresis	O
in	O
all	O
54	O
coding	O
exons	O
of	O
DMBT1	O
.	O

Twelve	O
different	O
base	O
substitutions	O
were	O
detected	O
in	O
26	O
(25%)	O
tumors	O
.	O

Eight	O
base	O
substitutions	O
resulted	O
in	O
amino	O
acid	O
changes	O
and	O
4	O
were	O
silent	O
.	O

These	O
base	O
changes	O
were	O
also	O
detected	O
in	O
tumor-matched	O
blood	O
samples	O
,	O
however	O
,	O
indicating	O
that	O
the	O
base	O
variations	O
represent	O
genetic	O
polymorphisms	O
.	O

We	O
also	O
assessed	O
homozygous	O
deletions	O
of	O
the	O
DMBT1	O
gene	O
in	O
the	O
series	O
and	O
found	O
that	O
16	O
of	O
95	O
(	O
5	O
glioblastomas	O
,	O
5	O
medulloblastomas	O
,	O
6	O
oligodendroglial	O
tumors	O
;	O
total	O
17%	O
)	O
tumors	O
harbor	O
such	O
alteration	O
.	O

High-quality	O
blood	O
DNA	O
samples	O
were	O
available	O
in	O
5	O
tumors	O
carrying	O
homozygous	O
deletion	O
and	O
,	O
using	O
long-range	O
PCR	O
,	O
3	O
of	O
these	O
blood	O
samples	O
showed	O
germline	O
hemizygous	O
deletions	O
in	O
a	O
region	O
between	O
introns	O
10	O
and	O
26	O
of	O
DMBT1	O
.	O

Our	O
results	O
showed	O
that	O
mutation	O
does	O
not	O
play	O
a	O
role	O
in	O
inactivation	O
of	O
DMBT1	O
in	O
brain	O
tumors	O
.	O

Intragenic	O
homozygous	O
deletion	O
of	O
DMBT1	O
is	O
common	O
in	O
brain	O
tumors	O
and	O
is	O
likely	O
a	O
result	O
of	O
a	O
germline	O
deletion	O
of	O
1	O
allele	O
followed	O
by	O
loss	O
of	O
the	O
second	O
allele	O
during	O
tumor	O
development	O
.	O

Relation	O
of	O
shyness	O
in	O
grade	O
school	O
children	O
to	O
the	O
genotype	O
for	O
the	O
long	O
form	O
of	O
the	O
serotonin	O
transporter	O
promoter	O
region	O
polymorphism	O
.	O

OBJECTIVE	O
:	O
Studies	O
have	O
shown	O
that	O
genetic	O
factors	O
are	O
significant	O
in	O
predisposing	O
individuals	O
to	O
shyness	O
and	O
social	O
phobia	O
.	O

Toward	O
further	O
elucidating	O
the	O
genetic	O
structure	O
of	O
shyness	O
,	O
the	O
authors	O
examined	O
four	O
functional	O
polymorphisms	O
that	O
make	O
biological	O
sense	O
for	O
contributing	O
to	O
the	O
development	O
of	O
this	O
phenotype	O
:	O
serotonin	O
transporter	O
promoter	O
region	O
44	O
base	O
pair	O
insertion/deletion	O
(5-HTTLPR)	O
,	O
dopamine	O
D(4)	O
receptor	O
exon	O
III	O
repeat	O
(DRD4)	O
,	O
catechol	O
O-methyltransferase	O
(COMT)	O
,	O
and	O
monoamine	O
oxidase	O
A	O
promoter	O
region	O
repeat	O
(MAO(A))	O
.	O

METHOD	O
:	O
The	O
authors	O
assessed	O
shyness	O
after	O
recruitment	O
of	O
a	O
nonclinical	O
sample	O
(	O
N=118	O
,	O
unscreened	O
second-grade	O
children	O
)	O
using	O
a	O
composite	O
scale	O
derived	O
from	O
questionnaires	O
administered	O
to	O
the	O
children	O
,	O
parents	O
,	O
and	O
teachers	O
.	O

DNA	O
from	O
buccal	O
smears	O
successfully	O
obtained	O
from	O
98	O
children	O
was	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
methods	O
for	O
the	O
5-HTTLPR	O
,	O
DRD4	O
,	O
COMT	O
,	O
and	O
MAO(A)	O
polymorphisms	O
.	O

RESULTS	O
:	O
Significant	O
correlations	O
were	O
observed	O
for	O
parents'	O
,	O
teachers'	O
,	O
and	O
children's	O
ratings	O
of	O
shyness	O
,	O
and	O
Cronbach's	O
alpha	O
reliability	O
was	O
high	O
for	O
all	O
three	O
scales	O
.	O

A	O
significant	O
association	O
was	O
observed	O
between	O
the	O
long	O
5-HTTLPR	O
polymorphism	O
and	O
shyness	O
,	O
both	O
by	O
the	O
functional	O
classification	O
of	O
Lesch	O
as	O
well	O
as	O
by	O
consideration	O
of	O
all	O
three	O
genotypes	O
.	O

No	O
significant	O
association	O
was	O
observed	O
for	O
the	O
DRD4	O
,	O
COMT	O
,	O
or	O
MAO(A)	O
polymorphisms	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provisionally	O
identifies	O
a	O
common	O
genetic	O
polymorphism	O
,	O
5-HTTLPR	O
,	O
that	O
modestly	O
(	O
effect	O
size=7%	O
)	O
contributed	O
to	O
greater	O
shyness	O
scores	O
in	O
a	O
nonclinical	O
group	O
of	O
second-grade	O
students	O
.	O

These	O
first	O
findings	O
may	O
be	O
relevant	O
to	O
previous	O
reports	O
that	O
have	O
shown	O
an	O
association	O
between	O
the	O
5-HTTLPR	O
long	O
form	O
and	O
obsessive-compulsive	O
disorder	O
and	O
autism	O
.	O

Restricted	O
genetic	O
defects	O
underlie	O
human	O
complement	O
C6	O
deficiency	O
.	O

Complement	O
C6	O
homozygous	O
deficiency	O
(C6D)	O
has	O
been	O
rarely	O
observed	O
in	O
Caucasians	O
but	O
was	O
reported	O
at	O
higher	O
prevalence	O
among	O
African-Americans	O
.	O

We	O
report	O
on	O
the	O
molecular	O
basis	O
of	O
C6D	O
in	O
seven	O
unrelated	O
black	O
individuals	O
of	O
North	O
or	O
Central	O
Africa	O
descent	O
who	O
live	O
in	O
France	O
.	O

These	O
patients	O
have	O
presented	O
Neisseria	O
meningitidis	O
infection	O
(	O
four	O
cases	O
)	O
,	O
focal	O
and	O
segmental	O
glomerulosclerosis	O
with	O
hyalinosis	O
(	O
one	O
case	O
)	O
,	O
systemic	O
lupus	O
erythematosus	O
(	O
one	O
case	O
)	O
or	O
Still's	O
disease	O
(	O
one	O
case	O
)	O
.	O

All	O
patients	O
exhibited	O
undetectable	O
antigenic	O
C6	O
by	O
using	O
a	O
sensitive	O
ELISA	O
assay	O
.	O

An	O
additional	O
four	O
cases	O
of	O
complete	O
C6	O
deficiency	O
with	O
no	O
associated	O
disease	O
have	O
been	O
characterized	O
after	O
family	O
studies	O
.	O

Exons	O
6	O
,	O
7	O
and	O
12	O
have	O
been	O
described	O
recently	O
as	O
the	O
location	O
of	O
molecular	O
defects	O
on	O
the	O
C6	O
gene	O
in	O
randomly	O
chosen	O
black	O
Americans	O
.	O

Genomic	O
DNA	O
from	O
the	O
seven	O
patients	O
were	O
subjected	O
to	O
direct	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
three	O
exons	O
.	O

Nucleotide	O
sequencing	O
analysis	O
of	O
the	O
amplified	O
DNA	O
fragments	O
revealed	O
a	O
homozygous	O
single-base	O
deletion	O
1936delG	B-DNAMutation
in	O
exon	O
12	O
in	O
three	O
cases	O
and	O
four	O
compound	O
heterozygous	O
deletions	O
for	O
a	O
single	O
base	O
in	O
exon	O
7	O
1195delC	B-DNAMutation
or	O
in	O
exon	O
6	O
878delA	B-DNAMutation
associated	O
with	O
the	O
same	O
deletion	O
in	O
exon	O
12	O
1936delG	B-DNAMutation
.	O

Our	O
observations	O
further	O
establish	O
the	O
restricted	O
pattern	O
of	O
genetic	O
defects	O
associated	O
with	O
homozygous	O
C6	O
complement	O
deficiency	O
in	O
individuals	O
of	O
African	O
descent	O
.	O

A	O
novel	O
DFNB31	O
mutation	O
associated	O
with	O
Usher	O
type	O
2	O
syndrome	O
showing	O
variable	O
degrees	O
of	O
auditory	O
loss	O
in	O
a	O
consanguineous	O
Portuguese	O
family	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
defect	O
of	O
a	O
consanguineous	O
Portuguese	O
family	O
with	O
rod-cone	O
dystrophy	O
and	O
varying	O
degrees	O
of	O
decreased	O
audition	O
.	O

METHODS	O
:	O
A	O
detailed	O
ophthalmic	O
and	O
auditory	O
examination	O
was	O
performed	O
on	O
a	O
Portuguese	O
patient	O
with	O
severe	O
autosomal	O
recessive	O
rod-cone	O
dystrophy	O
.	O

Known	O
genetic	O
defects	O
were	O
excluded	O
by	O
performing	O
autosomal	O
recessive	O
retinitis	O
pigmentosa	O
(arRP)	O
genotyping	O
microarray	O
analysis	O
and	O
by	O
Sanger	O
sequencing	O
of	O
the	O
coding	O
exons	O
and	O
flanking	O
intronic	O
regions	O
of	O
eyes	O
shut	O
homolog-drosophila	O
(EYS)	O
and	O
chromosome	O
2	O
open	O
reading	O
frame	O
71	O
(C2orf71)	O
.	O

Subsequently	O
,	O
genome-wide	O
homozygosity	O
mapping	O
was	O
performed	O
in	O
DNA	O
samples	O
from	O
available	O
family	O
members	O
using	O
a	O
700K	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
microarray	O
.	O

Candidate	O
genes	O
present	O
in	O
the	O
significantly	O
large	O
homozygous	O
regions	O
were	O
screened	O
for	O
mutations	O
using	O
Sanger	O
sequencing	O
.	O

RESULTS	O
:	O
The	O
largest	O
homozygous	O
region	O
(	O
~11	O
Mb	O
)	O
in	O
the	O
affected	O
family	O
members	O
was	O
mapped	O
to	O
chromosome	O
9	O
,	O
which	O
harbors	O
deafness	O
,	O
autosomal	O
recessive	O
31	O
(	O
DFNB31	O
;	O
a	O
gene	O
previously	O
associated	O
with	O
Usher	O
syndrome	O
)	O
.	O

Mutation	O
analysis	O
of	O
DFNB31	O
in	O
the	O
index	O
patient	O
identified	O
a	O
novel	O
one-base-pair	O
deletion	O
c.737delC	B-DNAMutation
,	O
which	O
is	O
predicted	O
to	O
lead	O
to	O
a	O
truncated	O
protein	O
p.Pro246HisfsX13	B-ProteinMutation
and	O
co-segregated	O
with	O
the	O
disease	O
in	O
the	O
family	O
.	O

Ophthalmic	O
examination	O
of	O
the	O
index	O
patient	O
and	O
the	O
affected	O
siblings	O
showed	O
severe	O
rod-cone	O
dystrophy	O
.	O

Pure	O
tone	O
audiometry	O
revealed	O
a	O
moderate	O
hearing	O
loss	O
in	O
the	O
index	O
patient	O
,	O
whereas	O
the	O
affected	O
siblings	O
were	O
reported	O
with	O
more	O
profound	O
and	O
early	O
onset	O
hearing	O
impairment	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
a	O
novel	O
truncating	O
mutation	O
in	O
DFNB31	O
associated	O
with	O
severe	O
rod-cone	O
dystrophy	O
and	O
varying	O
degrees	O
of	O
hearing	O
impairment	O
in	O
a	O
consanguineous	O
family	O
of	O
Portuguese	O
origin	O
.	O

This	O
is	O
the	O
second	O
report	O
of	O
DFNB31	O
implication	O
in	O
Usher	O
type	O
2	O
.	O

Variation	O
in	O
the	O
CXCR1	O
gene	O
(IL8RA)	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
chronic	O
periodontitis	O
.	O

BACKGROUND	O
:	O
The	O
chemokine	O
receptor	O
1	O
CXCR-1	O
(	O
or	O
IL8R-alpha	O
)	O
is	O
a	O
specific	O
receptor	O
for	O
the	O
interleukin	O
8	O
(IL-8)	O
,	O
which	O
is	O
chemoattractant	O
for	O
neutrophils	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
response	O
.	O

The	O
polymorphism	O
rs2234671	B-SNP
at	O
position	O
Ex2+860G>C	B-DNAMutation
of	O
the	O
CXCR1	O
gene	O
causes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
S276T	B-ProteinMutation
.	O

This	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
seemed	O
to	O
be	O
functional	O
as	O
it	O
was	O
associated	O
with	O
decreased	O
lung	O
cancer	O
risk	O
.	O

Previous	O
studies	O
of	O
our	O
group	O
found	O
association	O
of	O
haplotypes	O
in	O
the	O
IL8	O
and	O
in	O
the	O
CXCR2	O
genes	O
with	O
the	O
multifactorial	O
disease	O
chronic	O
periodontitis	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
polymorphism	O
rs2234671	B-SNP
in	O
395	O
Brazilian	O
subjects	O
with	O
and	O
without	O
chronic	O
periodontitis	O
.	O

FINDINGS	O
:	O
Similar	O
distribution	O
of	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
observed	O
between	O
the	O
groups	O
(p>0.05)	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphism	O
rs2234671	B-SNP
in	O
the	O
CXCR1	O
gene	O
was	O
not	O
associated	O
with	O
the	O
susceptibility	O
to	O
chronic	O
periodontitis	O
in	O
the	O
studied	O
Brazilian	O
population	O
.	O

A	O
case	O
of	O
Werner	O
syndrome	O
without	O
metabolic	O
abnormality	O
:	O
implications	O
for	O
the	O
early	O
pathophysiology	O
.	O

Werner	O
syndrome	O
(WS)	O
is	O
an	O
autosomal	O
recessive	O
progeroid	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
WRN	O
DNA	O
helicase	O
.	O

It	O
is	O
characterized	O
by	O
the	O
graying	O
and	O
loss	O
of	O
hair	O
,	O
juvenile	O
cataracts	O
,	O
sclerosis	O
and	O
ulceration	O
of	O
skin	O
,	O
insulin-resistant	O
diabetes	O
mellitus	O
,	O
dyslipidemia	O
,	O
abdominal	O
adiposity	O
,	O
osteoporosis	O
,	O
atherosclerosis	O
,	O
and	O
malignant	O
neoplasm	O
.	O

Patients	O
are	O
usually	O
diagnosed	O
in	O
their	O
30s	O
or	O
40s	O
,	O
but	O
the	O
early	O
pathophysiology	O
of	O
the	O
syndrome	O
is	O
still	O
not	O
fully	O
understood	O
.	O

Here	O
we	O
report	O
a	O
29-year-old	O
female	O
patient	O
who	O
displayed	O
cataracts	O
,	O
hair	O
graying	O
,	O
and	O
tendinous	O
calcinosis	O
.	O

Her	O
parents	O
were	O
first	O
cousins	O
.	O

Interestingly	O
,	O
the	O
patient	O
lacked	O
the	O
metabolic	O
signs	O
typical	O
for	O
WS	O
,	O
including	O
glucose	O
intolerance	O
,	O
dyslipidemia	O
,	O
and	O
visceral	O
fat	O
accumulation	O
.	O

A	O
hyperinsulinemic	O
response	O
at	O
30	O
min	O
was	O
observed	O
in	O
an	O
oral	O
glucose	O
tolerance	O
test	O
.	O

Mutational	O
analysis	O
for	O
the	O
WRN	O
gene	O
revealed	O
a	O
homozygous	O
nucleotide	O
substitution	O
3190C>T	B-DNAMutation
in	O
exon	O
24	O
,	O
resulting	O
in	O
a	O
protein	O
product	O
with	O
replacement	O
of	O
an	O
arginine	O
residue	O
at	O
position	O
573	O
by	O
termination	O
codon	O
Arg987Ter	B-ProteinMutation
.	O

The	O
mutated	O
WRN	O
protein	O
was	O
unable	O
to	O
translocate	O
into	O
the	O
nucleus	O
in	O
an	O
in	O
vitro	O
cell	O
assay	O
.	O

A	O
WS	O
patient	O
with	O
an	O
Arg987Ter	B-ProteinMutation
mutation	O
has	O
been	O
previously	O
reported	O
in	O
Switzerland	O
,	O
the	O
present	O
case	O
is	O
the	O
first	O
to	O
be	O
identified	O
in	O
Asia	O
.	O

This	O
case	O
demonstrates	O
the	O
early	O
clinical	O
features	O
of	O
WS	O
and	O
suggests	O
that	O
metabolic	O
abnormality	O
,	O
including	O
insulin	O
resistance	O
,	O
is	O
not	O
an	O
essential	O
component	O
of	O
WS	O
at	O
disease	O
onset	O
.	O

Moreover	O
,	O
a	O
follow-up	O
study	O
of	O
such	O
case	O
would	O
be	O
useful	O
to	O
understand	O
how	O
the	O
various	O
clinical	O
symptoms	O
in	O
WS	O
develop	O
and	O
progress	O
over	O
the	O
years	O
.	O

Enhanced	O
replication	O
of	O
hepatitis	O
B	O
virus	O
with	O
frameshift	O
in	O
the	O
precore	O
region	O
found	O
in	O
fulminant	O
hepatitis	O
patients	O
.	O

BACKGROUND	O
:	O
The	O
genotype	O
B	O
of	O
hepatitis	O
B	O
virus	O
(HBV)	O
was	O
reported	O
to	O
associate	O
with	O
fulminant	O
hepatitis	O
(FH)	O
.	O

We	O
aimed	O
to	O
clarify	O
the	O
characteristics	O
of	O
HBV	O
obtained	O
from	O
FH	O
patients	O
in	O
an	O
area	O
of	O
Japan	O
where	O
genotype	O
B	O
HBV	O
is	O
prevalent	O
.	O

METHODS	O
:	O
Using	O
serum	O
samples	O
of	O
16	O
HBV-associated	O
FH	O
patients	O
,	O
partial	O
HBV	O
sequences	O
were	O
determined	O
.	O

The	O
effects	O
of	O
HBV	O
mutation/insertion/deletion	O
were	O
evaluated	O
using	O
an	O
in	O
vitro	O
HBV	O
replication	O
system	O
.	O

RESULTS	O
:	O
Of	O
the	O
16	O
HBV	O
isolates	O
,	O
31%	O
belonged	O
to	O
subgenotype	O
B1/Bj	O
,	O
38%	O
were	O
subgenotype	O
B2/Ba	O
,	O
and	O
31%	O
were	O
subgenotype	O
C2/Ce	O
.	O

Notably	O
,	O
the	O
single	O
nucleotide	O
insertion/deletion	O
that	O
resulted	O
in	O
a	O
frameshift	O
of	O
the	O
precore	O
protein	O
was	O
found	O
exclusively	O
in	O
60%	O
of	O
B1/Bj	O
strains	O
.	O

An	O
in	O
vitro	O
study	O
showed	O
that	O
all	O
of	O
the	O
frameshift	O
mutants	O
had	O
significantly	O
higher	O
amounts	O
of	O
HBV	O
DNA	O
than	O
did	O
the	O
wild	O
type	O
.	O

One	O
of	O
the	O
isolates	O
had	O
a	O
novel	O
insertion	O
of	O
A	O
between	O
nucleotides	O
1900	O
and	O
1901	O
,	O
which	O
resulted	O
in	O
a	O
3-nucleotide	O
change	O
within	O
the	O
Kozak	O
sequence	O
of	O
the	O
core	O
protein	O
and	O
enhanced	O
the	O
core	O
protein	O
expression	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
The	O
frameshift	O
insertion/deletion	O
in	O
the	O
precore	O
region	O
enhanced	O
HBV	O
replication	O
and	O
might	O
be	O
associated	O
with	O
the	O
development	O
of	O
FH	O
by	O
the	O
subgenotype	O
B1/Bj	O
HBV	O
.	O

A	O
complete	O
deficiency	O
of	O
Hyaluronoglucosaminidase	O
1	O
(HYAL1)	O
presenting	O
as	O
familial	O
juvenile	O
idiopathic	O
arthritis	O
.	O

We	O
describe	O
a	O
single	O
consanguineous	O
family	O
with	O
three	O
affected	O
children	O
exhibiting	O
knee	O
and/or	O
hip	O
pain	O
associated	O
with	O
swelling	O
.	O

Detailed	O
clinical	O
evaluation	O
demonstrated	O
diffuse	O
joint	O
involvement	O
with	O
an	O
unusual	O
proliferative	O
synovitis	O
on	O
MRI	O
.	O

Synovial	O
biopsies	O
were	O
notable	O
for	O
an	O
infiltration	O
of	O
macrophages	O
with	O
abundant	O
cytoplasm	O
filled	O
with	O
faintly	O
basophilic	O
vacuoles	O
.	O

We	O
used	O
homozygosity	O
mapping	O
with	O
a	O
panel	O
of	O
262,000	O
single	O
nucleotide	O
polymorphism	O
markers	O
to	O
identify	O
a	O
homozygous	O
stretch	O
of	O
40.52	O
	O
Mb	O
on	O
chromosome	O
3p22.3	O
-	O
3p13	O
that	O
segregated	O
with	O
the	O
arthropathy	O
in	O
the	O
family	O
.	O

Of	O
the	O
378	O
genes	O
in	O
the	O
interval	O
,	O
the	O
three	O
hyaluronoglucosaminidase	O
genes	O
were	O
considered	O
good	O
candidates	O
based	O
on	O
the	O
phenotype	O
.	O

Dideoxy	O
sequencing	O
identified	O
a	O
homozygous	O
deletion	O
in	O
HYAL1	O
,	O
c.104delT	B-DNAMutation
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
,	O
p.Val35AlafsX25	B-ProteinMutation
,	O
found	O
in	O
all	O
three	O
affected	O
children	O
.	O

Enzymatic	O
analysis	O
confirmed	O
total	O
HYAL1	O
deficiency	O
in	O
the	O
three	O
affected	O
children	O
.	O

This	O
confirms	O
the	O
diagnosis	O
of	O
Mucopolysaccharidosis	O
IX	O
(	O
MPS	O
IX	O
)	O
which	O
has	O
only	O
been	O
described	O
in	O
a	O
single	O
patient	O
to	O
date	O
.	O

In	O
contrast	O
to	O
the	O
previously	O
described	O
MPS	O
IX	O
patient	O
,	O
our	O
three	O
patients	O
display	O
a	O
phenotype	O
limited	O
to	O
the	O
joints	O
,	O
suggesting	O
that	O
this	O
is	O
the	O
primary	O
manifestation	O
of	O
HYAL1	O
deficiency	O
.	O

WT1	O
mutations	O
and	O
polymorphisms	O
in	O
Southeast	O
Asian	O
acute	O
myeloid	O
leukemia	O
.	O

Genomic	O
alterations	O
of	O
the	O
Wilms'	O
Tumor	O
1	O
(WT1)	O
gene	O
have	O
been	O
reported	O
to	O
occur	O
in	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(AML)	O
.	O

No	O
data	O
presently	O
exists	O
regarding	O
the	O
frequency	O
of	O
WT1	O
mutations	O
in	O
the	O
Southeast	O
Asian	O
AML	O
population	O
.	O

This	O
study	O
focused	O
on	O
WT1	O
exons	O
7-10	O
mutations	O
and	O
their	O
correlation	O
with	O
other	O
molecular	O
markers	O
and	O
patients'	O
characteristics	O
.	O

The	O
zinc	O
finger	O
domain	O
of	O
WT1	O
gene	O
covering	O
exons	O
7-10	O
was	O
directly	O
sequenced	O
.	O

Six	O
types	O
of	O
mutations	O
were	O
identified	O
among	O
49	O
cases	O
(12.24%)	O
;	O
4	O
localized	O
on	O
exon	O
7	O
and	O
2	O
on	O
exon	O
9	O
.	O

Two	O
novel	O
mutations	O
were	O
identified	O
including	O
the	O
insertion	O
within	O
codon	O
313	O
and	O
codon	O
314	O
.	O

Patients	O
harboring	O
WT1	O
mutations	O
seemed	O
to	O
have	O
a	O
younger	O
age	O
(	O
29.5	O
vs	O
45.4	O
years	O
)	O
,	O
a	O
higher	O
white	O
blood	O
cell	O
count	O
(	O
120.3	O
vs	O
19.8	O
10(9)/L	O
)	O
,	O
and	O
a	O
lower	O
platelet	O
count	O
(	O
54.2	O
vs	O
104.3	O
10(9)/L	O
)	O
as	O
compared	O
to	O
those	O
without	O
the	O
mutations	O
although	O
statistical	O
differences	O
could	O
not	O
be	O
demonstrated	O
.	O

All	O
exon	O
7	O
mutations	O
were	O
frameshift	O
mutations	O
and	O
had	O
NRAS	O
mutation	O
while	O
exon	O
9	O
mutations	O
were	O
base	O
substitutions	O
and	O
had	O
FLT3-ITD	O
mutation	O
.	O

Interestingly	O
,	O
the	O
major	O
allele	O
for	O
rs16754	B-SNP
single	O
nucleotide	O
polymorphism	O
was	O
G	O
(	O
25-homozygous	O
and	O
6-heterozygous	O
)	O
which	O
was	O
in	O
contrast	O
to	O
A	O
in	O
the	O
Western	O
reports	O
.	O

The	O
frequency	O
of	O
WT1	O
mutation	O
in	O
the	O
Southeast	O
Asian	O
AML	O
was	O
thus	O
comparable	O
to	O
the	O
figures	O
reported	O
from	O
the	O
West	O
although	O
the	O
designated	O
major	O
allele	O
for	O
rs16754	B-SNP
polymorphism	O
was	O
different	O
.	O

A	O
recurrent	O
missense	O
mutation	O
in	O
GJA3	O
associated	O
with	O
autosomal	O
dominant	O
cataract	O
linked	O
to	O
chromosome	O
13q	O
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	O
the	O
genetic	O
defect	O
underlying	O
autosomal	O
dominant	O
cataract	O
segregating	O
in	O
a	O
5-generation	O
Caucasian	O
American	O
family	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
prepared	O
from	O
blood	O
leukocytes	O
,	O
genotyping	O
was	O
performed	O
using	O
microsatellite	O
markers	O
,	O
and	O
logarithm	O
of	O
the	O
odds	O
(LOD)	O
scores	O
were	O
calculated	O
using	O
the	O
LINKAGE	O
programs	O
.	O

Mutation	O
profiling	O
was	O
performed	O
using	O
direct	O
exon	O
cycle-sequencing	O
and	O
restriction	O
fragment	O
analysis	O
.	O

Protein	O
function	O
effects	O
were	O
evaluated	O
using	O
in	O
silico	O
prediction	O
algorithms	O
.	O

RESULTS	O
:	O
Significant	O
evidence	O
of	O
linkage	O
was	O
obtained	O
at	O
marker	O
D13S175	O
(	O
maximum	O
LOD	O
score	O
[Z(max)]=3.67	O
;	O
maximum	O
recombination	O
fraction	O
[	O
	O
(	O
max)]=0.04	O
)	O
and	O
D13S1316	O
(	O
Z(max)=2.80	O
,	O
	O
	O
(	O
max)=0.0	O
)	O
.	O

Haplotyping	O
indicated	O
that	O
the	O
disease	O
lay	O
in	O
the	O
~170	O
Kb	O
physical	O
interval	O
between	O
D13S1316	O
and	O
D13S175	O
,	O
which	O
contained	O
the	O
gene	O
for	O
gap-junction	O
protein	O
alpha-3	O
(GJA3)	O
or	O
connexin-46	O
.	O

Sequencing	O
of	O
GJA3	O
detected	O
a	O
heterozygous	O
transition	O
c.130G>A	B-DNAMutation
in	O
exon-2	O
that	O
resulted	O
in	O
gain	O
of	O
an	O
Hsp92	O
II	O
restriction	O
site	O
.	O

Allele-specific	O
PCR	O
amplification	O
and	O
restriction	O
analysis	O
confirmed	O
that	O
the	O
novel	O
Hsp92	O
II	O
site	O
co-segregated	O
with	O
cataract	O
in	O
the	O
family	O
but	O
was	O
not	O
detected	O
in	O
192	O
normal	O
unrelated	O
individuals	O
.	O

The	O
c.130G>A	B-DNAMutation
transition	O
was	O
predicted	O
to	O
result	O
in	O
a	O
non-conservative	O
substitution	O
of	O
valine-to-methionine	O
at	O
codon	O
44	O
p.V44M	B-ProteinMutation
with	O
damaging	O
effects	O
on	O
protein	O
function	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
confirm	O
GJA3	O
as	O
one	O
of	O
the	O
most	O
frequently	O
mutated	O
genes	O
that	O
underlie	O
autosomal	O
dominant	O
cataract	O
in	O
humans	O
,	O
and	O
further	O
emphasize	O
the	O
importance	O
of	O
connexin	O
function	O
in	O
maintaining	O
lens	O
transparency	O
.	O

Plasminogen	O
activator	O
inhibitor	O
type	O
1	O
serum	O
levels	O
and	O
4G/5G	O
gene	O
polymorphism	O
in	O
morbidly	O
obese	O
Hispanic	O
patients	O
with	O
non-alcoholic	O
fatty	O
liver	O
disease	O
.	O

BACKGROUND	O
:	O
The	O
plasminogen	O
activator	O
inhibitor	O
type-1	O
(PAI-1)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
fibrinolysis	O
and	O
extracellular	O
matrix	O
components	O
.	O

The	O
single	O
base	O
pair	O
guanine	O
insertion/deletion	O
polymorphism	O
(4G/5G)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
PAI-1	O
gene	O
influences	O
PAI-1	O
synthesis	O
and	O
may	O
modulate	O
hepatic	O
fibrogenesis	O
.	O

AIM	O
:	O
To	O
evaluate	O
the	O
influence	O
of	O
PAI-1	O
serum	O
levels	O
and	O
4G/5G	O
polymorphism	O
on	O
the	O
risk	O
of	O
liver	O
fibrosis	O
associated	O
to	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(NAFLD)	O
in	O
morbidly	O
obese	O
patients	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Case-control	O
study	O
of	O
50	O
obese	O
patients	O
undergoing	O
bariatric	O
surgery	O
and	O
71	O
non-obese	O
subjects	O
matched	O
by	O
age	O
and	O
sex	O
.	O

Anthropometric	O
and	O
biochemical	O
measurements	O
were	O
performed	O
,	O
including	O
PAI-1	O
serum	O
levels	O
.	O

Genomic	O
DNA	O
was	O
obtained	O
to	O
assess	O
the	O
presence	O
of	O
4G/5G	O
polymorphism	O
.	O

RESULTS	O
:	O
BMI	O
,	O
insulinemia	O
,	O
triglycerides	O
,	O
HOMA-IR	O
,	O
hypertension	O
and	O
diabetes	O
were	O
significantly	O
higher	O
in	O
obese	O
patients	O
compared	O
to	O
control	O
subjects	O
.	O

PAI-1	O
serum	O
levels	O
observed	O
in	O
obese	O
patients	O
were	O
significantly	O
lower	O
(	O
10.63	O
	O
	O
	O
4.82	O
)	O
compared	O
to	O
controls	O
(	O
14.26	O
	O
	O
	O
11.4	O
;	O
p	O
<	O
0.05	O
)	O
.	O

No	O
differences	O
were	O
observed	O
in	O
the	O
PAI-1	O
4G/5G	O
promoter	O
genotypes	O
frequencies	O
(	O
p	O
=	O
0.12	O
)	O
.	O

No	O
differences	O
were	O
observed	O
in	O
PAI-1	O
plasma	O
levels	O
among	O
obese	O
patients	O
with	O
liver	O
fibrosis	O
(	O
10.64	O
	O
	O
	O
4.35	O
)	O
compared	O
to	O
patients	O
without	O
liver	O
fibrosis	O
(	O
10.61	O
	O
	O
	O
5.2	O
;	O
p	O
=	O
0.985	O
)	O
.	O

PAI-1	O
4G/5G	O
promoter	O
genotypes	O
frequencies	O
were	O
similar	O
in	O
patients	O
with	O
or	O
without	O
liver	O
fibrosis	O
associated	O
to	O
NASH	O
(	O
p	O
=	O
0.6	O
)	O
.	O

CONCLUSIONS	O
:	O
Morbidly	O
obese	O
patients	O
had	O
significantly	O
lower	O
PAI-1	O
serum	O
levels	O
with	O
similar	O
PAI-1	O
4G/5G	O
genotypes	O
frequencies	O
compared	O
to	O
non-obese	O
subjects	O
.	O

The	O
frequency	O
of	O
4G/5G	O
genotypes	O
in	O
Chilean	O
Hispanic	O
healthy	O
subjects	O
was	O
similar	O
to	O
that	O
described	O
in	O
other	O
populations	O
.	O

No	O
association	O
was	O
found	O
between	O
PAI-1	O
serum	O
levels	O
or	O
4G/5G	O
genotype	O
with	O
liver	O
fibrosis	O
in	O
obese	O
patients	O
.	O

A	O
13-bp	O
deletion	O
in	O
the	O
3'	O
untranslated	O
region	O
of	O
the	O
b-globin	O
gene	O
causes	O
b-thalassemia	O
major	O
in	O
compound	O
heterozygosity	O
with	O
IVSII-1	O
mutation	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
hematological	O
and	O
molecular	O
features	O
of	O
a	O
13-bp	O
deletion	O
in	O
the	O
3'	O
untranslated	O
region(3'	O
UTR	O
)	O
of	O
the	O
b-globin	O
gene	O
in	O
carrier	O
individuals	O
and	O
a	O
compound	O
heterozygous	O
patient	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
Five	O
members	O
of	O
an	O
Iranian	O
family	O
of	O
Persian	O
ethnic	O
origin	O
were	O
studied	O
.	O

Red	O
blood	O
cell	O
indices	O
and	O
hemoglobin	O
analysis	O
were	O
carried	O
out	O
according	O
to	O
standard	O
methods	O
.	O

Genomic	O
DNA	O
was	O
obtained	O
from	O
peripheral	O
blood	O
cells	O
by	O
salting-out	O
procedures	O
.	O

b-Globin	O
gene	O
amplification	O
and	O
DNA	O
sequencing	O
were	O
performed	O
.	O

RESULTS	O
:	O
One	O
patient	O
had	O
a	O
13-bp	O
deletion	O
in	O
the	O
3'	O
UTR	O
of	O
the	O
b-globin	O
gene	O
that	O
causes	O
the	O
b-thalassemia	O
phenotype	O
in	O
combination	O
with	O
the	O
IVSII-1	B-DNAMutation
(	I-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	I-DNAMutation
mutation	O
.	O

The	O
patient	O
had	O
inherited	O
the	O
IVSII-1	B-DNAMutation
(	I-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	I-DNAMutation
mutation	O
from	O
his	O
mother	O
,	O
while	O
the	O
second	O
b-globin	O
gene	O
(	O
inherited	O
paternally	O
)	O
had	O
a	O
13-bp	O
deletion	O
at	O
nucleotide	O
90	O
downstream	O
of	O
the	O
termination	O
codon	O
(	O
CD	B-DNAMutation
+90	I-DNAMutation
del	I-DNAMutation
13	I-DNAMutation
bp	I-DNAMutation
)	O
.	O

The	O
patient's	O
father	O
and	O
paternal	O
grandmother	O
,	O
who	O
are	O
carriers	O
of	O
this	O
deletion	O
,	O
had	O
no	O
hematological	O
abnormalities	O
.	O

CONCLUSION	O
:	O
This	O
case	O
showed	O
a	O
patient	O
with	O
a	O
13-bp	O
deletion	O
in	O
the	O
3'	O
UTR	O
of	O
b-globin	O
gene	O
that	O
could	O
cause	O
a	O
slight	O
decrease	O
in	O
the	O
stability	O
of	O
the	O
mRNA	O
,	O
but	O
did	O
not	O
have	O
a	O
hematological	O
effect	O
in	O
the	O
heterozygotes	O
.	O

The	O
13-bp	O
deletion	O
could	O
be	O
clinically	O
important	O
only	O
in	O
situations	O
where	O
b-chain	O
synthesis	O
in	O
trans	O
is	O
compromised	O
.	O

The	O
Arabic	O
allele	O
:	O
a	O
single	O
base	O
pair	O
substitution	O
activates	O
a	O
10-base	O
downstream	O
cryptic	O
splice	O
acceptor	O
site	O
in	O
exon	O
12	O
of	O
LDLR	O
and	O
severely	O
decreases	O
LDLR	O
expression	O
in	O
two	O
unrelated	O
Arab	O
families	O
with	O
familial	O
hypercholesterolemia	O
.	O

Familial	O
hypercholesterolemia	O
(FH)	O
is	O
a	O
monogenic	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
defects	O
in	O
LDLR	O
.	O

Few	O
reports	O
describe	O
FH	O
mutations	O
among	O
Arabs	O
.	O

We	O
describe	O
a	O
mutation	O
in	O
LDLR	O
of	O
two	O
unrelated	O
Arab	O
families	O
.	O

We	O
investigated	O
19	O
patients	O
using	O
DNA	O
sequencing	O
,	O
RFLP	O
,	O
and	O
real-time	O
(RT)	O
PCR	O
.	O

DNA	O
sequencing	O
showed	O
a	O
base	O
pair	O
substitution	O
(	O
c.1706-2	B-DNAMutation
A>T	I-DNAMutation
)	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
LDLR	O
intron	O
11	O
.	O

Our	O
results	O
were	O
confirmed	O
by	O
RFLP	O
on	O
2%	O
agarose	O
gel	O
.	O

In	O
silico	O
analysis	O
predicted	O
a	O
new	O
cryptic	O
splice	O
site	O
downstream	O
of	O
the	O
original	O
position	O
generating	O
a	O
10-base	O
deletion	O
from	O
the	O
beginning	O
of	O
exon	O
12	O
;	O
c.1706-1715del.ATCTCCTCAG	B-DNAMutation
.	O

cDNA	O
sequencing	O
of	O
exon	O
12	O
confirmed	O
the	O
computational	O
analysis	O
.	O

The	O
deletion	O
was	O
visualized	O
on	O
4%	O
agarose	O
gel	O
.	O

The	O
deletion	O
generates	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(	O
c.1991-1993	O
;	O
p.(Asp569Valfs*93)	B-ProteinMutation
.	O

RT-PCR	O
revealed	O
that	O
LDLR	O
mRNA	O
is	O
9.3%	O
	O
6.5	O
and	O
17.9%	O
	O
8.0	O
for	O
FH	O
homozygote	O
and	O
heterozygote	O
individuals	O
respectively	O
,	O
compared	O
to	O
a	O
healthy	O
family	O
control	O
.	O

We	O
predict	O
a	O
class	O
II	O
LDLR	O
mutation	O
that	O
leads	O
to	O
a	O
truncated	O
receptor	O
missing	O
exons	O
14-18	O
.	O

We	O
called	O
this	O
mutation	O
"the	O
Arabic	O
allele"	O
.	O

We	O
expect	O
a	O
significant	O
contribution	O
of	O
this	O
mutation	O
to	O
the	O
prevalence	O
of	O
FH	O
among	O
Arabs	O
.	O

Also	O
,	O
we	O
propose	O
that	O
the	O
severe	O
down	O
regulation	O
of	O
LDLR	O
mRNA	O
expression	O
is	O
due	O
to	O
nonsense-mediated-decay	O
.	O

XRCC1	O
Arg399Gln	B-ProteinMutation
gene	O
polymorphism	O
and	O
the	O
risk	O
of	O
systemic	O
lupus	O
erythematosus	O
in	O
the	O
Polish	O
population	O
.	O

It	O
has	O
been	O
shown	O
that	O
DNA	O
repair	O
is	O
reduced	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
and	O
that	O
the	O
X-ray	O
repair	O
cross-complementing	O
(XRCC1)	O
Arg399Gln	B-ProteinMutation
rs25487	B-SNP
polymorphism	O
may	O
contribute	O
to	O
DNA	O
repair	O
.	O

We	O
evaluated	O
the	O
frequency	O
of	O
the	O
XRCC1	O
Arg399Gln	B-ProteinMutation
substitution	O
in	O
patients	O
with	O
SLE	O
(n=265)	O
and	O
controls	O
(n=360)	O
in	O
a	O
sample	O
of	O
the	O
Polish	O
population	O
.	O

The	O
odds	O
ratio	O
(OR)	O
for	O
SLE	O
patients	O
with	O
the	O
Gln/Gln	O
versus	O
Gln/Arg	O
or	O
Arg/Arg	O
genotypes	O
was	O
1.553	O
(	O
95%	O
confidence	O
interval	O
[CI]=0.9573-2.520	O
;	O
p=0.0729	O
)	O
.	O

OR	O
for	O
the	O
Gln/Gln	O
or	O
Gln/Arg	O
versus	O
Arg/Arg	O
genotype	O
was	O
1.551	O
(	O
95%	O
CI=1.122-2.144	O
,	O
p=0.0077	O
)	O
.	O

The	O
OR	O
for	O
the	O
399	O
Gln	O
allele	O
in	O
patients	O
with	O
SLE	O
was	O
1.406	O
(	O
95%	O
CI=1.111-1.779	O
,	O
p=0.0045	O
)	O
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
p-value	O
of	O
the	O
	O
	O
(2)	O
test	O
for	O
the	O
trend	O
observed	O
in	O
the	O
XRCC1	O
Arg399Gln	B-ProteinMutation
polymorphism	O
(ptrend=0.0048)	O
.	O

We	O
also	O
found	O
a	O
significant	O
contribution	O
of	O
the	O
Gln/Gln	O
or	O
Arg/Gln	O
versus	O
Arg/Arg	O
genotype	O
to	O
the	O
presence	O
of	O
either	O
the	O
malar	O
rash	O
or	O
photosensitivity	O
manifestations	O
of	O
SLE	O
OR=2.241	O
(	O
1.328-3.781	O
,	O
p=0.0023	O
,	O
pcorr=0.0414	O
)	O
.	O

Moreover	O
,	O
the	O
meta-analysis	O
of	O
Taiwanese	O
Han	O
Chinese	O
,	O
Brazilian	O
,	O
and	O
Polish	O
populations	O
showed	O
that	O
the	O
Gln/Gln	O
or	O
Gln/Arg	O
genotype	O
and	O
Gln	O
allele	O
were	O
associated	O
with	O
SLE	O
incidence	O
.	O

OR	O
for	O
the	O
Gln/Gln	O
or	O
Gln/Arg	O
versus	O
Arg/Arg	O
genotype	O
was	O
1.440	O
(	O
95%	O
CI=1.15-1.80	O
,	O
p=0.0019	O
)	O
and	O
OR	O
for	O
the	O
Gln	O
allele	O
was	O
1.27	O
(	O
95%	O
CI=1.08-1.51	O
,	O
p=0.0051	O
)	O
.	O

Our	O
studies	O
may	O
confirm	O
that	O
the	O
XRCC1	O
Arg399Gln	B-ProteinMutation
polymorphism	O
may	O
increase	O
the	O
risk	O
of	O
incidence	O
of	O
SLE	O
and	O
the	O
occurrence	O
of	O
some	O
SLE	O
manifestations	O
.	O

Mutational	O
analysis	O
of	O
CYP2C8	O
in	O
hypertensive	O
patients	O
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

WHAT	O
IS	O
KNOWN	O
AND	O
OBJECTIVE	O
:	O
CYP2C8	O
is	O
involved	O
in	O
the	O
cytochrome	O
P450	O
(CYP)	O
epoxygenase	O
pathway	O
.	O

Arachidonic	O
acid	O
metabolites	O
such	O
as	O
epoxyeicosatrienenoic	O
acids	O
and	O
hydroxyeicosatetrenoic	O
acids	O
,	O
produced	O
may	O
have	O
a	O
role	O
in	O
hypertension	O
.	O

We	O
aimed	O
to	O
develop	O
a	O
medium	O
through-put	O
method	O
for	O
screening	O
samples	O
of	O
known	O
and	O
new	O
mutations	O
of	O
CYP2C8	O
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(DHPLC)	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
200	O
subjects	O
(	O
hypertensive	O
patients	O
and	O
healthy	O
controls	O
)	O
were	O
screened	O
for	O
SNPs	O
in	O
CYP2C8	O
using	O
DHPLC	O
.	O

Genotypes	O
and	O
allelic	O
frequencies	O
of	O
CYP2C8	O
between	O
the	O
healthy	O
controls	O
and	O
patients	O
with	O
hypertension	O
were	O
compared	O
.	O

RESULTS	O
AND	O
DISCUSSIONS	O
:	O
Six	O
variants	O
were	O
detected	O
and	O
two	O
were	O
new	O
;	O
T	O
deletion	O
at	O
5063	O
and	O
substitution	O
of	O
C	O
to	O
T	O
at	O
33468	O
in	O
exon	O
8	O
.	O

Differences	O
in	O
variant	O
frequencies	O
were	O
detected	O
between	O
the	O
controls	O
and	O
hypertensive	O
patients	O
.	O

The	O
controls	O
have	O
significantly	O
higher	O
prevalence	O
of	O
C35322C	O
compared	O
to	O
the	O
patients	O
.	O

The	O
functional	O
significance	O
of	O
the	O
SNP	O
at	O
35322	O
requires	O
further	O
study	O
.	O

Having	O
homozygous	O
C35322C	O
could	O
be	O
a	O
protective	O
factor	O
for	O
hypertension	O
.	O

WHAT	O
IS	O
NEW	O
AND	O
CONCLUSION	O
:	O
Denaturing	O
high	O
performance	O
liquid	O
chromatography	O
is	O
useful	O
for	O
population	O
screening	O
to	O
identify	O
new	O
and	O
existing	O
SNPs	O
.	O

A	O
higher	O
frequency	O
of	O
the	O
C35322T	O
SNP	O
was	O
observed	O
among	O
hypertensive	O
patients	O
than	O
control	O
subjects	O
.	O

This	O
potentially	O
important	O
observation	O
requires	O
confirmation	O
and	O
the	O
clinical	O
significance	O
assessed	O
.	O

High	O
frequency	O
of	O
lamivudine	O
resistance	O
mutations	O
in	O
Brazilian	O
patients	O
co-infected	O
with	O
HIV	O
and	O
hepatitis	O
B	O
.	O

This	O
study	O
analyzed	O
the	O
genotype	O
distribution	O
and	O
frequency	O
of	O
lamivudine	O
(LAM)	O
and	O
tenofovir	O
(TDF)	O
resistance	O
mutations	O
in	O
a	O
group	O
of	O
patients	O
co-infected	O
with	O
HIV	O
and	O
hepatitis	O
B	O
virus	O
(HBV)	O
.	O

A	O
cross-sectional	O
study	O
of	O
847	O
patients	O
with	O
HIV	O
was	O
conducted	O
.	O

Patients	O
provided	O
blood	O
samples	O
for	O
HBsAg	O
detection	O
.	O

The	O
load	O
of	O
HBV	O
was	O
determined	O
using	O
an	O
"in-house"	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

HBV	O
genotypes/subgenotypes	O
,	O
antiviral	O
resistance	O
,	O
basal	O
core	O
promoter	O
(BCP)	O
,	O
and	O
precore	O
mutations	O
were	O
detected	O
by	O
DNA	O
sequencing	O
.	O

Twenty-eight	O
patients	O
with	O
co-infection	O
were	O
identified	O
.	O

The	O
distribution	O
of	O
HBV	O
genotypes	O
among	O
these	O
patients	O
was	O
A	O
(	O
n	O
=	O
9	O
;	O
50%	O
)	O
,	O
D	O
(	O
n	O
=	O
4	O
;	O
22.2%	O
)	O
,	O
G	O
(	O
n	O
=	O
3	O
;	O
16.7%	O
)	O
,	O
and	O
F	O
(	O
n	O
=	O
2	O
;	O
11.1%	O
)	O
.	O

Eighteen	O
patients	O
were	O
treated	O
with	O
LAM	O
and	O
six	O
patients	O
were	O
treated	O
with	O
LAM	O
plus	O
TDF	O
.	O

The	O
length	O
of	O
exposure	O
to	O
LAM	O
and	O
TDF	O
varied	O
from	O
4	O
to	O
216	O
months	O
.	O

LAM	O
resistance	O
substitutions	O
(	O
rtL180M	B-ProteinMutation
+	O
rtM204V	B-ProteinMutation
)	O
were	O
detected	O
in	O
10	O
(50%)	O
of	O
the	O
20	O
patients	O
with	O
viremia	O
.	O

This	O
pattern	O
and	O
an	O
accompanying	O
rtV173L	B-ProteinMutation
mutation	O
was	O
found	O
in	O
four	O
patients	O
.	O

Three	O
patients	O
with	O
the	O
triple	O
polymerase	O
substitution	O
pattern	O
(	O
rtV173L	B-ProteinMutation
+	O
rtL180M	B-ProteinMutation
+	O
rtM204V	B-ProteinMutation
)	O
had	O
associated	O
changes	O
in	O
the	O
envelope	O
gene	O
(	O
sE164D	B-ProteinMutation
+	O
sI195M	B-ProteinMutation
)	O
.	O

Mutations	O
in	O
the	O
BCP	O
region	O
(	O
A1762T	B-DNAMutation
,	O
G1764A	B-DNAMutation
)	O
and	O
in	O
the	O
precore	O
region	O
(	O
G1896A	B-DNAMutation
,	O
G1899A	B-DNAMutation
)	O
were	O
also	O
found	O
.	O

No	O
putative	O
TDF	O
resistance	O
substitution	O
was	O
detected	O
.	O

The	O
data	O
suggest	O
that	O
prolonged	O
LAM	O
use	O
is	O
associated	O
with	O
the	O
emergence	O
of	O
particular	O
changes	O
in	O
the	O
HBV	O
genome	O
,	O
including	O
substitutions	O
that	O
may	O
elicit	O
a	O
vaccine	O
escape	O
phenotype	O
.	O

No	O
putative	O
TDF	O
resistance	O
change	O
was	O
detected	O
after	O
prolonged	O
use	O
of	O
TDF	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
connexin	O
26	O
gene	O
(GJB2)	O
in	O
a	O
child	O
with	O
clinical	O
and	O
histological	O
features	O
of	O
keratitis-ichthyosis-deafness	O
(KID)	O
syndrome	O
.	O

BACKGROUND	O
:	O
Keratitis-ichthyosis-deafness	O
(KID)	O
syndrome	O
is	O
a	O
rare	O
congenital	O
ectodermal	O
disorder	O
,	O
caused	O
by	O
heterozygous	O
missense	O
mutation	O
in	O
GJB2	O
,	O
encoding	O
the	O
gap	O
junction	O
protein	O
connexin	O
26	O
.	O

The	O
commonest	O
mutation	O
is	O
the	O
p.Asp50Asn	B-ProteinMutation
mutation	O
,	O
and	O
only	O
a	O
few	O
other	O
mutations	O
have	O
been	O
described	O
to	O
date	O
.	O

AIM	O
:	O
To	O
report	O
the	O
fatal	O
clinical	O
course	O
and	O
characterize	O
the	O
genetic	O
background	O
of	O
a	O
premature	O
male	O
neonate	O
with	O
the	O
clinical	O
and	O
histological	O
features	O
of	O
KID	O
syndrome	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
GJB2	O
gene	O
.	O

Direct	O
sequencing	O
was	O
used	O
for	O
mutation	O
analysis	O
.	O

RESULTS	O
:	O
The	O
clinical	O
features	O
included	O
hearing	O
impairment	O
,	O
ichthyosiform	O
erythroderma	O
with	O
hyperkeratotic	O
plaques	O
,	O
palmoplantar	O
keratoderma	O
,	O
alopecia	O
of	O
the	O
scalp	O
and	O
eyelashes	O
,	O
and	O
a	O
thick	O
vernix	O
caseosa-like	O
covering	O
of	O
the	O
scalp	O
.	O

On	O
histological	O
analysis	O
,	O
features	O
characteristic	O
of	O
KID	O
syndrome	O
,	O
such	O
as	O
acanthosis	O
and	O
papillomatosis	O
of	O
the	O
epidermis	O
with	O
basket-weave	O
hyperkeratosis	O
,	O
were	O
seen	O
.	O

The	O
skin	O
symptoms	O
were	O
treated	O
successfully	O
with	O
acitretin	O
0.5	O
mg/kg	O
.	O

The	O
boy	O
developed	O
intraventricular	O
and	O
intracerebral	O
haemorrhage	O
,	O
leading	O
to	O
hydrocephalus	O
.	O

His	O
condition	O
was	O
further	O
complicated	O
by	O
septicaemia	O
and	O
meningitis	O
caused	O
by	O
infection	O
with	O
extended-spectrum	O
beta-lactamase-producing	O
Klebsiella	O
pneumoniae	O
.	O

Severe	O
respiratory	O
failure	O
followed	O
,	O
and	O
the	O
child	O
died	O
at	O
46	O
weeks	O
of	O
gestational	O
age	O
(	O
13	O
weeks	O
postnatally	O
)	O
.	O

Sequencing	O
of	O
the	O
GJB2	O
gene	O
showed	O
that	O
the	O
child	O
was	O
heterozygous	O
for	O
a	O
novel	O
nucleotide	O
change	O
,	O
c.263C>T	B-DNAMutation
,	O
in	O
exon	O
2	O
,	O
leading	O
to	O
a	O
substitution	O
of	O
alanine	O
for	O
valine	O
at	O
position	O
88	O
p.Ala88Val	B-ProteinMutation
.	O

CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
a	O
new	O
heterozygous	O
de	O
novo	O
mutation	O
in	O
the	O
Cx26	O
gene	O
(	O
c.263C>T	B-DNAMutation
;	O
p.Ala88Val	B-ProteinMutation
)	O
leading	O
to	O
KID	O
syndrome	O
.	O

Analysis	O
of	O
a	O
SNP	O
linked	O
to	O
lactase	O
persistence	O
:	O
An	O
exercise	O
for	O
teaching	O
molecular	O
biology	O
techniques	O
to	O
undergraduates	O
.	O

Recent	O
experimental	O
evidence	O
indicates	O
that	O
the	O
ability	O
of	O
adults	O
to	O
tolerate	O
milk	O
,	O
cheese	O
,	O
and	O
other	O
lactose-containing	O
dairy	O
products	O
is	O
an	O
autosomal	O
dominant	O
trait	O
that	O
co-evolved	O
with	O
dairy	O
farming	O
in	O
Central	O
Europe	O
about	O
7,500	O
years	O
ago	O
.	O

Among	O
persons	O
of	O
European	O
descent	O
,	O
this	O
trait	O
is	O
strongly	O
associated	O
with	O
a	O
C	O
to	O
T	O
substitution	O
at	O
a	O
polymorphic	O
site	O
13,910	O
bp	O
upstream	O
of	O
the	O
lactase	O
gene	O
.	O

This	O
mutation	O
results	O
in	O
the	O
persistent	O
expression	O
of	O
lactase	O
into	O
adulthood	O
enabling	O
individuals	O
carrying	O
a	O
T(-13,910)	O
allele	O
to	O
digest	O
lactose	O
as	O
adults	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
laboratory	O
exercise	O
for	O
an	O
undergraduate	O
molecular	O
biology	O
course	O
in	O
which	O
students	O
determine	O
their	O
own	O
genotype	O
at	O
the	O
-13,910	O
polymorphic	O
site	O
and	O
correlate	O
this	O
with	O
their	O
ability	O
to	O
tolerate	O
dairy	O
products	O
.	O

The	O
exercise	O
is	O
used	O
as	O
a	O
tool	O
to	O
teach	O
basic	O
molecular	O
biology	O
procedures	O
such	O
as	O
agarose	O
gel	O
electrophoresis	O
,	O
PCR1	O
,	O
and	O
DNA	O
sequencing	O
.	O

Students	O
are	O
actively	O
engaged	O
in	O
the	O
learning	O
process	O
,	O
not	O
only	O
by	O
analyzing	O
their	O
own	O
DNA	O
but	O
also	O
by	O
applying	O
their	O
knowledge	O
and	O
skills	O
to	O
answer	O
an	O
authentic	O
question	O
.	O

The	O
exercise	O
is	O
also	O
integrated	O
with	O
lecture	O
material	O
on	O
the	O
control	O
of	O
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
in	O
particular	O
,	O
how	O
transcription	O
factors	O
can	O
influence	O
the	O
activity	O
of	O
a	O
promoter	O
by	O
binding	O
to	O
cis-acting	O
DNA	O
regulatory	O
elements	O
located	O
within	O
the	O
proximal	O
promoter	O
of	O
a	O
gene	O
or	O
distant	O
enhancer	O
regions	O
.	O

The	O
distribution	O
of	O
human	O
endogenous	O
retrovirus	O
K-113	O
in	O
health	O
and	O
autoimmune	O
diseases	O
in	O
Poland	O
.	O

OBJECTIVE	O
:	O
During	O
the	O
evolution	O
of	O
the	O
human	O
genome	O
,	O
a	O
number	O
of	O
retroviral	O
integrations	O
have	O
occurred	O
creating	O
a	O
group	O
of	O
human	O
endogenous	O
retroviruses	O
(HERVs)	O
.	O

As	O
of	O
now	O
several	O
studies	O
have	O
pointed	O
to	O
the	O
association	O
of	O
HERVs	O
with	O
certain	O
autoimmune	O
diseases	O
such	O
as	O
RA	O
,	O
SLE	O
,	O
multiple	O
sclerosis	O
(MS)	O
and	O
SS	O
as	O
well	O
as	O
various	O
neoplasms	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
prevalence	O
of	O
HERV-K113	O
in	O
patients	O
with	O
RA	O
,	O
SLE	O
and	O
in	O
healthy	O
subjects	O
in	O
the	O
Polish	O
population	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
samples	O
from	O
155	O
RA	O
patients	O
,	O
139	O
SLE	O
patients	O
and	O
261	O
newborns	O
(	O
as	O
controls	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
the	O
HERV-K113	O
allele	O
using	O
PCR	O
.	O

Each	O
individual's	O
DNA	O
was	O
genotyped	O
for	O
null	O
,	O
homozygous	O
or	O
heterozygous	O
insertion	O
of	O
HERV-K113	O
.	O

RESULTS	O
:	O
Our	O
data	O
revealed	O
statistically	O
significant	O
differences	O
in	O
the	O
insertion	O
frequencies	O
of	O
HERV-K113	O
between	O
the	O
groups	O
of	O
RA	O
and	O
SLE	O
patients	O
vs	O
healthy	O
controls	O
(	O
provirus	O
DNA	O
was	O
found	O
in	O
14.19	O
,	O
15.11	O
and	O
8.05%	O
of	O
individuals	O
,	O
respectively	O
)	O
.	O

No	O
homozygous	O
individuals	O
for	O
the	O
K113	O
allele	O
were	O
found	O
in	O
each	O
of	O
the	O
groups	O
.	O

There	O
was	O
no	O
evidence	O
for	O
HERV-K113	O
association	O
with	O
clinical	O
features	O
in	O
either	O
group	O
.	O

CONCLUSION	O
:	O
Our	O
study-the	O
first	O
such	O
performed	O
for	O
the	O
Polish	O
population-provides	O
a	O
consistent	O
observation	O
with	O
previous	O
reports	O
on	O
the	O
genetic	O
association	O
of	O
HERV-K113	O
integrations	O
in	O
autoimmune	O
disorders	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
prevalence	O
of	O
insertionally	O
polymorphic	O
HERV-K113	O
was	O
significantly	O
increased	O
in	O
Polish	O
patients	O
with	O
SLE	O
and	O
RA	O
.	O

Association	O
of	O
GSTM1	O
and	O
GSTT1	O
gene	O
deletions	O
with	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
in	O
Pakistan	O
:	O
a	O
case	O
control	O
study	O
.	O

Polymorphic	O
deletions	O
of	O
GSTM1	O
and	O
GSTT1	O
genes	O
involved	O
in	O
the	O
detoxification	O
of	O
potentially	O
carcinogenic	O
agents	O
may	O
be	O
risk	O
factors	O
for	O
various	O
cancers	O
,	O
including	O
head	O
and	O
neck	O
cancer	O
(HNC)	O
.	O

In	O
the	O
present	O
case-control	O
study	O
we	O
aimed	O
to	O
access	O
possible	O
associations	O
of	O
HNC	O
with	O
GSTM1	O
and	O
GSTT1	O
null	O
genotypes	O
in	O
a	O
Pakistani	O
population	O
.	O

DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
388	O
cancer	O
patients	O
and	O
150	O
healthy	O
controls	O
by	O
phenol-chloroform	O
procedure	O
.	O

GSTM1	O
and	O
GSTT1	O
deletion	O
variants	O
were	O
genotyped	O
by	O
multiplex	O
PCR	O
assay	O
with	O
CYP1A1	O
as	O
an	O
internal	O
control	O
and	O
further	O
analyzed	O
by	O
primer	O
specific	O
PCR	O
assay	O
and	O
sequencing	O
.	O

Mean	O
age	O
of	O
cases	O
and	O
controls	O
was	O
48	O
(	O
	O
16.6	O
)	O
years	O
with	O
a	O
male	O
to	O
female	O
ratio	O
of	O
1:1	O
.	O

Cancer	O
of	O
the	O
oral	O
cavity	O
(57%)	O
was	O
most	O
prevalent	O
in	O
the	O
sampled	O
population	O
followed	O
by	O
pharynx	O
and	O
larynx	O
(	O
30%	O
and	O
13%	O
respectively	O
)	O
.	O

A	O
statistically	O
significant	O
(P<0.05)	O
association	O
was	O
observed	O
for	O
both	O
null	O
genotypes	O
in	O
contribution	O
to	O
HNC	O
as	O
compared	O
with	O
the	O
controls	O
.	O

The	O
odds	O
ratio	O
(OR)	O
for	O
the	O
GSTM1	O
null	O
genotype	O
was	O
2.3	O
with	O
a	O
95%	O
CI	O
of	O
1.5-5.5	O
and	O
for	O
GSTT1	O
OR	O
was	O
2.04	O
with	O
95%	O
CI	O
of	O
1.3-3.1	O
.	O

These	O
results	O
suggest	O
that	O
the	O
GSTM1	O
and	O
GSTT1	O
null	O
genotypes	O
are	O
risk	O
factors	O
for	O
HNC	O
development	O
among	O
the	O
Pakistani	O
population	O
.	O

A	O
novel	O
apolipoprotein	O
E	O
mutation	O
,	O
ApoE	O
Osaka	O
(	O
Arg158	B-ProteinMutation
Pro	I-ProteinMutation
)	O
,	O
in	O
a	O
dyslipidemic	O
patient	O
with	O
lipoprotein	O
glomerulopathy	O
.	O

Lipoprotein	O
glomerulopathy	O
(LPG)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
thrombuslike	O
deposition	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
is	O
often	O
accompanied	O
by	O
an	O
increased	O
serum	O
apolipoprotein	O
E	O
(apoE)	O
level	O
.	O

Several	O
gene	O
mutations	O
of	O
apoE	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
LPG	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
an	O
LPG	O
patient	O
with	O
a	O
novel	O
apoE	O
mutation	O
,	O
apoE	O
Osaka	O
.	O

The	O
patient	O
was	O
a	O
45-year-old	O
man	O
who	O
was	O
hospitalized	O
due	O
to	O
nephrotic	O
syndrome	O
.	O

Light	O
and	O
electron	O
microscopic	O
observations	O
of	O
renal	O
biopsy	O
clearly	O
showed	O
characteristic	O
findings	O
of	O
LPG	O
,	O
including	O
lamellate	O
thrombi	O
in	O
the	O
lumen	O
of	O
dilated	O
glomerular	O
capillaries	O
.	O

His	O
apoE	O
phenotype	O
was	O
apoE3/2	O
and	O
he	O
had	O
mild	O
dyslipidemia	O
with	O
a	O
mid-band	O
on	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

It	O
is	O
intriguing	O
that	O
the	O
serum	O
apoE	O
level	O
was	O
within	O
normal	O
limits	O
.	O

We	O
determined	O
the	O
sequence	O
of	O
the	O
apoE	O
gene	O
using	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
products	O
.	O

ApoE	O
gene	O
analysis	O
showed	O
a	O
nucleotide	O
substitution	O
of	O
G	O
to	O
C	O
at	O
codon	O
158	O
of	O
exon	O
4	O
.	O

This	O
mutation	O
denoted	O
an	O
amino	O
acid	O
substitution	O
of	O
arginine	O
residue	O
for	O
the	O
proline	O
residue	O
at	O
position	O
158	O
of	O
apoE	O
.	O

The	O
result	O
of	O
PCR	O
associated	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
suggested	O
that	O
this	O
mutation	O
is	O
heterozygous	O
.	O

It	O
is	O
possible	O
that	O
apoE	O
Osaka	O
mutation	O
causes	O
a	O
conformational	O
change	O
of	O
apoE	O
protein	O
and	O
affects	O
the	O
interaction	O
between	O
abnormal	O
apoE-containing	O
lipoproteins	O
and	O
the	O
endothelial	O
cells	O
of	O
glomerular	O
capillaries	O
.	O

The	O
precise	O
mechanism	O
of	O
LPG	O
related	O
with	O
apoE	O
Osaka	O
,	O
however	O
,	O
remains	O
to	O
be	O
elucidated	O
.	O

PAX2	O
gene	O
mutations	O
in	O
pediatric	O
and	O
young	O
adult	O
transplant	O
recipients	O
:	O
kidney	O
and	O
urinary	O
tract	O
malformations	O
without	O
ocular	O
anomalies	O
.	O

Heterozygous	O
humans	O
for	O
PAX2	O
mutations	O
show	O
autosomal	O
dominant	O
papillorenal	O
syndrome	O
(PRS)	O
,	O
consisting	O
of	O
ocular	O
colobomas	O
,	O
renal	O
hypo/dysplasia	O
and	O
progressive	O
renal	O
failure	O
in	O
childhood	O
.	O

PAX2	O
mutations	O
have	O
also	O
been	O
identified	O
in	O
patients	O
with	O
isolated	O
renal	O
hypo/dysplasia	O
.	O

Twenty	O
unrelated	O
children	O
and	O
young	O
adults	O
with	O
kidney	O
and	O
urinary	O
tract	O
malformations	O
and	O
no	O
ocular	O
abnormalities	O
were	O
retrospectively	O
recruited	O
for	O
PAX2	O
mutational	O
analysis	O
.	O

All	O
patients	O
had	O
undergone	O
renal	O
transplantation	O
after	O
end-stage	O
renal	O
disease	O
.	O

We	O
identified	O
two	O
new	O
sequence	O
variations	O
:	O
(i)	O
a	O
deletion	O
causing	O
a	O
frameshift	O
c.69delC	B-DNAMutation
and	O
(ii)	O
a	O
nucleotide	O
substitution	O
determining	O
a	O
splice	O
site	O
mutation	O
(	O
c.410+5	B-DNAMutation
G/A	I-DNAMutation
)	O
by	O
predictive	O
analysis	O
.	O

Therefore	O
,	O
we	O
suggest	O
PAX2	O
molecular	O
analysis	O
to	O
be	O
extended	O
to	O
all	O
patients	O
with	O
congenital	O
malformations	O
of	O
kidney	O
and	O
urinary	O
tract	O
(CAKUT)	O
.	O

Acquired	O
TNFRSF14	O
mutations	O
in	O
follicular	O
lymphoma	O
are	O
associated	O
with	O
worse	O
prognosis	O
.	O

Clinical	O
correlative	O
studies	O
have	O
linked	O
1p36	O
deletions	O
with	O
worse	O
prognosis	O
in	O
follicular	O
lymphoma	O
(FL)	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
identify	O
the	O
critical	O
gene(s)	O
in	O
this	O
region	O
that	O
is	O
responsible	O
for	O
conferring	O
inferior	O
prognosis	O
.	O

BAC	O
array	O
technology	O
applied	O
to	O
141	O
FL	O
specimens	O
detected	O
a	O
minimum	O
region	O
of	O
deletion	O
(MRD)	O
of	O
	O
	O
	O
97	O
kb	O
within	O
1p36.32	O
in	O
20%	O
of	O
these	O
cases	O
.	O

Frequent	O
single-nucleotide	O
polymorphism-detected	O
copy-neutral	O
loss	O
of	O
heterozygosity	O
was	O
also	O
found	O
in	O
this	O
region	O
.	O

Analysis	O
of	O
promoter	O
CpGs	O
in	O
the	O
MRD	O
did	O
not	O
reveal	O
differential	O
patterns	O
of	O
DNA	O
methylation	O
in	O
samples	O
that	O
differed	O
in	O
1p36	O
status	O
.	O

Exon	O
sequencing	O
of	O
MRD	O
genes	O
identified	O
somatic	O
alterations	O
in	O
the	O
TNFRSF14	O
gene	O
in	O
3	O
of	O
11	O
selected	O
cases	O
with	O
matching	O
normal	O
DNA	O
.	O

An	O
expanded	O
cohort	O
consisting	O
of	O
251	O
specimens	O
identified	O
46	O
cases	O
(18.3%)	O
with	O
nonsynonymous	O
mutations	O
affecting	O
TNFRSF14	O
.	O

Overall	O
survival	O
(OS)	O
and	O
disease-specific	O
survival	O
(DSS)	O
were	O
associated	O
with	O
the	O
presence	O
of	O
TNFRSF14	O
mutation	O
in	O
patients	O
whose	O
overall	O
treatment	O
included	O
rituximab	O
.	O

We	O
further	O
showed	O
that	O
inferior	O
OS	O
and	O
DSS	O
were	O
most	O
pronounced	O
in	O
patients	O
whose	O
lymphomas	O
contained	O
both	O
TNFRSF14	O
mutations	O
and	O
1p36	O
deletions	O
after	O
adjustment	O
for	O
the	O
International	O
Prognostic	O
Index	O
[	O
hazard	O
ratios	O
of	O
3.65	O
(	O
95%	O
confidence	O
interval	O
,	O
1.35-9.878	O
,	O
P=0.011	O
)	O
and	O
3.19	O
(	O
95%	O
confidence	O
interval	O
,	O
1.06-9.57	O
,	O
P=0.039	O
)	O
,	O
respectively	O
]	O
.	O

Our	O
findings	O
identify	O
TNFRSF14	O
as	O
a	O
candidate	O
gene	O
associated	O
with	O
a	O
subset	O
of	O
FL	O
,	O
based	O
on	O
frequent	O
occurrence	O
of	O
acquired	O
mutations	O
and	O
their	O
correlation	O
with	O
inferior	O
clinical	O
outcomes	O
.	O

Familial	O
pycnodysostosis	O
:	O
identification	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
CTSK	O
gene	O
(	O
cathepsin	O
K	O
)	O
.	O

BACKGROUND	O
:	O
Pycnodysostosis	O
,	O
an	O
autosomal	O
recessive	O
skeletal	O
dysplasia	O
,	O
is	O
characterized	O
by	O
short	O
stature	O
,	O
osteosclerosis	O
,	O
delayed	O
cranial	O
suture	O
closure	O
,	O
hypoplastic	O
mandible	O
,	O
acro-osteolysis	O
,	O
hypoplastic	O
clavicle	O
,	O
and	O
dental	O
anomalies	O
.	O

The	O
disorder	O
is	O
caused	O
by	O
CTSK	O
gene	O
defects	O
,	O
a	O
gene	O
localized	O
on	O
1q21	O
.	O

PURPOSE	O
:	O
To	O
describe	O
the	O
clinical	O
,	O
radiological	O
,	O
and	O
molecular	O
findings	O
in	O
a	O
family	O
with	O
pycnodysostosis	O
.	O

METHODS	O
:	O
The	O
CTSK	O
gene	O
was	O
analyzed	O
from	O
genomic	O
DNA	O
in	O
a	O
nonconsanguinity	O
Mexican	O
family	O
with	O
3	O
affected	O
members	O
with	O
pycnodysostosis	O
and	O
100	O
healthy	O
controls	O
.	O

RESULTS	O
AND	O
INTERPRETATION	O
:	O
We	O
identified	O
the	O
novel	O
homozygous	O
mutation	O
c.908G>A	B-DNAMutation
within	O
exon	O
8	O
of	O
the	O
CTSK	O
gene	O
.	O

This	O
missense	O
mutation	O
leads	O
to	O
the	O
substitution	O
of	O
the	O
amino	O
acid	O
glycine	O
at	O
position	O
303	O
by	O
glutamic	O
acid	O
G303E	B-ProteinMutation
in	O
cathepsin	O
K	O
protease	O
.	O

No	O
genotype/phenotype	O
correlation	O
was	O
present	O
in	O
affected	O
members	O
of	O
the	O
family	O
with	O
pycnodysostosis	O
.	O

Ankyloblepharon-ectodermal	O
dysplasia-clefting	O
syndrome	O
:	O
a	O
novel	O
p63	O
mutation	O
associated	O
with	O
generalized	O
neonatal	O
erosions	O
.	O

Ankyloblepharon-ectodermal	O
dysplasia-clefting	O
(AEC)	O
syndrome	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
ankyloblepharon	O
(	O
congenital	O
adhesions	O
of	O
the	O
eyelids	O
)	O
,	O
ectodermal	O
dysplasia	O
,	O
and	O
orofacial	O
clefts	O
.	O

Here	O
,	O
we	O
report	O
the	O
case	O
of	O
an	O
infant	O
born	O
with	O
severe	O
ectodermal	O
dysplasia	O
including	O
generalized	O
neonatal	O
erosions	O
with	O
scalp	O
involvement	O
,	O
facial	O
clefting	O
but	O
notably	O
without	O
ankyloblepharon	O
.	O

Mutational	O
analysis	O
of	O
the	O
p63	O
gene	O
showed	O
a	O
novel	O
heterozygous	O
T>C	B-DNAMutation
nucleotide	O
substitution	O
on	O
exon	O
14	O
I597T	B-ProteinMutation
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
a	O
novel	O
mutation	O
that	O
has	O
not	O
previously	O
been	O
reported	O
in	O
the	O
pathogenesis	O
of	O
AEC	O
,	O
or	O
other	O
p63-related	O
syndromes	O
.	O

This	O
case	O
further	O
highlights	O
the	O
clinical	O
and	O
genetic	O
heterogeneity	O
of	O
p63	O
syndromes	O
.	O

Association	O
study	O
of	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	O
with	O
schizophrenia	O
,	O
depression	O
,	O
and	O
heroin	O
addiction	O
.	O

This	O
study	O
investigated	O
the	O
possible	O
association	O
between	O
three	O
functional	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
dopamine	O
D4	O
receptor	O
(DRD4)	O
gene	O
and	O
schizophrenia	O
,	O
depression	O
,	O
and	O
heroin	O
addiction	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
venous	O
blood	O
leukocytes	O
of	O
322	O
unrelated	O
patients	O
with	O
schizophrenia	O
,	O
156	O
patients	O
with	O
depression	O
,	O
300	O
patients	O
with	O
heroin	O
addiction	O
,	O
and	O
300	O
healthy	O
unrelated	O
individuals	O
.	O

Polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	O
(	O
-120	O
bp	O
duplication	O
,	O
-616C/G	B-DNAMutation
,	O
and	O
-521C/T	B-DNAMutation
)	O
were	O
genotyped	O
using	O
allele-specific	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Genotype	O
and	O
allele	O
were	O
analyzed	O
using	O
SPSS	O
11.5	O
software	O
.	O

Results	O
of	O
this	O
analysis	O
indicated	O
that	O
there	O
is	O
a	O
strong	O
finding	O
of	O
-120	O
bp	O
duplication	O
allele	O
frequencies	O
with	O
schizophrenia	O
(p=0.008)	O
and	O
weak	O
finding	O
with	O
-1240	B-ProteinMutation
L/S	I-ProteinMutation
and	O
for	O
paranoid	O
schizophrenia	O
(p=0.022)	O
.	O

Interestingly	O
,	O
there	O
is	O
a	O
stronger	O
finding	O
with	O
-521	B-DNAMutation
C/T	I-DNAMutation
allele	O
frequencies	O
with	O
heroin	O
dependence	O
(p=0.0002)	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
-120-bp	O
duplication	O
polymorphism	O
of	O
DRD4	O
is	O
associated	O
with	O
schizophrenia	O
and	O
that	O
the	O
-521	B-DNAMutation
C/T	I-DNAMutation
polymorphism	O
is	O
associated	O
with	O
heroin	O
addiction	O
.	O

Mutations	O
in	O
the	O
sarcomere	O
gene	O
MYH7	O
in	O
Ebstein	O
anomaly	O
.	O

BACKGROUND	O
:	O
Ebstein	O
anomaly	O
is	O
a	O
rare	O
congenital	O
heart	O
malformation	O
characterized	O
by	O
adherence	O
of	O
the	O
septal	O
and	O
posterior	O
leaflets	O
of	O
the	O
tricuspid	O
valve	O
to	O
the	O
underlying	O
myocardium	O
.	O

An	O
association	O
between	O
Ebstein	O
anomaly	O
with	O
left	O
ventricular	O
noncompaction	O
(LVNC)	O
and	O
mutations	O
in	O
MYH7	O
encoding	O
b-myosin	O
heavy	O
chain	O
has	O
been	O
shown	O
;	O
in	O
this	O
report	O
,	O
we	O
have	O
screened	O
for	O
MYH7	O
mutations	O
in	O
a	O
cohort	O
of	O
probands	O
with	O
Ebstein	O
anomaly	O
in	O
a	O
large	O
population-based	O
study	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Mutational	O
analysis	O
in	O
a	O
cohort	O
of	O
141	O
unrelated	O
probands	O
with	O
Ebstein	O
anomaly	O
was	O
performed	O
by	O
next-generation	O
sequencing	O
and	O
direct	O
DNA	O
sequencing	O
of	O
MYH7	O
.	O

Heterozygous	O
mutations	O
were	O
identified	O
in	O
8	O
of	O
141	O
samples	O
(6%)	O
.	O

Seven	O
distinct	O
mutations	O
were	O
found	O
;	O
5	O
were	O
novel	O
and	O
2	O
were	O
known	O
to	O
cause	O
hypertrophic	O
cardiomyopathy	O
.	O

All	O
mutations	O
except	O
for	O
1	O
3-bp	O
deletion	O
were	O
missense	O
mutations	O
;	O
1	O
was	O
a	O
de	O
novo	O
change	O
.	O

Mutation-positive	O
probands	O
and	O
family	O
members	O
showed	O
various	O
congenital	O
heart	O
malformations	O
as	O
well	O
as	O
LVNC	O
.	O

Among	O
8	O
mutation-positive	O
probands	O
,	O
6	O
had	O
LVNC	O
,	O
whereas	O
among	O
133	O
mutation-negative	O
probands	O
,	O
none	O
had	O
LVNC	O
.	O

The	O
frequency	O
of	O
MYH7	O
mutations	O
was	O
significantly	O
different	O
between	O
probands	O
with	O
and	O
without	O
LVNC	O
accompanying	O
Ebstein	O
anomaly	O
(P<0.0001)	O
.	O

LVNC	O
segregated	O
with	O
the	O
MYH7	O
mutation	O
in	O
the	O
pedigrees	O
of	O
3	O
of	O
the	O
probands	O
,	O
1	O
of	O
which	O
also	O
included	O
another	O
individual	O
with	O
Ebstein	O
anomaly	O
.	O

CONCLUSIONS	O
:	O
Ebstein	O
anomaly	O
is	O
a	O
congenital	O
heart	O
malformation	O
that	O
is	O
associated	O
with	O
mutations	O
in	O
MYH7	O
.	O

MYH7	O
mutations	O
are	O
predominantly	O
found	O
in	O
Ebstein	O
anomaly	O
associated	O
with	O
LVNC	O
and	O
may	O
warrant	O
genetic	O
testing	O
and	O
family	O
evaluation	O
in	O
this	O
subset	O
of	O
patients	O
.	O

Impact	O
of	O
CCR5	O
delta32	B-DNAMutation
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
HIV-1	O
intrahost	O
evolutionary	O
processes	O
:	O
efficient	O
hypothesis	O
testing	O
through	O
hierarchical	O
phylogenetic	O
models	O
.	O

The	O
interplay	O
between	O
C-C	O
chemokine	O
receptor	O
type	O
5	O
(CCR5)	O
host	O
genetic	O
background	O
,	O
disease	O
progression	O
,	O
and	O
intrahost	O
HIV-1	O
evolutionary	O
dynamics	O
remains	O
unclear	O
because	O
differences	O
in	O
viral	O
evolution	O
between	O
hosts	O
limit	O
the	O
ability	O
to	O
draw	O
conclusions	O
across	O
hosts	O
stratified	O
into	O
clinically	O
relevant	O
populations	O
.	O

Similar	O
inference	O
problems	O
are	O
proliferating	O
across	O
many	O
measurably	O
evolving	O
pathogens	O
for	O
which	O
intrahost	O
sequence	O
samples	O
are	O
readily	O
available	O
.	O

To	O
this	O
end	O
,	O
we	O
propose	O
novel	O
hierarchical	O
phylogenetic	O
models	O
(HPMs)	O
that	O
incorporate	O
fixed	O
effects	O
to	O
test	O
for	O
differences	O
in	O
dynamics	O
across	O
host	O
populations	O
in	O
a	O
formal	O
statistical	O
framework	O
employing	O
stochastic	O
search	O
variable	O
selection	O
and	O
model	O
averaging	O
.	O

To	O
clarify	O
the	O
role	O
of	O
CCR5	O
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
viral	O
evolutionary	O
patterns	O
,	O
we	O
obtain	O
gp120	O
envelope	O
sequences	O
from	O
clonal	O
HIV-1	O
variants	O
isolated	O
at	O
multiple	O
time	O
points	O
in	O
the	O
course	O
of	O
infection	O
from	O
populations	O
of	O
HIV-1-infected	O
individuals	O
who	O
only	O
harbored	O
CCR5-using	O
HIV-1	O
variants	O
at	O
all	O
time	O
points	O
.	O

Presence	O
or	O
absence	O
of	O
a	O
CCR5	O
wt//\32	O
genotype	O
and	O
progressive	O
or	O
long-term	O
nonprogressive	O
course	O
of	O
infection	O
stratify	O
the	O
clinical	O
populations	O
in	O
a	O
two-way	O
design	O
.	O

As	O
compared	O
with	O
the	O
standard	O
approach	O
of	O
analyzing	O
sequences	O
from	O
each	O
patient	O
independently	O
,	O
the	O
HPM	O
provides	O
more	O
efficient	O
estimation	O
of	O
evolutionary	O
parameters	O
such	O
as	O
nucleotide	O
substitution	O
rates	O
and	O
d(N)/d(S)	O
rate	O
ratios	O
,	O
as	O
shown	O
by	O
significant	O
shrinkage	O
of	O
the	O
estimator	O
variance	O
.	O

The	O
fixed	O
effects	O
also	O
correct	O
for	O
nonindependence	O
of	O
data	O
between	O
populations	O
and	O
results	O
in	O
even	O
further	O
shrinkage	O
of	O
individual	O
patient	O
estimates	O
.	O

Model	O
selection	O
suggests	O
an	O
association	O
between	O
nucleotide	O
substitution	O
rate	O
and	O
disease	O
progression	O
,	O
but	O
a	O
role	O
for	O
CCR5	O
genotype	O
remains	O
elusive	O
.	O

Given	O
the	O
absence	O
of	O
clear	O
d(N)/d(S)	O
differences	O
between	O
patient	O
groups	O
,	O
delayed	O
onset	O
of	O
AIDS	O
symptoms	O
appears	O
to	O
be	O
solely	O
associated	O
with	O
lower	O
viral	O
replication	O
rates	O
rather	O
than	O
with	O
differences	O
in	O
selection	O
on	O
amino	O
acid	O
fixation	O
.	O

The	O
dopamine	O
b-hydroxylase	O
-1021C/T	B-DNAMutation
polymorphism	O
is	O
associated	O
with	O
the	O
risk	O
of	O
Alzheimer's	O
disease	O
in	O
the	O
Epistasis	O
Project	O
.	O

BACKGROUND	O
:	O
The	O
loss	O
of	O
noradrenergic	O
neurones	O
of	O
the	O
locus	O
coeruleus	O
is	O
a	O
major	O
feature	O
of	O
Alzheimer's	O
disease	O
(AD)	O
.	O

Dopamine	O
b-hydroxylase	O
(DBH)	O
catalyses	O
the	O
conversion	O
of	O
dopamine	O
to	O
noradrenaline	O
.	O

Interactions	O
have	O
been	O
reported	O
between	O
the	O
low-activity	O
-1021T	O
allele	O
rs1611115	B-SNP
of	O
DBH	O
and	O
polymorphisms	O
of	O
the	O
pro-inflammatory	O
cytokine	O
genes	O
,	O
IL1A	O
and	O
IL6	O
,	O
contributing	O
to	O
the	O
risk	O
of	O
AD	O
.	O

We	O
therefore	O
examined	O
the	O
associations	O
with	O
AD	O
of	O
the	O
DBH	O
-1021T	O
allele	O
and	O
of	O
the	O
above	O
interactions	O
in	O
the	O
Epistasis	O
Project	O
,	O
with	O
1757	O
cases	O
of	O
AD	O
and	O
6294	O
elderly	O
controls	O
.	O

METHODS	O
:	O
We	O
genotyped	O
eight	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
three	O
genes	O
,	O
DBH	O
,	O
IL1A	O
and	O
IL6	O
.	O

We	O
used	O
logistic	O
regression	O
models	O
and	O
synergy	O
factor	O
analysis	O
to	O
examine	O
potential	O
interactions	O
and	O
associations	O
with	O
AD	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
the	O
presence	O
of	O
the	O
-1021T	O
allele	O
was	O
associated	O
with	O
AD	O
:	O
odds	O
ratio	O
=	O
1.2	O
(	O
95%	O
confidence	O
interval	O
:	O
1.06-1.4	O
,	O
p	O
=	O
0.005	O
)	O
.	O

This	O
association	O
was	O
nearly	O
restricted	O
to	O
men	O
<	O
75	O
years	O
old	O
:	O
odds	O
ratio	O
=	O
2.2	O
(	O
1.4-3.3	O
,	O
0.0004	O
)	O
.	O

We	O
also	O
found	O
an	O
interaction	O
between	O
the	O
presence	O
of	O
DBH	O
-1021T	O
and	O
the	O
-889TT	O
genotype	O
rs1800587	B-SNP
of	O
IL1A	O
:	O
synergy	O
factor	O
=	O
1.9	O
(	O
1.2-3.1	O
,	O
0.005	O
)	O
.	O

All	O
these	O
results	O
were	O
consistent	O
between	O
North	O
Europe	O
and	O
North	O
Spain	O
.	O

CONCLUSIONS	O
:	O
Extensive	O
,	O
previous	O
evidence	O
(	O
reviewed	O
here	O
)	O
indicates	O
an	O
important	O
role	O
for	O
noradrenaline	O
in	O
the	O
control	O
of	O
inflammation	O
in	O
the	O
brain	O
.	O

Thus	O
,	O
the	O
-1021T	O
allele	O
with	O
presumed	O
low	O
activity	O
may	O
be	O
associated	O
with	O
misregulation	O
of	O
inflammation	O
,	O
which	O
could	O
contribute	O
to	O
the	O
onset	O
of	O
AD	O
.	O

We	O
suggest	O
that	O
such	O
misregulation	O
is	O
the	O
predominant	O
mechanism	O
of	O
the	O
association	O
we	O
report	O
here	O
.	O

Mutation	O
screening	O
of	O
the	O
GUCA1B	O
gene	O
in	O
patients	O
with	O
autosomal	O
dominant	O
cone	O
and	O
cone	O
rod	O
dystrophy	O
.	O

Background	O
:	O
Heterozygous	O
mutations	O
in	O
GUCA1A	O
(	O
MIM	O
#	O
600364	O
)	O
have	O
been	O
identified	O
to	O
cause	O
autosomal	O
dominantly	O
inherited	O
cone	O
dystrophy	O
,	O
cone	O
rod	O
dystrophy	O
and	O
macular	O
dystrophy	O
.	O

However	O
,	O
the	O
role	O
of	O
GUCA1B	O
gene	O
mutations	O
in	O
inherited	O
retinal	O
disease	O
has	O
been	O
controversial	O
.	O

We	O
therefore	O
performed	O
a	O
mutation	O
analysis	O
of	O
the	O
GUCA1B	O
gene	O
in	O
a	O
clinically	O
well	O
characterized	O
group	O
of	O
patients	O
of	O
European	O
and	O
North-American	O
geographical	O
origin	O
with	O
autosomal	O
dominantly	O
inherited	O
cone	O
dystrophy	O
and	O
cone	O
rod	O
dystrophy	O
.	O

Material	O
and	O
Methods	O
:	O
Twenty-four	O
unrelated	O
patients	O
diagnosed	O
with	O
cone	O
dystrophy	O
or	O
cone	O
rod	O
dystrophy	O
according	O
to	O
standard	O
diagnostic	O
criteria	O
and	O
a	O
family	O
history	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
were	O
included	O
in	O
the	O
study	O
.	O

Mutation	O
analysis	O
of	O
all	O
coding	O
exons	O
of	O
the	O
GUCA1B	O
gene	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
genomic	O
DNA	O
and	O
subsequent	O
DNA	O
sequencing	O
.	O

Results	O
:	O
Three	O
different	O
sequence	O
variants	O
,	O
c.-17T>C	B-DNAMutation
,	O
c.171T>C	B-DNAMutation
,	O
c.465G>T	B-DNAMutation
were	O
identified	O
.	O

The	O
sequence	O
variant	O
c.465G>T	B-DNAMutation
encodes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
,	O
p.Glu155Asp	B-ProteinMutation
,	O
located	O
in	O
EF-hand	O
4	O
,	O
the	O
calcium	O
binding	O
site	O
of	O
GCAP2	O
protein	O
.	O

All	O
sequence	O
variants	O
were	O
previously	O
reported	O
in	O
healthy	O
subjects	O
.	O

Conclusion	O
:	O
The	O
absence	O
of	O
clearly	O
pathogenic	O
mutations	O
in	O
the	O
selected	O
patient	O
group	O
suggests	O
that	O
the	O
GUCA1B	O
gene	O
is	O
a	O
minor	O
cause	O
for	O
retinal	O
degenerations	O
in	O
Europeans	O
or	O
North-Americans	O
.	O

AluYb8	O
insertion	O
in	O
the	O
MUTYH	O
gene	O
is	O
related	O
to	O
increased	O
8-OHdG	O
in	O
genomic	O
DNA	O
and	O
could	O
be	O
a	O
risk	O
factor	O
for	O
type	O
2	O
diabetes	O
in	O
a	O
Chinese	O
population	O
.	O

The	O
Mutyh	O
DNA	O
glycosylase	O
is	O
involved	O
in	O
the	O
repair	O
of	O
oxidized	O
DNA	O
bases	O
.	O

Because	O
oxidative	O
stress	O
may	O
contribute	O
to	O
increased	O
diabetes	O
risk	O
,	O
the	O
common	O
variant	O
of	O
the	O
MUTYH	O
gene	O
(AluYb8MUTYH)	O
was	O
investigated	O
for	O
its	O
possible	O
role	O
in	O
type	O
2	O
diabetes	O
mellitus	O
(T2DM)	O
.	O

A	O
total	O
of	O
565	O
T2DM	O
patients	O
and	O
565	O
healthy	O
subjects	O
from	O
China	O
were	O
enrolled	O
in	O
a	O
case-control	O
study	O
.	O

The	O
distribution	O
of	O
AluYb8MUTYH	O
differed	O
in	O
diabetic	O
patients	O
from	O
controls	O
,	O
with	O
a	O
moderately	O
increased	O
percentage	O
of	O
the	O
mutant	O
allele	O
(P)	O
(	O
44.7%	O
versus	O
40.3%	O
,	O
P	O
=	O
0.033	O
,	O
OR	O
=	O
1.199	O
)	O
.	O

However	O
,	O
this	O
distribution	O
was	O
similar	O
between	O
the	O
diabetic	O
early-onset	O
and	O
late-onset	O
subgroups	O
.	O

Another	O
66	O
T2DM	O
patients	O
were	O
further	O
evaluated	O
for	O
8-hydroxy-2'deoxyguanosine	O
(8-OHdG)	O
levels	O
in	O
leukocytic	O
DNA	O
.	O

The	O
average	O
value	O
of	O
8-OHdG/10(6)	O
dG	O
was	O
10.4	O
in	O
patients	O
with	O
the	O
wild-type	O
genotype	O
,	O
15.9	O
in	O
heterozygotes	O
,	O
and	O
22.3	O
in	O
homozygotes	O
with	O
the	O
variation	O
(	O
P	O
<	O
0.001	O
,	O
compared	O
with	O
the	O
wild-type	O
)	O
.	O

Therefore	O
,	O
the	O
AluYb8MUTYH	O
polymorphism	O
could	O
be	O
a	O
novel	O
genetic	O
risk	O
factor	O
for	O
T2DM	O
,	O
and	O
accumulated	O
8-OHdG	O
could	O
contribute	O
to	O
this	O
disease	O
.	O

The	O
fibrinogen	O
gamma	O
10034C>T	B-DNAMutation
polymorphism	O
is	O
not	O
associated	O
with	O
Peripheral	O
Arterial	O
Disease	O
.	O

Conversion	O
of	O
fibrinogen	O
to	O
fibrin	O
plays	O
an	O
essential	O
role	O
in	O
hemostasis	O
and	O
results	O
in	O
stabilization	O
of	O
the	O
fibrin	O
clot	O
.	O

Fibrinogen	O
consists	O
of	O
three	O
pairs	O
of	O
non-identical	O
polypeptide	O
chains	O
,	O
encoded	O
by	O
different	O
genes	O
(	O
fibrinogen	O
alpha	O
[FGA]	O
,	O
fibrinogen	O
beta	O
[FGB]	O
and	O
fibrinogen	O
gamma	O
[	O
FGG	O
]	O
)	O
.	O

A	O
functional	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
3'	O
untranslated	O
region	O
of	O
the	O
FGG	O
gene	O
(	O
FGG	O
10034C>T	B-DNAMutation
,	O
rs2066865	B-SNP
)	O
has	O
been	O
associated	O
with	O
deep	O
venous	O
thrombosis	O
and	O
myocardial	O
infarction	O
.	O

Aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
this	O
polymorphism	O
in	O
peripheral	O
arterial	O
disease	O
(PAD)	O
.	O

The	O
study	O
was	O
designed	O
as	O
case-control	O
study	O
including	O
891	O
patients	O
with	O
documented	O
PAD	O
and	O
777	O
control	O
subjects	O
.	O

FGG	O
genotypes	O
were	O
determined	O
by	O
exonuclease	O
(TaqMan)	O
assays	O
.	O

FGG	O
genotype	O
frequencies	O
were	O
not	O
significantly	O
different	O
between	O
PAD	O
patients	O
(	O
CC	O
:	O
57.3%	O
,	O
CT	O
:	O
36.7%	O
,	O
TT	O
:	O
5.8%	O
)	O
and	O
control	O
subjects	O
(	O
CC	O
:	O
60.9%	O
,	O
CT	O
:	O
33.5%	O
,	O
TT	O
5.6%	O
;	O
p=0.35	O
)	O
.	O

In	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
including	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
diabetes	O
,	O
arterial	O
hypertension	O
and	O
hypercholesterolemia	O
,	O
the	O
FGG	O
10034	O
T	O
variant	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
PAD	O
(	O
Odds	O
ratio	O
1.07	O
,	O
95%	O
confidence	O
interval	O
0.84	O
-	O
1.37	O
;	O
p	O
=	O
0.60	O
)	O
.	O

The	O
FGG	O
10034C>T	B-DNAMutation
polymorphism	O
was	O
furthermore	O
not	O
associated	O
with	O
age	O
at	O
onset	O
of	O
PAD	O
.	O

We	O
conclude	O
that	O
the	O
thrombophilic	O
FGG	O
10034	O
T	O
gene	O
variant	O
does	O
not	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
to	O
PAD	O
.	O

Multilocus	O
association	O
of	O
genetic	O
variants	O
in	O
MLL	O
,	O
CREBBP	O
,	O
EP300	O
,	O
and	O
TOP2A	O
with	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
in	O
Hispanics	O
from	O
Texas	O
.	O

BACKGROUND	O
:	O
Hispanic	O
children	O
have	O
both	O
a	O
higher	O
incidence	O
and	O
a	O
poorer	O
outcome	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
.	O

Moreover	O
,	O
a	O
higher	O
incidence	O
for	O
therapy-related	O
acute	O
myeloid	O
leukemia	O
with	O
11q23	O
translocations	O
after	O
treatment	O
with	O
topoisomerase	O
II	O
(	O
topo	O
II	O
)	O
inhibitors	O
has	O
been	O
observed	O
in	O
Hispanic	O
children	O
with	O
ALL	O
.	O

We	O
sought	O
to	O
determine	O
the	O
potential	O
role	O
of	O
genetic	O
variants	O
within	O
the	O
topoisomerase	O
IIa	O
gene	O
(TOP2A)	O
,	O
within	O
the	O
mixed	O
lineage	O
leukemia	O
gene	O
(MLL)	O
and	O
two	O
of	O
its	O
translocation	O
partners	O
,	O
cyclin	O
AMP	O
response	O
element-binding	O
protein	O
gene	O
(CREBBP)	O
and	O
E1A	O
binding	O
protein	O
gene	O
(EP300)	O
in	O
the	O
increased	O
sensitivity	O
of	O
Hispanic	O
children	O
with	O
ALL	O
to	O
topo	O
II	O
inhibitors	O
.	O

METHODS	O
:	O
Fifty-two	O
tagged	O
single	O
nucleotide	O
polymorphisms	O
(SNP)	O
covering	O
the	O
four	O
genes	O
were	O
genotyped	O
in	O
241	O
samples	O
(	O
66	O
children	O
with	O
ALL	O
and	O
175	O
age	O
matched	O
controls	O
)	O
of	O
self-identified	O
Hispanic	O
origin	O
.	O

RESULTS	O
:	O
Two	O
SNPs	O
within	O
MLL	O
(	O
rs525549	B-SNP
and	O
rs6589664	B-SNP
)	O
and	O
three	O
SNPs	O
within	O
EP300	O
(	O
rs5758222	B-SNP
,	O
rs7286979	B-SNP
,	O
and	O
rs20551	B-SNP
)	O
were	O
significantly	O
associated	O
with	O
ALL	O
(	O
P	O
=	O
0.001-0.04	O
)	O
.	O

A	O
significant	O
gene-dosage	O
effect	O
for	O
increasing	O
numbers	O
of	O
potential	O
high-risk	O
genotypes	O
(	O
OR	O
=	O
16.66	O
;	O
P	O
=	O
2	O
	O
	O
10(-5)	O
)	O
and	O
a	O
major	O
haplotype	O
significantly	O
associated	O
with	O
ALL	O
(	O
OR	O
=	O
5.68	O
;	O
P	O
=	O
2	O
	O
	O
10(-6)	O
)	O
were	O
found	O
.	O

Replication	O
in	O
a	O
sample	O
of	O
137	O
affected	O
White	O
children	O
and	O
239	O
controls	O
showed	O
that	O
only	O
rs6589664	B-SNP
(MLL)	O
was	O
significantly	O
associated	O
in	O
this	O
ethnic	O
group	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
indicate	O
that	O
the	O
association	O
between	O
ALL	O
and	O
common	O
genetic	O
variants	O
within	O
MLL	O
and	O
EP300	O
is	O
population	O
specific	O
.	O

IMPACT	O
:	O
Replication	O
of	O
our	O
findings	O
in	O
independent	O
Hispanic	O
populations	O
is	O
warranted	O
to	O
elucidate	O
the	O
role	O
of	O
these	O
variants	O
in	O
ALL	O
susceptibility	O
and	O
define	O
their	O
importance	O
in	O
the	O
ethnic	O
specific	O
differences	O
in	O
ALL	O
risk	O
.	O

Homozygous	O
loss	O
of	O
ADAM3A	O
revealed	O
by	O
genome-wide	O
analysis	O
of	O
pediatric	O
high-grade	O
glioma	O
and	O
diffuse	O
intrinsic	O
pontine	O
gliomas	O
.	O

Overall	O
,	O
pediatric	O
high-grade	O
glioma	O
(pHGG)	O
has	O
a	O
poor	O
prognosis	O
,	O
in	O
part	O
due	O
to	O
the	O
lack	O
of	O
understanding	O
of	O
the	O
underlying	O
biology	O
.	O

High-resolution	O
244	O
K	O
oligo	O
array	O
comparative	O
genomic	O
hybridization	O
(CGH)	O
was	O
used	O
to	O
analyze	O
DNA	O
from	O
38	O
formalin-fixed	O
paraffin-embedded	O
predominantly	O
pretreatment	O
pHGG	O
samples	O
,	O
including	O
13	O
diffuse	O
intrinsic	O
pontine	O
gliomas	O
(DIPGs)	O
.	O

The	O
patterns	O
of	O
gains	O
and	O
losses	O
were	O
distinct	O
from	O
those	O
seen	O
in	O
HGG	O
arising	O
in	O
adults	O
.	O

In	O
particular	O
,	O
we	O
found	O
1q	O
gain	O
in	O
up	O
to	O
27%	O
of	O
our	O
cohort	O
compared	O
with	O
9%	O
reported	O
in	O
adults	O
.	O

A	O
total	O
of	O
13%	O
had	O
a	O
balanced	O
genetic	O
profile	O
with	O
no	O
large-scale	O
copy	O
number	O
alterations	O
.	O

Homozygous	O
loss	O
at	O
8p12	O
was	O
seen	O
in	O
6	O
of	O
38	O
(16%)	O
cases	O
of	O
pHGG	O
.	O

This	O
novel	O
deletion	O
,	O
which	O
includes	O
the	O
ADAM3A	O
gene	O
,	O
was	O
confirmed	O
by	O
quantitative	O
real-time	O
PCR	O
(qPCR)	O
.	O

Loss	O
of	O
CDKN2A/CDKN2B	O
in	O
4	O
of	O
38	O
(10%)	O
samples	O
by	O
oligo	O
array	O
CGH	O
was	O
confirmed	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
on	O
tissue	O
microarrays	O
and	O
was	O
restricted	O
to	O
supratentorial	O
tumors	O
.	O

Only	O
	O
	O
	O
50%	O
of	O
supratentorial	O
tumors	O
were	O
positive	O
for	O
CDKN2B	O
expression	O
by	O
immunohistochemistry	O
(IHC)	O
,	O
while	O
	O
	O
	O
75%	O
of	O
infratentorial	O
tumors	O
were	O
positive	O
for	O
CDKN2B	O
expression	O
(	O
P	O
=	O
0.03	O
)	O
.	O

Amplification	O
of	O
the	O
4q11-13	O
region	O
was	O
detected	O
in	O
8%	O
of	O
cases	O
and	O
included	O
PDGFRA	O
and	O
KIT	O
,	O
and	O
subsequent	O
qPCR	O
analysis	O
was	O
consistent	O
with	O
the	O
amplification	O
of	O
PDGFRA	O
.	O

MYCN	O
amplification	O
was	O
seen	O
in	O
5%	O
of	O
samples	O
being	O
significantly	O
associated	O
with	O
anaplastic	O
astrocytomas	O
(	O
P=	O
0.03	O
)	O
.	O

Overall	O
,	O
DIPG	O
shared	O
similar	O
spectrum	O
of	O
changes	O
to	O
supratentorial	O
HGG	O
with	O
some	O
notable	O
differences	O
,	O
including	O
high-frequency	O
loss	O
of	O
17p	O
and	O
14q	O
and	O
lack	O
of	O
CDKN2A/CDKN2B	O
deletion	O
.	O

Informative	O
genetic	O
data	O
providing	O
insight	O
into	O
the	O
underlying	O
biology	O
and	O
potential	O
therapeutic	O
possibilities	O
can	O
be	O
generated	O
from	O
archival	O
tissue	O
and	O
typically	O
small	O
biopsies	O
from	O
DIPG	O
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
obtaining	O
pretreatment	O
samples	O
.	O

Hepatic	O
but	O
not	O
brain	O
iron	O
is	O
rapidly	O
chelated	O
by	O
deferasirox	O
in	O
aceruloplasminemia	O
due	O
to	O
a	O
novel	O
gene	O
mutation	O
.	O

BACKGROUND	O
_#38	O
;	O
AIMS	O
:	O
Aceruloplasminemia	O
is	O
a	O
rare	O
autosomal	O
recessive	O
neurodegenerative	O
disease	O
associated	O
with	O
brain	O
and	O
liver	O
iron	O
accumulation	O
which	O
typically	O
presents	O
with	O
movement	O
disorders	O
,	O
retinal	O
degeneration	O
,	O
and	O
diabetes	O
mellitus	O
.	O

Ceruloplasmin	O
is	O
a	O
multi-copper	O
ferroxidase	O
that	O
is	O
secreted	O
into	O
plasma	O
and	O
facilitates	O
cellular	O
iron	O
export	O
and	O
iron	O
binding	O
to	O
transferrin	O
.	O

RESULTS	O
:	O
A	O
novel	O
homozygous	O
ceruloplasmin	O
gene	O
mutation	O
,	O
c.2554+1G>T	B-DNAMutation
,	O
was	O
identified	O
as	O
the	O
cause	O
of	O
aceruloplasminemia	O
in	O
three	O
affected	O
siblings	O
.	O

Two	O
siblings	O
presented	O
with	O
movement	O
disorders	O
and	O
diabetes	O
.	O

Complementary	O
DNA	O
sequencing	O
showed	O
that	O
this	O
mutation	O
causes	O
skipping	O
of	O
exon	O
14	O
and	O
deletion	O
of	O
amino	O
acids	O
809-852	O
while	O
preserving	O
the	O
open	O
reading	O
frame	O
.	O

Western	O
blotting	O
of	O
liver	O
extracts	O
and	O
sera	O
of	O
affected	O
patients	O
showed	O
retention	O
of	O
the	O
abnormal	O
protein	O
in	O
the	O
liver	O
.	O

Aceruloplasminemia	O
was	O
associated	O
with	O
severe	O
brain	O
and	O
liver	O
iron	O
overload	O
,	O
where	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
iron	O
hormone	O
hepcidin	O
was	O
increased	O
,	O
corresponding	O
to	O
the	O
degree	O
of	O
iron	O
overload	O
.	O

Hepatic	O
iron	O
concentration	O
normalized	O
after	O
3	O
and	O
5months	O
of	O
iron	O
chelation	O
therapy	O
with	O
deferasirox	O
,	O
which	O
was	O
also	O
associated	O
with	O
reduced	O
insulin	O
demands	O
.	O

During	O
short	O
term	O
treatment	O
there	O
was	O
no	O
clinical	O
or	O
imaging	O
evidence	O
for	O
significant	O
effects	O
on	O
brain	O
iron	O
overload	O
.	O

CONCLUSIONS	O
:	O
Aceruloplasminemia	O
can	O
show	O
an	O
incomplete	O
clinical	O
penetrance	O
but	O
is	O
invariably	O
associated	O
with	O
iron	O
accumulation	O
in	O
the	O
liver	O
and	O
in	O
the	O
brain	O
.	O

Iron	O
accumulation	O
in	O
aceruloplasminemia	O
is	O
a	O
result	O
of	O
defective	O
cellular	O
iron	O
export	O
,	O
where	O
hepcidin	O
regulation	O
is	O
appropriate	O
for	O
the	O
degree	O
of	O
iron	O
overload	O
.	O

Iron	O
chelation	O
with	O
deferasirox	O
was	O
effective	O
in	O
mobilizing	O
hepatic	O
iron	O
but	O
has	O
no	O
effect	O
on	O
brain	O
iron	O
.	O

A	O
genome-wide	O
analysis	O
of	O
loss	O
of	O
heterozygosity	O
and	O
chromosomal	O
copy	O
number	O
variation	O
in	O
Proteus	O
syndrome	O
using	O
high-density	O
SNP	O
microarrays	O
.	O

Excessive	O
cell	O
proliferation	O
and	O
genetic	O
changes	O
such	O
as	O
loss	O
of	O
an	O
allele	O
(	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
)	O
or	O
amplifications	O
or	O
deletions	O
of	O
parts	O
of	O
chromosomes	O
(	O
copy	O
number	O
variations	O
(	O
CNV	O
)	O
)	O
are	O
common	O
findings	O
in	O
cancers	O
.	O

It	O
is	O
unknown	O
whether	O
these	O
changes	O
are	O
also	O
present	O
in	O
patients	O
with	O
overgrowth	O
syndromes	O
,	O
although	O
the	O
presence	O
of	O
small-scale	O
CNVs	O
(	O
such	O
as	O
duplication	O
of	O
11p15	O
in	O
Beckwith-Wiedemann	O
syndrome	O
)	O
,	O
excessive	O
cell	O
proliferation	O
and	O
an	O
increased	O
frequency	O
of	O
tumors	O
have	O
all	O
been	O
reported	O
in	O
these	O
patients	O
.	O

We	O
present	O
results	O
of	O
a	O
genome-wide	O
scan	O
for	O
LOH	O
and	O
CNV	O
in	O
Proteus	O
syndrome	O
(PS)	O
,	O
a	O
severely	O
disfiguring	O
overgrowth	O
syndrome	O
.	O

We	O
investigated	O
CNV	O
and	O
LOH	O
in	O
DNA	O
derived	O
from	O
affected	O
and	O
normal	O
tissue	O
samples	O
from	O
six	O
PS	O
patients	O
using	O
Affymetrix	O
GeneChip	O
Mapping	O
250	O
	O
	O
K	O
Nsp	O
high-density	O
single-nucleotide	O
polymorphism	O
microarrays	O
.	O

Analysis	O
revealed	O
that	O
LOH	O
and	O
CNVs	O
were	O
not	O
common	O
in	O
PS	O
.	O

We	O
attempted	O
to	O
validate	O
selected	O
CNVs	O
detected	O
by	O
microarray	O
analysis	O
using	O
quantitative	O
genomic	O
PCR	O
,	O
but	O
the	O
observed	O
changes	O
were	O
not	O
confirmed	O
.	O

These	O
results	O
suggest	O
that	O
large-scale	O
genome-wide	O
CNVs	O
and	O
LOH	O
as	O
seen	O
in	O
cancer	O
syndromes	O
are	O
not	O
characteristic	O
findings	O
in	O
PS	O
,	O
although	O
we	O
cannot	O
rule	O
out	O
the	O
possibility	O
that	O
newer	O
arrays	O
with	O
a	O
higher	O
number	O
of	O
probes	O
could	O
uncover	O
smaller	O
CNVs	O
not	O
detected	O
in	O
this	O
study	O
.	O

A	O
single	O
heterozygous	O
nucleotide	O
substitution	O
displays	O
two	O
different	O
altered	O
mechanisms	O
in	O
the	O
FBN1	O
gene	O
of	O
five	O
Italian	O
Marfan	O
patients	O
.	O

The	O
Fibrillin-1	O
gene	O
(	O
FBN1	O
;	O
chromosome	O
15q21.1	O
)	O
encodes	O
a	O
major	O
glycoprotein	O
component	O
of	O
the	O
extracellular	O
matrix	O
.	O

Mutations	O
in	O
FBN1	O
,	O
TGFBR1	O
,	O
TGFBR2	O
are	O
known	O
to	O
cause	O
Marfan	O
syndrome	O
(	O
MIM	O
154700	O
)	O
,	O
a	O
pleiotropic	O
disorder	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
five	O
novel	O
missense	O
FBN1	O
mutations	O
in	O
five	O
Marfan	O
patients	O
that	O
have	O
the	O
peculiarity	O
to	O
activate	O
two	O
contemporary	O
mutational	O
mechanisms	O
:	O
a	O
missense	O
mutation	O
and	O
exon	O
skipping	O
.	O

Mutation	O
and	O
association	O
analysis	O
of	O
GEN1	O
in	O
breast	O
cancer	O
susceptibility	O
.	O

GEN1	O
was	O
recently	O
identified	O
as	O
a	O
key	O
Holliday	O
junction	O
resolvase	O
involved	O
in	O
homologous	O
recombination	O
.	O

Somatic	O
truncating	O
GEN1	O
mutations	O
have	O
been	O
reported	O
in	O
two	O
breast	O
cancers	O
.	O

Together	O
these	O
data	O
led	O
to	O
the	O
proposition	O
that	O
GEN1	O
is	O
a	O
breast	O
cancer	O
predisposition	O
gene	O
.	O

In	O
this	O
article	O
we	O
have	O
formally	O
investigated	O
this	O
hypothesis	O
.	O

We	O
performed	O
full-gene	O
mutational	O
analysis	O
of	O
GEN1	O
in	O
176	O
BRCA1/2-negative	O
familial	O
breast	O
cancer	O
samples	O
and	O
159	O
controls	O
.	O

We	O
genotyped	O
six	O
SNPs	O
tagging	O
the	O
30	O
common	O
variants	O
in	O
the	O
transcribed	O
region	O
of	O
GEN1	O
in	O
3,750	O
breast	O
cancer	O
cases	O
and	O
4,907	O
controls	O
.	O

Mutation	O
analysis	O
revealed	O
one	O
truncating	O
variant	O
,	O
c.2515_2519delAAGTT	B-DNAMutation
,	O
which	O
was	O
present	O
in	O
4%	O
of	O
cases	O
and	O
4%	O
of	O
controls	O
.	O

We	O
identified	O
control	O
individuals	O
homozygous	O
for	O
the	O
deletion	O
,	O
demonstrating	O
that	O
the	O
last	O
69	O
amino	O
acids	O
of	O
GEN1	O
are	O
dispensable	O
for	O
its	O
function	O
.	O

We	O
identified	O
17	O
other	O
variants	O
,	O
but	O
their	O
frequency	O
did	O
not	O
significantly	O
differ	O
between	O
cases	O
and	O
controls	O
.	O

Analysis	O
of	O
3,750	O
breast	O
cancer	O
cases	O
and	O
4,907	O
controls	O
demonstrated	O
no	O
evidence	O
of	O
significant	O
association	O
with	O
breast	O
cancer	O
for	O
six	O
SNPs	O
tagging	O
the	O
30	O
common	O
GEN1	O
variants	O
.	O

These	O
data	O
indicate	O
that	O
although	O
it	O
also	O
plays	O
a	O
key	O
role	O
in	O
double-strand	O
DNA	O
break	O
repair	O
,	O
GEN1	O
does	O
not	O
make	O
an	O
appreciable	O
contribution	O
to	O
breast	O
cancer	O
susceptibility	O
by	O
acting	O
as	O
a	O
high-	O
or	O
intermediate-penetrance	O
breast	O
cancer	O
predisposition	O
gene	O
like	O
BRCA1	O
,	O
BRCA2	O
,	O
CHEK2	O
,	O
ATM	O
,	O
BRIP1	O
and	O
PALB2	O
and	O
that	O
common	O
GEN1	O
variants	O
do	O
not	O
act	O
as	O
low-penetrance	O
susceptibility	O
alleles	O
analogous	O
to	O
SNPs	O
in	O
FGFR2	O
.	O

Furthermore	O
,	O
our	O
analyses	O
demonstrate	O
the	O
importance	O
of	O
undertaking	O
appropriate	O
genetic	O
investigations	O
,	O
typically	O
full	O
gene	O
screening	O
in	O
cases	O
and	O
controls	O
together	O
with	O
large-scale	O
case-control	O
association	O
analyses	O
,	O
to	O
evaluate	O
the	O
contribution	O
of	O
genes	O
to	O
cancer	O
susceptibility	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
TACSTD2	O
mutation	O
in	O
gelatinous	O
drop-like	O
corneal	O
dystrophy	O
.	O

PURPOSE	O
:	O
To	O
study	O
the	O
clinical	O
,	O
histological	O
,	O
in	O
vivo	O
confocal	O
microscopic	O
,	O
and	O
molecular	O
profile	O
in	O
a	O
family	O
with	O
gelatinous	O
drop-like	O
corneal	O
dystrophy	O
(GDLD)	O
from	O
north	O
India	O
.	O

METHODS	O
:	O
Two	O
siblings	O
from	O
a	O
consanguineous	O
family	O
presented	O
with	O
clinical	O
features	O
analogous	O
to	O
GDLD	O
.	O

Detailed	O
clinical	O
evaluations	O
were	O
performed	O
for	O
all	O
the	O
available	O
affected	O
and	O
unaffected	O
members	O
of	O
this	O
family	O
.	O

In	O
vivo	O
confocal	O
microscopy	O
and	O
histology	O
was	O
done	O
wherever	O
necessary	O
.	O

DNA	O
isolated	O
from	O
peripheral	O
blood	O
samples	O
was	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(PCR)	O
followed	O
by	O
direct	O
sequencing	O
to	O
detect	O
mutations	O
in	O
the	O
tumor-associated	O
calcium	O
signal	O
transducer	O
2	O
(TACSTD2)	O
gene	O
.	O

Protein	O
modeling	O
studies	O
were	O
done	O
to	O
asses	O
the	O
effect	O
of	O
the	O
mutation	O
on	O
the	O
protein	O
structure	O
.	O

RESULTS	O
:	O
The	O
diagnosis	O
of	O
GDLD	O
was	O
established	O
in	O
the	O
patient	O
and	O
the	O
affected	O
sibling	O
on	O
slit-lamp	O
examinations	O
,	O
which	O
revealed	O
mulberry-like	O
opacities	O
in	O
the	O
subepithelium	O
and	O
anterior	O
stroma	O
that	O
were	O
confirmed	O
on	O
histopathology	O
.	O

The	O
findings	O
of	O
the	O
in	O
vivo	O
confocal	O
microscopy	O
were	O
consistent	O
with	O
those	O
reported	O
in	O
previous	O
reports	O
.	O

Sequencing	O
TACSTD2	O
revealed	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
c.356G>A	B-DNAMutation
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
C119Y	B-ProteinMutation
in	O
the	O
two	O
affected	O
siblings	O
.	O

The	O
mutation	O
was	O
found	O
to	O
be	O
pathogenic	O
on	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
(SIFT)	O
analysis	O
and	O
was	O
not	O
found	O
in	O
normal	O
controls	O
and	O
unaffected	O
individuals	O
of	O
the	O
family	O
.	O

A	O
synonymous	O
,	O
previously	O
reported	O
,	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
;	O
rs13267	B-SNP
)	O
was	O
also	O
seen	O
in	O
all	O
the	O
individuals	O
of	O
the	O
family	O
.	O

Protein	O
modeling	O
studies	O
involving	O
wild-type	O
and	O
mutant	O
protein	O
indicated	O
an	O
exposed	O
cysteine	O
residue	O
in	O
the	O
mutant	O
protein	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
TACSTD2	O
C119Y	B-ProteinMutation
mutation	O
leading	O
to	O
an	O
amino	O
acid	O
substitution	O
was	O
identified	O
in	O
two	O
affected	O
siblings	O
of	O
a	O
family	O
.	O

Protein	O
modeling	O
studies	O
revealed	O
an	O
exposed	O
cysteine	O
residue	O
,	O
which	O
might	O
cause	O
interchain	O
disulfide	O
bond	O
formation	O
and	O
protein	O
aggregation	O
leading	O
to	O
disturbed	O
cell	O
junctions	O
of	O
the	O
corneal	O
epithelium	O
.	O

Mutation	O
analysis	O
in	O
a	O
Chinese	O
family	O
with	O
multiple	O
endocrine	O
neoplasia	O
type	O
1	O
.	O

BACKGROUND	O
:	O
Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(MEN1)	O
is	O
an	O
autosomal	O
dominant	O
cancer	O
syndrome	O
which	O
is	O
caused	O
by	O
germline	O
mutations	O
of	O
the	O
tumor	O
suppressor	O
gene	O
MEN1	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
mutations	O
in	O
a	O
Chinese	O
pedigree	O
with	O
MEN1	O
.	O

METHODS	O
:	O
A	O
large	O
Chinese	O
family	O
with	O
MEN1	O
was	O
collected	O
.	O

All	O
of	O
the	O
coded	O
regions	O
and	O
their	O
adjacent	O
sequences	O
of	O
the	O
MEN1	O
gene	O
were	O
amplified	O
and	O
sequenced	O
.	O

RESULTS	O
:	O
In	O
this	O
family	O
,	O
a	O
heterozygous	O
cytosine	O
insertion	O
in	O
exon	O
10	O
c.1546_1547insC	B-DNAMutation
inducing	O
a	O
frame	O
shift	O
mutation	O
of	O
MEN1	O
was	O
found	O
in	O
the	O
proband	O
and	O
the	O
other	O
two	O
suffering	O
members	O
of	O
his	O
family	O
.	O

This	O
mutation	O
was	O
linked	O
to	O
a	O
novel	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
intron	O
3	O
(	O
IVS3	B-DNAMutation
+	I-DNAMutation
18C	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
)	O
.	O

CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
exon	O
10	O
of	O
MEN1	O
gene	O
might	O
induce	O
development	O
of	O
parathyroid	O
hyperplasia	O
and	O
pituitary	O
adenoma	O
and	O
cosegregate	O
with	O
MEN1	O
syndrome	O
.	O

The	O
significance	O
of	O
the	O
new	O
found	O
IVS3	B-DNAMutation
+	I-DNAMutation
18C	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
of	O
MEN1	O
needs	O
a	O
further	O
investigation	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
helix	O
10	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
causes	O
generalized	O
glucocorticoid	O
resistance	O
by	O
disrupting	O
the	O
structure	O
of	O
the	O
ligand-binding	O
domain	O
.	O

CONTEXT	O
:	O
Generalized	O
glucocorticoid	O
resistance	O
syndrome	O
is	O
a	O
rare	O
familial	O
or	O
sporadic	O
condition	O
characterized	O
by	O
partial	O
insensitivity	O
to	O
glucocorticoids	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
glucocorticoid	O
receptor	O
(GR)	O
gene	O
.	O

Most	O
of	O
the	O
reported	O
cases	O
are	O
adults	O
,	O
demonstrating	O
symptoms	O
associated	O
with	O
mineralocorticoid	O
and/or	O
adrenal	O
androgen	O
excess	O
caused	O
by	O
compensatively	O
increased	O
secretion	O
of	O
the	O
adrenocorticotropic	O
hormone	O
.	O

PATIENT	O
:	O
We	O
identified	O
a	O
new	O
2-yr-old	O
female	O
case	O
of	O
generalized	O
glucocorticoid	O
resistance	O
syndrome	O
.	O

The	O
patient	O
(TJ)	O
presented	O
with	O
a	O
generalized	O
seizure	O
associated	O
with	O
hypoglycemia	O
and	O
hypokalemia	O
.	O

She	O
also	O
had	O
hypertension	O
and	O
premature	O
pubarche	O
,	O
whereas	O
dexamethasone	O
effectively	O
suppressed	O
these	O
clinical	O
manifestations	O
.	O

RESULTS	O
:	O
The	O
patient's	O
GR	O
gene	O
had	O
a	O
heterozygotic	O
mutation	O
G-->A	B-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
2141	I-DNAMutation
(	O
exon	O
8	O
)	O
,	O
which	O
resulted	O
in	O
substitution	O
of	O
arginine	O
by	O
glutamine	O
at	O
amino	O
acid	O
position	O
714	O
in	O
the	O
ligand-binding	O
domain	O
(LBD)	O
of	O
the	O
GR	O
alpha	O
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
mutant	O
receptor	O
had	O
significantly	O
impaired	O
transactivation	O
activity	O
with	O
a	O
2-fold	O
reduction	O
in	O
affinity	O
to	O
ligand	O
.	O

It	O
showed	O
attenuated	O
transactivation	O
of	O
the	O
activation	O
function	O
(AF)-2	O
and	O
reduced	O
binding	O
to	O
a	O
p160	O
nuclear	O
receptor	O
coactivator	O
.	O

Computer-based	O
structural	O
analysis	O
revealed	O
that	O
replacement	O
of	O
arginine	O
by	O
glutamine	O
at	O
position	O
714	O
transmitted	O
a	O
conformational	O
change	O
to	O
the	O
LBD	O
and	O
the	O
AF-2	O
transactivation	O
surface	O
,	O
resulting	O
in	O
a	O
decreased	O
binding	O
affinity	O
to	O
ligand	O
and	O
to	O
the	O
LXXLL	O
coactivator	O
motif	O
.	O

CONCLUSIONS	O
:	O
Dexamethasone	O
treatment	O
is	O
effective	O
in	O
controlling	O
the	O
premature	O
pubarche	O
,	O
hypoglycemia	O
,	O
hypertension	O
,	O
and	O
hypokalemia	O
in	O
this	O
child	O
case	O
,	O
wherein	O
arginine	O
714	O
plays	O
a	O
key	O
role	O
in	O
the	O
proper	O
formation	O
of	O
the	O
ligand-binding	O
pocket	O
and	O
the	O
AF-2	O
surface	O
of	O
the	O
GR	O
alpha	O
LBD	O
.	O

Mutation	O
analysis	O
of	O
the	O
LCE3B/LCE3C	O
genes	O
in	O
Psoriasis	O
.	O

BACKGROUND	O
:	O
An	O
association	O
between	O
a	O
common	O
deletion	O
comprising	O
the	O
late	O
cornified	O
envelope	O
LCE3B	O
and	O
LCE3C	O
genes	O
(LCE3C_LCE3B-del)	O
and	O
Psoriasis	O
(Ps)	O
has	O
been	O
reported	O
.	O

The	O
expression	O
of	O
these	O
LCE	O
genes	O
was	O
induced	O
after	O
skin	O
barrier	O
disruption	O
and	O
was	O
also	O
strong	O
in	O
psoriatic	O
lesions	O
.	O

The	O
damage	O
to	O
the	O
skin	O
barrier	O
could	O
trigger	O
an	O
epidermal	O
response	O
that	O
includes	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
formation	O
of	O
skin	O
barrier	O
.	O

METHODS	O
:	O
We	O
determined	O
the	O
LCE3C_LCE3B-del	O
genotype	O
in	O
405	O
Ps	O
patients	O
and	O
400	O
healthy	O
controls	O
from	O
a	O
Northern	O
Spain	O
region	O
(Asturias)	O
.	O

These	O
patients	O
and	O
controls	O
were	O
also	O
genotyped	O
for	O
the	O
rs4112788	B-SNP
single	O
nucleotide	O
polymorphism	O
,	O
in	O
strong	O
linkage	O
disequilibrium	O
with	O
the	O
LCE3C_B	O
cluster	O
.	O

The	O
LCE3B	O
and	O
LCE3C	O
gene	O
variant	O
was	O
determined	O
in	O
the	O
patients	O
through	O
SSCA	O
,	O
DHPLC	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Allele	O
and	O
genotype	O
frequencies	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
for	O
the	O
rs4112788	B-SNP
and	O
LCE3C_LCE3B-del	O
polymorphisms	O
.	O

However	O
,	O
del/del	O
homozygotes	O
were	O
significantly	O
higher	O
among	O
patients	O
with	O
chronic	O
plaque	O
type	O
Ps	O
who	O
did	O
not	O
develop	O
arthritis	O
(	O
p	O
=	O
0.03	O
;	O
OR	O
=	O
1.4	O
;	O
95%CI	O
=	O
1.03-1.92	O
)	O
.	O

The	O
analysis	O
of	O
the	O
coding	O
sequence	O
of	O
LCE3B	O
and	O
LCE3C	O
in	O
the	O
patients	O
who	O
had	O
at	O
least	O
one	O
copy	O
of	O
this	O
showed	O
that	O
only	O
one	O
patient	O
has	O
a	O
no	O
previously	O
reported	O
LCE3B	O
variant	O
R68C	B-ProteinMutation
.	O

CONCLUSION	O
:	O
Our	O
work	O
suggested	O
that	O
homozygosity	O
for	O
a	O
common	O
LCE3C_LCE3B	O
deletion	O
contributes	O
to	O
the	O
risk	O
of	O
developing	O
chronic	O
plaque	O
type	O
Ps	O
without	O
psoriatic	O
arthritis	O
.	O

Our	O
work	O
confirmed	O
previous	O
reports	O
that	O
described	O
an	O
association	O
of	O
this	O
marker	O
with	O
only	O
skin	O
manifestations	O
,	O
and	O
supported	O
the	O
concept	O
of	O
different	O
genetic	O
risk	O
factors	O
contributing	O
to	O
skin	O
and	O
joint	O
disease	O
.	O

Loss	O
of	O
heterozygosity	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Tg737	O
in	O
the	O
side	O
population	O
cells	O
of	O
hepatocellular	O
carcinomas	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O

Analysis	O
of	O
loss	O
of	O
heterozygosity	O
(LOH)	O
is	O
a	O
useful	O
method	O
for	O
finding	O
genetic	O
alterations	O
in	O
tumor	O
and	O
precancerous	O
lesion	O
tissues	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
LOH	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Tg737	O
in	O
side	O
population	O
cells	O
of	O
human	O
hepatocellular	O
carcinomas	O
.	O

Side	O
population	O
cells	O
were	O
sorted	O
and	O
identification	O
by	O
flow	O
cytometry	O
from	O
suspensions	O
of	O
hepatocarcinoma	O
or	O
normal	O
liver	O
cells	O
generated	O
from	O
95	O
hepatocellular	O
carcinoma	O
and	O
normal	O
tissues	O
,	O
respectively	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
two	O
groups	O
of	O
side	O
population	O
cells	O
and	O
peripheral	O
blood	O
specimens	O
.	O

Five	O
microsatellite	O
markers	O
on	O
the	O
Tg737	O
gene	O
were	O
used	O
to	O
analyze	O
the	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
in	O
the	O
side	O
population	O
cells	O
of	O
the	O
hepatocellular	O
carcinoma	O
.	O

Twenty-four	O
(25.30%)	O
tumor	O
samples	O
had	O
a	O
large	O
deletion	O
in	O
more	O
than	O
three	O
microsatellite	O
markers	O
.	O

The	O
highest	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
was	O
observed	O
with	O
the	O
G64212	O
marker	O
(78.75%)	O
and	O
the	O
SHGC-57879	O
marker	O
(75.95%)	O
.	O

Statistical	O
analysis	O
of	O
the	O
correlation	O
between	O
loss	O
of	O
heterozygosity	O
of	O
Tg737	O
and	O
clinicopathological	O
features	O
indicated	O
a	O
strong	O
correlation	O
between	O
the	O
two	O
markers	O
associated	O
with	O
the	O
highest	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
and	O
survival	O
.	O

The	O
results	O
indicate	O
that	O
loss	O
of	O
heterozygosity	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Tg737	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
carcinogenetic	O
mechanism	O
of	O
liver	O
cancer	O
stem	O
cells	O
.	O

In	O
addition	O
,	O
the	O
independent	O
association	O
between	O
loss	O
of	O
heterozygosity	O
at	O
the	O
SHGC-57879	O
and	O
G64212	O
markers	O
and	O
worsened	O
short-term	O
survival	O
in	O
patients	O
could	O
be	O
used	O
as	O
a	O
novel	O
prognostic	O
predictor	O
.	O

Further	O
studies	O
of	O
side	O
population	O
cells	O
may	O
contribute	O
to	O
the	O
establishment	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
hepatocellular	O
carcinoma	O
.	O

Molecular	O
diversity	O
of	O
hemoglobin	O
H	O
disease	O
in	O
India	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
variable	O
clinical	O
expression	O
of	O
hemoglobin	O
(Hb)	O
H	O
disease	O
in	O
India	O
.	O

For	O
the	O
study	O
,	O
alpha	O
genotyping	O
was	O
done	O
in	O
8	O
patients	O
with	O
Hb	O
H	O
disease	O
using	O
multiplex	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
sequencing	O
.	O

The	O
study	O
revealed	O
that	O
4	O
genotypes	O
(	O
-	O
-(SEA)/	O
-alpha(3.7)	O
,	O
-	O
-(SA)/-alpha(3.7)	O
,	O
-	O
-(SEA)/-alpha(3.7	O
Sallanches	O
)	O
,	O
-	O
-alpha(3.7)/-alpha(3.7	O
Sallanches)	O
)	O
were	O
responsible	O
for	O
Hb	O
H	O
disease	O
,	O
the	O
alpha+	O
thalassemia	O
mutation	O
(	O
-alpha(3.7	O
)	O
deletion	O
)	O
being	O
the	O
most	O
common	O
defect	O
.	O

The	O
nondeletional	O
mutation	O
Hb	O
Sallanches	O
(	O
alpha	O
2	O
codon	B-DNAMutation
104	I-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
)	O
was	O
seen	O
in	O
3	O
cases	O
.	O

Two	O
unique	O
and	O
novel	O
genotypes	O
leading	O
to	O
Hb	O
H	O
disease	O
were	O
characterized	O
(	O
-	O
-(SEA)/-alpha(3.7	O
Sallanches	O
)	O
and	O
-alpha(3.7)/-alpha(3.7	O
Sallanches)	O
)	O
.	O

Because	O
a	O
majority	O
of	O
patients	O
with	O
Hb	O
H	O
disease	O
do	O
not	O
have	O
severe	O
manifestations	O
,	O
prenatal	O
diagnosis	O
is	O
usually	O
unwarranted	O
in	O
India	O
.	O

Promoter	O
insertion/deletion	O
in	O
the	O
IRF5	O
gene	O
is	O
highly	O
associated	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythematosus	O
in	O
distinct	O
populations	O
,	O
but	O
exerts	O
a	O
modest	O
effect	O
on	O
gene	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
examined	O
the	O
genetic	O
association	O
of	O
the	O
promoter	O
insertion/deletion	O
(indel)	O
in	O
IRF5	O
gene	O
with	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
in	O
distinct	O
populations	O
and	O
assessed	O
its	O
role	O
in	O
gene	O
expression	O
.	O

METHODS	O
:	O
Four	O
IRF5	O
polymorphisms	O
were	O
genotyped	O
in	O
1488	O
SLE	O
patients	O
and	O
1466	O
controls	O
.	O

Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
real-time	O
PCR	O
using	O
RNA	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMC)	O
.	O

RESULTS	O
:	O
The	O
promoter	O
indel	O
and	O
rs2070197	B-SNP
had	O
independent	O
genetic	O
effects	O
,	O
which	O
accounted	O
for	O
the	O
association	O
of	O
rs2004640	B-SNP
and	O
rs10954213	B-SNP
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
rs10954213	B-SNP
exerted	O
the	O
greatest	O
influence	O
on	O
IRF5	O
transcript	O
levels	O
.	O

CONCLUSION	O
:	O
We	O
corroborated	O
the	O
association	O
of	O
the	O
promoter	O
indel	O
with	O
SLE	O
in	O
5	O
different	O
populations	O
and	O
revealed	O
that	O
rs10954213	B-SNP
is	O
the	O
main	O
single-nucleotide	O
polymorphism	O
responsible	O
for	O
altered	O
IRF5	O
expression	O
in	O
PBMC	O
.	O

Novel	O
mutations	O
identification	O
in	O
exon	O
4	O
of	O
LDLR	O
gene	O
in	O
patients	O
with	O
moderate	O
hypercholesterolemia	O
in	O
a	O
Venezuelan	O
population	O
.	O

Familial	O
hypercholesterolemia	O
(FH)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
increase	O
in	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	O
levels	O
and	O
premature	O
coronary	O
artery	O
disease	O
.	O

In	O
Venezuela	O
,	O
the	O
molecular	O
basis	O
of	O
FH	O
has	O
not	O
been	O
characterized	O
,	O
thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
mutations	O
in	O
the	O
exon	O
4	O
of	O
the	O
LDLR	O
(LDL-receptor)	O
gene	O
in	O
225	O
Venezuelan	O
mixed	O
race	O
individuals	O
(	O
65	O
hypercholesterolemic	O
and	O
160	O
normolipidemic	O
)	O
.	O

The	O
exon	O
4	O
of	O
the	O
LDLR	O
gene	O
was	O
screened	O
by	O
polymerase	O
chain	O
reaction-single	O
strand	O
conformational	O
polymorphism	O
(PCR-SSCP)	O
analysis	O
and	O
DNA	O
sequencing	O
.	O

Additionally	O
,	O
ApoB-100	O
gene	O
mutations	O
were	O
investigated	O
.	O

Different	O
LDLR	O
gene	O
mutations	O
were	O
identified	O
in	O
5	O
hypercholesterolemic	O
patients	O
(7.7%)	O
,	O
3	O
missense	O
mutations	O
(4.6%)	O
,	O
and	O
2	O
frameshift	O
mutations	O
(3%)	O
.	O

All	O
mutations	O
were	O
heterozygous	O
.	O

The	O
missense	O
mutations	O
included	O
the	O
amino	O
acid	O
substitution	O
p.E180K	B-ProteinMutation
,	O
p.R194S	B-ProteinMutation
,	O
and	O
p.C152G	B-ProteinMutation
.	O

The	O
frameshift	O
mutations	O
are	O
caused	O
by	O
insertions	O
resulting	O
in	O
the	O
creation	O
of	O
stop	O
codons	O
:	O
p.D157fsX158	B-ProteinMutation
and	O
p.S173fsX174	B-ProteinMutation
,	O
which	O
could	O
code	O
for	O
truncated	O
LDLR	O
of	O
157	O
and	O
173	O
amino	O
acids	O
,	O
respectively	O
.	O

The	O
apoB	O
gene	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
our	O
patients	O
and	O
to	O
our	O
knowledge	O
4	O
mutations	O
identified	O
in	O
this	O
study	O
have	O
not	O
been	O
reported	O
previously	O
,	O
this	O
study	O
being	O
the	O
first	O
comprehensive	O
mutation	O
analysis	O
of	O
the	O
LDLR	O
causing	O
FH	O
in	O
our	O
region	O
.	O

The	O
early	O
identification	O
of	O
individuals	O
at	O
risk	O
allows	O
changes	O
in	O
lifestyle	O
,	O
including	O
dietary	O
intervention	O
,	O
followed	O
by	O
drug	O
treatment	O
.	O

hOGG1	O
Ser326Cys	B-ProteinMutation
polymorphism	O
and	O
risk	O
of	O
lung	O
cancer	O
by	O
histological	O
type	O
.	O

Human	O
8-oxoguanine	O
DNA	O
glycosylase	O
1	O
(hOGG1)	O
has	O
a	O
major	O
role	O
in	O
the	O
repair	O
of	O
8-hydroxyguanine	O
,	O
a	O
major	O
promutagenic	O
DNA	O
lesion	O
.	O

The	O
genetic	O
polymorphism	O
rs1052133	B-SNP
,	O
which	O
leads	O
to	O
substitution	O
of	O
the	O
amino	O
acid	O
at	O
codon	O
326	O
from	O
Ser	O
to	O
Cys	O
,	O
shows	O
functional	O
differences	O
,	O
namely	O
a	O
decrease	O
in	O
enzyme	O
activity	O
in	O
hOGG1-Cys326	O
.	O

Although	O
several	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
rs1052133	B-SNP
and	O
lung	O
cancer	O
susceptibility	O
,	O
the	O
effect	O
of	O
this	O
locus	O
on	O
lung	O
cancer	O
according	O
to	O
histology	O
remains	O
unclear	O
.	O

We	O
therefore	O
conducted	O
a	O
case-control	O
study	O
with	O
515	O
incident	O
lung	O
cancer	O
cases	O
and	O
1030	O
age-	O
and	O
sex-matched	O
controls	O
without	O
cancer	O
,	O
and	O
further	O
conducted	O
a	O
meta-analysis	O
.	O

In	O
overall	O
analysis	O
,	O
the	O
homozygous	O
Cys/Cys	O
genotype	O
showed	O
a	O
significant	O
association	O
with	O
lung	O
cancer	O
compared	O
to	O
Ser	O
allele	O
carrier	O
status	O
(	O
odds	O
ratio	O
(OR)=1.31	O
,	O
95%	O
confidence	O
interval	O
(	O
CI)=1.02-1.69	O
)	O
.	O

By	O
histology-based	O
analysis	O
,	O
the	O
Cys/Cys	O
genotype	O
showed	O
a	O
significantly	O
positive	O
association	O
with	O
small-cell	O
carcinoma	O
(	O
OR=2.40	O
,	O
95%	O
CI=1.32-4.49	O
)	O
and	O
marginally	O
significant	O
association	O
with	O
adenocarcinoma	O
(	O
OR=1.32	O
,	O
95%	O
CI=0.98-1.77	O
)	O
.	O

A	O
meta-analysis	O
of	O
previous	O
and	O
our	O
present	O
study	O
revealed	O
that	O
this	O
polymorphism	O
is	O
positively	O
associated	O
with	O
adenocarcinoma	O
,	O
although	O
suggestive	O
associations	O
were	O
also	O
found	O
for	O
squamous-	O
and	O
small-cell	O
lung	O
cancers	O
.	O

These	O
results	O
indicate	O
that	O
rs1052133	B-SNP
contributes	O
to	O
the	O
risk	O
of	O
adenocarcinoma	O
of	O
lung	O
.	O

TNF	O
receptor-associated	O
periodic	O
fever	O
syndrome	O
caused	O
by	O
sequence	O
alterations	O
in	O
exonic	O
splicing	O
enhancers	O
:	O
comment	O
on	O
the	O
article	O
by	O
Tr	O
	O
benbach	O
et	O
al	O
.	O

Tumor	O
necrosis	O
factor	O
receptor-associated	O
periodic	O
syndrome	O
(TRAPS)	O
,	O
an	O
autosomal	O
disease	O
belonging	O
to	O
human	O
autoinflammatory	O
syndromes	O
,	O
is	O
caused	O
by	O
mutations	O
in	O
Tumor	O
Necrosis	O
Factor	O
Receptor	O
Superfamily	O
Member	O
1A	O
(TNFRSF1A)	O
gene	O
.	O

Tr	O
	O
benbach	O
and	O
colleagues	O
described	O
a	O
patient	O
with	O
two	O
heterozygotic	O
nucleotide	O
transversions	O
in	O
exon	O
4	O
of	O
TNFRSF1A	O
gene	O
:	O
the	O
first	O
is	O
a	O
substitution	O
from	O
guanine	O
to	O
cytosine	O
at	O
position	O
263	O
of	O
the	O
nucleotide	O
sequence	O
(	O
c.263	B-DNAMutation
G>C	I-DNAMutation
)	O
;	O
the	O
second	O
is	O
a	O
substitution	O
from	O
cytosine	O
to	O
adenine	O
at	O
position	O
264	O
(	O
c.264	B-DNAMutation
C>A	I-DNAMutation
)	O
;	O
the	O
two	O
mutations	O
affect	O
the	O
amino	O
acid	O
number	O
88	O
of	O
the	O
protein	O
.	O

To	O
date	O
,	O
this	O
was	O
the	O
first	O
report	O
of	O
a	O
double	O
monoallelic	O
mutation	O
in	O
a	O
gene	O
related	O
to	O
autoinflammatory	O
syndromes	O
.	O

Using	O
two	O
web	O
interfaces	O
(	O
ESEfinder	O
and	O
RESCUE-ESE	O
)	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
double	O
nucleotide	O
change	O
may	O
affect	O
an	O
exonic	O
splicing	O
enhancer	O
(ESE)	O
,	O
a	O
sequence	O
element	O
distinct	O
from	O
the	O
canonical	O
splice	O
sites	O
that	O
are	O
needed	O
for	O
normal	O
splicing	O
.	O

ESEs	O
are	O
short	O
and	O
degenerate	O
sequences	O
found	O
within	O
coding	O
exons	O
and	O
required	O
for	O
efficient	O
splicing	O
and	O
splice	O
site	O
recognition	O
.	O

In	O
order	O
to	O
verify	O
if	O
these	O
changes	O
really	O
affect	O
an	O
ESE	O
,	O
it	O
would	O
be	O
useful	O
to	O
analyze	O
the	O
described	O
index	O
case	O
TNFRSF1A	O
cDNA	O
,	O
because	O
if	O
this	O
analysis	O
will	O
evidence	O
an	O
exon	O
skipping	O
in	O
the	O
TNFRSF1A	O
coding	O
sequence	O
,	O
it	O
would	O
then	O
represent	O
the	O
first	O
mutation	O
in	O
autoinflammatory	O
syndromes	O
demonstrated	O
to	O
be	O
caused	O
by	O
ESE	O
elements	O
alteration	O
.	O

Mutation	O
analysis	O
of	O
p63	O
gene	O
in	O
the	O
first	O
Chinese	O
family	O
with	O
ADULT	O
syndrome	O
.	O

BACKGROUND	O
:	O
ADULT	O
syndrome	O
(	O
acro-dermato-ungual-lacrimal-tooth	O
syndrome	O
)	O
is	O
a	O
rare	O
ectodermal	O
dysplasia	O
disorder	O
known	O
as	O
autosomal	O
dominant	O
inheritance	O
.	O

Recent	O
studies	O
have	O
linked	O
p63	O
gene	O
mutation	O
to	O
the	O
development	O
of	O
this	O
disease	O
.	O

However	O
,	O
the	O
genetic	O
characteristics	O
of	O
ADULT	O
syndrome	O
were	O
still	O
not	O
well	O
understood	O
.	O

METHODS	O
:	O
Mutation	O
analysis	O
of	O
p63	O
gene	O
in	O
the	O
first	O
Chinese	O
ADULT	O
syndrome	O
family	O
was	O
performed	O
using	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
The	O
sequence	O
analysis	O
of	O
exon	O
8	O
of	O
p63	O
gene	O
disclosed	O
a	O
heterozygous	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
893	I-DNAMutation
R298Q	B-ProteinMutation
in	O
the	O
proband	O
.	O

In	O
addition	O
,	O
a	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
rs16864880	B-SNP
in	O
the	O
downstream	O
flanking	O
region	O
(DFR)	O
of	O
p63	O
exon	O
8	O
was	O
also	O
identified	O
in	O
this	O
family	O
.	O

The	O
proband	O
and	O
the	O
paternal	O
side	O
including	O
her	O
father	O
exhibited	O
the	O
C/G	O
genotype	O
at	O
this	O
position	O
.	O

The	O
C/G	O
variant	O
frequency	O
in	O
the	O
paternal	O
was	O
significantly	O
higher	O
as	O
compared	O
with	O
the	O
maternal	O
(	O
6/10	O
vs	O
0/6	O
,	O
P	O
=	O
0.034	O
)	O
.	O

CONCLUSIONS	O
:	O
ADULT	O
syndrome	O
may	O
be	O
caused	O
by	O
the	O
p63	O
gene	O
mutation	O
,	O
and	O
it	O
might	O
have	O
closer	O
genetic	O
association	O
with	O
the	O
paternal	O
side	O
in	O
this	O
family	O
.	O

New	O
mutations	O
in	O
the	O
PKD1	O
gene	O
in	O
Czech	O
population	O
with	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(ADPKD)	O
is	O
the	O
most	O
common	O
hereditary	O
renal	O
disease	O
.	O

The	O
disease	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
PKD1	O
(	O
affecting	O
roughly	O
85%	O
of	O
ADPKD	O
patients	O
)	O
and	O
PKD2	O
(	O
affecting	O
roughly	O
14%	O
of	O
ADPKD	O
patients	O
)	O
genes	O
,	O
although	O
in	O
several	O
ADPKD	O
families	O
,	O
the	O
PKD1	O
and/or	O
PKD2	O
linkage	O
was	O
not	O
found	O
.	O

Mutation	O
analysis	O
of	O
the	O
PKD1	O
gene	O
is	O
complicated	O
by	O
the	O
presence	O
of	O
highly	O
homologous	O
genomic	O
duplications	O
of	O
the	O
first	O
two	O
thirds	O
of	O
the	O
gene	O
.	O

METHODS	O
:	O
The	O
direct	O
detection	O
of	O
mutations	O
in	O
the	O
non-duplicated	O
region	O
of	O
the	O
PKD1	O
gene	O
was	O
performed	O
in	O
90	O
unrelated	O
individuals	O
,	O
consisting	O
of	O
58	O
patients	O
with	O
end-stage	O
renal	O
failure	O
(	O
manifesting	O
before	O
their	O
50th	O
year	O
of	O
life	O
)	O
and	O
32	O
individuals	O
from	O
families	O
where	O
the	O
disease	O
was	O
clearly	O
linked	O
to	O
the	O
PKD1	O
gene	O
.	O

Mutation	O
screening	O
was	O
performed	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
.	O

DNA	O
fragments	O
showing	O
an	O
aberrant	O
electrophoretic	O
banding	O
pattern	O
were	O
sequenced	O
.	O

RESULTS	O
:	O
In	O
the	O
non-duplicated	O
region	O
of	O
the	O
PKD1	O
gene	O
,	O
19	O
different	O
likely	O
pathogenic	O
germline	O
sequence	O
changes	O
were	O
identified	O
in	O
19	O
unrelated	O
families/individuals	O
.	O

Fifteen	O
likely	O
pathogenic	O
sequence	O
changes	O
are	O
unique	O
for	O
the	O
Czech	O
population	O
.	O

The	O
following	O
probable	O
mutations	O
were	O
identified	O
:	O
9	O
nonsense	O
mutations	O
,	O
6	O
likely	O
pathogenic	O
missense	O
mutations	O
,	O
2	O
frameshifting	O
mutations	O
,	O
one	O
in-frame	O
deletion	O
and	O
probable	O
splice	O
site	O
mutation	O
.	O

In	O
the	O
non-duplicated	O
region	O
of	O
the	O
PKD1	O
gene	O
,	O
16	O
different	O
polymorphisms	O
or	O
unclassified	O
variants	O
were	O
detected	O
.	O

CONCLUSION	O
:	O
Twenty	O
probable	O
mutations	O
of	O
the	O
PKD1	O
gene	O
in	O
90	O
Czech	O
individuals	O
(	O
fifteen	O
new	O
probable	O
mutations	O
)	O
were	O
detected	O
.	O

The	O
establishment	O
of	O
localization	O
and	O
the	O
type	O
of	O
causal	O
mutations	O
and	O
their	O
genotype	O
phenotype	O
correlation	O
in	O
ADPKD	O
families	O
will	O
improve	O
DNA	O
diagnosis	O
and	O
could	O
help	O
in	O
the	O
assessment	O
of	O
the	O
clinical	O
prognosis	O
of	O
ADPKD	O
patients	O
.	O

Clusters	O
of	O
multidrug-resistant	O
Mycobacterium	O
tuberculosis	O
cases	O
,	O
Europe	O
.	O

Molecular	O
surveillance	O
of	O
multidrug-resistant	O
tuberculosis	O
(	O
MDR	O
TB	O
)	O
was	O
implemented	O
in	O
Europe	O
as	O
case	O
reporting	O
in	O
2005	O
.	O

For	O
all	O
new	O
MDR	O
TB	O
cases	O
detected	O
from	O
January	O
2003	O
through	O
June	O
2007	O
,	O
countries	O
reported	O
case-based	O
epidemiologic	O
data	O
and	O
DNA	O
fingerprint	O
patterns	O
of	O
MDR	O
TB	O
strains	O
when	O
available	O
.	O

International	O
clusters	O
were	O
detected	O
and	O
analyzed	O
.	O

From	O
2003	O
through	O
mid-2007	O
in	O
Europe	O
,	O
2,494	O
cases	O
of	O
MDR	O
TB	O
were	O
reported	O
from	O
24	O
European	O
countries	O
.	O

Epidemiologic	O
and	O
molecular	O
data	O
were	O
linked	O
for	O
593	O
(39%)	O
cases	O
,	O
and	O
672	O
insertion	O
sequence	O
6110	O
DNA	O
fingerprint	O
patterns	O
were	O
reported	O
from	O
19	O
countries	O
.	O

Of	O
these	O
patterns	O
,	O
288	O
(43%)	O
belonged	O
to	O
18	O
European	O
clusters	O
;	O
7	O
clusters	O
(	O
242/288	O
cases	O
,	O
84%	O
)	O
were	O
characterized	O
by	O
strains	O
of	O
the	O
Beijing	O
genotype	O
family	O
,	O
including	O
the	O
largest	O
cluster	O
(	O
175/288	O
cases	O
,	O
61%	O
)	O
.	O

Both	O
clustering	O
and	O
the	O
Beijing	O
genotype	O
were	O
associated	O
with	O
strains	O
originating	O
in	O
eastern	O
European	O
countries	O
.	O

Molecular	O
cluster	O
detection	O
contributes	O
to	O
identification	O
of	O
transmission	O
profile	O
,	O
risk	O
factors	O
,	O
and	O
control	O
measures	O
.	O

The	O
HLA-G	O
14	O
bp	O
insertion/deletion	O
polymorphism	O
is	O
a	O
putative	O
susceptible	O
factor	O
for	O
active	O
human	O
cytomegalovirus	O
infection	O
in	O
children	O
.	O

Human	O
leukocyte	O
antigen-G	O
(HLA-G)	O
expression	O
is	O
a	O
potential	O
factor	O
for	O
the	O
pathogenesis	O
of	O
virus	O
infection	O
.	O

A	O
14	O
bp	O
insertion/deletion	O
polymorphism	O
rs16375	B-SNP
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
HLA-G	O
gene	O
is	O
involved	O
in	O
the	O
stability	O
of	O
HLA-G	O
mRNA	O
and	O
HLA-G	O
protein	O
expression	O
.	O

Therefore	O
,	O
the	O
HLA-G	O
14	O
bp	O
polymorphism	O
might	O
be	O
involved	O
in	O
human	O
cytomegalovirus	O
(hCMV)	O
infection	O
.	O

To	O
test	O
a	O
possible	O
association	O
between	O
the	O
HLA-G	O
14	O
bp	O
deletion/insertion	O
polymorphism	O
and	O
the	O
active	O
hCMV	O
infection	O
,	O
in	O
this	O
study	O
,	O
a	O
total	O
of	O
54	O
patients	O
with	O
active	O
hCMV	O
infection	O
and	O
165	O
age-	O
and	O
sex-matched	O
,	O
unrelated	O
,	O
normal	O
Chinese	O
Han	O
population	O
were	O
genotyped	O
for	O
the	O
14	O
bp	O
insertion/deletion	O
polymorphism	O
.	O

Association	O
of	O
14	O
bp	O
polymorphism	O
with	O
hCMV	O
urine	O
DNA	O
copies	O
and	O
the	O
odds	O
ratio	O
(OR)	O
of	O
the	O
polymorphism	O
as	O
a	O
risk	O
factor	O
for	O
active	O
hCMV	O
infection	O
were	O
analyzed	O
.	O

Our	O
results	O
showed	O
that	O
the	O
prevalence	O
of	O
-14	O
bp/	O
-14	O
bp	O
genotype	O
in	O
active	O
hCMV	O
patients	O
was	O
markedly	O
increased	O
[	O
P(c	O
)	O
=	O
0.00034	O
,	O
OR	O
=	O
3.31	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
:	O
1.77-6.18	O
]	O
,	O
and	O
similar	O
significance	O
was	O
also	O
observed	O
for	O
the	O
frequency	O
of	O
-14	O
bp	O
allele	O
(	O
P	O
c	O
=	O
0.0023	O
,	O
OR	O
=	O
2.24	O
,	O
95%	O
CI	O
:	O
1.38-3.64	O
)	O
when	O
compared	O
with	O
that	O
of	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
urine	O
hCMV	O
DNA	O
copies	O
in	O
patients	O
with	O
the	O
-14	O
bp/	O
-14	O
bp	O
genotype	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
patients	O
with	O
the	O
+14	O
bp/	O
+14	O
bp	O
genotype	O
(	O
P	O
=	O
0.041	O
)	O
.	O

Our	O
findings	O
support	O
a	O
potential	O
role	O
of	O
HLA-G	O
14	O
bp	O
insertion/deletion	O
polymorphism	O
as	O
a	O
susceptible	O
factor	O
for	O
the	O
active	O
hCMV	O
infection	O
.	O

Adenosine	O
A(2A)	O
receptor	O
gene	O
(ADORA2A)	O
variants	O
may	O
increase	O
autistic	O
symptoms	O
and	O
anxiety	O
in	O
autism	O
spectrum	O
disorder	O
.	O

Autism	O
spectrum	O
disorders	O
(ASDs)	O
are	O
heterogeneous	O
disorders	O
presenting	O
with	O
increased	O
rates	O
of	O
anxiety	O
.	O

The	O
adenosine	O
A(2A)	O
receptor	O
gene	O
(ADORA2A)	O
is	O
associated	O
with	O
panic	O
disorder	O
and	O
is	O
located	O
on	O
chromosome	O
22q11.23	O
.	O

Its	O
gene	O
product	O
,	O
the	O
adenosine	O
A(2A)	O
receptor	O
,	O
is	O
strongly	O
expressed	O
in	O
the	O
caudate	O
nucleus	O
,	O
which	O
also	O
is	O
involved	O
in	O
ASD	O
.	O

As	O
autistic	O
symptoms	O
are	O
increased	O
in	O
individuals	O
with	O
22q11.2	O
deletion	O
syndrome	O
,	O
and	O
large	O
22q11.2	O
deletions	O
and	O
duplications	O
have	O
been	O
observed	O
in	O
ASD	O
individuals	O
,	O
in	O
this	O
study	O
,	O
98	O
individuals	O
with	O
ASD	O
and	O
234	O
control	O
individuals	O
were	O
genotyped	O
for	O
eight	O
single-nucleotide	O
polymorphisms	O
in	O
ADORA2A	O
.	O

Nominal	O
association	O
with	O
the	O
disorder	O
was	O
observed	O
for	O
rs2236624	B-SNP
-	O
CC	O
,	O
and	O
phenotypic	O
variability	O
in	O
ASD	O
symptoms	O
was	O
influenced	O
by	O
rs3761422	B-SNP
,	O
rs5751876	B-SNP
and	O
rs35320474	B-SNP
.	O

In	O
addition	O
,	O
association	O
of	O
ADORA2A	O
variants	O
with	O
anxiety	O
was	O
replicated	O
for	O
individuals	O
with	O
ASD	O
.	O

Findings	O
point	O
toward	O
a	O
possible	O
mediating	O
role	O
of	O
ADORA2A	O
variants	O
on	O
phenotypic	O
expression	O
in	O
ASD	O
that	O
need	O
to	O
be	O
replicated	O
in	O
a	O
larger	O
sample	O
.	O

Protein	O
kinase	O
C	O
gamma	O
,	O
a	O
protein	O
causative	O
for	O
dominant	O
ataxia	O
,	O
negatively	O
regulates	O
nuclear	O
import	O
of	O
recessive-ataxia-related	O
aprataxin	O
.	O

Spinocerebellar	O
ataxia	O
type	O
14	O
(SCA14)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
protein	O
kinase	O
C	O
gamma	O
(	O
PKC	O
gamma	O
)	O
.	O

We	O
report	O
an	O
SCA14	O
family	O
with	O
a	O
novel	O
deletion	O
of	O
a	O
termination-codon-containing	O
region	O
,	O
resulting	O
in	O
a	O
missense	O
change	O
and	O
a	O
C-terminal	O
13-amino-acid	O
extension	O
with	O
increased	O
kinase	O
activity	O
.	O

Notably	O
,	O
one	O
patient	O
with	O
a	O
severe	O
phenotype	O
is	O
the	O
first	O
homozygote	O
for	O
the	O
mutation	O
causing	O
SCA14	O
.	O

We	O
show	O
the	O
novel	O
molecular	O
consequences	O
of	O
increased	O
kinase	O
activities	O
of	O
mutants	O
:	O
aprataxin	O
(APTX)	O
,	O
a	O
DNA	O
repair	O
protein	O
causative	O
for	O
autosomal	O
recessive	O
ataxia	O
,	O
was	O
found	O
to	O
be	O
a	O
preferential	O
substrate	O
of	O
mutant	O
PKC	O
gamma	O
,	O
and	O
phosphorylation	O
inhibited	O
its	O
nuclear	O
entry	O
.	O

The	O
phosphorylated	O
residue	O
was	O
Thr111	O
,	O
located	O
adjacent	O
to	O
the	O
nuclear	O
localization	O
signal	O
,	O
and	O
disturbed	O
interactions	O
with	O
importin	O
alpha	O
,	O
a	O
nuclear	O
import	O
adaptor	O
.	O

Decreased	O
nuclear	O
APTX	O
increased	O
oxidative	O
stress-induced	O
DNA	O
damage	O
and	O
cell	O
death	O
.	O

Phosphorylation-resistant	O
APTX	O
,	O
kinase	O
inhibitors	O
,	O
and	O
antioxidants	O
may	O
be	O
therapeutic	O
options	O
for	O
SCA14	O
.	O

CYP1A1	O
genotype	O
modifies	O
the	O
impact	O
of	O
smoking	O
on	O
effectiveness	O
of	O
HAART	O
among	O
women	O
.	O

We	O
have	O
recently	O
shown	O
that	O
cigarette	O
smoking	O
is	O
associated	O
with	O
lesser	O
responses	O
to	O
potent	O
antiretroviral	O
therapies	O
.	O

Certain	O
Cytochrome	O
P-450	O
enzymes	O
activate	O
compounds	O
derived	O
from	O
tobacco	O
smoke	O
into	O
toxic	O
forms	O
that	O
may	O
promote	O
HIV-1	O
gene	O
expression	O
through	O
promotion	O
of	O
DNA-adduct	O
formation	O
by	O
the	O
oxidation	O
of	O
chemical	O
constituents	O
of	O
cigarette	O
smoke	O
,	O
such	O
as	O
polyaromatic	O
hydrocarbons	O
and	O
dioxins	O
.	O

To	O
explore	O
the	O
association	O
between	O
environmental	O
and	O
genetic	O
factors	O
to	O
viral	O
replication	O
in	O
women	O
who	O
smoke	O
and	O
receive	O
highly	O
active	O
anti-retroviral	O
therapy	O
(HAART)	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
polymorphisms	O
in	O
a	O
panel	O
of	O
four	O
Cytochrome	O
P-450	O
genes	O
(	O
CYP1A1	O
,	O
CYP2A6	O
,	O
CYP2D6	O
,	O
and	O
CYP2E1	O
)	O
and	O
two	O
Glutathione	O
S-transferase	O
genes	O
(	O
GSTM1	O
and	O
GSST1	O
)	O
in	O
924	O
participants	O
of	O
the	O
Women's	O
Interagency	O
HIV	O
Study	O
(WIHS)	O
.	O

Our	O
findings	O
showed	O
that	O
GSTM1	O
and	O
GSST1	O
deletions	O
were	O
not	O
associated	O
with	O
HAART	O
effectiveness	O
.	O

By	O
contrast	O
,	O
homozygosity	O
for	O
the	O
CYP1A1-m1	O
polymorphism	O
,	O
was	O
associated	O
with	O
impaired	O
viral	O
response	O
to	O
treatment	O
among	O
smokers	O
(	O
relative	O
hazard	O
(RH)	O
=	O
0.54	O
;	O
95%	O
confidence	O
interval	O
=	O
0.31-0.94	O
)	O
after	O
adjustment	O
for	O
pretreament	O
viral	O
load	O
,	O
CD4	O
count	O
,	O
age	O
,	O
hepatitis	O
C	O
infection	O
,	O
prior	O
HAART	O
therapy	O
and	O
race	O
,	O
although	O
it	O
had	O
no	O
effect	O
among	O
nonsmokers	O
.	O

We	O
conclude	O
that	O
the	O
association	O
of	O
the	O
CPY1A1-m1	O
variant	O
with	O
a	O
reduced	O
response	O
to	O
HAART	O
therapy	O
in	O
HIV	O
infected	O
smokers	O
is	O
consistent	O
with	O
this	O
enzyme's	O
role	O
in	O
the	O
metabolic	O
conversion	O
of	O
environmental	O
toxins	O
to	O
DNA	O
adducts	O
,	O
which	O
may	O
directly	O
promote	O
HIV-1	O
gene	O
expression	O
.	O

RPGR	O
ORF15	O
genotype	O
and	O
clinical	O
variability	O
of	O
retinal	O
degeneration	O
in	O
an	O
Australian	O
population	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
the	O
retinitis	O
pigmentosa	O
GTPase	O
regulator	O
gene	O
(RPGR)	O
are	O
estimated	O
to	O
cause	O
up	O
to	O
20%	O
of	O
all	O
Caucasian	O
retinitis	O
pigmentosa	O
and	O
up	O
to	O
75%	O
of	O
cases	O
of	O
X-Linked	O
RP	O
(XLRP)	O
.	O

Exon	O
open	O
reading	O
frame	O
15	O
(ORF15)	O
is	O
a	O
purine-rich	O
mutation	O
hotspot	O
.	O

Mutations	O
in	O
RPGR	O
ORF15	O
have	O
also	O
been	O
documented	O
to	O
cause	O
X	O
linked	O
cone-rod	O
dystrophy	O
(XLCORD)	O
and	O
atrophic	O
macular	O
degeneration	O
at	O
an	O
unknown	O
frequency	O
.	O

METHODS	O
:	O
From	O
a	O
hospital	O
clinic	O
population	O
,	O
probands	O
with	O
probable	O
XLRP	O
and	O
XLCORD	O
were	O
screened	O
for	O
RPGR	O
ORF15	O
mutations	O
and	O
fully	O
phenotyped	O
.	O

RESULTS	O
:	O
Four	O
different	O
RPGR	O
ORF15	O
mutations	O
were	O
found	O
in	O
four	O
probands	O
.	O

All	O
mutations	O
in	O
the	O
ORF15	O
exon	O
resulted	O
in	O
premature	O
truncation	O
of	O
the	O
RPGR	O
protein	O
.	O

Three	O
were	O
nonsense	O
mutations	O
:	O
c.507G>T	B-DNAMutation
p.E169stop	B-ProteinMutation
,	O
c.867G>T	B-DNAMutation
p.G289stop	B-ProteinMutation
,	O
c.897G>T	B-DNAMutation
p.E299stop	B-ProteinMutation
and	O
the	O
fourth	O
a	O
single	O
nucleotide	O
insertion	O
c.1558-1559insA	B-DNAMutation
(	O
p.S522fs	B-ProteinMutation
525stop	I-ProteinMutation
)	O
.	O

One	O
family	O
exhibited	O
typical	O
XLRP	O
,	O
two	O
XLCORD	O
and	O
one	O
a	O
combination	O
of	O
the	O
phenotypes	O
.	O

CONCLUSION	O
:	O
RPGR	O
ORF15	O
mutations	O
produce	O
intrafamilial	O
and	O
interfamilial	O
clinical	O
variability	O
with	O
varying	O
degrees	O
of	O
cone	O
degeneration	O
.	O

In	O
an	O
Australian	O
clinic	O
population	O
RPGR	O
ORF15	O
mutations	O
cause	O
XLCORD	O
in	O
addition	O
to	O
XLRP	O
.	O

Somatic	O
LKB1	O
mutations	O
promote	O
cervical	O
cancer	O
progression	O
.	O

Human	O
Papilloma	O
Virus	O
(HPV)	O
is	O
the	O
etiologic	O
agent	O
for	O
cervical	O
cancer	O
.	O

Yet	O
,	O
infection	O
with	O
HPV	O
is	O
not	O
sufficient	O
to	O
cause	O
cervical	O
cancer	O
,	O
because	O
most	O
infected	O
women	O
develop	O
transient	O
epithelial	O
dysplasias	O
that	O
spontaneously	O
regress	O
.	O

Progression	O
to	O
invasive	O
cancer	O
has	O
been	O
attributed	O
to	O
diverse	O
host	O
factors	O
such	O
as	O
immune	O
or	O
hormonal	O
status	O
,	O
as	O
no	O
recurrent	O
genetic	O
alterations	O
have	O
been	O
identified	O
in	O
cervical	O
cancers	O
.	O

Thus	O
,	O
the	O
pressing	O
question	O
as	O
to	O
the	O
biological	O
basis	O
of	O
cervical	O
cancer	O
progression	O
has	O
remained	O
unresolved	O
,	O
hampering	O
the	O
development	O
of	O
novel	O
therapies	O
and	O
prognostic	O
tests	O
.	O

Here	O
we	O
show	O
that	O
at	O
least	O
20%	O
of	O
cervical	O
cancers	O
harbor	O
somatically-acquired	O
mutations	O
in	O
the	O
LKB1	O
tumor	O
suppressor	O
.	O

Approximately	O
one-half	O
of	O
tumors	O
with	O
mutations	O
harbored	O
single	O
nucleotide	O
substitutions	O
or	O
microdeletions	O
identifiable	O
by	O
exon	O
sequencing	O
,	O
while	O
the	O
other	O
half	O
harbored	O
larger	O
monoallelic	O
or	O
biallelic	O
deletions	O
detectable	O
by	O
multiplex	O
ligation	O
probe	O
amplification	O
(MLPA)	O
.	O

Biallelic	O
mutations	O
were	O
identified	O
in	O
most	O
cervical	O
cancer	O
cell	O
lines	O
;	O
HeLa	O
,	O
the	O
first	O
human	O
cell	O
line	O
,	O
harbors	O
a	O
homozygous	O
25	O
kb	O
deletion	O
that	O
occurred	O
in	O
vivo	O
.	O

LKB1	O
inactivation	O
in	O
primary	O
tumors	O
was	O
associated	O
with	O
accelerated	O
disease	O
progression	O
.	O

Median	O
survival	O
was	O
only	O
13	O
months	O
for	O
patients	O
with	O
LKB1-deficient	O
tumors	O
,	O
but	O
>100	O
months	O
for	O
patients	O
with	O
LKB1-wild	O
type	O
tumors	O
(	O
P	O
=	O
0.015	O
,	O
log	O
rank	O
test	O
;	O
hazard	O
ratio	O
=	O
0.25	O
,	O
95%	O
CI	O
=	O
0.083	O
to	O
0.77	O
)	O
.	O

LKB1	O
is	O
thus	O
a	O
major	O
cervical	O
tumor	O
suppressor	O
,	O
demonstrating	O
that	O
acquired	O
genetic	O
alterations	O
drive	O
progression	O
of	O
HPV-induced	O
dysplasias	O
to	O
invasive	O
,	O
lethal	O
cancers	O
.	O

Furthermore	O
,	O
LKB1	O
status	O
can	O
be	O
exploited	O
clinically	O
to	O
predict	O
disease	O
recurrence	O
.	O

Novel	O
promoter	O
and	O
exon	O
mutations	O
of	O
the	O
BMPR2	O
gene	O
in	O
Chinese	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
.	O

Pulmonary	O
arterial	O
hypertension	O
(PAH)	O
,	O
which	O
is	O
clinically	O
characterized	O
by	O
a	O
sustained	O
elevation	O
in	O
mean	O
pulmonary	O
artery	O
pressure	O
leading	O
to	O
significant	O
morbidity	O
and	O
mortality	O
,	O
is	O
caused	O
by	O
intense	O
remodeling	O
of	O
small	O
pulmonary	O
arteries	O
by	O
endothelial	O
and	O
smooth	O
muscle	O
proliferation	O
.	O

Genetic	O
studies	O
in	O
familial	O
PAH	O
(FPAH)	O
have	O
revealed	O
heterozygous	O
germline	O
mutations	O
in	O
the	O
bone	O
morphogenetic	O
protein	O
type	O
II	O
receptor	O
(BMPR2)	O
,	O
a	O
receptor	O
for	O
the	O
transforming	O
growth	O
factor	O
(TGF)-beta/BMP	O
superfamily	O
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
mutation	O
screening	O
in	O
the	O
promoter	O
region	O
and	O
the	O
entire	O
coding	O
regions	O
as	O
well	O
as	O
the	O
intron/exon	O
boundaries	O
of	O
the	O
BMPR2	O
gene	O
in	O
20	O
Chinese	O
patients	O
with	O
either	O
idiopathic	O
or	O
FPAH	O
.	O

All	O
novel	O
detected	O
mutations	O
were	O
excluded	O
by	O
their	O
presence	O
in	O
a	O
panel	O
of	O
200	O
chromosomes	O
from	O
normal	O
individuals	O
.	O

A	O
novel	O
mutation	O
,	O
G-669A	B-DNAMutation
,	O
in	O
the	O
promoter	O
sequence	O
of	O
the	O
BMPR2	O
gene	O
was	O
identified	O
in	O
one	O
patient	O
with	O
FPAH	O
,	O
and	O
no	O
exonic	O
mutations	O
were	O
detected	O
in	O
the	O
proband	O
.	O

This	O
mutation	O
abolished	O
a	O
potential	O
specificity	O
protein	O
3	O
(sp3)	O
transcription	O
factor-binding	O
site	O
,	O
and	O
a	O
dual	O
luciferase	O
assay	O
showed	O
that	O
the	O
promoter	O
carrying	O
the	O
-669A	O
allele	O
had	O
significantly	O
decreased	O
transcriptional	O
activity	O
compared	O
with	O
-669G	O
allele	O
.	O

Of	O
the	O
other	O
19	O
patients	O
,	O
three	O
novel	O
heterozygous	O
exonic	O
mutations	O
were	O
identified	O
:	O
a	O
frame	O
shift	O
mutation	O
with	O
deletion	O
of	O
TG	O
at	O
the	O
nucleotide	O
position	O
608-609	O
in	O
exon	O
5	O
Leu203fsX15	B-ProteinMutation
,	O
a	O
nonsense	O
mutation	O
at	O
the	O
nucleotide	O
position	O
292	O
in	O
exon	O
3	O
Glu98X	B-ProteinMutation
and	O
a	O
missense	O
single	O
nucleotide	O
substitution	O
in	O
exon	O
12	O
Ser863Asn	B-ProteinMutation
.	O

Relation	O
between	O
angiotensin-converting	O
enzyme	O
I/D	O
gene	O
polymorphism	O
and	O
pulse	O
pressure	O
in	O
patients	O
with	O
a	O
first	O
anterior	O
acute	O
myocardial	O
infarction	O
.	O

OBJECTIVE	O
:	O
Evidence	O
shows	O
that	O
an	O
elevated	O
pulse	O
pressure	O
(PP)	O
may	O
lead	O
to	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
polymorphism	O
of	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
on	O
the	O
PP	O
after	O
a	O
first	O
anterior	O
acute	O
myocardial	O
infarction	O
(AMI)	O
.	O

METHODS	O
:	O
Overall	O
116	O
patients	O
with	O
a	O
first	O
anterior	O
AMI	O
were	O
included	O
in	O
this	O
cross-sectional	O
study	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
.	O

The	O
ID	O
status	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
by	O
a	O
laboratory	O
staff	O
member	O
who	O
was	O
unaware	O
of	O
the	O
clinical	O
details	O
.	O

Based	O
on	O
the	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
,	O
they	O
were	O
classified	O
into	O
3	O
groups	O
:	O
Deletion/Deletion	O
(DD)	O
genotype	O
(	O
Group	O
1	O
,	O
n=45	O
)	O
,	O
Insertion/Deletion	O
(ID)	O
genotype	O
(	O
Group	O
2	O
,	O
n=58	O
)	O
,	O
Insertion/Insertion	O
(II)	O
genotype	O
(	O
Group	O
3	O
,	O
n=13	O
)	O
.	O

Blood	O
pressure	O
measurements	O
were	O
performed	O
in	O
all	O
patients	O
within	O
10	O
minutes	O
admitted	O
to	O
coronary	O
care	O
unit	O
.	O

The	O
PP	O
was	O
calculated	O
by	O
subtraction	O
of	O
diastolic	O
blood	O
pressure	O
(DBP)	O
from	O
systolic	O
blood	O
pressure	O
(SBP)	O
.	O

Echocardiographic	O
examinations	O
were	O
performed	O
using	O
the	O
parasternal	O
longitudinal	O
axis	O
and	O
apical	O
4-chamber	O
windows	O
in	O
accordance	O
with	O
the	O
recommendations	O
of	O
the	O
American	O
Echocardiography	O
Committee	O
.	O

One-way	O
analysis	O
of	O
variance	O
(ANOVA)	O
and	O
Chi-square	O
analyses	O
were	O
used	O
to	O
compare	O
differences	O
among	O
subjects	O
with	O
different	O
genotypes	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
among	O
clinical	O
parameters	O
of	O
patients	O
.	O

Pulse	O
pressure	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
have	O
ACE	O
DD	O
and	O
ID	O
genotypes	O
than	O
in	O
patients	O
who	O
have	O
ACE	O
II	O
genotype	O
(	O
47+/-	O
16	O
,	O
47+/-	O
14	O
and	O
39+/-	O
12	O
,	O
F=3.4	O
,	O
p<0.05	O
)	O
.	O

But	O
SBP	O
,	O
DBP	O
and	O
heart	O
rate	O
were	O
not	O
significantly	O
different	O
among	O
ACE	O
DD	O
,	O
ACE	O
ID	O
and	O
ACE	O
II	O
genotypes	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggested	O
that	O
,	O
ACE	O
Gene	O
I/D	O
polymorphism	O
D	O
allele	O
may	O
affect	O
PP	O
in	O
patients	O
with	O
a	O
first	O
anterior	O
AMI	O
.	O

Identification	O
of	O
microdeletions	O
in	O
candidate	O
genes	O
for	O
cleft	O
lip	O
and/or	O
palate	O
.	O

BACKGROUND	O
:	O
Genome-wide	O
association	O
studies	O
are	O
now	O
used	O
routinely	O
to	O
identify	O
genes	O
implicated	O
in	O
complex	O
traits	O
.	O

The	O
panels	O
used	O
for	O
such	O
analyses	O
can	O
detect	O
single	O
nucleotide	O
polymorphisms	O
and	O
copy	O
number	O
variants	O
,	O
both	O
of	O
which	O
may	O
help	O
to	O
identify	O
small	O
deleted	O
regions	O
of	O
the	O
genome	O
that	O
may	O
contribute	O
to	O
a	O
particular	O
disease	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
candidate	O
gene	O
analysis	O
involving	O
1,221	O
SNPs	O
in	O
333	O
candidate	O
genes	O
for	O
orofacial	O
clefting	O
,	O
using	O
2,823	O
samples	O
from	O
725	O
two-	O
and	O
three-generation	O
families	O
with	O
a	O
proband	O
having	O
cleft	O
lip	O
with	O
or	O
without	O
cleft	O
palate	O
.	O

We	O
used	O
SNP	O
genotyping	O
,	O
DNA	O
sequencing	O
,	O
high-resolution	O
DNA	O
microarray	O
analysis	O
,	O
and	O
long-range	O
PCR	O
to	O
confirm	O
and	O
characterize	O
the	O
deletion	O
events	O
.	O

RESULTS	O
:	O
This	O
dataset	O
had	O
a	O
high	O
duplicate	O
reproducibility	O
rate	O
(99.98%)	O
,	O
high	O
Mendelian	O
consistency	O
rate	O
(99.93%)	O
,	O
and	O
low	O
missing	O
data	O
rate	O
(0.55%)	O
,	O
which	O
provided	O
a	O
powerful	O
opportunity	O
for	O
deletion	O
detection	O
.	O

Apparent	O
Mendelian	O
inconsistencies	O
between	O
parents	O
and	O
children	O
suggested	O
deletion	O
events	O
in	O
15	O
individuals	O
in	O
11	O
genomic	O
regions	O
.	O

We	O
confirmed	O
deletions	O
involving	O
CYP1B1	O
,	O
FGF10	O
,	O
SP8	O
,	O
SUMO1	O
,	O
TBX1	O
,	O
TFAP2A	O
,	O
and	O
UGT7A1	O
,	O
including	O
both	O
de	O
novo	O
and	O
familial	O
cases	O
.	O

Deletions	O
of	O
SUMO1	O
,	O
TBX1	O
,	O
and	O
TFAP2A	O
are	O
likely	O
to	O
be	O
etiologic	O
.	O

CONCLUSIONS	O
:	O
These	O
deletions	O
suggest	O
the	O
potential	O
roles	O
of	O
genes	O
or	O
regulatory	O
elements	O
contained	O
within	O
deleted	O
regions	O
in	O
the	O
etiology	O
of	O
clefting	O
.	O

Our	O
analysis	O
took	O
advantage	O
of	O
genotypes	O
from	O
a	O
candidate-gene-based	O
SNP	O
survey	O
and	O
proved	O
to	O
be	O
an	O
efficient	O
analytical	O
approach	O
to	O
interrogate	O
genes	O
potentially	O
involved	O
in	O
clefting	O
.	O

This	O
can	O
serve	O
as	O
a	O
model	O
to	O
find	O
genes	O
playing	O
a	O
role	O
in	O
complex	O
traits	O
in	O
general	O
.	O

Hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
tilt	O
test	O
in	O
relation	O
to	O
gene	O
polymorphism	O
of	O
renin-angiotensin	O
and	O
serotonin	O
system	O
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
renin-angiotensin	O
system	O
and	O
serotonin	O
transporter	O
gene	O
polymorphisms	O
in	O
relation	O
to	O
hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
head-up	O
tilt	O
test	O
(HUT)	O
in	O
patients	O
with	O
vasovagal	O
syncope	O
.	O

METHODS	O
:	O
DNA	O
was	O
collected	O
from	O
191	O
patients	O
(	O
mean	O
age	O
44+/-18	O
years	O
,	O
61	O
men	O
,	O
130	O
women	O
)	O
.	O

The	O
following	O
gene	O
polymorphisms	O
were	O
determined	O
in	O
genomic	O
DNA	O
:	O
angiotensin-converting	O
enzyme	O
insertion/deletion	O
polymorphism	O
(	O
I/D	O
ACE	O
)	O
,	O
angiotensinogen	O
gene	O
polymorphism	O
(	O
M	O
235	O
)	O
,	O
angiotensin	O
II	O
receptor	O
type	O
1	O
(ATR1)	O
polymorphism	O
(	O
A	B-DNAMutation
11666C	I-DNAMutation
)	O
,	O
and	O
polymorphism	O
of	O
serotonin	O
transporter	O
gene	O
(5HTTLPR).Heart	O
rate	O
variability	O
during	O
HUT	O
was	O
assessed	O
in	O
5-minute	O
intervals	O
by	O
low	O
frequency	O
,	O
high	O
frequency	O
,	O
standard	O
deviation	O
of	O
the	O
normal-to-normal	O
(SDNN)	O
,	O
and	O
root	O
mean	O
square	O
successive	O
difference	O
parameters	O
.	O

RESULTS	O
:	O
AA	O
genotype	O
of	O
A	B-DNAMutation
1166C	I-DNAMutation
polymorphism	O
was	O
associated	O
with	O
lower	O
minimal	O
systolic	O
blood	O
pressure	O
(SBP)	O
and	O
diastolic	O
blood	O
pressure	O
(DBP)	O
during	O
HUT	O
compared	O
with	O
other	O
genotypes	O
(	O
minimal	O
SBP	O
:	O
AA	O
59.6+/-21,8	O
,	O
AC	O
79.9+/-22.7	O
,	O
CC	O
65.4+/-22.7	O
mmHg	O
,	O
P=0.007	O
)	O
,	O
(	O
minimal	O
DBP	O
:	O
AA	O
36.4+/-22.7	O
,	O
AC	O
52.3+/-22.9	O
,	O
CC	O
45.4+/-19.5	O
mmHg	O
,	O
P=0.007).AA	O
genotype	O
was	O
also	O
associated	O
with	O
higher	O
SDNN	O
compared	O
to	O
other	O
genotypes	O
in	O
the	O
early	O
phase	O
of	O
HUT	O
(	O
SDNN	O
in	O
5	O
minutes	O
of	O
tilt	O
:	O
AA	O
59.7+/-24.6	O
,	O
AC	O
50.6+/-20.6	O
,	O
CC	O
46.0+/-13.2	O
,	O
P=0.01	O
)	O
and	O
at	O
syncope	O
occurrence	O
(	O
SDNN	O
:	O
AA	O
71.0+/-20.9	O
,	O
AC	O
58.2+/-17.9	O
,	O
CC	O
58+/-10	O
,	O
P=0.04	O
)	O
CONCLUSION	O
:	O
AA	O
genotype	O
of	O
A	B-DNAMutation
1166C	I-DNAMutation
polymorphism	O
in	O
the	O
ATR1	O
gene	O
may	O
be	O
associated	O
with	O
hypotension	O
and	O
decline	O
in	O
sympathetic	O
tone	O
during	O
HUT	O
.	O

Its	O
role	O
in	O
genetic	O
predisposition	O
to	O
vasovagal	O
syncope	O
cannot	O
be	O
excluded	O
.	O

R58fs	B-ProteinMutation
mutation	O
in	O
the	O
HGD	O
gene	O
in	O
a	O
family	O
with	O
alkaptonuria	O
in	O
the	O
UAE	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
alkaptonuria	O
in	O
the	O
UAE	O
population	O
and	O
to	O
identify	O
the	O
genotype	O
of	O
affected	O
individuals	O
.	O

In	O
a	O
3	O
stage	O
sampling	O
technique	O
2981	O
pupils	O
from	O
Government	O
schools	O
in	O
Al	O
Ain	O
and	O
private	O
schools	O
in	O
Dubai	O
were	O
selected	O
to	O
take	O
part	O
in	O
the	O
study	O
,	O
of	O
whom	O
2857	O
provided	O
urine	O
samples	O
.	O

Urine	O
collected	O
was	O
analysed	O
for	O
homogentisic	O
acid	O
by	O
gas	O
chromatography-mass	O
spectrometry	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
white	O
blood	O
cells	O
of	O
all	O
family	O
members	O
of	O
the	O
affected	O
case	O
following	O
standard	O
established	O
protocols	O
.	O

Specific	O
PRC	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
14	O
exons	O
of	O
the	O
HGD	O
gene	O
with	O
the	O
flanking	O
intronic	O
sequences	O
including	O
the	O
splice	O
site	O
sequences	O
.	O

2857	O
children	O
returned	O
a	O
viable	O
urine	O
sample	O
,	O
of	O
which	O
one	O
was	O
highly	O
positive	O
for	O
homogentisic	O
acid	O
.	O

All	O
12	O
members	O
of	O
this	O
girl's	O
family	O
were	O
studied	O
and	O
one	O
,	O
a	O
22	O
year	O
old	O
brother	O
,	O
was	O
found	O
to	O
excrete	O
HGA	O
.	O

Another	O
,	O
a	O
sister	O
who	O
had	O
not	O
provided	O
a	O
urine	O
sample	O
,	O
was	O
discovered	O
by	O
genetic	O
testing	O
.	O

There	O
were	O
no	O
complaints	O
of	O
joint	O
pain	O
or	O
other	O
symptoms	O
in	O
any	O
member	O
of	O
this	O
family	O
.	O

Parents	O
were	O
first	O
cousins	O
.	O

We	O
found	O
a	O
single	O
nucleotide	O
deletion	O
c.342delA	B-DNAMutation
,	O
located	O
in	O
exon	O
3	O
,	O
which	O
resulted	O
in	O
a	O
frameshift	O
at	O
amino	O
acid	O
position	O
58	O
(	O
p.Arg58fs	B-ProteinMutation
or	O
p.R58fs	B-ProteinMutation
)	O
.	O

Alkaptonuria	O
may	O
be	O
more	O
common	O
than	O
it	O
is	O
thought	O
to	O
be	O
with	O
an	O
allele	O
prevalence	O
estimated	O
at	O
0.0107	O
(	O
95%	O
CI	O
0.000392-0.03473	O
)	O
.	O

The	O
R58fs	B-ProteinMutation
mutation	O
is	O
old	O
,	O
perhaps	O
having	O
occurred	O
several	O
thousand	O
years	O
ago	O
,	O
and	O
has	O
spread	O
over	O
a	O
large	O
geographical	O
area	O
.	O

Peters	O
plus	O
syndrome	O
.	O

A	O
10-year-old	O
boy	O
,	O
issue	O
of	O
unrelated	O
parents	O
presented	O
with	O
visual	O
impairment	O
,	O
short	O
stature	O
and	O
mental	O
retardation	O
.	O

The	O
presence	O
of	O
a	O
Peters'	O
anomaly	O
,	O
mental	O
retardation	O
,	O
disproportionate	O
short	O
stature	O
,	O
skeletal	O
abnormalities	O
and	O
distinctive	O
facial	O
features	O
(	O
broad	O
forehead	O
,	O
telecanthus	O
,	O
cupid	O
bow	O
shaped	O
upper	O
lip	O
)	O
established	O
the	O
diagnosis	O
of	O
Peters'	O
plus	O
syndrome	O
.	O

Analysis	O
of	O
his	O
genomic	O
DNA	O
revealed	O
a	O
homozygous	O
deletion	O
in	O
the	O
beta1,3-galactosyltransferase-like	O
gene	O
(B3GALTL)	O
,	O
a	O
recently	O
identified	O
gene	O
.	O

Expression	O
of	O
TSLC1	O
,	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
mapped	O
to	O
chromosome	O
11q23	O
,	O
is	O
downregulated	O
in	O
unfavorable	O
neuroblastoma	O
without	O
promoter	O
hypermethylation	O
.	O

Although	O
it	O
has	O
been	O
well	O
documented	O
that	O
loss	O
of	O
human	O
chromosome	O
11q	O
is	O
frequently	O
observed	O
in	O
primary	O
neuroblastomas	O
,	O
the	O
smallest	O
region	O
of	O
overlap	O
(SRO)	O
has	O
not	O
yet	O
been	O
precisely	O
identified	O
.	O

Previously	O
,	O
we	O
performed	O
array-comparative	O
genomic	O
hybridization	O
(array-CGH)	O
analysis	O
for	O
236	O
primary	O
neuroblastomas	O
to	O
search	O
for	O
genomic	O
aberrations	O
with	O
high-resolution	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
identified	O
the	O
SRO	O
of	O
deletion	O
(	O
10-Mb	O
or	O
less	O
)	O
at	O
11q23	O
.	O

Within	O
this	O
region	O
,	O
there	O
exists	O
a	O
TSLC1/IGSF4/CADM1	O
gene	O
(	O
Tumor	O
suppressor	O
in	O
lung	O
cancer	O
1/Immunoglobulin	O
superfamily	O
4/Cell	O
adhesion	O
molecule	O
1	O
)	O
,	O
which	O
has	O
been	O
identified	O
as	O
a	O
putative	O
tumor	O
suppressor	O
gene	O
for	O
lung	O
and	O
some	O
other	O
cancers	O
.	O

Consistent	O
with	O
previous	O
observations	O
,	O
we	O
have	O
found	O
that	O
35%	O
of	O
primary	O
neuroblastomas	O
harbor	O
loss	O
of	O
heterozygosity	O
(LOH)	O
on	O
TSLC1	O
locus	O
.	O

In	O
contrast	O
to	O
other	O
cancers	O
,	O
we	O
could	O
not	O
detect	O
the	O
hypermethylation	O
in	O
its	O
promoter	O
region	O
in	O
primary	O
neuroblastomas	O
as	O
well	O
as	O
neuroblastoma-derived	O
cell	O
lines	O
.	O

The	O
clinicopathological	O
analysis	O
demonstrated	O
that	O
TSLC1	O
expression	O
levels	O
significantly	O
correlate	O
with	O
stage	O
,	O
Shimada's	O
pathological	O
classification	O
,	O
MYCN	O
amplification	O
status	O
,	O
TrkA	O
expression	O
levels	O
and	O
DNA	O
index	O
in	O
primary	O
neuroblastomas	O
.	O

The	O
immunohistochemical	O
analysis	O
showed	O
that	O
TSLC1	O
is	O
remarkably	O
reduced	O
in	O
unfavorable	O
neuroblastomas	O
.	O

Furthermore	O
,	O
decreased	O
expression	O
levels	O
of	O
TSLC1	O
were	O
significantly	O
associated	O
with	O
a	O
poor	O
prognosis	O
in	O
108	O
patients	O
with	O
neuroblastoma	O
.	O

Additionally	O
,	O
TSLC1	O
reduced	O
cell	O
proliferation	O
in	O
human	O
neuroblastoma	O
SH-SY5Y	O
cells	O
.	O

Collectively	O
,	O
our	O
present	O
findings	O
suggest	O
that	O
TSLC1	O
acts	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
for	O
neuroblastoma	O
.	O

Integrated	O
genomic	O
and	O
expression	O
profiling	O
in	O
mantle	O
cell	O
lymphoma	O
:	O
identification	O
of	O
gene-dosage	O
regulated	O
candidate	O
genes	O
.	O

Mantle	O
cell	O
lymphoma	O
(MCL)	O
is	O
characterized	O
by	O
the	O
t(11;14)(q13;q32)	O
translocation	O
and	O
several	O
other	O
cytogenetic	O
aberrations	O
,	O
including	O
heterozygous	O
loss	O
of	O
chromosomal	O
arms	O
1p	O
,	O
6q	O
,	O
11q	O
and	O
13q	O
and/or	O
gains	O
of	O
3q	O
and	O
8q	O
.	O

The	O
common	O
intervals	O
of	O
chromosomal	O
imbalance	O
have	O
been	O
narrowed	O
down	O
using	O
array-comparative	O
genomic	O
hybridization	O
(CGH)	O
.	O

However	O
,	O
the	O
chromosomal	O
intervals	O
still	O
contain	O
many	O
genes	O
potentially	O
involved	O
in	O
MCL	O
pathogeny	O
.	O

Combined	O
analysis	O
of	O
tiling-resolution	O
array-CGH	O
with	O
gene	O
expression	O
profiling	O
on	O
11	O
MCL	O
tumours	O
enabled	O
the	O
identification	O
of	O
genomic	O
alterations	O
and	O
their	O
corresponding	O
gene	O
expression	O
profiles	O
.	O

Only	O
subsets	O
of	O
genes	O
located	O
within	O
given	O
cytogenetic	O
anomaly-intervals	O
showed	O
a	O
concomitant	O
change	O
in	O
mRNA	O
expression	O
level	O
.	O

The	O
genes	O
that	O
showed	O
consistent	O
correlation	O
between	O
DNA	O
copy	O
number	O
and	O
RNA	O
expression	O
levels	O
are	O
likely	O
to	O
be	O
important	O
in	O
MCL	O
pathology	O
.	O

Besides	O
several	O
'anonymous	O
genes'	O
,	O
we	O
also	O
identified	O
various	O
fully	O
annotated	O
genes	O
,	O
whose	O
gene	O
products	O
are	O
involved	O
in	O
cyclic	O
adenosine	O
monophosphate-regulated	O
pathways	O
(PRKACB)	O
,	O
DNA	O
damage	O
repair	O
,	O
maintenance	O
of	O
chromosome	O
stability	O
and	O
prevention	O
of	O
rereplication	O
(	O
ATM	O
,	O
ERCC5	O
,	O
FBXO5	O
)	O
,	O
energy	O
metabolism	O
(	O
such	O
as	O
genes	O
that	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
proteins	O
encoded	O
by	O
the	O
mitochondrial	O
genome	O
)	O
and	O
signal	O
transduction	O
(ARHGAP29)	O
.	O

Deregulation	O
of	O
these	O
gene	O
products	O
may	O
interfere	O
with	O
the	O
signalling	O
pathways	O
that	O
are	O
involved	O
in	O
MCL	O
tumour	O
development	O
and	O
maintenance	O
.	O

Association	O
of	O
TMPRSS2-ERG	O
gene	O
fusion	O
with	O
clinical	O
characteristics	O
and	O
outcomes	O
:	O
results	O
from	O
a	O
population-based	O
study	O
of	O
prostate	O
cancer	O
.	O

BACKGROUND	O
:	O
The	O
presence	O
of	O
the	O
TMPRSS2-ERG	O
fusion	O
gene	O
in	O
prostate	O
tumors	O
has	O
recently	O
been	O
associated	O
with	O
an	O
aggressive	O
phenotype	O
,	O
as	O
well	O
as	O
recurrence	O
and	O
death	O
from	O
prostate	O
cancer	O
.	O

These	O
associations	O
suggest	O
the	O
hypothesis	O
that	O
the	O
gene	O
fusion	O
may	O
be	O
used	O
as	O
a	O
prognostic	O
indicator	O
for	O
prostate	O
cancer	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
fluorescent	O
in	O
situ	O
hybridization	O
(FISH)	O
assays	O
were	O
used	O
to	O
assess	O
TMPRSS2-ERG	O
fusion	O
status	O
in	O
a	O
group	O
of	O
214	O
prostate	O
cancer	O
cases	O
from	O
two	O
population-based	O
studies	O
.	O

The	O
FISH	O
assays	O
were	O
designed	O
to	O
detect	O
both	O
fusion	O
type	O
(	O
deletion	O
vs	O
.	O

translocation	O
)	O
and	O
the	O
number	O
of	O
fusion	O
copies	O
(	O
single	O
vs	O
.	O

multiple	O
)	O
.	O

Genotyping	O
of	O
four	O
ERG	O
and	O
one	O
TMPRSS2	O
SNPs	O
using	O
germline	O
DNA	O
was	O
also	O
performed	O
in	O
a	O
sample	O
of	O
the	O
cases	O
(	O
n	O
=	O
127	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
214	O
tumors	O
scored	O
for	O
the	O
TMPRSS2-ERG	O
fusion	O
,	O
64.5%	O
were	O
negative	O
and	O
35.5%	O
were	O
positive	O
for	O
the	O
fusion	O
.	O

Cases	O
with	O
the	O
TMPRSS2-ERG	O
fusion	O
did	O
not	O
exhibit	O
reduced	O
prostate	O
cancer	O
survival	O
(	O
HR	O
=	O
0.92	O
,	O
95%	O
CI	O
=	O
0.22-3.93	O
)	O
,	O
nor	O
was	O
there	O
a	O
significant	O
difference	O
in	O
cause-specific	O
survival	O
when	O
stratifying	O
by	O
translocation	O
or	O
deletion	O
(	O
HR	O
=	O
0.84	O
,	O
95%	O
CI	O
=	O
0.23-3.12	O
)	O
or	O
by	O
the	O
number	O
of	O
retained	O
fusion	O
copies	O
(	O
HR	O
=	O
1.22	O
,	O
95%	O
CI	O
=	O
0.45-3.34	O
)	O
.	O

However	O
,	O
evidence	O
for	O
reduced	O
prostate	O
cancer-specific	O
survival	O
was	O
apparent	O
in	O
those	O
cases	O
whose	O
tumor	O
had	O
multiple	O
copies	O
of	O
the	O
fusion	O
.	O

The	O
variant	O
T	O
allele	O
of	O
the	O
TMPRSS2	O
SNP	O
,	O
rs12329760	B-SNP
,	O
was	O
positively	O
associated	O
with	O
TMPRSS2-ERG	O
fusion	O
by	O
translocation	O
(	O
p	O
=	O
0.05	O
)	O
and	O
with	O
multiple	O
copies	O
of	O
the	O
gene	O
fusion	O
(	O
p	O
=	O
0.03	O
)	O
.	O

CONCLUSION	O
:	O
If	O
replicated	O
,	O
the	O
results	O
presented	O
here	O
may	O
provide	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
the	O
TMPRSS2-ERG	O
gene	O
fusion	O
arises	O
and	O
also	O
contribute	O
to	O
diagnostic	O
evaluations	O
for	O
determining	O
the	O
subset	O
of	O
men	O
who	O
will	O
go	O
on	O
to	O
develop	O
metastatic	O
prostate	O
cancer	O
.	O

GATA4	O
mutations	O
in	O
486	O
Chinese	O
patients	O
with	O
congenital	O
heart	O
disease	O
.	O

Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	O
gene	O
in	O
some	O
types	O
of	O
congenital	O
heart	O
disease	O
(CHD)	O
.	O

However	O
,	O
the	O
prevalence	O
of	O
GATA4	O
mutations	O
in	O
CHD	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	O
genotype	O
and	O
CHD	O
phenotype	O
have	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	O
gene	O
in	O
486	O
CHD	O
patients	O
by	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
(DHPLC)	O
,	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O

Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
46delS	B-DNAMutation
,	O
two	O
small	O
insertion	O
mutations	O
(	O
118-119insA	B-DNAMutation
and	O
125-126insAA	B-DNAMutation
)	O
,	O
and	O
six	O
non-synonymous	O
mutations	O
(	O
A6V	B-ProteinMutation
,	O
P163S	B-ProteinMutation
,	O
E359K	B-ProteinMutation
,	O
P407Q	B-ProteinMutation
,	O
S429T	B-ProteinMutation
and	O
A442V	B-ProteinMutation
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	O
(	O
nine	O
with	O
ventricular	O
septal	O
defect	O
,	O
two	O
with	O
Tetralogy	O
of	O
Fallot	O
,	O
and	O
one	O
with	O
endocardial	O
cushion	O
defect	O
)	O
.	O

Of	O
them	O
,	O
two	O
patients	O
carrying	O
E359K	B-ProteinMutation
mutation	O
were	O
from	O
two	O
generations	O
in	O
one	O
family	O
with	O
ventricular	O
septal	O
defect	O
(VSD)	O
.	O

Interestingly	O
,	O
a	O
nucleotide	O
insertion	O
of	O
c.1146+25insA	B-DNAMutation
in	O
exon	O
6	O
was	O
detected	O
in	O
five	O
VSD	O
patients	O
,	O
but	O
not	O
in	O
486	O
normal	O
healthy	O
controls	O
.	O

Our	O
findings	O
are	O
useful	O
in	O
understanding	O
the	O
prevalence	O
of	O
GATA4	O
mutations	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	O
genotype	O
and	O
the	O
CHD	O
phenotype	O
in	O
Chinese	O
patients	O
.	O

Chromosome	O
17	O
:	O
association	O
of	O
a	O
large	O
inversion	O
polymorphism	O
with	O
corticosteroid	O
response	O
in	O
asthma	O
.	O

A	O
900-kb	O
inversion	O
exists	O
within	O
a	O
large	O
region	O
of	O
conserved	O
linkage	O
disequilibrium	O
(LD)	O
on	O
chromosome	O
17	O
.	O

CRHR1	O
is	O
located	O
within	O
the	O
inversion	O
region	O
and	O
associated	O
with	O
inhaled	O
corticosteroid	O
response	O
in	O
asthma	O
.	O

We	O
hypothesized	O
that	O
CRHR1	O
variants	O
are	O
in	O
LD	O
with	O
the	O
inversion	O
,	O
supporting	O
a	O
potential	O
role	O
for	O
natural	O
selection	O
in	O
the	O
genetic	O
response	O
to	O
corticosteroids	O
.	O

We	O
genotyped	O
six	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
spanning	O
chromosome	O
17	O
:	O
40,410,565-42,372,240	O
,	O
including	O
four	O
SNPs	O
defining	O
inversion	O
status	O
.	O

Similar	O
allele	O
frequencies	O
and	O
strong	O
LD	O
were	O
noted	O
between	O
the	O
inversion	O
and	O
a	O
CRHR1	O
SNP	O
previously	O
associated	O
with	O
lung	O
function	O
response	O
to	O
inhaled	O
corticosteroids	O
.	O

Each	O
inversion-defining	O
SNP	O
was	O
strongly	O
associated	O
with	O
inhaled	O
corticosteroid	O
response	O
in	O
adult	O
asthma	O
(	O
P	O
values	O
0.002-0.005	O
)	O
.	O

The	O
CRHR1	O
response	O
to	O
inhaled	O
corticosteroids	O
may	O
thus	O
be	O
explained	O
by	O
natural	O
selection	O
resulting	O
from	O
inversion	O
status	O
or	O
by	O
long-range	O
LD	O
with	O
another	O
gene	O
.	O

Additional	O
pharmacogenetic	O
investigations	O
into	O
regions	O
of	O
chromosomal	O
diversity	O
,	O
including	O
copy	O
number	O
variation	O
and	O
inversions	O
,	O
are	O
warranted	O
.	O

Premature	O
stop	O
codons	O
in	O
a	O
facilitating	O
EF-hand	O
splice	O
variant	O
of	O
CaV2.1	O
cause	O
episodic	O
ataxia	O
type	O
2	O
.	O

Premature	O
stop	O
codons	O
in	O
CACNA1A	O
,	O
which	O
encodes	O
the	O
alpha(1A)	O
subunit	O
of	O
neuronal	O
P/Q-type	O
(Ca(V)2.1)	O
Ca(2+)	O
channels	O
,	O
cause	O
episodic	O
ataxia	O
type	O
2	O
(EA2)	O
.	O

CACNA1A	O
undergoes	O
extensive	O
alternative	O
splicing	O
,	O
which	O
contributes	O
to	O
the	O
pharmacological	O
and	O
kinetic	O
heterogeneity	O
of	O
Ca(V)2.1-mediated	O
Ca(2+)	O
currents	O
.	O

We	O
identified	O
three	O
novel	O
heterozygous	O
stop	O
codon	O
mutations	O
associated	O
with	O
EA2	O
in	O
an	O
alternately	O
spliced	O
exon	O
(37A)	O
,	O
which	O
encodes	O
part	O
of	O
an	O
EF-hand	O
motif	O
required	O
for	O
Ca(2+)-dependent	O
facilitation	O
.	O

One	O
family	O
had	O
a	O
C	O
to	O
G	O
transversion	O
Y1854X	B-ProteinMutation
.	O

A	O
dinucleotide	O
deletion	O
results	O
in	O
the	O
same	O
premature	O
stop	O
codon	O
in	O
a	O
second	O
family	O
,	O
and	O
a	O
further	O
single	O
nucleotide	O
change	O
leads	O
to	O
a	O
different	O
truncation	O
R1858X	B-ProteinMutation
in	O
a	O
de	O
novo	O
case	O
of	O
EA2	O
.	O

Expression	O
studies	O
of	O
the	O
Y1854X	B-ProteinMutation
mutation	O
revealed	O
loss	O
of	O
Ca(V)2.1-mediated	O
current	O
.	O

Because	O
these	O
mutations	O
do	O
not	O
affect	O
the	O
alternate	O
exon	O
37B	O
,	O
these	O
findings	O
reveal	O
unexpected	O
dependence	O
of	O
cerebellar	O
function	O
on	O
intact	O
exon	O
37A-containing	O
Ca(V)2.1	O
channels	O
.	O

A	O
metastasis	O
modifier	O
locus	O
on	O
human	O
chromosome	O
8p	O
in	O
uveal	O
melanoma	O
identified	O
by	O
integrative	O
genomic	O
analysis	O
.	O

PURPOSE	O
:	O
To	O
identify	O
genes	O
that	O
modify	O
metastatic	O
risk	O
in	O
uveal	O
melanoma	O
,	O
a	O
type	O
of	O
cancer	O
that	O
is	O
valuable	O
for	O
studying	O
metastasis	O
because	O
of	O
its	O
remarkably	O
consistent	O
metastatic	O
pattern	O
and	O
well-characterized	O
gene	O
expression	O
signature	O
associated	O
with	O
metastasis	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
53	O
primary	O
uveal	O
melanomas	O
by	O
gene	O
expression	O
profiling	O
,	O
array-based	O
comparative	O
genomic	O
hybridization	O
,	O
array-based	O
global	O
DNA	O
methylation	O
profiling	O
,	O
and	O
single	O
nucleotide	O
polymorphism-based	O
detection	O
of	O
loss	O
of	O
heterozygosity	O
to	O
identify	O
modifiers	O
of	O
metastatic	O
risk	O
.	O

A	O
candidate	O
gene	O
,	O
leucine	O
zipper	O
tumor	O
suppressor-1	O
(LZTS1)	O
,	O
was	O
examined	O
for	O
its	O
effect	O
on	O
proliferation	O
,	O
migration	O
,	O
and	O
motility	O
in	O
cultured	O
uveal	O
melanoma	O
cells	O
.	O

RESULTS	O
:	O
In	O
metastasizing	O
primary	O
uveal	O
melanomas	O
,	O
deletion	O
of	O
chromosome	O
8p12-22	O
and	O
DNA	O
hypermethylation	O
of	O
the	O
corresponding	O
region	O
of	O
the	O
retained	O
hemizygous	O
8p	O
allele	O
were	O
associated	O
with	O
more	O
rapid	O
metastasis	O
.	O

Among	O
the	O
11	O
genes	O
located	O
within	O
the	O
deleted	O
region	O
,	O
LZTS1	O
was	O
most	O
strongly	O
linked	O
to	O
rapid	O
metastasis	O
.	O

LZTS1	O
was	O
silenced	O
in	O
rapidly	O
metastasizing	O
and	O
metastatic	O
uveal	O
melanomas	O
but	O
not	O
in	O
slowly	O
metastasizing	O
and	O
nonmetastasizing	O
uveal	O
melanomas	O
.	O

Forced	O
expression	O
of	O
LZTS1	O
in	O
metastasizing	O
uveal	O
melanoma	O
cells	O
inhibited	O
their	O
motility	O
and	O
invasion	O
,	O
whereas	O
depletion	O
of	O
LZTS1	O
increased	O
their	O
motility	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
described	O
a	O
metastatic	O
modifier	O
locus	O
on	O
chromosome	O
8p	O
and	O
identified	O
LZTS1	O
as	O
a	O
potential	O
metastasis	O
suppressor	O
within	O
this	O
region	O
.	O

This	O
study	O
shows	O
the	O
utility	O
of	O
integrative	O
genomic	O
methods	O
for	O
identifying	O
modifiers	O
of	O
metastatic	O
risk	O
in	O
human	O
cancers	O
and	O
may	O
suggest	O
new	O
therapeutic	O
targets	O
in	O
metastasizing	O
tumor	O
cells	O
.	O

Variable	O
phenotypic	O
expression	O
of	O
homozygous	O
familial	O
hypobetalipoproteinaemia	O
due	O
to	O
novel	O
APOB	O
gene	O
mutations	O
.	O

Homozygous	O
familial	O
hypobetalipoproteinaemia	O
(Ho-FHBL)	O
is	O
a	O
rare	O
co-dominant	O
disorder	O
characterized	O
by	O
extremely	O
low	O
levels	O
of	O
low-density	O
lipoprotein	O
cholesterol	O
(LDL-C)	O
and	O
apolipoprotein	O
B	O
(apoB)	O
.	O

Most	O
patients	O
with	O
Ho-FHBL	O
have	O
mutations	O
in	O
APOB	O
gene	O
resulting	O
in	O
truncated	O
apoBs	O
.	O

Some	O
patients	O
are	O
asymptomatic	O
,	O
while	O
others	O
have	O
fatty	O
liver	O
,	O
intestinal	O
fat	O
malabsorption	O
and	O
neurological	O
dysfunctions	O
.	O

We	O
investigated	O
three	O
adult	O
subjects	O
with	O
severe	O
hypobetalipoproteinaemia	O
and	O
a	O
family	O
history	O
of	O
FHBL	O
.	O

Proband	O
FHBL-47	O
had	O
liver	O
cirrhosis	O
with	O
hepatocarcinoma	O
and	O
a	O
renal	O
carcinoma	O
but	O
no	O
clinical	O
manifestations	O
related	O
to	O
FHBL	O
.	O

He	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
7-bp	O
deletion	O
in	O
exon	O
21	O
and	O
a	O
base	O
insertion	O
in	O
exon	O
26	O
resulting	O
in	O
truncated	O
apoBs	O
(apoB-22.46/apoB-66.51)	O
.	O

Proband	O
FHBL-53	O
,	O
with	O
severe	O
hepatic	O
steatosis	O
and	O
fibrosis	O
,	O
had	O
a	O
nonsense	O
mutation	O
in	O
exon	O
19	O
resulting	O
in	O
a	O
truncated	O
apoB	O
(apoB-20.61)	O
and	O
a	O
rare	O
nucleotide	O
substitution	O
in	O
intron	O
14	O
c.2068-4T>A	B-DNAMutation
.	O

The	O
latter	O
was	O
also	O
present	O
in	O
her	O
daughter	O
,	O
found	O
to	O
have	O
low	O
plasma	O
LDL-C	O
and	O
apoB	O
.	O

Proband	O
FHBL-82	O
had	O
chronic	O
diarrhoea	O
and	O
steatorrhoea	O
.	O

She	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
nonsense	O
mutation	O
in	O
exon	O
24	O
resulting	O
in	O
a	O
truncated	O
apoB	O
(apoB-26.65)	O
.	O

In	O
adult	O
subjects	O
,	O
the	O
presence	O
of	O
chronic	O
liver	O
disease	O
and	O
chronic	O
diarrhoea	O
,	O
when	O
associated	O
with	O
severe	O
hypobetalipoproteinaemia	O
,	O
may	O
lead	O
to	O
the	O
diagnosis	O
of	O
Ho-FHBL	O
.	O

L1503R	B-ProteinMutation
is	O
a	O
member	O
of	O
group	O
I	O
mutation	O
and	O
has	O
dominant-negative	O
effect	O
on	O
secretion	O
of	O
full-length	O
VWF	O
multimers	O
:	O
an	O
analysis	O
of	O
two	O
patients	O
with	O
type	O
2A	O
von	O
Willebrand	O
disease	O
.	O

Type	O
2A	O
von	O
Willebrand	O
disease	O
(VWD)	O
is	O
characterized	O
by	O
decreased	O
platelet-dependent	O
function	O
of	O
von	O
Willebrand	O
factor	O
(VWF)	O
;	O
this	O
in	O
turn	O
is	O
associated	O
with	O
an	O
absence	O
of	O
high-molecular-weight	O
multimers	O
.	O

Sequence	O
analysis	O
of	O
the	O
VWF	O
gene	O
from	O
two	O
unrelated	O
type	O
2A	O
VWD	O
patients	O
showed	O
an	O
identical	O
,	O
novel	O
,	O
heterozygous	O
T-->G	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
4508	I-DNAMutation
,	O
resulting	O
in	O
the	O
substitution	O
of	O
L1503R	B-ProteinMutation
in	O
the	O
VWF	O
A2	O
domain	O
.	O

This	O
substitution	O
,	O
which	O
was	O
not	O
found	O
in	O
60	O
unrelated	O
normal	O
individuals	O
,	O
was	O
introduced	O
into	O
a	O
full-length	O
VWF	O
cDNA	O
and	O
subsequently	O
expressed	O
in	O
293T	O
cells	O
.	O

Only	O
trace	O
amount	O
of	O
the	O
mutant	O
VWF	O
protein	O
was	O
secreted	O
but	O
most	O
of	O
the	O
same	O
was	O
retained	O
in	O
293T	O
cells	O
.	O

Co-transfection	O
experiment	O
of	O
both	O
wild-type	O
and	O
mutant	O
plasmids	O
indicated	O
the	O
dominant-negative	O
mechanism	O
of	O
disease	O
development	O
;	O
as	O
more	O
of	O
mutant	O
DNA	O
was	O
transfected	O
,	O
VWF	O
secretion	O
was	O
impaired	O
in	O
the	O
media	O
,	O
whereas	O
more	O
of	O
VWF	O
was	O
stored	O
in	O
the	O
cell	O
lysates	O
.	O

Molecular	O
dynamic	O
simulations	O
of	O
structural	O
changes	O
induced	O
by	O
L1503R	B-ProteinMutation
indicated	O
that	O
the	O
mean	O
value	O
of	O
all-atom	O
root-mean-squared-deviation	O
was	O
shifted	O
from	O
those	O
with	O
wild	O
type	O
or	O
another	O
mutation	O
L1503Q	B-ProteinMutation
that	O
has	O
been	O
reported	O
to	O
be	O
a	O
group	O
II	O
mutation	O
,	O
which	O
is	O
susceptible	O
to	O
ADAMTS13	O
proteolysis	O
.	O

Protein	O
instability	O
of	O
L1503R	B-ProteinMutation
may	O
be	O
responsible	O
for	O
its	O
intracellular	O
retention	O
and	O
perhaps	O
the	O
larger	O
VWF	O
multimers	O
,	O
containing	O
more	O
mutant	O
VWF	O
subunits	O
,	O
are	O
likely	O
to	O
be	O
mal-processed	O
and	O
retained	O
within	O
the	O
cell	O
.	O

Molecular	O
and	O
clinical	O
characterization	O
in	O
Japanese	O
and	O
Korean	O
patients	O
with	O
Hailey-Hailey	O
disease	O
:	O
six	O
new	O
mutations	O
in	O
the	O
ATP2C1	O
gene	O
.	O

BACKGROUND	O
:	O
The	O
autosomal	O
dominant	O
disorder	O
Hailey-Hailey	O
disease	O
(HHD)	O
results	O
from	O
mutations	O
in	O
the	O
ATP2C1	O
gene	O
,	O
which	O
encodes	O
the	O
human	O
secretory	O
pathway	O
Ca2+/Mn2+	O
-ATPase	O
protein	O
1	O
.	O

To	O
date	O
,	O
over	O
90	O
pathological	O
mutations	O
scattered	O
throughout	O
ATP2C1	O
have	O
been	O
described	O
with	O
no	O
indication	O
of	O
mutational	O
hotspots	O
or	O
clustering	O
of	O
mutations	O
.	O

No	O
paradigm	O
for	O
genotype-phenotype	O
correlation	O
has	O
emerged	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
pathogenic	O
ATP2C1	O
abnormality	O
in	O
additional	O
patients	O
with	O
HHD	O
in	O
order	O
to	O
provide	O
further	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
this	O
disorder	O
and	O
to	O
add	O
the	O
data	O
to	O
the	O
known	O
mutation	O
database	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
investigated	O
eight	O
unrelated	O
Japanese	O
and	O
Korean	O
patients	O
with	O
HHD	O
.	O

We	O
performed	O
direct	O
nucleotide	O
sequencing	O
of	O
the	O
ATP2C1	O
gene	O
in	O
all	O
patients	O
and	O
RT-PCR	O
analysis	O
,	O
using	O
RNA	O
extracted	O
from	O
a	O
skin	O
biopsy	O
,	O
in	O
a	O
patient	O
with	O
the	O
mildest	O
clinical	O
features	O
.	O

RESULTS	O
:	O
We	O
identified	O
seven	O
different	O
heterozygous	O
mutations	O
in	O
seven	O
of	O
the	O
eight	O
investigated	O
patients	O
,	O
including	O
three	O
new	O
single	O
nucleotide	O
deletion/duplication	O
mutations	O
:	O
c.520delC	B-DNAMutation
;	O
c.681dupA	B-DNAMutation
;	O
c.956delC	B-DNAMutation
,	O
three	O
new	O
donor	O
splice	O
site	O
mutations	O
:	O
c.360+1G>C	B-DNAMutation
;	O
c.899+1G>T	B-DNAMutation
;	O
c.1570+2T>C	B-DNAMutation
,	O
as	O
well	O
as	O
a	O
previously	O
described	O
nonsense	O
mutation	O
:	O
p.Arg153X	B-ProteinMutation
.	O

RT-PCR	O
analysis	O
in	O
the	O
mildest	O
affected	O
patient	O
with	O
a	O
heterozygous	O
c.360+1G>C	B-DNAMutation
mutation	O
,	O
demonstrated	O
expression	O
of	O
a	O
short	O
in-frame	O
mutant	O
transcript	O
with	O
exon	O
5	O
skipping	O
,	O
which	O
may	O
account	O
for	O
the	O
mild	O
phenotype	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
expand	O
the	O
known	O
mutation	O
spectrum	O
in	O
HHD	O
and	O
show	O
the	O
importance	O
of	O
RNA	O
analysis	O
for	O
understanding	O
the	O
genotype-phenotype	O
correlations	O
more	O
precisely	O
.	O

Molecular	O
allelokaryotyping	O
of	O
early-stage	O
,	O
untreated	O
chronic	O
lymphocytic	O
leukemia	O
.	O

BACKGROUND	O
:	O
To	O
the	O
authors'	O
knowledge	O
,	O
genetic	O
abnormalities	O
in	O
early-stage	O
chronic	O
lymphocytic	O
leukemia	O
(CLL)	O
have	O
not	O
been	O
examined	O
fully	O
.	O

Single	O
nucleotide	O
polymorphism	O
(SNP)	O
genomic	O
array	O
(SNP-chip)	O
is	O
a	O
new	O
tool	O
that	O
can	O
detect	O
copy	O
number	O
changes	O
and	O
uniparental	O
disomy	O
(UPD)	O
over	O
the	O
entire	O
genome	O
with	O
very	O
high	O
resolution	O
.	O

METHODS	O
:	O
The	O
authors	O
performed	O
SNP-chip	O
analysis	O
on	O
56	O
samples	O
from	O
patients	O
with	O
early-stage	O
,	O
untreated	O
CLL	O
.	O

To	O
validate	O
the	O
SNP-chip	O
data	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
analysis	O
was	O
performed	O
at	O
selected	O
sites	O
.	O

Expression	O
levels	O
of	O
ZAP-70	O
and	O
the	O
mutational	O
status	O
of	O
immunoglobulin	O
heavy-chain	O
gene	O
also	O
were	O
examined	O
.	O

RESULTS	O
:	O
SNP-chip	O
analysis	O
easily	O
detected	O
nearly	O
all	O
changes	O
that	O
were	O
identified	O
by	O
FISH	O
,	O
including	O
trisomy	O
12	O
,	O
deletion	O
of	O
TP53	O
(17p13)	O
,	O
deletion	O
of	O
ATM	O
(11q22)	O
,	O
and	O
deletion	O
of	O
13q14	O
.	O

Only	O
10	O
of	O
56	O
CLL	O
samples	O
(18%)	O
had	O
no	O
genomic	O
abnormalities	O
.	O

Excluding	O
the	O
4	O
common	O
abnormalities	O
mentioned	O
above	O
,	O
25	O
CLL	O
samples	O
(45%)	O
had	O
a	O
total	O
of	O
45	O
copy	O
number	O
changes	O
detected	O
by	O
SNP-chip	O
analysis	O
.	O

Four	O
samples	O
had	O
6q	O
deletion	O
at	O
6q21	O
that	O
involved	O
the	O
AIM1	O
gene	O
.	O

UPD	O
was	O
detected	O
in	O
4	O
samples	O
;	O
2	O
samples	O
involved	O
whole	O
chromosome	O
13	O
resulting	O
in	O
homozygous	O
deletion	O
of	O
micro-RNA-15a	O
(miR-15a)/miR-16-1	O
.	O

CLL	O
samples	O
with	O
deletion	O
of	O
13q14	O
and	O
trisomy	O
12	O
were	O
mutually	O
exclusive	O
.	O

CONCLUSIONS	O
:	O
Genetic	O
abnormalities	O
,	O
including	O
whole	O
chromosome	O
13	O
UPD	O
,	O
are	O
very	O
common	O
events	O
in	O
early-stage	O
CLL	O
.	O

SNP-chip	O
analysis	O
can	O
detect	O
small	O
genetic	O
abnormalities	O
in	O
CLL	O
and	O
may	O
be	O
able	O
to	O
support	O
or	O
even	O
supplant	O
FISH	O
and	O
cytogenetics	O
.	O

No	O
association	O
with	O
risk	O
for	O
colorectal	O
cancer	O
of	O
the	O
insertion/deletion	O
polymorphism	O
which	O
affects	O
levels	O
of	O
angiotensin-converting	O
enzyme	O
.	O

BACKGROUND	O
:	O
In	O
the	O
light	O
of	O
the	O
established	O
association	O
of	O
angiotensin-converting	O
enzyme	O
(ACE)	O
with	O
several	O
types	O
of	O
cancer	O
,	O
the	O
possible	O
contribution	O
of	O
the	O
insertion/deletion	O
(I/D)	O
polymorphism	O
that	O
affects	O
ACE	O
gene	O
expression	O
,	O
in	O
the	O
development	O
of	O
colorectal	O
cancer	O
was	O
investigated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
DNA	O
samples	O
of	O
92	O
patients	O
with	O
colorectal	O
cancer	O
(adenocarcinomas)	O
and	O
102	O
healthy	O
controls	O
were	O
examined	O
by	O
allele-specific	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
electrophoretic	O
analysis	O
.	O

The	O
resulting	O
allele	O
and	O
genotype	O
frequencies	O
of	O
the	O
patients	O
were	O
compared	O
to	O
those	O
of	O
the	O
controls	O
by	O
Fischer's	O
exact	O
test	O
and	O
odds	O
ratios	O
.	O

RESULTS	O
:	O
No	O
statistical	O
differences	O
were	O
observed	O
between	O
healthy	O
controls	O
and	O
patients	O
with	O
colorectal	O
cancer	O
regarding	O
either	O
genotype	O
distribution	O
or	O
low	O
expression	O
I	O
allele	O
frequency	O
.	O

CONCLUSION	O
:	O
The	O
ACE	O
I/D	O
polymorphism	O
is	O
not	O
a	O
genetic	O
predisposing	O
factor	O
concerning	O
the	O
risk	O
for	O
colorectal	O
cancer	O
.	O

RNASEL	O
and	O
RNASEL-inhibitor	O
variation	O
and	O
prostate	O
cancer	O
risk	O
in	O
Afro-Caribbeans	O
.	O

BACKGROUND	O
:	O
Afro-Caribbeans	O
from	O
Tobago	O
are	O
at	O
high	O
risk	O
of	O
developing	O
prostate	O
cancer	O
.	O

This	O
elevated	O
risk	O
of	O
prostate	O
cancer	O
is	O
shared	O
by	O
populations	O
of	O
African	O
ancestry	O
living	O
in	O
diverse	O
environments	O
in	O
the	O
Western	O
hemisphere	O
.	O

Variation	O
in	O
the	O
ribonuclease	O
L	O
(RNASEL)	O
gene	O
has	O
recently	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
prostate	O
cancer	O
.	O

However	O
,	O
whether	O
RNASEL	O
variation	O
contributes	O
to	O
the	O
increased	O
risk	O
of	O
prostate	O
cancer	O
observed	O
in	O
populations	O
of	O
African	O
ancestry	O
remains	O
unclear	O
.	O

METHODS	O
:	O
We	O
resequenced	O
the	O
positional	O
candidate	O
gene	O
RNASEL	O
in	O
48	O
prostate	O
cancer	O
cases	O
and	O
genotyped	O
the	O
previously	O
reported	O
R462Q	B-ProteinMutation
and	O
D541E	B-ProteinMutation
polymorphisms	O
in	O
230	O
prostate	O
cancer	O
cases	O
and	O
458	O
controls	O
.	O

We	O
also	O
examined	O
the	O
inhibitor	O
of	O
RNASEL	O
(ABCE1)	O
for	O
variation	O
associated	O
with	O
prostate	O
cancer	O
risk	O
.	O

RESULTS	O
:	O
We	O
found	O
no	O
evidence	O
of	O
association	O
between	O
R462Q	B-ProteinMutation
and	O
D541E	B-ProteinMutation
polymorphisms	O
and	O
prostate	O
cancer	O
risk	O
in	O
our	O
case/control	O
analysis	O
.	O

A	O
novel	O
variant	O
K294E	B-ProteinMutation
was	O
identified	O
in	O
a	O
single	O
heterozygous	O
individual	O
with	O
prostate	O
cancer	O
.	O

We	O
also	O
observed	O
a	O
20	O
bp	O
insertion/deletion	O
polymorphism	O
1,109	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
,	O
but	O
this	O
variant	O
was	O
not	O
associated	O
with	O
prostate	O
cancer	O
.	O

We	O
identified	O
16	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ABCE1	O
gene	O
,	O
only	O
3	O
of	O
which	O
had	O
a	O
minor	O
allele	O
frequency	O
>5%	O
.	O

A	O
common	O
A/G	B-DNAMutation
transition	I-DNAMutation
-1,071	I-DNAMutation
bp	I-DNAMutation
from	O
the	O
transcriptional	O
start	O
site	O
was	O
genotyped	O
and	O
showed	O
no	O
evidence	O
of	O
association	O
with	O
prostate	O
cancer	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
common	O
variation	O
in	O
the	O
putative	O
prostate	O
cancer	O
susceptibility	O
gene	O
,	O
RNASEL	O
,	O
or	O
its	O
inhibitor	O
does	O
not	O
contribute	O
significantly	O
to	O
prostate	O
cancer	O
risk	O
in	O
this	O
Afro-Caribbean	O
population	O
.	O

Genetic	O
investigation	O
of	O
four	O
meiotic	O
genes	O
in	O
women	O
with	O
premature	O
ovarian	O
failure	O
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
mutations	O
of	O
meiotic	O
genes	O
,	O
such	O
as	O
disrupted	O
meiotic	O
cDNA	O
(DMC1)	O
,	O
MutS	O
homolog	O
(MSH4)	O
,	O
MSH5	O
,	O
and	O
S	O
.	O

cerevisiae	O
homolog	O
(SPO11)	O
,	O
were	O
associated	O
with	O
premature	O
ovarian	O
failure	O
(POF)	O
.	O

DESIGN	O
:	O
Case-control	O
study	O
.	O

METHODS	O
:	O
Blood	O
sampling	O
,	O
karyotype	O
,	O
hormonal	O
dosage	O
,	O
ultrasound	O
,	O
and	O
ovarian	O
biopsy	O
were	O
carried	O
out	O
on	O
most	O
patients	O
.	O

However	O
,	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
samples	O
of	O
41	O
women	O
with	O
POF	O
and	O
36	O
fertile	O
women	O
(controls)	O
.	O

RESULTS	O
:	O
A	O
single	O
heterozygous	O
missense	O
mutation	O
,	O
substitution	O
of	O
a	O
cytosine	O
residue	O
with	O
thymidine	O
in	O
exon	O
2	O
of	O
MSH5	O
,	O
was	O
found	O
in	O
two	O
Caucasian	O
women	O
in	O
whom	O
POF	O
developed	O
at	O
18	O
and	O
36	O
years	O
of	O
age	O
.	O

This	O
mutation	O
resulted	O
in	O
replacement	O
of	O
a	O
non-polar	O
amino	O
acid	O
(proline)	O
with	O
a	O
polar	O
amino	O
acid	O
(serine)	O
at	O
position	O
29	O
P29S	B-ProteinMutation
.	O

Neither	O
36	O
control	O
women	O
nor	O
39	O
other	O
patients	O
with	O
POF	O
possessed	O
this	O
genetic	O
perturbation	O
.	O

Another	O
POF	O
patient	O
of	O
African	O
origin	O
showed	O
a	O
homozygous	O
nucleotide	O
change	O
in	O
the	O
tenth	O
of	O
DMC1	O
gene	O
that	O
led	O
to	O
an	O
alteration	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
M200V	B-ProteinMutation
.	O

CONCLUSIONS	O
:	O
The	O
symptoms	O
of	O
infertility	O
observed	O
in	O
the	O
DMC1	O
homozygote	O
mutation	O
carrier	O
and	O
in	O
both	O
patients	O
with	O
a	O
heterozygous	O
substitution	O
in	O
exon	O
2	O
of	O
the	O
MSH5	O
gene	O
provide	O
indirect	O
evidence	O
of	O
the	O
role	O
of	O
genes	O
involved	O
in	O
meiotic	O
recombination	O
in	O
the	O
regulation	O
of	O
ovarian	O
function	O
.	O

MSH5	O
and	O
DMC1	O
mutations	O
may	O
be	O
one	O
explanation	O
for	O
POF	O
,	O
albeit	O
uncommon	O
.	O

Mutation	O
analysis	O
of	O
FOXF2	O
in	O
patients	O
with	O
disorders	O
of	O
sex	O
development	O
(DSD)	O
in	O
combination	O
with	O
cleft	O
palate	O
.	O

In	O
contrast	O
to	O
disorders	O
of	O
sexual	O
differentiation	O
caused	O
by	O
lack	O
of	O
androgen	O
production	O
or	O
inhibited	O
androgen	O
action	O
,	O
defects	O
affecting	O
development	O
of	O
the	O
bipotent	O
genital	O
anlagen	O
have	O
rarely	O
been	O
investigated	O
in	O
humans	O
.	O

We	O
have	O
previously	O
documented	O
that	O
the	O
transcription	O
factor	O
FOXF2	O
is	O
highly	O
expressed	O
in	O
human	O
foreskin	O
.	O

Moreover	O
,	O
Foxf2	O
knockout	O
mice	O
present	O
with	O
cleft	O
palate	O
in	O
combination	O
with	O
hypoplasia	O
of	O
the	O
genital	O
tubercle	O
.	O

We	O
hypothesized	O
that	O
humans	O
with	O
disorders	O
of	O
sex	O
development	O
(DSD)	O
in	O
combination	O
with	O
cleft	O
palate	O
could	O
have	O
mutations	O
in	O
the	O
FOXF2	O
gene	O
.	O

Eighteen	O
children	O
with	O
DSD	O
and	O
cleft	O
palate	O
were	O
identified	O
in	O
the	O
L	O
	O
beck	O
DSD	O
database	O
(	O
about	O
1,500	O
entries	O
)	O
.	O

Genomic	O
DNA	O
sequence	O
analysis	O
of	O
the	O
FOXF2	O
gene	O
was	O
performed	O
and	O
compared	O
with	O
10	O
normal	O
female	O
and	O
10	O
normal	O
male	O
controls	O
,	O
respectively	O
.	O

Two	O
heterozygous	O
DNA	O
sequence	O
variations	O
were	O
solely	O
present	O
in	O
one	O
single	O
patient	O
each	O
but	O
in	O
none	O
of	O
the	O
20	O
normal	O
controls	O
:	O
a	O
duplication	O
of	O
GCC	O
c.97GCC[9]+[10]	B-DNAMutation
resulting	O
in	O
an	O
extra	O
alanine	O
within	O
exon	O
1	O
and	O
a	O
25*G>A	B-DNAMutation
substitution	O
in	O
the	O
3'-untranslated	O
region	O
.	O

Two	O
patients	O
carried	O
a	O
c.262G>A	B-DNAMutation
sequence	O
variation	O
predicting	O
for	O
an	O
Ala88Thr	B-ProteinMutation
exchange	O
which	O
was	O
also	O
detected	O
in	O
2	O
normal	O
controls	O
.	O

Two	O
silent	O
mutations	O
,	O
c.1272C>T	B-DNAMutation
Ser424Ser	B-ProteinMutation
and	O
c.1284T>C	B-DNAMutation
Tyr428Tyr	B-ProteinMutation
,	O
respectively	O
,	O
occurred	O
in	O
the	O
coding	O
region	O
of	O
exon	O
2	O
,	O
again	O
in	O
both	O
patients	O
and	O
normal	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
majority	O
of	O
the	O
detected	O
sequence	O
alterations	O
were	O
polymorphisms	O
without	O
obvious	O
functional	O
relevance	O
.	O

However	O
,	O
it	O
cannot	O
be	O
excluded	O
that	O
the	O
2	O
unique	O
DNA	O
sequence	O
alterations	O
could	O
have	O
affected	O
FOXF2	O
on	O
the	O
mRNA	O
or	O
protein	O
level	O
thus	O
contributing	O
to	O
the	O
observed	O
disturbances	O
in	O
genital	O
and	O
palate	O
development	O
.	O

Analysis	O
of	O
-1082	O
IL-10	O
gene	O
polymorphism	O
in	O
Iranian	O
patients	O
with	O
generalized	O
aggressive	O
periodontitis	O
.	O

BACKGROUND	O
:	O
Periodontitis	O
is	O
a	O
multifactorial	O
disease	O
and	O
its	O
severe	O
forms	O
,	O
such	O
as	O
aggressive	O
periodontitis	O
,	O
are	O
suggested	O
to	O
have	O
a	O
genetic	O
basis	O
.	O

Among	O
the	O
genetic	O
factors	O
,	O
polymorphisms	O
in	O
cytokine	O
genes	O
have	O
recently	O
been	O
described	O
in	O
susceptibility	O
to	O
periodontitis	O
.	O

IL-10	O
is	O
a	O
multi-functional	O
cytokine	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontitis	O
.	O

A	O
substitution	O
G/A	B-DNAMutation
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL-10	O
gene	O
at	O
position	O
-1082	O
has	O
been	O
associated	O
with	O
different	O
amounts	O
of	O
IL-10	O
production	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
links	O
between	O
-1082(G/A)	B-DNAMutation
polymorphism	O
of	O
the	O
IL-10	O
gene	O
and	O
the	O
generalized	O
form	O
of	O
aggressive	O
periodontitis	O
.	O

MATERIAL/METHODS	O
:	O
This	O
study	O
included	O
52	O
Iranian	O
Khorasanian	O
(	O
north-east	O
province	O
of	O
Iran	O
)	O
subjects	O
suffering	O
from	O
generalized	O
aggressive	O
periodontitis	O
referred	O
to	O
the	O
Periodontology	O
Department	O
of	O
Mashhad	O
Dental	O
School	O
.	O

They	O
were	O
compared	O
to	O
61	O
age	O
and	O
sex-matched	O
healthy	O
controls	O
of	O
the	O
same	O
race	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
genotyping	O
was	O
performed	O
by	O
means	O
of	O
the	O
amplification	O
refractory	O
mutation	O
system	O
polymerase	O
chain	O
reaction	O
(ARMS-PCR)	O
method	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
chi-squared	O
test	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
marked	O
difference	O
in	O
genotype	O
frequencies	O
between	O
the	O
controls	O
and	O
generalized	O
aggressive	O
periodontitis	O
patients	O
(p=0.585)	O
.	O

Moreover	O
,	O
no	O
association	O
between	O
patients	O
and	O
normal	O
subjects	O
was	O
found	O
in	O
their	O
allele	O
frequency	O
(p=0.329)	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
polymorphic	O
nucleotide	O
A	O
at	O
position	O
-1082	O
of	O
the	O
IL-10	O
gene	O
is	O
not	O
associated	O
with	O
generalized	O
aggressive	O
periodontitis	O
in	O
the	O
Iranian	O
population	O
.	O

In	O
vitro	O
expression	O
of	O
beta-thalassaemia	O
gene	O
IVS1-1G>C	B-DNAMutation
reveals	O
complete	O
inactivation	O
of	O
the	O
normal	O
5'	O
splice	O
site	O
and	O
alternative	O
aberrant	O
RNA	O
splicing	O
.	O

We	O
previously	O
reported	O
a	O
case	O
of	O
heterozygous	O
beta-thalassaemia	O
with	O
IVS1-1G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
substitution	O
in	O
the	O
beta-globin	O
gene	O
and	O
a	O
non-detectable	O
level	O
of	O
mutant	O
mRNA	O
in	O
the	O
patient's	O
reticulocytes	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
transcription	O
and	O
RNA	O
splicing	O
and	O
processing	O
of	O
the	O
mutant	O
gene	O
occurred	O
.	O

We	O
analysed	O
the	O
expression	O
of	O
the	O
mRNA	O
encoded	O
by	O
the	O
cloned	O
mutant	O
gene	O
in	O
COS-1	O
cells	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
followed	O
by	O
agarose	O
gel	O
electrophoresis	O
and	O
nucleotide	O
sequencing	O
.	O

The	O
G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
mutation	O
completely	O
inactivated	O
the	O
normal	O
5'	O
splice	O
site	O
and	O
resulted	O
in	O
the	O
activation	O
of	O
two	O
cryptic	O
5'	O
splice	O
sites	O
,	O
located	O
16	O
and	O
38	O
nt	O
upstream	O
of	O
the	O
normal	O
site	O
.	O

The	O
usage	O
of	O
these	O
two	O
cryptic	O
sites	O
accords	O
with	O
the	O
findings	O
of	O
reports	O
on	O
IVS1-1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
or	O
IVS1-1G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
substitution	O
of	O
exon	O
1	O
of	O
the	O
beta-globin	O
gene	O
.	O

Additional	O
experiments	O
that	O
involved	O
transfection	O
of	O
equal	O
amounts	O
of	O
both	O
normal	O
and	O
mutant	O
vectors	O
into	O
COS-1	O
cells	O
indicated	O
the	O
presence	O
of	O
mutant	O
mRNAs	O
.	O

In	O
conclusion	O
,	O
the	O
beta-thalassaemia	O
gene	O
(	O
IVS1-1G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
)	O
was	O
expressed	O
in	O
transfected	O
cells	O
,	O
but	O
showed	O
aberrant	O
RNA	O
splicing	O
.	O

Further	O
studies	O
will	O
be	O
required	O
to	O
clarify	O
the	O
molecular	O
mechanism	O
that	O
results	O
in	O
severe	O
reduction	O
in	O
the	O
mutant	O
mRNA	O
level	O
in	O
vivo	O
.	O

Somatic	O
and	O
gonadal	O
mosaicism	O
in	O
X-linked	O
retinitis	O
pigmentosa	O
.	O

The	O
g.ORF15	B-DNAMutation
+	I-DNAMutation
652-653delAG	I-DNAMutation
mutation	O
in	O
the	O
RPGR	O
gene	O
is	O
the	O
most	O
frequent	O
mutation	O
in	O
X-linked	O
retinitis	O
pigmentosa	O
(XLRP)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
possibility	O
of	O
mosaicism	O
in	O
an	O
XLRP	O
family	O
.	O

Eight	O
subjects	O
in	O
the	O
RP	O
family	O
were	O
recruited	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
DNA	O
extraction	O
.	O

Haplotype	O
analysis	O
and	O
mutational	O
screening	O
on	O
the	O
RPGR	O
gene	O
were	O
performed	O
.	O

Additionally	O
,	O
samples	O
of	O
hair	O
follicles	O
and	O
buccal	O
cells	O
from	O
the	O
mother	O
of	O
the	O
proband	O
were	O
acquired	O
for	O
DNA	O
extraction	O
and	O
molecular	O
analysis	O
.	O

Phenotype	O
was	O
characterized	O
with	O
routine	O
ophthalmic	O
examination	O
,	O
Goldmann	O
perimetry	O
,	O
electroretinography	O
,	O
and	O
color	O
fundus	O
photography	O
.	O

A	O
g.ORF15	B-DNAMutation
+	I-DNAMutation
652-653delAG	I-DNAMutation
mutation	O
was	O
identified	O
in	O
second-	O
and	O
third-generation	O
patients/carriers	O
.	O

A	O
first-generation	O
female	O
,	O
who	O
was	O
considered	O
to	O
be	O
an	O
obligate	O
carrier	O
,	O
demonstrated	O
a	O
normal	O
phenotype	O
as	O
well	O
as	O
a	O
normal	O
genotype	O
in	O
lymphocytic	O
DNA	O
,	O
indicating	O
the	O
gonadal	O
mosaicism	O
;	O
however	O
,	O
a	O
heterozygous	O
AG-deletion	O
at	O
nucleotide	O
652	O
and	O
653	O
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
hair	O
follicles	O
,	O
hair	O
shaft	O
,	O
and	O
buccal	O
cells	O
,	O
indicating	O
that	O
the	O
mutation	O
is	O
somatic	O
.	O

In	O
conclusion	O
,	O
we	O
reported	O
on	O
a	O
family	O
in	O
which	O
an	O
asymptomatic	O
woman	O
with	O
somatic-gonadal	O
mosaicism	O
for	O
a	O
RPGR	O
gene	O
mutation	O
transmitted	O
the	O
mutation	O
to	O
an	O
asymptomatic	O
daughter	O
and	O
to	O
a	O
son	O
with	O
XLRP	O
.	O

Gonadal	O
mosaicism	O
may	O
be	O
responsible	O
for	O
a	O
proportion	O
of	O
multiplex	O
or	O
simplex	O
RP	O
families	O
,	O
in	O
which	O
more	O
than	O
50%	O
of	O
all	O
cases	O
of	O
RP	O
are	O
found	O
.	O

(c)	O
2007	O
Wiley-Liss	O
,	O
Inc	O
.	O

Impact	O
of	O
the	O
CCR5	O
gene	O
polymorphism	O
on	O
the	O
survival	O
of	O
metastatic	O
melanoma	O
patients	O
receiving	O
immunotherapy	O
.	O

PURPOSE	O
:	O
Chemokines	O
influence	O
both	O
tumor	O
progression	O
and	O
anti-tumor	O
immune	O
response	O
.	O

A	O
32-bp-deletion	O
polymorphism	O
in	O
the	O
chemokine	O
receptor	O
5	O
gene	O
CCR5	O
Delta32	B-DNAMutation
has	O
been	O
shown	O
to	O
result	O
in	O
a	O
non-functional	O
protein	O
.	O

This	O
study	O
was	O
aimed	O
at	O
evaluating	O
the	O
potential	O
impact	O
of	O
this	O
gene	O
polymorphism	O
on	O
disease	O
progression	O
and	O
treatment	O
outcome	O
in	O
patients	O
with	O
melanoma	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
CCR5	O
genotyping	O
was	O
performed	O
by	O
PCR	O
on	O
DNA	O
extracted	O
from	O
serum	O
samples	O
of	O
782	O
cutaneous	O
melanoma	O
patients	O
with	O
known	O
disease	O
history	O
and	O
long-term	O
clinical	O
follow-up	O
.	O

Genotypes	O
were	O
correlated	O
with	O
patient	O
survival	O
and	O
types	O
of	O
treatment	O
.	O

RESULTS	O
:	O
Of	O
782	O
melanoma	O
patients	O
,	O
90	O
(11.5%)	O
were	O
heterozygous	O
and	O
12	O
(1.5%)	O
were	O
homozygous	O
for	O
CCR5	O
Delta32	B-DNAMutation
.	O

Analyzing	O
the	O
complete	O
cohort	O
,	O
the	O
disease-specific	O
survival	O
from	O
date	O
of	O
primary	O
diagnosis	O
was	O
not	O
influenced	O
by	O
CCR5	O
status	O
.	O

Similarly	O
,	O
no	O
significant	O
impact	O
could	O
be	O
detected	O
on	O
the	O
treatment	O
outcome	O
of	O
stage	O
III	O
patients	O
.	O

In	O
139	O
stage	O
IV	O
patients	O
receiving	O
immunotherapy	O
,	O
CCR5	O
Delta32	B-DNAMutation
was	O
associated	O
with	O
a	O
decreased	O
survival	O
compared	O
to	O
patients	O
not	O
carrying	O
the	O
deletion	O
(	O
median	O
12.5	O
vs	O
.	O

20.3	O
months	O
,	O
P	O
=	O
0.029	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
the	O
CCR5	O
genotype	O
as	O
an	O
independent	O
factor	O
impacting	O
disease-specific	O
survival	O
in	O
this	O
patient	O
population	O
(	O
P	O
=	O
0.002	O
)	O
,	O
followed	O
by	O
gender	O
(	O
P	O
=	O
0.019	O
)	O
and	O
pathological	O
classification	O
of	O
the	O
primary	O
(	O
pT	O
;	O
P	O
=	O
0.022	O
)	O
.	O

CONCLUSION	O
:	O
The	O
presence	O
of	O
the	O
CCR5	O
Delta32	B-DNAMutation
polymorphism	O
in	O
patients	O
with	O
stage	O
IV	O
melanoma	O
results	O
in	O
a	O
decreased	O
survival	O
following	O
immunotherapy	O
and	O
may	O
help	O
to	O
select	O
patients	O
less	O
likely	O
to	O
benefit	O
from	O
this	O
type	O
of	O
treatment	O
.	O

Characterization	O
of	O
the	O
BMPR2	O
5'-untranslated	O
region	O
and	O
a	O
novel	O
mutation	O
in	O
pulmonary	O
hypertension	O
.	O

RATIONALE	O
:	O
Familial	O
pulmonary	O
arterial	O
hypertension	O
results	O
from	O
heterozygous	O
inactivating	O
mutations	O
of	O
the	O
BMPR2	O
gene	O
.	O

Traditional	O
mutation	O
analysis	O
identifies	O
pathogenic	O
mutations	O
in	O
some	O
70%	O
of	O
linked	O
families	O
.	O

We	O
hypothesized	O
that	O
the	O
apparent	O
shortfall	O
is	O
due	O
to	O
mutations	O
located	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gene	O
,	O
resulting	O
in	O
abnormal	O
gene	O
regulation	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
mutations	O
in	O
untranslated	O
sequence	O
regulating	O
BMPR2	O
transcription	O
.	O

METHODS	O
:	O
DNA	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
analyzed	O
by	O
direct	O
sequencing	O
in	O
16	O
families	O
.	O

Reverse	O
transcription-polymerase	O
chain	O
reaction	O
analysis	O
and	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
of	O
normal	O
human	O
lung	O
RNA	O
were	O
used	O
to	O
investigate	O
transcription	O
of	O
this	O
region	O
.	O

Transcript	O
levels	O
were	O
assessed	O
by	O
allele-specific	O
expression	O
analysis	O
and	O
inhibition	O
of	O
nonsense-mediated	O
decay	O
in	O
lymphoblastoid	O
cell	O
lines	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
The	O
wild-type	O
transcriptional	O
start	O
site	O
of	O
BMPR2	O
was	O
defined	O
,	O
1,148	O
bp	O
upstream	O
of	O
the	O
ATG	O
.	O

Within	O
this	O
region	O
,	O
we	O
identified	O
a	O
double-substitution	O
mutation	O
,	O
predicted	O
to	O
form	O
a	O
cryptic	O
translational	O
start	O
site	O
,	O
in	O
one	O
family	O
.	O

The	O
mutant	O
transcript	O
contains	O
a	O
premature	O
stop	O
codon	O
predicted	O
to	O
trigger	O
nonsense-mediated	O
decay	O
.	O

Expression	O
analysis	O
in	O
the	O
patient's	O
cell	O
line	O
indeed	O
showed	O
reduced	O
expression	O
of	O
the	O
mutant	O
transcript	O
that	O
could	O
be	O
restored	O
to	O
normal	O
by	O
inhibiting	O
nonsense-mediated	O
decay	O
.	O

CONCLUSIONS	O
:	O
Activation	O
of	O
a	O
cryptic	O
translation	O
initiation	O
site	O
is	O
a	O
novel	O
mutational	O
mechanism	O
in	O
this	O
disorder	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
5'-untranslated	O
region	O
of	O
BMPR2	O
is	O
considerably	O
longer	O
than	O
previously	O
thought	O
,	O
emphasizing	O
the	O
need	O
to	O
fully	O
characterize	O
the	O
BMPR2	O
promoter	O
and	O
the	O
importance	O
of	O
analyzing	O
noncoding	O
regions	O
in	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
who	O
are	O
negative	O
for	O
mutations	O
within	O
the	O
coding	O
region	O
and	O
intron-exon	O
junctions	O
.	O

Identification	O
of	O
PVT1	O
as	O
a	O
candidate	O
gene	O
for	O
end-stage	O
renal	O
disease	O
in	O
type	O
2	O
diabetes	O
using	O
a	O
pooling-based	O
genome-wide	O
single	O
nucleotide	O
polymorphism	O
association	O
study	O
.	O

To	O
identify	O
genetic	O
variants	O
contributing	O
to	O
end-stage	O
renal	O
disease	O
(ESRD)	O
in	O
type	O
2	O
diabetes	O
,	O
we	O
performed	O
a	O
genome-wide	O
analysis	O
of	O
115,352	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
pools	O
of	O
105	O
unrelated	O
case	O
subjects	O
with	O
ESRD	O
and	O
102	O
unrelated	O
control	O
subjects	O
who	O
have	O
had	O
type	O
2	O
diabetes	O
for	O
>	O
or	O
=10	O
years	O
without	O
macroalbuminuria	O
.	O

Using	O
a	O
sliding	O
window	O
statistic	O
of	O
ranked	O
SNPs	O
,	O
we	O
identified	O
a	O
200-kb	O
region	O
on	O
8q24	O
harboring	O
three	O
SNPs	O
showing	O
substantial	O
differences	O
in	O
allelic	O
frequency	O
between	O
case	O
and	O
control	O
pools	O
.	O

These	O
SNPs	O
were	O
genotyped	O
in	O
individuals	O
comprising	O
each	O
pool	O
,	O
and	O
strong	O
evidence	O
for	O
association	O
was	O
found	O
with	O
rs2720709	B-SNP
(	O
P	O
=	O
0.000021	O
;	O
odds	O
ratio	O
2.57	O
[	O
95%	O
CI	O
1.66-3.96]	O
)	O
,	O
which	O
is	O
located	O
in	O
the	O
plasmacytoma	O
variant	O
translocation	O
gene	O
PVT1	O
.	O

We	O
sequenced	O
all	O
exons	O
,	O
exon-intron	O
boundaries	O
,	O
and	O
the	O
promoter	O
of	O
PVT1	O
and	O
identified	O
47	O
variants	O
,	O
11	O
of	O
which	O
represented	O
nonredundant	O
markers	O
with	O
minor	O
allele	O
frequency	O
>	O
or	O
=0.05	O
.	O

We	O
subsequently	O
genotyped	O
these	O
11	O
variants	O
and	O
an	O
additional	O
87	O
SNPs	O
identified	O
through	O
public	O
databases	O
in	O
319-kb	O
flanking	O
rs2720709	B-SNP
(	O
approximately	O
1	O
SNP/3.5	O
kb	O
)	O
;	O
23	O
markers	O
were	O
associated	O
with	O
ESRD	O
at	O
P	O
<	O
0.01	O
.	O

The	O
strongest	O
evidence	O
for	O
association	O
was	O
found	O
for	O
rs2648875	B-SNP
(	O
P	O
=	O
0.0000018	O
;	O
2.97	O
[	O
1.90-4.65	O
]	O
)	O
,	O
which	O
maps	O
to	O
intron	O
8	O
of	O
PVT1	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
PVT1	O
may	O
contribute	O
to	O
ESRD	O
susceptibility	O
in	O
diabetes	O
.	O

The	O
phosphatidylethanolamine	O
N-methyltransferase	O
gene	O
V175M	B-ProteinMutation
single	O
nucleotide	O
polymorphism	O
confers	O
the	O
susceptibility	O
to	O
NASH	O
in	O
Japanese	O
population	O
.	O

BACKGROUND/AIMS	O
:	O
The	O
genetic	O
predisposition	O
on	O
the	O
development	O
of	O
nonalcoholic	O
steatohepatitis	O
(NASH)	O
has	O
been	O
poorly	O
understood	O
.	O

A	O
functional	O
polymorphism	O
Val175Met	B-ProteinMutation
was	O
reported	O
in	O
phosphatidylethanolamine	O
N-methyltransferase	O
(PEMT)	O
that	O
catalyzes	O
the	O
conversion	O
of	O
phosphatidylethanolamine	O
to	O
phosphatidylcholine	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
carriers	O
of	O
Val175Met	B-ProteinMutation
variant	O
impaired	O
in	O
PEMT	O
activity	O
are	O
more	O
susceptible	O
to	O
NASH	O
.	O

METHODS	O
:	O
Blood	O
samples	O
of	O
107	O
patients	O
with	O
biopsy-proven	O
NASH	O
and	O
of	O
150	O
healthy	O
volunteers	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

RESULTS	O
:	O
Val175Met	B-ProteinMutation
variant	O
allele	O
of	O
the	O
PEMT	O
gene	O
was	O
significantly	O
more	O
frequent	O
in	O
NASH	O
patients	O
than	O
in	O
healthy	O
volunteers	O
(p<0.001)	O
,	O
and	O
carriers	O
of	O
Val175Met	B-ProteinMutation
variant	O
were	O
significantly	O
more	O
frequent	O
in	O
NASH	O
patients	O
than	O
in	O
healthy	O
volunteers	O
(p<0.01)	O
.	O

Among	O
NASH	O
patients	O
,	O
body	O
mass	O
index	O
was	O
significantly	O
lower	O
(p<0.05)	O
,	O
and	O
non-obese	O
patients	O
were	O
significantly	O
more	O
frequent	O
(p<0.001)	O
in	O
carriers	O
of	O
Val175Met	B-ProteinMutation
variant	O
than	O
in	O
homozygotes	O
of	O
wild	O
type	O
PEMT	O
.	O

CONCLUSIONS	O
:	O
Val175Met	B-ProteinMutation
variant	O
of	O
PEMT	O
could	O
be	O
a	O
candidate	O
molecule	O
that	O
determines	O
the	O
susceptibility	O
to	O
NASH	O
,	O
because	O
it	O
is	O
more	O
frequently	O
observed	O
in	O
NASH	O
patients	O
and	O
non-obese	O
persons	O
with	O
Val175Met	B-ProteinMutation
variant	O
of	O
PEMT	O
are	O
facilitated	O
to	O
develop	O
NASH	O
.	O

Semi-automated	O
,	O
reverse-hybridization	O
detection	O
of	O
multiple	O
mutations	O
causing	O
hereditary	O
fructose	O
intolerance	O
.	O

Hereditary	O
fructose	O
intolerance	O
(HFI)	O
is	O
a	O
potentially	O
fatal	O
nutritional	O
disease	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
liver	O
isoenzyme	O
of	O
fructoaldolase	O
(	O
aldolase	O
B	O
)	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
a	O
diagnostic	O
assay	O
capable	O
of	O
simultaneously	O
analyzing	O
three-point	O
mutations	O
and	O
a	O
small	O
deletion	O
in	O
the	O
aldolase	O
B	O
(ALDOB)	O
gene	O
.	O

The	O
test	O
under	O
investigation	O
is	O
based	O
on	O
multiplex	O
DNA	O
amplification	O
and	O
hybridization	O
to	O
membrane	O
strips	O
presenting	O
a	O
parallel	O
array	O
of	O
allele-specific	O
oligonucleotide	O
probes	O
.	O

We	O
used	O
the	O
novel	O
reverse-hybridization	O
(RH)	O
protocol	O
to	O
analyze	O
54	O
individuals	O
previously	O
genotyped	O
by	O
direct	O
sequencing	O
.	O

RH	O
genotyping	O
for	O
ALDOB	O
mutations	O
Delta4E4	O
,	O
A149P	B-ProteinMutation
,	O
A174D	B-ProteinMutation
,	O
and	O
N334K	B-ProteinMutation
was	O
in	O
complete	O
concordance	O
with	O
results	O
obtained	O
by	O
DNA	O
sequencing	O
.	O

The	O
procedure	O
is	O
rapid	O
(<6h)	O
and	O
may	O
be	O
automated	O
to	O
a	O
large	O
extent	O
.	O

The	O
RH	O
assay	O
tested	O
in	O
this	O
study	O
represents	O
an	O
accurate	O
and	O
robust	O
screening	O
tool	O
to	O
identify	O
common	O
ALDOB	O
mutations	O
.	O

Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphisms	O
do	O
not	O
predict	O
the	O
course	O
of	O
idiopathic	O
nephrotic	O
syndrome	O
in	O
Swiss	O
children	O
.	O

AIM	O
:	O
Contradictory	O
reports	O
exist	O
about	O
a	O
correlation	O
of	O
angiotensin	O
I	O
converting	O
enzyme	O
(ACE)	O
gene	O
polymorphisms	O
to	O
the	O
outcome	O
of	O
idiopathic	O
nephrotic	O
syndrome	O
(INS)	O
in	O
children	O
.	O

We	O
investigated	O
the	O
frequency	O
of	O
ACE	O
polymorphisms	O
and	O
their	O
impact	O
on	O
the	O
clinical	O
course	O
of	O
INS	O
in	O
children	O
in	O
a	O
Swiss	O
hospital	O
.	O

METHODS	O
:	O
The	O
ACE	O
gene	O
polymorphism	O
(	O
I	O
,	O
insertion	O
;	O
D	O
,	O
deletion	O
)	O
was	O
assessed	O
in	O
32	O
children	O
-	O
22	O
with	O
steroid-sensitive	O
INS	O
and	O
10	O
with	O
steroid-resistant	O
INS	O
-	O
with	O
a	O
median	O
age	O
at	O
onset	O
of	O
INS	O
of	O
2.9	O
years	O
(	O
range	O
1.1-15.0	O
)	O
.	O

Polymerase	O
chain	O
reaction	O
amplification	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
blood	O
leucocytes	O
.	O

Results	O
were	O
correlated	O
to	O
clinical	O
course	O
and	O
renal	O
morphology	O
.	O

RESULTS	O
:	O
The	O
ACE	O
genotype	O
was	O
I/I	O
,	O
I/D	O
and	O
D/D	O
in	O
two	O
,	O
12	O
and	O
eight	O
patients	O
,	O
respectively	O
,	O
with	O
steroid-sensitive	O
INS	O
,	O
and	O
in	O
one	O
,	O
eight	O
and	O
one	O
patient	O
,	O
respectively	O
,	O
with	O
steroid	O
resistance	O
.	O

Renal	O
morphology	O
,	O
available	O
in	O
25	O
patients	O
showed	O
minimal	O
change	O
glomerulopathy	O
in	O
17	O
patients	O
(	O
14	O
steroid-sensitive	O
;	O
three	O
steroid-resistant	O
)	O
and	O
focal	O
segmental	O
glomerulosclerosis	O
in	O
eight	O
(	O
one	O
steroid-sensitive	O
;	O
seven	O
steroid-resistant	O
)	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
ACE	O
genotype	O
and	O
steroid	O
responsiveness	O
,	O
histology	O
or	O
outcome	O
.	O

ACE	O
genotype	O
was	O
I/I	O
,	O
I/D	O
and	O
D/D	O
in	O
none	O
,	O
12	O
and	O
five	O
patients	O
,	O
respectively	O
,	O
with	O
minimal	O
change	O
glomerulopathy	O
,	O
and	O
in	O
one	O
,	O
five	O
and	O
two	O
patients	O
,	O
respectively	O
,	O
with	O
focal	O
segmental	O
glomerulosclerosis	O
.	O

Six	O
patients	O
with	O
steroid-resistant	O
nephrotic	O
syndrome	O
went	O
into	O
end	O
stage	O
renal	O
disease	O
;	O
ACE	O
genotype	O
was	O
I/I	O
in	O
one	O
and	O
I/D	O
in	O
five	O
,	O
but	O
none	O
were	O
D/D	O
.	O

CONCLUSION	O
:	O
In	O
contrast	O
to	O
previous	O
reports	O
,	O
ACE	O
gene	O
polymorphism	O
is	O
irrelevant	O
for	O
clinical	O
outcome	O
,	O
steroid	O
responsiveness	O
or	O
morphology	O
in	O
Swiss	O
children	O
with	O
INS	O
.	O

Association	O
between	O
an	O
endoglin	O
gene	O
polymorphism	O
and	O
systemic	O
sclerosis-related	O
pulmonary	O
arterial	O
hypertension	O
.	O

Systemic	O
sclerosis	O
(SSc)	O
is	O
a	O
connective	O
tissue	O
disorder	O
characterized	O
by	O
early	O
generalized	O
microangiopathy	O
with	O
disturbed	O
angiogenesis	O
.	O

Endoglin	O
gene	O
(ENG)	O
encodes	O
a	O
transmembrane	O
glycoprotein	O
which	O
acts	O
as	O
an	O
accessory	O
receptor	O
for	O
the	O
transforming	O
growth	O
factor-beta	O
(TGF-beta)	O
superfamily	O
,	O
and	O
is	O
crucial	O
for	O
maintaining	O
vascular	O
integrity	O
.	O

A	O
6-base	O
insertion	O
in	O
intron	O
7	O
6bINS	B-DNAMutation
of	O
ENG	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
microvascular	O
disturbance	O
.	O

OBJECTIVES	O
:	O
Our	O
objective	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
6bINS	B-DNAMutation
and	O
the	O
vascular	O
complication	O
pulmonary	O
arterial	O
hypertension	O
(PAH)	O
in	O
SSc	O
in	O
a	O
French	O
Caucasian	O
population	O
.	O

METHODS	O
:	O
Two	O
hundred	O
eighty	O
SSc	O
cases	O
containing	O
29/280	O
having	O
PAH	O
diagnosed	O
by	O
catheterism	O
were	O
compared	O
with	O
140	O
patients	O
with	O
osteoarthritis	O
.	O

Genotyping	O
was	O
performed	O
by	O
polymerase-chain-reaction-based	O
fluorescence	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
The	O
polymorphism	O
was	O
in	O
Hardy-Weinberg	O
equilibrium	O
.	O

We	O
observed	O
a	O
significant	O
lower	O
frequency	O
of	O
6bINS	B-DNAMutation
allele	O
in	O
SSc	O
patients	O
with	O
associated	O
PAH	O
compared	O
with	O
controls	O
[	O
10.3	O
vs	O
23.9%	O
,	O
P	O
=	O
0.01	O
;	O
odds	O
ratio	O
(OR)	O
0.37	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
0.15-0.89	O
]	O
,	O
and	O
a	O
trend	O
in	O
comparison	O
with	O
SSc	O
patients	O
without	O
PAH	O
(	O
10.3	O
vs	O
20.3%	O
,	O
P	O
=	O
0.05	O
;	O
OR	O
:	O
0.45	O
,	O
95%	O
CI	O
:	O
0.19-1.08	O
)	O
.	O

Genotypes	O
carrying	O
allele	O
6bINS	B-DNAMutation
were	O
also	O
less	O
frequent	O
in	O
SSc	O
patients	O
with	O
PAH	O
than	O
in	O
controls	O
(	O
20.7	O
vs	O
42.9%	O
,	O
P	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
:	O
Thus	O
the	O
frequency	O
of	O
6bINS	B-DNAMutation
differs	O
between	O
SSc	O
patients	O
with	O
or	O
without	O
PAH	O
,	O
suggesting	O
the	O
implication	O
of	O
ENG	O
in	O
this	O
devastating	O
vascular	O
complication	O
of	O
SSc	O
.	O

Severe	O
beta(0)	O
thalassemia/hemoglobin	O
E	O
disease	O
caused	O
by	O
de	O
novo	O
22-base	O
pair	O
duplication	O
in	O
the	O
paternal	O
allele	O
of	O
beta	O
globin	O
gene	O
.	O

beta	O
Thalassemia	O
is	O
a	O
major	O
public	O
health	O
concern	O
in	O
Southeast	O
Asia	O
.	O

A	O
prevention	O
program	O
has	O
been	O
implemented	O
in	O
Thailand	O
comprising	O
mass	O
carrier	O
screening	O
and	O
genetic	O
testing	O
.	O

In	O
this	O
study	O
,	O
a	O
Thai	O
girl	O
with	O
severe	O
beta	O
thalassemia/hemoglobin	O
(Hb)	O
E	O
disease	O
was	O
born	O
from	O
the	O
mother	O
with	O
Hb	O
E	O
trait	O
and	O
the	O
genotypically	O
normal	O
father	O
.	O

DNA	O
sequencing	O
revealed	O
novel	O
22-bp	O
tandem	O
duplication	O
in	O
the	O
paternal	O
allele	O
of	O
beta	O
globin	O
gene	O
,	O
producing	O
a	O
severely	O
truncated	O
product	O
.	O

A	O
short	O
recurring	O
nucleotide	O
at	O
the	O
insertion	O
site	O
suggested	O
a	O
predisposition	O
to	O
this	O
mutation	O
.	O

Therefore	O
,	O
spontaneous	O
beta	O
globin	O
mutations	O
occasionally	O
occur	O
in	O
normal	O
population	O
.	O

Its	O
clinical	O
significance	O
is	O
noteworthy	O
in	O
countries	O
with	O
high	O
prevalence	O
of	O
beta	O
thalassemia	O
.	O

Quantitative	O
analysis	O
of	O
CAPN3	O
transcripts	O
in	O
LGMD2A	O
patients	O
:	O
involvement	O
of	O
nonsense-mediated	O
mRNA	O
decay	O
.	O

Limb	O
girdle	O
muscular	O
dystrophy	O
type	O
2A	O
(LGMD2A)	O
is	O
caused	O
by	O
single	O
or	O
small	O
nucleotide	O
changes	O
widespread	O
along	O
the	O
CAPN3	O
gene	O
,	O
which	O
encodes	O
the	O
muscle-specific	O
proteolytic	O
enzyme	O
calpain-3	O
.	O

About	O
356	O
unique	O
allelic	O
variants	O
of	O
CAPN3	O
have	O
been	O
identified	O
to	O
date	O
.	O

We	O
performed	O
analysis	O
of	O
the	O
CAPN3	O
gene	O
in	O
LGMD2A	O
patients	O
at	O
both	O
the	O
mRNA	O
level	O
using	O
reverse	O
transcription-PCR	O
,	O
and	O
at	O
the	O
DNA	O
level	O
using	O
PCR	O
and	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

In	O
four	O
patients	O
,	O
we	O
detected	O
homozygous	O
occurrence	O
of	O
a	O
missense	O
mutation	O
or	O
an	O
in-frame	O
deletion	O
at	O
the	O
mRNA	O
level	O
although	O
the	O
DNA	O
was	O
heterozygous	O
for	O
this	O
mutation	O
in	O
conjunction	O
with	O
a	O
frame-shift	O
mutation	O
.	O

The	O
relationship	O
observed	O
in	O
12	O
patients	O
between	O
the	O
quantity	O
of	O
CAPN3	O
mRNA	O
,	O
determined	O
using	O
real-time	O
PCR	O
,	O
and	O
the	O
genotype	O
leads	O
us	O
to	O
propose	O
that	O
CAPN3	O
mRNAs	O
which	O
contain	O
frame-shift	O
mutations	O
are	O
degraded	O
by	O
nonsense-mediated	O
mRNA	O
decay	O
.	O

Our	O
results	O
illustrate	O
the	O
importance	O
of	O
DNA	O
analysis	O
for	O
reliable	O
establishment	O
of	O
mutation	O
status	O
,	O
and	O
provide	O
a	O
new	O
insight	O
into	O
the	O
process	O
of	O
mRNA	O
decay	O
in	O
cells	O
of	O
LGMD2A	O
patients	O
.	O

Putative	O
association	O
of	O
RUNX1	O
polymorphisms	O
with	O
IgE	O
levels	O
in	O
a	O
Korean	O
population	O
.	O

RUNX1	O
,	O
a	O
member	O
of	O
the	O
runt	O
domain	O
gene	O
family	O
of	O
transcription	O
factors	O
,	O
encodes	O
a	O
heterodimeric	O
transcription	O
factor	O
and	O
regulates	O
the	O
expression	O
of	O
various	O
genes	O
related	O
to	O
hematopoiesis	O
and	O
myeloid	O
differentiation	O
.	O

RUNX1	O
has	O
been	O
one	O
of	O
the	O
target	O
genes	O
for	O
research	O
into	O
various	O
autoimmune	O
diseases	O
due	O
to	O
its	O
properties	O
as	O
a	O
transcription	O
factor	O
and	O
functional	O
distribution	O
for	O
chromosomal	O
translocation	O
.	O

In	O
an	O
effort	O
to	O
identify	O
additional	O
gene	O
polymorphisms	O
in	O
which	O
variants	O
have	O
been	O
implicated	O
in	O
asthma	O
,	O
we	O
investigated	O
the	O
genetic	O
polymorphisms	O
in	O
RUNX1	O
to	O
evaluate	O
it	O
as	O
a	O
potential	O
candidate	O
gene	O
for	O
a	O
host	O
genetic	O
study	O
of	O
asthma	O
and	O
IgE	O
production	O
.	O

We	O
identified	O
19	O
sequence	O
variants	O
by	O
direct	O
DNA	O
sequencing	O
in	O
24	O
individuals	O
of	O
which	O
four	O
common	O
variants	O
were	O
selected	O
for	O
genotyping	O
in	O
our	O
asthma	O
cohort	O
(	O
1,055	O
asthmatic	O
patients	O
,	O
384	O
normal	O
controls	O
)	O
.	O

Using	O
logistic	O
regression	O
analysis	O
for	O
association	O
with	O
the	O
risk	O
of	O
asthma	O
,	O
while	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
and	O
smoking	O
status	O
as	O
covariates	O
,	O
no	O
significant	O
associations	O
with	O
the	O
risk	O
of	O
asthma	O
were	O
detected	O
.	O

However	O
,	O
two	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
(	O
-2084G>C	B-DNAMutation
and	O
-1282G>A	B-DNAMutation
)	O
showed	O
a	O
marginal	O
association	O
with	O
total	O
IgE	O
levels	O
(	O
0.03	O
and	O
0.03	O
in	O
recessive	O
models	O
,	O
respectively	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
polymorphisms	O
in	O
RUNX1	O
might	O
be	O
one	O
of	O
the	O
genetic	O
factors	O
for	O
the	O
regulation	O
of	O
IgE	O
production	O
.	O

Analysis	O
of	O
skin	O
cancer	O
risk	O
factors	O
in	O
immunosuppressed	O
renal	O
transplant	O
patients	O
shows	O
high	O
levels	O
of	O
UV-specific	O
tandem	O
CC	O
to	O
TT	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O

Immunosuppressed	O
renal	O
transplant	O
recipients	O
(RTRs)	O
are	O
predisposed	O
to	O
non-melanoma	O
skin	O
cancers	O
(NMSCs)	O
,	O
predominantly	O
squamous	O
cell	O
carcinomas	O
(SCCs)	O
.	O

We	O
have	O
analyzed	O
skin	O
lesions	O
from	O
RTRs	O
with	O
aggressive	O
tumors	O
for	O
p53	O
gene	O
modifications	O
,	O
the	O
presence	O
of	O
Human	O
Papillomas	O
Virus	O
(HPV)	O
DNA	O
in	O
relation	O
to	O
the	O
p53	O
codon	O
72	O
genotype	O
and	O
polymorphisms	O
of	O
the	O
XPD	O
repair	O
gene	O
.	O

We	O
detected	O
24	O
p53	O
mutations	O
in	O
15/25	O
(60%)	O
NMSCs	O
,	O
1	O
deletion	O
and	O
23	O
base	O
substitutions	O
,	O
the	O
majority	O
(78%)	O
being	O
UV-specific	O
C	O
to	O
T	O
transitions	O
at	O
bipyrimidine	O
sites	O
.	O

Importantly	O
,	O
35%	O
(6/17)	O
are	O
tandem	O
mutations	O
,	O
including	O
4	O
UV	O
signature	O
CC	O
to	O
TT	O
transitions	O
possibly	O
linked	O
to	O
modulated	O
DNA	O
repair	O
caused	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(CsA)	O
.	O

We	O
found	O
8	O
p53	O
mutations	O
in	O
7/17	O
(41%)	O
precancerous	O
actinic	O
keratosis	O
(AK)	O
,	O
suggesting	O
that	O
p53	O
mutations	O
are	O
early	O
events	O
in	O
RTR	O
skin	O
carcinogenesis	O
.	O

Immunohistochemical	O
analysis	O
shows	O
a	O
good	O
correlation	O
between	O
p53	O
accumulation	O
and	O
mutations	O
.	O

HPV	O
DNA	O
was	O
detected	O
in	O
78%	O
of	O
skin	O
lesions	O
(	O
60%	O
Basal	O
Cell	O
Carcinomas	O
,	O
82%AK	O
and	O
79%	O
SCCs	O
)	O
.	O

Thus	O
,	O
immunosuppression	O
has	O
increased	O
the	O
risk	O
of	O
infections	O
by	O
HPVs	O
,	O
predominantly	O
epidermodysplasia	O
verruciformis	O
,	O
speculated	O
to	O
play	O
a	O
role	O
in	O
skin	O
cancer	O
development	O
.	O

No	O
association	O
is	O
found	O
between	O
HPV	O
status	O
and	O
p53	O
mutation	O
.	O

Moreover	O
,	O
p53	O
codon	O
72	O
or	O
frequencies	O
of	O
three	O
XPD	O
genotypes	O
of	O
RTRs	O
are	O
comparable	O
with	O
control	O
populations	O
.	O

The	O
p53	O
mutation	O
spectrum	O
,	O
presenting	O
a	O
high	O
level	O
of	O
CC	O
to	O
TT	O
mutations	O
,	O
shows	O
that	O
the	O
UV	O
component	O
of	O
sunlight	O
is	O
the	O
major	O
risk	O
factor	O
and	O
modulated	O
DNA	O
repair	O
by	O
immunosuppressive	O
drug	O
treatment	O
may	O
be	O
significant	O
in	O
the	O
skin	O
carcinogenesis	O
of	O
RTRs	O
.	O

A	O
novel	O
splicing	O
mutation	O
in	O
SLC12A3	O
associated	O
with	O
Gitelman	O
syndrome	O
and	O
idiopathic	O
intracranial	O
hypertension	O
.	O

We	O
report	O
a	O
case	O
of	O
Gitelman	O
syndrome	O
(GS)	O
in	O
a	O
dizygotic	O
twin	O
who	O
presented	O
at	O
12	O
years	O
of	O
age	O
with	O
growth	O
delay	O
,	O
metabolic	O
alkalosis	O
,	O
hypomagnesemia	O
and	O
hypokalemia	O
with	O
inappropriate	O
kaliuresis	O
,	O
and	O
idiopathic	O
intracranial	O
hypertension	O
with	O
bilateral	O
papilledema	O
(	O
pseudotumor	O
cerebri	O
)	O
.	O

The	O
patient	O
,	O
her	O
twin	O
sister	O
,	O
and	O
her	O
mother	O
also	O
presented	O
with	O
cerebral	O
cavernous	O
malformations	O
.	O

Based	O
on	O
the	O
early	O
onset	O
and	O
normocalciuria	O
,	O
Bartter	O
syndrome	O
was	O
diagnosed	O
first	O
.	O

However	O
,	O
mutation	O
analysis	O
showed	O
that	O
the	O
proband	O
is	O
a	O
compound	O
heterozygote	O
for	O
2	O
mutations	O
in	O
SLC12A3	O
:	O
a	O
substitution	O
of	O
serine	O
by	O
leucine	O
at	O
amino	O
acid	O
position	O
555	O
p.Ser555Leu	B-ProteinMutation
and	O
a	O
novel	O
guanine	O
to	O
cytosine	O
transition	O
at	O
the	O
5'	O
splice	O
site	O
of	O
intron	O
22	O
c.2633+1G>C	B-DNAMutation
,	O
providing	O
the	O
molecular	O
diagnosis	O
of	O
GS	O
.	O

These	O
mutations	O
were	O
not	O
detected	O
in	O
200	O
normal	O
chromosomes	O
and	O
cosegregated	O
within	O
the	O
family	O
.	O

Analysis	O
of	O
complementary	O
DNA	O
showed	O
that	O
the	O
heterozygous	O
nucleotide	O
change	O
c.2633+1G>C	B-DNAMutation
caused	O
the	O
appearance	O
of	O
2	O
RNA	O
molecules	O
,	O
1	O
normal	O
transcript	O
and	O
1	O
skipping	O
the	O
entire	O
exon	O
22	O
r.2521_2634del	B-DNAMutation
.	O

Supplementation	O
with	O
potassium	O
and	O
magnesium	O
improved	O
clinical	O
symptoms	O
and	O
resulted	O
in	O
catch-up	O
growth	O
,	O
but	O
vision	O
remained	O
impaired	O
.	O

Three	O
similar	O
associations	O
of	O
Bartter	O
syndrome/GS	O
with	O
pseudotumor	O
cerebri	O
were	O
found	O
in	O
the	O
literature	O
,	O
suggesting	O
that	O
electrolyte	O
abnormalities	O
and	O
secondary	O
aldosteronism	O
may	O
have	O
a	O
role	O
in	O
idiopathic	O
intracranial	O
hypertension	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
for	O
the	O
phenotypical	O
heterogeneity	O
of	O
GS	O
and	O
its	O
association	O
with	O
severe	O
manifestations	O
in	O
children	O
.	O

It	O
also	O
shows	O
the	O
independent	O
segregation	O
of	O
familial	O
cavernomatosis	O
and	O
GS	O
.	O

Mutation	O
in	O
the	O
auxiliary	O
calcium-channel	O
subunit	O
CACNA2D4	O
causes	O
autosomal	O
recessive	O
cone	O
dystrophy	O
.	O

Retinal	O
signal	O
transmission	O
depends	O
on	O
the	O
activity	O
of	O
high	O
voltage-gated	O
l-type	O
calcium	O
channels	O
in	O
photoreceptor	O
ribbon	O
synapses	O
.	O

We	O
recently	O
identified	O
a	O
truncating	O
frameshift	O
mutation	O
in	O
the	O
Cacna2d4	O
gene	O
in	O
a	O
spontaneous	O
mouse	O
mutant	O
with	O
profound	O
loss	O
of	O
retinal	O
signaling	O
and	O
an	O
abnormal	O
morphology	O
of	O
ribbon	O
synapses	O
in	O
rods	O
and	O
cones	O
.	O

The	O
Cacna2d4	O
gene	O
encodes	O
an	O
l-type	O
calcium-channel	O
auxiliary	O
subunit	O
of	O
the	O
alpha	O
(2)	O
delta	O
type	O
.	O

Mutations	O
in	O
its	O
human	O
orthologue	O
,	O
CACNA2D4	O
,	O
were	O
not	O
yet	O
known	O
to	O
be	O
associated	O
with	O
a	O
disease	O
.	O

We	O
performed	O
mutation	O
analyses	O
of	O
34	O
patients	O
who	O
received	O
an	O
initial	O
diagnosis	O
of	O
night	O
blindness	O
,	O
and	O
,	O
in	O
two	O
affected	O
siblings	O
,	O
we	O
detected	O
a	O
homozygous	O
nucleotide	O
substitution	O
c.2406C-->A	B-DNAMutation
in	O
CACNA2D4	O
.	O

The	O
mutation	O
introduces	O
a	O
premature	O
stop	O
codon	O
that	O
truncates	O
one-third	O
of	O
the	O
corresponding	O
open	O
reading	O
frame	O
.	O

Both	O
patients	O
share	O
symptoms	O
of	O
slowly	O
progressing	O
cone	O
dystrophy	O
.	O

These	O
findings	O
represent	O
the	O
first	O
report	O
of	O
a	O
mutation	O
in	O
the	O
human	O
CACNA2D4	O
gene	O
and	O
define	O
a	O
novel	O
gene	O
defect	O
that	O
causes	O
autosomal	O
recessive	O
cone	O
dystrophy	O
.	O

A	O
haplotype-based	O
analysis	O
of	O
the	O
PTPN22	O
locus	O
in	O
type	O
1	O
diabetes	O
.	O

A	O
recent	O
addition	O
to	O
the	O
list	O
of	O
widely	O
confirmed	O
type	O
1	O
diabetes	O
risk	O
loci	O
is	O
the	O
PTPN22	O
gene	O
encoding	O
a	O
lymphoid-specific	O
phosphatase	O
(Lyp)	O
.	O

However	O
,	O
evidence	O
supporting	O
a	O
role	O
for	O
PTPN22	O
in	O
type	O
1	O
diabetes	O
derives	O
entirely	O
from	O
the	O
study	O
of	O
just	O
one	O
coding	O
single	O
nucleotide	O
polymorphism	O
,	O
1858C/T	B-DNAMutation
.	O

In	O
the	O
current	O
study	O
,	O
the	O
haplotype	O
structure	O
of	O
the	O
PTPN22	O
region	O
was	O
determined	O
,	O
and	O
individual	O
haplotypes	O
were	O
tested	O
for	O
association	O
with	O
type	O
1	O
diabetes	O
in	O
family-based	O
tests	O
.	O

The	O
1858T	O
risk	O
allele	O
occurred	O
on	O
only	O
a	O
single	O
haplotype	O
that	O
was	O
strongly	O
associated	O
with	O
type	O
1	O
diabetes	O
(	O
P	O
=	O
7.9	O
x	O
10(-5)	O
)	O
.	O

After	O
controlling	O
for	O
the	O
effects	O
of	O
this	O
allele	O
,	O
two	O
other	O
haplotypes	O
were	O
observed	O
to	O
be	O
weakly	O
associated	O
with	O
type	O
1	O
diabetes	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Sequencing	O
of	O
the	O
coding	O
region	O
of	O
PTPN22	O
on	O
these	O
haplotypes	O
revealed	O
a	O
novel	O
variant	O
2250G/C	B-DNAMutation
predicted	O
to	O
result	O
in	O
a	O
nonsynonymous	O
amino	O
acid	O
substitution	O
.	O

Analysis	O
of	O
PTPN22	O
transcripts	O
from	O
a	O
subject	O
heterozygous	O
for	O
this	O
variant	O
indicated	O
that	O
it	O
interfered	O
with	O
normal	O
mRNA	O
splicing	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
after	O
exon	O
17	O
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
the	O
1858C/T	B-DNAMutation
allele	O
is	O
the	O
major	O
risk	O
variant	O
for	O
type	O
1	O
diabetes	O
in	O
the	O
PTPN22	O
locus	O
,	O
but	O
they	O
suggest	O
that	O
additional	O
infrequent	O
coding	O
variants	O
at	O
PTPN22	O
may	O
also	O
contribute	O
to	O
type	O
1	O
diabetes	O
risk	O
.	O

16q-linked	O
autosomal	O
dominant	O
cerebellar	O
ataxia	O
:	O
a	O
clinical	O
and	O
genetic	O
study	O
.	O

The	O
autosomal	O
dominant	O
cerebellar	O
ataxias	O
(ADCAs)	O
comprise	O
a	O
genetically	O
and	O
clinically	O
heterogenous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

Very	O
recently	O
,	O
a	O
C-to-T	O
single	O
nucleotide	O
substitution	O
in	O
the	O
puratrophin-1	O
gene	O
was	O
found	O
to	O
be	O
strongly	O
associated	O
with	O
a	O
form	O
of	O
ADCA	O
linked	O
to	O
chromosome	O
16q22.1	O
(	O
16q-linked	O
ADCA	O
;	O
OMIM	O
600223	O
)	O
.	O

We	O
found	O
the	O
C-to-T	O
substitution	O
in	O
the	O
puratrophin-1	O
gene	O
in	O
20	O
patients	O
with	O
ataxia	O
(	O
16	O
heterozygotes	O
and	O
four	O
homozygotes	O
)	O
and	O
four	O
asymptomatic	O
carriers	O
in	O
9	O
of	O
24	O
families	O
with	O
an	O
unknown	O
type	O
of	O
ADCA	O
.	O

We	O
also	O
found	O
two	O
cases	O
with	O
16q-linked	O
ADCA	O
among	O
43	O
sporadic	O
patients	O
with	O
late-onset	O
cortical	O
cerebellar	O
atrophy	O
(LCCA)	O
.	O

The	O
mean	O
age	O
at	O
onset	O
in	O
the	O
22	O
patients	O
was	O
61.8	O
years	O
,	O
and	O
that	O
of	O
homozygous	O
patients	O
was	O
lower	O
than	O
that	O
of	O
heterozygous	O
ones	O
in	O
one	O
family	O
.	O

Neurological	O
examination	O
revealed	O
that	O
the	O
majority	O
of	O
our	O
patients	O
showed	O
exaggerated	O
deep	O
tendon	O
reflexes	O
in	O
addition	O
to	O
the	O
cardinal	O
symptom	O
of	O
cerebellar	O
ataxia	O
(100%)	O
,	O
and	O
37.5%	O
of	O
them	O
had	O
sensorineural	O
hearing	O
impairment	O
,	O
whereas	O
sensory	O
axonal	O
neuropathy	O
was	O
absent	O
.	O

The	O
frequency	O
of	O
16q-linked	O
ADCA	O
was	O
about	O
1/10	O
of	O
our	O
series	O
of	O
110	O
ADCA	O
families	O
,	O
making	O
it	O
the	O
third	O
most	O
frequent	O
ADCA	O
in	O
Japan	O
.	O

Association	O
of	O
TNF	O
haplotypes	O
with	O
asthma	O
,	O
serum	O
IgE	O
levels	O
,	O
and	O
correlation	O
with	O
serum	O
TNF-alpha	O
levels	O
.	O

Both	O
biochemical	O
and	O
genetic	O
evidence	O
have	O
implicated	O
the	O
genes	O
for	O
TNF-alpha	O
(TNFA)	O
and	O
lymphotoxin-alpha	O
(LTA)	O
in	O
atopic	O
asthma	O
.	O

Here	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
the	O
association	O
of	O
their	O
genotypes	O
and	O
haplotypes	O
with	O
atopic	O
asthma	O
in	O
Indian	O
populations	O
.	O

We	O
genotyped	O
seven	O
single	O
nucleotide	O
polymorphisms	O
,	O
encompassing	O
the	O
two	O
genes	O
,	O
in	O
patients	O
and	O
control	O
subjects	O
in	O
two	O
independent	O
cohorts	O
.	O

Serum	O
TNF-alpha	O
levels	O
of	O
selected	O
individuals	O
were	O
measured	O
and	O
correlated	O
with	O
genotypes	O
and	O
haplotypes	O
.	O

The	O
A	O
allele	O
of	O
the	O
TNFA	O
-863C	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
polymorphism	O
was	O
associated	O
with	O
reduced	O
risk	O
of	O
asthma	O
(	O
P	O
=	O
0.002	O
and	O
0.007	O
in	O
Cohorts	O
A	O
and	O
B	O
,	O
respectively	O
)	O
,	O
reduced	O
TsIgE	O
levels	O
(	O
P	O
=	O
0.0024	O
and	O
P	O
=	O
0.0029	O
in	O
Cohorts	O
A	O
and	O
B	O
,	O
respectively	O
)	O
,	O
and	O
reduced	O
serum	O
TNF-alpha	O
levels	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
marginal	O
association	O
was	O
also	O
observed	O
for	O
LTA_NcoI	O
polymorphism	O
with	O
asthma	O
and	O
TsIgE	O
levels	O
.	O

Furthermore	O
,	O
analysis	O
using	O
HAPLO	O
.	O

STATS	O
showed	O
significant	O
differences	O
in	O
the	O
major	O
haplotype	O
frequencies	O
(	O
>	O
3%	O
)	O
between	O
patients	O
and	O
control	O
subjects	O
(	O
P	O
=	O
0.002	O
and	O
P	O
=	O
0.006	O
for	O
Cohorts	O
A	O
and	O
B	O
,	O
respectively	O
)	O
.	O

Individually	O
,	O
the	O
haplotype	O
GATCCG	O
was	O
the	O
most	O
frequent	O
in	O
patients	O
(	O
P	O
=	O
0.0029	O
and	O
P	O
=	O
0.0025	O
for	O
Cohorts	O
A	O
and	O
B	O
,	O
respectively	O
)	O
,	O
and	O
was	O
associated	O
with	O
high	O
TsIgE	O
and	O
serum	O
TNF-alpha	O
levels	O
,	O
whereas	O
AACACG	O
was	O
the	O
most	O
frequent	O
in	O
the	O
control	O
subjects	O
(	O
P	O
=	O
0.0032	O
and	O
P	O
=	O
0.022	O
for	O
Cohorts	O
A	O
and	O
B	O
,	O
respectively	O
)	O
,	O
and	O
was	O
associated	O
with	O
low	O
TsIgE	O
and	O
serum	O
TNF-alpha	O
levels	O
.	O

We	O
also	O
report	O
here	O
that	O
the	O
C	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
-863	I-DNAMutation
of	O
the	O
TNFA	O
influences	O
the	O
binding	O
of	O
nuclear	O
proteins	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
experiments	O
.	O

Thus	O
,	O
the	O
TNFA	O
-863C	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
TNFA	O
may	O
influence	O
TNF-alpha	O
expression	O
and	O
affect	O
TsIgE	O
levels	O
and	O
susceptibility	O
to	O
asthma	O
.	O

A	O
functional	O
Tyr1306Cys	B-ProteinMutation
variant	O
in	O
LARG	O
is	O
associated	O
with	O
increased	O
insulin	O
action	O
in	O
vivo	O
.	O

Diminished	O
insulin	O
sensitivity	O
is	O
a	O
characteristic	O
feature	O
of	O
type	O
2	O
diabetes	O
.	O

Inhibition	O
of	O
insulin	O
action	O
,	O
resulting	O
in	O
reduced	O
skeletal	O
muscle	O
glucose	O
uptake	O
,	O
is	O
mediated	O
in	O
part	O
through	O
stimulation	O
of	O
RhoA	O
activity	O
.	O

One	O
regulator	O
of	O
RhoA	O
activity	O
is	O
leukemia-associated	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
(LARG)	O
.	O

The	O
LARG	O
gene	O
maps	O
to	O
a	O
region	O
on	O
chromosome	O
11q23-24	O
that	O
shows	O
genetic	O
linkage	O
to	O
BMI	O
and	O
type	O
2	O
diabetes	O
in	O
Pima	O
Indians	O
.	O

Because	O
of	O
its	O
role	O
in	O
RhoA	O
activation	O
,	O
the	O
LARG	O
gene	O
was	O
analyzed	O
as	O
a	O
positional	O
candidate	O
gene	O
for	O
this	O
linkage	O
.	O

Sequencing	O
of	O
the	O
LARG	O
gene	O
and	O
genotyping	O
of	O
variants	O
identified	O
several	O
polymorphisms	O
that	O
were	O
associated	O
with	O
in	O
vivo	O
rates	O
of	O
insulin-mediated	O
glucose	O
uptake	O
,	O
at	O
both	O
physiological	O
and	O
maximally	O
stimulating	O
insulin	O
concentrations	O
,	O
among	O
322	O
nondiabetic	O
Pima	O
Indians	O
who	O
had	O
undergone	O
a	O
hyperinsulinemic-euglycemic	O
clamp	O
.	O

The	O
strongest	O
association	O
with	O
rate	O
of	O
glucose	O
uptake	O
was	O
found	O
with	O
a	O
Tyr1306Cys	B-ProteinMutation
polymorphism	O
(	O
P	O
<	O
0.0001	O
,	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
percent	O
body	O
fat	O
,	O
and	O
nuclear	O
family	O
membership	O
)	O
.	O

In	O
transient	O
transfection	O
studies	O
in	O
NIH3T3	O
cells	O
,	O
the	O
LARG(Cys1306)	O
protein	O
had	O
reduced	O
activity	O
compared	O
with	O
LARG(Tyr1306)	O
protein	O
(	O
P	O
<	O
0.05	O
)	O
.	O

We	O
propose	O
that	O
the	O
Tyr1306Cys	B-ProteinMutation
substitution	O
in	O
LARG	O
,	O
through	O
its	O
differential	O
activation	O
of	O
RhoA	O
,	O
increases	O
insulin	O
sensitivity	O
in	O
nondiabetic	O
Pima	O
Indians	O
.	O

A	O
G1103R	B-ProteinMutation
mutation	O
in	O
CRB1	O
is	O
co-inherited	O
with	O
high	O
hyperopia	O
and	O
Leber	O
congenital	O
amaurosis	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
basis	O
of	O
recessive	O
inheritance	O
of	O
high	O
hyperopia	O
and	O
Leber	O
congenital	O
amaurosis	O
(LCA)	O
in	O
a	O
family	O
of	O
Middle	O
Eastern	O
origin	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
patients	O
were	O
examined	O
using	O
standard	O
ophthalmic	O
techniques	O
.	O

DNA	O
samples	O
were	O
obtained	O
and	O
genetic	O
linkage	O
was	O
carried	O
out	O
using	O
polymorphic	O
markers	O
flanking	O
the	O
known	O
genes	O
and	O
loci	O
for	O
LCA	O
.	O

Exons	O
were	O
amplified	O
and	O
sequenced	O
.	O

RESULTS	O
:	O
All	O
four	O
members	O
of	O
this	O
family	O
affected	O
by	O
LCA	O
showed	O
high	O
to	O
extreme	O
hyperopia	O
,	O
with	O
average	O
spherical	O
refractive	O
errors	O
ranging	O
from	O
+5.00	O
to	O
+10.00	O
.	O

Linkage	O
was	O
obtained	O
to	O
1q31.3	O
with	O
a	O
maximal	O
LOD	O
score	O
of	O
5.20	O
and	O
a	O
mutation	O
found	O
in	O
exon	O
9	O
of	O
the	O
CRB1	O
gene	O
,	O
causing	O
a	O
G1103R	B-ProteinMutation
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
the	O
protein	O
.	O

CRB1	O
is	O
a	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
crumbs	O
gene	O
,	O
which	O
is	O
required	O
for	O
photoreceptor	O
morphogenesis	O
,	O
and	O
has	O
been	O
associated	O
with	O
either	O
retinitis	O
pigmentosa	O
(RP)	O
or	O
LCA	O
.	O

This	O
sequence	O
variant	O
has	O
previously	O
been	O
reported	O
as	O
a	O
compound	O
heterozygote	O
in	O
one	O
sporadic	O
LCA	O
patient	O
.	O

CONCLUSION	O
:	O
Although	O
hyperopia	O
has	O
been	O
associated	O
with	O
LCA	O
,	O
it	O
is	O
typically	O
moderate	O
and	O
variable	O
between	O
patients	O
with	O
the	O
same	O
mutation	O
.	O

In	O
addition	O
,	O
some	O
CRB1	O
mutations	O
can	O
be	O
associated	O
with	O
either	O
RP	O
or	O
LCA	O
.	O

We	O
have	O
shown	O
that	O
hyperopia	O
and	O
LCA	O
are	O
linked	O
to	O
the	O
mutant	O
CRB1	O
gene	O
itself	O
and	O
are	O
not	O
dependent	O
on	O
unlinked	O
modifiers	O
.	O

Loss	O
of	O
p16	O
(INK4A)	O
expression	O
is	O
associated	O
with	O
allelic	O
imbalance/loss	O
of	O
heterozygosity	O
of	O
chromosome	O
9p21	O
in	O
microdissected	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumors	O
.	O

The	O
p16	O
is	O
a	O
tumor	O
suppressor	O
gene	O
on	O
the	O
short	O
arm	O
of	O
chromosome	O
9p21	O
.	O

The	O
product	O
of	O
the	O
p16	O
acts	O
as	O
a	O
negative	O
cell	O
cycle	O
regulator	O
by	O
inhibiting	O
G1	O
cyclin-dependent	O
kinases	O
that	O
phosphorylate	O
the	O
retinoblastoma	O
protein	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
frequency	O
of	O
genetic	O
loss	O
of	O
9p21	O
and	O
to	O
determine	O
the	O
role	O
of	O
p16	O
the	O
pathogenesis	O
of	O
sporadic	O
and	O
neurofibromatosis	O
1	O
(NF1)-associated	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumors	O
(MPNSTs)	O
.	O

The	O
authors	O
examined	O
15	O
cases	O
for	O
p16	O
protein	O
expression	O
and	O
10	O
cases	O
for	O
allelic	O
imbalance	O
(AI)/loss	O
of	O
heterozygosity	O
(LOH)	O
of	O
chromosome	O
9p	O
.	O

DNA	O
was	O
microdissected	O
from	O
normal	O
and	O
neoplastic	O
tissues	O
.	O

AI/LOH	O
analysis	O
was	O
performed	O
using	O
six	O
microsatellite	O
markers	O
on	O
the	O
9p	O
region	O
.	O

On	O
immunohistochemical	O
analysis	O
80%	O
of	O
cases	O
showed	O
abnormal	O
expression	O
of	O
p16	O
.	O

Similarly	O
,	O
8	O
of	O
10	O
cases	O
revealed	O
genetic	O
loss	O
with	O
at	O
least	O
one	O
microsatellite	O
marker	O
.	O

The	O
most	O
frequent	O
deletion	O
was	O
that	O
within	O
the	O
coding	O
sequence	O
.	O

Of	O
p16	O
at	O
me	O
D9S974	O
locus	O
.	O

These	O
findings	O
emphasize	O
the	O
role	O
of	O
loss	O
of	O
p16	O
in	O
the	O
development	O
of	O
both	O
sporadic	O
and	O
NF1-associated	O
MPNSTs	O
.	O

Mutations	O
in	O
coagulation	O
factor	O
XIII	O
A	O
gene	O
in	O
eight	O
unrelated	O
Indians	O
.	O

Five	O
novel	O
mutations	O
identified	O
by	O
a	O
novel	O
PCR-CSGE	O
approach	O
.	O

Factor	O
XIII	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
(1:2,000,000)	O
recessive	O
disorder	O
of	O
blood	O
coagulation	O
usually	O
attributed	O
to	O
mutations	O
in	O
the	O
coagulation	O
factor	O
XIII	O
(FXIII)	O
A	O
gene	O
.	O

We	O
have	O
studied	O
the	O
molecular	O
basis	O
of	O
FXIII	O
deficiency	O
in	O
eight	O
unrelated	O
South	O
Indian	O
patients	O
.	O

Their	O
diagnosis	O
was	O
based	O
on	O
clinical	O
history	O
,	O
normal	O
plasma	O
clotting	O
times	O
and	O
increased	O
solubility	O
of	O
fibrin	O
clot	O
in	O
5	O
mol/l	O
urea	O
.	O

Genomic	O
DNA	O
was	O
screened	O
for	O
FXIII	O
A	O
gene	O
defects	O
by	O
a	O
novel	O
PCR	O
and	O
CSGE	O
strategy	O
.	O

Mutations	O
were	O
identified	O
in	O
all	O
these	O
patients	O
.	O

Five	O
of	O
these	O
were	O
novel	O
mutations	O
occurring	O
in	O
four	O
patients	O
.	O

These	O
included	O
a	O
novel	O
c.210T	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
transversion	O
in	O
homozygosity	O
in	O
exon	O
3	O
predicting	O
a	O
Tyr69X	B-ProteinMutation
in	O
the	O
beta-sandwich	O
domain	O
in	O
one	O
patient	O
.	O

Another	O
patient	O
was	O
compound	O
heterozygote	O
for	O
a	O
novel	O
c.791C	B-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
transition	O
predicting	O
a	O
Ser263Phe	B-ProteinMutation
in	O
the	O
core	O
domain	O
and	O
a	O
novel	O
c.2045-1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
transition	O
at	O
the	O
acceptor	O
splice	O
junction	O
of	O
intron	O
14	O
.	O

Two	O
novel	O
frame	O
shifts	O
were	O
also	O
identified	O
in	O
two	O
patients	O
in	O
a	O
homozygous	O
condition	O
.	O

One	O
of	O
them	O
resulted	O
from	O
a	O
single	O
base	O
'G'	O
duplication	O
c.892_895dupG	B-DNAMutation
at	O
codons	O
Ser290/Ala291fs	B-ProteinMutation
affecting	O
the	O
core	O
domain	O
and	O
the	O
other	O
was	O
due	O
to	O
a	O
single	O
base	O
'A'	O
duplication	O
c.1642_1644dupA	B-DNAMutation
and	O
at	O
codonTyr547fs	B-ProteinMutation
affecting	O
barrel-1	O
domain	O
.	O

The	O
remaining	O
four	O
patients	O
had	O
the	O
previously	O
reported	O
Arg260His	B-ProteinMutation
,	O
Ser413Leu	B-ProteinMutation
,	O
and	O
Val414Phe	B-ProteinMutation
(	O
n	O
=	O
2	O
)	O
missense	O
mutations	O
in	O
the	O
core	O
domain	O
.	O

The	O
novel	O
mutations	O
identified	O
were	O
considered	O
to	O
be	O
disease	O
causative	O
by	O
studying	O
the	O
nature	O
of	O
mutation	O
,	O
the	O
degree	O
of	O
conservation	O
of	O
the	O
mutated	O
aminoacid	O
among	O
transglutaminases	O
of	O
different	O
species	O
and	O
by	O
molecular	O
modeling	O
.	O

Apart	O
from	O
describing	O
a	O
significant	O
number	O
of	O
novel	O
mutations	O
,	O
this	O
report	O
is	O
the	O
first	O
study	O
from	O
Southern	O
India	O
to	O
describe	O
FXIII	O
A	O
gene	O
mutations	O
.	O

Epstein-Barr	O
virus	O
infection	O
in	O
precursor	O
lesions	O
of	O
nasopharyngeal	O
carcinoma	O
.	O

BACKGROUND	O
_#38	O
;	O
OBJECTIVE	O
:	O
The	O
infiltrating	O
neoplastic	O
cells	O
within	O
early-stage	O
nasopharyngeal	O
carcinoma	O
(NPC)	O
are	O
consistently	O
infected	O
with	O
Epstein-Barr	O
virus	O
(EBV)	O
.	O

The	O
precursor	O
lesions	O
could	O
often	O
be	O
found	O
in	O
paracancerous	O
epithelium	O
of	O
early-stage	O
NPC	O
.	O

This	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
EBV	O
infection	O
and	O
the	O
intrahost	O
evolution	O
of	O
EBV	O
genotype	O
developed	O
in	O
nasopharyngeal	O
carcinogenesis	O
through	O
detection	O
of	O
EBV	O
harboring	O
in	O
precursor	O
lesions	O
.	O

METHODS	O
:	O
EBV-encoded	O
RNA	O
(EBER)	O
in	O
15	O
cases	O
of	O
early-stage	O
NPC	O
biopsy	O
tissue	O
was	O
detected	O
by	O
nucleic	O
acid	O
in	O
situ	O
hybridization	O
.	O

EBV	O
type	O
and	O
latent	O
membrane	O
protein	O
1	O
(LMP1)	O
EBV	O
strain	O
in	O
precursor	O
lesions	O
and	O
carcinoma	O
nests	O
were	O
detected	O
by	O
nested	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

DNA	O
sequencing	O
of	O
the	O
representative	O
PCR	O
products	O
of	O
carboxyl-terminus	O
of	O
LMP1	O
gene	O
was	O
analyzed	O
by	O
using	O
four-colored	O
fluorescence	O
terminator	O
sequencing	O
technique	O
.	O

RESULTS	O
:	O
Most	O
infiltrating	O
carcinoma	O
cells	O
of	O
all	O
15	O
cases	O
of	O
NPC	O
showed	O
EBER-positive	O
.	O

EBER-positive	O
abnormal	O
epithelial	O
cells	O
and/or	O
infiltrating	O
lymphocytes	O
were	O
found	O
in	O
14	O
of	O
15	O
cases	O
of	O
precursor	O
lesion	O
.	O

Single	O
A-type	O
EBV	O
was	O
detected	O
in	O
9	O
of	O
11	O
available	O
DNA	O
samples	O
of	O
carcinoma	O
nest	O
and	O
9	O
of	O
10	O
available	O
DNA	O
samples	O
of	O
precursor	O
lesion	O
.	O

The	O
carboxyl-terminus	O
of	O
EBV	O
LMP1	O
gene	O
was	O
detected	O
in	O
all	O
15	O
DNA	O
samples	O
of	O
carcinoma	O
nest	O
,	O
among	O
which	O
14	O
were	O
single	O
30-bp	O
deleted	O
LMP1	O
(del-LMP1)	O
EBV	O
infection	O
and	O
1	O
was	O
coinfection	O
of	O
wild-type	O
LMP1	O
(wt-LMP1)	O
EBV	O
strain	O
and	O
del-LMP1	O
EBV	O
strain	O
.	O

Among	O
the	O
11	O
available	O
DNA	O
samples	O
of	O
precursor	O
lesion	O
suitable	O
for	O
carboxyl-terminus	O
amplification	O
,	O
5	O
were	O
coinfection	O
of	O
wt-LMP1	O
and	O
del-LMP1	O
EBV	O
,	O
4	O
were	O
single	O
del-LMP1	O
EBV	O
infection	O
,	O
1	O
was	O
single	O
wt-LMP1	O
EBV	O
infection	O
,	O
and	O
1	O
showed	O
negative	O
reaction	O
.	O

The	O
DNA	O
sequence	O
of	O
the	O
carboxyl-terminus	O
of	O
wt-LMP1	O
gene	O
was	O
identical	O
with	O
that	O
of	O
B95-8	O
cells	O
,	O
while	O
that	O
of	O
del-LMP1	O
gene	O
had	O
a	O
30-bp	O
deletion	O
(	O
codon	O
:	O
346-355	O
)	O
and	O
4	O
missense	O
point	O
mutations	O
(	O
codon	O
:	O
334	O
,	O
335	O
,	O
338	O
,	O
and	O
366	O
)	O
.	O

CONCLUSION	O
:	O
EBV	O
infection	O
in	O
nasopharyngeal	O
epithelial	O
cells	O
is	O
a	O
preinvasive	O
event	O
of	O
carcinogenesis	O
of	O
NPC	O
,	O
and	O
the	O
intrahost	O
evolution	O
of	O
EBV	O
genotype	O
would	O
take	O
place	O
during	O
nasopharyngeal	O
carcinogenesis	O
.	O

A	O
juvenile	O
hemochromatosis	O
patient	O
homozygous	O
for	O
a	O
novel	O
deletion	O
of	O
cDNA	O
nucleotide	O
81	O
of	O
hemojuvelin	O
.	O

BACKGROUND	O
:	O
A	O
25-year-old	O
woman	O
of	O
English/Irish	O
background	O
was	O
diagnosed	O
with	O
hemochromatosis	O
.	O

She	O
manifested	O
hypogonadotrophic	O
hypogonadism	O
and	O
congestive	O
heart	O
failure	O
.	O

Although	O
there	O
were	O
abnormal	O
liver	O
function	O
tests	O
,	O
no	O
cirrhosis	O
was	O
present	O
.	O

The	O
patient	O
has	O
been	O
treated	O
intermittently	O
by	O
phlebotomy	O
for	O
24	O
years	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
genetic	O
basis	O
of	O
the	O
patient's	O
iron	O
overload	O
disease	O
.	O

METHODS	O
:	O
Genetic	O
analysis	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
the	O
genes	O
for	O
hemojuvelin	O
,	O
HFE	O
,	O
hepcidin	O
,	O
ferroportin	O
and	O
transferrin	O
receptor	O
2	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Molecular	O
analysis	O
showed	O
that	O
the	O
patient	O
was	O
homozygous	O
for	O
a	O
previously	O
undescribed	O
mutation	O
of	O
HJV	O
,	O
the	O
gene	O
encoding	O
hemojuvelin	O
.	O

This	O
mutation	O
,	O
nt	O
81G	O
deletion	O
,	O
causes	O
a	O
frameshift	O
encoding	O
23	O
additional	O
irrelevant	O
amino	O
acids	O
and	O
premature	O
termination	O
.	O

No	O
mutations	O
were	O
found	O
in	O
the	O
other	O
hemochromatosis	O
genes	O
,	O
hepcidin	O
,	O
HFE	O
,	O
ferroportin	O
or	O
transferrin	O
receptor	O
2	O
,	O
which	O
might	O
have	O
contributed	O
to	O
her	O
iron	O
overload	O
.	O

Homozygous	O
deletion	O
and	O
reduced	O
expression	O
of	O
the	O
DOCK8	O
gene	O
in	O
human	O
lung	O
cancer	O
.	O

A	O
homozygous	O
deletion	O
of	O
the	O
DOCK8	O
(	O
dedicator	O
of	O
cytokinesis	O
8	O
)	O
locus	O
at	O
chromosome	O
9p24	O
was	O
found	O
in	O
a	O
lung	O
cancer	O
cell	O
line	O
by	O
array-CGH	O
analysis	O
.	O

Cloning	O
of	O
the	O
full-length	O
DOCK8	O
cDNA	O
led	O
us	O
to	O
define	O
that	O
the	O
DOCK8	O
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
2,099	O
amino	O
acids	O
.	O

DOCK8	O
was	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
organs	O
,	O
including	O
the	O
lungs	O
,	O
and	O
was	O
also	O
expressed	O
in	O
type	O
II	O
alveolar	O
,	O
bronchiolar	O
epithelial	O
and	O
bronchial	O
epithelial	O
cells	O
,	O
which	O
are	O
considered	O
as	O
being	O
progenitors	O
for	O
lung	O
cancer	O
cells	O
.	O

DOCK8	O
expression	O
was	O
reduced	O
in	O
62/71	O
(87%)	O
primary	O
lung	O
cancers	O
compared	O
with	O
normal	O
lung	O
tissue	O
,	O
and	O
the	O
reduction	O
occurred	O
irrespective	O
of	O
the	O
histological	O
type	O
of	O
lung	O
cancer	O
.	O

5-Aza-2'-deoxy-cytidine	O
and/or	O
Trichostatin	O
A	O
treatments	O
induced	O
DOCK8	O
expression	O
in	O
lung	O
cancer	O
cell	O
lines	O
with	O
reduced	O
DOCK8	O
expression	O
.	O

Therefore	O
,	O
epigenetic	O
mechanisms	O
,	O
including	O
DNA	O
methylation	O
and	O
histone	O
deacetylation	O
,	O
were	O
indicated	O
to	O
be	O
involved	O
in	O
DOCK8	O
down-regulation	O
in	O
lung	O
cancer	O
cells	O
.	O

Further	O
screening	O
revealed	O
homozygous	O
deletions	O
of	O
the	O
DOCK8	O
gene	O
in	O
a	O
gastric	O
and	O
a	O
breast	O
cancer	O
cell	O
line	O
.	O

DOCK	O
family	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
roles	O
in	O
regulation	O
of	O
migration	O
,	O
morphology	O
,	O
adhesion	O
and	O
growth	O
of	O
cells	O
.	O

Thus	O
,	O
the	O
present	O
results	O
suggest	O
that	O
genetic	O
and	O
epigenetic	O
inactivation	O
of	O
DOCK8	O
is	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
lung	O
and	O
other	O
cancers	O
by	O
disturbing	O
such	O
regulations	O
.	O

Inactivating	O
mutations	O
in	O
ESCO2	O
cause	O
SC	O
phocomelia	O
and	O
Roberts	O
syndrome	O
:	O
no	O
phenotype-genotype	O
correlation	O
.	O

The	O
rare	O
,	O
autosomal	O
recessive	O
Roberts	O
syndrome	O
(RBS)	O
is	O
characterized	O
by	O
tetraphocomelia	O
,	O
profound	O
growth	O
deficiency	O
of	O
prenatal	O
onset	O
,	O
craniofacial	O
anomalies	O
,	O
microcephaly	O
,	O
and	O
mental	O
deficiency	O
.	O

SC	O
phocomelia	O
(SC)	O
has	O
a	O
milder	O
phenotype	O
,	O
with	O
a	O
lesser	O
degree	O
of	O
limb	O
reduction	O
and	O
with	O
survival	O
to	O
adulthood	O
.	O

Since	O
heterochromatin	O
repulsion	O
(HR)	O
is	O
characteristic	O
for	O
both	O
disorders	O
and	O
is	O
not	O
complemented	O
in	O
somatic-cell	O
hybrids	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
the	O
disorders	O
are	O
allelic	O
.	O

Recently	O
,	O
mutations	O
in	O
ESCO2	O
(	O
establishment	O
of	O
cohesion	O
1	O
homolog	O
2	O
)	O
on	O
8p21.1	O
have	O
been	O
reported	O
in	O
RBS	O
.	O

To	O
determine	O
whether	O
ESCO2	O
mutations	O
are	O
also	O
responsible	O
for	O
SC	O
,	O
we	O
studied	O
three	O
families	O
with	O
SC	O
and	O
two	O
families	O
in	O
which	O
variable	O
degrees	O
of	O
limb	O
and	O
craniofacial	O
abnormalities	O
,	O
detected	O
by	O
fetal	O
ultrasound	O
,	O
led	O
to	O
pregnancy	O
terminations	O
.	O

All	O
cases	O
were	O
positive	O
for	O
HR	O
.	O

We	O
identified	O
seven	O
novel	O
mutations	O
in	O
exons	O
3-8	O
of	O
ESCO2	O
.	O

In	O
two	O
families	O
,	O
affected	O
individuals	O
were	O
homozygous--for	O
a	O
5-nucleotide	O
deletion	O
in	O
one	O
family	O
and	O
a	O
splice-site	O
mutation	O
in	O
the	O
other	O
.	O

In	O
three	O
nonconsanguineous	O
families	O
,	O
probands	O
were	O
compound	O
heterozygous	O
for	O
a	O
single-nucleotide	O
insertion	O
or	O
deletion	O
,	O
a	O
nonsense	O
mutation	O
,	O
or	O
a	O
splice-site	O
mutation	O
.	O

Abnormal	O
splice	O
products	O
were	O
characterized	O
at	O
the	O
RNA	O
level	O
.	O

Since	O
only	O
protein-truncating	O
mutations	O
were	O
identified	O
,	O
regardless	O
of	O
clinical	O
severity	O
,	O
we	O
conclude	O
that	O
genotype	O
does	O
not	O
predict	O
phenotype	O
.	O

Having	O
established	O
that	O
RBS	O
and	O
SC	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
same	O
gene	O
,	O
we	O
delineated	O
the	O
clinical	O
phenotype	O
of	O
the	O
tetraphocomelia	O
spectrum	O
that	O
is	O
associated	O
with	O
HR	O
and	O
ESCO2	O
mutations	O
and	O
differentiated	O
it	O
from	O
other	O
types	O
of	O
phocomelia	O
that	O
are	O
negative	O
for	O
HR	O
.	O

Polymerase	O
chain	O
reaction-based	O
analysis	O
using	O
deaminated	O
DNA	O
of	O
dodecamer	O
expansions	O
in	O
CSTB	O
,	O
associated	O
with	O
Unverricht-Lundborg	O
myoclonus	O
epilepsy	O
.	O

Progressive	O
myoclonus	O
epilepsy	O
of	O
the	O
Unverricht-Lundborg	O
type	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
that	O
is	O
characterized	O
clinically	O
by	O
myoclonic	O
seizures	O
and	O
ataxia	O
.	O

The	O
majority	O
of	O
affected	O
individuals	O
carry	O
repeat	O
expansions	O
of	O
a	O
dodecamer	O
in	O
the	O
promoter	O
region	O
of	O
the	O
cystatin	O
B	O
gene	O
.	O

The	O
unusually	O
high	O
GC	O
content	O
of	O
this	O
tract	O
is	O
refractory	O
to	O
conventional	O
polymerase	O
chain	O
reaction	O
(PCR)	O
,	O
and	O
,	O
as	O
a	O
result	O
,	O
a	O
circumventive	O
procedure	O
involving	O
the	O
deamination	O
of	O
DNA	O
with	O
sodium	O
bisulfite	O
has	O
been	O
proposed	O
.	O

This	O
study	O
evaluates	O
the	O
effectiveness	O
of	O
this	O
deamination	O
modification	O
for	O
the	O
detection	O
of	O
dodecamer	O
repeat	O
variants	O
.	O

An	O
analysis	O
of	O
258	O
healthy	O
Japanese	O
individuals	O
revealed	O
an	O
allele	O
with	O
four	O
copies	O
of	O
the	O
dodecamer	O
repeat	O
with	O
a	O
frequency	O
of	O
0.01	O
,	O
in	O
addition	O
to	O
the	O
more	O
commonly	O
observed	O
two	O
and	O
three	O
copy	O
repeat	O
alleles	O
.	O

Homozygous	O
repeat	O
expansions	O
600	O
and	O
680	O
base	O
pairs	O
in	O
length	O
were	O
detected	O
in	O
the	O
analyses	O
of	O
two	O
affected	O
individuals	O
.	O

For	O
these	O
cases	O
,	O
sequencing	O
,	O
along	O
with	O
an	O
alternative	O
PCR-stutter	O
formation	O
,	O
revealed	O
41	O
and	O
48	O
copies	O
,	O
respectively	O
,	O
of	O
the	O
dodecamer	O
repeat	O
.	O

The	O
complete	O
conversion	O
of	O
C	O
to	O
T	O
was	O
observed	O
in	O
the	O
expanded	O
tracts	O
,	O
indicating	O
that	O
no	O
methylation	O
occurred	O
at	O
the	O
CpG	O
sites	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
was	O
concluded	O
that	O
the	O
use	O
of	O
deaminated	O
DNA	O
allows	O
for	O
a	O
precise	O
analysis	O
of	O
consecutive	O
GC	O
tracts	O
.	O

Distribution	O
of	O
insertion-	O
and	O
deletion-associated	O
genetic	O
polymorphisms	O
among	O
four	O
Mycobacterium	O
tuberculosis	O
phospholipase	O
C	O
genes	O
and	O
associations	O
with	O
extrathoracic	O
tuberculosis	O
:	O
a	O
population-based	O
study	O
.	O

The	O
Mycobacterium	O
tuberculosis	O
genome	O
contains	O
four	O
phospholipase	O
C	O
(PLC)-encoding	O
genes	O
,	O
designated	O
plcA	O
,	O
plcB	O
,	O
plcC	O
,	O
and	O
plcD	O
,	O
respectively	O
.	O

Each	O
of	O
the	O
four	O
genes	O
contributes	O
to	O
the	O
overall	O
PLC	O
activity	O
of	O
M	O
.	O

tuberculosis	O
.	O

PLC	O
is	O
hypothesized	O
to	O
contribute	O
to	O
M	O
.	O

tuberculosis	O
virulence	O
.	O

Infection	O
of	O
M	O
.	O

tuberculosis	O
strains	O
carrying	O
a	O
truncated	O
plcD	O
gene	O
is	O
associated	O
with	O
the	O
occurrence	O
of	O
extrathoracic	O
tuberculosis	O
.	O

However	O
,	O
whether	O
the	O
other	O
three	O
plc	O
genes	O
are	O
also	O
associated	O
with	O
extrathoracic	O
tuberculosis	O
remains	O
to	O
be	O
assessed	O
.	O

We	O
investigated	O
the	O
insertion-	O
and	O
deletion-associated	O
genetic	O
diversity	O
in	O
all	O
four	O
plc	O
genes	O
among	O
682	O
epidemiologically	O
and	O
clinically	O
well-characterized	O
M	O
.	O

tuberculosis	O
clinical	O
isolates	O
using	O
PCR	O
,	O
DNA	O
sequencing	O
,	O
and	O
Southern	O
hybridization	O
.	O

Two	O
hundred	O
sixty-six	O
(39%)	O
of	O
the	O
682	O
isolates	O
had	O
an	O
interruption	O
in	O
at	O
least	O
one	O
of	O
the	O
four	O
plc	O
genes	O
,	O
most	O
often	O
associated	O
with	O
an	O
IS6110	O
insertion	O
.	O

The	O
plcD	O
gene	O
interruption	O
was	O
the	O
most	O
common	O
:	O
it	O
was	O
observed	O
in	O
233	O
(34%)	O
of	O
the	O
isolates	O
,	O
compared	O
to	O
4.7%	O
,	O
4.1%	O
,	O
and	O
5.9%	O
for	O
plcA	O
,	O
plcB	O
,	O
and	O
plcC	O
gene	O
interruption	O
,	O
respectively	O
.	O

The	O
association	O
between	O
the	O
plc	O
gene	O
genotypes	O
and	O
disease	O
presentation	O
was	O
adjusted	O
for	O
clustering	O
using	O
generalized	O
estimating	O
equations	O
for	O
both	O
bivariate	O
and	O
multivariate	O
analyses	O
.	O

After	O
controlling	O
for	O
the	O
genotypes	O
of	O
the	O
plcABC	O
genes	O
and	O
the	O
host-related	O
risk	O
factors	O
,	O
interruption	O
in	O
the	O
plcD	O
gene	O
remained	O
significantly	O
associated	O
with	O
extrathoracic	O
tuberculosis	O
(	O
odds	O
ratio	O
,	O
3.27	O
;	O
95%	O
confidence	O
interval	O
,	O
1.32	O
to	O
8.14	O
)	O
.	O

The	O
data	O
suggest	O
that	O
the	O
plcD	O
gene	O
might	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
thoracic	O
TB	O
than	O
it	O
does	O
in	O
the	O
pathogenesis	O
of	O
extrathoracic	O
TB	O
.	O

Array-based	O
comparative	O
genomic	O
hybridization	O
analysis	O
reveals	O
recurrent	O
chromosomal	O
alterations	O
and	O
prognostic	O
parameters	O
in	O
primary	O
cutaneous	O
large	O
B-cell	O
lymphoma	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
clinical	O
relevance	O
of	O
genomic	O
aberrations	O
in	O
primary	O
cutaneous	O
large	O
B-cell	O
lymphoma	O
(PCLBCL)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Skin	O
biopsy	O
samples	O
of	O
31	O
patients	O
with	O
a	O
PCLBCL	O
classified	O
as	O
either	O
primary	O
cutaneous	O
follicle	O
center	O
lymphoma	O
(	O
PCFCL	O
;	O
n	O
=	O
19	O
)	O
or	O
PCLBCL	O
,	O
leg	O
type	O
(	O
n	O
=	O
12	O
)	O
,	O
according	O
to	O
the	O
WHO-European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
classification	O
,	O
were	O
investigated	O
using	O
array-based	O
comparative	O
genomic	O
hybridization	O
,	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
,	O
and	O
examination	O
of	O
promoter	O
hypermethylation	O
.	O

RESULTS	O
:	O
The	O
most	O
recurrent	O
alterations	O
in	O
PCFCL	O
were	O
high-level	O
DNA	O
amplifications	O
at	O
2p16.1	O
(63%)	O
and	O
deletion	O
of	O
chromosome	O
14q32.33	O
(68%)	O
.	O

FISH	O
analysis	O
confirmed	O
c-REL	O
amplification	O
in	O
patients	O
with	O
gains	O
at	O
2p16.1	O
.	O

In	O
PCLBCL	O
,	O
leg	O
type	O
,	O
most	O
prominent	O
aberrations	O
were	O
a	O
high-level	O
DNA	O
amplification	O
of	O
18q21.31-q21.33	O
(67%)	O
,	O
including	O
the	O
BCL-2	O
and	O
MALT1	O
genes	O
as	O
confirmed	O
by	O
FISH	O
,	O
and	O
deletions	O
of	O
a	O
small	O
region	O
within	O
9p21.3	O
containing	O
the	O
CDKN2A	O
,	O
CDKN2B	O
,	O
and	O
NSG-x	O
genes	O
.	O

Homozygous	O
deletion	O
of	O
9p21.3	O
was	O
detected	O
in	O
five	O
of	O
12	O
patients	O
with	O
PCLBCL	O
,	O
leg	O
type	O
,	O
but	O
in	O
zero	O
of	O
19	O
patients	O
with	O
PCFCL	O
.	O

Complete	O
methylation	O
of	O
the	O
promoter	O
region	O
of	O
the	O
CDKN2A	O
gene	O
was	O
demonstrated	O
in	O
one	O
PCLBCL	O
,	O
leg	O
type	O
,	O
patient	O
with	O
hemizygous	O
deletion	O
,	O
in	O
one	O
patient	O
without	O
deletion	O
,	O
but	O
in	O
zero	O
of	O
19	O
patients	O
with	O
PCFCL	O
.	O

Seven	O
of	O
seven	O
PCLBCL	O
,	O
leg	O
type	O
,	O
patients	O
with	O
deletion	O
of	O
9p21.3	O
and/or	O
complete	O
methylation	O
of	O
CDKN2A	O
died	O
as	O
a	O
result	O
of	O
their	O
lymphoma	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
demonstrate	O
prominent	O
differences	O
in	O
chromosomal	O
alterations	O
between	O
PCFCL	O
and	O
PCLBCL	O
,	O
leg	O
type	O
,	O
that	O
support	O
their	O
classification	O
as	O
separate	O
entities	O
within	O
the	O
WHO-EORTC	O
scheme	O
.	O

Inactivation	O
of	O
CDKN2A	O
by	O
either	O
deletion	O
or	O
methylation	O
of	O
its	O
promoter	O
could	O
be	O
an	O
important	O
prognostic	O
parameter	O
for	O
the	O
group	O
of	O
PCLBCL	O
,	O
leg	O
type	O
.	O

Phenylketonuria	O
mutations	O
in	O
Northern	O
China	O
.	O

Mutation	O
spectrum	O
of	O
phenylalanine	O
hydroxylase	O
(PAH)	O
gene	O
in	O
patients	O
with	O
phenylketonuria	O
(PKU)	O
in	O
Northern	O
China	O
is	O
described	O
with	O
a	O
discussion	O
on	O
genotype-phenotype	O
correlation	O
.	O

By	O
using	O
PCR/SSCP	O
and	O
DNA	O
sequencing	O
,	O
all	O
exons	O
of	O
PAH	O
gene	O
in	O
the	O
185	O
unrelated	O
patients	O
with	O
PKU	O
from	O
Northern	O
China	O
were	O
studied	O
.	O

A	O
total	O
of	O
70	O
different	O
mutations	O
,	O
including	O
42	O
missense	O
,	O
12	O
splice	O
,	O
7	O
nonsense	O
,	O
5	O
deletion	O
,	O
3	O
insertion	O
,	O
and	O
1	O
silence/splice	O
mutations	O
,	O
were	O
detected	O
in	O
349/370	O
mutant	O
alleles	O
(94.3%)	O
.	O

Deletion	O
,	O
insertion	O
,	O
and	O
frameshift	O
mutations	O
were	O
found	O
for	O
the	O
first	O
time	O
in	O
China	O
PKU	O
patients	O
.	O

The	O
mutations	O
R243Q	B-ProteinMutation
,	O
EX6-96A>G	B-DNAMutation
,	O
R111X	B-ProteinMutation
,	O
Y356X	B-ProteinMutation
,	O
and	O
R413P	B-ProteinMutation
were	O
the	O
prevalent	O
mutations	O
with	O
relative	O
frequencies	O
of	O
22.2	O
,	O
11.1	O
,	O
8.7	O
,	O
6.5	O
,	O
and	O
6.5%	O
,	O
respectively	O
.	O

Fifteen	O
novel	O
mutations	O
were	O
identified	O
in	O
this	O
study	O
:	O
I38fsX19	B-ProteinMutation
,	O
IVS4+3G>C	B-DNAMutation
,	O
Y154H	B-ProteinMutation
,	O
R157K	B-ProteinMutation
,	O
R157I	B-ProteinMutation
,	O
T200fsX6	B-ProteinMutation
,	O
Q267H	B-ProteinMutation
,	O
Q267E	B-ProteinMutation
,	O
F302fsX39	B-ProteinMutation
,	O
G346R	B-ProteinMutation
,	O
S349A	B-ProteinMutation
,	O
L367L	B-ProteinMutation
,	O
R400K	B-ProteinMutation
,	O
IVS12+4A>G	B-DNAMutation
,	O
and	O
IVS12+6T>A	B-DNAMutation
.	O

Each	O
of	O
them	O
occurs	O
at	O
very	O
low	O
frequency	O
(0.3-1.1%)	O
.	O

The	O
mutation	O
spectrum	O
of	O
PKU	O
in	O
Chinese	O
is	O
similar	O
to	O
other	O
Asian	O
populations	O
but	O
significantly	O
different	O
from	O
European	O
populations	O
.	O

Altogether	O
,	O
70	O
different	O
mutations	O
are	O
found	O
in	O
109	O
genotypes	O
distributed	O
among	O
185	O
PKU	O
patients	O
.	O

As	O
shown	O
by	O
the	O
analysis	O
,	O
the	O
predicted	O
residual	O
activity	O
found	O
in	O
the	O
majority	O
of	O
PKU	O
individuals	O
match	O
their	O
in	O
vivo	O
phenotypes	O
,	O
though	O
evidence	O
is	O
also	O
found	O
for	O
both	O
phenotypic	O
inconsistencies	O
among	O
subjects	O
with	O
similar	O
genotypes	O
and	O
discordance	O
between	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
effects	O
of	O
some	O
mutant	O
alleles	O
.	O

The	O
study	O
enables	O
us	O
to	O
construct	O
a	O
national	O
database	O
in	O
China	O
serving	O
as	O
a	O
valuable	O
tool	O
for	O
genetic	O
counseling	O
and	O
prognostic	O
evaluation	O
of	O
future	O
cases	O
of	O
PKU	O
.	O

Polymorphisms	O
of	O
the	O
DNA	O
mismatch	O
repair	O
gene	O
HMSH2	O
in	O
breast	O
cancer	O
occurence	O
and	O
progression	O
.	O

The	O
response	O
of	O
the	O
cell	O
to	O
DNA	O
damage	O
and	O
its	O
ability	O
to	O
maintain	O
genomic	O
stability	O
by	O
DNA	O
repair	O
are	O
crucial	O
in	O
preventing	O
cancer	O
initiation	O
and	O
progression	O
.	O

Therefore	O
,	O
polymorphism	O
of	O
DNA	O
repair	O
genes	O
may	O
affect	O
the	O
process	O
of	O
carcinogenesis	O
.	O

The	O
importance	O
of	O
genetic	O
variability	O
of	O
the	O
components	O
of	O
mismatch	O
repair	O
(MMR)	O
genes	O
is	O
well	O
documented	O
in	O
colorectal	O
cancer	O
,	O
but	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
breast	O
cancer	O
.	O

hMSH2	O
is	O
one	O
of	O
the	O
crucial	O
proteins	O
of	O
MMR	O
.	O

We	O
performed	O
a	O
case-control	O
study	O
to	O
test	O
the	O
association	O
between	O
two	O
polymorphisms	O
in	O
the	O
hMSH2	O
gene	O
:	O
an	O
A	B-DNAMutation
-->	I-DNAMutation
G	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
127	I-DNAMutation
position	I-DNAMutation
producing	O
an	O
Asn	B-ProteinMutation
-->	I-ProteinMutation
Ser	I-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
127	I-ProteinMutation
(	O
the	O
Asn127Ser	B-ProteinMutation
polymorphism	O
)	O
and	O
a	O
G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
1032	I-DNAMutation
position	I-DNAMutation
resulting	O
in	O
a	O
Gly	B-ProteinMutation
-->	I-ProteinMutation
Asp	I-ProteinMutation
change	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
322	I-ProteinMutation
(	O
the	O
Gly322Asp	B-ProteinMutation
polymorphism	O
)	O
and	O
breast	O
cancer	O
risk	O
and	O
cancer	O
progression	O
.	O

Genotypes	O
were	O
determined	O
in	O
DNA	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
150	O
breast	O
cancer	O
patients	O
and	O
150	O
age-matched	O
women	O
(controls)	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
allele-specific	O
PCR	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
studied	O
polymorphisms	O
and	O
breast	O
cancer	O
progression	O
evaluated	O
by	O
node-metastasis	O
,	O
tumor	O
size	O
and	O
Bloom-Richardson	O
grading	O
.	O

A	O
strong	O
association	O
between	O
breast	O
cancer	O
occurrence	O
and	O
the	O
Gly/Gly	O
phenotype	O
of	O
the	O
Gly322Asp	B-ProteinMutation
polymorphism	O
(	O
odds	O
ratio	O
8.39	O
;	O
95%	O
confidence	O
interval	O
1.44-48.8	O
)	O
was	O
found	O
.	O

Therefore	O
,	O
MMR	O
may	O
play	O
a	O
role	O
in	O
the	O
breast	O
carcinogenesis	O
and	O
the	O
Gly322Asp	B-ProteinMutation
polymorphism	O
of	O
the	O
hMSH2	O
gene	O
may	O
be	O
considered	O
as	O
a	O
potential	O
marker	O
in	O
breast	O
cancer	O
.	O

Characterization	O
of	O
Bietti	O
crystalline	O
dystrophy	O
patients	O
with	O
CYP4V2	O
mutations	O
.	O

PURPOSE	O
:	O
Mutations	O
of	O
the	O
CYP4V2	O
gene	O
,	O
a	O
novel	O
family	O
member	O
of	O
the	O
cytochrome	O
P450	O
genes	O
on	O
chromosome	O
4q35	O
,	O
have	O
recently	O
been	O
identified	O
in	O
patients	O
with	O
Bietti	O
crystalline	O
dystrophy	O
(BCD)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
BCD	O
patients	O
from	O
Singapore	O
,	O
and	O
to	O
characterize	O
their	O
phenotype	O
.	O

METHODS	O
:	O
Nine	O
patients	O
with	O
BCD	O
from	O
six	O
families	O
were	O
recruited	O
into	O
the	O
study	O
.	O

The	O
11	O
exons	O
of	O
the	O
CYP4V2	O
gene	O
were	O
amplified	O
from	O
genomic	O
DNA	O
of	O
patients	O
by	O
polymerase	O
chain	O
reaction	O
and	O
then	O
sequenced	O
.	O

Detailed	O
characterization	O
of	O
the	O
patients'	O
phenotype	O
was	O
performed	O
with	O
fundal	O
photography	O
,	O
visual	O
field	O
testing	O
,	O
fundal	O
fluorescein	O
angiography	O
,	O
and	O
electroretinography	O
(ERG)	O
.	O

RESULTS	O
:	O
Three	O
pathogenic	O
mutations	O
were	O
identified	O
;	O
two	O
mutations	O
,	O
S482X	B-ProteinMutation
and	O
K386T	B-ProteinMutation
,	O
were	O
novel	O
and	O
found	O
in	O
three	O
patients	O
.	O

The	O
third	O
mutation	O
,	O
a	O
previously	O
identified	O
15-bp	O
deletion	O
that	O
included	O
the	O
3'	O
splice	O
site	O
for	O
exon	O
7	O
,	O
was	O
found	O
in	O
all	O
nine	O
patients	O
,	O
with	O
six	O
patients	O
carrying	O
the	O
deletion	O
in	O
the	O
homozygous	O
state	O
.	O

Haplotype	O
analysis	O
in	O
patients	O
and	O
controls	O
indicated	O
a	O
founder	O
effect	O
for	O
this	O
deletion	O
mutation	O
in	O
exon	O
7	O
.	O

Clinical	O
heterogeneity	O
was	O
present	O
in	O
the	O
patients	O
.	O

Compound	O
heterozygotes	O
for	O
the	O
deletion	O
in	O
exon	O
7	O
seemed	O
to	O
have	O
more	O
severe	O
disease	O
compared	O
to	O
patients	O
homozygous	O
for	O
the	O
deletion	O
.	O

There	O
was	O
good	O
correlation	O
between	O
clinical	O
stage	O
of	O
disease	O
and	O
ERG	O
changes	O
,	O
but	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
identified	O
novel	O
mutations	O
in	O
the	O
CYP4V2	O
gene	O
as	O
a	O
cause	O
of	O
BCD	O
.	O

A	O
high	O
carrier	O
frequency	O
for	O
the	O
15-bp	O
deletion	O
in	O
exon	O
7	O
may	O
exist	O
in	O
the	O
Singapore	O
population	O
.	O

Phenotype	O
characterization	O
showed	O
clinical	O
heterogeneity	O
,	O
and	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O

Mono-allelic	O
POLG	O
expression	O
resulting	O
from	O
nonsense-mediated	O
decay	O
and	O
alternative	O
splicing	O
in	O
a	O
patient	O
with	O
Alpers	O
syndrome	O
.	O

Alpers	O
syndrome	O
is	O
an	O
autosomal	O
recessive	O
mitochondrial	O
DNA	O
depletion	O
disorder	O
that	O
affects	O
children	O
and	O
young	O
adults	O
.	O

It	O
is	O
characterized	O
by	O
a	O
progressive	O
,	O
fatal	O
brain	O
and	O
liver	O
disease	O
.	O

This	O
syndrome	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
POLG	O
,	O
the	O
gene	O
encoding	O
the	O
mitochondrial	O
DNA	O
polymerase	O
(	O
pol	O
gamma	O
)	O
.	O

Most	O
patients	O
with	O
Alpers	O
syndrome	O
have	O
been	O
found	O
to	O
be	O
compound	O
heterozygotes	O
,	O
carrying	O
two	O
pathogenic	O
mutations	O
in	O
trans	O
at	O
the	O
POLG	O
locus	O
.	O

POLG	O
is	O
a	O
nuclear-encoded	O
gene	O
whose	O
protein	O
product	O
is	O
imported	O
into	O
mitochondria	O
,	O
where	O
it	O
is	O
essential	O
for	O
mtDNA	O
replication	O
and	O
repair	O
.	O

We	O
studied	O
the	O
skin	O
fibroblasts	O
of	O
a	O
patient	O
with	O
Alpers	O
syndrome	O
having	O
the	O
genotype	O
E873stop	B-ProteinMutation
/	O
A467T	B-ProteinMutation
.	O

The	O
E873stop	B-ProteinMutation
mutation	O
produces	O
a	O
premature	O
termination	O
codon	O
(TAG)	O
in	O
exon	O
17	O
.	O

The	O
A467T	B-ProteinMutation
mutation	O
produces	O
a	O
threonine	O
to	O
alanine	O
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
exon	O
7	O
.	O

The	O
allele	O
bearing	O
the	O
stop	O
codon	O
E873-TAG	B-ProteinMutation
is	O
predicted	O
to	O
produce	O
a	O
truncated	O
,	O
catalytically	O
inactive	O
polymerase	O
.	O

However	O
,	O
only	O
full-length	O
pol	O
gamma	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O

Here	O
,	O
we	O
show	O
that	O
transcripts	O
containing	O
this	O
stop	O
codon	O
undergo	O
nonsense-associated	O
alternative	O
splicing	O
and	O
nonsense-mediated	O
decay	O
.	O

More	O
than	O
95%	O
of	O
the	O
functional	O
POLG	O
mRNA	O
was	O
derived	O
from	O
the	O
allele	O
bearing	O
the	O
A467T	B-ProteinMutation
mutation	O
and	O
less	O
than	O
5%	O
contained	O
the	O
E873stop	B-ProteinMutation
mutation	O
.	O

These	O
events	O
ensured	O
that	O
virtually	O
all	O
POLG	O
protein	O
in	O
the	O
cell	O
was	O
expressed	O
from	O
the	O
A467T	B-ProteinMutation
allele	O
.	O

Therefore	O
,	O
the	O
Alpers	O
phenotype	O
in	O
this	O
patient	O
was	O
a	O
consequence	O
of	O
a	O
single-copy	O
gene	O
dose	O
of	O
the	O
A467T	B-ProteinMutation
allele	O
,	O
and	O
selective	O
elimination	O
of	O
transcripts	O
bearing	O
the	O
E873stop	B-ProteinMutation
mutation	O
.	O

Combinations	O
of	O
genetic	O
changes	O
in	O
the	O
human	O
cAMP-responsive	O
element	O
modulator	O
gene	O
:	O
a	O
clue	O
towards	O
understanding	O
some	O
forms	O
of	O
male	O
infertility	O
.	O

The	O
cAMP-responsive	O
element	O
modulator	O
(CREM)	O
gene	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
mouse	O
spermatogenesis	O
,	O
but	O
its	O
role	O
in	O
the	O
human	O
infertility	O
has	O
not	O
been	O
fully	O
established	O
.	O

We	O
performed	O
a	O
mutation	O
screening	O
in	O
13	O
Slovenian	O
men	O
with	O
round	O
spermatid	O
arrest	O
and	O
in	O
six	O
controls	O
.	O

Eleven	O
genetic	O
changes	O
have	O
been	O
identified	O
in	O
the	O
human	O
CREM	O
gene	O
,	O
three	O
novel	O
single-nucleotide	O
polymorphisms	O
[	O
within	O
the	O
promoters	O
P1	O
,	O
P3	O
and	O
intervening	O
sequence	O
1	O
(	O
IVS1	O
)	O
]	O
,	O
one	O
insertion	O
(IVS2)	O
and	O
one	O
non-sense	O
mutation	O
(	O
exon	O
gamma	O
)	O
.	O

Some	O
infertile	O
patients	O
seem	O
to	O
accumulate	O
potentially	O
harmful	O
genetic	O
changes	O
.	O

We	O
identified	O
a	O
patient	O
with	O
no	O
CREM	O
immunoreactive	O
protein	O
that	O
was	O
homozygous	O
for	O
the	O
nucleotide	O
changes	O
in	O
all	O
promoters	O
,	O
IVS	O
1	O
,	O
2	O
,	O
6	O
,	O
and	O
was	O
heterozygous	O
for	O
the	O
mutation	O
in	O
exon	O
gamma	O
.	O

Interestingly	O
,	O
insertion	O
in	O
IVS2	O
IVS2-58_55insT	B-DNAMutation
results	O
in	O
a	O
four-fold	O
decrease	O
in	O
binding	O
of	O
nuclear	O
proteins	O
.	O

Computer	O
predictions	O
suggested	O
the	O
presence	O
of	O
a	O
potential	O
novel	O
CREM	O
promoter	O
,	O
however	O
,	O
random	O
amplification	O
of	O
cDNA	O
ends	O
from	O
the	O
human	O
testis	O
cDNA	O
library	O
was	O
not	O
successful	O
in	O
confirming	O
a	O
novel	O
transcription	O
start	O
site	O
of	O
the	O
CREM	O
gene	O
.	O

Screening	O
of	O
a	O
larger	O
number	O
of	O
patients	O
and	O
controls	O
is	O
required	O
to	O
elucidate	O
whether	O
the	O
observed	O
combinations	O
of	O
genetic	O
changes	O
in	O
the	O
CREM	O
gene	O
can	O
explain	O
some	O
forms	O
of	O
male	O
infertility	O
.	O

Novel	O
amino	O
acid	O
substitution	O
in	O
the	O
Y-position	O
of	O
collagen	O
type	O
II	O
causes	O
spondyloepimetaphyseal	O
dysplasia	O
congenita	O
.	O

We	O
report	O
on	O
monozygotic	O
twins	O
with	O
short	O
stature	O
and	O
severe	O
spondyloepimetaphyseal	O
dysplasia	O
congenita	O
(SEMDC)	O
from	O
the	O
Polish	O
population	O
.	O

Phenotype	O
of	O
the	O
twin	O
girls	O
resembles	O
spondyloepiphyseal	O
dysplasia	O
congenita	O
Spranger-Wiedemann	O
(SEDC-SW)	O
,	O
but	O
shortening	O
of	O
the	O
stature	O
is	O
more	O
severe	O
and	O
the	O
cranioface	O
is	O
normal	O
.	O

The	O
distinctive	O
radiographic	O
features	O
,	O
in	O
spite	O
of	O
similarity	O
to	O
SEDC-SW	O
,	O
indicate	O
different	O
spinal	O
and	O
,	O
notably	O
,	O
severe	O
metaphyseal	O
involvement	O
.	O

Molecular	O
analysis	O
of	O
the	O
COL2A1	O
gene	O
revealed	O
an	O
A	O
to	O
G	O
transition	O
at	O
nucleotide	O
+79	O
of	O
exon	O
41	O
that	O
converted	O
the	O
codon	O
for	O
arginine	O
at	O
amino	O
acid	O
792	O
to	O
a	O
codon	O
for	O
glycine	O
Arg792Gly	B-ProteinMutation
.	O

The	O
twins	O
were	O
heterozygous	O
for	O
the	O
mutation	O
and	O
neither	O
parent	O
had	O
this	O
change	O
.	O

The	O
Arg792Gly	B-ProteinMutation
substitution	O
is	O
located	O
at	O
the	O
Y-position	O
of	O
Gly-X-Y	O
triplet	O
,	O
and	O
it	O
is	O
likely	O
that	O
this	O
substitution	O
decreased	O
the	O
thermal	O
stability	O
of	O
the	O
triple	O
helix	O
and	O
may	O
affect	O
fibril	O
growth	O
by	O
replacement	O
of	O
an	O
arginine	O
residue	O
,	O
which	O
is	O
important	O
for	O
a	O
conformation	O
of	O
the	O
triple	O
helix	O
.	O

Polymorphism	O
of	O
the	O
PEMT	O
gene	O
and	O
susceptibility	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(NAFLD)	O
.	O

Phosphatidylethanolamine	O
N-methyltransferase	O
(PEMT)	O
catalyzes	O
phosphatidylcholine	O
synthesis	O
.	O

PEMT	O
knockout	O
mice	O
have	O
fatty	O
livers	O
,	O
and	O
it	O
is	O
possible	O
that	O
,	O
in	O
humans	O
,	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(NAFLD)	O
might	O
be	O
associated	O
with	O
PEMT	O
gene	O
polymorphisms	O
.	O

DNA	O
samples	O
from	O
59	O
humans	O
without	O
fatty	O
liver	O
and	O
from	O
28	O
humans	O
with	O
NAFLD	O
were	O
genotyped	O
for	O
a	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
8	O
of	O
PEMT	O
,	O
which	O
leads	O
to	O
a	O
V175M	B-ProteinMutation
substitution	O
.	O

V175M	B-ProteinMutation
is	O
a	O
loss	O
of	O
function	O
mutation	O
,	O
as	O
determined	O
by	O
transiently	O
transfecting	O
McArdle-RH7777	O
cells	O
with	O
constructs	O
of	O
wild-type	O
PEMT	O
open	O
reading	O
frame	O
or	O
the	O
V175M	B-ProteinMutation
mutant	O
.	O

Met/Met	O
at	O
residue	O
175	O
(	O
loss	O
of	O
function	O
SNP	O
)	O
occurred	O
in	O
67.9%	O
of	O
the	O
NAFLD	O
subjects	O
and	O
in	O
only	O
40.7%	O
of	O
control	O
subjects	O
(P<0.03)	O
.	O

For	O
the	O
first	O
time	O
we	O
report	O
that	O
a	O
polymorphism	O
of	O
the	O
human	O
PEMT	O
gene	O
V175M	B-ProteinMutation
is	O
associated	O
with	O
diminished	O
activity	O
and	O
may	O
confer	O
susceptibility	O
to	O
NAFLD	O
.	O

An	O
autosomal	O
dominant	O
cerebellar	O
ataxia	O
linked	O
to	O
chromosome	O
16q22.1	O
is	O
associated	O
with	O
a	O
single-nucleotide	O
substitution	O
in	O
the	O
5'	O
untranslated	O
region	O
of	O
the	O
gene	O
encoding	O
a	O
protein	O
with	O
spectrin	O
repeat	O
and	O
Rho	O
guanine-nucleotide	O
exchange-factor	O
domains	O
.	O

Autosomal	O
dominant	O
cerebellar	O
ataxia	O
(ADCA)	O
is	O
a	O
group	O
of	O
heterogeneous	O
neurodegenerative	O
disorders	O
.	O

By	O
positional	O
cloning	O
,	O
we	O
have	O
identified	O
the	O
gene	O
strongly	O
associated	O
with	O
a	O
form	O
of	O
degenerative	O
ataxia	O
(	O
chromosome	O
16q22.1-linked	O
ADCA	O
)	O
that	O
clinically	O
shows	O
progressive	O
pure	O
cerebellar	O
ataxia	O
.	O

Detailed	O
examination	O
by	O
use	O
of	O
audiogram	O
suggested	O
that	O
sensorineural	O
hearing	O
impairment	O
may	O
be	O
associated	O
with	O
ataxia	O
in	O
our	O
families	O
.	O

After	O
restricting	O
the	O
candidate	O
region	O
in	O
chromosome	O
16q22.1	O
by	O
haplotype	O
analysis	O
,	O
we	O
found	O
that	O
all	O
patients	O
from	O
52	O
unrelated	O
Japanese	O
families	O
harbor	O
a	O
heterozygous	O
C-->T	B-DNAMutation
single-nucleotide	O
substitution	O
,	O
16	O
nt	O
upstream	O
of	O
the	O
putative	O
translation	O
initiation	O
site	O
of	O
the	O
gene	O
for	O
a	O
hypothetical	O
protein	O
DKFZP434I216	O
,	O
which	O
we	O
have	O
called	O
"puratrophin-1"	O
(	O
Purkinje	O
cell	O
atrophy	O
associated	O
protein-1	O
)	O
.	O

The	O
full-length	O
puratrophin-1	O
mRNA	O
had	O
an	O
open	O
reading	O
frame	O
of	O
3,576	O
nt	O
,	O
predicted	O
to	O
contain	O
important	O
domains	O
,	O
including	O
the	O
spectrin	O
repeat	O
and	O
the	O
guanine-nucleotide	O
exchange	O
factor	O
(GEF)	O
for	O
Rho	O
GTPases	O
,	O
followed	O
by	O
the	O
Dbl-homologous	O
domain	O
,	O
which	O
indicates	O
the	O
role	O
of	O
puratrophin-1	O
in	O
intracellular	O
signaling	O
and	O
actin	O
dynamics	O
at	O
the	O
Golgi	O
apparatus	O
.	O

Puratrophin-1--normally	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
cells	O
,	O
including	O
epithelial	O
hair	O
cells	O
in	O
the	O
cochlea--was	O
aggregated	O
in	O
Purkinje	O
cells	O
of	O
the	O
chromosome	O
16q22.1-linked	O
ADCA	O
brains	O
.	O

Consistent	O
with	O
the	O
protein	O
prediction	O
data	O
of	O
puratrophin-1	O
,	O
the	O
Golgi-apparatus	O
membrane	O
protein	O
and	O
spectrin	O
also	O
formed	O
aggregates	O
in	O
Purkinje	O
cells	O
.	O

The	O
present	O
study	O
highlights	O
the	O
importance	O
of	O
the	O
5'	O
untranslated	O
region	O
(UTR)	O
in	O
identification	O
of	O
genes	O
of	O
human	O
disease	O
,	O
suggests	O
that	O
a	O
single-nucleotide	O
substitution	O
in	O
the	O
5'	O
UTR	O
could	O
be	O
associated	O
with	O
protein	O
aggregation	O
,	O
and	O
indicates	O
that	O
the	O
GEF	O
protein	O
is	O
associated	O
with	O
cerebellar	O
degeneration	O
in	O
humans	O
.	O

Polymorphisms	O
in	O
the	O
SLC2A2	O
(GLUT2)	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
to	O
type	O
2	O
diabetes	O
:	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
.	O

Impaired	O
insulin	O
secretion	O
is	O
a	O
fundamental	O
defect	O
in	O
type	O
2	O
diabetes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
genes	O
regulating	O
insulin	O
secretion	O
(	O
SLC2A2	O
[	O
encoding	O
GLUT2	O
]	O
,	O
GCK	O
,	O
TCF1	O
[	O
encoding	O
HNF-1alpha	O
]	O
,	O
HNF4A	O
,	O
GIP	O
,	O
and	O
GLP1R	O
)	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
to	O
type	O
2	O
diabetes	O
in	O
participants	O
of	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
.	O

With	O
the	O
exception	O
of	O
SLC2A2	O
,	O
other	O
genes	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

All	O
four	O
SNPs	O
of	O
SLC2A2	O
predicted	O
the	O
conversion	O
to	O
diabetes	O
,	O
and	O
rs5393	B-SNP
(	O
AA	O
genotype	O
)	O
increased	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
in	O
the	O
entire	O
study	O
population	O
by	O
threefold	O
(	O
odds	O
ratio	O
3.04	O
,	O
95%	O
CI	O
1.34-6.88	O
,	O
P	O
=	O
0.008	O
)	O
.	O

The	O
risk	O
for	O
type	O
2	O
diabetes	O
in	O
the	O
AA	O
genotype	O
carriers	O
was	O
increased	O
in	O
the	O
control	O
group	O
(	O
5.56	O
[1.78-17.39]	O
,	O
P	O
=	O
0.003	O
)	O
but	O
not	O
in	O
the	O
intervention	O
group	O
.	O

We	O
conclude	O
that	O
the	O
SNPs	O
of	O
SLC2A2	O
predict	O
the	O
conversion	O
to	O
diabetes	O
in	O
obese	O
subjects	O
with	O
IGT	O
.	O

Screening	O
for	O
exonic	O
copy	O
number	O
mutations	O
at	O
MSH2	O
and	O
MLH1	O
by	O
MAPH	O
.	O

BACKGROUND	O
:	O
Exonic	O
deletions	O
in	O
MSH2	O
and	O
MLH1	O
are	O
significant	O
contributors	O
to	O
the	O
mutation	O
spectrum	O
in	O
HNPCC	O
,	O
and	O
heterozygous	O
changes	O
in	O
exon	O
copy	O
number	O
are	O
not	O
detected	O
by	O
conventional	O
mutation	O
screening	O
methods	O
.	O

AIMS	O
:	O
We	O
aimed	O
to	O
develop	O
methods	O
for	O
screening	O
copy	O
number	O
changes	O
in	O
all	O
the	O
exons	O
of	O
the	O
MLH1	O
and	O
MSH2	O
genes	O
using	O
a	O
single	O
multiplex	O
amplifiable	O
probe	O
hybridisation	O
(MAPH)	O
assay	O
.	O

METHODS	O
:	O
We	O
developed	O
a	O
probe	O
set	O
consisting	O
of	O
probes	O
from	O
the	O
19	O
exons	O
of	O
MLH1	O
and	O
16	O
exons	O
of	O
MSH2	O
,	O
and	O
3	O
control	O
probes	O
,	O
and	O
applied	O
it	O
to	O
screening	O
for	O
deletions	O
and	O
duplications	O
using	O
fluorescent	O
detection	O
of	O
amplified	O
fragments	O
.	O

RESULTS	O
:	O
We	O
tested	O
73	O
DNA	O
samples	O
from	O
controls	O
and	O
50	O
from	O
HNPCC	O
patients	O
in	O
whom	O
no	O
point	O
mutations	O
had	O
been	O
found	O
,	O
and	O
detected	O
10	O
copy	O
number	O
changes	O
among	O
the	O
patient	O
samples	O
.	O

A	O
deletion	O
of	O
about	O
1.4	O
kb	O
including	O
exon	O
3	O
of	O
MSH2	O
was	O
confirmed	O
by	O
amplification	O
of	O
a	O
junction	O
fragment	O
,	O
and	O
was	O
shown	O
to	O
be	O
the	O
result	O
of	O
an	O
unequal	O
recombination	O
between	O
intronic	O
Alu	O
elements	O
.	O

CONCLUSIONS	O
:	O
MAPH	O
can	O
detect	O
exonic	O
copy	O
number	O
changes	O
in	O
MLH1	O
and	O
MSH2	O
in	O
DNA	O
from	O
HNPCC	O
patients	O
.	O

Since	O
finding	O
an	O
exonic	O
deletion	O
or	O
duplication	O
makes	O
full	O
sequence	O
analysis	O
unnecessary	O
,	O
it	O
may	O
be	O
most	O
cost-effective	O
to	O
pre-screen	O
samples	O
by	O
MAPH	O
or	O
MLPA	O
before	O
screening	O
for	O
point	O
mutations	O
.	O

Detection	O
of	O
a	O
new	O
3-base	O
pair	O
insertion	O
mutation	O
in	O
the	O
protease	O
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
during	O
highly	O
active	O
antiretroviral	O
therapy	O
(HAART)	O
.	O

To	O
investigate	O
a	O
new	O
insertion	O
mutation	O
in	O
the	O
protease	O
(PR)	O
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(HIV-1)	O
in	O
a	O
patient	O
extensively	O
pretreated	O
with	O
antiretroviral	O
drugs	O
,	O
genotypic	O
analyses	O
of	O
plasma-derived	O
viruses	O
were	O
performed	O
by	O
sequencing	O
segments	O
of	O
1302	O
nucleotides	O
in	O
the	O
pol	O
gene	O
of	O
HIV-1	O
.	O

Despite	O
optimal	O
compliance	O
to	O
highly	O
active	O
antiretroviral	O
therapy	O
(HAART)	O
the	O
patient	O
showed	O
poor	O
virological	O
success	O
.	O

Nucleotide	O
sequences	O
of	O
retrospective	O
available	O
plasma	O
samples	O
exhibited	O
a	O
previously	O
unknown	O
3-bp	O
insertion	O
mutation	O
,	O
corresponding	O
to	O
a	O
leucine	O
,	O
between	O
codons	O
31	O
and	O
32	O
of	O
the	O
PR	O
gene	O
.	O

This	O
kind	O
of	O
mutation	O
appears	O
to	O
be	O
very	O
rare	O
and	O
it	O
does	O
not	O
seem	O
to	O
be	O
associated	O
with	O
any	O
phenotypic	O
resistance	O
profile	O
known	O
so	O
far	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
insert	O
mutation	O
,	O
once	O
it	O
appeared	O
,	O
did	O
not	O
revert	O
to	O
the	O
wild-type	O
variant	O
,	O
suggesting	O
that	O
it	O
seems	O
to	O
correspond	O
to	O
a	O
better	O
fitness	O
of	O
the	O
variant	O
viruses	O
.	O

The	O
spectrum	O
of	O
aldolase	O
B	O
(ALDOB)	O
mutations	O
and	O
the	O
prevalence	O
of	O
hereditary	O
fructose	O
intolerance	O
in	O
Central	O
Europe	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
hereditary	O
fructose	O
intolerance	O
(HFI)	O
in	O
80	O
patients	O
from	O
72	O
families	O
by	O
means	O
of	O
a	O
PCR-based	O
mutation	O
screening	O
strategy	O
,	O
consisting	O
of	O
heteroduplex	O
analysis	O
,	O
restriction	O
enzyme	O
digest	O
,	O
DNA	O
single	O
strand	O
electrophoresis	O
,	O
and	O
direct	O
sequencing	O
.	O

For	O
a	O
subset	O
of	O
patients	O
mutation	O
screening	O
with	O
DHPLC	O
was	O
established	O
which	O
turned	O
out	O
to	O
be	O
as	O
fast	O
and	O
as	O
sensitive	O
as	O
the	O
more	O
conventional	O
methods	O
.	O

Fifteen	O
different	O
mutations	O
of	O
the	O
aldolase	O
B	O
(ALDOB)	O
gene	O
were	O
identified	O
in	O
HFI	O
patients	O
.	O

As	O
in	O
smaller	O
previous	O
studies	O
,	O
p.A150P	B-ProteinMutation
(65%)	O
,	O
p.A175D	B-ProteinMutation
(11%)	O
and	O
p.N335K	B-ProteinMutation
(8%)	O
were	O
the	O
most	O
common	O
mutated	O
alleles	O
,	O
followed	O
by	O
c.360_363delCAAA	B-DNAMutation
,	O
p.R60X	B-ProteinMutation
,	O
p.Y204X	B-ProteinMutation
,	O
and	O
c.865delC	B-DNAMutation
.	O

Eight	O
novel	O
mutations	O
were	O
identified	O
in	O
eight	O
families	O
with	O
HFI	O
:	O
a	O
small	O
indel	O
mutation	O
c.1044_1049delTTCTGGinsACACT	B-DNAMutation
,	O
two	O
small	O
deletions	O
(	O
c.345_372del28	B-DNAMutation
;	O
c.841_842delAC	B-DNAMutation
)	O
,	O
two	O
splice	O
site	O
mutations	O
(	O
c.113-1G>A	B-DNAMutation
,	O
c.799+2T>A	B-DNAMutation
)	O
,	O
one	O
nonsense	O
mutation	O
(	O
c.612T>G	B-DNAMutation
(	O
p.Y204X	B-ProteinMutation
)	O
)	O
,	O
and	O
two	O
missense	O
mutations	O
(	O
c.532T>C	B-DNAMutation
p.C178R	B-ProteinMutation
,	O
c.851T>C	B-DNAMutation
(	O
p.L284P	B-ProteinMutation
)	O
)	O
.	O

By	O
mutation	O
screening	O
for	O
the	O
three	O
most	O
common	O
ALDOB	O
mutations	O
by	O
DHPLC	O
in	O
2,000	O
randomly	O
selected	O
newborns	O
we	O
detected	O
21	O
heterozygotes	O
.	O

Based	O
on	O
these	O
data	O
and	O
after	O
correction	O
for	O
less	O
common	O
and	O
private	O
ALDOB	O
mutations	O
,	O
HFI	O
prevalence	O
in	O
central	O
Europe	O
is	O
estimated	O
to	O
be	O
1:26,100	O
(	O
95%	O
confidence	O
interval	O
1	O
:	O
12,600-79,000	O
)	O
.	O

Genetic	O
variants	O
of	O
the	O
T-cell	O
immunoglobulin	O
mucin	O
1	O
but	O
not	O
the	O
T-cell	O
immunoglobulin	O
mucin	O
3	O
gene	O
are	O
associated	O
with	O
asthma	O
in	O
an	O
African	O
American	O
population	O
.	O

BACKGROUND	O
:	O
The	O
T-cell	O
immunoglobulin	O
mucin	O
(	O
TIM	O
)	O
proteins	O
and	O
their	O
genetic	O
variants	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
regulating	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
Genetic	O
association	O
of	O
the	O
sequence	O
variants	O
for	O
TIM-1	O
and	O
TIM-3	O
genes	O
with	O
asthma	O
in	O
an	O
African	O
American	O
population	O
was	O
investigated	O
.	O

METHODS	O
:	O
Both	O
case-control	O
and	O
family-based	O
association	O
analyses	O
were	O
performed	O
for	O
a	O
total	O
of	O
7	O
polymorphisms	O
,	O
including	O
3	O
single	O
nucleotide	O
polymorphism	O
(SNPs)	O
and	O
1	O
insertion/deletion	O
polymorphism	O
in	O
the	O
TIM-1	O
and	O
3	O
SNPs	O
in	O
the	O
TIM-3	O
genes	O
.	O

The	O
exposure	O
to	O
hepatitis	O
A	O
virus	O
as	O
judged	O
by	O
seropositivity	O
was	O
also	O
examined	O
.	O

RESULTS	O
:	O
In	O
the	O
case-control	O
design	O
,	O
the	O
frequencies	O
of	O
the	O
TT	O
genotype	O
for	O
SNP	O
rs2277025	B-SNP
and	O
the	O
homozygous	O
deletion	O
variant	O
157delMTTTVP	B-ProteinMutation
in	O
the	O
fourth	O
exon	O
of	O
the	O
TIM-1	O
gene	O
were	O
higher	O
among	O
patients	O
with	O
patients	O
with	O
asthma	O
compared	O
with	O
the	O
controls	O
(	O
odds	O
ratio	O
[OR]	O
,	O
2.779	O
,	O
P	O
=	O
.016	O
;	O
and	O
OR	O
,	O
3.09	O
,	O
P	O
=	O
.022	O
,	O
respectively	O
)	O
.	O

This	O
association	O
was	O
substantiated	O
by	O
haplotype	O
analysis	O
of	O
these	O
and	O
2	O
additional	O
SNPs	O
(	O
OR	O
,	O
2.48	O
;	O
P	O
=	O
.004	O
)	O
,	O
and	O
also	O
by	O
family-based	O
tests	O
for	O
the	O
allele	O
and	O
haplotype	O
carrying	O
157delMTTTVP	B-ProteinMutation
(	O
P	O
=	O
.009	O
and	O
P	O
=	O
.048	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
this	O
association	O
seems	O
to	O
exist	O
even	O
in	O
the	O
hepatitis	O
A	O
virus-seronegative	O
subjects	O
in	O
our	O
data	O
.	O

None	O
of	O
the	O
3	O
variants	O
in	O
TIM-3	O
genes	O
yielded	O
significant	O
association	O
with	O
either	O
asthma	O
or	O
asthma-related	O
phenotypes	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
genetic	O
variants	O
of	O
the	O
TIM-1	O
but	O
not	O
the	O
TIM-3	O
gene	O
contribute	O
to	O
asthma	O
susceptibility	O
in	O
this	O
African-American	O
population	O
.	O

Nucleotide	O
mutations	O
associated	O
with	O
hepatitis	O
B	O
e	O
antigen	O
negativity	O
.	O

One	O
hundred	O
and	O
forty	O
four	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
were	O
tested	O
to	O
identify	O
new	O
mutations	O
associated	O
with	O
hepatitis	O
B	O
e	O
antigen	O
(HBeAg)	O
negativity	O
,	O
using	O
a	O
full	O
genome	O
sequence	O
analysis	O
.	O

All	O
the	O
patients	O
were	O
Chinese	O
and	O
had	O
hepatitis	O
B	O
virus	O
infection	O
of	O
genotype	O
C	O
.	O

Patients	O
with	O
none	O
of	O
the	O
pre-core	O
or	O
core	O
promoter	O
mutations	O
were	O
significantly	O
(	O
P	O
<	O
0.001	O
)	O
less	O
common	O
in	O
the	O
group	O
with	O
anti-HBe	O
(13%)	O
than	O
in	O
the	O
group	O
with	O
HBeAg	O
(56%)	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
was	O
determined	O
in	O
four	O
anti-HBe-positive	O
patients	O
who	O
had	O
neither	O
pre-core	O
nor	O
core	O
promoter	O
mutations	O
and	O
in	O
five	O
HBeAg-positive	O
patients	O
who	O
also	O
had	O
neither	O
of	O
these	O
mutations	O
(	O
the	O
groups	O
were	O
matched	O
for	O
age	O
and	O
sex	O
)	O
.	O

Six	O
mutations	O
were	O
found	O
to	O
be	O
significantly	O
more	O
common	O
in	O
the	O
former	O
group	O
than	O
in	O
the	O
latter	O
:	O
G529A	B-DNAMutation
(	O
3/4	O
vs	O
.	O

0/5	O
)	O
,	O
C934A	B-DNAMutation
(	O
4/4	O
vs	O
.	O

1/5	O
)	O
,	O
A1053G	B-DNAMutation
(	O
4/4	O
vs	O
.	O

1/5	O
)	O
,	O
G1915T/A	B-DNAMutation
(	O
4/4	O
vs	O
.	O

0/5	O
)	O
,	O
T2005C/A	B-DNAMutation
(	O
4/4	O
vs	O
.	O

0/5	O
)	O
,	O
and	O
C3026T	B-DNAMutation
(	O
3/4	O
vs	O
.	O

0/5	O
)	O
.	O

Three	O
of	O
the	O
six	O
mutations	O
were	O
significantly	O
more	O
common	O
in	O
the	O
four	O
anti-HBe-positive	O
patients	O
who	O
had	O
neither	O
pre-core	O
nor	O
core	O
promoter	O
mutations	O
,	O
compared	O
to	O
11	O
HBeAg-positive	O
patients	O
who	O
had	O
pre-core	O
and	O
core	O
promoter	O
mutations	O
,	O
and	O
also	O
compared	O
to	O
15	O
anti-HBe-positive	O
patients	O
who	O
had	O
pre-core	O
and	O
core	O
promoter	O
mutations	O
,	O
suggesting	O
further	O
the	O
specificity	O
of	O
these	O
mutations	O
.	O

Of	O
the	O
six	O
mutations	O
,	O
two	O
resulted	O
in	O
amino	O
acid	O
substitution	O
in	O
the	O
polymerase	O
protein	O
,	O
and	O
one	O
is	O
located	O
near	O
the	O
enhancer	O
I	O
region	O
.	O

The	O
results	O
suggest	O
that	O
the	O
six	O
newly	O
discovered	O
mutations	O
are	O
associated	O
with	O
HBeAg	O
negativity	O
.	O

No	O
Evidence	O
for	O
BRAF	O
as	O
a	O
melanoma/nevus	O
susceptibility	O
gene	O
.	O

Somatic	O
mutations	O
of	O
BRAF	O
have	O
been	O
identified	O
in	O
both	O
melanoma	O
tumors	O
and	O
benign	O
nevi	O
.	O

Germ	O
line	O
mutations	O
in	O
BRAF	O
have	O
not	O
been	O
identified	O
as	O
causal	O
in	O
families	O
predisposed	O
to	O
melanoma	O
.	O

However	O
,	O
a	O
recent	O
study	O
suggested	O
that	O
a	O
BRAF	O
haplotype	O
was	O
associated	O
with	O
risk	O
of	O
sporadic	O
melanoma	O
in	O
men	O
.	O

Polymorphisms	O
or	O
other	O
variants	O
in	O
the	O
BRAF	O
gene	O
may	O
therefore	O
act	O
as	O
candidate	O
low-penetrance	O
genes	O
for	O
nevus/melanoma	O
susceptibility	O
.	O

We	O
hypothesized	O
that	O
promoter	O
variants	O
would	O
be	O
the	O
most	O
likely	O
candidates	O
for	O
determinants	O
of	O
risk	O
.	O

Using	O
denaturing	O
high-pressure	O
liquid	O
chromatography	O
and	O
sequencing	O
,	O
we	O
screened	O
peripheral	O
blood	O
DNA	O
from	O
184	O
familial	O
melanoma	O
cases	O
for	O
BRAF	O
promoter	O
variants	O
.	O

We	O
identified	O
a	O
promoter	O
insertion/deletion	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
previously	O
described	O
BRAF	O
polymorphism	O
in	O
intron	O
11	O
rs1639679	B-SNP
reported	O
to	O
be	O
associated	O
with	O
melanoma	O
susceptibility	O
in	O
males	O
.	O

We	O
therefore	O
investigated	O
the	O
contribution	O
of	O
this	O
BRAF	O
polymorphism	O
to	O
melanoma	O
susceptibility	O
in	O
581	O
consecutively	O
recruited	O
incident	O
cases	O
,	O
258	O
incident	O
cases	O
in	O
a	O
study	O
of	O
late	O
relapse	O
,	O
673	O
female	O
general	O
practitioner	O
controls	O
,	O
and	O
the	O
184	O
familial	O
cases	O
.	O

We	O
found	O
no	O
statistically	O
significant	O
difference	O
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
cases	O
and	O
controls	O
overall	O
or	O
between	O
male	O
and	O
female	O
cases	O
for	O
the	O
BRAF	O
polymorphism	O
in	O
the	O
two	O
incident	O
case	O
series	O
.	O

Our	O
results	O
therefore	O
suggest	O
that	O
the	O
BRAF	O
polymorphism	O
is	O
not	O
significantly	O
associated	O
with	O
melanoma	O
and	O
the	O
promoter	O
insertion/deletion	O
linked	O
with	O
the	O
polymorphism	O
is	O
not	O
a	O
causal	O
variant	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
there	O
was	O
no	O
association	O
between	O
the	O
BRAF	O
genotype	O
and	O
mean	O
total	O
number	O
of	O
banal	O
or	O
atypical	O
nevi	O
in	O
either	O
the	O
cases	O
or	O
controls	O
.	O

Vitamin	O
D-binding	O
protein	O
gene	O
polymorphism	O
association	O
with	O
IA-2	O
autoantibodies	O
in	O
type	O
1	O
diabetes	O
.	O

BACKGROUND	O
:	O
Vitamin	O
D-binding	O
protein	O
(DBP)	O
is	O
the	O
main	O
systemic	O
transporter	O
of	O
1.25(OH)2D3	O
and	O
is	O
essential	O
for	O
its	O
cellular	O
endocytosis	O
.	O

There	O
are	O
two	O
known	O
polymorphisms	O
in	O
exon	O
11	O
of	O
the	O
DBP	O
gene	O
resulting	O
in	O
amino	O
acid	O
variants	O
:	O
GAT-->GAG	B-DNAMutation
substitution	O
replaces	O
aspartic	O
acid	O
by	O
glutamic	O
acid	O
in	O
codon	O
416	O
;	O
and	O
ACG-->AAG	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
420	I-DNAMutation
leads	O
to	O
an	O
exchange	O
of	O
threonine	O
for	O
lysine	O
.	O

These	O
DBP	O
variants	O
lead	O
to	O
differences	O
in	O
the	O
affinity	O
for	O
1.25(OH)2D3	O
.	O

Correlations	O
between	O
DBP	O
alleles	O
and	O
type	O
1	O
diabetes	O
have	O
been	O
described	O
in	O
different	O
populations	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
polymorphism	O
in	O
codon	O
416	O
of	O
the	O
DBP	O
gene	O
for	O
an	O
association	O
with	O
autoimmune	O
markers	O
of	O
type	O
1	O
diabetes	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
present	O
analysis	O
was	O
a	O
case	O
control	O
study	O
.	O

110	O
patients	O
,	O
68	O
controls	O
,	O
and	O
115	O
first-degree	O
relatives	O
were	O
genotyped	O
for	O
the	O
DBP	O
polymorphism	O
in	O
codon	O
416	O
.	O

DNA	O
typing	O
of	O
DBP	O
locus	O
was	O
performed	O
by	O
the	O
PCR-restriction	O
fragment	O
length	O
polymorphism	O
method	O
(RFLP)	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
Asp/Glu	O
and	O
Glu/Glu	O
were	O
significantly	O
increased	O
in	O
diabetic	O
subjects	O
with	O
detectable	O
IA-2	O
antibodies	O
(	O
P	O
<	O
0.01	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
DBP	O
Glu-containing	O
genotype	O
was	O
not	O
accompanied	O
by	O
differences	O
in	O
the	O
prevalence	O
of	O
GAD65	O
antibodies	O
.	O

These	O
finding	O
supports	O
a	O
role	O
of	O
the	O
vitamin	O
D	O
endocrine	O
system	O
in	O
the	O
autoimmune	O
process	O
of	O
type	O
1	O
diabetes	O
.	O

Sequence	O
variation	O
in	O
G-protein-coupled	O
receptors	O
:	O
analysis	O
of	O
single	O
nucleotide	O
polymorphisms	O
.	O

We	O
assessed	O
the	O
disease-causing	O
potential	O
of	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
based	O
on	O
a	O
simple	O
set	O
of	O
sequence-based	O
features	O
.	O

We	O
focused	O
on	O
SNPs	O
from	O
the	O
dbSNP	O
database	O
in	O
G-protein-coupled	O
receptors	O
(GPCRs)	O
,	O
a	O
large	O
class	O
of	O
important	O
transmembrane	O
(TM)	O
proteins	O
.	O

Apart	O
from	O
the	O
location	O
of	O
the	O
SNP	O
in	O
the	O
protein	O
,	O
we	O
evaluated	O
the	O
predictive	O
power	O
of	O
three	O
major	O
classes	O
of	O
features	O
to	O
differentiate	O
between	O
disease-causing	O
mutations	O
and	O
neutral	O
changes	O
:	O
(i)	O
properties	O
derived	O
from	O
amino-acid	O
scales	O
,	O
such	O
as	O
volume	O
and	O
hydrophobicity	O
;	O
(ii)	O
position-specific	O
phylogenetic	O
features	O
reflecting	O
evolutionary	O
conservation	O
,	O
such	O
as	O
normalized	O
site	O
entropy	O
,	O
residue	O
frequency	O
and	O
SIFT	O
score	O
;	O
and	O
(iii)	O
substitution-matrix	O
scores	O
,	O
such	O
as	O
those	O
derived	O
from	O
the	O
BLOSUM62	O
,	O
GRANTHAM	O
and	O
PHAT	O
matrices	O
.	O

We	O
validated	O
our	O
approach	O
using	O
a	O
control	O
dataset	O
consisting	O
of	O
known	O
disease-causing	O
mutations	O
and	O
neutral	O
variations	O
.	O

Logistic	O
regression	O
analyses	O
indicated	O
that	O
position-specific	O
phylogenetic	O
features	O
that	O
describe	O
the	O
conservation	O
of	O
an	O
amino	O
acid	O
at	O
a	O
specific	O
site	O
are	O
the	O
best	O
discriminators	O
of	O
disease	O
mutations	O
versus	O
neutral	O
variations	O
,	O
and	O
integration	O
of	O
all	O
our	O
features	O
improves	O
discrimination	O
power	O
.	O

Overall	O
,	O
we	O
identify	O
115	O
SNPs	O
in	O
GPCRs	O
from	O
dbSNP	O
that	O
are	O
likely	O
to	O
be	O
associated	O
with	O
disease	O
and	O
thus	O
are	O
good	O
candidates	O
for	O
genotyping	O
in	O
association	O
studies	O
.	O

New	O
mutations	O
,	O
hotspots	O
,	O
and	O
founder	O
effects	O
in	O
Brazilian	O
patients	O
with	O
steroid	O
5alpha-reductase	O
deficiency	O
type	O
2	O
.	O

Mutations	O
of	O
the	O
steroid	O
5alpha-reductase	O
type	O
2	O
(SRD5A2)	O
gene	O
in	O
46,XY	O
subjects	O
cause	O
masculinization	O
defects	O
of	O
varying	O
degrees	O
,	O
due	O
to	O
reduced	O
or	O
impaired	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
sequence	O
abnormalities	O
of	O
the	O
SRD5A2	O
gene	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
specific	O
primers	O
and	O
automated	O
sequencing	O
analysis	O
in	O
DNA	O
samples	O
from	O
20	O
patients	O
with	O
suspected	O
steroid	O
5alpha-reductase	O
type	O
2	O
deficiency	O
from	O
18	O
Brazilian	O
families	O
.	O

Eleven	O
subjects	O
presented	O
SRD5A2	O
homozygous	O
single-base	O
mutations	O
(	O
two	O
first	O
cousins	O
and	O
four	O
unrelated	O
patients	O
with	O
G183S	B-ProteinMutation
,	O
two	O
with	O
R246W	B-ProteinMutation
,	O
one	O
with	O
del642T	B-DNAMutation
,	O
one	O
with	O
G196S	B-ProteinMutation
,	O
and	O
one	O
with	O
217_218insC	B-DNAMutation
plus	O
the	O
A49T	B-ProteinMutation
variant	O
in	O
heterozygosis	O
)	O
,	O
whereas	O
four	O
were	O
compound	O
heterozygotes	O
(	O
one	O
with	O
Q126R	B-ProteinMutation
/	O
IVS3+1G>A	B-DNAMutation
,	O
one	O
with	O
Q126R	B-ProteinMutation
/	O
del418T	B-DNAMutation
,	O
and	O
two	O
brothers	O
with	O
Q126R	B-ProteinMutation
/	O
G158R	B-ProteinMutation
)	O
.	O

Three	O
patients	O
were	O
heterozygous	O
for	O
A207D	B-ProteinMutation
,	O
G196S	B-ProteinMutation
,	O
and	O
R266W	B-ProteinMutation
substitutions	O
.	O

The	O
V89L	B-ProteinMutation
polymorphism	O
was	O
found	O
in	O
heterozygosis	O
in	O
one	O
of	O
them	O
(	O
with	O
A207D	B-ProteinMutation
)	O
and	O
in	O
one	O
case	O
with	O
an	O
otherwise	O
normal	O
gene	O
sequence	O
.	O

The	O
A49T	B-ProteinMutation
variant	O
was	O
also	O
detected	O
in	O
heterozygosis	O
in	O
the	O
second	O
case	O
without	O
other	O
sequencing	O
abnormalities	O
.	O

Four	O
patients	O
harbor	O
yet	O
non-described	O
SRD5A2	O
gene	O
mutations	O
:	O
a	O
single	O
nucleotide	O
deletion	O
del642T	B-DNAMutation
,	O
a	O
G158R	B-ProteinMutation
amino	O
acid	O
substitution	O
,	O
a	O
splice	O
junction	O
mutation	O
IVS3+1G>A	B-DNAMutation
,	O
and	O
the	O
insertion	O
of	O
a	O
cytosine	O
217_218insC	B-DNAMutation
occurring	O
at	O
a	O
CCCC	O
motif	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
single-nucleotide	O
insertion	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
SRD5A2	O
gene	O
.	O

In	O
addition	O
to	O
these	O
new	O
mutations	O
,	O
this	O
investigation	O
reveals	O
the	O
prevalence	O
of	O
G183S	B-ProteinMutation
substitution	O
among	O
a	O
subset	O
of	O
African-Brazilian	O
patients	O
and	O
presents	O
evidences	O
of	O
the	O
recurrence	O
of	O
already	O
known	O
mutations	O
.	O

Common	O
dihydrofolate	O
reductase	O
19-base	O
pair	O
deletion	O
allele	O
:	O
a	O
novel	O
risk	O
factor	O
for	O
preterm	O
delivery	O
.	O

BACKGROUND	O
:	O
Folate	O
is	O
critical	O
for	O
cell	O
division	O
,	O
a	O
major	O
feature	O
of	O
in	O
utero	O
development	O
.	O

Dihydrofolate	O
reductase	O
(DHFR)	O
is	O
required	O
to	O
convert	O
the	O
folic	O
acid	O
used	O
in	O
supplements	O
and	O
for	O
food	O
fortification	O
and	O
the	O
dihydrofolate	O
produced	O
by	O
thymidylate	O
synthase	O
during	O
DNA	O
synthesis	O
to	O
the	O
reduced	O
folate	O
forms	O
used	O
by	O
the	O
cell	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
whether	O
a	O
common	O
,	O
recently	O
discovered	O
deletion	O
polymorphism	O
in	O
the	O
DHFR	O
gene	O
is	O
a	O
risk	O
factor	O
for	O
preterm	O
delivery	O
or	O
low	O
birth	O
weight	O
.	O

DESIGN	O
:	O
We	O
studied	O
324	O
pregnant	O
women	O
from	O
Camden	O
,	O
NJ	O
.	O

Folate	O
intake	O
was	O
computed	O
from	O
folate	O
supplement	O
intake	O
plus	O
the	O
mean	O
of	O
two	O
24-h	O
recalls	O
completed	O
during	O
the	O
course	O
of	O
pregnancy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
women's	O
leukocytes	O
and	O
genotyped	O
.	O

RESULTS	O
:	O
Women	O
with	O
a	O
deletion	O
allele	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	O
delivery	O
[	O
adjusted	O
odds	O
ratio	O
(AOR)	O
:	O
3.0	O
;	O
95%	O
CI	O
:	O
1.0	O
,	O
8.8	O
;	O
P	O
<	O
0.05	O
]	O
than	O
did	O
those	O
without	O
a	O
deletion	O
allele	O
.	O

Women	O
with	O
both	O
a	O
DHFR	O
deletion	O
allele	O
and	O
low	O
folate	O
intake	O
(	O
<400	O
microg/d	O
from	O
diet	O
plus	O
supplements	O
)	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	O
delivery	O
(	O
AOR	O
:	O
5.5	O
;	O
95%	O
CI	O
:	O
1.5	O
,	O
20.4	O
;	O
P	O
=	O
0.01	O
)	O
and	O
a	O
significantly	O
greater	O
risk	O
of	O
having	O
an	O
infant	O
with	O
a	O
low	O
birth	O
weight	O
(	O
AOR	O
:	O
8.3	O
;	O
95%	O
CI	O
:	O
1.8	O
,	O
38.6	O
;	O
P	O
=	O
0.01	O
)	O
than	O
did	O
women	O
without	O
a	O
deletion	O
allele	O
and	O
with	O
a	O
folate	O
intake	O
>/=400	O
microg/d	O
.	O

CONCLUSIONS	O
:	O
The	O
DHFR	O
19-base	O
pair	O
deletion	O
allele	O
may	O
be	O
a	O
risk	O
factor	O
for	O
preterm	O
delivery	O
.	O

In	O
the	O
presence	O
of	O
low	O
dietary	O
folate	O
,	O
the	O
allele	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
.	O

This	O
may	O
be	O
a	O
gene-environment	O
interaction	O
.	O

Novel	O
somatic	O
MEN1	O
gene	O
alterations	O
in	O
sporadic	O
primary	O
hyperparathyroidism	O
and	O
correlation	O
with	O
clinical	O
characteristics	O
.	O

Primary	O
hyperparathyroidism	O
(pHPT)	O
is	O
a	O
common	O
endocrine	O
disease	O
that	O
in	O
more	O
than	O
95%	O
of	O
cases	O
is	O
sporadic	O
and	O
only	O
in	O
some	O
cases	O
is	O
caused	O
by	O
inherited	O
disorders	O
,	O
isolated	O
or	O
as	O
part	O
of	O
multiple	O
endocrine	O
neoplasia	O
(	O
MEN1	O
and	O
2	O
)	O
.	O

Somatic	O
mutations	O
of	O
MEN1	O
gene	O
have	O
also	O
been	O
described	O
in	O
sporadic	O
parathyroid	O
tumors	O
.	O

In	O
our	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	O
gene	O
in	O
a	O
series	O
of	O
39	O
patients	O
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
pHPT	O
(	O
35	O
with	O
parathyroid	O
adenoma	O
or	O
hyperplasia	O
,	O
4	O
with	O
a	O
carcinoma	O
)	O
.	O

A	O
genotype-phenotype	O
correlation	O
was	O
also	O
analysed	O
.	O

After	O
DNA	O
extraction	O
from	O
paraffin-embedded	O
tissues	O
,	O
we	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
the	O
exons	O
2-10	O
of	O
the	O
MEN1	O
gene	O
.	O

Somatic	O
MEN1	O
mutations	O
were	O
detected	O
in	O
6	O
of	O
the	O
35	O
patients	O
with	O
a	O
benign	O
parathyroid	O
lesion	O
examined	O
(17.1%)	O
,	O
whereas	O
no	O
alterations	O
were	O
found	O
in	O
the	O
carcinomas	O
.	O

Four	O
novel	O
MEN1	O
gene	O
mutations	O
were	O
identified	O
as	O
follows	O
:	O
one	O
frameshift	O
mutation	O
(	O
222insT	B-DNAMutation
,	O
exon	O
2	O
)	O
,	O
one	O
frameshift	O
deletion	O
(	O
912delTA	B-DNAMutation
,	O
exon	O
5	O
)	O
,	O
one	O
in-frame	O
deletion	O
(	O
835del18	B-DNAMutation
,	O
exon	O
4	O
)	O
and	O
one	O
missense	O
mutation	O
(	O
P291A	B-ProteinMutation
,	O
exon	O
6	O
)	O
.	O

In	O
addition	O
,	O
one	O
missense	O
mutation	O
(	O
L89R	B-ProteinMutation
,	O
exon	O
2	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
Q536X	B-ProteinMutation
,	O
exon	O
10	O
)	O
were	O
previously	O
reported	O
.	O

Moreover	O
,	O
two	O
polymorphisms	O
were	O
also	O
found	O
:	O
one	O
allele	O
carried	O
a	O
R171Q	B-ProteinMutation
polymorphism	O
(	O
1/39	O
tumors	O
)	O
,	O
while	O
a	O
D418D	B-ProteinMutation
polymorphism	O
GAC/GAT	B-DNAMutation
was	O
found	O
in	O
15	O
and	O
8	O
tumors	O
in	O
hetero	O
(CT)	O
and	O
homozygosity	O
(TT)	O
,	O
respectively	O
.	O

In	O
no	O
case	O
(	O
mutations	O
and/or	O
polymorphisms	O
)	O
did	O
we	O
find	O
a	O
genotype-phenotype	O
correlation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
the	O
presence	O
of	O
somatic	O
alterations	O
of	O
the	O
MEN1	O
tumor	O
suppressor	O
gene	O
in	O
about	O
one	O
fifth	O
of	O
benign	O
sporadic	O
parathyroid	O
tumors	O
.	O

The	O
absence	O
of	O
a	O
genotype-phenotype	O
correlation	O
,	O
however	O
,	O
suggests	O
the	O
involvement	O
of	O
other	O
genetic/epigenetic	O
factors	O
for	O
the	O
full	O
expression	O
of	O
the	O
disease	O
.	O

Two	O
novel	O
mutations	O
,	O
L490R	B-ProteinMutation
and	O
V561X	B-ProteinMutation
,	O
of	O
the	O
transferrin	O
receptor	O
2	O
gene	O
in	O
Japanese	O
patients	O
with	O
hemochromatosis	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
low	O
prevalence	O
of	O
the	O
C282Y	B-ProteinMutation
mutation	O
of	O
the	O
HFE	O
gene	O
in	O
Japan	O
means	O
that	O
the	O
genetic	O
background	O
of	O
hemochromatosis	O
in	O
Japanese	O
patients	O
remains	O
unclear	O
.	O

In	O
a	O
previous	O
report	O
,	O
we	O
showed	O
that	O
3	O
patients	O
from	O
one	O
family	O
had	O
an	O
AVAQ	O
594-597	O
deletion	O
of	O
the	O
transferrin	O
receptor	O
(TfR2)	O
gene	O
.	O

This	O
suggests	O
that	O
the	O
TfR2	O
gene	O
is	O
involved	O
in	O
hemochromatosis	O
in	O
Japanese	O
patients	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Nine	O
patients	O
clinically	O
diagnosed	O
with	O
hemochromatosis	O
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
samples	O
collected	O
with	O
informed	O
consent	O
.	O

The	O
HFE	O
and	O
TfR2	O
genes	O
were	O
analyzed	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
splicing	O
sites	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
mutations	O
in	O
the	O
HFE	O
gene	O
.	O

In	O
the	O
TfR2	O
gene	O
,	O
2	O
novel	O
mutations	O
,	O
1469T->G	B-DNAMutation
L490R	B-ProteinMutation
and	O
1665delC	B-DNAMutation
V561X	B-ProteinMutation
,	O
were	O
found	O
in	O
2	O
patients	O
.	O

A	O
known	O
variation	O
,	O
714C->	O
I238M	B-ProteinMutation
,	O
was	O
also	O
found	O
in	O
the	O
patient	O
with	O
L490R	B-ProteinMutation
.	O

The	O
patient	O
homozygous	O
for	O
both	O
L490R	B-ProteinMutation
and	O
I238M	B-ProteinMutation
presented	O
with	O
a	O
mild	O
manifestation	O
of	O
hemochromatosis	O
at	O
the	O
age	O
of	O
41	O
years	O
.	O

His	O
liver	O
was	O
cirrhotic	O
with	O
parenchymal	O
iron	O
deposits	O
and	O
the	O
result	O
of	O
a	O
glucose	O
tolerance	O
test	O
was	O
compatible	O
with	O
diabetes	O
mellitus	O
.	O

The	O
patient	O
homozygous	O
for	O
V561X	B-ProteinMutation
had	O
severe	O
iron	O
overload	O
with	O
the	O
triad	O
of	O
cirrhosis	O
,	O
diabetes	O
mellitus	O
and	O
skin	O
pigmentation	O
at	O
the	O
age	O
of	O
58	O
years	O
.	O

INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
Taken	O
together	O
with	O
the	O
previous	O
report	O
,	O
5	O
of	O
our	O
12	O
patients	O
with	O
hemochromatosis	O
manifesting	O
in	O
middle	O
age	O
had	O
mutations	O
in	O
the	O
TfR2	O
gene	O
.	O

Thus	O
,	O
TfR2	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hemochromatosis	O
in	O
Japan	O
.	O

Association	O
between	O
SLC11A1	O
(	O
formerly	O
NRAMP1	O
)	O
and	O
the	O
risk	O
of	O
sarcoidosis	O
in	O
Poland	O
.	O

Sarcoidosis	O
(SA)	O
is	O
a	O
systemic	O
granulomatous	O
disorder	O
of	O
unknown	O
etiology	O
characterized	O
by	O
T	O
helper	O
1-type	O
inflammatory	O
responses	O
at	O
sites	O
of	O
disease	O
with	O
signs	O
of	O
B	O
cell	O
hyperactivity	O
.	O

Like	O
rheumatoid	O
arthritis	O
and	O
diabetes	O
,	O
an	O
infectious	O
etiology	O
has	O
frequently	O
been	O
postulated	O
but	O
no	O
single	O
infectious	O
trigger	O
definitively	O
identified	O
.	O

Polymorphic	O
alleles	O
at	O
SLC11A1	O
have	O
previously	O
been	O
associated	O
with	O
susceptibility	O
to	O
both	O
the	O
putative	O
infectious	O
agents	O
and	O
to	O
these	O
autoimmune	O
disorders	O
.	O

We	O
therefore	O
investigated	O
its	O
candidacy	O
as	O
a	O
genetic	O
determinant	O
of	O
SA	O
in	O
Poland	O
in	O
an	O
association-based	O
study	O
comparing	O
86	O
SA	O
patients	O
with	O
85	O
tuberculosis	O
(TB)	O
patients	O
and	O
93	O
control	O
subjects	O
.	O

The	O
functional	O
promoter	O
(GT)(n)	O
polymorphism	O
and	O
four	O
of	O
10	O
other	O
single	O
nucleotide	O
or	O
insertion/deletion	O
polymorphisms	O
genotyped	O
across	O
SLC11A1	O
were	O
informative	O
in	O
our	O
sample	O
.	O

Consistent	O
with	O
previous	O
autoimmune	O
disease	O
studies	O
,	O
allele	O
3	O
at	O
the	O
functional	O
(GT)(n)	O
promoter	O
region	O
repeat	O
polymorphism	O
was	O
significantly	O
associated	O
with	O
SA	O
when	O
compared	O
with	O
healthy	O
controls	O
(	O
odds	O
ratio	O
1.68	O
;	O
95%	O
CI	O
:	O
1.01-2.81	O
;	O
P=0.04	O
)	O
or	O
with	O
TB	O
patients	O
(	O
odds	O
ratio	O
1.69	O
;	O
95%	O
CI	O
:	O
1.042-0.78	O
;	O
P=0.03	O
)	O
.	O

Mutation	O
scanning	O
of	O
the	O
NF2	O
gene	O
:	O
an	O
improved	O
service	O
based	O
on	O
meta-PCR/sequencing	O
,	O
dosage	O
analysis	O
,	O
and	O
loss	O
of	O
heterozygosity	O
analysis	O
.	O

We	O
describe	O
the	O
development	O
and	O
implementation	O
of	O
a	O
neurofibromatosis	O
type	O
2	O
(NF2)	O
mutation	O
scanning	O
service	O
based	O
on	O
novel	O
techniques	O
.	O

All	O
17	O
exons	O
of	O
the	O
NF2	O
gene	O
are	O
amplified	O
in	O
four	O
polymerase	O
chain	O
reaction	O
(PCR)	O
reactions	O
,	O
using	O
the	O
meta-PCR	O
technique	O
to	O
link	O
the	O
NF2	O
exons	O
into	O
chimeric	O
concatamers	O
.	O

The	O
meta-PCR	O
products	O
are	O
then	O
scanned	O
for	O
point	O
mutations	O
by	O
direct	O
sequencing	O
.	O

A	O
four-exon	O
dosage	O
assay	O
is	O
used	O
to	O
test	O
for	O
large	O
deletion/duplication	O
mutations	O
.	O

In	O
certain	O
cases	O
when	O
tumour	O
studies	O
are	O
necessary	O
,	O
these	O
techniques	O
are	O
also	O
combined	O
with	O
loss	O
of	O
heterozygosity	O
analysis	O
with	O
three	O
highly	O
polymorphic	O
microsatellite	O
markers	O
located	O
within	O
or	O
close	O
to	O
the	O
NF2	O
gene	O
.	O

Over	O
a	O
period	O
of	O
2	O
years	O
,	O
we	O
have	O
applied	O
these	O
techniques	O
in	O
a	O
service	O
setting	O
to	O
the	O
analysis	O
of	O
271	O
patient	O
samples	O
(	O
245	O
lymphocyte	O
DNA	O
;	O
26	O
schwannoma	O
DNA	O
)	O
.	O

Meta-PCR	O
and	O
sequencing	O
identified	O
90	O
point	O
mutations	O
in	O
the	O
271	O
blood	O
and	O
tumor	O
samples	O
,	O
48	O
of	O
which	O
have	O
not	O
been	O
reported	O
previously	O
.	O

Dosage	O
analysis	O
identified	O
large	O
deletions	O
in	O
12	O
of	O
the	O
lymphocyte	O
DNA	O
samples	O
.	O

In	O
addition	O
,	O
over	O
84%	O
of	O
mutations	O
were	O
identified	O
in	O
23	O
schwannoma	O
DNA	O
samples	O
in	O
which	O
complete	O
analysis	O
was	O
possible	O
.	O

Adoption	O
of	O
this	O
novel	O
strategy	O
has	O
increased	O
the	O
overall	O
mutation	O
detection	O
rate	O
in	O
familial	O
NF2	O
cases	O
to	O
88%	O
and	O
sporadic	O
NF2	O
cases	O
to	O
59%	O
.	O

It	O
has	O
also	O
allowed	O
us	O
to	O
decrease	O
our	O
reporting	O
turnaround	O
times	O
,	O
and	O
because	O
of	O
a	O
low	O
overall	O
failure	O
rate	O
,	O
permitted	O
the	O
running	O
of	O
an	O
efficient	O
and	O
cost-effective	O
service	O
.	O

A	O
single	O
nucleotide	O
A>G	B-DNAMutation
polymorphism	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
-670	I-DNAMutation
in	O
the	O
Fas	O
gene	O
promoter	O
:	O
relationship	O
to	O
preterm	O
premature	O
rupture	O
of	O
fetal	O
membranes	O
in	O
multifetal	O
pregnancies	O
.	O

OBJECTIVE	O
:	O
The	O
relationship	O
between	O
a	O
polymorphism	O
at	O
position	O
-670	O
in	O
the	O
Fas	O
gene	O
(TNFRSF6)	O
and	O
preterm	O
premature	O
rupture	O
of	O
membranes	O
(PPROM)	O
in	O
multifetal	O
pregnancies	O
was	O
examined	O
.	O

METHODS	O
:	O
Buccal	O
swabs	O
from	O
119	O
mother-infant	O
sets	O
were	O
analyzed	O
for	O
an	O
adenine	O
(A)	O
to	O
guanine	O
(G)	O
substitution	O
at	O
position	O
-670	O
in	O
the	O
TNFRSF6	O
promoter	O
.	O

Pregnancy	O
outcome	O
data	O
were	O
subsequently	O
obtained	O
.	O

Analysis	O
was	O
by	O
Fisher	O
exact	O
test	O
.	O

RESULTS	O
:	O
Maternal	O
allele	O
G	O
homozygosity	O
(TNFRSF6*G)	O
was	O
observed	O
in	O
42.4%	O
of	O
33	O
PPROM	O
pregnancies	O
as	O
opposed	O
to	O
19.5%	O
of	O
77	O
with	O
no	O
spontaneous	O
preterm	O
birth	O
(	O
P	O
=	O
.01	O
)	O
.	O

Similarly	O
,	O
TNFRSF6*G	O
homozygosity	O
was	O
present	O
in	O
37.5%	O
of	O
32	O
first-born	O
neonates	O
from	O
PPROM	O
pregnancies	O
as	O
opposed	O
to	O
18.7%	O
of	O
75	O
uncomplicated	O
pregnancies	O
(	O
P	O
=	O
.04	O
)	O
.	O

PPROM	O
occurred	O
in	O
8	O
of	O
14	O
(57.1%)	O
pregnancies	O
in	O
which	O
mother	O
and	O
all	O
neonates	O
were	O
TNFRSF6*G	O
homozygotes	O
as	O
opposed	O
to	O
25	O
of	O
105	O
(23.8%)	O
cases	O
in	O
which	O
uniform	O
TNFRSF6*G	O
homozygosity	O
was	O
not	O
observed	O
(	O
P	O
=	O
.02	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
genetic	O
variant	O
in	O
the	O
Fas	O
gene	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
PPROM	O
in	O
multifetal	O
pregnancies	O
.	O

Common	O
BRCA2	O
variants	O
and	O
modification	O
of	O
breast	O
and	O
ovarian	O
cancer	O
risk	O
in	O
BRCA1	O
mutation	O
carriers	O
.	O

The	O
HH	O
genotype	O
of	O
the	O
nonconservative	O
amino	O
acid	O
substitution	O
polymorphism	O
N372H	B-ProteinMutation
in	O
the	O
BRCA2	O
gene	O
was	O
reported	O
to	O
be	O
associated	O
with	O
a	O
1.3-	O
to	O
1.5-fold	O
increase	O
in	O
risk	O
of	O
both	O
breast	O
and	O
ovarian	O
cancer	O
.	O

As	O
these	O
studies	O
concerned	O
sporadic	O
cancer	O
cases	O
,	O
we	O
investigated	O
whether	O
N372H	B-ProteinMutation
and	O
another	O
common	O
variant	O
located	O
in	O
the	O
5'-untranslated	O
region	O
(	O
203G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
of	O
the	O
BRCA2	O
gene	O
modify	O
breast	O
or	O
ovarian	O
cancer	O
risk	O
in	O
BRCA1	O
mutation	O
carriers	O
.	O

The	O
study	O
includes	O
778	O
women	O
carrying	O
a	O
BRCA1	O
germ-line	O
mutation	O
belonging	O
to	O
403	O
families	O
.	O

The	O
two	O
BRCA2	O
variants	O
were	O
analyzed	O
by	O
the	O
TaqMan	O
allelic	O
discrimination	O
technique	O
.	O

Genotypes	O
were	O
analyzed	O
by	O
disease-free	O
survival	O
analysis	O
using	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

We	O
found	O
no	O
evidence	O
of	O
a	O
significant	O
modification	O
of	O
breast	O
cancer	O
penetrance	O
in	O
BRCA1	O
mutation	O
carriers	O
by	O
either	O
polymorphism	O
.	O

In	O
respect	O
of	O
ovarian	O
cancer	O
risk	O
,	O
we	O
also	O
saw	O
no	O
effect	O
with	O
the	O
N372H	B-ProteinMutation
variant	O
but	O
we	O
did	O
observe	O
a	O
borderline	O
association	O
with	O
the	O
5'-untranslated	O
region	O
203A	O
allele	O
(	O
hazard	O
ratio	O
,	O
1.43	O
;	O
CI	O
,	O
1.01-2.00	O
)	O
.	O

In	O
contrast	O
to	O
the	O
result	O
of	O
Healey	O
et	O
al	O
.	O

on	O
newborn	O
females	O
and	O
adult	O
female	O
controls	O
,	O
we	O
found	O
no	O
departure	O
from	O
Hardy-Weinberg	O
equilibrium	O
in	O
the	O
distribution	O
of	O
N372H	B-ProteinMutation
alleles	O
for	O
our	O
female	O
BRCA1	O
carriers	O
.	O

We	O
conclude	O
that	O
if	O
these	O
single-nucleotide	O
polymorphisms	O
do	O
modify	O
the	O
risk	O
of	O
cancer	O
in	O
BRCA1	O
mutation	O
carriers	O
,	O
their	O
effects	O
are	O
not	O
significantly	O
larger	O
than	O
that	O
of	O
N372H	B-ProteinMutation
previously	O
observed	O
in	O
the	O
general	O
population	O
.	O

Severe	O
FVII	O
deficiency	O
caused	O
by	O
a	O
new	O
point	O
mutation	O
combined	O
with	O
a	O
previously	O
undetected	O
gene	O
deletion	O
.	O

A	O
3-week-old	O
Caucasian	O
female	O
presented	O
with	O
severe	O
unprovoked	O
parenchymal	O
cerebral	O
haemorrhage	O
.	O

Her	O
plasma	O
factor	O
VII	O
(FVII)	O
activity	O
was	O
<0.01	O
units/ml	O
.	O

FVII	O
activities	O
for	O
her	O
mother	O
and	O
sister	O
were	O
0.65	O
units/ml	O
and	O
0.51	O
units/ml	O
,	O
respectively	O
,	O
while	O
her	O
father's	O
level	O
was	O
normal	O
.	O

These	O
results	O
indicated	O
that	O
the	O
mother	O
was	O
heterozygous	O
for	O
a	O
non-functional	O
F7	O
gene	O
that	O
had	O
also	O
been	O
inherited	O
by	O
the	O
proband's	O
sister	O
.	O

The	O
proband's	O
severe	O
FVII	O
deficiency	O
was	O
caused	O
by	O
a	O
new	O
mutation	O
in	O
her	O
paternal	O
F7	O
gene	O
coupled	O
with	O
the	O
inheritance	O
of	O
the	O
non-functional	O
maternal	O
F7	O
gene	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
proband	O
had	O
apparent	O
homozygosity	O
for	O
a	O
novel	O
single	O
point	O
mutation	O
(	O
g.3907G	B-DNAMutation
>A	I-DNAMutation
)	O
changing	O
the	O
codon	O
for	O
Glu29	B-ProteinMutation
to	I-ProteinMutation
Lys	I-ProteinMutation
E29K	B-ProteinMutation
;	O
neither	O
parent	O
had	O
the	O
E29K	B-ProteinMutation
mutation	O
.	O

Because	O
of	O
the	O
unlikelihood	O
that	O
the	O
proband	O
was	O
homozygous	O
for	O
two	O
identical	O
new	O
point	O
mutations	O
,	O
the	O
DNA	O
sequence	O
abnormality	O
was	O
more	O
likely	O
to	O
have	O
arisen	O
from	O
a	O
single	O
mutated	O
gene	O
on	O
one	O
allele	O
and	O
a	O
F7	O
gene	O
deletion	O
on	O
the	O
other	O
allele	O
.	O

Real	O
time	O
polymerase	O
chain	O
reaction	O
(PCR)	O
analysis	O
confirmed	O
that	O
the	O
proband	O
had	O
inherited	O
a	O
gene	O
deletion	O
that	O
was	O
present	O
in	O
the	O
maternal	O
side	O
of	O
the	O
family	O
.	O

Subsequent	O
clotting	O
assays	O
and	O
real	O
time	O
PCR	O
revealed	O
that	O
the	O
maternal	O
deletion	O
also	O
included	O
the	O
closely	O
linked	O
F10	O
gene	O
.	O

Matrix	O
metalloproteinase	O
1	O
gene	O
polymorphism	O
as	O
a	O
prognostic	O
predictor	O
of	O
invasive	O
cervical	O
cancer	O
.	O

OBJECTIVES	O
:	O
Whereas	O
human	O
papillomavirus	O
(HPV)	O
infection	O
is	O
the	O
major	O
determinant	O
of	O
cervical	O
carcinogenesis	O
,	O
host	O
genetic	O
factors	O
may	O
confer	O
individual	O
susceptibility	O
and	O
prognosis	O
.	O

Matrix	O
metalloproteinase	O
1	O
(MMP-1)	O
is	O
an	O
important	O
modulator	O
of	O
carcinogenesis	O
.	O

A	O
guanine	O
insertion	O
(2G)	O
polymorphism	O
at	O
nucleotide	O
-1607	O
of	O
the	O
MMP-1	O
gene	O
promoter	O
creates	O
an	O
Ets-1-binding	O
site	O
,	O
which	O
increases	O
transcription	O
activity	O
.	O

The	O
present	O
study	O
investigates	O
the	O
association	O
between	O
MMP-1	O
polymorphism	O
and	O
cervical	O
neoplasia	O
,	O
and	O
their	O
prognostic	O
significance	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
the	O
MMP-1	O
polymorphism	O
was	O
assessed	O
in	O
135	O
high-grade	O
squamous	O
intraepithelial	O
lesions	O
(HSILs)	O
and	O
197	O
invasive	O
squamous	O
cell	O
carcinomas	O
(SCCs)	O
,	O
and	O
in	O
age-matched	O
controls	O
,	O
by	O
capillary	O
electrophoresis	O
.	O

The	O
association	O
of	O
clinicopathological	O
factors	O
and	O
HPV	O
status	O
with	O
MMP-1	O
genotypes	O
was	O
tested	O
.	O

RESULTS	O
:	O
Frequencies	O
of	O
the	O
2G	O
allele	O
in	O
HSIL	O
and	O
SCC	O
were	O
64%	O
and	O
65%	O
,	O
respectively	O
,	O
which	O
did	O
not	O
differ	O
significantly	O
from	O
control	O
values	O
(	O
66%	O
and	O
64%	O
,	O
respectively	O
)	O
.	O

The	O
2G	O
allele	O
was	O
associated	O
with	O
advanced	O
stages	O
of	O
disease	O
(	O
P	O
=	O
0.03	O
)	O
,	O
whereas	O
the	O
G	O
allele	O
was	O
more	O
common	O
in	O
patients	O
with	O
regional	O
lymph	O
node	O
metastases	O
(	O
P	O
=	O
0.02	O
)	O
.	O

The	O
survival	O
time	O
in	O
patients	O
with	O
the	O
heterozygous	O
genotype	O
G/2G	O
(	O
median	O
,	O
55.3	O
months	O
)	O
was	O
significantly	O
longer	O
than	O
those	O
with	O
either	O
the	O
G/G	O
(	O
50.3	O
months	O
)	O
or	O
2G/2G	O
genotype	O
(	O
43.9	O
months	O
)	O
(	O
P	O
=	O
0.02	O
)	O
.	O

No	O
significant	O
correlation	O
between	O
HPV	O
status	O
and	O
MMP-1	O
genotype	O
was	O
identified	O
.	O

CONCLUSIONS	O
:	O
The	O
genetic	O
polymorphisms	O
of	O
MMP-1	O
are	O
not	O
associated	O
with	O
the	O
risk	O
of	O
HSIL	O
and	O
SCC	O
,	O
but	O
with	O
the	O
invasiveness	O
and	O
prognosis	O
of	O
SCC	O
.	O

The	O
heterozygous	O
genotype	O
of	O
MMP-1	O
can	O
be	O
used	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
invasive	O
cervical	O
cancer	O
.	O

Polymorphic	O
changes	O
in	O
the	O
KAL1	O
gene	O
:	O
not	O
all	O
of	O
them	O
should	O
be	O
classified	O
as	O
polymorphisms	O
.	O

The	O
KAL1	O
gene	O
has	O
a	O
closely	O
related	O
nonfunctional	O
pseudogene	O
on	O
the	O
Y	O
chromosome	O
;	O
a	O
high	O
degree	O
of	O
X-Y	O
sequence	O
similarity	O
is	O
observed	O
.	O

Some	O
individuals	O
present	O
a	O
T	O
to	O
C	O
substitution	O
at	O
position	O
1833	O
(	O
exon	O
12	O
)	O
.	O

Because	O
this	O
nucleotide	O
differs	O
in	O
the	O
X	O
(thymine)	O
and	O
in	O
the	O
Y	O
(cytosine)	O
chromosome	O
,	O
we	O
investigated	O
if	O
this	O
was	O
truly	O
a	O
polymorphism	O
,	O
or	O
if	O
in	O
some	O
cases	O
the	O
Y	O
sequence	O
had	O
been	O
amplified	O
.	O

The	O
complete	O
sequence	O
of	O
exon	O
12	O
of	O
KAL1	O
was	O
analyzed	O
in	O
11	O
Kallmann	O
Syndrome	O
(KS)	O
males	O
,	O
in	O
50	O
normal	O
males	O
,	O
in	O
50	O
normal	O
females	O
,	O
and	O
in	O
16	O
patients	O
with	O
Ullrich-Turner	O
Syndrome	O
(UTS)	O
.	O

Nucleotide	O
1833	O
was	O
found	O
in	O
a	O
heterozygous	O
or	O
a	O
homozygous	O
state	O
in	O
KS	O
,	O
normal	O
males	O
and	O
normal	O
females	O
;	O
UTS	O
patients	O
were	O
always	O
homozygous	O
.	O

Of	O
the	O
61	O
males	O
,	O
17	O
were	O
heterozygous	O
,	O
while	O
11	O
were	O
TT	O
and	O
33	O
were	O
CC	O
.	O

With	O
these	O
observations	O
we	O
can	O
not	O
assure	O
whether	O
these	O
patients	O
present	O
a	O
"real"	O
polymorphism	O
.	O

Besides	O
,	O
all	O
males	O
were	O
heterozygous	O
in	O
nucleotides	O
1678	O
,	O
1694	O
,	O
1699	O
,	O
1708	O
and	O
1825	O
,	O
whilst	O
females	O
were	O
homozygous	O
;	O
and	O
in	O
these	O
positions	O
,	O
KAL1	O
also	O
differs	O
from	O
its	O
pseudogene	O
.	O

These	O
results	O
indicate	O
that	O
we	O
are	O
identifying	O
the	O
X	O
and	O
the	O
Y	O
nucleotide	O
and	O
these	O
variants	O
are	O
not	O
polymorphisms	O
.	O

Sequence	O
variations	O
may	O
be	O
pseudogene	O
products	O
rather	O
than	O
true	O
polymorphisms	O
,	O
so	O
we	O
should	O
always	O
determine	O
if	O
the	O
position	O
where	O
the	O
variation	O
is	O
located	O
differs	O
between	O
KAL1	O
and	O
its	O
pseudogene	O
,	O
because	O
it	O
has	O
been	O
suggested	O
that	O
the	O
presence	O
of	O
various	O
polymorphisms	O
in	O
affected	O
individuals	O
could	O
be	O
the	O
cause	O
of	O
KS	O
.	O

Treatment	O
of	O
MDS	O
patients	O
with	O
recombinant	O
human	O
erythropoietin	O
and	O
the	O
role	O
of	O
GSTs	O
.	O

Glutathione	O
S-transferases	O
(GSTs)	O
are	O
a	O
group	O
of	O
enzymes	O
involved	O
in	O
the	O
detoxification	O
process	O
of	O
carcinogens	O
and	O
other	O
substances	O
.	O

The	O
genes	O
encoding	O
isoenzymes	O
M1	O
and	O
T1	O
have	O
"null"	O
alleles	O
,	O
which	O
are	O
polymorphic	O
in	O
humans	O
.	O

Our	O
purpose	O
was	O
to	O
examine	O
whether	O
the	O
GSTM1	O
and	O
GSTT1	O
homozygous	O
null	O
genotypes	O
have	O
an	O
impact	O
on	O
the	O
response	O
to	O
recombinant	O
human	O
erythropoietin	O
(rhuEpo)	O
treatment	O
in	O
MDS	O
patients	O
.	O

We	O
analyzed	O
lymphocyte	O
DNA	O
samples	O
from	O
27	O
patients	O
with	O
all	O
types	O
of	O
myelodysplastic	O
syndromes	O
(MDS)	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

All	O
patients	O
were	O
scheduled	O
to	O
receive	O
rHuEpo	O
in	O
doses	O
of	O
150	O
u/Kg/day	O
for	O
a	O
period	O
of	O
12	O
weeks	O
in	O
order	O
to	O
obtain	O
and	O
maintain	O
stable	O
responses	O
.	O

A	O
multiplex	O
polymerase	O
chain	O
reaction	O
(PCR)	O
was	O
used	O
to	O
genotype	O
both	O
GSTM1	O
and	O
GSTT1	O
simultaneously	O
,	O
in	O
responders	O
and	O
non-responders	O
to	O
rhuEpo	O
with	O
respect	O
to	O
various	O
pretreatment	O
parameters	O
:	O
haemoglobin	O
,	O
white	O
blood	O
cell	O
count	O
,	O
platelets	O
,	O
serum	O
erythropoietin	O
,	O
transfusion	O
requirements	O
and	O
bone	O
marrow	O
blasts	O
.	O

The	O
data	O
obtained	O
were	O
evaluated	O
by	O
chi2	O
test	O
and	O
odds	O
ratio	O
were	O
extracted	O
.	O

Twelve	O
out	O
of	O
27	O
evaluated	O
patients	O
demonstrated	O
an	O
erythroid	O
response	O
(44%)	O
.	O

Nine	O
out	O
of	O
the	O
12	O
patients	O
(75%)	O
responding	O
after	O
12	O
weeks	O
of	O
treatment	O
had	O
GSTM1	O
null	O
genotype	O
(OR=3.4)	O
.	O

In	O
contrast	O
,	O
only	O
1	O
responder	O
(8.3%)	O
was	O
homozygotes	O
of	O
GSTT1	O
null	O
genotype	O
.	O

Furthermore	O
,	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
response	O
rate	O
of	O
the	O
different	O
MDS	O
subgroups	O
was	O
observed	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
treatment	O
with	O
rHuEpo	O
may	O
be	O
effective	O
in	O
achieving	O
a	O
stable	O
erythroid	O
response	O
in	O
MDS	O
patients	O
who	O
carry	O
an	O
homozygous	O
deletion	O
of	O
the	O
GSTM1	O
gene	O
.	O

Sequence	O
variant	O
in	O
the	O
intron	O
10	O
of	O
the	O
RET	O
oncogene	O
in	O
a	O
patient	O
with	O
microfollicular	O
thyroid	O
carcinoma	O
with	O
medullar	O
differentiation	O
:	O
implications	O
for	O
newly	O
generated	O
chi-like	O
sequence	O
.	O

Sequence	O
alterations	O
in	O
the	O
RET	O
proto-oncogene	O
are	O
becoming	O
increasingly	O
important	O
to	O
clinical	O
assessment	O
of	O
the	O
malignant	O
disease	O
of	O
the	O
thyroid	O
.	O

A	O
spectrum	O
of	O
mutations	O
is	O
necessary	O
to	O
establish	O
comprehensive	O
phenotype	O
to	O
genotype	O
relationship	O
relevant	O
to	O
diagnosis	O
and	O
therapy	O
of	O
thyroid	O
malignancies	O
.	O

We	O
aimed	O
to	O
append	O
to	O
the	O
increasing	O
database	O
of	O
these	O
oncogenic	O
lesions	O
and	O
,	O
therefore	O
,	O
analyzed	O
DNA	O
from	O
tumor	O
tissue	O
and	O
constitutive	O
DNA	O
from	O
a	O
patient	O
with	O
thyroid	O
carcinoma	O
.	O

Mutational	O
screening	O
and	O
sequence	O
characterization	O
of	O
the	O
RET	O
proto-oncogene	O
was	O
performed	O
to	O
include	O
part	O
of	O
the	O
intronic	O
sequences	O
.	O

We	O
report	O
a	O
germline	O
sequence	O
variant	O
in	O
DNA	O
from	O
the	O
patient	O
diagnosed	O
with	O
microfollicular	O
thyroid	O
carcinoma	O
.	O

The	O
carcinoma	O
presented	O
not	O
as	O
fully	O
developed	O
medullar	O
carcinoma	O
(MTC)	O
but	O
as	O
microfollicular	O
carcinoma	O
with	O
tendency	O
to	O
evolve	O
into	O
MTC	O
.	O

We	O
characterized	O
the	O
sequence	O
variant	O
located	O
in	O
the	O
intron	O
10	O
of	O
the	O
RET	O
oncogene	O
as	O
an	O
A	O
to	O
G	O
substitution	O
denoted	O
IVS10	B-DNAMutation
+	I-DNAMutation
4G	I-DNAMutation
.	O

The	O
described	O
sequence	O
alteration	O
generates	O
a	O
chi-like	O
sequence	O
surrounded	O
by	O
several	O
chi-like	O
sequences	O
with	O
recombinational	O
potential	O
.	O

Such	O
alteration	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
microfollicular	O
carcinoma	O
via	O
genome	O
destabilization	O
through	O
homologous	O
recombination	O
in	O
the	O
process	O
of	O
tumor	O
progression	O
.	O

This	O
result	O
further	O
substantiates	O
the	O
importance	O
of	O
the	O
database	O
correlating	O
specific	O
sequence	O
variations	O
in	O
the	O
RET	O
gene	O
with	O
distinct	O
disease	O
phenotypes	O
.	O

High-resolution	O
gene	O
copy	O
number	O
and	O
expression	O
profiling	O
of	O
human	O
chromosome	O
22	O
in	O
ovarian	O
carcinomas	O
.	O

Previous	O
low-resolution	O
studies	O
of	O
chromosome	O
22	O
in	O
ovarian	O
carcinoma	O
have	O
suggested	O
its	O
involvement	O
in	O
the	O
development	O
of	O
the	O
disease	O
.	O

We	O
report	O
a	O
high-resolution	O
analysis	O
of	O
DNA	O
copy	O
number	O
and	O
gene	O
expression	O
of	O
22q	O
in	O
18	O
ovarian	O
carcinomas	O
using	O
a	O
22q-specific	O
genomic	O
microarray	O
.	O

We	O
identified	O
aberrations	O
in	O
67%	O
of	O
the	O
studied	O
tumors	O
,	O
which	O
displayed	O
3	O
distinct	O
gene	O
copy	O
number	O
profiles	O
.	O

The	O
majority	O
of	O
the	O
cases	O
(	O
11	O
of	O
18	O
)	O
demonstrated	O
heterozygous	O
terminal	O
deletions	O
of	O
various	O
sizes	O
,	O
the	O
smallest	O
of	O
which	O
was	O
3.5	O
Mb	O
.	O

The	O
second	O
profile	O
,	O
detected	O
in	O
3	O
tumors	O
,	O
revealed	O
the	O
coexistence	O
of	O
heterozygous	O
deletions	O
and	O
different	O
patterns	O
of	O
low-copy-number	O
gain	O
that	O
involved	O
the	O
proximal	O
half	O
of	O
22q	O
.	O

The	O
latter	O
finding	O
has	O
not	O
been	O
reported	O
previously	O
in	O
ovarian	O
carcinoma	O
.	O

One	O
case	O
displayed	O
a	O
continuous	O
deletion	O
encompassing	O
the	O
entire	O
22q	O
,	O
consistent	O
with	O
monosomy	O
22	O
.	O

Furthermore	O
,	O
we	O
compared	O
the	O
results	O
with	O
the	O
available	O
data	O
on	O
these	O
tumors	O
by	O
using	O
cDNA	O
microarrays	O
to	O
define	O
the	O
degree	O
of	O
correlation	O
between	O
abnormalities	O
at	O
the	O
DNA	O
level	O
and	O
variation	O
in	O
mRNA	O
expression	O
.	O

By	O
a	O
comparison	O
with	O
the	O
expression	O
data	O
,	O
we	O
were	O
able	O
to	O
identify	O
21	O
deleted	O
genes	O
showing	O
low	O
mRNA	O
levels	O
and	O
12	O
amplified	O
genes	O
displaying	O
elevated	O
gene	O
expression	O
,	O
several	O
of	O
which	O
play	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
the	O
induction	O
of	O
apoptosis	O
.	O

Our	O
results	O
indicated	O
significant	O
correlation	O
between	O
DNA	O
copy	O
number	O
aberrations	O
and	O
variation	O
in	O
mRNA	O
expression	O
.	O

We	O
also	O
identified	O
several	O
regions	O
and	O
candidate	O
genes	O
on	O
22q	O
that	O
should	O
be	O
studied	O
further	O
to	O
determine	O
their	O
role	O
in	O
the	O
development	O
of	O
ovarian	O
cancer	O
.	O

A	O
novel	O
SCN5A	O
mutation	O
manifests	O
as	O
a	O
malignant	O
form	O
of	O
long	O
QT	O
syndrome	O
with	O
perinatal	O
onset	O
of	O
tachycardia/bradycardia	O
.	O

OBJECTIVE	O
:	O
Congenital	O
long	O
QT	O
syndrome	O
(LQTS)	O
with	O
in	O
utero	O
onset	O
of	O
the	O
rhythm	O
disturbances	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

In	O
this	O
study	O
we	O
investigated	O
a	O
newborn	O
patient	O
with	O
fetal	O
bradycardia	O
,	O
2:1	O
atrioventricular	O
block	O
and	O
ventricular	O
tachycardia	O
soon	O
after	O
birth	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
and	O
DNA	O
sequencing	O
were	O
conducted	O
in	O
a	O
newborn	O
.	O

The	O
2:1	O
atrioventricular	O
block	O
improved	O
to	O
1:1	O
conduction	O
only	O
after	O
intravenous	O
lidocaine	O
infusion	O
or	O
a	O
high	O
dose	O
of	O
mexiletine	O
,	O
which	O
also	O
controlled	O
the	O
ventricular	O
tachycardia	O
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
spontaneous	O
LQTS-3	O
mutation	O
was	O
identified	O
in	O
the	O
transmembrane	O
segment	O
6	O
of	O
domain	O
IV	O
of	O
the	O
Na(v)1.5	O
cardiac	O
sodium	O
channel	O
,	O
with	O
a	O
G-->A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
1763	I-DNAMutation
,	O
which	O
changed	O
a	O
valine	O
(GTG)	O
to	O
a	O
methionine	O
(ATG)	O
.	O

The	O
proband	O
was	O
heterozygous	O
but	O
the	O
mutation	O
was	O
absent	O
in	O
the	O
parents	O
and	O
the	O
sister	O
.	O

Expression	O
of	O
this	O
mutant	O
channel	O
in	O
tsA201	O
mammalian	O
cells	O
by	O
site-directed	O
mutagenesis	O
revealed	O
a	O
persistent	O
tetrodotoxin-sensitive	O
but	O
lidocaine-resistant	O
current	O
that	O
was	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
the	O
steady-state	O
inactivation	O
curve	O
,	O
steeper	O
activation	O
curve	O
and	O
faster	O
recovery	O
from	O
inactivation	O
.	O

We	O
also	O
found	O
a	O
similar	O
electrophysiological	O
profile	O
for	O
the	O
neighboring	O
V1764M	B-ProteinMutation
mutant	O
.	O

But	O
,	O
the	O
other	O
neighboring	O
I1762A	B-ProteinMutation
mutant	O
had	O
no	O
persistent	O
current	O
and	O
was	O
still	O
associated	O
with	O
a	O
positive	O
shift	O
of	O
inactivation	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
Na(v)1.5	O
/	O
V1763M	B-ProteinMutation
channel	O
dysfunction	O
and	O
possible	O
neighboring	O
mutants	O
contribute	O
to	O
a	O
persistent	O
inward	O
current	O
due	O
to	O
altered	O
inactivation	O
kinetics	O
and	O
clinically	O
congenital	O
LQTS	O
with	O
perinatal	O
onset	O
of	O
arrhythmias	O
that	O
responded	O
to	O
lidocaine	O
and	O
mexiletine	O
.	O

Influence	O
of	O
interleukin	O
12B	O
(IL12B)	O
polymorphisms	O
on	O
spontaneous	O
and	O
treatment-induced	O
recovery	O
from	O
hepatitis	O
C	O
virus	O
infection	O
.	O

BACKGROUND/AIMS	O
:	O
Interleukin-12	O
(IL-12)	O
governs	O
the	O
Th1-type	O
immune	O
response	O
,	O
affecting	O
the	O
spontaneous	O
and	O
treatment-induced	O
recovery	O
from	O
HCV-infection	O
.	O

We	O
investigated	O
whether	O
the	O
IL12B	O
polymorphisms	O
within	O
the	O
promoter	O
region	O
(	O
4	O
bp	O
insertion/deletion	O
)	O
and	O
the	O
3'-UTR	O
1188-A/C	B-DNAMutation
,	O
which	O
have	O
been	O
reported	O
to	O
influence	O
IL-12	O
synthesis	O
,	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
HCV	O
infection	O
.	O

METHODS	O
:	O
We	O
analyzed	O
186	O
individuals	O
with	O
spontaneous	O
HCV	O
clearance	O
,	O
501	O
chronically	O
HCV	O
infected	O
patients	O
,	O
and	O
217	O
healthy	O
controls	O
.	O

IL12B	O
3'-UTR	O
and	O
promoter	O
genotyping	O
was	O
performed	O
by	O
Taqman-based	O
assays	O
with	O
allele-specific	O
oligonucleotide	O
probes	O
and	O
PCR-based	O
allele-specific	O
DNA-amplification	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
proportion	O
of	O
IL12B	O
promoter	O
and	O
3'-UTR	O
genotypes	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
different	O
cohorts	O
.	O

However	O
,	O
HCV	O
genotype	O
1-infected	O
patients	O
with	O
high	O
baseline	O
viremia	O
carrying	O
the	O
IL12B	O
3'-UTR	O
1188-C-allele	O
showed	O
significantly	O
higher	O
sustained	O
virologic	O
response	O
(SVR)	O
rates	O
(	O
25.3%	O
vs	O
.	O

46%	O
vs	O
.	O

54.5%	O
for	O
A/A	O
,	O
A/C	O
and	O
C/C	O
)	O
due	O
to	O
reduced	O
relapse	O
rates	O
(	O
24.2%	O
vs	O
.	O

12%	O
vs	O
.	O

zero	O
%	O
for	O
A/A	O
,	O
A/C	O
and	O
C/C	O
)	O
.	O

CONCLUSIONS	O
:	O
IL12B	O
3'-UTR	O
1188-C-allele	O
carriers	O
appear	O
to	O
be	O
capable	O
of	O
responding	O
more	O
efficiently	O
to	O
antiviral	O
combination	O
therapy	O
as	O
a	O
consequence	O
of	O
a	O
reduced	O
relapse	O
rate	O
.	O

No	O
association	O
of	O
IL12B	O
polymorphisms	O
and	O
self-limited	O
HCV	O
infection	O
could	O
be	O
demonstrated	O
.	O

Vaccine	O
candidates	O
derived	O
from	O
a	O
novel	O
infectious	O
cDNA	O
clone	O
of	O
an	O
American	O
genotype	O
dengue	O
virus	O
type	O
2	O
.	O

BACKGROUND	O
:	O
A	O
dengue	O
virus	O
type	O
2	O
(	O
DEN-2	O
Tonga/74	O
)	O
isolated	O
from	O
a	O
1974	O
epidemic	O
was	O
characterized	O
by	O
mild	O
illness	O
and	O
belongs	O
to	O
the	O
American	O
genotype	O
of	O
DEN-2	O
viruses	O
.	O

To	O
prepare	O
a	O
vaccine	O
candidate	O
,	O
a	O
previously	O
described	O
30	O
nucleotide	O
deletion	O
Delta30	B-DNAMutation
in	O
the	O
3'	O
untranslated	O
region	O
of	O
DEN-4	O
has	O
been	O
engineered	O
into	O
the	O
DEN-2	O
isolate	O
.	O

METHODS	O
:	O
A	O
full-length	O
cDNA	O
clone	O
was	O
generated	O
from	O
the	O
DEN-2	O
virus	O
and	O
used	O
to	O
produce	O
recombinant	O
DEN-2	O
(rDEN-2)	O
and	O
rDEN2	O
Delta30	B-DNAMutation
.	O

Viruses	O
were	O
evaluated	O
for	O
replication	O
in	O
SCID	O
mice	O
transplanted	O
with	O
human	O
hepatoma	O
cells	O
(	O
SCID-HuH-7	O
mice	O
)	O
,	O
in	O
mosquitoes	O
,	O
and	O
in	O
rhesus	O
monkeys	O
.	O

Neutralizing	O
antibody	O
induction	O
and	O
protective	O
efficacy	O
were	O
also	O
assessed	O
in	O
rhesus	O
monkeys	O
.	O

RESULTS	O
:	O
The	O
rDEN2	O
Delta30	B-DNAMutation
virus	O
was	O
ten-fold	O
reduced	O
in	O
replication	O
in	O
SCID-HuH-7	O
mice	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
.	O

The	O
rDEN-2	O
viruses	O
were	O
not	O
infectious	O
for	O
Aedes	O
mosquitoes	O
,	O
but	O
both	O
readily	O
infected	O
Toxorynchites	O
mosquitoes	O
.	O

In	O
rhesus	O
monkeys	O
,	O
rDEN2	O
Delta30	B-DNAMutation
appeared	O
to	O
be	O
slightly	O
attenuated	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
as	O
measured	O
by	O
duration	O
and	O
peak	O
of	O
viremia	O
and	O
neutralizing	O
antibody	O
induction	O
.	O

A	O
derivative	O
of	O
rDEN2	O
Delta30	B-DNAMutation
,	O
designated	O
rDEN2	O
Delta30	B-DNAMutation
-4995	O
,	O
was	O
generated	O
by	O
incorporation	O
of	O
a	O
point	O
mutation	O
previously	O
identified	O
in	O
the	O
NS3	O
gene	O
of	O
DEN-4	O
and	O
was	O
found	O
to	O
be	O
more	O
attenuated	O
than	O
rDEN2	O
Delta30	B-DNAMutation
in	O
SCID-HuH-7	O
mice	O
.	O

CONCLUSIONS	O
:	O
The	O
rDEN2	O
Delta30	B-DNAMutation
and	O
rDEN2	O
Delta30	B-DNAMutation
-4995	O
viruses	O
can	O
be	O
considered	O
for	O
evaluation	O
in	O
humans	O
and	O
for	O
inclusion	O
in	O
a	O
tetravalent	O
dengue	O
vaccine	O
.	O

Breast	O
cancer	O
risk	O
associated	O
with	O
genotype	O
polymorphism	O
of	O
the	O
catechol	O
estrogen-metabolizing	O
genes	O
:	O
a	O
multigenic	O
study	O
on	O
cancer	O
susceptibility	O
.	O

Estrogen	O
has	O
been	O
suggested	O
to	O
trigger	O
breast	O
cancer	O
development	O
via	O
an	O
initiating	O
mechanism	O
involving	O
its	O
metabolite	O
,	O
catechol	O
estrogen	O
(CE)	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
carried	O
out	O
a	O
multigenic	O
case-control	O
study	O
of	O
469	O
incident	O
breast	O
cancer	O
patients	O
and	O
740	O
healthy	O
controls	O
to	O
define	O
the	O
role	O
of	O
important	O
genes	O
involved	O
in	O
the	O
different	O
metabolic	O
steps	O
that	O
protect	O
against	O
the	O
potentially	O
harmful	O
effects	O
of	O
CE	O
metabolism	O
.	O

We	O
studied	O
the	O
3	O
genes	O
involved	O
in	O
CE	O
detoxification	O
by	O
conjugation	O
reactions	O
involving	O
methylation	O
(	O
catechol-O-methyltransferase	O
,	O
COMT	O
)	O
,	O
sulfation	O
(	O
sulfotransferase	O
1A1	O
,	O
SULT1A1	O
)	O
,	O
or	O
glucuronidation	O
(	O
UDP-glucuronosyltransferase	O
1A1	O
,	O
UGT1A1	O
)	O
,	O
one	O
(	O
manganese	O
superoxide	O
dismutase	O
,	O
MnSOD	O
)	O
involved	O
in	O
protection	O
against	O
reactive	O
oxidative	O
species-mediated	O
oxidation	O
during	O
the	O
conversion	O
of	O
CE-semiquinone	O
(CE-SQ)	O
to	O
CE-quinone	O
(CE-Q)	O
,	O
and	O
2	O
of	O
the	O
glutathione	O
S-transferase	O
superfamily	O
,	O
GSTM1	O
and	O
GSTT1	O
,	O
involved	O
in	O
CE-Q	O
metabolism	O
.	O

Support	O
for	O
this	O
hypothesis	O
came	O
from	O
the	O
observations	O
that	O
(i)	O
there	O
was	O
a	O
trend	O
toward	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
in	O
women	O
harboring	O
a	O
greater	O
number	O
of	O
putative	O
high-risk	O
genotypes	O
of	O
these	O
genes	O
(	O
p	O
<	O
0.05	O
)	O
;	O
(ii)	O
this	O
association	O
was	O
stronger	O
and	O
more	O
significant	O
in	O
those	O
women	O
who	O
were	O
more	O
susceptible	O
to	O
estrogen	O
[	O
no	O
history	O
of	O
pregnancy	O
or	O
older	O
(	O
>	O
or	O
=26	O
years	O
)	O
at	O
first	O
full-term	O
pregnancy	O
(	O
FFTP	O
)	O
]	O
;	O
and	O
(iii)	O
the	O
risks	O
associated	O
with	O
having	O
one	O
or	O
more	O
high-risk	O
genotypes	O
were	O
not	O
the	O
same	O
in	O
women	O
having	O
experienced	O
different	O
menarche-to-FFTP	O
intervals	O
,	O
being	O
more	O
significant	O
in	O
women	O
having	O
been	O
exposed	O
to	O
estrogen	O
for	O
a	O
longer	O
period	O
(	O
>	O
or	O
=12	O
years	O
)	O
before	O
FFTP	O
.	O

Furthermore	O
,	O
because	O
CE-Q	O
can	O
attack	O
DNA	O
,	O
leading	O
to	O
the	O
formation	O
of	O
double-strand	O
breaks	O
(DSB)	O
,	O
we	O
examined	O
whether	O
the	O
relationship	O
between	O
cancer	O
risk	O
and	O
the	O
genotypic	O
polymorphism	O
of	O
CE-metabolizing	O
genes	O
was	O
modified	O
by	O
the	O
genotypes	O
of	O
DSB	O
repair	O
genes	O
,	O
and	O
found	O
that	O
a	O
joint	O
effect	O
of	O
CE-metabolizing	O
genes	O
and	O
one	O
of	O
the	O
two	O
DSB	O
repair	O
pathways	O
,	O
the	O
homologous	O
recombination	O
pathway	O
,	O
was	O
significantly	O
associated	O
with	O
breast	O
cancer	O
development	O
.	O

Based	O
on	O
comprehensive	O
CE	O
metabolizing	O
gene	O
profiles	O
,	O
our	O
study	O
provides	O
support	O
to	O
the	O
hypotheses	O
that	O
breast	O
cancer	O
can	O
be	O
initiated	O
by	O
estrogen	O
exposure	O
and	O
that	O
increased	O
estrogen	O
exposure	O
confers	O
a	O
higher	O
risk	O
of	O
breast	O
cancer	O
by	O
causing	O
DSB	O
to	O
DNA	O
.	O

Genetic	O
polymorphisms	O
of	O
bilirubin	O
uridine	O
diphosphate-glucuronosyltransferase	O
gene	O
in	O
Japanese	O
patients	O
with	O
Crigler-Najjar	O
syndrome	O
or	O
Gilbert's	O
syndrome	O
as	O
well	O
as	O
in	O
healthy	O
Japanese	O
subjects	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Numerous	O
mutations	O
of	O
bilirubin	O
uridine	O
diphosphate-glucuronosyltransferase	O
gene	O
(UGT1A1)	O
have	O
been	O
reported	O
in	O
patients	O
with	O
familial	O
unconjugated	O
hyperbilirubinemia	O
.	O

The	O
UGT1A1	O
mutation	O
appears	O
to	O
be	O
considerably	O
different	O
among	O
ethnic	O
groups	O
.	O

To	O
clarify	O
the	O
incidence	O
of	O
this	O
gene	O
mutation	O
in	O
the	O
Japanese	O
population	O
,	O
the	O
presence	O
of	O
UGT1A1	O
mutation	O
was	O
investigated	O
in	O
a	O
group	O
of	O
Japanese	O
patients	O
with	O
Crigler-Najjar	O
syndrome	O
type	O
2	O
(CNS2)	O
and	O
Gilbert's	O
syndrome	O
(GS)	O
,	O
as	O
well	O
as	O
in	O
healthy	O
anicteric	O
subjects	O
.	O

METHODS	O
:	O
Four	O
patients	O
with	O
CNS2	O
,	O
63	O
patients	O
with	O
GS	O
,	O
and	O
71	O
healthy	O
subjects	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
promoter	O
and	O
coding	O
regions	O
of	O
UGT1A1	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
from	O
genomic	O
DNA	O
isolated	O
from	O
leukocytes	O
.	O

The	O
PCR	O
products	O
were	O
directly	O
sequenced	O
by	O
a	O
dye	O
terminating	O
method	O
.	O

The	O
UGT1A1	O
enzyme	O
activity	O
was	O
determined	O
in	O
COS7	O
cells	O
transfected	O
with	O
wild	O
or	O
P364L	B-ProteinMutation
(	O
1091	B-DNAMutation
C	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
)	O
mutant	O
DNA	O
.	O

RESULTS	O
:	O
Homozygous	O
Y486D	B-ProteinMutation
was	O
observed	O
in	O
all	O
four	O
patients	O
with	O
CNS2	O
.	O

The	O
GS	O
patients	O
had	O
UGT1A1	O
mutations	O
with	O
13	O
different	O
genotypes	O
in	O
the	O
promoter	O
and	O
coding	O
region	O
.	O

Homozygous	O
TA	O
insertion	O
in	O
the	O
TATA	O
box	O
(TA7)	O
of	O
the	O
promoter	O
region	O
(	O
TA7/7	O
;	O
33%	O
)	O
,	O
homozygous	O
G71R	B-ProteinMutation
(9%)	O
,	O
and	O
combination	O
of	O
TA7/6	O
and	O
heterozygous	O
G71R	B-ProteinMutation
(17%)	O
were	O
the	O
most	O
frequent	O
findings	O
in	O
GS	O
patients	O
.	O

Homozygous	O
or	O
heterozygous	O
Y486D	B-ProteinMutation
(8%)	O
and	O
P229Q	B-ProteinMutation
(8%)	O
were	O
also	O
observed	O
in	O
GS	O
.	O

A	O
novel	O
mutation	O
,	O
heterozygous	O
P364L	B-ProteinMutation
,	O
was	O
also	O
identified	O
in	O
a	O
GS	O
patient	O
.	O

In	O
addition	O
to	O
GS	O
patients	O
,	O
homozygous	O
or	O
heterozygous	O
TA7	O
,	O
G71R	B-ProteinMutation
,	O
and	O
heterozygous	O
Y486D	B-ProteinMutation
were	O
also	O
observed	O
in	O
healthy	O
subjects	O
.	O

The	O
allele	O
frequency	O
of	O
G71R	B-ProteinMutation
and	O
TA7	O
was	O
0.183	O
and	O
0.113	O
in	O
healthy	O
subjects	O
,	O
respectively	O
.	O

The	O
P364L	B-ProteinMutation
UGT1A1	O
enzyme	O
activity	O
was	O
64.4%	O
lower	O
than	O
the	O
wild-type	O
enzyme	O
activity	O
.	O

CONCLUSIONS	O
:	O
Polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
UGT1A1	O
were	O
commonly	O
observed	O
in	O
Japanese	O
patients	O
with	O
GS	O
and	O
in	O
healthy	O
subjects	O
.	O

The	O
genetic	O
basis	O
of	O
hyperbilirubinemia	O
appears	O
to	O
be	O
different	O
between	O
the	O
Japanese	O
and	O
Caucasian	O
populations	O
.	O

De	O
novo	O
germline	O
mutation	O
in	O
the	O
serine-threonine	O
kinase	O
STK11/LKB1	O
gene	O
associated	O
with	O
Peutz-Jeghers	O
syndrome	O
.	O

Peutz-Jeghers	O
syndrome	O
(PJS)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
,	O
characterized	O
phenotypically	O
by	O
mucocutaneous	O
pigmentation	O
and	O
hamartomatous	O
polyposis	O
.	O

Affected	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
developing	O
gastrointestinal	O
and	O
other	O
malignancies	O
.	O

Mutations	O
in	O
the	O
STK11/LKB1	O
(LKB1)	O
gene	O
,	O
which	O
encodes	O
for	O
a	O
serine-threonine	O
kinase	O
,	O
have	O
been	O
identified	O
as	O
a	O
genetic	O
cause	O
of	O
PJS	O
.	O

Molecular	O
analysis	O
of	O
the	O
LKB1	O
gene	O
in	O
a	O
simplex	O
case	O
of	O
PJS	O
revealed	O
a	O
substitution	O
of	O
cytosine	O
(C)	O
for	O
guanine	O
(G)	O
at	O
codon	O
246	O
in	O
exon	O
6	O
,	O
resulting	O
in	O
the	O
Tyr246X	B-ProteinMutation
mutation	O
.	O

The	O
nucleotide	O
substitution	O
leads	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
the	O
246	O
residue	O
,	O
predicting	O
a	O
truncated	O
protein	O
and	O
presumed	O
loss	O
of	O
kinase	O
activity	O
.	O

Analysis	O
of	O
DNA	O
from	O
both	O
parents	O
of	O
the	O
PJS	O
patient	O
did	O
not	O
show	O
this	O
mutation	O
,	O
which	O
is	O
therefore	O
a	O
de	O
novo	O
mutation	O
.	O

We	O
isolated	O
DNA	O
from	O
microdissected	O
gastrointestinal	O
hamartomatous	O
polyps	O
in	O
the	O
PJS	O
patient	O
and	O
investigated	O
the	O
loss	O
of	O
heterozygosity	O
(LOH)	O
at	O
the	O
LKB1	O
locus	O
by	O
real-time	O
fluorescence	O
polymerase	O
chain	O
reaction	O
genotyping	O
using	O
a	O
fluorescent	O
resonance	O
energy	O
transfer	O
technique	O
.	O

The	O
results	O
suggest	O
a	O
different	O
mechanism	O
from	O
LOH	O
in	O
the	O
formation	O
of	O
hamartomatous	O
polyps	O
.	O

Quantitative	O
PCR	O
analysis	O
reveals	O
a	O
high	O
incidence	O
of	O
large	O
intragenic	O
deletions	O
in	O
the	O
FANCA	O
gene	O
in	O
Spanish	O
Fanconi	O
anemia	O
patients	O
.	O

Fanconi	O
anaemia	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
chromosome	O
fragility	O
,	O
multiple	O
congenital	O
abnormalities	O
,	O
progressive	O
bone	O
marrow	O
failure	O
and	O
a	O
high	O
predisposition	O
to	O
develop	O
malignancies	O
.	O

Most	O
of	O
the	O
Fanconi	O
anaemia	O
patients	O
belong	O
to	O
complementation	O
group	O
FA-A	O
due	O
to	O
mutations	O
in	O
the	O
FANCA	O
gene	O
.	O

This	O
gene	O
contains	O
43	O
exons	O
along	O
a	O
4.3-kb	O
coding	O
sequence	O
with	O
a	O
very	O
heterogeneous	O
mutational	O
spectrum	O
that	O
makes	O
the	O
mutation	O
screening	O
of	O
FANCA	O
a	O
difficult	O
task	O
.	O

In	O
addition	O
,	O
as	O
the	O
FANCA	O
gene	O
is	O
rich	O
in	O
Alu	O
sequences	O
,	O
it	O
was	O
reported	O
that	O
Alu-mediated	O
recombination	O
led	O
to	O
large	O
intragenic	O
deletions	O
that	O
cannot	O
be	O
detected	O
in	O
heterozygous	O
state	O
by	O
conventional	O
PCR	O
,	O
SSCP	O
analysis	O
,	O
or	O
DNA	O
sequencing	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
a	O
method	O
based	O
on	O
quantitative	O
fluorescent	O
multiplex	O
PCR	O
was	O
proposed	O
to	O
detect	O
intragenic	O
deletions	O
in	O
FANCA	O
involving	O
the	O
most	O
frequently	O
deleted	O
exons	O
(	O
exons	O
5	O
,	O
11	O
,	O
17	O
,	O
21	O
and	O
31	O
)	O
.	O

Here	O
we	O
apply	O
the	O
proposed	O
method	O
to	O
detect	O
intragenic	O
deletions	O
in	O
25	O
Spanish	O
FA-A	O
patients	O
previously	O
assigned	O
to	O
complementation	O
group	O
FA-A	O
by	O
FANCA	O
cDNA	O
retroviral	O
transduction	O
.	O

A	O
total	O
of	O
eight	O
heterozygous	O
deletions	O
involving	O
from	O
one	O
to	O
more	O
than	O
26	O
exons	O
were	O
detected	O
.	O

Thus	O
,	O
one	O
third	O
of	O
the	O
patients	O
carried	O
a	O
large	O
intragenic	O
deletion	O
that	O
would	O
have	O
not	O
been	O
detected	O
by	O
conventional	O
methods	O
.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
previously	O
published	O
data	O
and	O
indicate	O
that	O
large	O
intragenic	O
deletions	O
are	O
one	O
of	O
the	O
most	O
frequent	O
mutations	O
leading	O
to	O
Fanconi	O
anaemia	O
.	O

Consequently	O
,	O
this	O
technology	O
should	O
be	O
applied	O
in	O
future	O
studies	O
on	O
FANCA	O
to	O
improve	O
the	O
mutation	O
detection	O
rate	O
.	O

Genetic	O
variants	O
of	O
the	O
extra-large	O
stimulatory	O
Gs	O
protein	O
alpha-subunit	O
and	O
risk	O
of	O
thrombotic	O
and	O
haemorrhagic	O
disorders	O
.	O

A	O
polymorphism	O
of	O
the	O
gene	O
encoding	O
the	O
extra-large	O
stimulatory	O
G-protein	O
alpha-subunit	O
(XLalphas)	O
,	O
originally	O
identified	O
in	O
three	O
patients	O
with	O
a	O
bleeding	O
tendency	O
,	O
involved	O
a	O
36-bp	O
insertion	O
and	O
two	O
missense	O
changes	O
.	O

A	O
paternally-inherited	O
insertion	O
displayed	O
a	O
moderate	O
platelet	O
Gsalpha	O
over-expression	O
,	O
which	O
lead	O
to	O
platelet	O
hypo-reactivity	O
.	O

These	O
data	O
prompted	O
us	O
to	O
investigate	O
the	O
genetic	O
,	O
functional	O
and	O
clinical	O
relevance	O
of	O
this	O
polymorphism	O
in	O
the	O
Mediterranean	O
population	O
.	O

We	O
included	O
414	O
healthy	O
subjects	O
and	O
three	O
case/control	O
studies	O
:	O
263	O
consecutive	O
patients	O
with	O
a	O
first	O
episode	O
of	O
primary	O
intracerebral	O
haemorrhage	O
,	O
195	O
patients	O
with	O
deep	O
venous	O
thrombosis	O
,	O
and	O
104	O
patients	O
with	O
cerebrovascular	O
disease	O
.	O

Controls	O
were	O
selected	O
by	O
approximating	O
criteria	O
to	O
match	O
selected	O
risk	O
factors	O
to	O
patients	O
.	O

Moreover	O
,	O
we	O
performed	O
studies	O
of	O
platelet	O
function	O
.	O

We	O
developed	O
a	O
simple	O
method	O
to	O
determine	O
the	O
methylated	O
allele	O
,	O
by	O
digestion	O
of	O
genomic	O
DNA	O
with	O
Sma	O
I	O
before	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O

We	O
identified	O
two	O
new	O
rare	O
variants	O
,	O
resulting	O
from	O
the	O
loss	O
of	O
repeat	O
units	O
7	O
and	O
5	O
.	O

The	O
AB	O
genotype	O
was	O
present	O
in	O
3.6%	O
of	O
healthy	O
population	O
and	O
the	O
prevalence	O
of	O
the	O
B	O
allele	O
was	O
similar	O
among	O
cases	O
and	O
controls	O
.	O

Accordingly	O
,	O
the	O
non-methylated	O
B	O
allele	O
did	O
not	O
modify	O
either	O
the	O
expression	O
of	O
platelet	O
Gsalpha	O
or	O
the	O
platelet	O
response	O
to	O
Gs-agonists	O
.	O

Thus	O
,	O
our	O
study	O
suggests	O
a	O
minor	O
functional	O
role	O
of	O
XLalphas	O
polymorphism	O
in	O
thrombotic	O
or	O
in	O
haemorrhagic	O
disorders	O
.	O

Does	O
the	O
position	O
of	O
the	O
premature	O
termination	O
codon	O
in	O
COL7A1	O
correlate	O
with	O
the	O
clinical	O
severity	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

Recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(RDEB)	O
is	O
an	O
inherited	O
skin	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
VII	O
collagen	O
(COL7A1)	O
.	O

The	O
mutations	O
are	O
highly	O
variable	O
and	O
this	O
greatly	O
complicates	O
the	O
study	O
of	O
the	O
genotype-phenotype	O
relationships	O
.	O

To	O
date	O
,	O
three	O
recurrent	O
mutations	O
,	O
specific	O
to	O
Japanese	O
RDEB	O
patients	O
have	O
been	O
reported	O
.	O

By	O
comparing	O
the	O
phenotypes	O
of	O
RDEB	O
patients	O
with	O
different	O
recurrent	O
mutations	O
,	O
the	O
upstream	O
positions	O
of	O
the	O
premature	O
termination	O
codons	O
(PTCs)	O
showed	O
strong	O
correlation	O
with	O
the	O
RDEB	O
clinical	O
disease	O
severity	O
.	O

However	O
,	O
such	O
correlations	O
have	O
not	O
been	O
supported	O
by	O
patients	O
with	O
mutations	O
that	O
were	O
different	O
from	O
these	O
recurrent	O
Japanese	O
patients	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
case	O
of	O
RDEB	O
with	O
a	O
very	O
mild	O
clinical	O
phenotype	O
,	O
who	O
was	O
a	O
compound	O
heterozygote	O
harbouring	O
both	O
a	O
recurrent	O
Japanese	O
mutation	O
and	O
a	O
novel	O
deletion	O
mutation	O
resulting	O
in	O
a	O
more	O
upstream	O
PTC	O
.	O

The	O
patient	O
and	O
his	O
mother	O
were	O
shown	O
to	O
have	O
a	O
recurrent	O
donor	O
splice	O
site	O
mutation	O
within	O
intron	O
81	O
(	O
6573	B-DNAMutation
+	I-DNAMutation
1G	I-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
)	O
,	O
a	O
recurrent	O
Japanese	O
mutation	O
that	O
activates	O
a	O
cryptic	O
donor	O
splicing	O
site	O
and	O
results	O
in	O
a	O
downstream	O
PTC	O
.	O

The	O
patient	O
and	O
his	O
father	O
shared	O
a	O
single-nucleotide	O
deletion	O
within	O
exon	O
64	O
5504delA	B-DNAMutation
,	O
which	O
causes	O
a	O
downstream	O
frame	O
shift	O
in	O
five	O
amino	O
acids	O
before	O
creating	O
a	O
PTC	O
.	O

Occurrence	O
of	O
the	O
PTCs	O
in	O
mRNA	O
was	O
confirmed	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(RT)-PCR	O
.	O

The	O
patient's	O
skin	O
showed	O
reduced	O
immunofluorescence	O
staining	O
for	O
COL7A1	O
and	O
reduced	O
number	O
of	O
abnormal	O
or	O
short	O
anchoring	O
fibrils	O
by	O
electron	O
microscopy	O
.	O

Although	O
the	O
position	O
of	O
the	O
mutation	O
5504delA	B-DNAMutation
PTC	O
was	O
located	O
upstream	O
of	O
the	O
previous	O
mutations	O
reported	O
in	O
combination	O
with	O
the	O
6573	B-DNAMutation
+	I-DNAMutation
1G	I-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
mutation	O
,	O
the	O
two	O
mutations	O
together	O
give	O
an	O
apparently	O
milder	O
clinical	O
phenotype	O
.	O

Therefore	O
,	O
genotype-phenotype	O
relationships	O
in	O
RDEB	O
cannot	O
be	O
explained	O
purely	O
by	O
the	O
position	O
of	O
PTC	O
.	O

Nijmegen	O
breakage	O
syndrome	O
in	O
13%	O
of	O
age-matched	O
Czech	O
children	O
with	O
primary	O
microcephaly	O
.	O

The	O
Nijmegen	O
breakage	O
syndrome	O
is	O
a	O
rare	O
autosomal	O
recessive	O
chromosomal	O
instability	O
disorder	O
characterized	O
by	O
early	O
growth	O
retardation	O
,	O
congenital	O
microcephaly	O
,	O
immunodeficiency	O
,	O
borderline	O
mental	O
development	O
,	O
and	O
a	O
high	O
tendency	O
to	O
lymphoreticular	O
malignancies	O
.	O

Most	O
Nijmegen	O
breakage	O
syndrome	O
patients	O
are	O
of	O
Slavonic	O
origin	O
,	O
and	O
all	O
of	O
them	O
known	O
so	O
far	O
carry	O
a	O
founder	O
homozygous	O
5	O
nucleotide	O
deletion	O
in	O
the	O
NBS1	O
gene	O
.	O

Microcephaly	O
was	O
present	O
in	O
100%	O
of	O
Nijmegen	O
breakage	O
syndrome	O
patients	O
in	O
a	O
recent	O
large	O
international	O
cooperative	O
study	O
.	O

The	O
frequency	O
of	O
Nijmegen	O
breakage	O
syndrome	O
among	O
children	O
with	O
primary	O
microcephaly	O
was	O
not	O
known	O
.	O

Early	O
correct	O
diagnosis	O
of	O
the	O
syndrome	O
is	O
crucial	O
for	O
appropriate	O
preventive	O
care	O
and	O
therapy	O
.	O

We	O
tested	O
67	O
Czech	O
patients	O
of	O
different	O
ages	O
with	O
simple	O
microcephaly	O
for	O
the	O
presence	O
of	O
the	O
most	O
common	O
mutation	O
in	O
the	O
NBS1	O
gene	O
.	O

Three	O
new	O
Nijmegen	O
breakage	O
syndrome	O
cases	O
were	O
detected	O
in	O
this	O
cohort	O
,	O
representing	O
4.5%	O
of	O
the	O
cohort	O
.	O

All	O
these	O
newly	O
diagnosed	O
Nijmegen	O
breakage	O
syndrome	O
patients	O
were	O
younger	O
than	O
10	O
months	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

They	O
were	O
all	O
born	O
within	O
a	O
2.5-year	O
period	O
.	O

Twenty-three	O
of	O
the	O
67	O
children	O
in	O
the	O
cohort	O
were	O
born	O
within	O
this	O
2.5-year	O
period	O
,	O
representing	O
a	O
13%	O
incidence	O
of	O
Nijmegen	O
breakage	O
syndrome	O
.	O

Frequency	O
of	O
Nijmegen	O
breakage	O
syndrome	O
heterozygotes	O
among	O
infants	O
in	O
the	O
Czech	O
Republic	O
is	O
1	O
:	O
130-158	O
and	O
the	O
birth	O
rate	O
is	O
90,000	O
per	O
year	O
,	O
therefore	O
in	O
the	O
time	O
span	O
of	O
2.5	O
years	O
,	O
three	O
new	O
Nijmegen	O
breakage	O
syndrome	O
homozygotes	O
are	O
expected	O
to	O
be	O
born	O
.	O

Therefore	O
we	O
assume	O
that	O
by	O
DNA	O
testing	O
of	O
Czech	O
primary	O
microcephalic	O
children	O
it	O
is	O
possible	O
to	O
detect	O
all	O
Nijmegen	O
breakage	O
syndrome	O
patients	O
to	O
be	O
expected	O
.	O

The	O
age	O
at	O
correct	O
diagnosis	O
was	O
lowered	O
from	O
7.1	O
years	O
at	O
the	O
time	O
before	O
DNA	O
testing	O
,	O
to	O
well	O
under	O
1	O
year	O
of	O
age	O
.	O

All	O
new	O
Nijmegen	O
breakage	O
syndrome	O
patients	O
could	O
receive	O
appropriate	O
preventive	O
care	O
,	O
which	O
should	O
significantly	O
improve	O
their	O
life	O
expectancy	O
and	O
prognosis	O
.	O

Autosomal	O
dominant	O
lateral	O
temporal	O
epilepsy	O
:	O
two	O
families	O
with	O
novel	O
mutations	O
in	O
the	O
LGI1	O
gene	O
.	O

PURPOSE	O
:	O
Mutations	O
in	O
the	O
leucine	O
rich	O
,	O
glioma	O
inactivated	O
gene	O
(LGI1)	O
were	O
recently	O
described	O
in	O
a	O
small	O
number	O
of	O
families	O
with	O
autosomal	O
dominant	O
lateral	O
temporal	O
epilepsy	O
(ADLTE)	O
.	O

ADLTE	O
is	O
characterized	O
by	O
partial	O
seizures	O
with	O
symptoms	O
suggestive	O
of	O
a	O
lateral	O
temporal	O
onset	O
,	O
including	O
frequent	O
auditory	O
aura	O
.	O

Here	O
we	O
report	O
the	O
results	O
of	O
clinical	O
and	O
genetic	O
analyses	O
of	O
two	O
newly	O
identified	O
families	O
with	O
ADTLE	O
.	O

METHODS	O
:	O
We	O
identified	O
two	O
families	O
whose	O
seizure	O
semiology	O
was	O
suggestive	O
of	O
ADLTE	O
.	O

Evaluation	O
included	O
a	O
detailed	O
history	O
and	O
neurologic	O
examination	O
,	O
as	O
well	O
as	O
collection	O
of	O
DNA	O
.	O

The	O
coding	O
sequence	O
of	O
the	O
LGI1	O
gene	O
from	O
affected	O
subjects	O
from	O
both	O
families	O
was	O
analyzed	O
for	O
evidence	O
of	O
mutation	O
.	O

RESULTS	O
:	O
Each	O
patient	O
had	O
a	O
history	O
of	O
partial	O
seizures	O
,	O
often	O
with	O
secondary	O
generalization	O
earlier	O
in	O
the	O
course	O
.	O

Auditory	O
aura	O
was	O
reported	O
by	O
approximately	O
two	O
thirds	O
of	O
affected	O
patients	O
in	O
each	O
pedigree	O
.	O

Novel	O
mutations	O
in	O
LGI1	O
were	O
detected	O
in	O
both	O
families	O
.	O

A	O
heterozygous	O
single-nucleotide	O
deletion	O
at	O
position	O
329	O
(	O
del	B-DNAMutation
329C	I-DNAMutation
)	O
was	O
detected	O
in	O
affected	O
individuals	O
from	O
one	O
family	O
,	O
whereas	O
patients	O
from	O
the	O
second	O
family	O
had	O
a	O
nonsynonymous	O
variation	O
,	O
corresponding	O
to	O
C435G	B-DNAMutation
.	O

CONCLUSIONS	O
:	O
We	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
LGI1	O
gene	O
.	O

The	O
phenotype	O
of	O
these	O
two	O
families	O
was	O
similar	O
to	O
that	O
of	O
other	O
kindreds	O
with	O
ADLTE	O
,	O
as	O
auditory	O
aura	O
was	O
absent	O
in	O
one	O
third	O
of	O
affected	O
individuals	O
.	O

Our	O
results	O
further	O
support	O
that	O
LGI1	O
mutations	O
should	O
be	O
considered	O
in	O
patients	O
with	O
a	O
history	O
of	O
partial	O
seizures	O
if	O
the	O
semiology	O
of	O
seizures	O
is	O
consistent	O
with	O
the	O
onset	O
in	O
the	O
lateral	O
temporal	O
lobe	O
.	O

Thyroperoxidase	O
gene	O
mutations	O
in	O
congenital	O
goitrous	O
hypothyroidism	O
with	O
total	O
and	O
partial	O
iodide	O
organification	O
defect	O
.	O

Mutations	O
of	O
the	O
thyroperoxidase	O
(TPO)	O
gene	O
have	O
been	O
reported	O
as	O
being	O
the	O
most	O
severe	O
and	O
frequent	O
abnormality	O
in	O
thyroid	O
iodide	O
organification	O
defect	O
(IOD)	O
causing	O
goitrous	O
congenital	O
hypothyroidism	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
screen	O
and	O
subsequently	O
identify	O
TPO	O
gene	O
mutations	O
in	O
patients	O
with	O
congenital	O
hypothyroidism	O
with	O
evidence	O
of	O
total	O
iodine	O
organification	O
defects	O
(TIOD)	O
or	O
partial	O
iodine	O
organification	O
defect	O
(PIOD)	O
as	O
defined	O
by	O
the	O
perchlorate	O
discharge	O
test	O
.	O

Seven	O
goitrous	O
patients	O
with	O
TIOD	O
and	O
seven	O
patients	O
with	O
PIOD	O
,	O
from	O
three	O
and	O
five	O
unrelated	O
families	O
,	O
respectively	O
,	O
were	O
studied	O
.	O

We	O
were	O
able	O
to	O
detect	O
different	O
TPO	O
genes	O
mutations	O
in	O
patients	O
with	O
TIOD	O
and	O
PIOD	O
.	O

In	O
TIOD	O
families	O
the	O
results	O
were	O
as	O
follows	O
:	O
(1)	O
a	O
homozygous	O
GGCC	O
insertion	O
at	O
exon	O
8	O
,	O
position	O
1277	O
(	O
family	O
1	O
)	O
;	O
(2)	O
compound	O
heterozygosity	O
with	O
a	O
GGCC	O
insertion	O
at	O
exon	O
8	O
(1277)	O
and	O
a	O
nucleotide	O
substitution	O
in	O
exon	O
11	O
2068G>C	B-DNAMutation
(	O
family	O
2	O
)	O
;	O
(3)	O
compound	O
heterozygosity	O
with	O
the	O
mutation	O
2068G>C	B-DNAMutation
in	O
exon	O
11	O
and	O
a	O
C	O
insertion	O
in	O
exon	O
14	O
between	O
positions	O
2505-2511	O
(	O
family	O
3	O
)	O
.	O

In	O
patients	O
with	O
PIOD	O
we	O
have	O
detected	O
:	O
(1)	O
only	O
one	O
heterozygous	O
mutation	O
in	O
two	O
families	O
(	O
4	O
and	O
5	O
)	O
,	O
in	O
exons	O
11	O
and	O
10	O
(	O
2084G>A	B-DNAMutation
and	O
1780C>A	B-DNAMutation
)	O
;	O
(2)	O
a	O
compound	O
heterozygous	O
condition	O
in	O
one	O
family	O
(	O
family	O
6	O
)	O
,	O
with	O
mutations	O
,	O
respectively	O
in	O
exons	O
8	O
and	O
10	O
(	O
1242G>T	B-DNAMutation
and	O
1780C>A	B-DNAMutation
)	O
;	O
(3)	O
only	O
polymorphisms	O
(	O
family	O
VII	O
)	O
and	O
(4)	O
a	O
heterozygous	O
mutation	O
in	O
the	O
first	O
base	O
of	O
the	O
border	O
exon/intron	O
9	B-DNAMutation
+1G>T	I-DNAMutation
(	O
family	O
VIII	O
)	O
.	O

We	O
did	O
not	O
detect	O
inactivating	O
mutations	O
in	O
exons	O
11	O
,	O
16	O
,	O
and	O
21	O
of	O
the	O
THOX2	O
gene	O
where	O
mutations	O
have	O
been	O
previously	O
described	O
.	O

We	O
concluded	O
that	O
homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
found	O
in	O
TIOD	O
characterized	O
the	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
and	O
will	O
translate	O
a	O
nonfunctional	O
protein	O
or	O
a	O
protein	O
that	O
may	O
not	O
reach	O
the	O
apical	O
membrane	O
.	O

As	O
for	O
PIOD	O
,	O
the	O
majority	O
of	O
the	O
studied	O
kindreds	O
had	O
only	O
heterozygous	O
mutations	O
and/or	O
polymorphisms	O
.	O

It	O
is	O
conceivable	O
that	O
these	O
TPO	O
gene	O
sequence	O
alterations	O
may	O
partially	O
affect	O
the	O
functional	O
state	O
of	O
the	O
translated	O
protein	O
or	O
affect	O
its	O
transport	O
to	O
the	O
apical	O
membrane	O
.	O

Deletion	O
and	O
reduced	O
expression	O
of	O
the	O
Fanconi	O
anemia	O
FANCA	O
gene	O
in	O
sporadic	O
acute	O
myeloid	O
leukemia	O
.	O

Fanconi	O
anemia	O
(FA)	O
is	O
an	O
autosomal	O
recessive	O
chromosomal	O
instability	O
disorder	O
caused	O
by	O
mutations	O
in	O
one	O
of	O
seven	O
known	O
genes	O
(	O
FANCA,C,D2,E,F,G	O
and	O
BRCA2	O
)	O
.	O

Mutations	O
in	O
the	O
FANCA	O
gene	O
are	O
the	O
most	O
prevalent	O
,	O
accounting	O
for	O
two-thirds	O
of	O
FA	O
cases	O
.	O

Affected	O
individuals	O
have	O
greatly	O
increased	O
risks	O
of	O
acute	O
myeloid	O
leukemia	O
(AML)	O
.	O

This	O
raises	O
the	O
question	O
as	O
to	O
whether	O
inherited	O
or	O
acquired	O
mutations	O
in	O
FA	O
genes	O
might	O
be	O
involved	O
in	O
the	O
development	O
of	O
sporadic	O
AML	O
.	O

Quantitative	O
fluorescent	O
PCR	O
was	O
used	O
to	O
screen	O
archival	O
DNA	O
from	O
sporadic	O
AML	O
cases	O
for	O
FANCA	O
deletions	O
,	O
which	O
account	O
for	O
40%	O
of	O
FANCA	O
mutations	O
in	O
FA	O
homozygotes	O
.	O

Four	O
heterozygous	O
deletions	O
were	O
found	O
in	O
101	O
samples	O
screened	O
,	O
which	O
is	O
35-fold	O
higher	O
than	O
the	O
expected	O
population	O
frequency	O
for	O
germline	O
FANCA	O
deletions	O
(P<0.0001)	O
.	O

Sequencing	O
FANCA	O
in	O
the	O
AML	O
samples	O
with	O
FANCA	O
deletions	O
did	O
not	O
detect	O
mutations	O
in	O
the	O
second	O
allele	O
and	O
there	O
was	O
no	O
evidence	O
of	O
epigenetic	O
silencing	O
by	O
hypermethylation	O
.	O

However	O
,	O
real-time	O
quantitative	O
PCR	O
analysis	O
in	O
these	O
samples	O
showed	O
reduced	O
expression	O
of	O
FANCA	O
compared	O
to	O
nondeleted	O
AML	O
samples	O
and	O
to	O
controls	O
.	O

These	O
findings	O
suggest	O
that	O
gene	O
deletions	O
and	O
reduced	O
expression	O
of	O
FANCA	O
may	O
be	O
involved	O
in	O
the	O
promotion	O
of	O
genetic	O
instability	O
in	O
a	O
subset	O
of	O
cases	O
of	O
sporadic	O
AML	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
internal	O
tandem	O
duplication	O
mutations	O
of	O
the	O
CBP	O
gene	O
are	O
frequent	O
events	O
in	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

PURPOSE	O
:	O
Cyclic	O
AMP	O
response	O
element	O
binding	O
protein	O
binding	O
protein	O
(CBP)	O
,	O
a	O
nuclear	O
transcriptional	O
coactivator	O
protein	O
,	O
is	O
an	O
important	O
component	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
systematically	O
analyzed	O
the	O
pattern	O
and	O
frequency	O
of	O
CBP	O
gene	O
alterations	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(ESCC)	O
samples	O
from	O
Linzhou	O
(Linxian)	O
,	O
China	O
.	O

Experimental	O
Design	O
:	O
Using	O
microsatellite	O
markers	O
D16S475	O
,	O
D16S2622	O
,	O
and	O
D16S523	O
within	O
the	O
chromosome	O
16p13.3	O
locus	O
flanking	O
the	O
CBP	O
gene	O
,	O
we	O
observed	O
loss	O
of	O
heterozygosity	O
(LOH)	O
,	O
microsatellite	O
instability	O
(MSI)	O
,	O
or	O
homozygous	O
deletion	O
in	O
16	O
of	O
26	O
ESCC	O
samples	O
.	O

Additional	O
ESCC	O
samples	O
were	O
analyzed	O
using	O
different	O
sets	O
of	O
microsatellite	O
markers	O
(CS1-CS5)	O
within	O
the	O
introns	O
or	O
in	O
close	O
proximity	O
to	O
the	O
3'	O
end	O
of	O
the	O
CBP	O
gene	O
.	O

RESULTS	O
:	O
The	O
data	O
showed	O
that	O
CBP	O
gene	O
LOH	O
or	O
MSI	O
occurred	O
in	O
9	O
of	O
19	O
ESCC	O
samples	O
.	O

A	O
detailed	O
genetic	O
alteration	O
map	O
of	O
the	O
CBP	O
gene	O
showed	O
that	O
an	O
LOH	O
or	O
MSI	O
hot	O
spot	O
occurred	O
within	O
intron	O
2	O
of	O
the	O
CBP	O
gene	O
.	O

Furthermore	O
,	O
ESCC	O
samples	O
were	O
investigated	O
for	O
CBP	O
gene	O
mutation	O
by	O
conformation	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
.	O

These	O
results	O
revealed	O
that	O
most	O
of	O
the	O
shifted	O
fragments	O
contained	O
internal	O
tandem	O
duplication	O
(ITD)	O
,	O
frequently	O
in	O
the	O
regions	O
encoding	O
the	O
histone	O
acetyltransferase	O
domain	O
and	O
COOH-terminal	O
transactivating	O
domain	O
one	O
of	O
the	O
CBP	O
gene	O
.	O

The	O
presence	O
of	O
ITD	O
within	O
the	O
CBP	O
gene	O
was	O
additionally	O
confirmed	O
by	O
Southern	O
blot	O
analysis	O
and	O
sequencing	O
.	O

CONCLUSIONS	O
:	O
These	O
studies	O
show	O
that	O
LOH	O
and	O
ITD	O
of	O
the	O
CBP	O
gene	O
are	O
frequent	O
genetic	O
events	O
in	O
human	O
ESCC	O
.	O

These	O
alterations	O
may	O
have	O
functional	O
importance	O
in	O
the	O
development	O
of	O
human	O
ESCC	O
.	O

Reciprocal	O
crossovers	O
and	O
a	O
positional	O
preference	O
for	O
strand	O
exchange	O
in	O
recombination	O
events	O
resulting	O
in	O
deletion	O
or	O
duplication	O
of	O
chromosome	O
17p11.2	O
.	O

Smith-Magenis	O
syndrome	O
(SMS)	O
is	O
caused	O
by	O
an	O
approximately	O
4-Mb	O
heterozygous	O
interstitial	O
deletion	O
on	O
chromosome	O
17p11.2	O
in	O
approximately	O
80%-90%	O
of	O
affected	O
patients	O
.	O

Three	O
large	O
(	O
approximately	O
200	O
kb	O
)	O
,	O
complex	O
,	O
and	O
highly	O
homologous	O
(	O
approximately	O
98%	O
)	O
low-copy	O
repeats	O
(LCRs)	O
are	O
located	O
inside	O
or	O
flanking	O
the	O
SMS	O
common	O
deletion	O
.	O

These	O
repeats	O
,	O
also	O
known	O
as	O
"SMS-REPs,"	O
are	O
termed	O
"distal,"	O
"middle,"	O
and	O
"proximal."	O
The	O
directly	O
oriented	O
distal	O
and	O
proximal	O
copies	O
act	O
as	O
substrates	O
for	O
nonallelic	O
homologous	O
recombination	O
resulting	O
in	O
both	O
the	O
deletion	O
associated	O
with	O
SMS	O
and	O
the	O
reciprocal	O
duplication	O
:	O
dup(17)(p11.2p11.2)	O
.	O

Using	O
restriction	O
enzyme	O
cis-morphism	O
analyses	O
and	O
direct	O
sequencing	O
,	O
we	O
mapped	O
the	O
regions	O
of	O
strand	O
exchange	O
in	O
16	O
somatic-cell	O
hybrids	O
that	O
harbor	O
only	O
the	O
recombinant	O
SMS-REP	O
.	O

Our	O
studies	O
showed	O
that	O
the	O
sites	O
of	O
crossovers	O
were	O
distributed	O
throughout	O
the	O
region	O
of	O
homology	O
between	O
the	O
distal	O
and	O
proximal	O
SMS-REPs	O
.	O

However	O
,	O
despite	O
approximately	O
170	O
kb	O
of	O
high	O
homology	O
,	O
50%	O
of	O
the	O
recombinant	O
junctions	O
occurred	O
in	O
a	O
12.0-kb	O
region	O
within	O
the	O
KER	O
gene	O
clusters	O
.	O

DNA	O
sequencing	O
of	O
this	O
hotspot	O
(	O
positional	O
preference	O
for	O
strand	O
exchange	O
)	O
in	O
seven	O
recombinant	O
SMS-REPs	O
narrowed	O
the	O
crossovers	O
to	O
an	O
approximately	O
8-kb	O
interval	O
.	O

Four	O
of	O
them	O
occurred	O
in	O
a	O
1,655-bp	O
region	O
rich	O
in	O
polymorphic	O
nucleotides	O
that	O
could	O
potentially	O
reflect	O
frequent	O
gene	O
conversion	O
.	O

For	O
further	O
evaluation	O
of	O
the	O
strand	O
exchange	O
frequency	O
in	O
patients	O
with	O
SMS	O
,	O
novel	O
junction	O
fragments	O
from	O
the	O
recombinant	O
SMS-REPs	O
were	O
identified	O
.	O

As	O
predicted	O
by	O
the	O
reciprocal-recombination	O
model	O
,	O
junction	O
fragments	O
were	O
also	O
identified	O
from	O
this	O
hotspot	O
region	O
in	O
patients	O
with	O
dup(17)(p11.2p11.2)	O
,	O
documenting	O
reciprocity	O
of	O
the	O
positional	O
preference	O
for	O
strand	O
exchange	O
.	O

Several	O
potential	O
cis-acting	O
recombination-promoting	O
sequences	O
were	O
identified	O
within	O
the	O
hotspot	O
.	O

It	O
is	O
interesting	O
that	O
we	O
found	O
2.1-kb	O
AT-rich	O
inverted	O
repeats	O
flanking	O
the	O
proximal	O
and	O
middle	O
KER	O
gene	O
clusters	O
but	O
not	O
the	O
distal	O
one	O
.	O

The	O
role	O
of	O
any	O
or	O
all	O
of	O
these	O
in	O
stimulating	O
double-strand	O
breaks	O
around	O
this	O
positional	O
recombination	O
hotspot	O
remains	O
to	O
be	O
explored	O
.	O

Mutations	O
of	O
the	O
PML	O
tumor	O
suppressor	O
gene	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
promyelocytic	O
leukemia	O
(PML)	O
tumor	O
suppressor	O
of	O
acute	O
promyelocytic	O
leukemia	O
(APL)	O
is	O
essential	O
for	O
a	O
number	O
of	O
proapoptotic	O
and	O
growth-suppressive	O
pathways	O
as	O
well	O
as	O
for	O
the	O
activity	O
of	O
differentiating	O
agents	O
such	O
as	O
retinoic	O
acid	O
(RA)	O
.	O

In	O
human	O
APL	O
,	O
the	O
dose	O
of	O
PML	O
is	O
reduced	O
to	O
heterozygosity	O
given	O
that	O
one	O
allele	O
is	O
involved	O
in	O
the	O
chromosomal	O
translocation	O
while	O
the	O
status	O
of	O
the	O
remaining	O
PML	O
allele	O
is	O
unknown	O
.	O

We	O
have	O
therefore	O
used	O
single-strand	O
conformational	O
polymorphism	O
(SSCP)	O
and	O
sequencing	O
analysis	O
to	O
screen	O
DNA	O
from	O
APL	O
patients	O
for	O
mutations	O
at	O
the	O
PML	O
locus	O
.	O

We	O
identified	O
DNA	O
sequence	O
variations	O
resulting	O
in	O
a	O
truncated	O
PML	O
protein	O
in	O
APL	O
cases	O
that	O
displayed	O
RA	O
resistance	O
and	O
a	O
very	O
poor	O
prognosis	O
.	O

Mutation	O
analysis	O
also	O
led	O
to	O
the	O
identification	O
of	O
aberrant	O
PML	O
sequence	O
variations	O
in	O
other	O
hematopoietic	O
malignancies	O
.	O

Complete	O
functional	O
loss	O
of	O
PML	O
is	O
therefore	O
selected	O
by	O
the	O
APL	O
phenotype	O
and	O
associates	O
with	O
poor	O
prognosis	O
and	O
RA	O
unresponsiveness	O
.	O

The	O
C270T	B-DNAMutation
polymorphism	O
of	O
the	O
brain-derived	O
neurotrophic	O
factor	O
gene	O
is	O
associated	O
with	O
schizophrenia	O
.	O

We	O
investigated	O
a	O
novel	O
polymorphism	O
of	O
single	O
nucleotide	O
substitution	O
C270T	B-DNAMutation
of	O
the	O
brain-derived	O
neurotrophic	O
factor	O
(BDNF)	O
gene	O
in	O
schizophrenia	O
patients	O
(n=101)	O
and	O
in	O
controls	O
(n=68)	O
.	O

The	O
frequency	O
of	O
the	O
C/T	O
genotype	O
and	O
the	O
T	O
allele	O
were	O
significantly	O
higher	O
in	O
the	O
schizophrenia	O
patients	O
(	O
25.7%	O
and	O
13.9%	O
,	O
respectively	O
)	O
compared	O
with	O
the	O
controls	O
(	O
5.9%	O
and	O
2.9%	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
(PANSS)	O
items	O
and	O
Global	O
Assessment	O
of	O
Functioning	O
(GAF)	O
scores	O
between	O
the	O
patients	O
with	O
C/C	O
and	O
C/T	O
genotypes	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
elucidate	O
the	O
significance	O
of	O
this	O
finding	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O

Polymorphisms	O
in	O
the	O
CYP1B1	O
gene	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
prostate	O
cancer	O
.	O

CYP1B1	O
has	O
been	O
evaluated	O
as	O
a	O
candidate	O
gene	O
for	O
various	O
cancers	O
because	O
of	O
its	O
function	O
in	O
activating	O
environmental	O
procarcinogens	O
and	O
catalysing	O
the	O
conversion	O
of	O
oestrogens	O
to	O
genotoxic	O
catechol	O
oestrogens	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
genetic	O
polymorphisms	O
in	O
the	O
CYP1B1	O
gene	O
may	O
associate	O
with	O
the	O
risk	O
for	O
prostate	O
cancer	O
(CaP)	O
,	O
we	O
compared	O
the	O
allele	O
,	O
genotype	O
,	O
and	O
haplotype	O
frequencies	O
of	O
13	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
of	O
CYP1B1	O
among	O
159	O
hereditary	O
prostate	O
cancer	O
(HPC)	O
probands	O
,	O
245	O
sporadic	O
CaP	O
cases	O
,	O
and	O
222	O
unaffected	O
men	O
.	O

When	O
each	O
of	O
the	O
SNPs	O
was	O
analysed	O
separately	O
,	O
marginally	O
significant	O
differences	O
were	O
observed	O
for	O
allele	O
frequencies	O
between	O
sporadic	O
cases	O
and	O
controls	O
for	O
three	O
consecutive	O
SNPs	O
(	O
-1001C/T	B-DNAMutation
,	O
-263G/A	B-DNAMutation
,	O
and	O
-13C/T	B-DNAMutation
,	O
P=0.04-0.07	O
)	O
.	O

Similarly	O
,	O
marginally	O
significant	O
differences	O
between	O
sporadic	O
cases	O
and	O
controls	O
in	O
the	O
frequency	O
of	O
variant	O
allele	O
carriers	O
were	O
observed	O
for	O
five	O
consecutive	O
SNPs	O
(	O
-1001C/T	B-DNAMutation
,	O
-263G/A	B-DNAMutation
,	O
-13C/T	B-DNAMutation
,	O
+142C/G	B-DNAMutation
,	O
and	O
+355G/T	B-DNAMutation
,	O
P=0.02-0.08	O
)	O
.	O

Interestingly	O
,	O
when	O
the	O
combination	O
of	O
these	O
five	O
SNPs	O
was	O
analysed	O
using	O
a	O
haplotype	O
approach	O
,	O
a	O
larger	O
difference	O
was	O
found	O
(P=0.009)	O
.	O

One	O
frequent	O
haplotype	O
(	O
C-G-C-C-G	O
of	O
-1001C/T	B-DNAMutation
,	O
-263G/A	B-DNAMutation
,	O
-13C/T	B-DNAMutation
,	O
+142C/G	B-DNAMutation
,	O
and	O
+355G/T	B-DNAMutation
)	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
CaP	O
,	O
while	O
the	O
other	O
frequent	O
haplotype	O
(T-A-T-G-T)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
CaP	O
.	O

These	O
findings	O
suggest	O
that	O
genetic	O
polymorphisms	O
in	O
CYP1B1	O
may	O
modify	O
the	O
risk	O
for	O
CaP	O
.	O

Identification	O
of	O
twelve	O
novel	O
mutations	O
in	O
patients	O
with	O
classic	O
and	O
variant	O
forms	O
of	O
maple	O
syrup	O
urine	O
disease	O
.	O

Maple	O
syrup	O
urine	O
disease	O
(MSUD)	O
is	O
an	O
autosomal	O
recessive	O
metabolic	O
disorder	O
of	O
panethnic	O
distribution	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
activity	O
of	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
(BCKD)	O
complex	O
.	O

Mutations	O
in	O
the	O
human	O
BCKD	O
genes	O
E1alpha	O
(BCKDHA)	O
,	O
E1beta	O
(BCKDHB)	O
and	O
E2	O
(DBT)	O
are	O
known	O
to	O
result	O
in	O
MSUD	O
,	O
referred	O
to	O
as	O
type	O
Ia	O
,	O
Ib	O
and	O
II	O
mutations	O
respectively	O
.	O

In	O
this	O
study	O
16	O
patients	O
with	O
the	O
classic	O
severe	O
form	O
of	O
MSUD	O
and	O
three	O
patients	O
with	O
milder	O
variant	O
forms	O
of	O
the	O
disease	O
were	O
investigated	O
for	O
mutations	O
in	O
the	O
E1alpha-	O
,	O
E1beta-	O
and	O
E2-gene	O
by	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
and	O
DNA	O
sequencing	O
.	O

The	O
patients'	O
clinical	O
and	O
biochemical	O
phenotypes	O
were	O
well	O
characterized	O
.	O

One	O
novel	O
type	O
Ia	O
missense	O
mutation	O
,	O
eight	O
novel	O
type	O
Ib	O
(	O
three	O
missense	O
,	O
two	O
nonsense	O
,	O
two	O
small	O
deletions	O
,	O
one	O
small	O
duplication	O
)	O
and	O
three	O
novel	O
type	O
II	O
(	O
two	O
missense	O
,	O
one	O
splice	O
site	O
)	O
mutations	O
were	O
identified	O
in	O
patients	O
.	O

Moreover	O
,	O
eleven	O
previously	O
described	O
mutations	O
were	O
detected	O
:	O
five	O
type	O
Ia	O
(	O
four	O
missense	O
,	O
one	O
nonsense	O
)	O
,	O
three	O
type	O
Ib	O
mutations	O
(	O
two	O
missense	O
,	O
one	O
nonsense	O
)	O
and	O
three	O
type	O
II	O
mutations	O
(	O
two	O
missense	O
,	O
one	O
small	O
deletion	O
)	O
.	O

Fourteen	O
patients	O
are	O
homozygous	O
for	O
one	O
single	O
mutation	O
,	O
five	O
patients	O
are	O
compound-heterozygous	O
for	O
two	O
different	O
mutations	O
affecting	O
one	O
of	O
the	O
three	O
genes	O
.	O

Thus	O
,	O
in	O
all	O
19	O
patients	O
the	O
identified	O
mutations	O
can	O
most	O
probably	O
be	O
considered	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
renin-angiotensin-aldosterone	O
system	O
and	O
arterial	O
hypertension	O
in	O
the	O
Italian	O
population	O
:	O
the	O
GENIPER	O
Project	O
.	O

OBJECTIVE	O
:	O
To	O
detect	O
the	O
association	O
of	O
single	O
polymorphisms	O
of	O
the	O
renin-angiotensin-aldosterone	O
system	O
(RAAS)	O
,	O
or	O
different	O
combinations	O
thereof	O
,	O
with	O
hypertension	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
GENIPER	O
database	O
is	O
the	O
result	O
of	O
a	O
collaborative	O
effort	O
of	O
13	O
Italian	O
research	O
centres	O
to	O
collect	O
genomic	O
DNA	O
in	O
subjects	O
well	O
characterized	O
in	O
terms	O
of	O
blood	O
pressure	O
status	O
.	O

A	O
total	O
of	O
2461	O
subjects	O
(	O
normotensive	O
=	O
611	O
;	O
hypertensive	O
=	O
1850	O
)	O
were	O
selected	O
and	O
genotyped	O
for	O
the	O
angiotensin-converting	O
enzyme	O
insertion/deletion	O
(	O
ACE	O
I/D	O
)	O
,	O
angiotensinogen	O
(AGT)	O
T/C704	B-DNAMutation
,	O
angiotensin	O
receptor	O
type	O
1	O
(AT1)	O
A/C1166	B-DNAMutation
and	O
aldosterone	O
synthase	O
(ALDO)	O
T/C-344	B-DNAMutation
genetic	O
variants	O
.	O

RESULTS	O
:	O
Allele	O
frequencies	O
were	O
homogeneous	O
over	O
the	O
Italian	O
territory	O
,	O
with	O
the	O
relevant	O
exception	O
of	O
the	O
ACE	O
I/D	O
,	O
the	O
D	O
allele	O
being	O
significantly	O
less	O
frequent	O
in	O
the	O
northern	O
region	O
(61%)	O
than	O
in	O
the	O
rest	O
of	O
the	O
country	O
(	O
67%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

When	O
comparing	O
allele	O
and	O
genotype	O
distributions	O
in	O
normotensives	O
and	O
hypertensives	O
,	O
the	O
latter	O
presented	O
a	O
small	O
but	O
statistically	O
significant	O
increase	O
of	O
the	O
C	O
allele	O
of	O
AGT	O
T/C704	B-DNAMutation
,	O
the	O
A	O
allele	O
of	O
AT1	O
A/C1166	B-DNAMutation
and	O
the	O
T	O
allele	O
of	O
ALDO	O
T/C-344	B-DNAMutation
polymorphisms	O
(	O
P	O
=	O
0.018	O
,	O
P	O
=	O
0.037	O
and	O
P	O
=	O
0.015	O
,	O
respectively	O
)	O
,	O
with	O
similar	O
trends	O
all	O
over	O
the	O
country	O
.	O

A	O
step-wise	O
logistic	O
regression	O
analysis	O
confirmed	O
these	O
findings	O
,	O
by	O
entering	O
in	O
the	O
model	O
as	O
independent	O
predictors	O
of	O
blood	O
pressure	O
status	O
of	O
AGT	O
T/C704	B-DNAMutation
(	O
P	O
=	O
0.013	O
)	O
,	O
ALDO	O
T/C-344	B-DNAMutation
(	O
P	O
=	O
0.032	O
)	O
and	O
AT1	O
A/C1166	B-DNAMutation
polymorphisms	O
(	O
P	O
=	O
0.075	O
)	O
,	O
but	O
not	O
ACE	O
I/D	O
(	O
P	O
=	O
0.996	O
)	O
.	O

We	O
also	O
found	O
some	O
evidence	O
of	O
an	O
additive	O
effect	O
of	O
individual	O
genetic	O
variants	O
of	O
the	O
RAAS	O
,	O
modulating	O
at	O
different	O
levels	O
the	O
same	O
functional	O
pathway	O
,	O
on	O
the	O
risk	O
of	O
developing	O
hypertension	O
,	O
but	O
no	O
synergistic	O
interaction	O
was	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
some	O
allelic	O
variants	O
of	O
RAAS	O
genes	O
carry	O
a	O
small	O
but	O
identifiable	O
risk	O
of	O
developing	O
arterial	O
hypertension	O
.	O

Progressive	O
familial	O
intrahepatic	O
cholestasis	O
type	O
1	O
and	O
extrahepatic	O
features	O
:	O
no	O
catch-up	O
of	O
stature	O
growth	O
,	O
exacerbation	O
of	O
diarrhea	O
,	O
and	O
appearance	O
of	O
liver	O
steatosis	O
after	O
liver	O
transplantation	O
.	O

BACKGROUND/AIMS	O
:	O
Progressive	O
familial	O
intrahepatic	O
cholestasis	O
characterized	O
by	O
normal	O
serum	O
gamma-glutamyltransferase	O
activity	O
can	O
be	O
due	O
to	O
mutations	O
in	O
familial	O
intrahepatic	O
cholestasis	O
type	O
1	O
(FIC1)	O
(ATP8B1)	O
,	O
a	O
gene	O
expressed	O
in	O
several	O
organs	O
.	O

In	O
some	O
cases	O
,	O
it	O
is	O
associated	O
with	O
extrahepatic	O
features	O
.	O

We	O
searched	O
for	O
FIC1	O
mutations	O
and	O
analyzed	O
the	O
outcome	O
of	O
extrahepatic	O
features	O
after	O
liver	O
transplantation	O
in	O
two	O
children	O
with	O
this	O
form	O
of	O
progressive	O
familial	O
intrahepatic	O
cholestasis	O
associated	O
with	O
chronic	O
unexplained	O
diarrhea	O
and	O
short	O
stature	O
.	O

METHODS	O
:	O
FIC1	O
sequence	O
was	O
determined	O
after	O
polymerase	O
chain	O
reaction	O
(PCR)	O
of	O
genomic	O
lymphocyte	O
DNA	O
and/or	O
reverse	O
transcription-PCR	O
of	O
liver	O
or	O
lymphocyte	O
RNA	O
.	O

RESULTS	O
:	O
A	O
homozygous	O
amino	O
acid	O
change	O
deletion	O
was	O
found	O
in	O
one	O
child	O
.	O

The	O
second	O
child	O
harboured	O
compound	O
heterozygous	O
missense	O
and	O
nonsense	O
mutations	O
.	O

In	O
both	O
children	O
,	O
despite	O
successful	O
liver	O
transplantation	O
,	O
evolution	O
(	O
follow-up	O
:	O
9.5-11	O
years	O
)	O
was	O
characterized	O
by	O
exacerbation	O
of	O
diarrhea	O
and	O
no	O
catch-up	O
of	O
stature	O
growth	O
,	O
and	O
appearance	O
of	O
liver	O
steatosis	O
.	O

CONCLUSIONS	O
:	O
Progressive	O
familial	O
intrahepatic	O
cholestasis	O
characterized	O
by	O
normal	O
serum	O
gamma-glutamyltransferase	O
activity	O
and	O
extrahepatic	O
features	O
corresponds	O
to	O
progressive	O
familial	O
intrahepatic	O
cholestasis	O
type	O
1	O
.	O

Extrahepatic	O
symptomatology	O
is	O
not	O
corrected	O
or	O
may	O
be	O
aggravated	O
by	O
liver	O
transplantation	O
,	O
impairing	O
life	O
quality	O
.	O

Distinct	O
mutations	O
in	O
IRAK-4	O
confer	O
hyporesponsiveness	O
to	O
lipopolysaccharide	O
and	O
interleukin-1	O
in	O
a	O
patient	O
with	O
recurrent	O
bacterial	O
infections	O
.	O

We	O
identified	O
previously	O
a	O
patient	O
with	O
recurrent	O
bacterial	O
infections	O
who	O
failed	O
to	O
respond	O
to	O
gram-negative	O
LPS	O
in	O
vivo	O
,	O
and	O
whose	O
leukocytes	O
were	O
profoundly	O
hyporesponsive	O
to	O
LPS	O
and	O
IL-1	O
in	O
vitro	O
.	O

We	O
now	O
demonstrate	O
that	O
this	O
patient	O
also	O
exhibits	O
deficient	O
responses	O
in	O
a	O
skin	O
blister	O
model	O
of	O
aseptic	O
inflammation	O
.	O

A	O
lack	O
of	O
IL-18	O
responsiveness	O
,	O
coupled	O
with	O
diminished	O
LPS	O
and/or	O
IL-1-induced	O
nuclear	O
factor-kappaB	O
and	O
activator	O
protein-1	O
translocation	O
,	O
p38	O
phosphorylation	O
,	O
gene	O
expression	O
,	O
and	O
dysregulated	O
IL-1R-associated	O
kinase	O
(IRAK)-1	O
activity	O
in	O
vitro	O
support	O
the	O
hypothesis	O
that	O
the	O
defect	O
lies	O
within	O
the	O
signaling	O
pathway	O
common	O
to	O
toll-like	O
receptor	O
4	O
,	O
IL-1R	O
,	O
and	O
IL-18R	O
.	O

This	O
patient	O
expresses	O
a	O
"compound	O
heterozygous"	O
genotype	O
,	O
with	O
a	O
point	O
mutation	O
(	O
C877T	B-DNAMutation
in	I-DNAMutation
cDNA	I-DNAMutation
)	O
and	O
a	O
two-nucleotide	O
,	O
AC	O
deletion	O
(	O
620-621del	B-DNAMutation
in	I-DNAMutation
cDNA	I-DNAMutation
)	O
encoded	O
by	O
distinct	O
alleles	O
of	O
the	O
IRAK-4	O
gene	O
(	O
GenBank/EMBL/DDBJ	O
accession	O
nos	O
.	O

AF445802	O
and	O
AY186092	O
)	O
.	O

Both	O
mutations	O
encode	O
proteins	O
with	O
an	O
intact	O
death	O
domain	O
,	O
but	O
a	O
truncated	O
kinase	O
domain	O
,	O
thereby	O
precluding	O
expression	O
of	O
full-length	O
IRAK-4	O
(	O
i.e.	O
,	O
a	O
recessive	O
phenotype	O
)	O
.	O

When	O
overexpressed	O
in	O
HEK293T	O
cells	O
,	O
neither	O
truncated	O
form	O
augmented	O
endogenous	O
IRAK-1	O
kinase	O
activity	O
,	O
and	O
both	O
inhibited	O
endogenous	O
IRAK-1	O
activity	O
modestly	O
.	O

Thus	O
,	O
IRAK-4	O
is	O
pivotal	O
in	O
the	O
development	O
of	O
a	O
normal	O
inflammatory	O
response	O
initiated	O
by	O
bacterial	O
or	O
nonbacterial	O
insults	O
.	O

Refinement	O
of	O
heterozygosity	O
loss	O
on	O
chromosome	O
5p15	O
in	O
sporadic	O
colorectal	O
cancer	O
.	O

AIM	O
:	O
To	O
refine	O
the	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
5p15	O
and	O
to	O
identify	O
the	O
new	O
tumor	O
suppressor	O
gene	O
(s)	O
in	O
colorectal	O
tumorigenesis	O
.	O

METHODS	O
:	O
Sixteen	O
polymorphic	O
microsatellite	O
markers	O
were	O
analyzed	O
on	O
chromosome	O
5	O
and	O
another	O
6	O
markers	O
were	O
applied	O
on	O
chromosome	O
5p15	O
in	O
83	O
cases	O
of	O
colorectal	O
and	O
normal	O
DNA	O
by	O
PCR	O
.	O

PCR	O
products	O
were	O
electrophoresed	O
on	O
an	O
ABI	O
377	O
DNA	O
sequencer	O
.	O

Genescan	O
3.1	O
and	O
Genotype	O
2.1	O
software	O
were	O
used	O
for	O
LOH	O
scanning	O
and	O
analysis	O
.	O

RESULTS	O
:	O
We	O
observed	O
2	O
distinct	O
regions	O
of	O
frequent	O
allelic	O
deletions	O
on	O
Chromosome	O
5	O
,	O
at	O
D5S416	O
on	O
5p15	O
and	O
D5S428-D5S410	O
on	O
5q	O
.	O

Another	O
6	O
polymorphric	O
microsatellite	O
markers	O
were	O
applied	O
to	O
5p15	O
and	O
the	O
minimal	O
region	O
of	O
frequent	O
loss	O
of	O
heterozygosity	O
was	O
established	O
on	O
5p15	O
spanning	O
the	O
D5S416	O
locus	O
.	O

CONCLUSION	O
:	O
Through	O
our	O
detailed	O
deletion	O
mapping	O
studies	O
,	O
we	O
have	O
found	O
a	O
critical	O
and	O
precise	O
location	O
of	O
5p	O
deletions	O
,	O
5p15.2-5p15.3	O
,	O
which	O
must	O
contain	O
one	O
or	O
more	O
unknown	O
tumor	O
suppressor	O
gene	O
(s)	O
of	O
colorectal	O
cancer	O
.	O

Uncoupling	O
protein-2	O
polymorphisms	O
in	O
type	O
2	O
diabetes	O
,	O
obesity	O
,	O
and	O
insulin	O
secretion	O
.	O

The	O
onset	O
of	O
type	O
2	O
diabetes	O
(T2DM)	O
is	O
preceded	O
by	O
obesity	O
,	O
insulin	O
resistance	O
,	O
and	O
impaired	O
beta-cell	O
function	O
.	O

Uncoupling	O
protein-2	O
(UCP2)	O
is	O
a	O
widely	O
expressed	O
inner	O
mitochondrial	O
membrane	O
protein	O
.	O

Common	O
polymorphisms	O
of	O
the	O
UCP2	O
gene	O
have	O
been	O
implicated	O
in	O
diabetes	O
,	O
in	O
obesity	O
,	O
and	O
with	O
changes	O
in	O
UCP2	O
mRNA	O
levels	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
common	O
UCP2	O
variants	O
influence	O
T2DM	O
susceptibility	O
in	O
four	O
parallel	O
studies	O
of	O
separate	O
populations	O
.	O

We	O
typed	O
the	O
-866	B-DNAMutation
promoter	I-DNAMutation
(G/A)	I-DNAMutation
variant	O
,	O
a	O
nonsynonymous	O
(	O
Ala55Val	B-ProteinMutation
or	O
A55V	B-ProteinMutation
)	O
single-nucleotide	O
polymorphism	O
in	O
exon	O
4	O
,	O
and	O
a	O
45-nt	O
insertion	O
in	O
the	O
3'-untranslated	O
(3'UTR)	O
region	O
.	O

Study	O
populations	O
included	O
a	O
case-control	O
population	O
study	O
,	O
a	O
family-based	O
association	O
study	O
,	O
and	O
a	O
metabolic	O
study	O
of	O
individuals	O
who	O
had	O
been	O
characterized	O
for	O
insulin	O
sensitivity	O
and	O
secretion	O
.	O

To	O
evaluate	O
UCP2	O
mRNA	O
levels	O
,	O
we	O
examined	O
a	O
fourth	O
population	O
of	O
subjects	O
,	O
who	O
had	O
undergone	O
subcutaneous	O
fat	O
biopsy	O
.	O

All	O
three	O
variants	O
showed	O
a	O
trend	O
to	O
an	O
association	O
with	O
T2DM	O
(	O
P	O
=	O
0.05	O
to	O
0.07	O
)	O
in	O
the	O
population	O
but	O
not	O
the	O
family-based	O
association	O
study	O
.	O

The	O
3'	O
insertion/deletion	O
(	O
3'UTR	O
I/D	O
)	O
variant	O
was	O
associated	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
,	O
P	O
=	O
0.035	O
)	O
among	O
nondiabetic	O
family	O
members	O
.	O

Haplotype	O
combinations	O
were	O
significantly	O
associated	O
with	O
BMI	O
(	O
P	O
=	O
0.028	O
)	O
,	O
triglyceride	O
levels	O
(	O
P	O
=	O
0.026	O
)	O
,	O
and	O
fasting	O
insulin	O
(	O
P	O
=	O
0.029	O
)	O
;	O
highest	O
values	O
for	O
the	O
three	O
traits	O
were	O
observed	O
in	O
individuals	O
with	O
the	O
heterozygous	O
combination	O
GVI/AVD	O
.	O

In	O
the	O
metabolic	O
study	O
,	O
all	O
three	O
variants	O
were	O
associated	O
with	O
an	O
index	O
of	O
beta-cell	O
compensation	O
for	O
insulin	O
sensitivity	O
(	O
disposition	O
index	O
)	O
,	O
particularly	O
in	O
interaction	O
with	O
family	O
membership	O
(	O
P	O
<	O
0.000001	O
)	O
.	O

Individuals	O
homozygous	O
for	O
the	O
-866	O
A	O
allele	O
had	O
decreased	O
adipose	O
mRNA	O
levels	O
relative	O
to	O
GG	O
homozygous	O
individuals	O
(	O
P	O
=	O
0.009	O
)	O
,	O
but	O
the	O
3'UTR	O
I/D	O
variant	O
had	O
no	O
impact	O
on	O
mRNA	O
levels	O
.	O

We	O
confirm	O
modest	O
effects	O
of	O
UCP2	O
variants	O
on	O
BMI	O
and	O
T2DM	O
and	O
show	O
significant	O
effects	O
on	O
insulin	O
secretion	O
in	O
interaction	O
with	O
family-specific	O
factors	O
.	O

However	O
,	O
the	O
associated	O
allele	O
and	O
the	O
effects	O
on	O
gene	O
expression	O
are	O
opposite	O
to	O
those	O
reported	O
previously	O
.	O

A	O
genetic	O
and	O
phenotypic	O
analysis	O
in	O
Spanish	O
spinal	O
muscular	O
atrophy	O
patients	O
with	O
c.399_402del	B-DNAMutation
AGAG	I-DNAMutation
,	O
the	O
most	O
frequently	O
found	O
subtle	O
mutation	O
in	O
the	O
SMN1	O
gene	O
.	O

Spinal	O
muscular	O
atrophy	O
(SMA)	O
is	O
an	O
autosomal	O
recessive	O
neuromuscular	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
SMN1	O
(	O
survival	O
motor	O
neuron	O
)	O
gene	O
.	O

It	O
is	O
classified	O
by	O
age	O
of	O
onset	O
and	O
maximal	O
motor	O
milestones	O
achieved	O
in	O
type	O
I	O
,	O
II	O
,	O
and	O
III	O
(	O
severe	O
,	O
intermediate	O
,	O
and	O
mild	O
form	O
,	O
respectively	O
)	O
.	O

Of	O
369	O
unrelated	O
SMA	O
patients	O
who	O
were	O
investigated	O
for	O
homozygous	O
deletions	O
in	O
the	O
SMN1	O
gene	O
,	O
18	O
patients	O
(4.8%)	O
revealed	O
at	O
least	O
one	O
copy	O
of	O
exon	O
7	O
.	O

A	O
4-bp	O
deletion	O
in	O
exon	O
3	O
c.399_402delAGAG	B-DNAMutation
was	O
detected	O
in	O
15	O
patients	O
from	O
10	O
families	O
.	O

This	O
mutation	O
was	O
associated	O
with	O
a	O
large	O
spectrum	O
of	O
phenotypes	O
from	O
type	O
I	O
to	O
asymptomatic	O
patients	O
.	O

Five	O
patients	O
from	O
two	O
consanguineous	O
families	O
were	O
homozygous	O
for	O
the	O
mutation	O
with	O
diverse	O
mild	O
phenotypes	O
.	O

Determination	O
of	O
the	O
SMN2	O
copy	O
number	O
showed	O
that	O
the	O
presence	O
of	O
two	O
or	O
three	O
copies	O
generally	O
correlated	O
with	O
a	O
better	O
evolution	O
.	O

RT-PCR	O
studies	O
of	O
SMN	O
transcripts	O
in	O
control	O
and	O
patients	O
with	O
the	O
same	O
SMN2	O
copy	O
number	O
showed	O
that	O
the	O
full-length/Delta7	O
ratio	O
is	O
influenced	O
by	O
the	O
SMN1	O
genotype	O
although	O
it	O
seems	O
independent	O
of	O
the	O
SMN2	O
copy	O
number	O
.	O

Moreover	O
,	O
protein	O
analysis	O
in	O
these	O
patients	O
showed	O
a	O
reduction	O
in	O
SMN	O
protein	O
in	O
compound	O
heterozygous	O
patients	O
c.399_402delAGAG	B-DNAMutation
/	O
deletion	O
when	O
compared	O
with	O
homozygous	O
c.399_402delAGAG	B-DNAMutation
/	O
c.399_402delAGAG	B-DNAMutation
patients	O
.	O

Microsatellite	O
DNA	O
markers	O
flanking	O
the	O
SMA	O
locus	O
revealed	O
the	O
occurrence	O
of	O
the	O
4-bp	O
deletion	O
in	O
the	O
background	O
of	O
the	O
same	O
haplotype	O
,	O
suggesting	O
that	O
a	O
single	O
mutational	O
event	O
was	O
involved	O
in	O
the	O
10	O
families	O
.	O

The	O
geographic	O
origins	O
of	O
ancestors	O
point	O
to	O
a	O
founder	O
effect	O
from	O
the	O
south	O
and	O
east	O
of	O
Spain	O
.	O

The	O
c.399_402delAGAG	B-DNAMutation
,	O
which	O
is	O
to	O
date	O
unique	O
to	O
the	O
Spanish	O
population	O
,	O
constitutes	O
the	O
most	O
frequently	O
found	O
subtle	O
mutation	O
in	O
SMA	O
.	O

Hum	O
Mutat	O
22:136-143	O
,	O
2003	O
.	O

Promoter	O
polymorphisms	O
of	O
the	O
TNF-alpha	O
G-308A	B-DNAMutation
and	O
IL-6	O
C-174G	B-DNAMutation
genes	O
predict	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
to	O
type	O
2	O
diabetes	O
:	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
.	O

High	O
levels	O
of	O
cytokines	O
are	O
risk	O
factors	O
for	O
type	O
2	O
diabetes	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
the	O
promoter	O
polymorphisms	O
of	O
the	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
;	O
G-308A	B-DNAMutation
)	O
and	O
interleukin	O
6	O
(	O
IL-6	O
;	O
C-174G	B-DNAMutation
)	O
genes	O
predict	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
to	O
type	O
2	O
diabetes	O
in	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
.	O

Altogether	O
,	O
490	O
overweight	O
subjects	O
with	O
IGT	O
whose	O
DNA	O
was	O
available	O
were	O
randomly	O
divided	O
into	O
one	O
of	O
the	O
two	O
treatment	O
assignments	O
:	O
the	O
control	O
group	O
and	O
the	O
intensive	O
,	O
individualized	O
diet	O
and	O
exercise	O
intervention	O
group	O
.	O

The	O
-308A	O
allele	O
of	O
the	O
TNF-alpha	O
gene	O
was	O
associated	O
with	O
an	O
approximate	O
twofold	O
higher	O
risk	O
for	O
type	O
2	O
diabetes	O
compared	O
with	O
the	O
G-308G	O
genotype	O
(	O
odds	O
ratio	O
1.80	O
,	O
95%	O
CI	O
1.05-3.09	O
;	O
P	O
=	O
0.034	O
)	O
.	O

Subjects	O
with	O
both	O
the	O
A	O
allele	O
of	O
the	O
TNF-alpha	O
gene	O
and	O
the	O
C-174C	O
genotype	O
of	O
the	O
IL-6	O
gene	O
had	O
a	O
2.2-fold	O
(	O
CI	O
1.02-4.85	O
,	O
P	O
=	O
0.045	O
)	O
higher	O
risk	O
of	O
developing	O
type	O
2	O
diabetes	O
than	O
subjects	O
without	O
the	O
risk	O
genotypes	O
.	O

We	O
conclude	O
that	O
the	O
-308A	O
allele	O
of	O
the	O
promoter	O
polymorphism	O
G-308A	B-DNAMutation
of	O
the	O
TNF-alpha	O
gene	O
is	O
a	O
predictor	O
for	O
the	O
conversion	O
from	O
IGT	O
to	O
type	O
2	O
diabetes	O
.	O

Furthermore	O
,	O
this	O
polymorphism	O
seems	O
to	O
have	O
a	O
gene-gene	O
interaction	O
with	O
the	O
C-174C	O
genotype	O
of	O
the	O
IL-6	O
gene	O
.	O

Polymorphism	O
at	O
position	O
-174	O
of	O
IL-6	O
gene	O
is	O
associated	O
with	O
susceptibility	O
to	O
chronic	O
periodontitis	O
in	O
a	O
Caucasian	O
Brazilian	O
population	O
.	O

BACKGROUND	O
:	O
Interleukin-6	O
(IL-6)	O
is	O
a	O
multifunctional	O
cytokine	O
that	O
mediates	O
inflammatory	O
tissue	O
destruction	O
.	O

A	O
G	O
to	O
C	O
substitution	O
at	O
position	O
-174	O
in	O
the	O
promoter	O
of	O
IL-6	O
gene	O
reduces	O
in	O
vitro	O
transcription	O
of	O
IL-6	O
.	O

This	O
polymorphism	O
has	O
been	O
associated	O
with	O
inflammatory	O
diseases	O
like	O
chronic	O
arthritis	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
IL-6-174	O
polymorphism	O
and	O
susceptibility	O
to	O
chronic	O
periodontitis	O
in	O
Brazilians	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Eighty-four	O
nonsmoking	O
subjects	O
over	O
25	O
years	O
(	O
mean	O
age	O
42.4	O
)	O
were	O
divided	O
according	O
to	O
the	O
severity	O
level	O
of	O
periodontal	O
disease	O
:	O
36	O
healthy	O
individuals	O
(	O
control	O
group	O
)	O
,	O
24	O
subjects	O
with	O
moderate	O
and	O
24	O
with	O
severe	O
periodontitis	O
.	O

Genomic	O
DNA	O
was	O
obtained	O
from	O
epithelial	O
cells	O
through	O
a	O
mouthwash	O
with	O
3%	O
glucose	O
and	O
scraping	O
of	O
oral	O
mucosa	O
.	O

The	O
samples	O
were	O
analyzed	O
for	O
IL-6-174	O
polymorphism	O
using	O
PCR-RFLP	O
.	O

The	O
significance	O
of	O
the	O
differences	O
in	O
the	O
frequencies	O
of	O
the	O
polymorphism	O
in	O
the	O
control	O
and	O
groups	O
with	O
periodontitis	O
was	O
assessed	O
by	O
chi2	O
test	O
(p<0.05)	O
.	O

RESULTS	O
:	O
Differences	O
were	O
found	O
between	O
control	O
and	O
groups	O
with	O
periodontitis	O
in	O
the	O
genotype	O
(	O
p=0.0036	O
,	O
OR=3.0	O
)	O
and	O
in	O
the	O
allele	O
(	O
p=0.0838	O
,	O
OR=1.9	O
)	O
frequencies	O
.	O

CONCLUSION	O
:	O
We	O
concluded	O
that	O
the	O
IL-6-174	O
polymorphism	O
is	O
associated	O
with	O
susceptibility	O
to	O
chronic	O
periodontitis	O
in	O
the	O
population	O
studied	O
.	O

KLF5	O
is	O
frequently	O
deleted	O
and	O
down-regulated	O
but	O
rarely	O
mutated	O
in	O
prostate	O
cancer	O
.	O

BACKGROUND	O
:	O
Previous	O
studies	O
mapped	O
a	O
region	O
at	O
the	O
q21	O
band	O
of	O
chromosome	O
13	O
(13q21)	O
,	O
which	O
is	O
frequently	O
deleted	O
in	O
various	O
human	O
cancers	O
including	O
prostate	O
cancer	O
,	O
suggesting	O
the	O
existence	O
of	O
a	O
tumor	O
suppressor	O
gene	O
at	O
13q21	O
.	O

The	O
target	O
gene	O
of	O
deletion	O
in	O
prostate	O
cancer	O
,	O
however	O
,	O
has	O
not	O
been	O
identified	O
at	O
present	O
.	O

METHODS	O
:	O
We	O
examined	O
four	O
non-neoplastic	O
and	O
18	O
neoplastic	O
prostatic	O
cell	O
lines	O
or	O
xenografts	O
.	O

Homozygous/hemizygous	O
deletion	O
was	O
detected	O
by	O
assays	O
of	O
duplex	O
PCR	O
and	O
real-time	O
PCR	O
.	O

Expression	O
levels	O
of	O
genes	O
were	O
determined	O
by	O
the	O
methods	O
of	O
RT-PCR	O
,	O
real	O
time	O
PCR	O
,	O
and	O
northern	O
blot	O
analysis	O
.	O

Mutations	O
of	O
KLF5	O
were	O
detected	O
by	O
the	O
approaches	O
of	O
single	O
strand	O
conformational	O
polymorphism	O
(SSCP)	O
and	O
direct	O
sequencing	O
.	O

For	O
the	O
detection	O
of	O
promoter	O
methylation	O
,	O
Southern	O
blotting	O
of	O
genomic	O
DNA	O
and	O
restriction	O
digestion	O
or	O
SSCP	O
analysis	O
of	O
methylation	O
specific	O
PCR	O
products	O
were	O
used	O
.	O

Finally	O
,	O
an	O
expression	O
plasmid	O
of	O
KLF5	O
was	O
introduced	O
into	O
prostate	O
cancer	O
cell	O
lines	O
with	O
reduced	O
KLF5	O
expression	O
to	O
investigate	O
colony	O
formation	O
for	O
cell	O
growth	O
.	O

RESULTS	O
:	O
A	O
2-Mb	O
region	O
of	O
homozygous	O
deletion	O
at	O
13q21	O
was	O
detected	O
in	O
the	O
LUCaP70	O
xenograft	O
of	O
prostate	O
cancer	O
.	O

This	O
region	O
of	O
deletion	O
was	O
further	O
narrowed	O
to	O
142	O
Kb	O
by	O
a	O
hemizygous	O
deletion	O
in	O
the	O
NCI-H660	O
cell	O
line	O
.	O

KLF5	O
was	O
identified	O
as	O
the	O
only	O
complete	O
gene	O
in	O
the	O
smallest	O
region	O
of	O
deletion	O
.	O

Quantitative	O
deletion	O
of	O
KLF5	O
genome	O
occurred	O
in	O
six	O
of	O
the	O
18	O
(33%)	O
prostate	O
cancer	O
xenografts/cell	O
lines	O
.	O

Each	O
of	O
the	O
six	O
samples	O
with	O
deletion	O
also	O
showed	O
loss	O
of	O
expression	O
for	O
KLF5	O
,	O
suggesting	O
that	O
hemizygous	O
deletion	O
is	O
one	O
mechanism	O
for	O
loss	O
of	O
KLF5	O
expression	O
.	O

In	O
total	O
,	O
16	O
of	O
the	O
18	O
cases	O
(89%)	O
showed	O
loss	O
of	O
KLF5	O
expression	O
at	O
different	O
degrees	O
.	O

In	O
contrast	O
,	O
mutations	O
and	O
promoter	O
methylations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
samples	O
.	O

Functionally	O
,	O
restoration	O
of	O
KLF5	O
in	O
DU	O
145	O
and	O
22Rv1	O
cell	O
lines	O
significantly	O
inhibited	O
their	O
growth	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
Frequent	O
genomic	O
deletion	O
and	O
loss	O
of	O
expression	O
as	O
well	O
as	O
cell	O
growth	O
suppression	O
indicate	O
that	O
KLF5	O
is	O
a	O
reasonable	O
candidate	O
for	O
the	O
tumor	O
suppressor	O
gene	O
at	O
13q21	O
in	O
prostate	O
cancer	O
.	O

Mutation	O
and	O
promoter	O
methylation	O
are	O
not	O
common	O
mechanisms	O
for	O
the	O
inactivation	O
of	O
KLF5	O
in	O
prostate	O
cancer	O
.	O

Card15	O
and	O
Crohn's	O
disease	O
:	O
healthy	O
homozygous	O
carriers	O
of	O
the	O
3020insC	B-DNAMutation
frameshift	O
mutation	O
.	O

OBJECTIVES	O
:	O
Single	O
nucleotide	O
variations	O
in	O
the	O
CARD15	O
gene	O
have	O
recently	O
been	O
shown	O
to	O
be	O
associated	O
with	O
Crohn's	O
disease	O
(CD)	O
.	O

Of	O
special	O
interest	O
is	O
a	O
cytosine	O
insertion	O
at	O
position	O
3020	O
of	O
exon	O
11	O
3020insC	B-DNAMutation
,	O
which	O
leads	O
to	O
a	O
stop	O
codon	O
,	O
truncation	O
of	O
the	O
CARD15	O
protein	O
,	O
and	O
an	O
altered	O
function	O
of	O
CARD15	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
this	O
frameshift	O
mutation	O
in	O
Dutch	O
,	O
multiple-affected	O
families	O
with	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
.	O

METHODS	O
:	O
Ninety-three	O
Caucasian	O
,	O
multiple-affected	O
families	O
with	O
IBD	O
were	O
recruited	O
by	O
interviewing	O
patients	O
attending	O
our	O
department	O
.	O

Sixty-one	O
probands	O
had	O
CD	O
,	O
and	O
32	O
probands	O
ulcerative	O
colitis	O
(UC)	O
.	O

The	O
diagnosis	O
of	O
probands	O
and	O
affected	O
family	O
members	O
was	O
verified	O
according	O
to	O
standard	O
criteria	O
.	O

In	O
addition	O
,	O
81	O
healthy	O
,	O
unrelated	O
controls	O
were	O
included	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
venous	O
blood	O
of	O
all	O
participants	O
to	O
determine	O
the	O
CARD15	O
3020insC	B-DNAMutation
mutation	O
by	O
using	O
an	O
allele-specific	O
polymerase	O
chain	O
reaction	O
,	O
followed	O
by	O
agarose	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Association	O
with	O
CARD15	O
3020insC	B-DNAMutation
was	O
statistically	O
significant	O
for	O
CD	O
,	O
but	O
not	O
for	O
UC	O
.	O

In	O
one	O
of	O
the	O
multiple-affected	O
families	O
,	O
middle-aged	O
and	O
elderly	O
homozygous	O
carriers	O
were	O
identified	O
without	O
CD	O
.	O

CONCLUSIONS	O
:	O
Although	O
CARD15	O
3020insC	B-DNAMutation
appears	O
to	O
be	O
etiologically	O
important	O
in	O
CD	O
,	O
homozygous	O
carriage	O
does	O
not	O
always	O
lead	O
to	O
IBD	O
.	O

Total	O
C4B	O
deficiency	O
due	O
to	O
gene	O
deletion	O
and	O
gene	O
conversion	O
in	O
a	O
patient	O
with	O
severe	O
infections	O
.	O

Deficiencies	O
of	O
the	O
early	O
components	O
of	O
the	O
classical	O
complement	O
pathway	O
impair	O
the	O
actions	O
of	O
innate	O
and	O
humoral	O
immunity	O
and	O
may	O
lead	O
to	O
increased	O
susceptibility	O
to	O
infections	O
.	O

We	O
have	O
studied	O
the	O
genetic	O
basis	O
of	O
total	O
C4B	O
deficiency	O
in	O
a	O
Finnish	O
patient	O
with	O
recurrent	O
meningitis	O
,	O
chronic	O
fistulas	O
and	O
abscesses	O
.	O

The	O
maternal	O
chromosome	O
carried	O
a	O
four-gene	O
deletion	O
including	O
the	O
C4B	O
gene	O
,	O
and	O
a	O
conversion	O
from	O
C4B	O
to	O
C4A	O
gene	O
was	O
found	O
on	O
the	O
paternal	O
chromosome	O
resulting	O
in	O
complete	O
deficiency	O
of	O
C4B	O
.	O

In	O
the	O
converted	O
C4A	O
gene	O
,	O
mutation	O
screening	O
did	O
not	O
reveal	O
any	O
amino	O
acid	O
changes	O
or	O
prominent	O
mutations	O
,	O
yet	O
a	O
large	O
number	O
of	O
nucleotide	O
variations	O
were	O
found	O
.	O

Further	O
,	O
the	O
patient	O
was	O
heterozygous	O
for	O
structural	O
deficiency	O
of	O
mannan	O
binding	O
lectin	O
(MBL)	O
associating	O
with	O
medium	O
levels	O
of	O
serum	O
MBL	O
.	O

Our	O
data	O
provides	O
new	O
information	O
on	O
the	O
genetic	O
instability	O
of	O
the	O
C4	O
gene	O
region	O
,	O
and	O
on	O
the	O
association	O
of	O
homozygous	O
C4B	O
deficiency	O
and	O
variant	O
MBL	O
genotype	O
with	O
increased	O
susceptibility	O
to	O
recurrent	O
and	O
chronic	O
infections	O
.	O

Importantly	O
,	O
plasma	O
therapy	O
induced	O
a	O
prompt	O
clinical	O
cure	O
with	O
long-term	O
effects	O
.	O